Authorization for Credit Card Transactions

Department of Homeland Security

Form G-1450

How To Fill Out Form G-1450

1. Type or print legibly in black ink.
2. Complete the "**Applicant's/Petitioner's/Requester's Information**," "**Credit Card Billing Information**," and "**Credit Card Information**" sections and sign the authorization. **NOTE:** The credit card must be issued by a U.S. bank.
3. Place your Form G-1450 ON TOP of your application, petition, or request package.

NOTE: Failure to provide the requested information may result in DHS and your financial institution not accepting the payment. DHS cannot process credit card payments without an authorized signature.

NOTE: Please see the USCIS Form G-1450 website for additional information.

We recommend that you print or save a copy of your completed Form G-1450 to review in the future and for your records.

By completing this transaction, you agree that you have paid for a government service and that the filing fee, biometric services fee and all related financial transactions are final and not refundable, regardless of any action DHS takes on an application, petition, or request. You must submit all fees in the exact amounts. DHS will charge your credit card up to the amount you authorize below.

Please refer to the form(s) you are filing for additional information, or you may call the USCIS Customer Contact number at **1-800-375-5283**. For TTY (deaf or hard of hearing) call: **1-800-767-1833**.

Applicant's/Petitioner's/Requester's Information (Full Legal Name)		
Given Name (First Name) Marcio	Middle Name (if any)	Family Name (Last Name) LAMAS LOPES
Credit Card Billing Information (Credit Card Holder's Name as it Appears on the Card)		
Given Name (First Name) Otavio	Middle Name (if any) H	Family Name (Last Name) SILVA
Credit Card Holder's Billing Address:		
Street Number and Name 5051 La Jolla Blvd	Apt. Ste. Flr. ☒ ☐ ☐	Number 202
City or Town San Diego	State CA	ZIP Code 92109
Credit Card Holder's Signature and Contact Information:		
Credit Card Holder's Signature		
Credit Card Holder's Daytime Telephone Number 5102419336	Credit Card Holder's Email Address otavio@yousalaw.com	
Credit Card Information		
Credit Card Number	**Credit Card Type:** ☐ Visa ☐ MasterCard ☐ American Express ☐ Discover	Authorized Payment Amount $ 715.00
Credit Card Expiration Date (mm/yyyy) CVV Code		

Authorization for Credit Card Transactions

Department of Homeland Security

Form G-1450

How To Fill Out Form G-1450

1. Type or print legibly in black ink.
2. Complete the "**Applicant's/Petitioner's/Requester's Information**," "**Credit Card Billing Information**," and "**Credit Card Information**" sections and sign the authorization. **NOTE:** The credit card must be issued by a U.S. bank.
3. Place your Form G-1450 ON TOP of your application, petition, or request package.

NOTE: Failure to provide the requested information may result in DHS and your financial institution not accepting the payment. DHS cannot process credit card payments without an authorized signature.

NOTE: Please see the USCIS Form G-1450 website for additional information.

We recommend that you print or save a copy of your completed Form G-1450 to review in the future and for your records.

By completing this transaction, you agree that you have paid for a government service and that the filing fee, biometric services fee and all related financial transactions are final and not refundable, regardless of any action DHS takes on an application, petition, or request. You must submit all fees in the exact amounts. DHS will charge your credit card up to the amount you authorize below.

Please refer to the form(s) you are filing for additional information, or you may call the USCIS Customer Contact number at **1-800-375-5283**. For TTY (deaf or hard of hearing) call: **1-800-767-1833**.

Applicant's/Petitioner's/Requester's Information (Full Legal Name)		
Given Name (First Name) Marcio	Middle Name (if any)	Family Name (Last Name) LAMAS LOPES
Credit Card Billing Information (Credit Card Holder's Name as it Appears on the Card)		
Given Name (First Name) Otavio	Middle Name (if any) H	Family Name (Last Name) SILVA
Credit Card Holder's Billing Address:		
Street Number and Name 5051 La Jolla Blvd	Apt. Ste. Flr. ☒ ☐ ☐	Number 202
City or Town San Diego	State CA	ZIP Code 92109
Credit Card Holder's Signature and Contact Information:		
Credit Card Holder's Signature		
Credit Card Holder's Daytime Telephone Number 5102419336	Credit Card Holder's Email Address otavio@yousalaw.com	
Credit Card Information		
Credit Card Number	**Credit Card Type:** ☐ Visa ☐ MasterCard ☐ American Express ☐ Discover	Authorized Payment Amount $ 300.00
Credit Card Expiration Date (mm/yyyy) CVV Code		

TABLE OF CONTENTS

Petitioner: **LAMAS LOPES, Marcio**

Type of Petition: **I-140, EB-2 National Interest Waiver**

Classification Sought: **Immigration and Nationality Act 203(b)(2)(B)**

Forms	• Form G-1450 in the amount of $715 towards I-140 form filing fee • Form G-1450 in the amount of $300 towards Asylum Program Fee • Form G-1145 • Form G-28 • Form I-140 • ETA-9089
Petition Cover Letter	• Summary of Cover Letter • Petition Cover Letter • Exhibit List
Exhibit A	Resume
Exhibit B **ELIGIBILITY CRITERIA**	**Advanced Degree:** • Physician Diploma from University of Vale do Itajai – UNIVALI in Brazil, and transcripts and corresponding translation • Academic Evaluation • Work Records: - Declaration of employers - Company records - Accountant letter
Exhibit C **NATIONAL INTEREST WAIVER**	**C.I – First Prong – Substantial Merit and National Importance:** • Business Plan for Advanced Endoscopic Weight Loss Institute • Research and Government Initiatives Supporting the Business **C.II – Second Prong – Well-Positioned to Advance the Proposed Endeavor:** • All the documents of Exhibit B • All the courses and certificates • Specialization Course in Endoscopy from Hospital Ipiranga in Brazil • General Surgery specialty course from Hospital Ipiranga in Brazil • Endoscopy Specialist from AMB in Brazil • License – Certificate and CRM Card • Technical Reviewer – COVID-19 Prevention and Treatment Manual • The company's own balance sheet • Income Tax

	• Salary comparison • SOBED Membership Certificate • SOBED Declaration and Bylaws • BANDNEWS Interview • Letters of Support and Resume - Dr. Jose Celso Ardengh - Dr. Denis Pajecki - Dr. Jose Afonso Sallet - Dr. Artur Adolfo Parada - Dr. Manoel dos Passos Galvão Neto - Professor Eduardo Grecco - Dr. Douglas Charpinel • Financial Feasibility • Bank Statements • Currency Conversion
Exhibit D **PERSONAL DOCUMENTS**	• Birth Certificate and Corresponding Translation • Passport's Biometrics Page • US Visa • Marriage Certificate and Corresponding Translation • Derivative's Birth Certificate and Corresponding Translation • Derivative's Passport Biometrics • US Visa

e-Notification of Application/Petition Acceptance

Department of Homeland Security
U.S. Citizenship and Immigration Services

USCIS
Form G-1145

What Is the Purpose of This Form?

Use this form to request an electronic notification (e-Notification) when U.S. Citizenship and Immigration Services accepts your immigration application. This service is available for applications filed at a USCIS Lockbox facility.

General Information

Complete the information below and clip this form to the first page of your application package. You will receive one e-mail and/or text message for each form you are filing.

We will send the e-Notification within 24 hours after we accept your application. Domestic customers will receive an e-mail and/or text message; overseas customers will only receive an e-mail. Undeliverable e-Notifications cannot be resent.

The e-mail or text message will display your receipt number and tell you how to get updated case status information. It will not include any personal information. The e-Notification does not grant any type of status or benefit; rather it is provided as a convenience to customers.

USCIS will also mail you a receipt notice (I-797C), which you will receive within 10 days after your application has been accepted; use this notice as proof of your pending application or petition.

USCIS Privacy Act Statement

AUTHORITIES: The information requested on this form is collected pursuant to section 103(a) of the Immigration and Nationality Act, as amended INA section 101, et seq.

PURPOSE: The primary purpose for providing the information on this form is to request an electronic notification when USCIS accepts immigration form. The information you provide will be used to send you a text and/or email message.

DISCLOSURE: The information you provide is voluntary. However, failure to provide the requested information may prevent USCIS from providing you a text and/or email message receipting your immigration form.

ROUTINE USES: The information provided on this form will be used by and disclosed to DHS personnel and contractors in accordance with approved routine uses, as described in the associated published system of records notices [**DHS/USCIS-007 - Benefits Information System and DHS/USCIS-001 - Alien File (A-File) and Central Index System (CIS)**, which can be found at **www.dhs.gov/privacy**]. The information may also be made available, as appropriate for law enforcement purposes or in the interest of national security.

Complete this form and clip it on top of the first page of your immigration form(s).

Applicant/Petitioner Full Last Name	Applicant/Petitioner Full First Name	Applicant/Petitioner Full Middle Name
LAMAS LOPES	**Marcio**	**N/A**

Email Address	Mobile Phone Number (Text Message)
malamaslopes@gmail.com	

Notice of Entry of Appearance as Attorney or Accredited Representative

Department of Homeland Security

DHS Form G-28
OMB No. 1615-0105
Expires 05/31/2021

Part 1. Information About Attorney or Accredited Representative

1. USCIS Online Account Number (if any)

▶ 0 0 7 4 9 2 6 2 5 4 3 8

Name of Attorney or Accredited Representative

2.a. Family Name (Last Name): HAVERROTH SILVA

2.b. Given Name (First Name): Otavio

2.c. Middle Name: N/A

Address of Attorney or Accredited Representative

3.a. Street Number and Name: PO Box 90487

3.b. ☐ Apt. ☐ Ste. ☐ Flr. N/A

3.c. City or Town: San Diego

3.d. State: CA **3.e.** ZIP Code: 92169

3.f. Province: N/A

3.g. Postal Code: N/A

3.h. Country: USA

Contact Information of Attorney or Accredited Representative

4. Daytime Telephone Number: 5102419336

5. Mobile Telephone Number (if any): 5102419336

6. Email Address (if any): otavio@legalhs.com

7. Fax Number (if any): N/A

Part 2. Eligibility Information for Attorney or Accredited Representative

Select **all applicable** items.

1.a. ☒ I am an attorney eligible to practice law in, and a member in good standing of, the bar of the highest courts of the following states, possessions, territories, commonwealths, or the District of Columbia. If you need extra space to complete this section, use the space provided in **Part 6. Additional Information**.

Licensing Authority: California

1.b. Bar Number (if applicable): 343486

1.c. I (select **only one** box) ☒ am not ☐ am subject to any order suspending, enjoining, restraining, disbarring, or otherwise restricting me in the practice of law. If you are subject to any orders, use the space provided in **Part 6. Additional Information** to provide an explanation.

1.d. Name of Law Firm or Organization (if applicable): HS Law Corp

2.a. ☐ I am an accredited representative of the following qualified nonprofit religious, charitable, social service, or similar organization established in the United States and recognized by the Department of Justice in accordance with 8 CFR part 1292.

2.b. Name of Recognized Organization: N/A

2.c. Date of Accreditation (mm/dd/yyyy): N/A

3. ☐ I am associated with N/A, the attorney or accredited representative of record who previously filed Form G-28 in this case, and my appearance as an attorney or accredited representative for a limited purpose is at his or her request.

4.a. ☐ I am a law student or law graduate working under the direct supervision of the attorney or accredited representative of record on this form in accordance with the requirements in 8 CFR 292.1(a)(2).

4.b. Name of Law Student or Law Graduate: N/A

Part 3. Notice of Appearance as Attorney or Accredited Representative

If you need extra space to complete this section, use the space provided in **Part 6. Additional Information**.

This appearance relates to immigration matters before (select **only one** box):

1.a. ☒ U.S. Citizenship and Immigration Services (USCIS)

1.b. List the form numbers or specific matter in which appearance is entered.

I-140 ETA-9089

2.a. ☐ U.S. Immigration and Customs Enforcement (ICE)

2.b. List the specific matter in which appearance is entered.

N/A

3.a. ☐ U.S. Customs and Border Protection (CBP)

3.b. List the specific matter in which appearance is entered.

N/A

4. Receipt Number (if any)

► N/A

5. I enter my appearance as an attorney or accredited representative at the request of the (select **only one** box):

☐ Applicant ☒ Petitioner ☐ Requestor
☐ Beneficiary/Derivative ☐ Respondent (ICE, CBP)

Information About Client (Applicant, Petitioner, Requestor, Beneficiary or Derivative, Respondent, or Authorized Signatory for an Entity)

6.a. Family Name (Last Name) LAMAS LOPES

6.b. Given Name (First Name) Marcio

6.c. Middle Name N/A

7.a. Name of Entity (if applicable)

N/A

7.b. Title of Authorized Signatory for Entity (if applicable)

N/A

8. Client's USCIS Online Account Number (if any)

► N/A

9. Client's Alien Registration Number (A-Number) (if any)

► A- N/A

Client's Contact Information

10. Daytime Telephone Number

+5511984096670

11. Mobile Telephone Number (if any)

+5511984096670

12. Email Address (if any)

malamaslopes@gmail.com

Mailing Address of Client

NOTE: Provide the client's mailing address. **Do not** provide the business mailing address of the attorney or accredited representative **unless** it serves as the safe mailing address on the application or petition being filed with this Form G-28.

13.a. Street Number and Name PO Box 90487

13.b. ☐ Apt. ☐ Ste. ☐ Flr. N/A

13.c. City or Town San Diego

13.d. State CA **13.e.** ZIP Code 92169

13.f. Province N/A

13.g. Postal Code N/A

13.h. Country

USA

Part 4. Client's Consent to Representation and Signature

Consent to Representation and Release of Information

I have requested the representation of and consented to being represented by the attorney or accredited representative named in **Part 1.** of this form. According to the Privacy Act of 1974 and U.S. Department of Homeland Security (DHS) policy, I also consent to the disclosure to the named attorney or accredited representative of any records pertaining to me that appear in any system of records of USCIS, ICE, or CBP.

Part 4. Client's Consent to Representation and Signature (continued)

Options Regarding Receipt of USCIS Notices and Documents

USCIS will send notices to both a represented party (the client) and his, her, or its attorney or accredited representative either through mail or electronic delivery. USCIS will send all secure identity documents and Travel Documents to the client's U.S. mailing address.

If you want to have notices and/or secure identity documents sent to your attorney or accredited representative of record rather than to you, please select **all applicable** items below. You may change these elections through written notice to USCIS.

1.a. ☒ I request that USCIS send original notices on an application or petition to the business address of my attorney or accredited representative as listed in this form.

1.b. ☒ I request that USCIS send any secure identity document (Permanent Resident Card, Employment Authorization Document, or Travel Document) that I receive to the U.S. business address of my attorney or accredited representative (or to a designated military or diplomatic address in a foreign country (if permitted)).

NOTE: If your notice contains Form I-94, Arrival-Departure Record, USCIS will send the notice to the U.S. business address of your attorney or accredited representative. If you would rather have your Form I-94 sent directly to you, select **Item Number 1.c.**

1.c. ☐ I request that USCIS send my notice containing Form I-94 to me at my U.S. mailing address.

Signature of Client or Authorized Signatory for an Entity

2.a. Signature of Client or Authorized Signatory for an Entity

➡ [signature]

2.b. Date of Signature (mm/dd/yyyy) 08/06/2026

Part 5. Signature of Attorney or Accredited Representative

I have read and understand the regulations and conditions contained in 8 CFR 103.2 and 292 governing appearances and representation before DHS. I declare under penalty of perjury under the laws of the United States that the information I have provided on this form is true and correct.

1. a. Signature of Attorney or Accredited Representative

[signature]

1.b. Date of Signature (mm/dd/yyyy) 08/06/2026

2.a. Signature of Law Student or Law Graduate

2.b. Date of Signature (mm/dd/yyyy) N/A

Part 6. Additional Information

If you need extra space to provide any additional information within this form, use the space below. If you need more space than what is provided, you may make copies of this page to complete and file with this form or attach a separate sheet of paper. Type or print your name at the top of each sheet; indicate the **Page Number**, **Part Number**, and **Item Number** to which your answer refers; and sign and date each sheet.

1.a Family Name (Last Name): LAMAS LOPES

1.b. Given Name (First Name): Marcio

1.c. Middle Name: N/A

2.a. Page Number: N/A **2.b.** Part Number: N/A **2.c.** Item Number: N/A

2.d. N/A

3.a. Page Number: N/A **3.b.** Part Number: N/A **3.c.** Item Number: N/A

3.d. N/A

4.a. Page Number: N/A **4.b.** Part Number: N/A **4.c.** Item Number: N/A

4.d. N/A

5.a. Page Number: N/A **5.b.** Part Number: N/A **5.c.** Item Number: N/A

5.d. N/A

6.a. Page Number: N/A **6.b.** Part Number: N/A **6.c.** Item Number: N/A

6.d. N/A

Immigrant Petition for Alien Workers

Department of Homeland Security
U.S. Citizenship and Immigration Services

USCIS
Form I-140
OMB No. 1615-0015
Expires 02/28/2027

For USCIS Use Only	Fee Stamp	Priority Date	Consulate	Action Block

Classification

- ☐ 203(b)(1)(A) Alien of Extraordinary Ability
- ☐ 203(b)(1)(B) Outstanding Professor or Researcher
- ☐ 203(b)(1)(C) Multinational Executive or Manager
- ☐ 203(b)(2) Member of Professions with Advanced Degree/Exceptional Ability
- ☐ 203(b)(3)(A)(i) Skilled Worker
- ☐ 203(b)(3)(A)(ii) Professional
- ☐ 203(b)(3)(A)(iii) Other Worker

Certification

- ☐ National Interest Waiver (NIW)
- ☐ Schedule A, Group I
- ☐ Schedule A, Group II

Remarks

To be completed by an Attorney or Accredited Representative (if any).	☒ Select this box if Form G-28 or Form G-28I is attached.	Attorney State Bar Number (if applicable)	Attorney or Accredited Representative USCIS Online Account Number (if any)
		343486	007492625438

► **START HERE - Type or print in black ink.**

Part 1. Information About the Person or Organization Filing This Petition

If an individual is filing this petition, answer **Item Numbers 1.a. - 1.c.** If a company or organization is filing this petition, answer **Item Number 2.**

1.a. Family Name (Last Name): LAMAS LOPES

1.b. Given Name (First Name): Marcio

1.c. Middle Name: N/A

2. Company or Organization Name: N/A

Mailing Address

3.a. In Care Of Name: Otavio Haverroth Silva

3.b. Street Number and Name: PO Box 90487

3.c. ☐ Apt. ☐ Ste. ☐ Flr. N/A

3.d. City or Town: San Diego

3.e. State: CA **3.f.** ZIP Code: 92169

3.g. Province: N/A

3.h. Postal Code: N/A

3.i. Country: USA

Other Information

4. IRS Employer Identification Number (EIN) ► N/A

5. Are you a nonprofit organized as tax exempt or a governmental research organization? ☐ Yes ☒ No

6. Do you currently employ a total of 25 or fewer full-time equivalent employees in the United States, including all affiliates or subsidiaries of this company/organization? ☒ Yes ☐ No

7. U.S. Social Security Number (SSN) (if any) ► N/A

8. USCIS Online Account Number (if any) ► N/A

Part 2. Petition Type

This petition is being filed for (select **only one** box):

1.a. ☐ An alien of extraordinary ability.

1.b. ☐ An outstanding professor or researcher.

1.c. ☐ A multinational executive or manager.

1.d. ☐ A member of the professions holding an advanced degree or an alien of exceptional ability (who is **NOT** seeking a National Interest Waiver (NIW)).

1.e. ☐ A professional (at a minimum, possessing a bachelor's degree or a foreign degree equivalent to a U.S. bachelor's degree).

Part 2. Petition Type (continued)

1.f. ☐ A skilled worker (requiring at least two years of specialized training or experience).

1.g. ☐ Any other worker (requiring less than two years of training or experience).

1.h. ☒ An alien applying for an NIW (who **IS** a member of the professions holding an advanced degree or an alien of exceptional ability).

This petition is being filed (select **only one** box):

2.a. ☐ To amend a previously filed petition.

Previous Petition Receipt Number
► N/A

2.b. ☐ For the Schedule A, Group I or II designation.

Part 3. Information About the Person for Whom You Are Filing

1.a. Family Name (Last Name): LAMAS LOPES

1.b. Given Name (First Name): Marcio

1.c. Middle Name: N/A

Mailing Address

2.a. In Care Of Name: Otavio Haverroth Silva

2.b. Street Number and Name: PO Box 90487

2.c. ☐ Apt. ☐ Ste. ☐ Flr. N/A

2.d. City or Town: San Diego

2.e. State: CA **2.f.** ZIP Code: 92169

2.g. Province: N/A

2.h. Postal Code: N/A

2.i. Country: USA

Other Information

3. Date of Birth (mm/dd/yyyy): 10/08/1981

4. City/Town/Village of Birth: Sao Paulo

5. State or Province of Birth: Sao Paulo

6. Country of Birth: Brazil

7. Country of Citizenship or Nationality: Brazil

8. Alien Registration Number (A-Number) (if any)
► A- N/A

9. U.S. SSN (if any) ► N/A

Information About His or Her Last Arrival in the United States

If the person for whom you are filing is in the United States, provide the following information.

10. Date of Last Arrival (mm/dd/yyyy): N/A

11.a. Form I-94 Arrival-Departure Record Number
► N/A

11.b. Expiration Date of Authorized Stay Shown on Form I-94 (mm/dd/yyyy): N/A

11.c. Status on Form I-94 (for example, class of admission, or paroled, if paroled): N/A

12. Passport Number: N/A

13. Travel Document Number: N/A

14. Country of Issuance for Passport or Travel Document: N/A

15. Expiration Date for Passport or Travel Document (mm/dd/yyyy): N/A

Part 4. Processing Information

Provide the following information for the person named in **Part 3.** (select **only one** box):

1.a. ☒ Alien will apply for a visa abroad at a U.S. Embassy or U.S. Consulate at:

1.b. City or Town: Rio de Janeiro

1.c. Country: Brazil

2.a. ☐ Alien is in the United States and will apply for adjustment of status to that of lawful permanent resident.

Part 4. Processing Information (continued)

2.b. Alien's current country of residence or, if now in the United States, last country of permanent residence abroad.

Brazil

If you provided a United States address in **Part 3.**, provide the person's foreign address in **Item Numbers 3.a. - 3.f.**:

3.a. Street Number and Name: 732 Tuiuti St

3.b. ☒ Apt. ☐ Ste. ☐ Flr. 172

3.c. City or Town: Sao Paulo

3.d. Province: Sao Paulo

3.e. Postal Code: 03081015

3.f. Country: Brazil

If the person's native alphabet is other than Roman letters, type or print the person's foreign name and address in the native alphabet in **Item Numbers 4.a. - 5.g.**:

4.a. Family Name (Last Name): N/A

4.b. Given Name (First Name): N/A

4.c. Middle Name: N/A

Mailing Address

5.a. In Care Of Name: N/A

5.b. Street Number and Name: N/A

5.c. ☐ Apt. ☐ Ste. ☐ Flr. N/A

5.d. City or Town: N/A

5.e. Province: N/A

5.f. Postal Code: N/A

5.g. Country: N/A

If you answer "Yes" to **Item Numbers 6.a. - 10.**, provide the case number, office location, date of decision, and disposition of the decision in the space provided in **Part 11. Additional Information**.

6.a. Are you filing any other petitions or applications with this Form I-140? ☐ Yes ☒ No

6.b. If you answered "Yes" **to Item Number 6.a.**, select all applicable boxes:

- ☐ Form I-485
- ☐ Form I-131
- ☐ Form I-765
- ☐ Other (Provide an explanation in **Part 11. Additional Information**.)

7. Is the person for whom you are filing in removal proceedings? ☐ Yes ☒ No

8. Has any immigrant visa petition ever been filed by or on behalf of this person? ☐ Yes ☒ No

9. Are you filing this petition without an original labor certification because the original labor certification was previously submitted in support of another Form I-140? ☐ Yes ☒ No

10. If you are filing this petition without an original labor certification, are you requesting that U.S. Citizenship and Immigration Services (USCIS) request a duplicate labor certification from the Department of Labor (DOL)? ☐ Yes ☒ No

Part 5. Additional Information About the Petitioner

Type of petitioner (select **only one** box):

1.a. ☐ Employer

1.b. ☒ Self

1.c. ☐ Other (For example, Lawful Permanent Resident, U.S. citizen or any other person filing on behalf of the alien)

If a company or an organization is filing this petition, provide the following information:

2. Type of Business: N/A

3. Date Established (mm/dd/yyyy): N/A

4. Current Number of U.S. Employees: N/A

5. Gross Annual Income $ N/A

6. Net Annual Income $ N/A

7. NAICS Code ▶ N/A

8. Labor Certification DOL Case Number: N/A

Part 5. Additional Information About the Petitioner (continued)

9. Labor Certification DOL Filing Date (mm/dd/yyyy)

N/A

10. Labor Certification Expiration Date (mm/dd/yyyy)

N/A

If an individual is filing this petition, provide the following information.

11. Occupation

Physician

12. Annual Income $ N/A

Part 6. Basic Information About the Proposed Employment

1. Job Title

General and Operations Managers

2. SOC Code ▶ 11 - 1021

3. Nontechnical Job Description

See page 8.

4. Is this a full-time position? ☒ Yes ☐ No

5. If the answer to **Item Number 4.** is "No," how many hours per week for the position?

6. Is this a permanent position? ☒ Yes ☐ No

7. Is this a new position? ☒ Yes ☐ No

8. Wages (Specify hour, week, month, or year):

$ 96,000.00 per year

Worksite Location

For **Item Numbers 9.a. - 9.e.**, provide the address where the person will work if different from the address provided in **Part 1.**

9.a. Street Number and Name: To be determined

9.b. ☐ Apt. ☐ Ste. ☐ Flr. To be determined

9.c. City or Town: Orlando

9.d. State: FL **9.e.** ZIP Code: To be determined

Part 7. Information About the Spouse and All Children of the Person for Whom You Are Filing

For **Part 7.**, provide information on the spouse and all children related to the individual for whom you are filing this petition. Also, note if the individual will apply for a visa abroad or adjustment of status as the dependent of the individual for whom the petition is filed. If you need extra space to provide information about additional family members, use the space provided in **Part 11. Additional Information**.

Person 1

1.a. Family Name (Last Name): DE OLINDA GIANNOCCARO

1.b. Given Name (First Name): Lilian

1.c. Middle Name: N/A

2. Date of Birth (mm/dd/yyyy): 04/22/1983

3. Country of Birth: Brazil

4. Relationship: Spouse

5. Is he or she applying for adjustment of status? ☐ Yes ☒ No

6. Is he or she applying for a visa abroad? ☒ Yes ☐ No

Person 2

7.a. Family Name (Last Name): GIANNOCCARO LOPES

7.b. Given Name (First Name): Lavinia

7.c. Middle Name: N/A

8. Date of Birth (mm/dd/yyyy): 10/09/2018

9. Country of Birth: Brazil

10. Relationship: Daughter

11. Is he or she applying for adjustment of status? ☐ Yes ☒ No

12. Is he or she applying for a visa abroad? ☒ Yes ☐ No

Part 7. Information About Spouse and All Children of the Person for Whom You Are Filing (continued)

Person 3

13.a. Family Name (Last Name): GIANNOCCARO LOPES

13.b. Given Name (First Name): Bruno

13.c. Middle Name: N/A

14. Date of Birth (mm/dd/yyyy): 08/17/2016

15. Country of Birth: Brazil

16. Relationship: Son

17. Is he or she applying for adjustment of status? ☐ Yes ☒ No

18. Is he or she applying for a visa abroad? ☒ Yes ☐ No

Person 4

19.a. Family Name (Last Name): N/A

19.b. Given Name (First Name): N/A

19.c. Middle Name: N/A

20. Date of Birth (mm/dd/yyyy): N/A

21. Country of Birth: N/A

22. Relationship: N/A

23. Is he or she applying for adjustment of status? ☐ Yes ☐ No

24. Is he or she applying for a visa abroad? ☐ Yes ☐ No

Person 5

25.a. Family Name (Last Name): N/A

25.b. Given Name (First Name): N/A

25.c. Middle Name: N/A

26. Date of Birth (mm/dd/yyyy): N/A

27. Country of Birth: N/A

28. Relationship: N/A

29. Is he or she applying for adjustment of status? ☐ Yes ☐ No

30. Is he or she applying for a visa abroad? ☐ Yes ☐ No

Person 6

31.a. Family Name (Last Name): N/A

31.b. Given Name (First Name): N/A

31.c. Middle Name: N/A

32. Date of Birth (mm/dd/yyyy): N/A

33. Country of Birth: N/A

34. Relationship: N/A

35. Is he or she applying for adjustment of status? ☐ Yes ☐ No

36. Is he or she applying for a visa abroad? ☐ Yes ☐ No

Part 8. Contact Information, Certification, and Signature of the Petitioner or Authorized Signatory

Petitioner or Authorized Signatory's Contact Information

1.a. Petitioner's or Authorized Signatory's Family Name (Last Name)

LAMAS LOPES

1.b. Petitioner's or Authorized Signatory's Given Name (First Name)

Marcio

2. Petitioner's or Authorized Signatory's Title

N/A

3. Petitioner's or Authorized Signatory's Daytime Telephone Number

+5511984096670

4. Petitioner's or Authorized Signatory's Mobile Telephone Number (if any)

+5511984096670

5. Petitioner's or Authorized Signatory's Email Address (if any)

malamaslopes@gmail.com

Petitioner's or Authorized Signatory's Certification and Signature

If filing this petition on behalf of an organization, I certify that I am authorized to do so by the organization:

a. I reviewed and provided or authorized all of the responses and information in my petition;

b. I understood all of the responses and information contained in, and submitted with, my petition; and

c. All of the responses and information were complete, true, and correct at the time of filing

Furthermore, I authorize the release of any information from any and all of my records as authorized signatory and the petitioner's records that USCIS may need to determine the petitioner's eligibility for an immigration request and to other entities and persons where necessary for the administration and enforcement of U.S. immigration law.

6.a. Petitioner's or Authorized Signatory's Signature



6.b. Date of Signature (mm/dd/yyyy) 08/06/2026

Part 9. Interpreter's Contact Information, Certification, and Signature

Interpreter's Full Name

1.a. Interpreter's Family Name (Last Name)

N/A

1.b. Interpreter's Given Name (First Name)

N/A

2. Interpreter's Business or Organization Name

N/A

Interpreter's Contact Information

3. Interpreter's Daytime Telephone Number

N/A

4. Interpreter's Mobile Telephone Number (if any)

N/A

5. Interpreter's Email Address (if any)

N/A

Interpreter's Certification and Signature

I certify, under penalty of perjury, that I am fluent in English and N/A and I have interpreted every question on the petition and Instructions and interpreted the petitioner's or authorized signatory's answers to the questions in that language, and the petitioner or authorized signatory informed me that they understood every instruction, question, and answer on the petition.

6.a. Interpreter's Signature

N/A

6.b. Date of Signature (mm/dd/yyyy)

Part 10. Contact Information, Certification, and Signature of the Person Preparing this Petition, if Other Than the Petitioner or Authorized Signatory

Preparer's Full Name

1. Preparer's Family Name (Last Name)

HAVERROTH SILVA

Preparer's Given Name (First Name)

Otavio

2. Preparer's Business or Organization Name

HS Law Corp

Preparer's Contact Information

3. Preparer's Daytime Telephone Number

5102419336

4. Preparer's Mobile Telephone Number (if any)

5102419336

5. Preparer's Email Address (if any)

otavio@legalhs.com

Preparer's Certification and Signature

I certify, under penalty of perjury, that I prepared this petition for the petitioner or authorized signatory at their request and with express consent and that all of the responses and information contained in and submitted with the petition are complete, true, and correct and reflects only information provided by the petitioner or authorized signatory. The petitioner or authorized signatory reviewed the responses and information and informed me that they understand the responses and information in or submitted with the petition.

6. Preparer's Signature



Date of Signature (mm/dd/yyyy) 07/21/2026

Part 11. Additional Information

If you need extra space to provide any additional information within this petition, use the space below. If you need more space than what is provided, you may make copies of this page to complete and file with this petition or attach a separate sheet of paper. Type or print your name and A-Number (if any) at the top of each sheet; indicate the **Page Number**, **Part Number**, and **Item Number** to which your answer refers; and sign and date each sheet.

1. Family Name (Last Name): LAMAS LOPES

Given Name (First Name): Marcio

Middle Name: N/A

2. IRS EIN ► N/A

3.

Page Number	Part Number	Item Number
4	6	3

Leads the practice's strategy and operations, overseeing weight management clinical programs, coordinating contracted staff, and driving financial growth and business partnerships.

4.

Page Number	Part Number	Item Number
N/A	N/A	N/A

N/A

5.

Page Number	Part Number	Item Number
N/A	N/A	N/A

N/A

6.

Page Number	Part Number	Item Number
N/A	N/A	N/A

7.

Page Number	Part Number	Item Number
N/A	N/A	N/A

N/A

Employment OMB Approval: 1205-0451
Expiration Date: 02/28/2029

Application for Permanent Employment Certification
Form ETA-9089 – Final Determination: Permanent Employment Certification Approval
U.S. Department of Labor

PERMANENT EMPLOYMENT CERTIFICATION APPROVAL

A. U.S. Government Agency Use Only

Pursuant to the provisions of Sections 212(a)(5)(A) of the Immigration and Nationality Act, as amended, the Department hereby certifies that there are not sufficient workers who are able, willing, and qualified, and who will be available at the time of application for a visa and admission into the United States and place needed to fill the job opportunities for which certification is sought, and the permanent employment of the foreign worker will not adversely affect the wages and working conditions of workers in the United States similarly employed.

Therefore, by virtue of the signature below, the Department hereby acknowledges granting certification for the following *Application for Permanent Employment Certification* (Form ETA-9089):

1. DOL Case Number		2. Case Status
3. Employer Legal Business Name		4. Employer FEIN
5. Foreign Worker's Last (family) Name		
6. Foreign Worker's First (given) Name		
7. Foreign Worker's Middle Name(s)		
8. Job Title		
9. SOC Code	10. SOC Occupational Title	
Labor Certification Validity Information		
11. Filing Date	12. Determination Date	13. Expiration Date
14. Department of Labor Office of Foreign Labor Certification *(electronic signature)*		

Pursuant to 20 CFR 656, the aforementioned permanent labor certification is valid only for the job opportunity, the foreign worker, and the area of intended employment specified on the approved Form ETA-9089, including all appendices and any modifications approved by the Department. The aforementioned filing date on this approved *Application for Permanent Employment Certification*, established under 20 CFR 656.17(c), may be used as a priority date by the Department of Homeland Security and the Department of State, as appropriate. This approved *Application for Permanent Employment Certification* will expire if not filed in support of *Immigrant Petition for Alien Workers* (Form I-140) with the Department of Homeland Security by the aforementioned expiration date.

The foreign worker covered by this approved *Application for Permanent Employment Certification* has declared under Section B below, under penalty of perjury, that the foreign worker has read and reviewed every page of Appendix A for this approved Form ETA-9089, takes full responsibility for the accuracy of all information contained therein, and intends to accept permanent employment in the job opportunity specified on the approved Form ETA-9089, including all appendices, offered by the employer if granted a visa or an adjustment of status based on this permanent labor certification.

The employer covered by this approved *Application for Permanent Employment Certification* has declared under Section D below under penalty of perjury that it has read and reviewed every page of this approved Form ETA-9089, including all appendices, and takes full responsibility for the accuracy of all information contained therein and all documentation supporting this approved *Application for Permanent Employment Certification*, including any representations made by the employer's authorized preparer, agent or attorney, as applicable.

Application for Permanent Employment Certification
Form ETA-9089 – Final Determination: Permanent Labor Certification Approval
U.S. Department of Labor

B. Foreign Worker Declaration

I declare under penalty of perjury that I have read and reviewed all information contained in Appendix A of this approved Form ETA-9089, and that to the best of my knowledge the information contained therein is true and accurate. *I understand that to knowingly and/or willfully furnish materially false information in the preparation of this form and any supplement thereto or to aid, abet, or counsel another to do so is a federal offense punishable by fines, imprisonment, or both (18 U.S.C. 2, 1001, 1546, 1621).*

I **further declare** that I am the person identified under Section A, Fields 5, 6, and 7 above. I did not participate in any activities involving the interviewing or consideration of U.S. workers and intend to accept permanent employment in the job opportunity specified on this approved Form ETA-9089, including all appendices, offered by the employer if granted a visa or an adjustment of status based on this permanent labor certification.

1. Signature *	2. Date Signed *
	08/06/2026

C. Attorney or Agent Declaration

I declare under penalty of perjury that I am an attorney for the employer, or that I am an employee of, or hired by, the employer listed in Section C of the Form ETA-9089, and that I have been designated by that employer in accordance with 20 CFR 656.10(b) to act on its behalf in connection with this application.

I hereby certify that I have provided to the employer the entire Form ETA-9089, appendices, and all supporting documentation for review and to the best of my knowledge the information contained herein is true and accurate, including the employer's declaration regarding activities that I have undertaken on the employer's behalf in connection with this application. *I understand that to knowingly and/or willfully furnish materially false information in the preparation of this form and any supplement hereto or to aid, abet, or counsel another to do so is a federal offense punishable by fines, imprisonment, or both (18 U.S.C. 2, 1001, 1546, 1621).*

1. Attorney or Agent's Last (family) Name *	2. First (given) Name *	3. Middle Initial §
HAVERROTH SILVA	Otavio	N/A
4. Firm/Business Name §		
HS Law Corp		
5. Signature *	6. Date Signed *	
	08/06/2026	

D. Employer Declaration

I hereby designate the agent or attorney identified in Section C (if any) of the Form ETA-9089 to represent me for the purpose of labor certification and, by virtue of my signature in Field 5 below, I **take full responsibility** for the accuracy of any representations made by my agent or attorney, and my designated preparer identified in Section C above, on every page of the Form ETA-9089, including all appendices, and documentation supporting this application.

I declare under penalty of perjury that I have read and reviewed this application, including every page of the Form ETA-9089, appendices, and supporting documentation, and that to the best of my knowledge the information contained therein is true and accurate. *I understand that to knowingly and/or willfully furnish materially false information in the preparation of this form and any supplement thereto or to aid, abet, or counsel another to do so is a federal offense punishable by fines, imprisonment, or both (18 U.S.C. 2, 1001, 1546, 1621).*

1. Last (family) Name *	2. First (given) Name *	3. Middle Initial §
4. Title *		
5. Signature *	6. Date Signed *	

For Public Burden Statement, see the Instructions for Form ETA-9089.

OMB Approval: 1205-0451
Expiration Date:02/28/2029

Application for Permanent Employment Certification
Form ETA-9089 – Appendix A: Foreign Worker Information
U.S. Department of Labor

FOREIGN WORKER INFORMATION

A. Foreign Worker Contact Information

1. Foreign Worker's Last (family) Name * LAMAS LOPES		
2. Foreign Worker's First (given) Name * Marcio		
3. Foreign Worker's Middle Name(s) * N/A		
4. Address 1 *(current)* * 732 Tuiuti St		
5. Address 2 *(apartment/suite/floor and number)* ***§*** Apt 172		
6. City * Tatuape	7. State * N/A	8. Postal Code * 03081015
9. Country * Brazil	10. Province ***§*** Sao Paulo	
11. Date of Birth *(mm/dd/yyyy)* * 10/08/1981	12. Class of Admission * N/A	13. Alien Registration Number (A#) (if applicable) * N/A
14. Country of Birth * Brazil		
15. Country of Citizenship or Nationality * Brazil		

B. Foreign Worker Education §

a. Educational Attainment Information 1

1. Education: U.S. Diploma/Degree attained relevant to the job opportunity ☐ None ☐ High School/GED ☐ Associate ☐ Bachelor's ☐ Master's ☐ Doctorate (PhD) ■ Other Degree (JD, MD, etc.)	
1a. If "Other Degree" in question 1, specify the diploma/degree attained Specialty	
1b. Specify major(s) and/or field(s) of study (may list more than one related major and more than one field) Endoscopy Specialist Certification	
1c. Name of Institution that issued the degree/diploma Brazilian Medical Association Brazilian Society of Digestive Endoscopy	
1d. Name of Country of institution identified in question 1c Brazil	1e. Month/year attained (*mm/yyyy*) 11/2017

b. Educational Attainment Information 2

1. Education: U.S. Diploma/Degree attained relevant to the job opportunity ☐ None ☐ High School/GED ☐ Associate ☐ Bachelor's ☐ Master's ☐ Doctorate (PhD) ■ Other Degree (JD, MD, etc.)	
1a. If "Other Degree" in question 1, specify the diploma/degree attained Specialty	
1b. Specify major(s) and/or field(s) of study (may list more than one related major and more than one field) Residency in Digestive Endoscopy	
1c. Name of Institution that issued the degree/diploma State Department of Health Ipiranga Hospital	
1d. Name of Country of Institution identified in question 1c Brazil	1e. Month/year attained (*mm/yyyy*) 02/2015

PERM Case Number: _____ Case Status: _____ Determination Date: _____ Expiration Date: _____

***B. Foreign Worker Education** (continued)*

c. Educational Attainment Information 3

1. Education: U.S. Diploma/Degree attained relevant to the job opportunity ☐ None ☐ High School/GED ☐ Associate ☐ Bachelor's ☐ Master's ☐ Doctorate (PhD) ■ Other Degree (JD, MD, etc.)
1a. If "Other Degree" in question 1, specify the diploma/degree attained Specialty
1b. Specify major(s) and/or field(s) of study (may list more than one related major and more than one field) Residency in General Surgery
1c. Name of Institution that issued the degree/diploma Sao Paulo State Department of Health Ipiranga Hospital

1d. Name of Country of Institution identified in question 1c	1e. Month/year attained (*mm/yyyy*)
Brazil	01/2013

d. Educational Attainment Information 4

1. Education: U.S. Diploma/Degree attained relevant to the job opportunity ☐ None ☐ High School/GED ☐ Associate's ■ Bachelor's ☐ Master's ☐ Doctorate (PhD) ☐ Other Degree (JD, MD, etc.)
1a. If "Other Degree" in question 1, specify the diploma/degree attained
1b. Specify major(s) and/or field(s) of study (may list more than one related major and more than one field) Doctor of Medicine
1c. Name of Institution that issued the degree/diploma Vale do Itajai University

1d. Name of Country of Institution identified in question 1c	1e. Month/year attained (*mm/yyyy*)
Brazil	07/2008

e. Educational Attainment Information 5

1. Education: U.S. Diploma/Degree attained relevant to the job opportunity ☐ None ☐ High School/GED ☐ Associate's ☐ Bachelor's ☐ Master's ☐ Doctorate (PhD) ☐ Other Degree (JD, MD, etc.)
1a. If "Other Degree" in question 1, specify the diploma/degree attained
1b. Specify major(s) and/or field(s) of study (may list more than one related major and more than one field)
1c. Name of Institution that issued the degree/diploma

1d. Name of Country of Institution identified in question 1c	1e. Month/year attained (*mm/yyyy*)

C. Foreign Worker Training Qualifications §

a. Training, Certification(s), and/or License(s) Information 1

1. Name of Institution/School/Training provider 24th Brazilian Digestive System Week
1a. Name of training, coursework, experience received CRE balloon dilation and triamcinolona injection in rectal stenosis. And argon plasma in rectovaginal fistula: a casa report in a 8-month- old infant.

1b. Training/Certifications/licenses attained (if applicable)		
N/A		
1c. Start date of training (*mm/yyyy*)	1d. End date of training (*mm/yyyy*)	1e. Month/year awarded (*mm/yyyy*)
N/A	N/A	09/2025

b. Training, Certification(s), and/or License(s) Information 2

1. Name of Institution/School/Training provider		
Boston Scentific		
1a. Name of training, coursework, experience received		
Endobariatric Course LATAM - IRCAD'		
1b. Training/Certifications/Licenses attained (if applicable)		
N/A		
1c. Start date of training (*mm/yyyy*)	1d. End date of training (*mm/yyyy*)	1e. Month/year awarded (*mm/yyyy*)
10/2024	10/2024	10/2024

c. Training, Certification(s), and/or License(s) Information 3

1. Name of Institution/School/Training provider		
2nd World Congress of GI Endoscopy and 24th Pan American Congress of Digestive Endoscopy		
1a. Name of training, coursework, experience received		
Aortoenteric fistula to duodenum: case report		
1b. Training/certifications/licenses attained (if applicable)		
N/A		
1c. Start date of training (*mm/yyyy*)	1d. End date of training (*mm/yyyy*)	1e. Month/year awarded (*mm/yyyy*)
03/2020	03/2020	03/2020

D. Foreign Worker Training Qualifications §

a. Skills, Abilities, and Proficiencies 1

1. Name of Employer/Institution/School/Training Provider	
N/A	
1a. Country	1b. State, Territory, or Province
N/A	N/A
1c. Description of specific skills, abilities, and/or proficiencies the foreign worker possesses or attained, which help establish whether the foreign worker meets the requirements identified for the job opportunity *(up to 1,500 characters)*	
N/A	

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	**Foreign Worker Training Qualifications**

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider : DAD - Digestive System Diseases.

Name of training, coursework, experience received:Colorectal cancer medical screening project.

Month/year awarded: 08/2017.

B. Supplemental Information 2 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	**Foreign Worker Training Qualifications**

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:SBDA

Name of training, coursework, experience received:XVI Brazilian digestive system week

Start date of training - End date of training: 11/11/2017 - 11/15/2017.

Month/year awarded:11/2017.

For Public Burden Statement, see the Instructions for Form ETA-9089.

OMB Approval: 1205-0451
Expiration Date: 02/28/2029

Application for Permanent Employment Certification
Form ETA-9089 – Appendix C: Supplemental Information
U.S. Department of Labor

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:DAD - Digestive System Diseases

Name of training, coursework, experience received:Monthly multidisciplinary continuing education - Session: Upper gastrointestinal Bleeding.

Month/year awarded:02/2016.

B. Supplemental Information 2 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:DAD - Digestive System Diseases

Name of training, coursework, experience received:Monthly multidisciplinary continuing education - Session: LGIB, ANEMIA, AND OGIB, delivergin a lecture on the topic ''Clinical case presentation''.

Month/year awarded:04/2016.

For Public Burden Statement, see the Instructions for Form ETA-9089.

OMB Approval: 1205-0451
Expiration Date: 02/28/2029

Application for Permanent Employment Certification
Form ETA-9089 – Appendix C: Supplemental Information
U.S. Department of Labor

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:DAD - Digestive System Diseases

Name of training, coursework, experience received:Monthly multidisciplinary continuing education - Session: LGIB, ANEMIA, AND OGIB, delivering a lecture on the topic ''Vascular malformations and dieulafoy''.

Month/year awarded:04/2016.

B. Supplemental Information 2 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:DAD - Digestive System Diseases

Name of training, coursework, experience received:Monthly multidisciplinary continuing education - Session: LGIB, ANEMIA, AND OGIB.

Month/year awarded:04/2016.

For Public Burden Statement, see the Instructions for Form ETA-9089.

OMB Approval: 1205-0451
Expiration Date: 02/28/2029

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:DAD - Digestive System Diseases

Name of training, coursework, experience received:Monthly multidisciplinary continuing education - Session: OBESITY.

Month/year awarded:06/2016.

B. Supplemental Information 2 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:DAD - Digestive System Diseases

Name of training, coursework, experience received:Monthly multidisciplinary continuing education - Session: OBESITY, delivering a lecture on the topic ''Clinical case presentation''.

Month/year awarded:06/2016.

For Public Burden Statement, see the Instructions for Form ETA-9089.

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	**Foreign Worker Training Qualifications**

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:Organization accredited by joint comission international.

Name of training, coursework, experience received:Cardiopulmonary resuscitation response.

Month/year awarded:09/2015.

B. Supplemental Information 2 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	**Foreign Worker Training Qualifications**

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:SBAD

Name of training, coursework, experience received:XIV Brazilian Digestive System Week.

Month/year awarded:11/2015.

For Public Burden Statement, see the Instructions for Form ETA-9089.

OMB Approval: 1205-0451
Expiration Date: 02/28/2029

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider:AMB - Brazilian Medical Association.

Name of training, coursework, experience received:Intragastric Balloon Workshop.

Month/year awarded:03/2014.

B. Supplemental Information 2 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider: XIII SBAD - Brazilian Digestive System Week

Name of training, coursework, experience received:Critical analysis of the use of midazolam, fentanyl, and propofol in conscious sedation for upper gastrointestinal endoscopy in a non-hospital setting.

Month/year awarded:11/2014.

For Public Burden Statement, see the Instructions for Form ETA-9089.

OMB Approval: 1205-0451
Expiration Date: 02/28/2029

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider: SOBED SP

Name of training, coursework, experience received:Monthly meetings of the residents '' study group''.

Month/year awarded:11/2013.

B. Supplemental Information 2 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider: Ethicon Endo- Surgery

Name of training, coursework, experience received:Theoretical-practical video surgery training with emphasis on Endosutures and Laparoscopy.

Month/year awarded:08/2012.

For Public Burden Statement, see the Instructions for Form ETA-9089.

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	C	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider: Conselho federal de medicina.

Name of training, coursework, experience received:Medical License.

Training/Certifications/Licenses attained: Brazilian Medical License CRM/SP 133420

Month/year awarded:08/2008.

B. Supplemental Information 2 §

1. Section and Item Number	E	1a. Section Name or Category of Supplemental Information	Foreign Worker Training Qualifications

1b. Supplemental Information. *(up to 1,500 characters)*

Training, Certification(s), and/or License(s) Information

Name of Institution/School/Training provider: Brazilian society of digestive esdoscopy - SOBED.

Name of training, coursework, experience received:Membership certificate.

Month/year awarded:03/2007.

For Public Burden Statement, see the Instructions for Form ETA-9089.

OMB Approval: 1205-0451
Expiration Date: 02/28/2029

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	E	1a. Section Name or Category of Supplemental Information	**Foreign Worker Experience**

1b. Supplemental Information. *(up to 1,500 characters)*

Work Experience 2

Employer name:Hospital 9 de Julho

Address:545 Peixoto Gomide St, São Paulo/SP, Brazil, 01409-002.

Job Title:Staff Endoscopist

Start date - End date: 03/2015 - Present.

Job duties: Perform upper endoscopy and colonoscopy procedures; Manage emergency and elective gastrointestinal cases; Experience in therapeutic interventions including hemostasis and dilation.

B. Supplemental Information 2 §

1. Section and Item Number	E	1a. Section Name or Category of Supplemental Information	**Foreign Worker Experience**

1b. Supplemental Information. *(up to 1,500 characters)*

Work Experience 3

Employer name:O.S.S Santa Marcelina

Address:177 Santa Marcelina St - São Paulo/SP, Brazil, 08270-070

Job Title: General Practitioner

Start date - End date: 04/2010 - 02/2011

Job duties: Provided primary care in a public health setting; Managed a high volume of patients in community-based care.

For Public Burden Statement, see the Instructions for Form ETA-9089.

SUPPLEMENTAL INFORMATION

A. Supplemental Information 1 §

1. Section and Item Number	E	1a. Section Name or Category of Supplemental Information	Foreign Worker Experience

1b. Supplemental Information. *(up to 1,500 characters)*

Work Experience 4

Employer name:Associação Saúde da Família

Address:65 Marechal Cordeiro de Farias Sq, São Paulo/SP, Brazil, 01244-050.

Job Title: General Practitioner

Start date - End date: 07/2008 - 03/2010

Job duties: Provided primary care in a public health setting; Managed a high volume of patients in community-based care.

B. Supplemental Information 2 §

1. Section and Item Number		1a. Section Name or Category of Supplemental Information	

1b. Supplemental Information. *(up to 1,500 characters)*

For Public Burden Statement, see the Instructions for Form ETA-9089.

SUMMARY OF COVER LETTER

Petitioner: **LAMAS LOPES, Marcio**

Type of Petition: **I-140, EB-2 National Interest Waiver**

Classification Sought: **Immigration and Nationality Act 203(b)(2)(B)**

This petition is submitted on behalf of Dr. Marcio Lamas Lopes**,** a physician specializing in digestive and bariatric endoscopy who qualifies for EB-2 classification as a **member of the professions holding an advanced degree**. Dr. Lopes holds a foreign academic degree evaluated as equivalent to a U.S. **Doctor of Medicine (M.D.)**, together with graduate-level study in General Surgery and Endoscopy. Alternatively, his academic qualifications, combined with more than fifteen years of progressive professional experience in medicine, further establish his eligibility for the EB-2 classification. Dr. Lopes proposes to advance a specialized healthcare endeavor focused on expanding access to **minimally invasive obesity and metabolic care, structured weight management, treatment of post-bariatric weight regain, and specialized physician education and training**. The endeavor will be implemented through **Advanced Endoscopic Weight Loss Institute LLC**, which will serve as the organizational mechanism for advancing this specialized model in the United States.

Dr. Lopes seeks a waiver of the labor certification requirement pursuant to *Matter of Dhanasar*, 26 I&N Dec. 884 (AAO 2016), as the evidence demonstrates that both his qualifications and his proposed endeavor satisfy each element of the three-prong framework governing National Interest Waiver petitions.

1. Substantial Merit and National Importance: Dr. Lopes's proposed endeavor addresses the substantial public-health burden associated with **obesity and related metabolic conditions** by expanding access to minimally invasive treatment options, structured and longitudinal weight management, and care for patients experiencing weight regain following bariatric surgery. The endeavor further supports physician education, specialized workforce development, employment creation, and economic activity. These objectives directly align with current federal priorities addressing obesity, chronic disease, prevention, expanded treatment options, and improved health outcomes, demonstrating substantial merit and national importance.

2. Well-Positioned to Advance the Proposed Endeavor: Dr. Lopes holds the foreign equivalent of a U.S. **Doctor of Medicine (M.D.)**, together with graduate-level study in General Surgery and Endoscopy, and possesses more than fifteen years of medical experience, including over ten years focused on advanced bariatric endoscopy. He has personally performed more than **2,000 bariatric endoscopy procedures**, coordinated endoscopy-service operations, trained physicians, participated in scientific activities, and successfully owned and managed **ABC Endoscopia Ltda.** His specialized credentials, continuing medical education, professional recognition, support from distinguished medical experts, demonstrated entrepreneurial success, documented financial capacity, and comprehensive Business Plan (Exhibit C.I.) collectively establish that he is exceptionally well-positioned to advance the proposed endeavor in the United States.

3. Balancing of Benefits to the United States: Dr. Lopes's proposed endeavor extends well beyond the interests of any single employer. Through **Advanced Endoscopic Weight Loss Institute LLC**, he will establish and lead the organizational mechanism necessary to advance a multidisciplinary model of minimally invasive obesity and metabolic care while supporting physician education, specialized workforce development, and expanded treatment access. Because the proposed endeavor is entrepreneurial in nature and designed to generate broader public-health and economic benefits, including employment creation and specialized healthcare access, the traditional labor certification process is impractical. Waiving this requirement will facilitate the implementation of an endeavor that directly addresses important healthcare needs and national priorities in the United States.

Considering these factors, Dr. Marcio Lamas Lopes fully satisfies the requirements for a National Interest Waiver. We respectfully request a thorough review of the accompanying Cover Letter and supporting documentation, which collectively establish his advanced qualifications, demonstrated record of success, and the substantial merit and national importance of his proposed endeavor. A favorable adjudication of this Form I-140 petition is warranted in recognition of Dr. Lopes's anticipated contributions to **expanding minimally invasive obesity and metabolic care, advancing specialized medical expertise, strengthening the healthcare workforce, and generating meaningful public-health and economic benefits in the United States.**

Thank you for your attention to this matter.

Sincerely,



Otavio Haverroth Silva
California Bar # 343486

September 02, 2026.

VIA USPS

USCIS
Attn: I-140
P.O. Box 660128
Dallas, TX 75266-0128

Ref: I-140 Immigrant Visa Self-Petition of Dr. Marcio Lamas - Request for National Interest Waiver under the EB-2 Classification

Our firm represents **Dr. Marcio Lamas Lopes** (hereinafter "Dr. Lopes") in his I-140 immigrant visa self-petition under the EB-2 category. We respectfully request his classification as a member of the professions holding an advanced degree, and he seeks a waiver of the job offer and labor certification requirements pursuant to a National Interest Waiver (NIW), as provided under section **203(b)(2)(B)(i)** of the Immigration and Nationality Act and interpreted by the USCIS in *Matter of Dhanasar*, 26 I&N Dec. 884 (AAO 2016).

Dr. Lopes is a physician specialized in **General Surgery and Digestive Endoscopy**, with more than fifteen years of clinical experience in Brazil and over ten years of focused practice in advanced bariatric endoscopy. He holds the foreign equivalent of a U.S. **Doctor of Medicine (M.D.)**, as established by the submitted academic credentials evaluation, as well as the equivalent of one year of graduate study in General Surgery and one year of graduate study in Endoscopy. Throughout his career, he has developed extensive expertise in diagnostic and therapeutic endoscopy, including advanced bariatric endoscopic procedures, and has served as Endoscopy Service Coordinator at Hospital Adventista de São Paulo. His experience includes intragastric balloon placement, Endoscopic Sleeve Gastroplasty, and the management of weight regain after bariatric surgery using endoscopic techniques, including Transoral Outlet Reduction and Argon Plasma Coagulation. Over the course of his career in Brazil, he has personally performed more than **thousand bariatric endoscopy procedures**.

Through his endeavor, Dr. Lopes will establish and manage a specialized outpatient model focused on the **minimally invasive treatment of obesity and related metabolic conditions**, integrating primary endoscopic interventions, revisional endoscopic procedures, structured weight management, and longitudinal clinical and metabolic follow-up. The mechanism for this endeavor will be **Advanced Endoscopic Weight Loss Institute LLC**, a specialized clinic to be established in **Orlando, Florida**. Dr. Lopes will serve as **General Manager & Managing Director**, establishing, organizing, and managing the Institute and designing its clinical programs and care protocols. He will not personally perform endoscopic procedures; all endoscopic procedures and physician-directed care will be provided by United States licensed physicians, with a contracted United States licensed Medical Director providing clinical governance and oversight of patient

San Diego, CA - PO Box 90487

care. Once Dr. Lopes' classification is established, according to the framework set forth in *Matter of Dhanasar*, we will demonstrate that:

- His proposed endeavor has substantial merit and national importance, particularly in expanding access to **minimally invasive and revisional weight-management care** for patients underserved by conventional surgical options, providing structured and longitudinal management of obesity and related metabolic conditions, and addressing a significant public health and economic burden in the United States – **Section 3.1;**
- He is well-positioned to advance this endeavor based on his more than fifteen years of clinical experience, over ten years of focused practice in advanced bariatric endoscopy, specialized training in General Surgery and Digestive Endoscopy, experience coordinating endoscopy services, expertise in primary and revisional bariatric endoscopic procedures, and his performance of more than **thousand bariatric endoscopy procedures** throughout his career in Brazil – **Section 3.2;**
- On balance, it is beneficial to the United States to waive the job offer and labor certification requirements, as this will enable Dr. Lopes to establish and manage a specialized outpatient model designed to expand access to minimally invasive and revisional weight-management care, support coordinated management of obesity-related metabolic conditions, create qualified clinical and administrative employment, and contribute to economic activity in the United States **– Section 3.3.**

The evidence presented with this petition will demonstrate, by a preponderance of the evidence, that the endeavor proposed by **Dr. Lopes** serves the national interest of the United States and satisfies all the requirements of the EB-2 National Interest Waiver standard.

1. THE EB-2 CLASSIFICATION

1.1 ADVANCED DEGREE

To qualify as a member of the professions holding an advanced degree under the EB-2 classification, the petitioner must demonstrate possession of an advanced degree or its foreign equivalent. Pursuant to **8 C.F.R. § 204.5(k)(2)**, an advanced degree is "any United States academic or professional degree or a foreign equivalent degree above that of baccalaureate." **Dr. Lopes fully satisfies this requirement through his foreign medical education, which has been evaluated as equivalent to a U.S. Doctor of Medicine (M.D.) degree.**

Dr. Lopes' academic credentials were submitted to an evaluation performed by Carnegie Evaluations LLC. The evaluation reviewed his *Diploma de Médico*, awarded by Universidade do Vale do Itajaí in July 2008, his *Especialidade de Cirurgia Geral*, completed at Hospital Ipiranga in January 2013, and his *Especialização em Endoscopia*, completed at Hospital Ipiranga in February 2015.

San Diego, CA - PO Box 90487

After evaluating these credentials, Carnegie Evaluations concluded that Dr. Lopes has attained **the equivalent of a Doctor of Medicine (M.D.) degree from an accredited institution of higher education in the United States**, together with **one year of graduate study in General Surgery and one year of graduate study in Endoscopy**. Accordingly, his foreign academic credential is equivalent to a U.S. professional degree above the baccalaureate level and independently satisfies the advanced-degree requirement for EB-2 classification (Exhibit B).

Academic Equivalency in the United States

DOCTOR OF MEDICINE (M.D)

ONE YEAR OF GRADUATE STUDY IN GENERAL SURGERY

ONE YEAR OF GRADUATE STUDY IN ENDOSCOPY

In addition to his qualifying academic credentials, Dr. Lopes has accumulated more than fifteen years of professional experience in medicine. He earned his medical degree in July 2008 and subsequently developed his career through clinical practice, specialized training in General Surgery and Digestive Endoscopy, and positions involving increasing specialization and responsibility. His professional background includes primary care, diagnostic and therapeutic endoscopy, management of emergency and elective gastrointestinal cases, advanced bariatric endoscopy, and coordination of endoscopy services. His experience further demonstrates the progressive development of specialized expertise following completion of his medical degree.

Attached are his resume and supporting academic documentation (Exhibits A and B), summarized below:

- **From February 2018 to the present – Endoscopy Service Coordinator / Endoscopist, Hospital Adventista de São Paulo:** Dr. Lopes coordinates endoscopy service operations and clinical workflow, performs diagnostic and therapeutic endoscopic procedures, contributes to patient-care optimization and procedural efficiency, and participates in case discussions and clinical decision-making.
- **From March 2015 to the present – Staff Endoscopist, Hospital 9 de Julho:** Dr. Lopes performs upper endoscopy and colonoscopy procedures, manages emergency and elective gastrointestinal cases, and performs therapeutic interventions including hemostasis and dilation.
- **From April 2010 to February 2011 – General Practitioner, O.S.S. Santa Marcelina:** Dr. Lopes provided primary medical care in a public-health setting and managed a high volume of patients in community-based care.
- **From July 2008 to March 2010 – General Practitioner, Associação Saúde da Família:** Dr. Lopes provided primary medical care in a public-health setting and managed a high volume of patients in community-based care.

Dr. Lopes' professional development was further strengthened through specialized postgraduate medical training. He completed his General Surgery residency at Hospital Ipiranga in January 2013

San Diego, CA - PO Box 90487

and his Digestive Endoscopy residency at Hospital Ipiranga in March 2015, after earning his Doctor of Medicine degree from Universidade do Vale do Itajaí in July 2008. His subsequent professional practice has concentrated increasingly on digestive and therapeutic endoscopy, including advanced bariatric endoscopic procedures. His curriculum further documents specialized training and scientific participation in gastrointestinal bleeding, vascular lesions, endoscopic bariatric procedures and complications, colorectal neoplasms, diagnostic and therapeutic endoscopic ultrasound, and intragastric balloon procedures.

Over the course of his professional career, Dr. Lopes has developed more than ten years of focused experience in advanced bariatric endoscopy. His experience includes intragastric balloon placement, Endoscopic Sleeve Gastroplasty, and management of weight regain after bariatric surgery through endoscopic techniques, including Transoral Outlet Reduction and Argon Plasma Coagulation. The Business Plan further documents that Dr. Lopes has personally performed more than **thousand bariatric endoscopy procedures** during his career in Brazil.

Accordingly, **Dr. Lopes independently qualifies as a member of the professions holding an advanced degree** because his foreign medical education has been evaluated as equivalent to a U.S. **Doctor of Medicine (M.D.)**, a professional degree above the baccalaureate level, pursuant to 8 C.F.R. § 204.5(k)(2) and 8 C.F.R. § 204.5(k)(3)(i)**.**

Moreover, and as additional evidence of his qualifications, Dr. Lopes has accumulated well over five years of progressive professional experience following completion of his medical degree. His career progressed from primary-care practice to specialized surgical and endoscopic training, followed by sustained practice as an endoscopist and ultimately responsibility for coordinating endoscopy-service operations and clinical workflow. Thus, his extensive post-degree professional experience provides additional support for his qualification as an advanced-degree professional.

Under 8 C.F.R. § 204.5(k)(3)(i)**,** the advanced-degree requirement may be demonstrated through:

- an official academic record showing possession of a United States advanced degree or a foreign equivalent degree; or
- an official academic record showing possession of a United States baccalaureate degree or a foreign equivalent degree, followed by at least five years of progressive post-baccalaureate experience in the specialty.

Dr. Lopes satisfies the first and independently sufficient basis through his foreign medical degree, which has been evaluated as equivalent to a U.S. Doctor of Medicine (M.D.). His extensive progressive professional experience following completion of that degree further reinforces the advanced level of his qualifications and the sustained development of his expertise in General Surgery, Digestive Endoscopy, and advanced bariatric endoscopy.

Therefore, the evidence establishes that **Dr. Lopes qualifies as a member of the professions holding an advanced degree and satisfies the threshold requirements for EB-2 classification under section 203(b)(2) of the Immigration and Nationality Act and 8 C.F.R. § 204.5(k).**

2. THE PROPOSED ENDEAVOR

Dr. Lopes proposes to expand access to **minimally invasive treatment for obesity and related metabolic conditions in the United States** through an integrated model combining primary bariatric endoscopic interventions, revisional endoscopic procedures for weight regain, structured weight management, and longitudinal clinical and metabolic follow-up. To operationalize this initiative, he intends to establish and lead **Advanced Endoscopic Weight Loss Institute LLC**, which will serve as the platform through which the proposed endeavor will be developed and implemented in Orlando, Florida**.**

His work will focus on expanding access to minimally invasive and nonsurgical weight-management options, addressing weight regain following prior bariatric surgery, supporting the coordinated management of obesity-related metabolic conditions, and promoting continuity of care through a structured multidisciplinary model. The Institute will organize these activities through its Integrated Weight Management Pathway (IWMP), a coordinated care model designed to connect primary endoscopic interventions, revisional procedures, structured weight-management support, and longitudinal metabolic follow-up within a single clinical pathway.

The proposed endeavor centers on a specialized outpatient model integrating bariatric endoscopy and metabolic medicine. The IWMP will operate through three coordinated tiers: primary endoscopic interventions, including intragastric balloon placement and Endoscopic Sleeve Gastroplasty (ESG); revisional endoscopic treatment for patients experiencing weight regain after prior bariatric surgery, including Transoral Outlet Reduction (TORe) and Argon Plasma Coagulation (APC); and longitudinal metabolic follow-up combined with structured weight-management support.

The core mission of Advanced Endoscopic Weight Loss Institute LLC is to provide a structured continuum of minimally invasive obesity and metabolic care for patients who may be underserved by conventional surgical treatment options. Through the integration of endoscopic interventions, revisional treatment, structured weight management, and ongoing metabolic follow-up, the Institute seeks to expand access to coordinated weight-management care while supporting sustained clinical outcomes and continuity of patient care.

This initiative represents a direct extension of Dr. Lopes' expertise in **General Surgery, Digestive Endoscopy, advanced bariatric endoscopy, and endoscopy-service coordination**. Over more than ten years, he has concentrated his practice in advanced bariatric endoscopy, including intragastric balloon placement, Endoscopic Sleeve Gastroplasty, and the management of weight regain after bariatric surgery through endoscopic techniques, including Transoral Outlet Reduction and Argon Plasma Coagulation. Throughout his career in Brazil, he has personally performed more than **thousand bariatric endoscopy procedures**. In addition, as Endoscopy Service Coordinator at Hospital Adventista de São Paulo, he developed direct experience organizing, coordinating, and directing endoscopy operations, including familiarity with the operational, staffing, and quality-management requirements of an endoscopy service.

In the United States, Dr. Lopes will serve as **General Manager & Managing Director** of Advanced Endoscopic Weight Loss Institute LLC. In this capacity, he will establish, organize, and

San Diego, CA - PO Box 90487

manage the Institute, design its clinical programs, define its operational and quality standards, coordinate its multidisciplinary model, and direct its overall operational execution. **Dr. Lopes will not personally perform endoscopic procedures.** All endoscopic procedures will be performed by United States licensed physicians engaged by the company, while a contracted United States licensed Medical Director will provide clinical governance and oversight of patient care.

Obesity represents a substantial public-health and economic challenge in the United States. The Business Plan identifies approximately **40 percent of U.S. adults—more than 100 million people—as living with obesity**, with obesity-related medical costs estimated at approximately **$173 billion annually**. At the same time, fewer than two percent of clinically eligible patients receive bariatric surgical treatment, leaving a substantial population underserved by existing surgical capacity. Dr. Lopes' proposed endeavor is designed to address this gap by expanding access to minimally invasive alternatives for patients who are not candidates for, prefer alternatives to, or have experienced weight regain following conventional bariatric surgery.

The company will operate through five core service lines:

1. Intragastric Balloon Program – The Institute will provide intragastric balloon placement as a primary, temporary endoscopic intervention for eligible patients, supporting initial weight reduction and behavioral adjustment without permanent anatomical alteration.

2. Endoscopic Sleeve Gastroplasty (ESG) – The Institute will offer ESG as a primary endoscopic procedure that reduces gastric volume through suturing techniques, providing a minimally invasive alternative to surgical sleeve procedures for appropriate candidates.

3. Endoscopic Revision for Weight Regain (TORe/APC) – The Institute will provide revisional endoscopic procedures, including **Transoral Outlet Reduction and Argon Plasma Coagulation**, to address weight regain in patients who have undergone prior bariatric surgery.

4. Structured Weight Management Program – The Institute will provide a structured weight-management program combining clinical supervision, nutritional guidance, and behavioral support designed to reinforce and sustain the results of endoscopic intervention.

5. Clinical and Metabolic Follow-up – The Institute will provide longitudinal clinical and metabolic follow-up to monitor patient progress and support the management of obesity-related metabolic conditions through coordinated, ongoing care.

In addition to its direct clinical-service model, the Institute plans to pursue **research, education, and training initiatives** designed to extend the impact of the endeavor beyond direct patient care. These initiatives include structured physician education and proctoring in bariatric endoscopy techniques; hands-on bariatric endoscopy workshops and continuing-education activities; development of standardized telemedicine protocols for longitudinal metabolic follow-up; creation of a training pipeline for clinical and operational personnel; and establishment of a multicenter outcomes registry to track procedural outcomes, safety, and long-term weight and metabolic results. These activities are intended to support the dissemination of best practices, development

San Diego, CA - PO Box 90487

of specialized clinical expertise, generation of outcomes data, and continuous quality improvement.

Further details regarding the company's operational strategy, market positioning, clinical model, research and training initiatives, and anticipated contributions to obesity and metabolic care in the United States can be found in the attached **Business Plan (Exhibit C.I)** and will also be thoroughly examined in the following sections discussing the substantial merit and national importance of the proposed endeavor.

The Connection Between Dr. Lopes' Advanced Degree Qualifications and His Proposed Endeavor

As described in the USCIS Policy Alert of January 15, 2025, a National Interest Waiver requires a direct relationship between the petitioner's qualifications and the proposed endeavor. Dr. Lopes' qualifications are closely aligned with the objectives and activities of his proposed endeavor.

Dr. Lopes has more than fifteen years of medical experience, including over ten years focused on **advanced bariatric endoscopy**, with expertise in primary and revisional endoscopic weight-loss interventions, including intragastric balloon placement, Endoscopic Sleeve Gastroplasty, Transoral Outlet Reduction, and Argon Plasma Coagulation. He has personally performed more than **thousand bariatric endoscopy procedures**, providing substantial practical experience in the same specialized field underlying his proposed endeavor.

His background also includes service as **Endoscopy Service Coordinator at Hospital Adventista de São Paulo/Brazil**, where he gained direct experience organizing and coordinating endoscopy operations, staffing, clinical workflows, and quality management. This combination of specialized clinical knowledge and operational leadership directly supports his intended role as **General Manager & Managing Director of Advanced Endoscopic Weight Loss Institute LLC**, the mechanism through which the proposed endeavor will be implemented.

The proposed endeavor will operate through the **Integrated Weight Management Pathway (IWMP)**, integrating primary and revisional endoscopic interventions, structured weight management, and longitudinal metabolic follow-up. Dr. Lopes will **not personally perform endoscopic procedures in the United States**; rather, procedures will be performed by U.S.-licensed physicians, with clinical governance provided by a U.S.-licensed Medical Director. Dr. Lopes will apply his specialized expertise to **program design, operational standards, quality management, multidisciplinary coordination, and overall implementation**.

Consequently, the record establishes a direct relationship between **Dr. Lopes' specialized medical education, extensive bariatric-endoscopy experience, endoscopy-service leadership, and the activities contemplated by his proposed endeavor**. His background provides the technical and operational foundation necessary to design and manage a specialized model of minimally invasive obesity and metabolic care in the United States.

San Diego, CA - PO Box 90487

3. THE NATIONAL INTEREST WAIVER

Framework Under *Matter of Dhanasar*

Those who apply for a National Interest Waiver request that the Labor Certification requirement be waived because it would be in the best interest of the United States to allow the beneficiary to pursue their proposed endeavor without the restrictions of a permanent job offer. While the law does not strictly define the types of occupations that qualify for a National Interest Waiver, such waivers are generally granted to individuals who possess an advanced degree or exceptional ability in their field and whose work in the United States would provide tangible national benefits.

According to section 203(b)(2)(B) of the Immigration and Nationality Act, the Secretary of Homeland Security may waive the job offer requirement, and consequently the labor certification requirement, when it is determined to be in the national interest of the United States. See 8 C.F.R. § 204.5(k)(4)(i).

In Matter of Dhanasar, 26 I&N Dec. 884 (AAO 2016), the USCIS Administrative Appeals Office (AAO) established a revised analytical framework for determining eligibility for a discretionary waiver of the job offer and labor certification requirements for individuals seeking classification in the EB-2 category:

> **(i) The first prong** assesses whether the proposed endeavor has substantial merit and national importance.
>
> **(ii) The second prong** assesses whether the individual is well-positioned to advance the proposed endeavor.
>
> **(iii) The third prong** considers whether, on balance, it would be beneficial to the United States to waive the job offer and labor certification requirements.

Dr. Lopes' proposed endeavor is directly aligned with his extensive background in **General Surgery, Digestive Endoscopy, advanced bariatric endoscopy, and endoscopy-service coordination**. He proposes to expand access to minimally invasive treatment for obesity and related metabolic conditions in the United States through an integrated model combining primary bariatric endoscopic interventions, revisional endoscopic procedures for weight regain, structured weight management, and longitudinal clinical and metabolic follow-up. **Advanced Endoscopic Weight Loss Institute LLC will serve as the mechanism through which Dr. Lopes will operationalize and advance this endeavor.**

The following sections demonstrate how Dr. Lopes' proposed endeavor satisfies each of the three prongs established under the *Dhanasar* framework and therefore supports his eligibility for a National Interest Waiver.

3.1 <u>First PRONG:</u>

The Proposed Endeavor has Substantial Merit and National Importance

Matter of Dhanasar moved away from the purely geographical consideration of "national in scope", to a broader evaluation of the endeavor's "national importance" no longer considering whether the

San Diego, CA - PO Box 90487

endeavor would benefit the entire geographic region of the country (national scope), but instead determines whether the endeavor seeks to solve a problem that affects the entire country, even if the immediate impact is focused on one local geographic area ("national importance"), as follows:

> *"Certain locally or regionally focused endeavors, however, may be of national importance despite being difficult to quantify with respect to geographic scope."*

Therefore, the first prong, substantial merit and national importance, focuses on the specific endeavor that the foreign national proposes to undertake. The endeavor's merit may be demonstrated in a range of areas such as business, entrepreneurialism, science, technology, culture, health, or education. To establish that an endeavor has substantial merit, the petitioner should provide a detailed description of the endeavor and why it is meritorious. In determining whether the proposed endeavor has national importance, USCIS considers its potential impact.

Likewise, the *Dhanasar* decision allowed for the consideration of a much broader and more diverse pool of petitioners in a wide range of areas such as business, entrepreneurship, science, technology, culture, health, or education.

3.1.1 BUSINESS PLAN

A detailed description of the proposed endeavor and why it is of substantial merit:

Dr. Lopes proposes to expand access to **minimally invasive treatment for obesity and related metabolic conditions in the United States** through an integrated model combining primary bariatric endoscopic interventions, revisional endoscopic procedures for weight regain, structured weight management, and longitudinal clinical and metabolic follow-up. **Advanced Endoscopic Weight Loss Institute LLC**, to be established and led by Dr. Lopes in Orlando, Florida, will serve as the mechanism through which this proposed endeavor will be operationalized and advanced.

As detailed in the Business Plan, the proposed endeavor is structured around the **Integrated Weight Management Pathway (IWMP)**, a coordinated care model that connects primary endoscopic interventions, revisional treatment for patients experiencing weight regain following prior bariatric surgery, structured weight-management support, and ongoing metabolic follow-up. This model is designed to provide patients with a continuum of nonsurgical and revisional weight-management care within a coordinated outpatient setting.

The proposed endeavor addresses a significant public-health need in the United States. Approximately **40 percent of U.S. adults, more than 100 million individuals—live with obesity**, while severe obesity affects approximately nine percent of adults. Obesity-related medical costs are estimated at approximately **$173 billion annually**, demonstrating the substantial burden that the condition places on the national healthcare system.

Despite the prevalence of obesity, conventional bariatric surgery reaches only a small portion of the clinically eligible population. Approximately **280,000 metabolic and bariatric surgical procedures** are performed annually in the United States, while fewer than **two percent of clinically eligible patients** receive surgical treatment. This leaves a substantial population

underserved by existing surgical capacity. Dr. Lopes' proposed endeavor is designed to help address this treatment gap by expanding access to minimally invasive endoscopic alternatives for patients who are not candidates for, prefer alternatives to, or have experienced weight regain following traditional bariatric surgery.

The endeavor also addresses the broader metabolic consequences associated with obesity. Approximately **38 million Americans live with diabetes**, while approximately **48 percent of U.S. adults have hypertension**, conditions that frequently accompany obesity and benefit from sustained and coordinated metabolic care. By combining procedural intervention with structured weight management and longitudinal clinical and metabolic follow-up, the proposed endeavor seeks to support continuity of care rather than limiting treatment to a single intervention.

Taken together, these elements demonstrate the substantial merit of the proposed endeavor in the areas of health and healthcare. By expanding access to minimally invasive obesity treatment, addressing weight regain after bariatric surgery, and integrating procedural care with structured weight management and longitudinal metabolic follow-up, Dr. Lopes' initiative responds to a widespread and costly health condition affecting a substantial portion of the U.S. population.


The proposed endeavor will be implemented through five principal service areas:

- **Intragastric Balloon Program;**
- **Endoscopic Sleeve Gastroplasty (ESG);**
- **Endoscopic Revision for Weight Regain (TORe/APC);**
- **Structured Weight Management Program; and**
- **Clinical and Metabolic Follow-up.**


In addition to these core services, the proposed endeavor includes **research, education, and training initiatives** intended to extend its impact beyond direct patient care. The Business Plan provides for structured physician education and proctoring in bariatric endoscopy techniques, hands-on bariatric endoscopy workshops and continuing-education activities, standardized telemedicine protocols for longitudinal metabolic follow-up, a structured training pipeline for clinical and operational personnel, and the establishment of a **multicenter outcomes registry** to track procedural outcomes, safety, and long-term weight and metabolic results. These initiatives are designed to support the dissemination of best practices, development of specialized clinical expertise, generation of outcomes data, and continuous quality improvement.

Additionally, the Business Plan projects significant economic growth for the mechanism through which the endeavor will be implemented. **Advanced Endoscopic Weight Loss Institute LLC is projected to increase its revenue from $804,000 in Year 1 to approximately $3.629 million by Year 5**, while expanding from four salaried employees in Year 1 to fifteen salaried employees by Year 5. The company will also engage contracted United States licensed physicians and a contracted Medical Director and procure medical supplies, endoscopy-support equipment, and professional services from U.S. vendors and suppliers.

San Diego, CA - PO Box 90487



The Business Plan further projects approximately **$562,993 in federal, state, and payroll tax contributions over five years**, consisting of approximately $337,006 in federal and state taxes and $225,987 in payroll taxes.



The U.S. weight-management sector provides a substantial and growing environment for the implementation of Dr. Lopes' proposed endeavor. As documented in the Business Plan, the **U.S. weight management market is valued in the tens of billions of dollars and is projected to grow at a mid-single-digit compound annual rate through the end of the decade**. Within this market, minimally invasive and endoscopic obesity procedures represent a growing segment as patients and healthcare providers increasingly seek alternatives to traditional surgery.

San Diego, CA - PO Box 90487

The Business Plan further identifies U.S. weight-loss services as a multibillion-dollar industry characterized by sustained demand. At the same time, the combination of rising obesity prevalence and the low percentage of clinically eligible patients who receive bariatric surgery demonstrates a continuing need for additional weight-management options, including minimally invasive endoscopic approaches.

Dr. Lopes' proposed endeavor directly responds to these healthcare and industry conditions by expanding access to minimally invasive bariatric endoscopic treatment, providing revisional options for patients experiencing weight regain after previous bariatric surgery, and integrating these interventions with structured weight-management and metabolic follow-up.

Furthermore, the endeavor is designed to extend beyond the treatment of individual patients through **physician education, clinical workshops, telemedicine protocols, workforce training, and outcomes-data collection**. These activities complement the direct healthcare services contemplated by the endeavor and create mechanisms for disseminating specialized knowledge, supporting clinical quality, and developing expertise in bariatric endoscopy and minimally invasive metabolic medicine.

Accordingly, Dr. Lopes' proposed endeavor possesses **substantial merit** because it addresses the treatment of obesity and related metabolic conditions through minimally invasive healthcare services, expands alternatives to conventional bariatric surgery, supports continuity of weight-management and metabolic care, promotes specialized professional education and training, and contributes to the development and dissemination of clinical knowledge and outcomes data in the field of bariatric endoscopy.

3.1.2 NATIONAL OR EVEN GLOBAL IMPLICATIONS WITHIN A PARTICULAR FIELD:

The national importance of Dr. Lopes' proposed endeavor is demonstrated by its potential to contribute to the broader U.S. response to **obesity and related metabolic conditions by expanding access to minimally invasive treatment, addressing an existing treatment gap, supporting longitudinal metabolic care, and advancing specialized knowledge and clinical practices in bariatric endoscopy and minimally invasive metabolic medicine**. As detailed in the Business Plan (Exhibit C.I.), the proposed endeavor addresses a widespread public-health challenge affecting more than 100 million U.S. adults and imposing substantial costs on the national healthcare system.

The importance of the endeavor extends beyond the patients who will receive services through Advanced Endoscopic Weight Loss Institute LLC. Despite approximately 280,000 metabolic and bariatric surgical procedures being performed annually in the United States, fewer than **two percent of clinically eligible patients receive surgical treatment**, leaving a substantial population underserved by existing surgical capacity. Dr. Lopes proposes to contribute to addressing this gap by expanding access to minimally invasive endoscopic alternatives for patients who are not candidates for, prefer alternatives to, or have experienced weight regain following conventional bariatric surgery.

San Diego, CA - PO Box 90487

The proposed endeavor further incorporates a coordinated model that connects primary bariatric endoscopic interventions, revisional procedures for weight regain, structured weight management, and longitudinal clinical and metabolic follow-up. This approach is particularly relevant because obesity is closely associated with major metabolic conditions, including diabetes and hypertension, and therefore requires sustained and coordinated management extending beyond a single procedural intervention.

Importantly, Dr. Lopes' proposed endeavor is designed to generate impact **beyond the direct delivery of patient care**. The Business Plan provides for physician education and proctoring, bariatric endoscopy workshops and continuing-education activities, standardized telemedicine protocols, development of a specialized training pipeline, and establishment of a **multicenter outcomes registry**. These initiatives are specifically intended to disseminate best practices, develop specialized clinical expertise, generate outcomes data, and support continuous quality improvement in bariatric endoscopy and minimally invasive metabolic medicine.

The following points further demonstrate the national importance of Dr. Lopes' proposed endeavor:

- **Expanding Access to Minimally Invasive Obesity Treatment:** Dr. Lopes' proposed endeavor will expand access to bariatric endoscopic alternatives for patients who may not be candidates for, may prefer alternatives to, or may not have achieved sustained results through conventional bariatric surgery.

  National Importance: With more than 100 million U.S. adults affected by obesity and fewer than two percent of clinically eligible patients receiving bariatric surgical treatment, expanding the availability of minimally invasive alternatives addresses a treatment gap affecting a substantial population across the United States.

- **Addressing Weight Regain Following Bariatric Surgery:** The proposed endeavor specifically incorporates revisional endoscopic interventions, including Transoral Outlet Reduction (TORe) and Argon Plasma Coagulation (APC), for patients experiencing weight regain after prior bariatric surgery.

  National Importance: By addressing patients who have experienced weight regain after prior surgical treatment, the endeavor extends the continuum of obesity care beyond initial intervention and provides an additional minimally invasive treatment pathway for an existing patient population.

- **Supporting Longitudinal Management of Obesity and Related Metabolic Conditions:** Through its Integrated Weight Management Pathway, the endeavor combines procedural intervention with structured weight management and ongoing clinical and metabolic follow-up rather than treating obesity solely through an isolated procedure.

  National Importance: This coordinated approach is relevant to the broader management of a condition closely associated with diabetes, hypertension, and other metabolic complications and supports sustained patient management and continuity of care.

San Diego, CA - PO Box 90487

- **Advancing Physician Education and Specialized Workforce Development:** Dr. Lopes' proposed endeavor includes structured physician education and proctoring in intragastric balloon placement, ESG, TORe, and APC; hands-on workshops and continuing-education activities; and a training pipeline designed to develop clinical and operational talent.

  National Importance: These activities extend the impact of the endeavor beyond Dr. Lopes and the Institute by disseminating specialized bariatric-endoscopy knowledge and supporting the development of professionals capable of implementing minimally invasive weight-management procedures and protocols.

- **Developing Standardized Telemedicine Protocols:** The proposed endeavor includes the development of standardized telemedicine protocols for longitudinal metabolic follow-up and remote patient management.

  National Importance: These protocols are specifically intended to expand access to coordinated follow-up care across locations, creating a mechanism through which elements of the proposed model may reach patients beyond the Institute's immediate geographic area.

- **Generating and Disseminating Clinical Outcomes Data:** The proposed endeavor includes the establishment of a **multicenter outcomes registry** to track procedural outcomes, safety, and long-term weight and metabolic results.

  National Importance: The generation of multicenter outcomes data has implications beyond the treatment of individual patients by contributing to clinical evidence, informing continuous quality improvement, and supporting the broader development of bariatric endoscopy and minimally invasive metabolic medicine.

Taken together, these factors demonstrate that **Dr. Lopes' proposed endeavor extends beyond the establishment and operation of a single clinical practice**. Its broader implications arise from addressing a widespread national health burden and treatment gap while incorporating mechanisms for physician education, specialized workforce development, standardized telemedicine protocols, dissemination of best practices, and multicenter outcomes-data collection. These activities create the potential for the knowledge, protocols, clinical evidence, and specialized expertise developed through the endeavor to benefit patients and healthcare professionals beyond those directly served by Advanced Endoscopic Weight Loss Institute LLC.

Accordingly, Dr. Lopes' proposed endeavor possesses **national importance within the fields of obesity treatment, bariatric endoscopy, and minimally invasive metabolic medicine**, and therefore satisfies the national-importance component of the first prong of *Matter of Dhanasar*.

3.1.3 ENDEAVOR'S IMPACT

The proposed endeavor has significant potential to employ U.S. workers:

San Diego, CA - PO Box 90487

Dr. Lopes' proposed endeavor has significant potential to contribute to job creation and workforce development in the United States. Through **Advanced Endoscopic Weight Loss Institute LLC**, which will serve as the mechanism for implementing the endeavor, the operation is projected to grow from **four salaried employees in Year 1 to fifteen salaried employees by Year 5**, across clinical, nutritional, administrative, and outreach functions.

In addition to these direct salaried positions, the Institute will engage **contracted United States licensed physicians and a contracted United States licensed Medical Director**, generating additional professional opportunities for U.S. healthcare providers. The operation will also procure medical supplies, endoscopy-support equipment, and professional services from United States vendors and suppliers, thereby supporting additional economic activity beyond its direct workforce.

The proposed endeavor further supports **workforce development** through research, education, and training initiatives specifically contemplated in the Business Plan. These initiatives include structured physician education and proctoring in bariatric endoscopy techniques, hands-on bariatric endoscopy workshops and continuing-education events, and a structured training pipeline designed to develop clinical and operational talent and support the onboarding and credentialing of contracted physicians and clinical staff.

Through these activities, the proposed endeavor will contribute not only to direct employment but also to the development of specialized expertise in **bariatric endoscopy and minimally invasive metabolic medicine**. By combining the creation of clinical, nutritional, administrative, and outreach positions with opportunities for contracted U.S. healthcare professionals and specialized workforce training, Dr. Lopes' proposed endeavor has the potential to strengthen the healthcare workforce supporting minimally invasive obesity and metabolic care in the United States

Five-Year Personnel Plan					
	Year 1	Year 2	Year 3	Year 4	Year 5
General Manager & Managing Director - Mr. Marcio Lamas Lopes	1	1	1	1	1
Medical Assistant	1	1	2	2	3
Patient Care Coordinator	1	1	1	2	2
Administrative Assistant	1	1	1	1	1
Bariatric Program Coordinator	0	1	1	1	1
Registered Nurse	0	1	1	2	2
Nutritionist / Dietitian	0	0	1	1	2
Billing and Insurance Specialist	0	0	1	1	1
Marketing and Outreach Coordinator	0	0	0	1	1
Front Desk / Scheduling Clerk	0	0	0	0	1
Total People	4	6	9	12	15

San Diego, CA - PO Box 90487

In evaluating the broader economic impact of job creation, it is important to consider not only the direct positions generated through the implementation of the proposed endeavor, but also the indirect and induced employment effects supported across the broader economy. One established approach to evaluating this extended economic impact is using **employment multipliers, such as those published by the Economic Policy Institute (EPI)**.

As detailed in the Business Plan, each industry maintains backward linkages to the sectors that supply the materials and services necessary for its operations, as well as broader economic linkages generated through employee spending. Consequently, direct employment in an industry can support additional indirect and induced employment throughout the economy.

Employment multipliers per 100 direct jobs, by major private-sector industry group

Major industry group	Direct jobs	Supplier jobs*	Induced jobs**	Total indirect jobs
Educational services	100	63.8	129.9	193.7
Health care and social assistance	100	69.4	136.2	205.6
Arts, entertainment, and recreation	100	123.3	255.2	378.5
Accommodation and food services	100	53.8	107.4	161.2
Other services (except public administration)	100	70.7	139.6	210.3

Applying the national employment multiplier identified in the Business Plan for the **health care services industry**, the **15 direct salaried positions** projected to be created through Advanced Endoscopic Weight Loss Institute LLC by the end of Year 5 are estimated to support approximately **27 jobs in total**, including direct, indirect, and induced employment.

This broader employment effect is consistent with the operational structure described in the Business Plan. In addition to its salaried workforce, the Institute will engage contracted **United States licensed physicians and a contracted Medical Director** and will procure medical supplies, endoscopy-support equipment, and professional services from United States vendors and suppliers, generating economic activity beyond the company's direct payroll.

Please note that *Dhanasar* expressly states that one can prove national importance through the "significant potential to employ U.S. workers". That is NOT the same as "**potential to employ a significant number of U.S. workers**" as the "significance" is in the "potential" or "probability", not in the "number of jobs" the endeavor may create. This is a matter of semantics.

San Diego, CA - PO Box 90487

The *Matter of Dhanasar* framework recognizes that initiatives advancing public health and workforce development may qualify as nationally important. **Dr. Lopes' proposed endeavor aligns with these principles by expanding access to minimally invasive obesity and metabolic care, supporting specialized workforce development, and improving health outcomes in the United States.**

In Dr. Lopes' case, the employment impact forms only one component of the broader national significance of his proposed endeavor. His initiative is designed to expand access to minimally invasive treatment for obesity and related metabolic conditions, address weight regain following bariatric surgery, provide structured and longitudinal weight-management care, and advance specialized expertise in bariatric endoscopy and minimally invasive metabolic medicine.

The implementation of the proposed endeavor through Advanced Endoscopic Weight Loss Institute LLC is expected to generate direct employment across **clinical, nutritional, administrative, and outreach functions**, growing from four salaried employees in Year 1 to fifteen by Year 5. The Institute will additionally engage contracted U.S.-licensed physicians and a U.S.-licensed Medical Director, further supporting professional opportunities within the U.S. healthcare sector.


Furthermore, the proposed endeavor will contribute to workforce development through physician education, specialized training, and clinical-development initiatives, while generating measurable economic contributions. The Business Plan projects approximately **$562,993 in federal, state, and payroll taxes over five years**, in addition to the employment and economic activity supported through the Institute's operations.

In conclusion, the implementation of Dr. Lopes' proposed endeavor is projected to support **15 direct salaried positions and approximately 27 additional indirect and induced jobs**, while generating tax revenue and economic activity through contracted U.S. healthcare professionals and U.S. vendors. These economic and workforce benefits further complement the broader public-health implications of the proposed endeavor and reinforce its national importance.

Furthermore, Dr. Lopes' proposed endeavor is strategically connected to the **Orlando, Florida metropolitan area**, which includes economically distressed and historically underserved communities. As detailed in the Business Plan, **ZIP Code 32805**, which includes the historically underserved Parramore neighborhood, is classified as **distressed under the Distressed Communities Index (DCI), with a Distress Score of 90.9**.

The Business Plan further documents significant socioeconomic challenges within this community, including a median household income of approximately **$38,885** and a poverty rate of approximately **16.3 percent**. Educational attainment also remains below national levels, with approximately **16.1 percent of adults holding a bachelor's degree or higher, compared with approximately 35.7 percent nationally**. These indicators reflect structural economic challenges affecting income, employment, and economic opportunity within communities in the Orlando metropolitan area.

San Diego, CA - PO Box 90487



By establishing operations in the Orlando area and creating skilled employment, **Advanced Endoscopic Weight Loss Institute LLC**, as the mechanism through which Dr. Lopes will implement his proposed endeavor, will contribute to local economic activity and opportunity. The Institute's projected hiring, engagement of U.S.-licensed healthcare professionals, procurement of goods and professional services from U.S. vendors, and tax contributions will generate economic activity while the proposed endeavor expands access to minimally invasive obesity and metabolic care within the broader Orlando and Florida population.

The proposed endeavor is particularly relevant in this context because its impact combines **healthcare access with workforce and economic development**. Through the mechanism established to implement the endeavor, the operation is projected to grow from four salaried employees in Year 1 to fifteen by Year 5, while also engaging contracted U.S.-licensed physicians and a U.S.-licensed Medical Director and supporting additional indirect and induced employment.

Consistent with *Matter of Dhanasar*, the economic impact of an endeavor may be particularly relevant when considered in the context of an economically depressed area. Here, Dr. Lopes' proposed endeavor will operate within a metropolitan region that includes communities experiencing substantial economic distress while generating skilled employment, economic activity, and expanded access to specialized obesity and metabolic care.

Accordingly, the proposed endeavor's combination of **healthcare access, direct and indirect employment, workforce development, local economic activity, and tax contributions** provides an additional dimension to its broader impact. These benefits complement the national public-health implications discussed above and further reinforce the national importance of Dr. Lopes' proposed endeavor.

The endeavor impacts on a matter that a government entity has described as having national importance, or it's a subject of national importance:

The proposed endeavor directly impacts matters that the Federal Government has identified as priorities of national importance, particularly the growing prevalence of **obesity, diabetes, and other chronic diseases**, the need to expand treatment options, improve disease prevention, strengthen long-term health outcomes, and develop effective approaches to the chronic-disease burden affecting the American population.

The current Administration has placed the reduction of chronic disease at the center of its federal health agenda. These priorities are particularly relevant to Dr. Lopes' proposed endeavor, which seeks to expand access to minimally invasive treatment for obesity and related metabolic conditions through an integrated model combining bariatric endoscopic interventions, revisional treatment for weight regain, structured weight management, and longitudinal clinical and metabolic follow-up.

On **February 13, 2025**, President Donald J. Trump issued the Executive Order **"Establishing the President's Make America Healthy Again Commission."**[1] The Order expressly identifies the prevalence of chronic disease as a major national health and economic concern, noting that six in ten Americans have at least one chronic disease and that ninety percent of the Nation's $4.5 trillion in annual healthcare expenditures is attributable to individuals with chronic and mental health conditions. The Order further declares it the policy of the Federal Government to **"aggressively combat"** critical health challenges facing Americans, expressly including **obesity, diabetes, and other chronic diseases.**

Significantly, the Executive Order directs federal health agencies to focus on reversing chronic disease and specifically calls for the **availability of expanded treatment options** and greater flexibility to support beneficial lifestyle changes and disease prevention. These federal objectives closely correspond to Dr. Lopes' proposed endeavor, which seeks to expand the availability of minimally invasive obesity-treatment alternatives while integrating procedural intervention with structured weight management and ongoing metabolic care.

The Administration subsequently reinforced these priorities through the broader **Make America Healthy Again (MAHA)** agenda[2]. The White House has characterized chronic disease as a problem affecting not only individual health but also the national economy and future workforce, while identifying obesity and metabolic health among the conditions requiring coordinated federal attention. The MAHA framework emphasizes prevention, scientific research, healthier lifestyles, and approaches designed to address the underlying drivers of chronic disease rather than merely managing its consequences.

The Administration has also specifically recognized **obesity as a major driver of chronic disease**. In addressing obesity-treatment policy, the White House has stated that approximately 40 percent of American adults are affected by obesity and identified the condition as increasing the risk of **type 2 diabetes, hypertension, heart disease, stroke, and certain cancers**. The Administration

[1] https://www.whitehouse.gov/presidential-actions/2025/02/establishing-the-presidents-make-america-healthy-again-commission/
[2] https://www.whitehouse.gov/priorities/maha/

San Diego, CA - PO Box 90487

has further emphasized the importance of expanding treatment availability while coupling treatment with lifestyle changes designed to preserve and improve long-term health outcomes[3].

These priorities bear a particularly close relationship to Dr. Lopes' proposed endeavor. Rather than providing an isolated procedural intervention, his proposed model integrates minimally invasive obesity treatment with structured weight management and longitudinal clinical and metabolic follow-up. It is therefore designed to address both access to treatment and the sustained management of obesity and its associated metabolic conditions.

Federal policy has also emphasized the importance of developing healthcare professionals capable of addressing chronic disease through prevention and improved clinical education. In **August 2025**, the U.S. Department of Health and Human Services, together with the Department of Education, announced an initiative urging leading medical-education organizations to implement comprehensive nutrition education and training. HHS expressly described the initiative as part of the Trump Administration's MAHA agenda and its emphasis on **prevention and reducing chronic disease**[4]. This priority complements the educational component of Dr. Lopes' endeavor, which includes physician education, proctoring, bariatric endoscopy workshops, continuing-education activities, and development of specialized clinical expertise.

Moreover, HHS continues to identify nutrition and metabolic health as central components of its current chronic-disease strategy, emphasizing disease prevention, nutrition education, and training of health professionals to incorporate these principles into patient care[5]. These objectives are consistent with the proposed endeavor's integration of endoscopic treatment, nutritional guidance, behavioral support, and longitudinal metabolic management.

Taken together, these federal initiatives demonstrate that **obesity, metabolic health, chronic-disease reduction, expanded treatment options, prevention, and healthcare-professional development are matters currently receiving explicit attention from the Federal Government**. Dr. Lopes' proposed endeavor directly intersects with these priorities by expanding minimally invasive obesity-treatment options, addressing weight regain following bariatric surgery, integrating treatment with structured weight management and metabolic follow-up, and supporting specialized professional education in bariatric endoscopy and minimally invasive metabolic medicine.

Accordingly, the proposed endeavor is closely aligned with matters that the current Administration has expressly identified as important to the health and economic well-being of the United States, further supporting the national importance of Dr. Lopes' work under the first prong of *Matter of Dhanasar*

3.2 <u>Second PRONG:</u>

[3] https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
[4] https://www.hhs.gov/press-room/hhs-education-nutrition-medical-training-reforms.html
[5] https://www.hhs.gov/nutrition/index.html

San Diego, CA - PO Box 90487

The Self-Petitioner is Well-Positioned to Advance the Proposed Endeavor in the United States

Under the second prong of *Matter of Dhanasar*, the Petitioner must demonstrate that he is well-positioned to advance his proposed endeavor. This does not require proof of guaranteed success, but rather credible evidence of the individual's education, skills, knowledge, record of success in related or similar efforts, and progress toward advancing the proposed endeavor.

Dr. Lopes clearly satisfies this requirement. He is a physician specialized in **General Surgery and Digestive Endoscopy**, with more than fifteen years of clinical experience in Brazil and over ten years of focused practice in advanced bariatric endoscopy. His qualifications include the foreign equivalent of a U.S. **Doctor of Medicine (M.D.)**, graduate-level study in General Surgery and Endoscopy, extensive experience in minimally invasive bariatric procedures, coordination of endoscopy services, scientific participation, professional recognition, and a demonstrated record of successfully managing a healthcare enterprise. These qualifications directly correspond to the knowledge and managerial capabilities required to advance his proposed endeavor in the United States.

3.2.1 EDUCATION, SKILLS, KNOWLEDGE, AND RECORD OF SUCCESS:

Dr. Lopes is exceptionally well-positioned to advance the proposed endeavor due to his advanced medical education, specialized clinical training, extensive bariatric-endoscopy experience, leadership in endoscopy-service operations, entrepreneurial background, and demonstrated professional success. His academic credentials have been evaluated as equivalent to a U.S. **Doctor of Medicine (M.D.)**, together with **one year of graduate study in General Surgery and one year of graduate study in Endoscopy**.

His professional standing is further demonstrated by his Brazilian medical registration with the **Conselho Regional de Medicina do Estado de São Paulo (CRM-SP No. 133420)** and his specialized professional credentials in General Surgery and Digestive Endoscopy. The record also establishes that Dr. Lopes is a **Titular Member of the Brazilian Society of Digestive Endoscopy (SOBED)**, the national professional association that congregates physicians practicing Endoscopy and Digestive Endoscopy in Brazil. The SOBED statute identifies the organization as a national body representing physicians practicing Endoscopy and Digestive Endoscopy and promoting education, research, and practice in the specialty.

Throughout his professional career, Dr. Lopes has continuously expanded his technical expertise through specialized training and scientific activities directly connected to digestive endoscopy, bariatric endoscopy, minimally invasive procedures, and the clinical areas underlying his proposed endeavor. Among the numerous certificates and continuing-education records submitted with this petition, the documentary record includes his participation in the **"Obesity: Interface of Bariatric Endoscopy with Complications – Vertical Gastrostomy"** multidisciplinary continuing-education course in 2016; the **"Digestive Hemorrhage – Upper"** multidisciplinary course in 2016; and the **"Colorectal Cancer Screening Project"** multidisciplinary course in 2017. He also completed theoretical and practical training in **Endosutures and Laparoscopy** through Johnson

& Johnson Medical Innovation Institute. These activities demonstrate a sustained pattern of specialized professional development, including training directly related to bariatric endoscopy and advanced minimally invasive techniques.

His continued scientific engagement is further evidenced by his participation as an author of **"Aortoenteric Fistula to Duodenum: Case Report,"** accepted for ePoster presentation at **ENDO 2020 – 2nd World Congress of GI Endoscopy and 24th Pan American Congress of Digestive Endoscopy**. In 2025, he was also an author of **"Dilatação com balão CRE e injeção de triancinolona em estenose de reto e plasma de argônio em fístula reto-vaginal: um relato de caso em lactente de 8 meses,"** presented at the **XXIV Semana Brasileira do Aparelho Digestivo**. These scientific activities demonstrate continued engagement with therapeutic endoscopy and the dissemination of clinical knowledge beyond routine patient care.

Over more than ten years, Dr. Lopes has concentrated his practice in **advanced bariatric endoscopy**. His experience includes intragastric balloon placement, Endoscopic Sleeve Gastroplasty, and the management of weight regain following bariatric surgery through techniques including Transoral Outlet Reduction and Argon Plasma Coagulation. The documentary record establishes that he has personally performed more than **thousand bariatric endoscopy procedures**, treating more than thousand patients through minimally invasive techniques.

Dr. Lopes also possesses substantial leadership and operational experience directly relevant to his proposed endeavor. As **Endoscopy Service Coordinator at Hospital Adventista de São Paulo**, he developed direct experience organizing, coordinating, and directing endoscopy operations, including familiarity with staffing, clinical workflow, quality management, and the operational requirements of a specialized endoscopy service. This experience closely corresponds to his intended role in the United States, where he will establish, organize, and manage the mechanism through which the proposed endeavor will be implemented and oversee program design, operational standards, multidisciplinary coordination, and quality management.

His record of success is further demonstrated by his entrepreneurial experience as owner and manager of **ABC Endoscopia Ltda.**, an active Brazilian healthcare company established in 2015 whose principal registered activity is diagnostic services through endoscopy and analogous examinations. Its registered activities also include professional training, outpatient medical services, nutrition, psychology, and physiotherapy. In 2025 alone, ABC Endoscopia reported approximately **R$2.55 million in gross operating revenue** and approximately **R$1.64 million in net profit**, providing objective evidence of Dr. Lopes' experience in operating a financially successful healthcare enterprise.

Dr. Lopes' professional record is further supported by objective evidence of **substantial market recognition of his expertise**. Accounting documentation submitted with this petition demonstrates that his professional income reached **R$503,152.99 in 2021, R$404,744.00 in 2022, R$623,768.00 in 2023, R$776,944.00 in 2024, and R$749,636.56 in 2025**, reflecting sustained high earnings over a five-year period rather than an isolated year of elevated compensation.

This compensation substantially exceeds available market benchmarks for comparable medical specialists in Brazil. According to **Portal Salário**, based on CAGED employment data, a **Médico**

Endoscopista in Brazil currently earns an average of approximately **R$8,207.07 per month**, or approximately **R$98,485 annually**, with an estimated salary ceiling of approximately R$15,055.67 per month. By comparison, Dr. Lopes' documented 2025 professional income of **R$749,636.56** was approximately **7.6 times the reported annual market average**. Because the benchmark reflects formal CLT employment while Dr. Lopes' income derives from his professional and entrepreneurial activities, the comparison is not presented as an identical compensation structure; rather, it provides additional objective evidence of the **strong market recognition and economic value of his specialized expertise**.

Dr. Lopes' professional expertise has also received **external media recognition**. He was featured in a television report produced through a partnership between **CCTV and BandNews** concerning the Brazilian Portuguese edition of the *Manual de Prevenção e Tratamento contra o COVID-19*. The report explained that Brazilian physicians and healthcare professionals were recruited to assist with the technical adaptation of the manual, which was developed from Chinese clinical experience and made available to support Brazilian healthcare professionals during the COVID-19 pandemic. Dr. Lopes appeared in the report as an invited physician and explained that he had been **specifically invited to assist with the technical review and correction of the manual**, including medical terminology and clinical guidance intended for healthcare professionals.

This media coverage corroborates the documentary evidence identifying Dr. Lopes as a **Technical Reviewer**, surgeon, and endoscopist for the Brazilian Portuguese edition of the manual. His selection to contribute technical medical expertise to a publication intended for healthcare professionals during a major public-health emergency, together with the independent television coverage of that contribution, provides additional evidence of his professional standing and recognition beyond his routine clinical practice.

Taken together, these achievements establish a record encompassing **specialized clinical expertise, directly relevant continuing medical education, high procedural volume, leadership of endoscopy operations, scientific participation, professional recognition, technical contribution to medical educational material, and successful healthcare-business management**.

Looking ahead, this combination of specialized medical knowledge, operational leadership, entrepreneurial experience, and demonstrated success directly supports Dr. Lopes' ability to advance his proposed endeavor. Although he will not personally perform endoscopic procedures in the United States, his extensive experience in bariatric endoscopy and endoscopy-service coordination provides the technical and operational foundation necessary to design programs, establish quality standards, coordinate multidisciplinary care, and manage the implementation of a specialized minimally invasive obesity and metabolic-care model.

In summary, Dr. Lopes' **advanced academic qualifications, specialized training, more than fifteen years of medical experience, over ten years of focused bariatric-endoscopy practice, performance of more than thousand bariatric endoscopy procedures, leadership experience, scientific participation, professional recognition, sustained entrepreneurial success, and documented market recognition** establish that he is exceptionally well-positioned to advance the proposed endeavor in the United States.

San Diego, CA - PO Box 90487

3.2.2 SUPPORT LETTERS FROM INDUSTRY EXPERTS AND RECOGNITIONS

Dr. Lopes' ability to advance the proposed endeavor is further supported by recommendation letters from distinguished physicians, academic leaders, hospital directors, and recognized specialists in digestive and bariatric endoscopy who have directly observed his professional development, clinical expertise, leadership, teaching activities, and contributions to the field. Collectively, these letters provide independent and firsthand assessments of the specialized knowledge and professional capabilities that directly support the proposed endeavor.

Dr. Denis Pajecki, Professor of Digestive System Surgery at the **University of São Paulo (USP)** and Supervisor of the Bariatric and Metabolic Surgery Unit at Hospital das Clínicas, has worked with Dr. Lopes since 2013, when Dr. Lopes was in his first year of medical residency in endoscopy. Over more than a decade of direct professional interaction, Dr. Pajecki observed Dr. Lopes performing diagnostic and therapeutic endoscopic procedures, including the management of complex postoperative complications following bariatric surgery. He describes Dr. Lopes as a primary reference within the department whose approaches and procedural protocols are frequently followed by other specialists. Dr. Pajecki further states that Dr. Lopes contributed to processes that led the endoscopy service to obtain quality certifications and recognition as a training center for endoscopists by SOBED. Significantly, he connects this expertise directly to the treatment of obesity, emphasizing the importance of advanced endoscopic procedures such as gastric balloon placement, endoscopic gastroplasty, and bariatric revisions and concluding that Dr. Lopes possesses the technical maturity and experience necessary to contribute to the evolution of obesity-treatment standards in the United States.

Dr. Manoel dos Passos Galvão Neto, Director of Bariatric Research at **Orlando Health** and Scientific Director at IRCAD India, provides particularly relevant independent recognition because of his extensive international experience in bariatric surgery and endoscopic innovation. Having observed Dr. Lopes since his residency at Hospital 9 de Julho, Dr. Galvão describes his progression into an expert in minimally invasive endoscopic procedures, particularly bariatric endoscopy. He specifically recalls Dr. Lopes' role in the 2016 and 2017 educational courses, where Dr. Galvão served as mentor and advisor and Dr. Lopes lectured on bariatric-surgery complications and endoscopic therapies before audiences averaging approximately 100 physicians. He further confirms Dr. Lopes' continuing role in training new generations of endoscopists and teaching techniques involving intragastric balloons, argon plasma, and endoscopic gastroplasty. Based on his experience training hundreds of endoscopists in Brazil, Latin America, Europe, India, and the United States, Dr. Galvão considers Dr. Lopes among the most capable bariatric endoscopists he has encountered at a comparable stage of professional development and concludes that his expertise would meaningfully contribute to patient care and physician training in the United States.

Dr. José Afonso Sallet, Medical Director of Instituto de Medicina Sallet and a physician with extensive experience in digestive and bariatric surgery, provides additional firsthand evidence specifically concerning Dr. Lopes' bariatric-endoscopy expertise. Dr. Sallet began working with Dr. Lopes in 2017 after seeking an endoscopist capable of performing intragastric balloon placement and removal for patients in his obesity-treatment program. Over approximately five

years, Dr. Lopes performed an average of ten intragastric-balloon procedures per month for Dr. Sallet's patients, totaling **more than 600 successful interventions**. According to Dr. Sallet, Dr. Lopes' standardized methodology became a reference point within his clinical workflow and contributed to safer preparation of patients with morbid obesity for surgical treatment. He further recognizes Dr. Lopes' experience with intragastric balloons, argon plasma coagulation, and endoscopic gastroplasty and concludes that his expertise can increase the availability of safe and effective nonsurgical weight-loss solutions.

Dr. José Celso Ardengh, Chief of the Gastrointestinal Endoscopy Service and President of the Research Ethics Committee at **Hospital Moriah**, has followed Dr. Lopes' professional trajectory since 2013. He highlights Dr. Lopes' expertise in high-complexity endoscopic interventions and his ability to manage difficult clinical cases with precision and judgment. Dr. Ardengh also confirms Dr. Lopes' contributions to the implementation of clinical protocols and optimization of workflow standards, his scientific work involving advanced endoscopic topics, and his leadership in coordinating medical teams and training residents and fellows. Based on his experience as a senior academic and head of service, Dr. Ardengh expressly places Dr. Lopes' technical and institutional impact above the average of his peers and considers his combination of procedural mastery and scientific rigor directly relevant to the standards of the U.S. healthcare system.

Dr. Douglas Charpinel, Medical Director of **Hospital Adventista de São Paulo**, provides institutional confirmation of Dr. Lopes' leadership and operational capabilities. Dr. Charpinel states that Dr. Lopes has served as an Endoscopist Physician and **Coordinator of the Endoscopy Service since 2018**, with direct responsibility for supervising and optimizing the operational, clinical, and quality aspects of a high-volume endoscopy unit. He credits Dr. Lopes' leadership with improvements in procedural efficiency, patient-safety standards, multidisciplinary integration, and the overall quality of gastrointestinal care. He further recognizes Dr. Lopes as possessing a combination of clinical excellence, leadership capacity, and professional integrity that distinguishes him among physicians with whom he has worked.

Dr. Eduardo Grecco, Professor in the Department of General and Digestive Surgery and Coordinator of the Endoscopy Service and Medical Residency Program at **ABC Medical School University Center (FMABC)**, provides an assessment from the perspective of a physician familiar with Dr. Lopes through scientific meetings, professional interaction between medical teams, and direct observation of endoscopic procedures. Dr. Grecco recognizes Dr. Lopes as a specialist in digestive endoscopy and advanced procedures whose professional reputation extends beyond his immediate workplace. He emphasizes Dr. Lopes' experience with gastrointestinal bleeding, colorectal diseases, and bariatric endoscopic interventions, as well as his work within a medical-residency environment, concluding that the combination of clinical practice and physician training gives his activities an impact extending beyond routine patient care and contributes to medical education and professional qualification.

Dr. Artur Adolfo Parada, Medical Director of Artur Parada Medicina Diagnóstica, former founder and coordinator of the Gastrointestinal Endoscopy Sector at Hospital 9 de Julho, and former President of the Brazilian Society of Digestive Endoscopy, has directly observed Dr. Lopes since the beginning of his specialized endoscopy training in 2013. Dr. Parada describes Dr. Lopes' consistent performance in advanced endoscopic procedures and emphasizes that, after completing


his training, Dr. Lopes remained as an attending physician and became involved in training new residents. He also recalls Dr. Lopes' participation as a speaker and discussant in educational courses and describes a study conducted by Dr. Lopes concerning sedation safety in endoscopic examinations, which demonstrated both patient-safety awareness and attention to system-level quality. Dr. Parada concludes that Dr. Lopes possesses the technical discipline and clinical mindset necessary to contribute to safe, minimally invasive care and the training of healthcare professionals.

Although these experts have observed Dr. Lopes in different professional contexts, including **bariatric surgery, digestive endoscopy, hospital administration, academic medicine, medical residency, clinical research, and physician education, their assessments are remarkably consistent**. They independently identify his advanced technical expertise, clinical judgment, ability to manage complex cases, leadership of endoscopy services, implementation of clinical protocols, commitment to patient safety, and ability to train other physicians. Particularly significant to the proposed endeavor, multiple experts specifically confirm his experience with **bariatric endoscopy, intragastric balloons, endoscopic gastroplasty, argon plasma techniques, management of bariatric complications, multidisciplinary obesity care, and physician training**.

Taken together, these letters provide compelling independent evidence that Dr. Lopes possesses not merely the academic qualifications necessary to pursue his proposed endeavor, but a **demonstrated record of successfully applying the same specialized knowledge, leadership capabilities, clinical protocols, training methods, and operational expertise on which the endeavor is based**. His recognition by senior specialists and institutional leaders, including professionals who have directly observed his work for more than a decade and an internationally experienced bariatric-endoscopy specialist currently serving as Director of Bariatric Research at Orlando Health, further establishes that Dr. Lopes is exceptionally well-positioned to advance his proposed minimally invasive obesity and metabolic-care endeavor in the United States.

3.2.3 PLAN FOR FUTURE ACTIVITIES AND FINANCIAL FEASIBILITY:

Dr. Lopes will serve as **General Manager and Managing Director of Advanced Endoscopic Weight Loss Institute LLC**, the organizational mechanism through which his proposed endeavor will be implemented in the United States. His specialized expertise in bariatric and digestive endoscopy, extensive experience in endoscopy-service coordination, multidisciplinary leadership, and entrepreneurial background are fundamental to the successful implementation of the proposed endeavor. As described in the Business Plan, the Institute will progressively expand its capacity to support minimally invasive obesity and metabolic care through a multidisciplinary structure integrating clinical coordination, nutritional support, patient care, administrative operations, and outreach activities under Dr. Lopes' strategic and operational leadership.




The Business Plan demonstrates that the proposed endeavor is supported by a structured operational strategy and a sustainable financial model. Dr. Lopes' prior experience owning and managing **ABC Endoscopia Ltda.**, together with his leadership of endoscopy-service operations, further demonstrates his ability to manage healthcare operations, personnel, and financial resources.

The proposed endeavor requires approximately **US$200,000 in startup capital**, including **US$35,000 in startup expenses and US$165,000 in startup assets**, covering equipment, build-out, furniture, medical supplies, credentialing, insurance, technology, and other implementation costs.

Startup	
Requirements	
Startup Expenses	
Legal, Incorporation and Permits	$7,000
Website, Branding and Launch Marketing	$7,000
Initial Medical Supplies and Disposables	$8,000
Credentialing and Insurance Setup	$5,000
IT / EMR Software Setup	$8,000
Total Startup Expenses	$35,000
Startup Assets	
Cash Required	$93,000
Long-term Assets (Equipment, Build-out, Furniture)	$72,000
Total Assets	$165,000
Total Requirements	**$200,000**

San Diego, CA - PO Box 90487

Dr. Lopes possesses substantial documented financial resources to support these requirements. His **BTG Pactual** investment account reports a net balance of **R$1,024,733.53**, equivalent to approximately **US$201,291.26**[6] based on the official currency conversion submitted with the petition. In addition, his **Avenue Securities** account documents approximately **US$41,670.85** in investments. Together, these accounts demonstrate approximately **US$242,962.11 in documented financial assets**, exceeding the startup requirements projected in the Business Plan


Conversion result

Conversion from: Real/BRL (790)
Amount to convert: 1,024,733.53

To: United States Dollar/USD (220)
Conversion result: 201.291,2568

Exchange rate used: 07/08/2026
Rate:
1 Real/BRL (790) = 0.1964328 US Dollar/USD (220)
1 US Dollar/USD (220) = 5.0908 Real/BRL (790)

Accordingly, the Business Plan, Dr. Lopes' established entrepreneurial and healthcare-management experience, and his documented financial resources provide credible evidence that the proposed endeavor is operationally viable and financially feasible, further confirming that he is well-positioned to advance it in the United States.

3.3 Third PRONG:

On Balance, It Would be Beneficial to the United States to Waive the Requirement of a Job Offer and Labor Certification

Congress established the National Interest Waiver to address the inherent limitations of the labor certification process. When a foreign national proposes an endeavor that extends beyond the scope of traditional employment and provides substantial benefits to the United States, permanent residence should not depend solely upon the availability of a specific job offer or the labor certification process.

Dr. Lopes clearly exemplifies the principle underlying the third criterion of *Matter of Dhanasar*. As a physician holding the foreign equivalent of a U.S. **Doctor of Medicine (M.D.)**, with extensive expertise in digestive and bariatric endoscopy, minimally invasive obesity treatment, endoscopy-service coordination, physician training, and healthcare management, his proposed endeavor extends far beyond the duties of a conventional clinical position. Through **Advanced Endoscopic Weight Loss Institute LLC**, as the mechanism for implementing his endeavor, he seeks to advance a specialized model of minimally invasive obesity and metabolic care focused on expanding access to less-invasive treatment options, supporting multidisciplinary care, promoting physician education and specialized workforce development, and improving outcomes for patients affected by obesity and related metabolic conditions.

[6] https://www.bcb.gov.br/conversao

Requiring Dr. Lopes to undergo the labor certification process, despite the theoretical availability of other qualified healthcare professionals in the labor market, would overlook the unique value of his proposed endeavor. The purpose of this petition is not to fill an existing position within an established medical practice, but rather to establish and expand a healthcare initiative that integrates minimally invasive obesity and metabolic care, multidisciplinary patient support, physician education and training, and specialized program development. These activities are entrepreneurial in nature and are not dependent upon a single employer or traditional employment relationship.

According to the third criterion established under the *Dhanasar* framework, adjudicators must conduct a balancing test comparing the national interest in requiring a job offer and labor certification against the foreign national's ability to advance important U.S. priorities. Relevant considerations include:

- Whether it would be impractical for the foreign national to obtain a traditional job offer or for an employer to pursue labor certification given the nature of the proposed endeavor;
- Whether the United States would continue to benefit from the foreign national's contributions even if other qualified workers are theoretically available; and
- Whether the national interest in the foreign national's contributions is sufficiently urgent or substantial to justify waiving the labor certification requirement.

The *Matter of Dhanasar* decision makes clear that these factors are not rigid requirements, but rather guiding considerations in determining whether waiving the job offer and labor certification requirements would benefit the United States.

The evidence presented in this petition demonstrates that waiving the labor certification requirement is clearly in the national interest. Dr. Lopes' proposed endeavor will expand access to **minimally invasive obesity and metabolic care**, support multidisciplinary treatment, promote physician education and specialized workforce development, create employment opportunities, stimulate economic activity within economically distressed communities, and contribute to addressing the substantial public-health burden associated with obesity and related metabolic conditions. These benefits would likely be delayed or substantially limited if the proposed endeavor were conditioned upon the traditional PERM labor certification process or restricted to a conventional employment relationship.

Therefore, granting a National Interest Waiver through the favorable exercise of discretion is fully justified.

3.3.1 IMPRACTICABILITY OF A LABOR CERTIFICATION:

Given the entrepreneurial and independent nature of the proposed endeavor, in which Dr. Lopes will serve as **General Manager and Managing Director of Advanced Endoscopic Weight Loss Institute LLC**, the traditional labor certification process is impractical. The PERM system was designed to protect U.S. workers from displacement by foreign labor; however, Dr. Lopes is not seeking to fill a preexisting employment position. Instead, his proposed endeavor is intended to expand access to minimally invasive obesity and metabolic care, support multidisciplinary

San Diego, CA - PO Box 90487

treatment, promote physician education and specialized workforce development, and create new employment opportunities while contributing to improved public health in the United States.

- **Nature of the Proposed Endeavor:** As an independent healthcare entrepreneur and physician with extensive expertise in bariatric and digestive endoscopy, Dr. Lopes is establishing and leading an initiative focused on minimally invasive obesity and metabolic care, multidisciplinary patient support, physician education, and specialized program development. The proposed endeavor is fundamentally different from a traditional employer-employee relationship because it depends directly on Dr. Lopes' specialized medical knowledge, extensive bariatric-endoscopy experience, operational leadership, and demonstrated experience managing endoscopy services and healthcare operations. Rather than competing with U.S. workers, the proposed endeavor is structured to expand healthcare services, create employment opportunities, and strengthen the specialized healthcare workforce.
- **Job Creation and Economic Impact:** The proposed endeavor is structured to generate both direct and indirect employment as operations expand. According to the Business Plan, **Advanced Endoscopic Weight Loss Institute LLC** anticipates creating **15 direct salaried positions by Year 5**, including clinical, patient-care, administrative, and operational personnel. In addition, the proposed endeavor is expected to stimulate indirect economic activity through collaboration with U.S. healthcare professionals, medical suppliers, laboratories, technology providers, and other vendors and service providers supporting the delivery of specialized obesity and metabolic care, thereby contributing to broader economic activity and workforce participation within the healthcare sector.
- **Self-Sustainability and Broader Contribution:** Through the proposed endeavor, Dr. Lopes will not only establish an operationally and financially sustainable healthcare initiative, but also contribute meaningfully to the United States by expanding access to minimally invasive obesity and metabolic care, supporting multidisciplinary treatment, promoting physician education and specialized workforce development, and addressing the substantial public-health burden associated with obesity and related metabolic conditions. By implementing this specialized healthcare model while creating new employment opportunities and expanding access to less-invasive treatment options, the proposed endeavor advances important public-health objectives. These contributions render the traditional labor certification process impractical, particularly given the entrepreneurial nature of the proposed endeavor.

Dr. Lopes has presented substantial evidence of his intention and ability to establish and operate **Advanced Endoscopic Weight Loss Institute LLC as the mechanism through which the proposed endeavor will be implemented**, demonstrating that the endeavor will create employment opportunities, expand access to minimally invasive obesity and metabolic care, stimulate economic activity, support specialized workforce development, and contribute to improved public-health outcomes. These factors make the labor certification requirement incompatible with the structure and objectives of the proposed endeavor, strongly reinforcing his eligibility for a National Interest Waiver.

San Diego, CA - PO Box 90487

3.3.2 THE U.S. WOULD STILL BENEFIT FROM THE FOREIGN NATIONAL'S CONTRIBUTION EVEN IF QUALIFIED U.S. WORKERS ARE AVAILABLE:

Given Dr. Lopes' extensive experience in digestive and bariatric endoscopy, minimally invasive obesity treatment, endoscopy-service coordination, physician training, and healthcare management, he is uniquely positioned to advance the proposed endeavor in the United States. While qualified healthcare professionals exist within the American labor market, Dr. Lopes' specialized medical education, extensive clinical background, entrepreneurial experience, and leadership in endoscopy-service operations provide distinct and substantial benefits to the country.

- **Exceptional Qualifications and Experience:** Dr. Lopes possesses more than fifteen years of medical experience, including over ten years focused on advanced bariatric endoscopy. His background combines specialized expertise in digestive and bariatric endoscopy with substantial experience in minimally invasive obesity treatment, including intragastric balloon placement, Endoscopic Sleeve Gastroplasty, Transoral Outlet Reduction, and Argon Plasma Coagulation. Having personally performed more than **thousand bariatric endoscopy procedures**, while also coordinating endoscopy services and managing healthcare operations, Dr. Lopes brings a combination of specialized clinical knowledge, operational leadership, and entrepreneurial experience directly relevant to the proposed endeavor.
- **Recognition and Proven Record of Success:** Throughout his professional career, Dr. Lopes has demonstrated a consistent record of success through high-volume specialized clinical practice, leadership of endoscopy-service operations, physician education, scientific participation, and healthcare entrepreneurship. His professional standing is further supported by his membership in **SOBED**, scientific presentations at national and international medical events, technical contribution to medical educational material, independent recognition from experienced physicians and specialists, and the successful operation of **ABC Endoscopia Ltda.**
- **Specialized Expertise and Demonstrated Healthcare Impact:** Dr. Lopes' documented experience and proposed endeavor demonstrate his ability to expand access to minimally invasive approaches for obesity and related metabolic conditions, support multidisciplinary care, develop specialized clinical programs, and promote physician education and training. His extensive experience in bariatric endoscopy and management of weight regain following bariatric surgery provides the professional foundation necessary to advance a specialized obesity and metabolic-care model while supporting improved access to less-invasive treatment options.
- **Additional Contributions:** Although the United States has qualified physicians and healthcare professionals, Dr. Lopes offers a distinctive combination of specialized bariatric-endoscopy expertise, extensive procedural experience, endoscopy-service leadership, physician training, healthcare management, and entrepreneurial initiative. His ability to integrate these capabilities into a multidisciplinary model of minimally invasive obesity and metabolic care enables him to advance an endeavor that extends beyond traditional clinical practice and produces broader public-health, workforce, and economic benefits.

San Diego, CA - PO Box 90487

In summary, Dr. Lopes' specialized medical education, extensive bariatric-endoscopy expertise, healthcare leadership, entrepreneurial experience, physician-training activities, and demonstrated record of success distinguish his contributions from those associated with a traditional clinical position. Through the proposed endeavor, his contributions will **expand access to minimally invasive obesity and metabolic care, support multidisciplinary treatment, promote specialized workforce development and physician education, create employment opportunities, and contribute to addressing the substantial public-health burden associated with obesity and related metabolic conditions**, reinforcing the conclusion that the United States would continue to benefit from his contributions even where qualified U.S. workers are theoretically available.

3.3.3 WHETHER THE NATIONAL INTEREST IN THE FOREIGN NATIONAL'S CONTRIBUTIONS IS URGENT ENOUGH TO JUSTIFY BYPASSING THE LABOR CERTIFICATION PROCESS:

The national interest in Dr. Lopes' contributions is evident and clearly justifies waiving the labor certification process. His specialized expertise in digestive and bariatric endoscopy, minimally invasive obesity treatment, endoscopy-service coordination, physician training, and healthcare management, combined with his demonstrated ability to establish and manage successful healthcare operations, underscores the immediate and strategic benefits that his proposed endeavor will bring to the United States.

Current Healthcare Needs: Communities throughout the United States continue to face significant challenges associated with the high prevalence of obesity and related metabolic conditions, the need for expanded treatment options, weight regain following bariatric surgery, and access to effective and less-invasive obesity care. As detailed in the Business Plan, the proposed endeavor specifically addresses these challenges by expanding access to minimally invasive obesity and metabolic care, supporting structured and longitudinal weight management, addressing post-bariatric weight regain, and promoting specialized physician education and training. Dr. Lopes possesses more than ten years of focused experience in advanced bariatric endoscopy and has personally performed more than **thousand bariatric endoscopy procedures**, providing specialized clinical and operational expertise directly relevant to these healthcare needs.

Immediate Public Health and Economic Impact: The timely implementation of the proposed endeavor will generate direct and measurable benefits, including expanded access to minimally invasive obesity and metabolic care, multidisciplinary patient support, creation of employment opportunities, specialized workforce development, and increased economic activity. Requiring labor certification would unnecessarily delay the establishment of a specialized healthcare initiative designed to expand treatment options for obesity and related metabolic conditions while contributing to current public-health needs.

Industry Support and Documented Evidence: The evidence presented with this petition, including the Business Plan, academic credentials evaluation, curriculum vitae, professional certifications, scientific activities, financial documentation, and support letters from experienced physicians and industry experts, demonstrates both the relevance of Dr. Lopes' proposed endeavor

San Diego, CA - PO Box 90487

and his ability to advance it. His documented history of performing more than **thousand bariatric endoscopy procedures**, coordinating endoscopy-service operations, training physicians, participating in scientific activities, and successfully operating **ABC Endoscopia Ltda.** demonstrates his ability to implement the proposed endeavor and generate meaningful healthcare and economic benefits.

Strategic Advantage for the United States: Allowing Dr. Lopes to advance the proposed endeavor without delay provides tangible public-health, economic, and workforce-development benefits to the United States. His proposed endeavor integrates minimally invasive obesity and metabolic care, structured weight management, multidisciplinary patient support, physician education and training, and specialized program development into a comprehensive model designed to expand treatment options and improve access to obesity care. The proposed endeavor will also support direct and indirect job creation, generate economic activity, and contribute to addressing obesity and related chronic conditions that have been identified as important national healthcare priorities.

In summary, the national interest in Dr. Lopes' contributions is clear and immediate. His unique combination of specialized medical education, extensive bariatric-endoscopy expertise, healthcare-management experience, entrepreneurial leadership, physician-training activities, and demonstrated record of success fully justifies waiving the labor certification requirement. His direct involvement will **expand access to minimally invasive obesity and metabolic care, support specialized workforce development, create employment opportunities, and generate lasting public-health and economic benefits for the United States.**

4. FINAL CONSIDERATIONS

From all topics discussed above and the attached evidence, it is "more likely than not" that:

1. **The petitioner, Dr. Marcio Lamas Lopes, qualifies for EB-2 classification as a member of the professions holding an advanced degree.** The evidence establishes that he possesses the foreign equivalent of a U.S. **Doctor of Medicine (M.D.)**, as confirmed by the submitted academic credentials evaluation, together with **one year of graduate study in General Surgery and one year of graduate study in Endoscopy**. His advanced academic background, specialized medical training, and more than fifteen years of professional experience fully satisfy the statutory and regulatory requirements for EB-2 classification.
2. **The petitioner's endeavor has substantial merit and national importance.** Consistent with *Matter of Dhanasar*, Dr. Lopes' proposed endeavor seeks to expand access to **minimally invasive obesity and metabolic care**, provide structured and longitudinal weight-management support, address weight regain following bariatric surgery, promote physician education and specialized workforce development, create employment opportunities, and contribute to improved public-health outcomes in the United States. His endeavor further generates economic benefits through direct and indirect employment, tax contributions, and economic activity, including within a metropolitan region containing economically distressed and underserved communities.

San Diego, CA - PO Box 90487

3. **The self-petitioner is well-positioned to advance the endeavor.** Dr. Lopes possesses more than fifteen years of medical experience, including over ten years focused on advanced bariatric endoscopy and the performance of more than **thousand bariatric endoscopy procedures**. He further demonstrates a strong record of success through his specialized expertise in digestive and bariatric endoscopy, leadership and coordination of endoscopy-service operations, physician education and training, scientific participation, professional recognition, successful ownership and management of **ABC Endoscopia Ltda.**, substantial documented financial resources, and independent support from experienced physicians and recognized specialists whose letters confirm his expertise and ability to advance the proposed endeavor.
4. **On balance, it would be beneficial to the United States to waive the requirement of a job offer and labor certification.** The labor certification process is impractical for an entrepreneurial healthcare initiative such as the one proposed by Dr. Lopes, whose objective is not to fill a conventional employment position, but rather to establish and advance a specialized model of minimally invasive obesity and metabolic care that expands treatment options, supports multidisciplinary care, promotes physician education and specialized workforce development, creates employment opportunities, and generates meaningful public-health and economic benefits. His proposed endeavor directly addresses the substantial burden associated with obesity and related metabolic conditions and fully justifies a waiver of the labor certification requirement.

Through this petition, it is respectfully submitted that **Dr. Marcio Lamas Lopes** merits favorable consideration for a National Interest Waiver of the job offer and labor certification requirements pursuant to Section 203(b)(2)(B)(i) of the Immigration and Nationality Act. Dr. Lopes' specialized medical education, extensive bariatric-endoscopy expertise, healthcare leadership, entrepreneurial experience, physician-training activities, and demonstrated record of success uniquely qualify him to successfully advance the proposed endeavor in the United States. His work directly supports important **public-health, healthcare-access, workforce-development, and economic priorities**, reinforcing the importance of allowing him to apply his specialized knowledge and experience for the benefit of the United States.

We respectfully request favorable consideration of this Form I-140 immigrant petition, classifying **Dr. Marcio Lamas Lopes** as a member of the professions holding an advanced degree under the employment-based second preference category, together with a waiver of the job offer and labor certification requirements, as his proposed endeavor will substantially benefit the national interest of the United States.

Should you require any further information or documentation, please do not hesitate to contact my office. Thank you in advance for your kind assistance with this matter.

Sincerely,

Otavio Haverroth Silva
California Bar # 343486

San Diego, CA - PO Box 90487

Exhibit list

Exhibits:	Pages:
Exhibit A	
Resume	1-3
Exhibit B - Eligibility Criteria: Advanced Degree	
Physician Diploma from University of Vale do Itajai – UNIVALI in Brazil, and transcripts and corresponding translation	4-16
Academic Evaluation	17-42
Exhibit B - Eligibility Criteria: Work Records	
Declaration of employers	43-60
Company records	61-110
Accountant Letter	111-115
Exhibit C.I - First Prong - Substantial Merit and National Importance	
Business Plan for Advanced Endoscopic Weight Loss Institute	116-163
Research and Government Initiatives Supporting the Business	164-185
Exhibit C.II - Second Prong - Well Positioned to Advance the Proposed Endeavor	
All the documents of Exhibit B	186
All the courses and certificates	187-242
Specialization Course in Endoscopy from Hospital Ipiranga in Brazil	243-247
General Surgery specialty course from Hospital Ipiranga in Brazil	248-252

Endoscopy Specialist from AMB in Brazil	253-257
License – Certificate and CRM Card	258-263
Technical Reviewer – COVID-19 Prevention and Treatment Manual	264-284
The company's own balance sheet	285-316
Income Tax	317-417
SOBED Membership Certificate	418-420
SOBED Declaration and Bylaws	421-442
BANDNEWS Interview	443-451

Exhibit C.II - Second Prong - Letters of Support and Resume

Dr. Jose Celso Ardengh	452-460
Dr. Denis Pajecki	461-467
Dr. Jose Afonso Sallet	468-474
Dr. Artur Adolfo Parada	475-480
Dr. Manoel dos Passos Galvão Neto	481-488
Professor Eduardo Grecco	489-493
Dr. Douglas Charpinel	494-502

Exhibit C.II - Second Prong - Financial Feasibility

Investment Account Statements	503-543
Currency Conversion	544-545

Exhibit D - Personal Documents

Birth Certificate and Corresponding Translation	546-550
Passport’s Biometrics Page	551-552
US Visa	553
Marriage Certificate and Corresponding Translation	554-556

Derivative’s Birth Certificate and Corresponding Translation	557-565
Derivative’s Passport Biometrics	566-570
US Visa	571-573

Exhibit A

MARCIO LAMAS LOPES
E-mail: malamaslopes@gmail.com
Telefone: +55 11 98409-6670

PROFESSIONAL SUMMARY

Physician specialized in General Surgery and Digestive Endoscopy with over 10 years of clinical experience in Brazil. Currently serving as an endoscopist and coordinator of endoscopy services in a private hospital in São Paulo. Experienced in diagnostic and therapeutic endoscopic procedures, including management of gastrointestinal bleeding, colorectal diseases, and endoscopic bariatric interventions. Demonstrated leadership in clinical settings and active participation in medical conferences and scientific activities.

PROFESSIONAL EXPERIENCE

Endoscopy Service Coordinator / Endoscopist
Hospital Adventista de São Paulo | São Paulo, SP, Brazil
02/2018 – Present

- Coordinate endoscopy service operations and clinical workflow
- Perform diagnostic and therapeutic endoscopic procedures
- Contribute to patient care optimization and procedural efficiency
- Participate in case discussions and clinical decision-making

Staff Endoscopist
Hospital 9 de Julho | São Paulo, SP, Brazil
03/2015 – Present

- Perform upper endoscopy and colonoscopy procedures
- Manage emergency and elective gastrointestinal cases
- Experience in therapeutic interventions including hemostasis and dilation

General Practitioner
Associação Saúde da Família | São Paulo, SP, Brazil
07/2008 – 03/2010

O.S.S. Santa Marcelina | São Paulo, SP, Brazil
04/2010 – 02/2011

- Provided primary care in a public health setting

- Managed a high volume of patients in community-based care

EDUCATION

Residency in Digestive Endoscopy
Hospital Ipiranga UGA-II
São Paulo, SP, Brazil
Completed: 02/2015

Residency in General Surgery
Hospital Ipiranga UGA-II
São Paulo, SP, Brazil
Completed: 01/2013

Doctor of Medicine (MD)
Universidade do Vale do Itajaí (UNIVALI)
Itajaí, SC, Brazil
Completed: 07/2008

COURSES / SEMINARS

- Endobariatric Course – IRCAD / Boston Scientific – 10/2024
- Cardiopulmonary Resuscitation Training – Hospital 9 de Julho – 2015, 2017, 2019, 2021
- Brazilian Week of Digestive Diseases (SBAD) – 2014, 2015, 2017
  Participation in national congresses focused on digestive diseases and endoscopy
  - Presentation: Critical analysis of sedation using Midazolam, Fentanyl, and Propofol in upper GI endoscopy in non-hospital settings – 11/2014
- Digestive Diseases Meetings (DAD) – 2016, 2017
  Delivered lectures, presented clinical cases, and participated in panel discussions and case-based learning sessions, including:
  - Gastrointestinal bleeding – 02/2016
  - Vascular lesions (Dieulafoy and related conditions) – 04/2016
  - Endoscopic bariatric procedures and complications – 06/2016
  - Colorectal neoplasms 09/2016
- Course in Diagnostic and Therapeutic Endoscopic Ultrasound (CEDIT) – 11/2014
  Hands-on and theoretical training in advanced endoscopic techniques
- Intragastric Balloon Workshop – 04/2014

- Videolaparoscopy Training – Johnson & Johnson – 08/2012
- ACLS Provider – Fundação Zerbini – 2010

CERTIFICATIONS

- ACLS – Advanced Cardiovascular Life Support

PROFESSIONAL LICENSE

Brazilian Medical License (CRM – São Paulo)

SCIENTIFIC PRESENTATIONS

- Endoscopic dilation with CRE balloon and triamcinolone injection in rectal stenosis – 2025
- Aortoenteric fistula in the duodenum – 2020
- Colorectal Non-Hodgkin Lymphoma – Case report – 2017

MEDIA

- Interview regarding COVID-19 patient management – 2020

https://www.facebook.com/502267346597124/videos/223552235590269

OTHER SKILLS

- Diagnostic and Therapeutic Endoscopy
- Gastrointestinal Disease Management
- Clinical Decision-Making
- Team Coordination and Leadership
- Languages: Portuguese (native), English (working proficiency), Spanish (intermediate)

Exhibit B - Eligibility Criteria: Advanced Degree

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL
ANTONIO DARI ANTUNES ZHBANOVA
TRADUTOR PÚBLICO E INTÉRPRETE COMERCIAL - *CERTIFIED PUBLIC TRANSLATOR*
Idioma/Language: Inglês - Português/*English - Portuguese*
Matrícula Jucepe nº 406 • CPF 756.770.758-68
Av. Bernardo Vieira de Melo nº 4937 - Candeias - Jaboatão dos Guararapes (PE) CEP: 54450-020
Telefone/Phone/Whatsapp +55 (11) 98784 1006 - (81) 92001-2614 - e-mail:dari.zhbanova@gmail.com

TRANSLATION No. F-87.086 BOOK No. 107 PAGE No. 001

I, the undersigned Sworn Translator and Commercial Interpreter, hereby CERTIFY this is the description and faithful translation of a DOCUMENT written in Portuguese, which I translate as follows:

==========

Universidade do Vale do Itajaí
[Vale do Itajaí University]

Accredited by Ministry Ordinance number 051/89, published in the D.O.U. on Feb/17/1989
Itajaí – Santa Catarina

Physician Diploma

he Dean of the Universidade do Vale do Itajaí, exercising his powers, considering that

Marcio Lamas Lopes,
Brazilian, native of the State of São Paulo, born on October 8th, 1981,
holder of Identity Card number 24.994.982-9/State of São Paulo,

completed the Course in Medicine recognized by State Decree number 1,048/03, published in the Official Gazette of the State of Santa Catarina on November 20th, 2003, and considering the Graduation Ceremony held on July 18th, 2008, hereby confers upon him this Diploma so that he may enjoy all legal rights and prerogatives.

Itajaí, July 18th, 2008.

[Signature]
Professor José Roberto Provesi, Ph.D.
Dean

[Signature]
Prof. Marcio Vieira Angelo, MSc.
Course Coordinator

[Illegible Signature]
Diploma Holder

[Signature]
Prof. Arlete Terezinha Besen
Soprano, MSc.
Center Director

REPÚBLICA FEDERATIVA DO BRASIL FEDERATIVE REPUBLIC OF BRAZIL

[Overleaf:]

Center of Health Sciences
Campus Itajaí

UNIVERSIDADE DO VALE DO ITAJAÍ
Pro-Deanship of Teaching
Student Administration Management
DIPLOMA registered under number 2476, book CS-06/08,
page 391. Process number 02.2479/08, pursuant to
§1st of Art. 48, Law number 9,394 – Law of Guidelines and Bases of National Education, of December 20th, 1996.
Itajaí, July 18th, 2008.

[Signature] Prof. Pedro Francisco Bettoni, MSc. Documents and Diplomas Area Ordinance no. 420/07 – Responsible	*[Signature]* Prof. Amândia Maria de Borba, Dr. Education Vice-Dean Delegation of Dean – Ordinance No. 251/06

[Seal:]

CREMESC
Regional Council of Medicine of the State of Santa Catarina
By requirement, he was registered under number 14736, on page 04,
of book number 02 – FLORIANÓPOLIS/STATE OF SANTA CATARINA – July 18th, 2008.
[Signature]
ANASTACIO KOTZIAS NETO
PRESIDENT

[Seal:]

CREMESP
Regional Council of Medicine of the State of São Paulo
Diploma Registration
On this date, the present diploma of Doctor MARCIO LAMAS LOPES was registered under number 133420,
in accordance with article 17 of Law number 3,268, of September 30th, 1957.

São Paulo, August 19th, 2008.

121.464

[Signature]
JAIR SOARES
Professional Registration Section

Key
D.O.U.: Official Gazette
CREMESC: Regional Council of Medicine of the State of Santa Catarina
CREMESP: Regional Council of Medicine of the State of São Paulo

REPÚBLICA FEDERATIVA DO BRASIL FEDERATIVE REPUBLIC OF BRAZIL

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL
ANTONIO DARI ANTUNES ZHBANOVA
TRADUTOR PÚBLICO E INTÉRPRETE COMERCIAL - *CERTIFIED PUBLIC TRANSLATOR*
Idioma/Language: Inglês - Português/*English - Portuguese*
Matrícula Jucepe nº 406 • CPF 756.770.758-68
Av. Bernardo Vieira de Melo nº 4937 - Candeias - Jaboatão dos Guararapes (PE) CEP: 54450-020
Telefone/Phone/Whatsapp +55 (11) 98784 1006 - (81) 92001-2614 - e-mail:dari.zhbanova@gmail.com

==========

Nothing else was contained in said original, which I return with this faithful translation. In witness whereof, I have hereunto set my hand and seal of office, March 02nd, 2026.

Emoluments according to the law.

ANTONIO DARI ANTUNES ZHBANOVA
CERTIFIED PUBLIC TRANSLATOR
BRAZIL
JUCEPE Reg. No. 406

This document was digitally signed by ANTONIO DARI ANTUNES ZHBANOVA.
To verify the signature access the link below.
https://www.qrassinaturas.com.br/CheckPadesRest?c=FCRW-K6BB-LMDU-SGRQ

ICP Brasil

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL
ANTONIO DARI ANTUNES ZHBANOVA
TRADUTOR PÚBLICO E INTÉRPRETE COMERCIAL - *CERTIFIED PUBLIC TRANSLATOR*
Idioma/Language: Inglês - Português/*English - Portuguese*
Matrícula Jucepe nº 406 • CPF 756.770.758-68
Av. Bernardo Vieira de Melo nº 4937 - Candeias - Jaboatão dos Guararapes (PE) CEP: 54450-020
Telefone/Phone/Whatsapp +55 (11) 98784 1006 - (81) 92001-2614 - e-mail:dari.zhbanova@gmail.com

TRANSLATION No. F-87.087 BOOK No. 107 PAGE No. 001

I, the undersigned Sworn Translator and Commercial Interpreter, hereby CERTIFY this is the description and faithful translation of a DOCUMENT written in Portuguese, which I translate as follows:
==========

UNIVALI

UNIVERSIDADE DO VALE DO ITAJAÍ

[Vale do Itajaí University]

UNOFFICIAL ACADEMIC TRANSCRIPT

DATE: Feb/19/2026

TIME: 01:06:34 p.m.

STUDENT: 2.2.2479 – MARCIO LAMAS LOPES PERSON CODE: 698253

COURSE: 150 – MEDICINE

MODALITY: 1 – BACHELOR'S DEGREE / CURRICULUM: 1

PERIOD REGULARLY ENROLLED: 12 SHIFT: 4 – FULL-TIME CLASS: 1 – SINGLE

			Year /	Workload				
DISC.	**SUBJECT NAME**	**Grade**	**Sem**	**Theo.**	**Pra.**	**TOT**	**Credits**	**Remarks**
	1st PERIOD							
341	SOCIOLOGY	9.50	02/2	30	0	30	2	Pass
2541	HUMAN ANATOMY	7.50	02/2	0	180	180	12	Pass
2542	HISTOLOGY	8.00	02/2	30	60	90	6	Pass
2543	HUMAN EMBRYOLOGY	7.00	02/2	30	30	60	4	Pass
2544	ANTHROPOLOGY	7.50	02/2	30	0	30	2	Pass
2545	MEDICAL ETHICS	7.50	02/2	15	0	15	1	Pass
	2nd PERIOD							
2575	HUMAN ANATOMY	8.00	03/1	60	120	180	12	Pass
2576	HISTOLOGY	7.00	03/1	30	90	120	8	Pass
2577	SCIENTIFIC METHODOLOGY	8.50	03/1	30	0	30	2	Pass
2578	HUMAN GROWTH AND DEVELOPMENT	7.00	03/1	30	0	30	2	Pass
2579	MEDICAL ETHICS	9.00	03/1	15	0	15	1	Pass
2580	HISTORY OF MEDICINE	9.00	03/1	15	0	15	1	Pass
	3rd PERIOD							
2660	MEDICAL GENETICS	8.00	03/1	30	15	45	3	Pass
2659	BASIC IMMUNOLOGY	6.50	03/2	45	15	60	4	Pass
2661	HUMAN PHYSIOLOGY AND BIOPHYSICS	9.50	03/2	90	30	120	8	Pass
2662	ORGANIZATION OF HEALTH SERVICES	8.50	03/2	30	0	30	2	Pass
2663	HUMAN ANATOMY	7.00	03/2	60	60	120	8	Pass
2664	PHYSIOLOGICAL CHEMISTRY	8.50	03/2	45	15	60	4	Pass
2665	MEDICAL ETHICS	9.00	03/2	15	0	15	1	Pass
	4th PERIOD							

REPÚBLICA FEDERATIVA DO BRASIL FEDERATIVE REPUBLIC OF BRAZIL

REPÚBLICA FEDERATIVA DO BRASIL FEDERATIVE REPUBLIC OF BRAZIL

2835	MOLECULAR BIOLOGY	7.50	04/1	30	30	60	4	Pass
2836	EPIDEMIOLOGY AND BIOSTATISTICS	7.00	04/1	45	0	45	3	Pass
2837	MEDICAL ETHICS	9.50	04/1	15	0	15	1	Pass
2838	HUMAN PHYSIOLOGY AND BIOPHYSICS	7.00	04/1	60	30	90	6	Pass
2839	IMMUNOPATHOLOGY	7.00	04/1	45	0	45	3	Pass
2840	MEDICAL MICROBIOLOGY	7.50	04/1	30	30	60	4	Pass
2841	MEDICAL PARASITOLOGY	8.50	04/1	30	30	60	4	Pass
2842	GENERAL PATHOLOGY	6.50	04/1	30	30	60	4	Pass
2843	MEDICAL SEMIOLOGY	7.00	04/1	30	30	60	4	Pass
	5th PERIOD							
2914	PATHOLOGICAL ANATOMY	9.00	04/2	15	15	30	2	Pass
2915	MEDICAL CLINIC	7.00	04/2	60	30	90	6	Pass
2916	SURGICAL CLINIC	7.00	04/2	60	30	90	6	Pass
2917	INFECTIOUS AND PARASITIC DISEASES	7.50	04/2	15	15	30	2	Pass
2918	DIAGNOSTIC IMAGING	6.50	04/2	15	30	45	3	Pass
2919	MEDICAL ETHICS	9.00	04/2	15	0	15	1	Pass
2920	PHARMACOLOGY AND THERAPEUTICS	9.00	04/2	60	30	90	6	Pass
2921	PREVENTIVE MEDICINE	8.50	04/2	45	0	45	3	Pass
2922	FAMILY AND COMMUNITY MEDICINE	7.50	04/2	15	15	30	2	Pass
2923	CLINICAL PATHOLOGY	10.00	04/2	15	15	30	2	Pass
	6th PERIOD							
2924	PATHOLOGICAL ANATOMY	8.50	05/1	15	15	30	2	Pass
2925	MEDICAL CLINIC	6.50	05/1	30	60	90	6	Pass
2926	SURGICAL CLINIC	6.50	05/1	30	60	90	6	Pass
2927	DIAGNOSTIC IMAGING	7.50	05/1	15	15	30	2	Pass
2928	MEDICAL ETHICS	10.00	05/1	15	0	15	1	Pass
2929	FAMILY AND COMMUNITY MEDICINE	9.00	05/1	30	30	60	4	Pass
2930	LEGAL MEDICINE	9.00	05/1	30	0	30	2	Pass
2931	OCCUPATIONAL MEDICINE	9.00	05/1	30	0	30	2	Pass
2932	PEDIATRICS	6.00	05/1	30	60	90	6	Pass
2933	MEDICAL PSYCHOLOGY	7.50	05/1	30	0	30	2	Pass
	7th PERIOD							
2934	PATHOLOGICAL ANATOMY	7.50	05/2	15	15	30	2	Pass
2935	MEDICAL CLINIC	6.50	05/2	30	60	90	6	Pass
2936	SURGICAL CLINIC	8.00	05/2	30	60	90	6	Pass
2937	DIAGNOSTIC IMAGING	7.00	05/2	15	15	30	2	Pass
2938	MEDICAL ETHICS	9.50	05/2	15	0	15	1	Pass
2939	GYNECOLOGY	8.00	05/2	30	30	60	4	Pass
2940	FAMILY AND COMMUNITY MEDICINE	8.00	05/2	30	30	60	4	Pass
2941	PEDIATRICS	9.00	05/2	30	30	60	4	Pass
2942	PSYCHIATRY	6.50	05/2	30	30	60	4	Pass
	8th PERIOD							
2943	PATHOLOGICAL ANATOMY	6.00	06/1	15	15	30	2	Pass
2944	MEDICAL CLINIC	6.50	06/1	30	45	75	5	Pass

REPÚBLICA FEDERATIVA DO BRASIL FEDERATIVE REPUBLIC OF BRAZIL

2945	SURGICAL CLINIC	7.00	06/1	30	45	75	5	Pass
2946	DIAGNOSTIC IMAGING	7.00	06/1	15	15	30	2	Pass
2947	ETHICS AND BIOETHICS	9.50	06/1	30	0	30	2	Pass
2948	GERIATRICS	7.00	06/1	30	0	30	2	Pass
2949	FAMILY AND COMMUNITY MEDICINE	7.50	06/1	30	15	45	3	Pass
2950	OBSTETRICS AND FETAL MEDICINE	6.50	06/1	30	60	90	6	Pass
2951	PEDIATRICS	6.50	06/1	15	15	30	2	Pass
2952	PEDIATRICS – SURGERY	7.00	06/1	15	15	30	2	Pass
3607	NUTRITION	8.00	06/1	15	15	30	2	Pass
	9th PERIOD							
2953	MEDICAL INTERNSHIP: FAMILY AND COMMUNITY MEDICINE	7.00	06/2	0	375	375	25	Pass
2987	SCIENTIFIC INITIATION PROJECT	9.50	06/2	0	30	30	2	Pass
3815	MEDICAL INTERNSHIP: PEDIATRICS	8.50	06/2	0	375	375	25	Pass
3816	MEDICAL INTERNSHIP: GYNECOLOGY/OBSTETRICS	8.50	06/2	0	375	375	25	Pass
	10th PERIOD							
2954	MEDICAL INTERNSHIP: FAMILY AND COMMUNITY MEDICINE	8.00	07/1	0	375	375	25	Pass
3869	MEDICAL INTERNSHIP: MEDICAL CLINIC	7.50	07/1	0	375	375	25	Pass
3870	MEDICAL INTERNSHIP: SURGICAL CLINIC	7.00	07/1	0	375	375	25	Pass
	ELECTIVE GROUP					0	Workload completed = 0	
6515	CLINICAL EMERGENCIES			15	15	30	2	Eligible to Attend
6516	ACUPUNCTURE			30		30	2	Eligible to Attend
	11th PERIOD							
2955	MEDICAL INTERNSHIP: FAMILY AND COMMUNITY MEDICINE	8.50	07/2	0	375	375	25	Pass
3871	MEDICAL INTERNSHIP: PEDIATRICS	8.50	07/2	0	375	375	25	Pass
3872	MEDICAL INTERNSHIP: GYNECOLOGY/OBSTETRICS	8.50	07/2	0	375	375	25	Pass
	12th PERIOD							
2956	MEDICAL INTERNSHIP: SURGICAL CLINIC	7.50	08/1	0	375	375	25	Pass
3873	MEDICAL INTERNSHIP: MEDICAL CLINIC	7.00	08/1	0	375	375	25	Pass
Group:	Optative Internship					375	Workload completed = 375	
3875	CLINICAL SURGICAL INTERNSHIP	7.50	08/1		375	375	25	Pass
3874	CLINICAL MEDICAL INTERNSHIP				375	375	25	Eligible to Attend
3876	PEDIATRIC INTERNSHIP				375	375	25	Eligible to Attend
3877	GYNECOLOGY AND OBSTETRICS INTERNSHIP				375	375	25	Eligible to Attend

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL
ANTONIO DARI ANTUNES ZHBANOVA
TRADUTOR PÚBLICO E INTÉRPRETE COMERCIAL - *CERTIFIED PUBLIC TRANSLATOR*
Idioma/Language: Inglês - Português/*English - Portuguese*
Matrícula Jucepe nº 406 • CPF 756.770.758-68
Av. Bernardo Vieira de Melo nº 4937 - Candeias - Jaboatão dos Guararapes (PE) CEP: 54450-020
Telefone/Phone/Whatsapp +55 (11) 98784 1006 - (81) 92001-2614 - e-mail:dari.zhbanova@gmail.com

3878	FAMILY AND COMMUNITY MEDICINE INTERNSHIP				375	375	25	Eligible to Attend
ANY PERIOD								
Group:	Optative					0	Workload completed = 0	
5381	BRAZILIAN SIGN LANGUAGE – LIBRAS			60		60	4	Eligible to Attend

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL

REPÚBLICA FEDERATIVA DO BRASIL
FEDERATIVE REPUBLIC OF BRAZIL
ANTONIO DARI ANTUNES ZHBANOVA
TRADUTOR PÚBLICO E INTÉRPRETE COMERCIAL - *CERTIFIED PUBLIC TRANSLATOR*
Idioma/Language: Inglês - Português/*English - Portuguese*
Matrícula Jucepe nº 406 • CPF 756.770.758-68
Av. Bernardo Vieira de Melo nº 4937 - Candeias - Jaboatão dos Guararapes (PE) CEP: 54450-020
Telefone/Phone/Whatsapp +55 (11) 98784 1006 - (81) 92001-2614 - e-mail:dari.zhbanova@gmail.com

TRANSLATION No. F-87.087 BOOK No. 107 PAGE No. 005

==========

Nothing else was contained in said original, which I return with this faithful translation. In witness whereof, I have hereunto set my hand and seal of office, March 02nd, 2026.

Emoluments according to the law.

ANTONIO DARI ANTUNES ZHBANOVA
CERTIFIED PUBLIC TRANSLATOR
BRAZIL
JUCEPE Reg. No. 406

This document was digitally signed by ANTONIO DARI ANTUNES ZHBANOVA.
To verify the signature access the link below.
https://www.qrassinaturas.com.br/CheckPadesRest?c=EG4E-DWGU-SGYZ-KP3W

REPÚBLICA FEDERATIVA DO BRASIL FEDERATIVE REPUBLIC OF BRAZIL

UNIVALI

UNIVERSIDADE DO VALE DO ITAJAÍ

HISTÓRICO ESCOLAR

Curso:	MEDICINA		
Habilitação/Ênfase/Modalidade:	----------	/	**BACHARELADO**
DECRETO ESTADUAL Nº 1.048/03		D.O./SC	20/11/03

Aluno(a):	MARCIO LAMAS LOPES						
Filiação:	ERALDO LOPES / JANETE DIAS LAMAS LOPES						
Nascimento:	08/10/1981	**Cidade:**	SÃO PAULO			**U.F.:**	SP
Documento de Identificação:	**Tipo:**	**Registro Geral**	**Nº:**	24.994.982-9		**U.F.:**	SP

ENSINO MÉDIO ou EQUIVALENTE

Instituição:	INSTITUTO NOSSA SENHORA AUXILIADORA				
Cidade:	SÃO PAULO	**U.F.:**	SP	**Ano:**	1998

FORMA DE INGRESSO NO ENSINO SUPERIOR

Ingresso:	VESTIBULAR		
Instituição:	UNIVERSIDADE DO VALE DO ITAJAÍ - UNIVALI	**Ano/Semestre:**	2002 / 2
Curso:	MEDICINA	**Classificação:**	47

Situação Acadêmica Atual:	FORMADO

Ano/Sem.	Cod.	Disciplina	Média	C/H	OBS.:
2002 / 2	0341	SOCIOLOGIA	9,50	30	
2002 / 2	2541	ANATOMIA HUMANA	7,50	180	
2002 / 2	2542	HISTOLOGIA	8,00	90	
2002 / 2	2543	EMBRIOLOGIA HUMANA	7,00	60	
2002 / 2	2544	ANTROPOLOGIA	7,50	30	
2002 / 2	2545	ETICA MEDICA	7,50	15	
2003 / 1	2575	ANATOMIA HUMANA	8,00	180	
2003 / 1	2576	HISTOLOGIA	7,00	120	
2003 / 1	2577	METODOLOGIA CIENTIFICA	8,50	30	
2003 / 1	2578	CRESCIMENTO E DESENVOLVIMENTO HUMANO	7,00	30	
2003 / 1	2579	ETICA MEDICA	9,00	15	
2003 / 1	2580	HISTORIA DA MEDICINA	9,00	15	
2003 / 2	2659	IMUNOLOGIA BASICA	6,50	60	
2003 / 1	2660	GENETICA MEDICA	8,00	45	
2003 / 2	2661	FISIOLOGIA HUMANA E BIOFISICA	9,50	120	
2003 / 2	2662	ORGANIZACAO DOS SERVICOS DA SAUDE	8,50	30	
2003 / 2	2663	ANATOMIA HUNAMA	7,00	120	
2003 / 2	2664	QUIMICA FISIOLOGICA	8,50	60	
2003 / 2	2665	ETICA MEDICA	9,00	15	
2004 / 1	2835	BIOLOGIA MOLECULAR	7,50	60	
2004 / 1	2836	EPIDEMIOLOGIA E BIOESTATISTICA	7,00	45	
2004 / 1	2837	ETICA MEDICA	9,50	15	
2004 / 1	2838	FISIOLOGIA HUMANA E BIOFISICA	7,00	90	
2004 / 1	2839	IMUNOPATOLOGIA	7,00	45	
2004 / 1	2840	MICROBIOLOGIA MEDICA	7,50	60	
2004 / 1	2841	PARASITOLOGIA MEDICA	8,50	60	
2004 / 1	2842	PATOLOGIA GERAL	6,50	60	

Este documento é válido somente sem rasuras, com rubrica, chancela em todas as folhas e assinatura na última folha

(Continuação)

Aluno(a): MARCIO LAMAS LOPES

Ano/Sem.	Cod.	Disciplina	Média	C/H	OBS.:
2004 / 1	2843	SEMIOLOGIA MEDICA	7,00	60	
2004 / 2	2914	ANATOMIA PATOLOGICA	9,00	30	
2004 / 2	2915	CLINICA MEDICA	7,00	90	
2004 / 2	2916	CLINICA CIRURGICA	7,00	90	
2004 / 2	2917	DOENCAS INFECCIOSAS E PARASITARIAS	7,50	30	
2004 / 2	2918	DIAGNOSTICO POR IMAGENS	6,50	45	
2004 / 2	2919	ETICA MEDICA	9,00	15	
2004 / 2	2920	FARMACOLOGIA E TERAPEUTICA	9,00	90	
2004 / 2	2921	MEDICINA PREVENTIVA	8,50	45	
2004 / 2	2922	MEDICINA FAMILIAR E COMUNITARIA	7,50	30	
2004 / 2	2923	PATOLOGIA CLINICA	10,00	30	
2005 / 1	2924	ANATOMIA PATOLOGICA	8,50	30	
2005 / 1	2925	CLINICA MEDICA	6,50	90	
2005 / 1	2926	CLINICA CIRURGICA	6,50	90	
2005 / 1	2927	DIAGNOSTICO POR IMAGENS	7,50	30	
2005 / 1	2928	ETICA MEDICA	10,00	15	
2005 / 1	2929	MEDICINA FAMILIAR E COMUNITARIA	9,00	60	
2005 / 1	2930	MEDICINA LEGAL	9,00	30	
2005 / 1	2931	MEDICINA OCUPACIONAL	9,00	30	
2005 / 1	2932	PEDIATRIA	6,00	90	
2005 / 1	2933	PSICOLOGIA MEDICA	7,50	30	
2005 / 2	2934	ANATOMIA PATOLOGICA	7,50	30	
2005 / 2	2935	CLINICA MEDICA	6,50	90	
2005 / 2	2936	CLINICA CIRURGICA	8,00	90	
2005 / 2	2937	DIAGNOSTICO POR IMAGENS	7,00	30	
2005 / 2	2938	ETICA MEDICA	9,50	15	
2005 / 2	2939	GINECOLOGIA	8,00	60	
2005 / 2	2940	MEDICINA FAMILIAR E COMUNITARIA	8,00	60	
2005 / 2	2941	PEDIATRIA	9,00	60	
2005 / 2	2942	PSIQUIATRIA	6,50	60	
2006 / 1	2943	ANATOMIA PATOLOGICA	6,00	30	
2006 / 1	2944	CLINICA MEDICA	6,50	75	
2006 / 1	2945	CLINICA CIRURGICA	7,00	75	
2006 / 1	2946	DIAGNOSTICO POR IMAGENS	7,00	30	
2006 / 1	2947	ETICA E BIOETICA	9,50	30	
2006 / 1	2948	GERIATRIA	7,00	30	
2006 / 1	2949	MEDICINA FAMILIAR E COMUNITARIA	7,50	45	
2006 / 1	2950	OBSTETRICIA E MEDICINA FETAL	6,50	90	
2006 / 1	2951	PEDIATRIA	6,50	30	
2006 / 1	2952	PEDIATRIA (CIRURGICA)	7,00	30	
2006 / 1	3607	NUTRICAO	8,00	30	
2006 / 2	2953	INTERNATO: MEDICINA FAMILIAR E COMUNITÁRIA	7,00	375	
2006 / 2	2987	TRABALHO DE CONCLUSAO DE CURSO (TCC)	9,50	30	
2006 / 2	3815	INTERNATO: PEDIATRIA	8,50	375	
2006 / 2	3816	INTERNATO: GINECOLOGIA/OBSTETRÍCIA	8,50	375	
2007 / 1	2954	INTERNATO: MEDICINA FAMILIAR E COMUNITÁRIAS	8,00	375	
2007 / 1	3869	INTERNATO: CLÍNICA MÉDICA	7,50	375	
2007 / 1	3870	INTERNATO: CLÍNICA CIRÚRGICA	7,00	375	
2007 / 2	2955	INTERNATO: MEDICINA FAMILIAR E COMUNITÁRIA	8,50	375	
2007 / 2	3871	INTERNATO: PEDIATRIA	8,50	375	
2007 / 2	3872	INTERNATO: GINECOLOGIA / OBSTETRÍCIA	8,50	375	

Este documento é válido somente sem rasuras, com rubrica, chancela em todas as folhas e assinatura na última folha

(Continuação)

Aluno(a):		MARCIO LAMAS LOPES			
2008 / 1	2956	INTERNATO: CLÍNICA CIRÚRGICA	7,50	375	
2008 / 1	3873	INTERNATO: CLÍNICA MÉDICA	7,00	375	
2008 / 1	3875	ESTÁGIO CLÍNICA CIRURGICA	7,50	375	
			Horas Cursadas:	**8250**	
			Total Geral:	**8250**	

Observações

ESTE HISTÓRICO REGISTRA APENAS AS DISCIPLINAS CURSADAS COM APROVAÇÃO

Data de Colação de Grau:	18/07/2008

Dispensado do ENADE pelo MEC nos termos do art. 5° da Lei n° 10861/2004.

Itajai (SC), 17 de Julho de 2008.

UNIVERSIDADE DO VALE DO ITAJAÍ
PRÓ-REITORIA DE ENSINO
Gerência de Administração Discente

Prof. Pedro Francisco Bettoni, MSc.
Responsável pela Área de Doc. e Diplomação - Port. nº 420/07
Carimbo do Responsável
(com o nome legível)

SELO DE AUTENTICIDADE
UNIVALI
UNIVERSIDADE DO VALE DO ITAJAÍ

Este documento é válido somente sem rasuras, com rubrica, chancela em todas as folhas e assinatura na última folha

Universidade do Vale do Itajaí

Reconhecida pela Portaria Ministerial nº 051/89, publicada no D.O.U., em 17.02.1989
Itajaí - Santa Catarina

UNIVALI

Diploma de Médico

O Reitor da Universidade do Vale do Itajaí, no uso de suas atribuições, tendo em vista que

Marcio Lamas Lopes,

brasileiro, natural do Estado de São Paulo, nascido no dia 08 de outubro de 1981,
portador de Cédula de Identidade nº 24.994.982-9/SP,

concluiu o curso de Medicina reconhecido pelo Decreto Estadual nº 1.048/03, publicado no Diário Oficial do Estado de Santa Catarina em 20 de novembro de 2003, e considerando o Termo de Colação de Grau em 18 de julho de 2008, outorga-lhe o presente Diploma a fim de que possa gozar de todos os direitos e prerrogativas legais.

Itajaí, 18 de julho de 2008

Prof. José Roberto Provesi, Ph.D.
Reitor

Prof. Marcio Vieira Angelo, MSc.
Coordenador do Curso

Marcio Lamas Lopes
Diplomado

Profª. Arlete Terezinha Besen Soprano, MSc.
Diretor do Centro

Centro de Ciências da Saúde
Campus de Itajaí

UNIVERSIDADE DO VALE DO ITAJAÍ
Pró-Reitoria de Ensino
Gerência de Administração Discente

DIPLOMA registrado sob o nº **2476,** livro CS-06/08, folha 391. Processo nº 02.2.2479/08, nos termos do §1º do Art. 48, Lei nº 9.394 – Lei de Diretrizes e Bases da Educação Nacional, de 20/12/1996.
Itajaí, 18 de julho de 2008.

Prof. Pedro Francisco Bettoni, MSc.
Área de Documentação e Diplomação
Port.nº 420/07 - Responsável

Profa. Amândia Maria de Borba, Dra.
Pró-Reitora de Ensino
Delegação do Reitor-Port.nº 251/06

CREMESC
Conselho Regional de Medicina do Estado de Santa Catarina
O(a) requerente foi inscrito(a) sob o nº 14736 às páginas 04, do livro nº 02 FLORIANÓPOLIS-SC 18/07/2008

ANASTACIO KOTZIAS NETO
PRESIDENTE

CREMESP
Conselho Regional de Medicina do Estado de São Paulo
Registro de Diploma
Nesta data, o presente diploma do Dr(a). **MARCIO LAMAS LOPES** foi registrado sob o número **133420**, de acordo com o artigo 17 da Lei Número 3.268 de 30 de setembro de 1957.
São Paulo, 19/08/2008
121.464
JAIR SOARES
Seção de Registro de Profissionais

Carnegie Evaluations LLC
315 East High Street, Bound Brook, New Jersey, 08805
Email: info@carnegieevaluations.com
Website: www.carnegieevaluations.com
Phone: (848)300-0099
Fax: (848) 300-5199

EVALUATION OF ACADEMICS

Carnegie Evaluations LLC, who specializes in the evaluation of foreign educational credentials, has prepared the following academic credential evaluation.

August 25, 2026

Name: **Mr. Marcio LAMAS LOPES**

Following is a description of Mr. Lamas Lopes's foreign degree:

Institution:	*Universidade do Vale do Itajai*
Degree:	*Diploma de Medico*
Date of Award:	July 2008
Country:	Brazil

Institution:	*Hospital Ipiranga*
Degree:	*Especialidade de Cirurgia Geral*
Date of Award:	January 2013
Country:	Brazil

Institution:	*Hospital Ipiranga*
Degree:	*Especializacao em Endoscopia*
Date of Award:	February 2015
Country:	Brazil

Academic Equivalency in the United States

DOCTOR OF MEDICINE (M.D)

ONE YEAR OF GRADUATE STUDY IN GENERAL SURGERY

ONE YEAR OF GRADUATE STUDY IN ENDOSCOPY

Carnegie Evaluations LLC offers this evaluation after reviewing copies of the original diploma certificates and transcripts provided. This evaluation is advisory in nature and is based on the assumption that the submitted documents are accurate. There are no apparent grounds to disbelieve the authenticity and accuracy of the documentation presented on behalf of Mr. Marcio Lamas Lopes. In addition, this evaluation is based on standard scholarly and professional sources as referenced at the end of this document. Carnegie Evaluations LLC is not responsible for how this evaluation report will be used and is not responsible for damages resulting from such use of this report.

DISCUSSION OF MR. LAMAS LOPES'S ACADEMICS

This credential evaluation is provided upon review of the degree certificates and transcripts awarded to Mr. Marcio Lamas Lopes during the course of his academic career. An analysis of Mr. Lamas Lopes's foreign educational courses for the *Diploma de Medico* (translated as Physician Diploma) from *Universidade do Vale do Itajai* (translated as Vale do Itajai University), *Especialidade de Cirurgia Geral* (translated as Specialty of General Surgery), and *Especializacao em Endoscopia* (translated as Specialization Program in Endoscopy) from *Hospital Ipiranga* (translated as Ipiranga Hospital) forms the basis for the following evaluation.

Mr. Lamas Lopes graduated with a Physician Diploma from Vale do Itajai University in July 2008. Vale do Itajai University is an accredited institution of higher education in Itajai, Brazil. Admission to this program requires graduation from the US equivalent of high school and competitive entrance examinations for admission and enrollment. Mr. Lamas Lopes satisfactorily completed the academic course requirements for a Physician Diploma program. He majored in Medicine and was awarded a *Diploma de Medico* from the institute.

This, according to the Electronic Database for Global Education (EDGE) created by the American Association of Collegiate Registrars and Admissions Officers (AACRAO), is equivalent to a level of education comparable to a first professional degree in medicine in the United States, namely a Doctor of Medicine (M.D.) Degree. The academic criterion maintained by Vale do Itajai University is significantly similar to those parameters upheld by any other accredited colleges and universities in the United States.

The *Diploma de Medico* curriculum includes advanced bachelor's-level coursework and examinations in Sociology, Human Anatomy, Histology, Human Embryology, Anthropology, Medical Ethics, Scientific Methodology, Human Growth and Development, History of Medicine, Medical Genetics, Basic Immunology, Human Physiology and Biophysics, Organization of Health Services, Physiological Chemistry, Molecular Biology, Epidemiology and Biostatistics, Immunopathology, Medical Microbiology, Medical Parasitology, General Pathology, Medical Semiology, Pathological Anatomy, Medical Clinic, Surgical Clinic, Infectious and Parasitic Diseases, Diagnostic Imaging, Pharmacology and Therapeutics, Preventive Medicine, Family and Community Medicine, Clinical Pathology, Legal Medicine, Occupational Medicine, Pediatrics, Medical Psychology, Gynecology, Psychiatry, Ethics and Bioethics, Geriatrics, Obstetrics and Fetal Medicine, Pediatric Surgery, Nutrition, Medical Internship: Family and Community Medicine, Scientific Initiation Project, Clinical Emergencies, Acupuncture, and other related subjects.

Thereafter, Mr. Lamas Lopes graduated with a Specialty of General Surgery from Ipiranga Hospital in January 2013. Ipiranga Hospital is an accredited institution of higher education in Sao Paulo, Brazil. Admission to this program requires graduation from Bachelor level studies and competitive entrance examinations for admission and enrollment. Mr. Lamas Lopes satisfactorily completed the academic course requirements for a Specialty of General Surgery program. He majored in General Surgery and was awarded *Especialidade de Cirurgia Geral* from the institute.

This is a one-year graduate program of study that is equivalent to one year of graduate study at an accredited institution of higher education in the United States. The academic criteria maintained by Ipiranga Hospital are substantially similar to those upheld by other accredited colleges and universities in the United States.

Thereafter, Mr. Lamas Lopes graduated with a Specialization Program in Endoscopy from Ipiranga Hospital in February 2015. Admission to this program requires graduation from Bachelor level studies and competitive entrance examinations for admission and enrollment. Mr. Lamas Lopes satisfactorily completed the academic course requirements for a Specialization Program in Endoscopy program. He majored in Endoscopy and was awarded *Especializacao em Endoscopia* from the institute. This is a one-year graduate program of study that is equivalent to one year of graduate study at an accredited institution of higher education in the United States.

Upon reviewing Mr. Lamas Lopes's academic history, it becomes apparent that Mr. Lamas Lopes has satisfied the coursework requirements that are substantially similar to and equivalent to those required for the completion of a Doctor of Medicine (M.D.) degree, and has completed two one-year periods of graduate study at an accredited institution of higher education in the United States.

SUMMARY

On the basis of the academic reputations of Vale do Itajai University, and Ipiranga Hospital, the nature and duration of the academic course work, and the grades attained in the courses, it is the judgment of Carnegie Evaluations LLC that Mr. Lamas Lopes has attained the equivalent of a Doctor of Medicine (M.D) degree, one year of graduate study in General Surgery and one year of graduate study in Endoscopy from an accredited institution of higher education in the United States.

Carnegie Evaluations LLC represents this evaluation report to be an accurate and correct evaluation to the best of its knowledge and belief, pursuant to the requirements of the Citizenship and Immigration Services of the United States Department of Homeland Security. Carnegie Evaluations LLC does not represent that the documentation submitted to it by anyone for evaluation meets the evidentiary standards of any state or federal agency or any court. This evaluation report, as are all such reports provided by Carnegie Evaluations LLC, is advisory for the customer who requested it.

The foregoing evaluation of Mr. Lamas Lopes has been reviewed and approved by me, Dr. Zach G. Zacharia, on August 25, 2026.

Sincerely,



Zach G. Zacharia, Ph.D.
Director, Carnegie Evaluations LLC.
Associate Professor of Supply Chain Management
Director, Lehigh Center for Supply Chain Research
Lehigh University

Evaluation Resources:

1. World Higher Education Database. International Association of Universities' Worldwide Database of Higher Education Institutions, Systems and Credentials. www.whed.net.
2. AACRAO EDGE. AACRAO Electronic Database for Global Education. https://www.aacrao.org/edge
3. Central Intelligence Agency (CIA). The World Factbook. https://www.cia.gov/the-world-factbook/
4. ENIC-NARIC. European Network of Information Centres in the European Region, National Academic Recognition Information Centres in the European Union. www.enic-naric.net.

Bio: Professor Zach G. Zacharia

I am the Interim Department Chair, Decision and Technology Analytics (DATA) Department, an Associate Professor of Supply Chain Management, and Director of the Center for Supply Chain Research Lehigh in the College of Business and Economics, Lehigh University, where I teach Graduate and Undergraduate courses in Supply Chain Operations Management and Logistics and Transportation. In addition, I am also a visiting Professor at the Indian Institute of Technology (IIT) in New Delhi, India. I graduated with a B.S. in Mechanical Engineering from the University of Calgary, an MBA from the University of Alberta, and a Ph.D. in Logistics with a minor in Marketing from the University of Tennessee. My current research interests include Collaboration/Competition within the Supply Chain, Supplier Satisfaction, and the Physical Internet.

Before joining Academia, I worked at the University of Tennessee, Center for Transportation Research, for six years as an Associate Director. I also worked at the Department of Transportation in Alberta, Canada, for ten years as an Equipment Engineer. I am a principal in BZS Consulting, which primarily focuses on teaching Supply Chain Operations Management and evaluating collaboration and procurement strategies across firms in a supply chain.

I have developed significant international contacts and collaborations with many affiliate schools in several countries in Europe, Asia, and South America. I have evaluated numerous portfolios of international students from countries around the world and have performed in-depth assessments of how these foreign courses are equated to corresponding courses in the United States.

I have 29 refereed publications, including 2 articles in the Journal of Operations Management, 8 articles in the *Journal of Business Logistics,* and articles in *Decision Sciences*, the *Journal of Supply Chain Management, Industrial Marketing Management, International Journal of Production Research, International Journal of Production and Operations Management, International Journal of Logistics Management, Journal of Retailing, Journal of Business and Industrial Marketing, Marketing Management, Supply Chain Management Review, Journal of International Technology and Information Management*, *Journal of Vehicle Design* and *Wall Street Journal*. As a member of a Supply Chain Research Group at the University of Tennessee, I co-authored a book titled "*Supply Chain Management*" (Sage Publications, December 2000). I also contributed a chapter on logistics service providers and new product development in the book titled *Managing Innovation: The New Competitive Edge for Logistics Service Providers*, Stephan M. Wagner ed.**,** Kuehne Foundation Book Series (2007).

Among the awards that I have received are the DATA Department Service Award (2023), Staub Faculty Excellence Award (2013) from the College of Business, Lehigh University, Best Paper Finalist (2010) from the Journal of Operations Management, Best Paper Award (2007) from NARTS and Best Dissertation Proposal Award (2000) from the University of Arkansas. As a member of a Supply Chain Research Group at the University of Tennessee, I coauthored a book titled Supply Chain Management (Sage Publications, December 2000).

A. Biographical Information

Zach G. Zacharia, Ph.D.
Interim Department Chair, Decision and Technology Analytics Department
Associate Professor Supply Chain Management
Director, Client Services, Carnegie Evaluations
Director, Center for Supply Chain Management Lehigh
Supply Chain Management Program Director
Department of Management, College of Business Administration and Economics
Lehigh University, 621 Taylor Street, Bethlehem, PA, 18015
Office: (610) 758-4433, Fax: (610) 758-6941
zgz208@lehigh.edu

EDUCATION

1996 - 2001 **THE UNIVERSITY OF TENNESSEE** **Knoxville, TN**
Doctor of Philosophy in Business Administration

- Major: Logistics, Minor: Marketing
- Dissertation Title: An Analysis of the Effect of Logistics Involvement in Cross-functional Integrated New Product Development Projects (Advisor: Dr. John T. Mentzer)

1988 – 1993 **THE UNIVERSITY OF ALBERTA** **Edmonton, AB**
Master of Business Administration

1981 - 1985 **THE UNIVERSITY OF CALGARY** **Calgary, AB**
Bachelor of Science, Mechanical Engineering

1980 - 1981 **RED DEER COLLGE** **Red Deer, AB**
Bachelor of Science

1979 – 1980 **THE UNIVERSITY OF ALBERTA** **Edmonton, AB**
Bachelor of Science

WORK EXPERIENCE SUMMARY

2016 – Present, Director, Center for Supply Chain Research Lehigh
2013 – Present, Associate Professor – Lehigh University
2008 – 2013 Assistant Professor – Lehigh University
2001 – 2008 Assistant Professor - Texas Christian University
1999 – 2001 Associate Director – Transportation Center, University of Tennessee
1997 – 1999 Assistant Director - Transportation Center, University of Tennessee
1995 – 1997 Senior Research Associate – University of Tennessee
1989 – 1995 Research Engineer – R&D Branch, Alberta Transportation & Utilities
1985 – 1989 Equipment Engineer – Alberta Transportation & Utilities

CONSULTING PROJECTS, EXECUTIVE EDUCATION

2023 Expert Witness – Real Estate Company, Bethlehem

2023	Ecofriendly Behavior on Personal Transportation, AFIT, Dalton
2020	Financial Flow in SC, DiCentral, Houston
2020	Expert Witness – Real Estate Company, Bethlehem
2020	Lehigh University, Executive Education, Bethlehem
2019	Lehigh University, Executive Education, Bethlehem
2019	SC Collaboration in Drop Ship, DiCentral, Houston
2018	Coopetition in the Defense Industry, AFIT, Dayton
2018	IIT New Delhi, Executive Education, Delhi, India
2017	Lehigh University, Executive Education, Bethlehem
2016	IIT Madras, Global Initiative of Academic Networks, Chennai, India
2015	Morrison Executive Education, Santo Domingo, Dominican Republic
2014	CSCMP Executive Seminar, Bogota, Columbia
2012	Supply Chain Management Simulation, WAM Systems, Philadelphia
2010	Supply Chain Management Overview, Universidad de Piura, Peru
2007	Procurement of Capability Guidelines, Lockheed Martin Aeronautics
2002	Truck Safety Recommendations, University of Tennessee

B. Publications and Creative Activities

EDITORIAL ROLES (6)

- Senior Editor- *International Journal of Logistics Management (2018- current)*
- Senior Editor- *Journal of Business Logistics (2016- current)*
- Special Issue Editor-(Physical Internet) - *Journal of Business Logistics (2018-2020)*
- Special Issue Editor- (Inter-Disciplinary Research) *Journal of Business Logistics (2014-2015)*
- Editorial Board Member – *Journal of Operations Management*
- Editorial Board Member –*Transportation Journal*
- Editorial Board Member – *Journal of Supply Chain Management*

DISSERTATION COMMITTEE MEMBER (3)

- Nathaniel R- *The American School As a Microcosm for the National Criminal and Legal Landscape: Two Case Studies* – Lehigh University, 2024
- Michael Plasch - *Supply Chain Collaboration - Investigating Motives, Drivers and Success Factors* – Johannes Kepler University Linz, Austria, 2021

- Kimberly K. Whitehead – *It's A Matter of Give And Take: Exploring The Role of Knowledge Transfer Within Supply Chain Collaboration* - University of Texas at Arlington, USA, 2014

BOOK CHAPTERS (5)

- **Zacharia, Zach G**. "Is there a role for Logistics Service Providers in New Product Development?" *Managing Innovation: The New Competitive Edge for Logistics Service Providers*, Stephan M. Wagner ed., Kuehne Foundation Book Series. Ch 7, 2008.
- Mentzer, John T., William J. DeWitt, James S. Keebler, Soonhong Min, Nancy W. Nix, Carlo D. Smith, and **Zach G. Zacharia**, "What is Supply Chain Management" *Supply Chain Management*, Thousand Oaks, CA: Sage Publications, Ch.1, 2000.
- **Zacharia, Zach G**., "R&D and New Product Development in Supply Chain Management" *Supply Chain Management*, John T. Mentzer ed.**,** Thousand Oaks, CA: Sage Publications, Ch.6, 2000.
- **Zacharia, Zach G**., "The Evolution and Growth of Production in Supply Chain Management" *Supply Chain Management*, John T. Mentzer ed., Thousand Oaks, CA: Sage Publications, Ch.8, 2000.
- **Zacharia, Zach G**, "The Evolution and Growth of Information Systems in Supply Chain Management" *Supply Chain Management*, John T. Mentzer ed., Thousand Oaks, CA: Sage Publications, Ch.11, 2000.

REFEREED PUBLICATIONS (30)

30. Gopal Kumar, **Zach Zacharia**, Mohit Goswami (2024) "Understanding interdependency of sustainability dimensions from the lens of collaborative relationship conditions: Findings from an emerging economy" *International Journal of Logistics Management,* Vol. 35, No. 4, 1277-1302

29. Varun Jain, Usha Mohan, **Zach G. Zacharia**, Nada R. Sanders (2022) "Improving patient satisfaction and outpatient diagnostic center efficiency using novel online real-time scheduling" *Operations Research for Health Care,* 32, 1-17, 100338

28. Saif Mir, Misty Blessley, **Zach Zacharia**, John Aloysius (2022) "Mending Fences in the Buyer-Supplier Relationship: The Role of Justice in Relationship Restoration" *Journal of Supply Chain Management*. Vol. 58, No. 3, 23 – 46.

27. Dev, Navin; Ravi Shankar; **Zach Zacharia**, Sanjeev Swami, (2021) "Supply chain resilience for managing the ripple effect in Industry 4.0 for green product

diffusion" *International Journal of Physical Distribution & Logistics Management* Vol. 51 No. 8, 897-930.

26. Ballot, Eric, Benoit Montreuil, **Zach G. Zacharia**, (2021) "Physical Internet: First Results and Next Challenges" *Journal of Business Logistics* Vol 42 No. 1, 1 – 7.

25. Treiblmaier, Horst, Kristijan Mirkovski, Paul B. Lowry, **Zach G. Zacharia**, (2020) "The Physical Internet as a New Supply Chain Paradigm: A Systematic Literature Review and a Comprehensive Framework" *International Journal of Logistics Management* Vol. 31 No. 2, 239-287.

24. **Zach G. Zacharia**, Michael Plasch, Usha Mohan, Markus Gerschberger (2019) "The Emerging Role of Coopetition Within Inter-Firm Relationships" *International Journal of Logistics Management* Vol. 30, No. 2, 414-437.

23. Soonhong Min, **Zach G. Zacharia**, Carlo D. Smith (2019) "Defining Supply Chain Management: In the Past, Present and Future" *Journal of Business Logistics* Vol. 40 No.1, 44-55.

22. Kimberly Whitehead, **Zach Zacharia**, Edmund Prater (2019) "Investigating the Role of Knowledge Transfer in Supply Chain Collaboration" *International Journal of Logistics Management"* Vol. 30, No. 1, 284-302.

21. Misty Blessly, Saif Mir, **Zach G. Zacharia**, John Aloysius (2018) "Breaching Relational Obligations In A Buyer-Supplier Relationship: Feelings Of Violation, Fairness Perceptions And Supplier Switching" *Industrial Marketing Management* Vol. 74, Oct, 215-226.

20. Faraz, Alireza, Nada R. Sanders, **Zach G. Zacharia**, Markus Gerschberger (2018) "Monitoring Type B Buyer-Supplier Relationships" *International Journal of Production Research* Vol. 56, No. 18, 6225-6239.

19. Whitehead, Kimberly, **Zach G. Zacharia**, Edmund Prater, (2016) "Absorptive Capacity Versus Distributive Capability: The Asymmetry of Knowledge Transfer" *International Journal of Operations and Production Management* Vol. 36, No 10, 1308-1332.

18. Nada R. Sanders, Brian R. Fugate, **Zach G. Zacharia**, (2016) "Interdisciplinary Research In SCM: Through the Lens of The Behavioral Theory of The Firm" *Journal of Business Logistics* Vol. 37, No 2, 107-112.

17. Nancy W. Nix, **Zach G. Zacharia,** (2014) "The Impact of Collaborative Engagement on Knowledge and Performance Gains in Episodic Collaborations" *International Journal of Logistics Management* Vol. 25, No 2, 245-269.

16. **Zach G. Zacharia,** Nada R. Sanders, Brian R. Fugate (2014) "The Evolving Role of Disciplines Within Supply Chain Management" *Journal of Supply Chain Management* Vol. 50, No 1, 73-88.

15. Nada R. Sanders, **Zach G. Zacharia**, Brian R. Fugate (2013) "The Interdisciplinary Future of Supply Chain Management Research" *Decision Sciences* Vol. 44, No. 3, 413-429.

14. Geoffrey T. Stewart, **Zach G. Zacharia,** Andrew B. Artis (2012) "Leveraging Relationship Orientation and its Impact on Relationship Outcomes" *Journal of Business and Industrial Marketing,* Vol. 27, No. 8, 644-658.

13. **Zach G. Zacharia,** Nancy W. Nix, Robert F. Lusch (2011) "Capabilities that Enhance Outcomes of an Episodic Supply Chain Collaboration" *Journal of Operations Management*, Vol. 29, No. 6, 591-603.

12. **Zach G. Zacharia,** Nada R. Sanders, Nancy W. Nix (2011) "The Emerging Role of the Third-Party Logistics Provider (3PL) as a Supply Chain Orchestrator" *Journal of Business Logistics*, Vol. 32, No. 1, 40-54.

11. Danny Lanier, Jr., William F. Wempe, **Zach G. Zacharia**, (2010) "Concentrated Supply Chain Membership and Financial Performance: Chain- and Firm-Level Perspectives" *Journal of Operations Management*, Vol.28, No.1, 1-16.

10. **Zach G. Zacharia**, Chad W. Autry, David S. Preston, Charles W. Lamb, (2009) "IT Alignment with Business Strategies in a Healthcare Organizations: An Empirical Analysis" *Journal of International Technology and Information Management*, Vol. 18, No. 3/4, 477-494.

9. **Zach G. Zacharia,** Nancy W. Nix and Robert F. Lusch, (2009) "An Analysis of Supply Chain Collaborations and Their Effect on Performance" *Journal of Business Logistics*, Vol. 30, No. 2, 101-123.

8. Chad W. Autry, **Zach G. Zacharia** and Charles W. Lamb, (2008) "A Logistics Strategy Taxonomy" *Journal of Business Logistics,* Vol. 29. No. 2, 53-74.

7. Nancy W. Nix, Robert F. Lusch, **Zach G. Zacharia**, and Wesley R. Bridges, (2008) "Competent Collaborations" *Marketing Management*, Vol. 17, No. 2, 18-24.

6. **Zach G. Zacharia** and John T. Mentzer (2007) "The Role of Logistics in New Product Development," *Journal of Business Logistics*, Vol. 28, No. 1, 83-110.

    a. Reprinted in:
    b. *Logistique and Management,* Vol. 16, No. 1, 35-53, (2008).

5. **Zach G. Zacharia** and John T. Mentzer (2004) "Logistics Salience In A Changing Environment," *Journal of Business Logistics*, Vol. 25, No. 1, 187-210.

    a. Reprinted in:
    b. *The ICFAI Journal of Supply Chain Management*, Vol. 3, No. 1, 53-72, (2006).

4. Mentzer, John T., William DeWitt, James S. Keebler, Soonhong Min, Nancy W. Nix, Carlo D. Smith, **Zach G. Zacharia** (2001) "Defining Supply Chain Management," *Journal of Business Logistics*, Vol. 22, No. 2, 1-25.

    c. Reprinted in:
    d. *Logistique and Management,* Vol. 9, No. 2, 3-19, (2001).

3. **Zacharia, Zach G**., John E. Tidwell and Stephen H. Richards (2001) "An Overview of Truck and Bus Safety:1999 Knoxville Symposium," *Journal of Vehicle Design*, Vol. 26, No. 4, 442-453.

2. Mentzer, John T., Min Soonhong and **Zach G. Zacharia** (2000) "The Nature of Interfirm Partnering in Supply Chain Management," *Journal of Retailing*, Winter, Vol. 76, Issue 4, 549-568.

1. **Zacharia, Zach G**. and Bart Jennings (1998) "The Use of Active Participation and Group Competition to Facilitate Training and Technology Transfer for Adult Learners," *Transportation Research Record,* No. 1637, 13-18.

PAPERS UNDER REVIEW (6)

- Zach G. Zacharia, Scott C. Ellis, Saif Mir, Robert J. Trent - "Gaining Advantage Through Social Exchange: How and Under What Conditions" (Revise and Resubmit)

- **Saif Mir, Timothy W. Breitbach, Zach G. Zacharia, Benjamin T. Hazen "Supplier Cultivation: An Accelerator Approach to Ecosystem Innovation" (Under Review)**

- Zach Zacharia, Robert Wiedmer, Kimberly Whitehead "Competing Governance Mechanisms in Buyer-Supplier Relationships" (Under Review)

- Zach Zacharia, Annibal Sodero "Drop Shipping and its Effects on the New E-Commerce Retail Paradigm" (Under Review)

- Michael Plasch, Zach Zacharia, "Voluntary or involuntary coopetition: Perspectives on innovation in supply chain network relationships" (Under Review)

- **Saif Mir, Dina Ribbinik,** Saurabh Bansal, Philip Coles, **Zach G. Zacharia, "The Impact of Ecosystem Shocks on the Operational Performance of**

Worker-heavy Systems in the Agricultural Domain: The Role of Cognitive Load" (Under Review)

NON - REFEREED PUBLICATIONS (5)

5. **Zach G. Zacharia** (2020), What Every CFO Needs to Know about Supply Chains

4. **Zach G. Zacharia** (2019), Supply Chain Collaboration in Transformative Vertical Industries (Implications of Omnichannel and Drop Shipping)

3. Robert J. Trent, **Zach G. Zacharia,** (2012) "The Wisdom of Becoming a Preferred Customer," *Supply Chain Management Review* Vol. 16, No. 6, 10-18.

2. Nix, W. Nancy, Robert F. Lusch, **Zach G. Zacharia**, and Wesley R. Bridges, (2007) "The Hand That Feeds You – What Makes Some Collaborations with Suppliers Succeed – When So Many Fail?" *The Journal Report- Business Insight* (A Joint Venture with MIT *Sloan Management Review* and *Wall Street Journal*), Dow Jones and Company

1. **Zacharia, Zach G**. (1994) "Expert System Simplifies Bridge Paint Maintenance Programs," *Materials Performance,* June, 25 - 28.

CONFERENCE PROCEEDINGS (19)

19. Ujjwal Kumar, Iana Shaheen, Zach Zacharia, Ravi Shankar (2024) "Competition and Cooperation in Humanitarian Operations, Academy of Management Conference**,** Chicago, IL, August 13.
18. **Zach Zacharia**, Timothy Breitbach, Ben Hazen, Saif Mir (2019) "Utilizing Accelerator Programs for adopting Innovations to Encourage the Adoption" *CSCMP Conference,* Anaheim, CA, September 15.
17. **Zach Zacharia**, Timothy Breitbach, Ben Hazen, Saif Mir (2018) "Utilizing Accelerator Programs to Encourage the Adoption of New Innovations in Large Organizations" *DSI Conference,* Chicago, IL, November 17.
16. Robert Weidmer, **Zach Zacharia**, (2018) "Competing Governance Mechanisms in Buyer-Supplier Relationships" *DSI Conference,* Chicago, IL, November 16.
15. **Zach Zacharia**, Michael Plasch, Usha Mohan, Markus Gerschberger (2017) "The Role of Coopetition in Buyer Supplier Relationships" *DSI Conference,* Washington, DC, November 18.
14. **Zach Zacharia**, Michael Plasch, Usha Mohan, Markus Gerschberger (2017) "Understanding the Antecedents and Outcomes of Coopetition" *CSCMP Academic Research Conference,* Atlanta, Georgia, September 24.

13. **Zach Zacharia**, Michael Plasch, Usha Mohan, Markus Gerschberger (2017) "The Evolving Role of Coopetition within the Supply Chain" *CSCMP European Research Seminar,* Barcelona, Spain, May 19.

12. Gouda, Sirish, **Zach Zacharia**, Haritha Saranga (2016) "Linking New Forms of Work Organization and External Integration: Mediating role of cross functional collaboration" *DSI Conference,* Austin, Texas, November 21.

11. Blessley, Misty, Saif Mir, **Zacharia, Zach G.,** John Aloysius (2016) "The role of apologies following transgressions in buyer-supplier relationships." *CSCMP Educator Conference,* Orlando, Florida, September 25.

10. Blessley, Misty, Saif Mir, **Zacharia, Zach G.,** John Aloysius (2016) "The role of transactional and relational psychological contract breach in supplier switching behavior." *CSCMP European Research Seminar,* Vienna, Austria, May 13.

9. Blessley, Misty, Saif Mir, **Zacharia, Zach G.,** John Aloysius (2015) "Should I stay or should I go? The role of transactional and relational psychological contract breach in supplier switching behavior." *CSCMP Educator Conference,* San Diego, California, September 27.

8. **Zacharia, Zach G.,** Nancy W. Nix and Robert F. Lusch (2007) "Supply Chain Collaborations: Project Performance and Business Performance" *18th North American Teaching and Research Conference,* Tempe, Arizona, March 29-31.

7. Zacharia, Zach G. (2005) "Team Based Learning in MBA and Undergraduate Supply Chain Management Classes" *16th North American Teaching and Research Conference,* Tempe, Arizona, March 17-19.

6. Nix, Nancy W., **Zach G. Zacharia** and Robert F. Lusch (2005) "Keys to Effective Supply Chain Collaboration" *16th North American Teaching and Research Conference,* Tempe, Arizona, March 17-19.

5. **Zacharia, Zach G.** and Marc E. Ruzicka (2003) "Experiential Learning: Live Business Cases in MBA Supply Management and Logistics Classes" *14th North American Teaching and Research Conference,* Tempe, Arizona , March 21- 23.

4. **Zacharia**, **Zach G** (2000) "The Evolution and Growth of Production in the Supply Chain", *Society for Marketing Advances Conference*, Orlando, Florida, November 8-10.

3. **Zacharia, Zach G**., John E. Tidwell and Stephen H. Richards (2000) "An Overview of Truck and Bus Safety:1999 Knoxville Symposium," *4th International Fatigue Management Conference*, Perth, Australia, March 19-2.

2. **Zacharia, Zach G**. and Bart Jennings (1998), "The Use of Active Participation and Group Competition to Facilitate Training and Technology Transfer for Adult Learners," *Transportation Research Board Conference Proceedings,* Washington, District of Columbia, January 4-8.

1. **Zacharia, Zach G**. (1992), "Bridge Paint Expert Systems"*, Second International Organization for Economic Cooperation and Development (OECD) Conference on Knowledge Based Expert Systems in Transportation*, Montreal, Canada, April 3-7.

PODCASTS (18)

- **Zacharia, Zach G**. (2024), "Why Cyber security is top threat in Supply Chain" https://business.lehigh.edu/blog/2024/zach-zacharia-why-cybersecurity-top-threat-supply-chain - Jan 2024

- **Zacharia, Zach G**. (2023), "Top 3rd Quarter Risks in Spply Chain Why Cyber security is top threat in Supply Chain" https://business.lehigh.edu/blog/2023/zach-zacharia-top-3rd-quarter-risks-supply-chain June 2023

- **Zacharia, Zach G**. (2023), "Biggest Risk in Supply Chain" https://www2.lehigh.edu/news/cybersecurity-tops-supply-chain-managers-list-of-biggest-risks-in-2nd-quarter - March 2023

- **Zacharia, Zach G**. (2023), "Biggest Threats in Global Supply Chain" https://business.lehigh.edu/blog/2023/zach-zacharia-biggest-threats-global-supply-chain - Jan 2023

- **Zacharia, Zach G**. (2022), "Supply Chain Managers are concerned about Economic Risk" https://www2.lehigh.edu/news/supply-chain-managers-concerned-about-economic-risks-and-cybersecurity-in-1st-quarter-of-2023 (December)

- **Zacharia, Zach G**. (2022), "Supply Chain Risk Management Index All-Time low" https://www2.lehigh.edu/news/lehigh-business-supply-chain-risk-management-index-at-all-time-low (September)

- **Zacharia, Zach G**. (2022), "Supply Chain Risks 3rd Quarter" https://business.lehigh.edu/blog/2022/zach-zacharia-supply-chain-risks-3rd-quarter-2022 (July)

- **Zacharia, Zach G**. (2022), "Supply Risks Threaten 2nd Quarter" https://www2.lehigh.edu/news/transportation-risk-threatens-supply-chain-in-2nd-quarter (March)

- **Zacharia, Zach G**. (2021), "What's happening in Supply Chain now" https://business.lehigh.edu/blog/2021/zach-zacharia-whats-happening-supply-chain-now - (December)

- **Zacharia, Zach G**. (2021), "Number one Supply Chain Threat – Transportation Disruption" https://business.lehigh.edu/news/2021/number-one-supply-chain-threat-transportation-disruption (October)

- **Zacharia, Zach G**. (2021), "Red Flags in the Supply Chain" https://business.lehigh.edu/blog/2021/zach-zacharia-red-flags-supply-chain (July 2nd)

- **Zacharia, Zach G**. (2021), "Disruptive New Paradigm of the Physical Internet" https://business.lehigh.edu/blog/2021/zach-zacharia-disruptive-new-paradigm-physical-internet (June 3rd)

- **Zacharia, Zach G**. (2021), "Red Flags in the Supply Chain" https://business.lehigh.edu/blog/2021/zach-zacharia-red-flags-supply-chain (July 2nd)

- **Zacharia, Zach G**. (2021), "Red Flags in the Supply Chain" https://business.lehigh.edu/blog/2021/zach-zacharia-red-flags-supply-chain (July 2nd)

- **Zacharia, Zach G**. (2021), "Disruptive New Paradigm of the Physical Internet" https://business.lehigh.edu/blog/2021/zach-zacharia-disruptive-new-paradigm-physical-internet (June 3rd)

- **Zacharia, Zach G**. (2018), "Dealing with Disruptive Innovations in the Supply Chain" (https://cbe.lehigh.edu/blog/posts/dealing-disruptive-innovations-supply-chain) (October 24)

- **Zacharia, Zach G**. (2017), "Drop Shipping: A New Opportunity for Retailers and Suppliers" (https://cbe.lehigh.edu/blog/posts/drop-shipping-new-opportunity-retailers-and-suppliers) December 11

- **Zacharia, Zach G**. (2017), "What You Need to Know About the Physical Internet" (https://cbe.lehigh.edu/blog/posts/what-you-need-know-about-physical-internet (March 14) (Ranked 4th in Google Search for Physical Internet)

WORKING PAPERS (4)

- Zach Zacharia, Michael Plasch, Markus Gerschberger "Explorative and exploitative motives for coopetition" *Target: International Journal of Production Economics*

- Zach Zacharia, Cedric Heuchenne, Nada Sanders, Faraz, Alireza "Comparison of populations based on binary characteristics in the presence of non-response" *Target: Production Operations Management Journal*

- Zach Zacharia, Iana Shaheen, Ravi Shankar, Ujjwal Kumar, "Competition and Cooperation in Humanitarian Operations" *Target: Production Operations Management Journal*

- Zach Zacharia, Saif Mir, Dina Ribbnik, Saurabh Bansal, Philip Coles "Shock and Worker Productivity- Evidence from a US Agricultural Sector" *Target: Production Operations Management Journal*

27. Honors and Awards (25)

2023	DATA Department Service Award, Lehigh University
2018	Teaching Innovation Grant, CBE, Lehigh University
2018	Senior Associate Editor for *International Journal of Logistics Management*
2017	Best Reviewer Award *Journal of Business Logistics*
2016	Editor for *Journal of Business Logistics News*
2016	Associate Editor for *Production Operations Management* Special Issue
2015	Associate Editor for *Journal of Business Logistics*
2015	Member of the *Transportation Journal* Editorial Board
2013	Robert and Christine Staub Faculty Excellence Award
2012	Member of the *Journal of Supply Chain Management* Editorial Board
2011	Best Paper Finalist for 2010 (*Journal of Operations Management*)
2011	Best Paper Award (European DSI Conference)
2010-2011	Council of Supply Chain Management Professional Educator Conference Chair
2010	Member of the *Journal of Operations Management* Editorial Board
2010	Member of the *Journal of Business Logistics* Editorial Board
2009-2010	Supply Chain Management Educator Conference Proceedings Editor
2007-2008	Council of Supply Chain Management Case Editor
2007	Best Paper Award (*NARTS-ISM Conference*)
2006	Tied for highest SPOT (Student Perception of Teaching) score
2005	Highest SPOT (Student Perception of Teaching) in INSC department
2000	Doctoral Dissertation Proposal Award (*University of Arkansas)*
2000	Outstanding Student Paper Award *(Society for Marketing Advances)*
2000	Finalist *(ISBM Doctoral Dissertation Award)*
2000	Scholarly Research Grant Recipient *(University of Tennessee)*
1999, 1997	Fellow *(Council of Logistics Management Doctoral Symposium)*

28. Research Funding (16)

2019	DiCentral – SCM and Financial Flow Research $20,000
2019	Ben Franklin Technology Partners and ESPI $20,000
2018	AFIT – Managing Customer Driven Coopettittion Projects $25,000
2017	DiCentral – Drop Shipment Research $20,000
2014-2015	International Travel Grant - One of 5 recipients selected across the entire University $5000
2011	Faculty Research Grant – Lehigh University (Principal Investigator), Catherine Ridings (Lehigh University) " Does investment in Supply Chain Management and Information Technology provide value for micro firms?" $4500
2009	Summer Research Grant – College of Business and Economics, Lehigh University (Principal Investigator), Nada R. Sanders (Lehigh University, Brian S. Fugate (Colorado State University) *"State of Supply Chain Management: A Visionary Perspective"* $3000
2002-2007	Charles Tandy American Enterprise Center Faculty Research Award *(Texas Christian University)* ($10,000/yr)
2003, 05, 07	Junior Faculty Research Grant *(Institute of Supply Management)* ($750/yr)
2005	Research Center for Teaching Excellence, Faculty Fellow Grant *(Texas Christian University)* ($2500)

F. Scholarly Presentations (87)

- **Zach Zacharia**, (2023) "Identifying and Ranking Supply Chain Risks" *DSI Conference,* Atlanta, GA, November 20.
- Michael Plasch**, Zach Zacharia**, (2023) "Supply chain visibility in a multi-partner collaboration for distribution logistics – A secondary data research approach" Euroama Conference, Brussels, July 3rd
- Michael Plasch**, Zach Zacharia**, (2023) "Voluntary or involuntary: Perspectives on coopetition in dyadic and triadic supply chain relationships in the light of balance theory" Euroama Conference, Brussels, July 3rd
- **Zach Zacharia**, (2023) "Supply Chain Collaboration and Coopetition" *World Class Supply Chain Summit,* Waterloo, Ontario, Canada, May 3rd
- Saif Mir**, Zach Zacharia**, (2022) "Risks in Procurement and Sourcing" DSI Conference Houston, November 21
- Annibal Sodero**, Zach Zacharia**, (2022) "Antecedents and outcomes of drop-shipping adoption in the retail supply chain" Euroama Conference, Berlin, July 3rd

- Zach Zacharia, (2022) “Identifying and Ranking Supply Chain Risks” WDSI Conference, Waikoloa, HI, April 7.
- Zach Zacharia, (2021) “Writing a publishable dissertation” CSCMP Doctoral Consortium, Atlanta, GA, Sep 20.

- Zacharia**, Zach G.,** “*Supply Chain Collaboration in Transformative Vertical Industries”* Retail Value Chain Federation Conference, Teaneck, New Jersey, May 6, 2019

- **Zacharia, Zach G.,** “*Theoretical and Conceptual Foundations of Supply Chain Management”* PhD Research Seminar, Indian Institute of Technology, New Delhi, January India, January 25, 2018.

- **Zach Zacharia**, Michael Plasch, Usha Mohan, Markus Gerschberger “*The Role of Coopetition in Buyer Supplier Relationships*” *DSI Conference,* Washington, DC, November 18, 2017

- **Zacharia, Zach G.,** “*Utilizing Drop Shipment to Improve Your Bottom Line”* Retail Value Chain Federation Conference, Phoenix, Arizona, November 6, 2017

- **Zach Zacharia**, Michael Plasch, Usha Mohan, Markus Gerschberger “*Understanding the Antecedents and Outcomes of Coopetition*” *CSCMP Academic Research Conference,* Atlanta, Georgia, September 24, 2017

- **Zacharia, Zach G.,** “*Complexity in Supply Chain Management”* PhD Research Seminar, Atlanta, Georgia, September 23, 2017

- **Zacharia, Zach G.,** “*Coopetition Research”* PhD Research Seminar, Atlanta, September 22, 2017

- **Zacharia, Zach G.,** “*Buyer Supplier Relationships”* PhD Research Seminar, Atlanta, September 21, 2017

- **Zacharia, Zach G.,** “*Publishing Research in American Supply Chain Journals”* Indian Institute of Technology, New Delhi, India, July 21, 2017.

- **Zacharia, Zach G.,** “*Transforming Traditional Networks Through the Use of Collaborative Environments”* Supply Chain Leaders in Action Conference, Naples, Florida June 5, 2017

- **Zach Zacharia**, Michael Plasch, Usha Mohan, Markus Gerschberger (2017) “*The Evolving Role of Coopetition within the Supply Chain*” CSCMP European Research Seminar*,* Barcelona, Spain, May 19.

- **Zacharia, Zach G.,** "*Logistics PhD programs in the US panel session"* Logistics Doctoral Symposium, Auburn University, Auburn, February 24, 2017.

- **Zacharia, Zach G.,** "*A Research Journey"* Indian Institute of Technology, Trichy, India, February 6, 2017.

- **Zacharia, Zach G.,** "*Orientation and Firm Infrastructure"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria January 12, 2017

- **Zacharia, Zach G.,** "*Strategy"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria January 11, 2017

- **Zacharia, Zach G.,** "*Conceptual Foundations from Procurement and Operations"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria January 10, 2017

- **Zacharia, Zach G.,** "*Conceptual Foundations from Marketing and Logistics"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria January 9, 2017

- **Zacharia, Zach G.,** "*Theoretical and Conceptual Foundations of Supply Chain Management"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria August 10, 2016

- **Zacharia, Zach G.,** "*Philosophy of Science"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria August 9, 2016

- **Zacharia, Zach G.,** " *Conceptual Foundations of Marketing"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria August 8, 2016

- **Zacharia, Zach G.,** " *Conceptual Foundations of Operations"* PhD Research Seminar, Logistikum, University of Applied Sciences, Steyr, Austria August 10, 2016

- Gouda, Sirish, **Zach Zacharia**, Haritha Saranga (2016) "Linking New Forms of Work Organization and External Integration: Mediating role of cross functional collaboration" *DSI Conference,* Austin, Texas, November 21.

- Blessley, Misty, Saif Mir, **Zacharia, Zach G.,** John Aloysius (2016) "The role of apologies following transgressions in buyer-supplier relationships." *CSCMP Educator Conference,* Orlando, Florida, September 25.

- **Zacharia, Zach G.,** " *Increasing Efficiency and Reducing Cost within a Supply Chain"* Indian Institute of Technology, Madras, India, June 13 2016.

- Blessley, Misty, Saif Mir, **Zacharia, Zach G.,** John Aloysius (2016) "The role of transactional and relational psychological contract breach in supplier switching behavior." *CSCMP European Research Seminar,* Vienna, Austria, May 13.

- Bleasley, Misty, Mir, Saif, **Zacharia, Zach G.,** Aloysius, John " *Should I stay or should I go? The role of transactional and relational psychological contract breach in supplier switching behavior"* Council of Supply Chain Management Educator Conference, San Diego, September 27, 2015.

- **Zacharia, Zach G.,** "*Qualitative and Quantitative Research Paths in SCM"* , University of Arkansas, Fayetteville, Arkansas Feb 27, 2015.

- **Zacharia, Zach G.,** "*Publishing Research in American Supply Chain Journals"* Indian Institute of Management, Bangalore, India, January 13, 2015.

- **Zacharia, Zach G.,** Scott Ellis, Robert J. Trent "*Gaining Advantage Through Social Exchange: How and Under What Conditions"* Production Operation Management Conference, Atlanta, Georgia, May 10, 2014.

- Ellis, Scott, **Zacharia, Zach G.,** Jae-Young Oh "*The Role of Functional Congruence in Cross-Functional and Inter-organizational Collaboration"* Decision Sciences Institute Conference, Baltimore, Maryland, November 19, 2013.

- **Zacharia, Zach G.,** "*Supply Chain Management, Collaboration and their Role Across Businesses and People"* Congress of Latin American Engineering Students, Lima, Peru, October 29, 2013.

- **Zacharia, Zach G.,** Scott Ellis, "*Antecedents to Buyer-Engineer Knowledge Transfer"* Production Operation Management Conference, Denver, Colorado, May 4, 2013.

- **Zacharia, Zach G.,** "*Balancing Effective Research and Teaching"* – Invited Panel Presentation, Council of Supply Chain Management Doctoral Symposium, Atlanta, Georgia, October 1, 2012.

- **Zacharia, Zach G.,** "*What are some of the Factors That Affect the Relationship Between Cross Functional New Product Development and New Product Project Performance?"* Decision Sciences Institute Conference, Boston, Massachusetts, November 22, 2011.

- **Zacharia, Zach G.,** "*Supply Chain Security - An Academic Discussion and Future Research"* Invited Panel Presentation, Decision Sciences Institute Conference, Boston, Massachusetts, November 21, 2011.

- **Zacharia, Zach G.,** "*Conference Chairperson Opening Remarks"* Council of Supply Chain Management Educator Conference, Philadelphia, Pennsylvania, October 2, 2011.

- **Zacharia, Zach G.,** William F. Wempe William and Danny Lanier, Jr. "*Concentrated Supply Chain Membership and Financial Performance: Chain- and Firm-Level Perspectives"* Academy of Management Conference, San Antonio, Texas, August 12 – August 17, 2011.

- **Zacharia, Zach G.** and Catherine M. Ridings *"Does investment in Supply Chain Management and Information Technology provide value for micro firms?"* Production Operations Management Conference, Reno, Nevada, April 28-May 1, 2011.

- **Zacharia, Zach G.** and Robert J. Trent *"Supplier Satisfaction and Innovation Sharing"* Decision Sciences Institute Conference, San Diego, November 20-23, 2010.

- Christoph Bode, Stephan M. Wagner and **Zacharia, Zach G.,** "*The Effect of Cooperation, Supplier Development, and Relationship-Specific Investments on Suppliers' Willingness to Share Innovation"* Decision Sciences Institute Conference, San Diego, November 20-23, 2010.

- **Zacharia, Zach G.** *"Personal Career Development in Academia: What now and How"* Council of Supply Chain Management Professionals Doctoral Symposium, San Diego, September 27, 2010.

- **Zacharia, Zach G.** *"Supply Chain Management Overview"* Executive MBA Program, Universidad de Piura, Piura, Peru, June 12, 2010.

- **Zacharia, Zach G.** *"Supply Chain Management Collaboration Strategies"* CSCMP Roundtable, Lima, Peru, June 11, 2010.

- **Zacharia, Zach G.** and John R. MacDonald *"Are differences in Risk Planning Significant?"* Production and Operations Management Conference, Vancouver, Canada, May 7-10, 2010.

- **Zacharia, Zach G.** and Robert J. Trent *"Supplier Satisfaction – How does it matter?"* Production and Operations Management Conference, Vancouver, Canada, May 7-10, 2010.

- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"The Moderating Role of Absorptive Capability and Collaborative Communication in Organizational Learning"* 19th *North American Teaching and Research Conference,* Tempe, Arizona, March 11-12, 2010

- **Zacharia, Zach G.** and John R. MacDonald *"Risk Planning: Is it of Value"* Decision Sciences Institute Conference, New Orleans, LA, November 17, 2009.

- **Zacharia, Zach G.** *"When Should New Product Development Managers Consider Distribution Logistics"* Decision Sciences Institute Conference, New Orleans, LA, November 15, 2009.

- John R. MacDonald and **Zacharia, Zach G.** *"Risk and Disruption Management: The Impact of Behavioral Interference"* Behavioral Operations Conference, Syracuse, NY, June 26, 2009.

- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"The Moderating Role of Absorptive Capability and Collaborative Communication in Organizational Learning"* Production and Operation Management Conference, Orlando, FL, May 2, 2009.

- **Zacharia, Zach G.,** Nancy W. Nix and Robert F. Lusch "Supply Chain Collaborations: Project Performance and Business Performance" *18th North American Teaching and Research Conference,* Tempe, Arizona, March 29-31. (2007)

- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"The Moderating Role of Absorptive Capability and Collaborative Communication in Organizational Learning"* University of Tennessee, Knoxville, TN, November 7, 2006.

- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"The Moderating Role of Absorptive Capability and Collaborative Communication in Knowledge Acquisition"* DFWCSMP Roundtable meeting, Dallas, TX, October 12, 2006.

- **Zacharia, Zach G.,** *"Early Supplier Involvement"* National Council for Advanced Manufacturing, Washington, MD, June 7, 2006.

- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"Keys to Effective Supply Chain Collaboration and Knowledge Acquisition"* National Council for Advanced Manufacturing, Washington, MD, June 7, 2006.

- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"Keys to Effective Supply Chain Collaboration"* Supplier Network Working Group Meeting, Fort Worth, TX March 16, 2006.

- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"Keys to Effective Supply Chain Collaboration"* Institute of Supply Management Group Meeting, Fort Worth, Texas, January 3, 2006.

- **Zacharia, Zach G.** "Team Based Learning in MBA and Undergraduate Supply Chain Management Classes" *16th North American Teaching and Research Conference,* Tempe, Arizona, March 17-19. (2005)

- Nix, Nancy W., **Zach G. Zacharia** and Robert F. Lusch "Keys to Effective Supply Chain Collaboration" *16th North American Teaching and Research Conference,* Tempe, Arizona, March 17-19. (2005)

- **Zacharia, Zach G.,** *"Education Strategies"* Council of Logistics Roundtable Leadership Forum, Chicago, Illinois, June 11-12, 2004.
- **Zacharia, Zach G.,** and Nancy W. Nix, *"Supply Chain Collaboration – The role of a 3PL intermediary"* Society of Marketing Advances, New Orleans, Louisiana, November 6 - 8, 2003.
- **Zacharia, Zach G.,** Nancy W. Nix, and Robert F. Lusch *"Collaboration Effectiveness in the Supply Chain: A Knowledge and Capabilities Based Approach"* American Marketing Faculty Consortium, Dallas, Texas, October 30-November 2, 2003.

- **Zacharia, Zach G.,** *"What does it mean to be an education officer in your roundtable?"* Council of Logistics Roundtable Leadership Forum, Chicago, Illinois, June 6-7, 2003.
- Nix, Nancy W. and **Zach G. Zacharia**, Track Chairs "*Going Beyond the Hype: Getting and Measuring the Value from your Supply Chain Initiatives"* Council of Logistics Management Conference, Chicago, Illinois, September 23-27, 2003.
- **Zach G. Zacharia,** *Top 10 Truck Safety Recommendations*, Federal Motor Carrier Safety Administration, Washington, District of Columbia, October 16, 2002.
- **Zach G. Zacharia,** *Logistics Involvement in New Product Development*, University of Arkansas, Fayetteville, Arkansas, September 18, 2002.
- **Zach G. Zacharia,** "Supply and Value Chain Certificate Program" presented at the Supply and Value Chain Conference, Ft. Worth, Texas, February 8, 2002.
- **Zach G. Zacharia,** "*Tennessee Transportation Assistance Program*" presented at the Region 4 LTAP conference, St. Petersburg, Florida, May 16, 2001.

- **Zach G. Zacharia,** "*The Evolution and Growth of Production in the Supply Chain*", *2000 Society for Marketing Advances Conference*, Orlando, Florida, November 8. 2000.
- **Zach G. Zacharia,** and Soonhong Min "*The Nature of Interfirm Partnering in Supply Chain Management*" presented at American Marketing Association, Chicago, Illinois, August 5, 2000.
- **Zach G. Zacharia,** *"Searching the Internet and Web Page Design"* presented at University of Tennessee, Knoxville, Tennessee, April 17, 2000.

- **Zach G. Zacharia,** *"An Overview of Truck and Bus Safety: 1999 Knoxville Symposium* presented at the 4th International Fatigue Management Conference, Perth, Australia, March 19 – 22, 2000.
- **Zach G. Zacharia,** "*Traffic Safety and the Internet*" presented at the Governor Highway Safety Conference, Memphis, Tennessee, July 12-14, 1999.
- **Zach G. Zacharia,** "*Tennessee Transportation Assistance Program*" presented at the Asphalt Emulsion Users Conference, Nashville, Tennessee, November 19, 1998.
- **Zach G. Zacharia** and Barton R. Jennings "*The Use of Active Participation and Group Competition to Facilitate Training and Technology Transfer for Adult Learners*" Transportation Research Board Conference, Washington, District of Columbia, January 10-14, 1998.
- **Zach G. Zacharia,** "*Training Requirements for Local Governments*" presented at the National Transportation Training Conference, Reno, Nevada, October 7-9, 1997.
- **Zach G. Zacharia,** "*Logistics Thought: Key Messages and Implications from the Field of Marketing*," presented at the Council of Logistics Management Doctoral Symposium, Chicago, Illinois, October 3-4, 1997.
- **Zach G. Zacharia,** "*Navigating the Internet*" presented at the Southeast Local Roads Conference, Biloxi, Mississippi, September 24-26, 1997.
- **Zach G. Zacharia,** "*Bridge Paint Expert Systems,"* presented at the Second International Organization for Economic Cooperation and Development (OECD) Conference on Knowledge Based Expert Systems in Transportation, Montreal, Canada, June 14-16, 1992.

G. Teaching and Research Advising

COURSES:

Lehigh University (2008 – Present)

- SCM 186 - Supply Chain Management and Operations (Undergraduate 2008 - present)
- SCM 354 - Logistics and Transportation (Undergraduate 2008-present)
- GBUS 453 – Logistics and Transportation (Graduate 2013 – present)
- GBUS 492- Supply Chain Management Strategy (Graduate 2010- 2015) (Summer Course)
- Advising 14 Supply Chain Management Majors (2021)
- Advising 11 Supply Chain Management Majors (2020)
- Advising 21 Supply Chain Management Majors (2019)
- Advising 5 Supply Chain Management Majors (2018)
- Advising 24 Supply Chain Management Majors (2017)

- Advising 9 Supply Chain Management Majors (2016)
- Advising 27 Supply Chain Management Majors (2015)
- Advising 28 Supply Chain Management Majors (2014)
- Advising 24 Supply Chain Management Majors (2013)
- Advising 9 Supply Chain Management Majors (2012)
- Advising 10 Supply Chain Management Majors (2011)
- Advising 13 Supply Chain Management Majors (2010)
- Advising 6 Supply Chain Management Majors (2009)

Texas Christian University (2001 – 2008)

- Strategic Sourcing and Procurement (Professional MBA) 2007
- Business Simulation (Professional MBA) 2007
- Supply Chain Management Concepts (Full-Time MBA) 2005 – 2008
- Supply Chain Management Concepts (Professional MBA) 2001– 2008
- Logistics and Transportation (Professional MBA) 2001 - 2008
- Supply Chain Tools and Technologies (Professional MBA) 2002
- Logistics and Transportation (Undergraduate) 2001 - 2008
- Supply Chain Management Concepts (Undergraduate) 2003 – 2004
- Supply Chain Tools and Technologies (Undergraduate) 2003
- Procurement and Supply Management (Undergraduate) 2003

University of Tennessee (1996-2001)

- Introduction to Transportation (Undergraduate) Summer 1998
- Introduction to Logistics (Undergraduate) Summer 1999
- Marketing Management (Undergraduate) Spring 2000
- Global Logistics and Transportation (Undergraduate) Summer 2000

H. SERVICE

University

Faculty Compensation Committee (2016 – 2019)

College

Director, Center for Supply Chain Research Lehigh
Promotion and Tenure Committee (2021 – onwards)
Chair, Database and Software Committee (2018 – onwards)
Ph.D. Task Force (2017)
Undergraduate Core Curriculum Committee (2016)
Math Committee to Assess Assessment Results (2010)

Department

BIS Assistant Professor Search Chair – Tenure Track (2021-2021)
SCM Assistant Professor Search Chair – Tenure Track (2020-2020)
DATA Department Chair Search – Tenure Track (2019-2019)
SCM Assistant Professor Search Chair – Tenure Track (2018-2018)

SCM POP Search Chair (2017-2017)
Research Seminar Committee (2010-2011)
SCM Club Faculty Liaison (2009-2019)

Professional (Council of Supply Chain Management Professionals)

Education Committee Member -Lehigh Valley Roundtable (2015-onwards)
President – Lehigh Valley Roundtable (2012-2015)
Education Conference Chair (2010 – 2011)
Education Strategies Committee Member (2007 – 3-year term)
Case Editor (3-year term)
President – Dallas Roundtable (2007-2008)
Vice President – Dallas Roundtable (2006-2007)
Education chair – Dallas Roundtable (2004-2006)
Member (1999 – onwards)

External Service

Rockefeller Group – Expert Service Consulting (Jan 2020)

Exhibit B - Eligibility Criteria: Work Records

São Paulo, April 30, 2026.

DECLARATION

For all appropriate purposes, we hereby certify that Dr. **Marcio Lamas Lopes**, registered with the São Paulo Regional Medical Council (CRM-SP) under No. 133.420 and holder of CPF No. 287.868.388-90, practices at Nove de Julho Hospital, whose legal corporate name is Ímpar Serviços Hospitalares S/A (CNPJ No. 60.884.855/0003-16). The main facility is located at Rua Peixoto Gomide, 625 - Jardim Paulista, São Paulo - SP, ZIP Code 01409-902.

The above-mentioned physician has been working as an Assistant Physician in the Endoscopy Service on an independent basis and without an employment relationship from March 2015 to the present date.

During this period, he serves as a teaching assistant in the institution's Digestive Endoscopy Specialization Program, actively participating in the education and supervision of physicians undergoing training.

In the performance of his duties, the physician provides patient care in a medium- and high-complexity hospital setting, with direct involvement in the performance of diagnostic and therapeutic endoscopic procedures, as well as the clinical management of patients with gastrointestinal diseases.

His responsibilities include:

- Performing diagnostic and therapeutic endoscopic procedures, including upper gastrointestinal endoscopy, colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP);
- Performing advanced therapeutic procedures, including polypectomy, endoscopic mucosal resection (EMR), endoscopic hemostasis, endoscopic variceal band ligation, endoscopic dilation, stent placement, endoscopic vacuum therapy, and endoscopic sleeve gastroplasty (ESG);
- Providing endoscopic care in urgent and emergency situations, including the management of gastrointestinal bleeding and other acute conditions;
- Conducting pre-procedure clinical assessment, risk stratification, and post-procedure follow-up;
- Diagnosing and managing gastrointestinal disorders based on evidence-based medical practice;
- Ordering and interpreting ancillary diagnostic tests;
- Working collaboratively with the multidisciplinary healthcare team and other hospital departments;

- Supervising and mentoring physicians in training during the performance of endoscopic procedures;

- Actively participating in the practical and didactic components of the Digestive Endoscopy Specialization Program, delivering lectures;

- Maintaining accurate and complete medical records in accordance with ethical standards, legal requirements, and institutional protocols.

It is noteworthy that practicing in a high-complexity endoscopy service, together with active involvement in teaching activities, requires a high level of technical expertise, advanced procedural skills, and sound clinical decision-making.

During his tenure, Dr. Marcio Lamas Lopes has consistently demonstrated technical competence, ethical responsibility, and a strong commitment to the quality of patient care and the education of future specialists.

We hereby certify that the information provided above is true and may be verified upon request.

We remain at your disposal should any additional information or clarification be required.

Sincerely,

-----//Signature//----

Dr. Beatriz Cortizo
CRM 66.170
Clinical Director 9JH

Beatriz da Silva Costa Cortizo
Clinical Director - Nove de Julho Hospital
CRM-SP No. 66.170
CPF No. 854.058.507-30
Email: Beatriz.cortizo.ext@americasmed.com.br

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 30, 2026.

São Paulo, 30 de abril de 2026.

DECLARAÇÃO

Para os devidos fins, declaramos que o Dr. **Marcio Lamas Lopes**, inscrito no CRM-SP sob o nº 133.420, portador do CPF nº 287.868.388-90, atua no Hospital Nove de Julho, cuja razão social é Ímpar Serviços Hospitalares S/A (CNPJ 60.884.855/0003-16). A unidade principal está localizada na Rua Peixoto Gomide, 625 – Jardim Paulista, São Paulo – SP, CEP 01409-902.

O referido médico exerce suas atividades como Médico Assistente do Serviço de Endoscopia, de forma autônoma e sem vínculo empregatício, desde março de 2015 até a presente data.

Nesse período, atua como assistente de ensino no programa de especialização em endoscopia digestiva da instituição, participando ativamente da formação e supervisão de médicos em treinamento.

No exercício de suas funções, o profissional desempenha atividades assistenciais em ambiente hospitalar de média e alta complexidade, com atuação direta na realização de procedimentos endoscópicos diagnósticos e terapêuticos, bem como no manejo clínico de pacientes com doenças do trato gastrointestinal.

As atribuições incluem:

- Realização de procedimentos endoscópicos diagnósticos e terapêuticos, incluindo endoscopia digestiva alta, colonoscopia e colangiopancreatografia endoscópica retrógrada (CPRE);
- Execução de procedimentos terapêuticos avançados, tais como polipectomias, mucosectomias (EMR), hemostasia endoscópica, ligadura elástica de varizes, dilatações endoscópicas, colocação de próteses, terapias endoscópicas a vácuo, gastroplastia endoscópica (ESG);
- Atuação em situações de urgência e emergência endoscópica, incluindo manejo de hemorragias digestivas e outras condições agudas;
- Avaliação clínica pré-procedimento, estratificação de risco e acompanhamento pós-procedimento;
- Diagnóstico e condução de patologias do trato gastrointestinal com base em evidências científicas;
- Solicitação e interpretação de exames complementares;
- Atuação integrada com equipe multiprofissional e demais setores hospitalares;

- Supervisão e orientação de médicos em treinamento durante a realização de procedimentos endoscópicos;
- Participação ativa no ensino prático e teórico da especialização em endoscopia digestiva ministrando aulas;
- Registro adequado em prontuário, respeitando normas éticas, legais e protocolos institucionais.

Destaca-se que a atuação em serviço de endoscopia de alta complexidade, aliada à participação em atividades de ensino, exige elevado nível de conhecimento técnico, habilidade prática especializada e capacidade de tomada de decisão clínica.

Durante o período de atuação, o Dr. Marcio Lamas Lopes demonstra competência técnica, responsabilidade ética e comprometimento com a qualidade da assistência e com a formação de novos profissionais.

Declaro que as informações acima são verdadeiras e podem ser confirmadas mediante solicitação.

Colocamo-nos à disposição para quaisquer informações adicionais ou esclarecimentos que se fizerem necessários.

Atenciosamente,

Beatriz da Silva Costa Cortizo

Dra. Beatriz Cortizo
CRM 66170
Diretora Clínica H9J

Beatriz da Silva Costa Cortizo
Diretora Clínica – Hospital 9 de Julho
CRM 66.170
CPF 854.058.507-30
E-mail: beatriz.cortizo.ext@americasmed.com.br

Adventist Hospital

EMPLOYMENT DECLARATION

To Whom It May Concern,

This letter is intended to certify that Dr. Márcio Lamas Lopes, a physician duly registered with the Regional Medical Council of the State of São Paulo (CREMESP), São Paulo Regional Medical Council (CRM-SP) 133.420, CPF No. 287.868.388-90, has worked alongside his partner since February 1, 2018, and continues to serve to the present date as the Coordinator Physician of the Endoscopy Service at the Adventist Hospital of São Paulo, CNPJ No. 43.586.122/0009-71, located at Rua Rocha Pombo, 49, Liberdade Neighborhood, São Paulo/SP, ZIP Code 01525-010.

In the performance of his duties, the physician simultaneously carries out clinical and managerial responsibilities, being responsible for the technical and operational coordination of the service, as well as for performing medium- and high-complexity diagnostic and therapeutic endoscopic procedures.

His responsibilities include, but are not limited to:

- Coordination of the Endoscopy Service, including the management of the medical and multidisciplinary team, organization of clinical workflows, and supervision of the department's activities;
- Planning, implementing, and overseeing clinical protocols, with a focus on patient safety, quality of care, and operational efficiency;
- Execution of diagnostic and therapeutic endoscopic procedures, including upper gastrointestinal endoscopy, colonoscopy, and endoscopic retrograde cholangiopancreatography (ERCP);
- Performance of advanced therapeutic procedures, including polypectomy, endoscopic mucosal resection (EMR), endoscopic hemostasis, endoscopic variceal band ligation, endoscopic dilation, stent placement, argon plasma coagulation, endoscopic vacuum therapy, and endoscopic sleeve gastroplasty (ESG);
- Performance in endoscopic urgent and emergency situations, including the management of gastrointestinal bleeding, obstructions, and other acute gastrointestinal conditions;
- Pre-procedure assessment, risk stratification, and clinical follow-up in the post-procedure period;
- Diagnosis and management of gastrointestinal tract disorders based on scientific evidence;
- Ordering, interpreting, and integrating ancillary diagnostic tests into clinical decision-making;
- Ensuring compliance with applicable technical, ethical, and regulatory standards;
- Training, supervising, and mentoring the medical staff and other professionals within the service;
- Monitoring clinical performance indicators and implementation of continuous quality improvement actions;

· Integration with other hospital departments, promoting continuity and comprehensiveness of patient care.

It is emphasized that serving as a coordinator, combined with the performance of advanced endoscopic procedures, demands a high degree of specialized technical knowledge, refined practical skills, leadership capability, and decision-making proficiency in medium and high-complexity environments.

During his tenure, Dr. Marcio Lamas Lopes has consistently demonstrated technical competence, ethical responsibility, and a strong commitment to excellence in patient care and service management.

I hereby certify that the information provided above is true and may be verified upon request.

Please do not hesitate to contact me by email at (dorival.duarte@hasp.org.br) or by telephone at +55-11-2838-7000 should you require any additional information regarding Dr. Marcio Lamas Lopes's professional experience or qualifications.

São Paulo, April 30, 2026

Sincerely,

-----//Signature//----

Dr. Dorival Duarte de Lima
Associate Medical Director - CRM-SP No. 105977
ADVENTIST HOSPITAL OF SÃO PAULO
Rua Rocha Pombo, Liberdade, 49, ZIP Code 01525-010 - São Paulo, SP
diretoria@hasp.org.br

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 30, 2026.

DECLARAÇÃO DE ATIVIDADES PROFISSIONAIS

A quem possa interessar,

A presente carta tem por finalidade certificar que o Dr. Márcio Lamas Lopes, médico regularmente inscrito no Conselho Regional de Medicina do Estado de São Paulo (CREMESP), CRM: 133.420, CPF: 287.868.388-90, atua juntamente ao seu sócio, desde 01 de fevereiro de 2018 até a presente data como Médico Coordenador do Serviço de Endoscopia no Hospital Adventista de São Paulo, CNPJ: 43.586.122/0009-71, localizado na Rua Rocha Pombo, 49, Bairro Liberdade, no município de São Paulo/SP, CEP: 01525-010.

No exercício de suas funções, o profissional desempenha simultaneamente atividades assistenciais e de gestão, sendo responsável pela coordenação técnica e operacional do serviço, bem como pela execução de procedimentos endoscópicos diagnósticos e terapêuticos de média e alta complexidade.

Suas atribuições incluem, mas não se limitam a:

· Coordenação do Serviço de Endoscopia, incluindo gestão de equipe médica e multiprofissional, organização de fluxos assistenciais e supervisão das atividades do setor;

· Planejamento, implementação e supervisão de protocolos clínicos, com foco em segurança do paciente, qualidade assistencial e eficiência operacional;

· Realização de procedimentos endoscópicos diagnósticos e terapêuticos, incluindo endoscopia digestiva alta, colonoscopia e colangiopancreatografia endoscópica retrógrada (CPRE);

· Execução de procedimentos terapêuticos avançados, tais como polipectomias, mucosectomias (EMR), hemostasia endoscópica, ligadura elástica de varizes, dilatações endoscópicas, colocação de próteses, aplicação de plasma de argônio, terapias endoscópicas a vácuo e gastroplastia endoscópica (ESG);

· Atuação em situações de urgência e emergência endoscópica, incluindo manejo de hemorragias digestivas, obstruções e outras condições agudas do trato gastrointestinal;

· Avaliação pré-procedimento, estratificação de risco e acompanhamento clínico no período pós-procedimento;

· Diagnóstico e condução de patologias do trato gastrointestinal com base em evidências científicas;

· Solicitação, interpretação e integração de exames complementares ao raciocínio clínico;

· Garantia do cumprimento de normas técnicas, éticas e regulatórias aplicáveis;

· Treinamento, supervisão e orientação da equipe médica e demais profissionais do serviço;

· Monitoramento de indicadores assistenciais e implementação de ações de melhoria contínua da qualidade;

· Integração com demais setores hospitalares, promovendo continuidade e integralidade do cuidado ao paciente.

Ressalta-se que a atuação como coordenador associada à execução de procedimentos endoscópicos avançados exige elevado grau de conhecimento técnico especializado, habilidade prática refinada, capacidade de liderança e tomada de decisão em ambiente de média e alta complexidade.

Durante seu período de atuação, o Dr. Márcio Lamas Lopes demonstra competência técnica, responsabilidade ética e compromisso com a excelência na assistência e na gestão do serviço.

Declaro que as informações acima são verdadeiras e podem ser confirmadas mediante solicitação.

Por favor, não hesite em entrar em contato comigo através do e-mail (dorival.duarte@hasp.org.br) ou pelo telefone +55-11-28387000, caso haja dúvidas adicionais quanto à experiência profissional ou qualificações do Dr. Marcio Lamas Lopes.

São Paulo, 30 de abril de 2026

Atenciosamente,

Dr. Dorival Duarte de Lima
Vice-Diretor Médico - CRM 105977
HOSPITAL ADVENTISTA DE SÃO PAULO
Rua Rocha Pombo, 49. Liberdade. CEP 01525-010 – São Paulo, S.P.
diretoria@hasp.org.br

Family
Health
Association

Declaration

We hereby declare, for all due purposes, that Mr. **MARCIO LAMAS LOPES**, registered under CPF No. **287.868.388-90**, holder of ID **249949829**, was an employee of this Social Health Organization - **Family Health Association**, registered office at Praça Marechal Cordeiro de Farias, 65, Higienópolis Neighborhood, São Paulo, State of São Paulo, registered with the CNPJ/MF under No. **68.311.216/0001-01**, under the CLT labor regime, from **07/28/2008** to **03/31/2010**. He held the position of **General Practitioner** at the **Sapopemba Basic Health Unit** (UBS), where he worked **20 hours per week**. With the following responsibilities:

- ✓ Perform initial patient assessment, collect information on symptoms, medical history, and severity factors that may assist in diagnostic investigation, as well as make a preliminary diagnosis of the presenting condition;
- ✓ Attention to the patient's medical history and maintenance of medical records in accordance with consultations, documenting clinical progress and treatments provided;
- ✓ Request diagnostic tests and evaluate the results to determine clinical management;
- ✓ Support referral to medium- and high-complexity services, in accordance with local referral and counter-referral pathways, while maintaining responsibility for follow-up of the user's therapeutic plan proposed by the referring service;
- ✓ Prescribe medications, treatments, and medical procedures, provide guidance or refer to other specialists, depending on the severity and nature of the patient's condition, in accordance with the established diagnoses, issuing clear and appropriate prescriptions and medical certificates.

São Paulo, May 11, 2026.

-----//Signature//----

Eder Melão

25.942.250-2
People Management Supervision
Family Health Association

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 30, 2026.

Associação Saúde da Família

Declaração

Declaramos para os devidos fins que o Sr. **MARCIO LAMAS LOPES**, inscrito no CPF sob nº **287.868.388-90,** portador(a) do RG **249949829,** foi funcionário desta Organização Social de Saúde - **Associação Saúde da Família**, sediada na Praça Marechal Cordeiro de Farias, 65. Bairro Higienópolis, na cidade de São Paulo, Estado de SP, inscrita no CNPJ do MF sob nº **68.311.216/0001-01,** pelo regime CLT, de **28.07.2008** a **31.03.2010**, exerceu a função de **Medico Generalista** na unidade **UBS Sapopemba**, onde cumpriu a carga horária de **20 horas semanais**. Com as seguintes atribuições:

- ✓ Realizar avaliação inicial do paciente, coletar informações sobre os sintomas, histórico médico, gravidade e fatores que possam auxiliar a investigação diagnóstica, bem como fazer diagnóstico preliminar da condição apresentada;
- ✓ Atenção ao histórico do paciente e manter registro em prontuários conforme atendimentos, formalizando as evoluções e tratativas realizadas;
- ✓ Solicitar exames e avaliar os resultados para estabelecimento de conduta;
- ✓ Apoiar encaminhamento para serviços de média e alta complexidade, respeitando fluxos de referência e contrarreferência locais, mantendo sua responsabilidade pelo acompanhamento do plano terapêutico do usuário, proposto pela referência;
- ✓ Prescrever medicamentos, tratamentos, procedimentos médicos, conceder orientações ou encaminhar para outros especialistas, dependendo da gravidade e natureza da condição do usuário, na conformidade dos diagnósticos efetuados, emitindo receituários e atestados claros e adequados.

São Paulo, 11 de maio de 2026.

Eder Melão
25.942.250-2
Supervisão de Gestão de Pessoas
Associação Saúde da Família

SANTA MARCELINA
Health

EMPLOYMENT DECLARATION

June 26, 2026

To Whom It May Concern,

This letter is intended to certify that Mr. **Marcio Lamas Lopes**, Regional Medical Council (CRM): 133.420, CPF: 287.868.388-90, physician, worked in 12-hour shifts as a General Practitioner at the AMA (Outpatient Medical Care Unit) Fazenda do Carmo, located in the eastern zone of São Paulo, under the Social Health Organization (O.S.S.) Santa Marcelina, Cidade Tiradentes/Guaianases unit, registered with CNPJ No. 60.742.616/0012-12, located at Rua Fontoura Xavier, 1035, São Paulo - ZIP Code 08295-300, during the period from April 9, 2010 to February 1, 2011.

During the aforementioned period, the professional performed clinical duties in accordance with the responsibilities of the position and institutional protocols.

In the performance of his duties, he was responsible for:

- Patient care on a walk-in basis, including triage, initial assessment, and clinical management;
- Diagnosis and treatment of acute conditions and chronic conditions in acute exacerbation or decompensation, based on clinical criteria and scientific evidence.
- Stabilization of patients in potentially severe conditions, including initial life support;
- Performance of medical procedures, such as suturing of lacerations, drainage procedures, and outpatient medical procedures consistent with his professional qualifications and the resources available at the unit;
- Request and interpretation of laboratory and imaging tests;
- Prescription of pharmacological therapies and clinical guidance;
- Referral of patients to higher-complexity services when necessary;
- Proper documentation in medical records and compliance with institutional protocols and the guidelines of the Brazilian Unified Health System (SUS);

- Integrated work with the multidisciplinary team.

It is emphasized that the practice of medicine in these units requires technical competence, agility in decision-making, and skill in managing high patient volume.

During his period of service, there is nothing that would discredit Dr. Marcio Lamas Lopes's professional conduct.

I hereby declare that the information provided above is true and may be verified upon request.

Please do not hesitate to contact me by email (**renata.antonelli@santamarcelina.org**) or by telephone at +55 (11) 2070-6000 | Extension 5231 should you require any additional information regarding Mr. **Marcio Lamas Lopes**'s professional experience or qualifications.

-----//Signature//----

Renata Cristina Antonelli

People Management Manager

Sincerely,

Renata Cristina Antonelli

People Management Manager

renata.antonelli@santamarcelina.org

Rua Santa Marcelina, 177 | Itaquera | São Paulo | SP

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 30, 2026.

SANTA MARCELINA
Saúde

DECLARAÇÃO DE ATIVIDADES PROFISSIONAIS

26 de junho de 2026

A quem possa interessar,

A presente carta tem por finalidade certificar que o Dr. **Marcio Lamas Lopes**, CRM: 133.420, CPF: 287.868.388-90, médico, atuou em períodos/plantões de 12h como médico clínico geral na AMA (Atendimento Médico Ambulatorial) Fazenda do Carmo, situada na zona leste de São Paulo, da instituição O.S.S. Santa Marcelina, unidade Cidade Tiradentes/Guaianases, inscrita no CNPJ nº 60.742.616/0012-12, localizada na Rua Fontoura Xavier, 1035, São Paulo – CEP 08295-300, no período de 09 de abril de 2010 a 01 de fevereiro de 2011.

Durante o período mencionado, o profissional exerceu as atividades assistenciais conforme atribuições do cargo e protocolos institucionais.

No desempenho de suas funções, esteve responsável por:

- Atendimento a pacientes em livre demanda, incluindo triagem, avaliação inicial e manejo clínico;
- Diagnóstico e tratamento de agravos agudos e de condições crônicas em situação de agudização ou descompensação, com base em critérios clínicos e evidências científicas.
- Estabilização de pacientes em condições potencialmente graves, incluindo suporte inicial à vida;
- Realização de procedimentos médicos, como suturas de lesões corto-contusas, drenagens e procedimentos médicos ambulatoriais compatíveis com sua habilitação profissional e com os recursos disponíveis na unidade;
- Solicitação e interpretação de exames laboratoriais e de imagem;
- Prescrição de terapias medicamentosas e orientações clínicas;
- Encaminhamento de pacientes para serviços de maior complexidade quando necessário;
- Registro adequado em prontuário e cumprimento de protocolos institucionais e diretrizes do Sistema Único de Saúde (SUS);

- Atuação integrada com equipe multiprofissional.

Ressalta-se que o exercício da medicina nessas unidades exige capacidade técnica, agilidade na tomada de decisão e habilidade no manejo do volume de pacientes.

Durante seu período de atuação, não há nada que desabone referente a atuação do Dr. Marcio Lamas Lopes.

Declaro que as informações acima são verdadeiras e podem ser confirmadas mediante solicitação.

Por favor, não hesite em entrar em contato comigo através do e-mail (**renata.antonelli@santamarcelina.org**) ou pelo telefone +55 (11) 2070-6000 | Ramal 5231, caso haja dúvidas adicionais quanto à experiência profissional ou qualificações do Sr. **Marcio Lamas Lopes**.

Renata Cristina Antonelli
Gerente de Gestão de Pessoas

Atenciosamente,

Renata Cristina Antonelli
Gerente de Gestão de Pessoas
renata.antonelli@santamarcelina.org
Rua Santa Marcelina, 177 | Itaquera | São Paulo | SP

Query of the Partners and Managers Chart - QSA

CNPJ:
21.850.272/0001-50
Corporate Name:
ABC ENDOSCOPIA LTDA
Share Capital:
R$40,000.00 (Forty thousand reais)

The Partners and Managers Chart (QSA) listed in the database of the National Registry of Legal Entities (CNPJ) is as follows:

Name/Corporate Name:
MARCIO LAMAS LOPES
Position:
49 - Managing Partner

Name/Corporate Name:
RODRIGO PORPHIRIO SANT ANA
Position:
49 - Managing Partner

Name/Corporate Name:
LILIAN DE OLINDA GIANNOCCARO
Position:
22-Partner

Name/Corporate Name:
THAIS LUCIANE DE LANA SANT ANA
Position:
49 - Managing Partner

For information regarding participation in the QSA, access the e-CAC with a digital certificate or visit a Brazilian Federal Revenue Service (RFB) unit.

Issued on **11/19/2025** at **1:46 PM** (Brasilia time).

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English, as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 17, 2026.

Consulta Quadro de Sócios e Administradores - QSA

CNPJ:
21.850.272/0001-50
NOME EMPRESARIAL:
ABC ENDOSCOPIA LTDA
CAPITAL SOCIAL:
R$40.000,00 (Quarenta mil reais)

O Quadro de Sócios e Administradores(QSA) constante da base de dados do Cadastro Nacional da Pessoa Jurídica (CNPJ) é o seguinte:

Nome/Nome Empresarial:
MARCIO LAMAS LOPES
Qualificação:
49-Sócio-Administrador

Nome/Nome Empresarial:
RODRIGO PORPHIRIO SANT ANA
Qualificação:
49-Sócio-Administrador

Nome/Nome Empresarial:
LILIAN DE OLINDA GIANNOCCARO
Qualificação:
22-Sócio

Nome/Nome Empresarial:
THAIS LUCIANE DE LANA SANT ANA
Qualificação:
49-Sócio-Administrador

Para informações relativas à participação no QSA, acessar o e-CAC com certificado digital ou comparecer a uma unidade da RFB.

Emitido no dia **19/11/2025** às **13:46** (data e hora de Brasília).

GOVERNMENT OF THE STATE OF SÃO PAULO
SECRETARIAT OF ECONOMIC DEVELOPMENT
COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

FULL CERTIFICATE OF INCORPORATION

DOCUMENT ISSUED VIA THE INTERNET

COMPANY INFORMATION			
CORPORATE NAME ABC ENDOSCOPIALTDA			
TRADE NAME			LEGAL FORM LIMITED LIABILITY COMPANY (Small Business - EPP)
NIRE 35229846938	CNPJ 21.850.272/0001-50	FILING NUMBER 392.562/25-0	FILING DATE 11/12/2025

CERTIFICATE INFORMATION		
ISSUE DATE 11/14/2025	TIME OF ISSUE 2:51:51 PM	CONTROL CODE 280693241
THE AUTHENTICITY OF THIS DOCUMENT, AS WELL AS ITS ELECTRONIC VERSION, CAN BE VERIFIED AT WWW.JUCESPONLINE.SP.GOV.BR		

THIS COPY WAS DIGITALLY AUTHENTICATED AND SIGNED ON 11/14/2025 BY THE JUCESP SECRETARY GENERAL – MARINA CENTURION DARDANI, UNDER ARTICLE 1 OF PROVISIONAL MEASURE NO. 2.200-2 OF 08/24/2001, WHICH ESTABLISHED THE BRAZILIAN PUBLIC KEY INFRASTRUCTURE – ICP-BRASIL, IN FORCE PURSUANT TO CONSTITUTIONAL AMENDMENT NO. 32 OF 09/11/2001 – ARTICLE 2.

ARTICLE 1. THE BRAZILIAN PUBLIC KEY INFRASTRUCTURE – ICP-BRASIL IS HEREBY ESTABLISHED TO ENSURE THE AUTHENTICITY, INTEGRITY, AND LEGAL VALIDITY OF ELECTRONIC DOCUMENTS, SUPPORTING APPLICATIONS, AND ENABLED APPLICATIONS THAT USE DIGITAL CERTIFICATES, AS WELL AS THE PERFORMANCE OF SECURE ELECTRONIC TRANSACTIONS.

LATEST DOCUMENT FILED FOR THE ABOVE-MENTIONED COMPANY.

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

JUCESP - COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

Ministry of Development, Industry and Foreign Trade
Secretariat of Commerce and Services
Department of Business Registration and Integration - DREI
Secretariat of Economic Development

PROTOCOL LABEL
JUCESP PROTOCOL
5.005.663/25-3

INTERNET CONTROL
035355353-1

11 12 25

APPLICATION COVER

REGISTRATION INFORMATION

ACT
Amendment of Economic Activity Code/Corporate Purpose; Consolidation of Headquarters; Inclusion/Amendment of Members;

CORPORATE NAME			SIZE
ABC ENDOSCOPIA LTDA			SMALL BUSINESS - EPP
STREET	**NUMBER**	**COMPLEMENT**	**ZIP CODE**
Rua General Osório	63	Contact Point	09310-050
CITY	**STATE**	**TELEPHONE**	**E-MAIL**
Mauá	SP		JucespMaua@Uol.com.br
NUMBER OF REQUIREMENT(S)	**CNPJ - REGISTERED OFFICE**	**NIRE - REGISTERED OFFICE**	
0	21.850.272/0001-50	3522984693-8	
IDENTIFICATION OF THE SIGNATORY OF THE APPLICATION COVER SHEET		**FEES PAID**	**DOC. SEQ.**
NAME: RODRIGO PORPHIRIO SANTANA (Partner)		**DARE: R$ 211.01**	**1 / 1**
SIGNATURE: -----//signature//----- DATE: 10/21/2025		**DARF: R$ 0.00**	

I HEREBY DECLARE, UNDER PENALTY OF LAW, THAT THE INFORMATION CONTAINED IN THIS APPLICATION/PROCESS IS TRUE AND CORRECT.

FOR THE EXCLUSIVE USE OF THE COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO (INCLUDING THE REVERSE SIDE)

PROTOCOL STAMP

JUCESP
REGISTERED OFFICE
COUNTER 18
NOV 06 2025
PROTOCOL

DISTRIBUTION STAMP

JUCESP
APPROVED
NOV 10 2025
Viviane Maria dos Santos
Technical Advisor for the Public Registry
ID: 27.359.892-2

ANALYSIS STAMP

JUCESP
VOID
VOID
VOID
Viviane Maria dos Santos
Technical Advisor for the Public Registry
ID: 27.359.892-2

ATTACHMENTS: EXCLUSIVE TO THE REVIEW DEPARTMENT

(X) Basic Entry Document (DBE)	(X) Personal Documents (CRC)
( ) Power of Attorney	( ) Appraisal Report
( ) Court Order	( ) Newspaper
( ) Probate Distribution Order	( ) Protocol / Statement of Justification
( ) Balance Sheet	( ) Certificate
(X) Others	

OBSERVATIONS:

REGISTRATION LABELS + STAMP

JUCESP
NOV 12 2025
SECRETARIAT OF ECONOMIC DEVELOPMENT - JUCESP
MARINA CENTURION DARDANI
GENERAL SECRETARY
I CERTIFY THE REGISTRATION UNDER THE NUMBER
392.562/25-0
JUCESP

DOCUMENTS NOT COLLECTED WITHIN 90 DAYS OF AVAILABILITY SHALL BE DISCARDED - ART. 57, ITEM 5, DECREE 1.800/96

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

-----//signature//------

Registration Stamp

JUCESP
COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

JUCESP PROTOCOL
5.005.663/25-3

PRIVATE INSTRUMENT OF AMENDMENT TO AND R
THE ARTICLES OF ASSOCIATION OF A LIMITED LIA
"ABC ENDOSCOPIA LTDA."
CNPJ: 21.850.272/0001-50
NIRE: 35.229.846.938

By means of this private instrument regarding the 2nd amendment and consolidation of the Articles of Association of a limited liability company, the undersigned: RODRIGO PORPHIRIO SANT'ANA, Brazilian, married under the Partial Community Property Regime, physician, holder of Identity Card (ID) No. 1.344.716 SSP/ES, enrolled in the CPF/MF under No. 072.042.457-76 and registered with CRM-SP under No. 114970; THAIS LUCIANE DE LANA SANTANA, Brazilian, married under the Partial Community Property Regime, physician, holder of Identity Card (ID) No. 27.907.662-9 SSP-SP, enrolled in the CPF under No. 274.732.898-88 and registered with CRM-SP under No. 174164; both residing and domiciled at Rua José Benedetti, No. 276, Apartment 22, Santo Antônio Neighborhood, São Caetano do Sul -SP, ZIP Code 09531-000; and MARCIO LAMAS LOPES, Brazilian, married under the Partial Community Property Regime, physician, holder of Identity Card (ID) No. 24.994.982-9 SSP-SP, enrolled in the CPF under No. 287.868.388-90 and registered with CRM-SP under No. 133420, residing and domiciled at Rua Santa Catarina, No. 541, 11th Floor, Building 1, Apartment 111, Parque São Jorge Neighborhood, São Paulo, ZIP Code 03086-025; and MARINA DE FREITAS ABRAO, Brazilian, single, born on 04/27/1987, physician, holder of Identity Card (ID) No. 1.271.194 SSP-MS, enrolled in the CPF under No. 014.425.131-01 and registered with CRM-SP under No. 160441, residing and domiciled at Rua Artur Prado, No. 341, Apartment 123, Bela Vista, São Paulo-SP, ZIP Code 01322-000. Partners of ABC ENDOSCOPIA LTDA., a limited liability company located at Rua General Osório, No. 63, Room 4, Vila Bocaina Neighborhood, Mauá-SP, ZIP Code 09310-050, duly enrolled in the CNPJ under No. 21.850.272/0001-50 and registered with the Commercial Registry of the State of São Paulo (JUCESP) under NIRE No. 35.229.846.938 at the session held on 05/06/2016, hereby mutually resolve to amend and consolidate the Articles of Association in accordance with the following provisions:

ESP
ED OFFICE
2025
CCOL

AMENDMENT TO THE MEMBERSHIP

Clause One – On this date, MARINA DE FREITAS ABRAO withdraws from the Company, holding 4,800 (four thousand eight hundred) quotas, each with a par value of R$ 1.00 (one Real), totaling R$ 4,800.00 (four thousand eight hundred Reais). She hereby assigns and transfers all of her equity interest to the incoming partner, LILIAN DE OLINDA GIANNOCCARO, Brazilian, married under the Partial Community Property Regime, nurse, registered with COREN-SP under No. 000.129.029, holder of Identity Card (ID) No. 32946359/SSP-SP and CPF No. 322.255.848-50, residing and domiciled at Rua Tuiuti, No. 732, APT. 172-Tatuapé, São Paulo-SP, ZIP Code 03081-015.

AMENDMENT TO THE CORPORATE PURPOSE

Clause Two – The Company's corporate purpose is hereby amended to read as follows: Provision of outsourced medical services in the fields of diagnostic and therapeutic endoscopy, with or without an anesthesiologist, and medical consultations performed in clinics and hospitals; preceptorship and lecturing services; outpatient medical activities restricted to consultations; nutrition services; psychological services; nursing services; and integrative and complementary healthcare activities. (The Company shall conduct its business activities in accordance with Articles 966 and 982 of the Brazilian Civil Code, Law No. 10,406/2002).)

REDISTRIBUTION OF THE SHARE CAPITAL

----//signature//----
Verified by
ID No. 27.359.892-2

JUCESP
COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

Clause Three - RODRIGO PORPHIRIO SANT'ANA hereby assigns and transfers 800 (eight hundred) quotas to the remaining partner, THAIS LUCIANE DE LANA SANT'ANA, previously identified above.

Clause Four - MARCIO LAMAS LOPES hereby assigns and transfers 800 (eight hundred) quotas to the remaining partner, THAIS LUCIANE DE LANA SANT'ANA, previously identified above.

SHARE CAPITAL

Clause Five - The Company's share capital is R$ 40,000.00 (forty thousand Reais), represented by 40,000 (forty thousand) quotas, each having a par value of R$ 1.00 (one Real), fully subscribed and paid in national currency, and is divided among the partners as follows:

a) RODRIGO PORPHIRIO SANT'ANA: 15,200 (fifteen thousand two hundred) quotas, with a par value of R$ 1.00 (one Real) each, totaling R$ 15,200.00 (fifteen thousand two hundred Reais), corresponding to 38% of the Company's share capital.

b) THAIS LUCIANE DE LANA SANTANA: 4,800 (four thousand eight hundred) quotas, with a par value of R$ 1.00 (one Real) each, totaling R$ 4,800.00 (four thousand eight hundred Reais), corresponding to 12% of the Company's share capital.

c) MARCIO LAMAS LOPES: 15,200 (fifteen thousand two hundred) quotas, with a par value of R$ 1.00 (one Real) each, totaling R$ 15,200.00 (fifteen thousand two hundred Reais), corresponding to 38% of the Company's share capital.

d) LILIAN DE OLINDA GIANNOCCARO: 4,800 (four thousand eight hundred) quotas, with a par value of R$ 1.00 (one Real) each, totaling R$ 4,800.00 (four thousand eight hundred Reais), corresponding to 12% of the Company's share capital.

Sole Paragraph - Each partner's liability is limited to the value of his or her quotas; however, all partners shall be jointly and severally liable for the full payment of the Company's share capital. (Article 1,052 of the Brazilian Civil Code.)

MANAGEMENT OF THE COMPANY

Clause Six - The management of the Company shall be exercised by the partners RODRIGO PORPHIRIO SANT'ANA, THAIS LUCIANE DE LANA SANTANA, and MARCIO LAMAS LOPES, who shall have full management powers and authority to use the Company's name, the managers may appoint such administrators as they deem necessary for the proper operation of the Company by means of a public power of attorney, however they are prohibited, from engaging in activities unrelated to the Company's corporate purpose or assuming obligations for the benefit of any member or third party, as well as encumbering or disposing of the Company's real property without the authorization of the other members.

Sole Paragraph - LILIAN DE OLINDA GIANNOCCARO shall participate in the Company solely as a quota-holding partner and shall have no authority to manage the Company or execute documents on its behalf.

Clause Seven - The managers declare, under penalty of law, that they are not legally prohibited from managing the Company by virtue of any special law, criminal conviction, or any legal disability that temporarily or permanently bars them from holding public office, nor have they been convicted of bankruptcy-related offenses, malfeasance in public office, bribery, extortion, embezzlement, crimes against the national economy, the national financial system, competition laws, consumer protection laws, public faith, or property. (Article 1,011, §1, of the Brazilian Civil Code.)

RESOLUTIONS

Clause Eight - In light of the amendments approved herein, the partners RESOLVE to further amend the wording of the Articles of Association and reorganize their provisions by CONSOLIDATING the Articles of Association into a single document for the purpose of facilitating their presentation and consultation. Accordingly, as of this date, the Articles of Association shall read as follows:

CONSOLIDATION OF THE ARTICLES OF ASSOCIATION OF THE LIMITED LIABILITY COMPANY "ABC ENDOSCOPIA LTDA"

//signature// Verified by ID No. 27.359.892-2

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

RODRIGO PORPHIRIO SANT'ANA, Brazilian, married under the Partial Community Property Regime, physician, holder of Identity Card (ID) No. 1.344.716 SSP/ES, enrolled in the CPF/MF under No. 072.042.457-76 and registered with CRM-SP under No. 114910; THAIS LUCIANE DE LANA SANT'ANA, Brazilian, married under the Partial Community Property Regime, physician, holder of Identity Card (ID) No. 27.907.662-9 SSP-SP, enrolled in the CPF under No. 274.732.898-88 and registered with CRM-SP under No. 174164; both residing and domiciled at Rua José Benedetti No. 276, Apartment 22, Santo Antônio Neighborhood, São Caetano do Sul-SP, ZIP Code 09531-000; MARCIO LAMAS LOPES, Brazilian, married under the Partial Community Property Regime, physician, holder of Identity Card (ID) No. 24.994.982-9 SSP-SP, enrolled in the CPF under No. 287.868.388-90 and registered with CRM-SP under No. 133420, residing and domiciled at Rua Santa Catarina No. 541, 11th Floor, Building 1, Apartment 111, Parque São Jorge Neighborhood, São Paulo/SP, ZIP Code 03086-025; and LILIAN DE OLINDA GIANNOCCARO, Brazilian, married under the Partial Community Property Regime, nurse, registered with COREN-SP under No. 000.129.029, holder of Identity Card (ID) No. 32946359/SSP-SP and CPF No. 322.255.848-50, residing and domiciled at Rua Tuiuti No. 732, APT. 172, Tatuapé Neighborhood, São Paulo-SP, ZIP Code 03081-015. Hereby mutually resolve to continue the Company's activities pursuant to Law No. 10,406, of January 10, 2002.

CHAPTER I – COMPANY NAME, REGISTERED OFFICE, CORPORATE PURPOSE, AND TERM

Clause One - The Company conducts its business under the trade name "ABC ENDOSCOPIA LTDA."

Clause Two. The Company's registered office is located at Rua General Osório No. 63, Room 04, Vila Bocaina Neighborhood, Municipality and Judicial District of Mauá, State of São Paulo, ZIP Code 09310-050 (Contact Address), and it may establish branch offices or representative offices anywhere within the national territory.

Clause Two - The Company's corporate purpose is the provision of outsourced medical services in the specialties of diagnostic and therapeutic endoscopy, with or without an anesthesiologist, and medical consultations performed in clinics and hospitals; preceptorship and lecturing services; outpatient medical activities restricted to consultations; nutrition services; psychological services; nursing services; and integrative and complementary healthcare activities (the Company shall conduct its business activities in accordance with Articles 966 and 982 of the Brazilian Civil Code Law No. 10,406/2002).

Clause Three - The Company commenced its activities on 02/06/2015, with its Articles of Association filed under NIRE No. 35.229.846.938, and its term shall be indefinite.

CHAPTER II – SHARE CAPITAL

Clause Four - The Company's share capital is R$ 40,000.00 (forty thousand Reais), represented by 40,000 (forty thousand) quotas, each having a par value of R$ 1.00 (one Real), fully subscribed and paid in Brazilian legal currency, and allocated among the Members as follows:

a) RODRIGO PORPHIRIO SANT'ANA, holding 15,200 (fifteen thousand two hundred) quotas, each with a par value of R$ 1.00 (one Real), totaling R$ 15,200.00 (fifteen thousand two hundred Reais), corresponding to 38% of the Company's share capital.

b) THAIS LUCIANE DE LANA SANT'ANA, holding 4,800 (four thousand eight hundred) quotas, each with a par value of R$ 1.00 (one Real), totaling R$ 4,800.00 (four thousand eight hundred Reais), corresponding to 12% of the Company's share capital.

c) MARCIO LAMAS LOPES, holding 15,200 (fifteen thousand two hundred) quotas, each with a par value of R$ 1.00 (one Real), totaling R$ 15,200.00 (fifteen thousand two hundred Reais), corresponding to 38% of the Company's share capital.

d) LILIAN DE OLINDA GIANNOCCARO, holding 4,800 (four thousand eight hundred) quotas, each with a par value of R$ 1.00 (one Real), totaling R$ 4,800.00 (four thousand eight hundred Reais), corresponding to 12% of the Company's share capital.

Sole Paragraph - Each Member's liability is limited to the value of his or her quotas; however, all Members are jointly and severally liable for the payment of the Company's share capital. (Article 1,052 of the Brazilian Civil Code.)

//signature// Verified by ID No. 27.359.892-2

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

CHAPTER III – MANAGEMENT OF THE COMPANY

Clause Five - The management of the Company shall be exercised by the partners RODRIGO PORPHIRIO SANT'ANA, THAIS LUCIANE DE LANA SANT'ANA, and MARCIO LAMAS LOPES, who shall have full managerial powers and authority to use the Company's trade name. They may appoint such managers as they deem necessary for the proper operation of the Company by means of a public power of attorney, they shall not, however, engage in activities unrelated to the Company's corporate purpose, assume obligations for the benefit of any partner or third party, or encumber or dispose of the Company's real property without the authorization of the other partners.

First Paragraph - The Partner LILIAN DE OLINDA GIANNOCCARO shall participate in the Company solely as a quota-holding partner and shall have no authority to manage the Company or execute documents on its behalf.

Second Paragraph - The power of attorney referred to in this Clause may be revoked only by the partners.

Third Paragraph - The appointed managers shall substitute for one another in the event of absence, temporary incapacity, or vacancy of the respective office, within the scope of the authority granted under the applicable power of attorney.

Fourth Paragraph - The Partners agree that the Company shall not establish a Fiscal Council.

Clause Five - The execution of documents unrelated to the Company's interests shall render the signatory personally liable. The use of the Company's name for matters unrelated to its corporate purpose or interests is prohibited.

Clause Six - Whenever a matter of significant interest arises, the partners shall hold a meeting to deliberate upon it, convened by any partner or by any of the managers.

Sole Paragraph - Notices of meetings may be given by any available means. Formal notice shall be deemed waived if all partners are present or declare in writing that they were aware of the place, date, time, and agenda of the meeting. If all partners, managers, and/or attorneys-in-fact express their decision in writing regarding the matter that would otherwise be submitted at the meeting, the holding of such meeting shall be waived.

CHAPTER IV – FISCAL YEAR AND RESULTS

Clause Seven - At the end of each fiscal year, on December 31, the Manager shall render an accounting of the Company's management by preparing the inventory, the balance sheet, and the statement of income, and the profits or losses determined therein shall be allocated to the partners in proportion to their respective quotas. (Article 1,065 of the Brazilian Civil Code.)

Clause Eight - In the performance of management duties, the Manager shall be entitled to receive a monthly compensation, the amount of which shall be established by mutual agreement among the partners.

CHAPTER V – OTHER PROVISIONS RELATING TO THE QUOTAS / CONTINUITY OF THE COMPANY

Clause Nine - The quotas comprising the Company's share capital are indivisible with respect to the Company and may be transferred to third parties, subject to the other partner's right of first refusal.

Clause Twelve - Any Member wishing to assign his or her quotas shall notify the other partner in writing of such intention, and the other partner shall have sixty (60) days to respond. The notice shall specify the proposed purchase price and all terms and conditions governing the proposed transfer.

//signature// Verified by ID No. 27.359.892-2

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

First Paragraph - If the partners are unable to reach an agreement regarding the value of the quotas, a special balance sheet shall be prepared to determine the value of the withdrawing partner's equity interest, and the withdrawing partner shall bear the costs of appraising the Company's assets and liabilities.

Second Paragraph - The partners may not assign or transfer their quotas, in whole or in part, to third parties without the express consent of the remaining partners.

Clause Ten - The Company shall not be dissolved upon the death of any partner and shall continue its activities with the surviving partner(s).

First Paragraph - Within thirty (30) days following the partner's death, a special balance sheet shall be prepared and the Company's assets shall be valued at their fair market value.

Second Paragraph - The value of the deceased partner's quotas shall be determined by dividing the Company's net equity, as determined pursuant to the preceding paragraph, by the number of quotas held by the deceased partner.

Third Paragraph - Payment of the value of the quotas shall be made to the person(s) legally entitled thereto as follows:

a) An amount equal to ten percent (10%) within sixty (60) days after the date of death; b) The remaining balance shall be paid in six (6) to twelve (12) equal and consecutive monthly installments, adjusted for inflation in accordance with the IGP-M (General Market Price Index) or, if discontinued, by the official index replacing it. The number of installments shall depend on the Company's financial condition at the time of the event and may exceed twelve (12) installments.

Fourth Paragraph - Until payment of the deceased partner's equity interest begins, the successors shall receive, as a monthly advance against such amount, a sum equivalent to the compensation previously received by the deceased partner.

Fifth Paragraph - The successors of the deceased partner may, at their own expense, monitor the preparation of the special balance sheet through a duly appointed representative.

Sixth Paragraph - If so agreed, the successors of the deceased partner may become partners of the Company as non-managing equity partners, without management authority, until such status is changed by resolution of the managing partner(s). If any of the current partners does not consent to the admission of the successors, the successors shall instead be compensated for the value of the deceased partner's interest.

Seventh Paragraph - The same procedure shall apply in any other circumstance in which the Company is dissolved with respect to a partner. (Articles 1,028 and 1,031 of the Brazilian Civil Code.)

Clause Eleven - Any matters not expressly provided for in these Articles of Association shall be governed by the applicable laws in force. The Parties hereby elect the court of the Judicial District of Mauá, State of São Paulo, as the exclusive venue for resolving any disputes arising out of these Articles of Association, expressly waiving any other venue, however privileged it may be.

Clause Twelve - The execution of documents on behalf of the Company, including those relating to banking transactions, shall require the joint signatures of two (2) partners.

In witness whereof, the partners have executed these Articles of Association in three (3) counterparts of equal form and content, for all legal purposes.

Mauá, May 20, 2025

PARTNERS:

-----//signature//------ Notary Stamp

RODRIGO PORPHIRIO SANT'ANA

-----//signature//------ Notary Stamp

THAIS LUCIANE DE LANA SANT'ANA

Rua General Osório, No. 63, Room 02, Vila Bocaina – Mauá-SP – ZIP Code 09310-050
Telephone: (11) 4514-1490 E-mail: contabilgaza@contabilgaza.com.br

-----//signature//----- Verified by ID No. 27.359.892-2

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

NOTARY STAMP

1st NOTARY PUBLIC AND PROTEST REGISTRY OF MAUÁ — LUCILA CIA MATOSINHO
R. Luis Mariani 46, Centro Maua/SP - ZIP Code 09390-050 - Phone: (11) 4541-8786 — NOTARY PUBLIC

1º

I HEREBY NOTARIZE, BY COMPARISON, THE AUTHENTICITY OF THE 2 SIGNATURES OF RODRIGO PORPHIRIO SANT'ANA AND THAIS LUCIANE DE LANA SANT'ANA, WITH DECLARED VALUE.
Mauá, October 21, 2025.
In witness whereof
EDNA APARECIDA TRINDADE - CLERK
Seal No. 0570AA-297171

VALID ONLY WITH AUTHENTICITY SEAL, NO ALTERATIONS AND/OR ERASURES.

1 Vrt R$ 24.80. C:520057

C20570AA02971710
ECONOMIC VALUE: 2
111369 SIGNATURE
Brazilian College of Notaries

NOTARY PUBLIC - MAUÁ - SP

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

NOTARY STAMP

-----//signature//------ Notary Stamp

MARCIO LAMAS LOPES

Notary Stamp -----//signature//------

LILIAN DE OLINDA GIANNOCCARO

IN FULL AGREEMENT:

Notary Stamp -----//signature//------

MARINA DE FREITAS ABRÃO

WITNESSES:

-----//signature//------

ANTONIO CARLOS FERNANDES
CPF No. 235.529.138-15

-----//signature//------

NELSON ROBERTO GONZALEZ GAZA
CPF No. 276.458.588-85

ATTORNEY-AT-LAW:

-----//signature//------

NELSON GAZA
Brazilian Bar Association (OAB/SP) Registration No. 53,306

Douglas Queiroz Novais
Authorized Clerk

CIVIL REGISTRY OFFICE FOR NATURAL PERSONS
Flavio Aparecido Rodrigues Gumieri - Registrar

I hereby notarize, by comparison, the authenticity of the signature: (1) MARCIO LAMAS LOPES and LILIAN DE OLINDA GIANNOCCARO with declared value.
São Paulo, June 24, 2025
I certify.
Valid only with the authenticity seal. Qty: 2 Total R$ 26.34
Seals: Seal(s): 2 Acts: C2AA- 357X6X

Brazilian College of Notaries
SIGNATURE ECONOMIC VALUE: 2
C21081AA0357560

CIVIL REGISTRY OF NATURAL PERSONS
TATUAPÉ SUBDISTRICT - CAPITAL
DOUGLAS QUEIROZ NOVAIS
AUTHORIZED CLERK

1st NOTARY PUBLIC AND PROTEST REGISTRY OF MAUÁ LUCILA CIA MATOSINHO
R. Luís Marliard 46, Centro Mauá/SP - ZIP Code 09390-050 - Phone: (11) 4541-8786 NOTARY PUBLIC

I HEREBY NOTARIZE, BY COMPARISON, THE AUTHENTICITY OF THE 1 SIGNATURE OF MARINA DE FREITAS ABRÃO, WITH DECLARED VALUE.
Mauá, October 21, 2025.
In witness _____ whereof.
EDNA APARECIDA TRINDADE - CLERK
Seal No. 0570AA-647562

VALID ONLY WITH AUTHENTICITY SEAL, NO ALTERATIONS AND/OR ERASURES.

Brazilian College of Notaries
SIGNATURE ECONOMIC VALUE: 1
C10570AA0647562

-----//signature//----- Verified by ID No. 27.359.892-2

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.



JUCESP
COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

DECLARATION OF AUTHENTICITY

I, **NELSON ROBERTO GONZALEZ GAZA**, duly registered and in good standing with the Regional Accounting Council of São Paulo (CRC-SP) under Registration No. SP310557/O-6, issued on 08/14/2025, and enrolled with the CPF under No. 276.458.588-85, HEREBY DECLARE, under the penalties of criminal law and without prejudice to the applicable administrative and civil sanctions, that this document is authentic and is a true copy of the original.

Documents submitted:

1 copy of the Identity Card of partner LILIAN DE OLINDA GIANNOCCARO.

Mauá, 10/20/2025.

-----//signature//------

NELSON ROBERTO GONZALEZ GAZA

JUCESP COMMERCIAL REGISTRY OF THE STATE OF SÃO PAULO

I certify the registration under No. 392.562/25-0 on 11/12/2025 of the company ABC ENDOSCOPIA LTDA, NIRE No. 35229846938, filed under No. 5005663253. This copy was digitally authenticated and signed on 11/14/2025 by MARINA CENTURION DARDANI – General Secretary. Authentication: 280693241. JUCESP guarantees the authenticity of the registration and the Full Certificate of Incorporation when viewed directly on the portal www.jucesponline.sp.gov.br.

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English, as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 24, 2026

GOVERNO DO ESTADO DE SÃO PAULO
SECRETARIA DE DESENVOLVIMENTO ECONÔMICO
JUNTA COMERCIAL DO ESTADO DE SÃO PAULO

CERTIDÃO DE INTEIRO TEOR

DOCUMENTO EMITIDO PELA INTERNET

DADOS DA EMPRESA			
NOME EMPRESARIAL ABC ENDOSCOPIA LTDA			
TITULO DE ESTABELECIMENTO			TIPO JURÍDICO SOCIEDADE LIMITADA (E.P.P.)
NIRE 35229846938	CNPJ 21.850.272/0001-50	NÚMERO DO ARQUIVAMENTO 392.562/25-0	DATA DO ARQUIVAMENTO 12/11/2025

DADOS DA CERTIDÃO		
DATA DE EXPEDIÇÃO 14/11/2025	HORA DE EXPEDIÇÃO 14:51:51	CÓDIGO DE CONTROLE 280693241
A AUTENTICIDADE DO PRESENTE DOCUMENTO, BEM COMO O ARQUIVO NA FORMA ELETRÔNICA PODEM SER VERIFICADOS NO ENDEREÇO WWW.JUCESPONLINE.SP.GOV.BR		

ESTA CÓPIA FOI AUTENTICADA DIGITALMENTE E ASSINADA EM 14/11/2025 PELA SECRETÁRIA GERAL DA JUCESP – MARINA CENTURION DARDANI, CONFORME ART. 1º DA MP2200-2 DE 24/08/2001, QUE INSTITUI A INFRAESTRUTURA DE CHAVES PÚBLICAS BRASILEIRAS – ICP BRASIL, EM VIGOR CONSOANTE E.C Nº32 DE 11/09/2001 M- ART.2º.

ART 1º. FICA INSTITUÍDA A INFRAESTRUTURA DE CHAVES PÚBLICAS BRASILEIRA – ICP BRASIL, PARA GARANTIR AUTENTICIDADE, INTEGRIDADE E VALIDADE JURÍDICA DE DOCUMENTOS EM FORMA ELETRÔNICA, DAS APLICAÇÕES DE SUPORTE E DAS APLICAÇÕES HABILITADAS QUE UTILIZEM CERTIFICADOS DIGITAIS, BEM COMO A REALIZAÇÃO DE TRANSAÇÕES ELETRÔNICAS SEGURAS.

ÚLTIMO DOCUMENTO ARQUIVADO PARA EMPRESA SUPRACITADA.

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

JUCESP - Junta Comercial do Estado de São Paulo

Ministério da Indústria, Comércio Exterior e Serviços
Departamento de Registro Empresarial e Integração – DREI
Secretaria de Desenvolvimento Econômico

12 11 25

ETIQUETA PROTOCOLO

JUCESP PROTOCOLO
5.005.663/25-3

CONTROLE INTERNET
035355353-1

CAPA DO REQUERIMENTO

DADOS CADASTRAIS

ATO
Alteração do Código de Atividade Econômica/ Objeto Social; Consolidação da Matriz; InclusÃ£o/Alteração de Integrantes;

NOME EMPRESARIAL			PORTE
ABC ENDOSCOPIA LTDA			EPP
LOGRADOURO	**NÚMERO**	**COMPLEMENTO**	**CEP**
Rua General Osorio	63	Ponto Contato	09310-050
MUNICÍPIO	**UF**	**TELEFONE**	**EMAIL**
Mauá	SP		JucespMaua@Uol.com.br
NÚMERO EXIGÊNCIA (S)	**CNPJ - SEDE**	**NIRE - SEDE**	
0	21.850.272/0001-50	3522984693-8	

IDENTIFICAÇÃO SIGNATÁRIO ASSINANTE REQUERIMENTO CAPA
NOME: RODRIGO PORPHIRIO SANT'ANA (Sócio)
ASSINATURA: Rodrigo P. Sant'Ana DATA: 21/10/2025

VALORES RECOLHIDOS
DARE: R$ 211,01
DARF: R$,00

Nº DE DOC.
1 / 1

DECLARO, SOB AS PENAS DA LEI, QUE AS INFORMAÇÕES CONSTANTES DO REQUERIMENTO/PROCESSO SÃO EXPRESSÃO DA VERDADE.

PARA USO EXCLUSIVO DA JUNTA COMERCIAL DO ESTADO DE SÃO PAULO (INCLUSIVE VERSO)

CARIMBO PROTOCOLO
JUCESP – SEDE
GUICHÊ 16
06 NOV 2025
PROTOCOLO

CARIMBO DISTRIBUIÇÃO
JUCESP
DEFERIDO
10 NOV 2025
Viviane Maria dos Santos
Assessora Técnica do Registro Público
RG: 27.359.892-2

CARIMBO ANÁLISE
JUCESP
SEM EFEITO
SEM EFEITO
SEM EFEITO
SEM EFEITO

ANEXOS:

EXCLUSIVO SETOR DE ANÁLISE

- (X) DBE
- ( ) Procuração
- ( ) Alvará Judicial
- ( ) Formal de Partilha
- ( ) Balanço Patrimonial
- (X) Outros
  Dud. aut.
- (X) Documentos Pessoais (CAC)
- ( ) Laudo de Avaliação
- ( ) Jornal
- ( ) Protocolo / Justificação
- ( ) Certidão

OBSERVAÇÕES:


ETIQUETAS DE REGISTRO + CARIMBO

JUCESP
07
12 NOV 2025
SECRETARIA DE DESENVOLVIMENTO ECONÔMICO – JUCESP
SEDE
MARINA CENTURION DARDANI
SECRETÁRIA GERAL
CERTIFICO O REGISTRO SOB O NÚMERO
392.562/25-0
JUCESP

DOCUMENTOS NÃO RETIRADOS EM ATÉ 90 DIAS DA DISPONIBILIDADE SERÃO DESCARTADOS - ART.57, § 5º, DECRETO 1.800/96

JUCESP
Junta Comercial do Estado de São Paulo

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.



Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

JUCESP PROTOCOLO
5.005.663/25-3

INSTRUMENTO PARTICULAR DE ALTERAÇ.
CONSOLIDAÇÃO DE CONTRATO SOCIAL DE S
"ABC ENDOSCOPIA LTDA"
CNPJ 21.850.272/0001-50
NIRE: 35.229.846.938

-SEDE
1E 18
2025
COLO

Pelo presente instrumento particular de 2ª alteração contratual e consolidação de contrato de sociedade empresária limitada, os infra-assinados: RODRIGO PORPHIRIO SANT´ANA, brasileiro, casado sob Regime de Comunhão Parcial de Bens, médico, portador da cédula de identidade RG n° 1.344.716 SSP/ES, inscrito no CPF/MF n° 072.042.457-76 e no CRM-SP sob n° 114910; THAIS LUCIANE DE LANA SANT´ANA, brasileira, casada sob Regime de Comunhão Parcial de Bens, médica, portadora da cédula de identidade RG. 27.907.662-9/SSP-SP, inscrita no CPF sob n° 274.732.898-88 e no CRM-SP sob nº 174164, ambos residentes e domiciliados na Rua José Benedetti, n° 276, Apto. 22, Bairro Santo Antônio, São Caetano do Sul-SP, CEP 09531-000 e MARCIO LAMAS LOPES, brasileiro, casado sob Regime de Comunhão Parcial de Bens, médico, portador da cédula de identidade RG. 24.994.982-9/SSP-SP, inscrito no CPF sob n° 287.868.388-90 e no CRM-SP sob nº 133420, residente e domiciliado na Rua Santa Catarina, n° 541, 11° andar BL 1 Apto. 111, Bairro Parque São Jorge, São Paulo, CEP 03086-025, MARINA DE FREITAS ABRAO, brasileira, solteira, nascida no dia 27/04/1987, médica, portadora da cédula de identidade RG. 1.271.194/SSP-MS, inscrita no CPF sob n° 014.425.131-01 e no CRM-SP sob nº 160441, residente e domiciliada na Rua Artur Prado, n° 341, Apto. 123, Bela Vista, São Paulo-SP, CEP 01322-000. Sócios componentes da sociedade empresária limitada ABC ENDOSCOPIA LTDA, situada na Rua General Osório, n° 63, Sala 4, Bairro Vila Bocaina, Mauá-SP, CEP 09310-050, devidamente inscrita no CNPJ sob nº. 21.850.272/0001-50 e registrada na Junta Comercial do Estado de São Paulo sob NIRE nº 35.229.846.938 em sessão de 06/05/2016, resolvem de comum acordo alterar e consolidar o contrato social mediante cláusulas seguintes:

DA ALTERAÇÃO DE SÓCIOS

Cláusula Primeira – Neste ato retira-se da sociedade a sócia MARINA DE FREITAS ABRAO, possuidora de 4.800 quotas no valor de R$ 1,00 (um real) cada uma, perfazendo um total de R$ 4.800,00 (quatro mil e oitocentos reais), que neste ato, cede e transfere a totalidade de suas quotas de capital a sócia ingressante LILIAN DE OLINDA GIANNOCCARO, de nacionalidade brasileira, casada no regime de comunhão parcial de bens, enfermeira , inscrita no COREN-SP sob n.º 000.129.029 , portadora da cédula de identidade RG. 32946359/SSP-SP, e no CPF sob número 322.255.848-50 residente e domiciliado na Rua Tuiuti , Nº 732 APTO 172-Tatuapé, São Paulo-SP, CEP 03081-015.

DA ALTERAÇÃO DO OBJETO SOCIAL

Cláusula Segunda - Alteração do objetivo social para: Prestação de serviços médicos terceirizados nas especialidades de endoscopia diagnóstica e terapêuticas, com ou sem Anestesiologista e consultas realizadas em clinicas e hospitais; Preceptoria e Palestrante; Atividade Médica Ambulatorial Restritas a Consultas; Nutricionista; Psicólogo; Atividades de Enfermagem e Atividades de Práticas Integrativas e Complementares em Saúde Humana. (A empresa irá explorar a atividade econômica nos termos dos artigos 966 e 982 do Novo Código Civil Lei. 10.406/02)

DA REDISTRIBUIÇÃO DO CAPITAL SOCIAL

JUCESP Junta Comercial do Estado de São Paulo

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

Clausula Terceira: O Sócio RODRIGO PORPHIRO SANT´ANA cede e transfere 800 (oitocentas) quotas a Sócia remanescente THAIS LUCIANE DE LANA SANT´ANA, acima qualificada.

Clausula Quarta: O Sócio MARCIO LAMAS LOPES cede e transfere 800 (oitocentas) quotas a Sócia remanescente THAIS LUCIANE DE LANA SANT´ANA, acima qualificada.

DO CAPITAL SOCIAL

Cláusula Quinta - O Capital social é de 40.000,00 (Quarenta Mil Reais) representados por 40.000 (Quarenta Mil) quotas no valor individual de R$ 1,00 (Um Real) cada uma, inteiramente subscrito e integralizado em moeda corrente nacional, estando assim dividido entre os sócios:

a) RODRIGO PORPHIRIO SANT´ANA, com 15.200 (Quinze Mil e Duzentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 15.200,00 (Quinze Mil e Duzentos Reais), que corresponde a 38% do capital social.

b) THAIS LUCIANE DE LANA SANT´ANA, com 4.800 (Quatro Mil e Oitocentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 4.800,00 (Quatro Mil e Oitocentos Reais), que corresponde a 12% do capital social.

c) MARCIO LAMAS LOPES, com 15.200 (Quinze Mil e Duzentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 15.200,00 (Quinze Mil e Duzentos Reais), que corresponde a 38% do capital social.

d) LILIAN DE OLINDA GIANNOCCARO com 4.800 (Quatro Mil Oitocentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 4.800,00 (Quatro Mil e Oitocentos Reais), que corresponde a 12% do capital social.

Parágrafo Único – A responsabilidade de cada sócio é restrita ao valor de suas quotas, mas ambos respondem solidariamente pela integralização do capital social. (Art. 1.052, CC/2002).

DA ADMINISTRAÇÃO DA SOCIEDADE

Cláusula Sexta – A administração da sociedade será exercida pelos sócios RODRIGO PORPHIRIO SANT´ANA; THAIS LUCIANE DE LANA SANT´ANA e MARCIO LAMAS LOPES, com os poderes e atribuições de gerência, autorizado o uso do nome empresarial, o qual poderá designar os administradores que entender necessário ao bom desempenho da sociedade, através de procuração por instrumento público, vedado ~~no~~ entanto, em atividades estranhas ao interesse social ou assumir obrigações seja em favor de qualquer cotista ou terceiro, bem como onerar ou alienar bens imóveis da sociedade, sem autorização dos outros sócios.

Parágrafo Único – A Sócia LILIAN DE OLINDA GIANNOCCARO participa na sociedade somente como sócia cotista e não terá poderes para administrar ou assinar pela empresa.

Cláusula Sétima - Os administradores declaram, sob as penas da lei, de que não estão impedidos de exercerem a administração da sociedade, por lei especial, ou em virtude de condenação criminal, ou por estarem sob os efeitos dela, a pena que vede, ainda que temporariamente o acesso a cargos públicos: ou por crime falimentar, de prevaricação, peita ou suborno, concussão, peculato, ou contra a economia popular, contra o sistema financeiro nacional, contra as normas de defesa da concorrência, contra as relações de consumo, fé pública, ou a propriedade. (Art. 1.011, 1º, CC/2002).

DELIBERAÇÕES

Cláusula Oitava - Em razão das alterações havidas, os sócios RESOLVEM alterar novamente a redação das cláusulas do Contrato Social, com a consequente mudança da sua forma de disposição para CONSOLIDÁ-LO, em um só documento, cujo objetivo maior é facilitar sua apresentação e consulta; passando a vigorar desta data em diante com a seguinte forma e redação, a saber:

CONSOLIDAÇÃO DO CONTRATO SOCIAL DA SOCIEDADE LIMITADA
"ABC ENDOSCOPIA LTDA"

Rua General Osório, nº 63 sala 02 Vila Bocaina - Mauá SP. CEP.09310-050
Fone: (11)45141490 e-mail contabilgaza@contabilgaza.com.br

Visto
Conferido
RG 27.359.892-2

JUCESP Junta Comercial do Estado de São Paulo

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

CNPJ 21.850.272/0001-50
NIRE: 35.229.846.938

RODRIGO PORPHIRIO SANT´ANA, brasileiro, casado sob Regime de Comunhão Parcial de Bens, médico, portador da cédula de identidade RG nº 1.344.716 SSP/ES, inscrito no CPF/MF nº 072.042.457-76 e no CRM-SP sob nº 114910; THAIS LUCIANE DE LANA SANT´ANA, brasileira, casada sob Regime de Comunhão Parcial de Bens, médica, portadora da cédula de identidade RG. 27.907.662-9/SSP-SP, inscrita no CPF sob nº 274.732.898-88 e no CRM-SP sob nº 174164, ambos residentes e domiciliados na Rua José Benedetti, nº 276, Apto. 22, Bairro Santo Antônio, São Caetano do Sul-SP, CEP 09531-000; MARCIO LAMAS LOPES, brasileiro, casado sob Regime de Comunhão Parcial de Bens, médico, portador da cédula de identidade RG. 24.994.982-9/SSP-SP, inscrito no CPF sob nº 287.868.388-90 e no CRM-SP sob nº 133420, residente e domiciliado na Rua Santa Catarina, nº 541, 11º andar BL 1 Apto. 111, Bairro Parque São Jorge, São Paulo/SP, CEP 03086-025 e LILIAN DE OLINDA GIANNOCCARO, de nacionalidade brasileira, casada no regime de comunhão parcial de bens, enfermeira, inscrita no COREN-SP sob n.º 000.129.029, portadora da cédula de identidade RG. 32946359/SSP-SP, e no CPF sob número 322.255.848-50 residente e domiciliado na Rua Tuiuti, nº 732 apto. 172 -Tatuapé, São Paulo-SP, CEP 03081-015. Resolvem de comum acordo dar continuidade desta sociedade com fulcro na Lei nº 10.406 de 10 de janeiro de 2002.

CAPÍTULO I – NOME EMPRESARIAL, SEDE, FINS E DURAÇÃO.

Cláusula Primeira - A sociedade desenvolve suas atividades sob o nome empresarial de "ABC ENDOSCOPIA LTDA".

Cláusula Segunda - A sociedade tem sede à Rua General Osório, nº 63, apto. 04, Bairro Vila Bocaina, Município e Comarca de Mauá, Estado de São Paulo/SP, CEP: 09310-050 (Ponto de Contato), podendo constituir filiais ou escritório de representação em todo território nacional.

Cláusula Segunda – A sociedade tem como objeto social: Prestação de serviços médicos terceirizados nas especialidades de endoscopia diagnóstica e terapêuticas, com ou sem Anestesiologista e consultas realizadas em clinicas e hospitais; Presceptoria e Palestrante; Atividade Médica Ambulatorial Restritas a Consultas; Nutricionista; Psicólogo; Atividades de Enfermagem e Atividades de Práticas Integrativas e Complementares em Saúde Humana(A empresa irá explorar a atividade econômica nos termos dos artigos 966 e 982 do Novo Código Civil Lei. 10.406/02)

Cláusula Terceira - A sociedade iniciou suas atividades em 06/02/2015, com contrato social arquivado sob NIRE 35.229.846.938; sendo seu prazo de duração indeterminado.

CAPÍTULO II – CAPITAL SOCIAL

Cláusula Quarta - O Capital social é de 40.000,00 (Quarenta Mil Reais) representados por 40.000 (Quarenta Mil) quotas no valor individual de R$ 1,00 (Um Real) cada uma, inteiramente subscrito e integralizado em moeda corrente nacional, estando assim dividido entre os sócios:

a) RODRIGO PORPHIRIO SANT´ANA, com 15.200 (Quinze Mil e Duzentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 15.200,00 (Quinze Mil e Duzentos Reais), que corresponde a 38% do capital social.

b) THAIS LUCIANE DE LANA SANT´ANA, com 4.800 (Quatro Mil e Oitocentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 4.800,00 (Quatro Mil e Oitocentos Reais), que corresponde a 12% do capital social.

c) MARCIO LAMAS LOPES, com 15.200 (Quinze Mil e Duzentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 15.200,00 (Quinze Mil e Duzentos Reais), que corresponde a 38% do capital social.

d) LILIAN DE OLINDA GIANNOCCARO, com 4.800 (Quatro Mil Oitocentas) Quotas, no valor nominal de R$ 1,00 (Um Real) cada uma, perfazendo o total de R$ 4.800,00 (Quatro Mil e Oitocentos Reais), que corresponde a 12% do capital social.

Parágrafo Único – A responsabilidade de cada sócio é restrita ao valor de suas quotas, mas ambos respondem solidariamente pela integralização do capital social. (art. 1.052, CC/2002).

Visto Conferido

JUCESP Junta Comercial do Estado de São Paulo

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

CAPÍTULO III – ADMINISTRAÇÃO DA SOCIEDADE

Cláusula Quinta - A administração da sociedade será exercida pelos sócios RODRIGO PORPHIRIO SANT'ANA, THAIS LUCIANE DE LANA SANT'ANA, MARCIO LAMAS LOPES, com os poderes e atribuições de gerência, autorizado o uso do nome empresarial, o qual poderá designar os administradores que entender necessário ao bom desempenho da sociedade, através de procuração por instrumento público, vedado no entanto, em atividades estranhas ao interesse social ou assumir obrigações seja em favor de qualquer cotista ou terceiro, bem como onerar ou alienar bens imóveis da sociedade, sem autorização dos outros sócios.

Parágrafo Primeiro – A Sócia LILIAN DE OLINDA GIANNOCCARO participa na sociedade somente como sócia cotista e não terá poderes para administrar ou assinar pela empresa.

Parágrafo Segundo – O mandato a que se refere este artigo somente poderá ser revogado por ambos os sócios.

Parágrafo Terceiro - Os administradores designados substituir-se-ão reciprocamente nos seus impedimentos, faltas, ou em caso de vaga do respectivo cargo, segundo a força de seu mandato, constante do competente instrumento.

Parágrafo Quarto - Ajustam os sócios que não constituirão Conselho Fiscal.

Cláusula Quinta - A assinatura de documentos estranhos aos interesses da sociedade responsabilizará pessoalmente o signatário do mesmo. É vedado o uso da sociedade em assuntos estranhos e alheios aos interesses da mesma.

Cláusula Sexta - Sempre que houver interesse relevante, haverá reunião dos sócios para deliberação, por convocação de um dos sócios ou um dos Administradores.
Parágrafo Único – As convocações para as reuniões serão realizadas por todos os meios disponíveis, ficando dispensada a convocação se ambos os sócios comparecerem ou declararem, por escrito, que estavam cientes do local, data, hora e ordem do dia. Se todos os sócios / administradores / procuradores, declararem por escrito, sobre a matéria que seria objeto da reunião, ficará dispensada a sua realização.

CAPÍTULO IV – DO EXERCÍCIO SOCIAL E DOS RESULTADOS

Cláusula Sétima - Ao término de cada exercício social, em 31 de dezembro, o administrador prestará contas justificadas de sua administração, procedendo à elaboração do inventário, do balanço patrimonial e do balanço de resultado econômico, cabendo aos sócios, na proporção de suas quotas, os lucros ou perdas apuradas. (Art. 1.065, CC/2002).
Cláusula Oitava - No exercício da administração, o administrador terá direito a uma retirada mensal, a título de pró-labore, cujo valor será definido de comum acordo entre os sócios.

CAPÍTULO V – OUTRAS DISPOSIÇÕES RELATIVAS ÀS QUOTAS SOCIAIS/ CONTINUIDADE DA SOCIEDADE

Cláusula Nona - As quotas do Capital Social são indivisíveis em relação à sociedade e são transmissíveis a terceiros, observando o direito de preferência do outro sócio.
Cláusula Décima Segunda - O sócio que pretender ceder suas quotas comunicará por escrito ao outro a sua decisão, com prazo para resposta de 60 (sessenta dias). No documento obrigatoriamente fará constar o preço e as condições em que pretende ceder suas quotas.

Visto
Conferido
RG: 27.359.892-2

JUCESP Junta Comercial do Estado de São Paulo

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

Parágrafo Primeiro – Não havendo acordo quanto ao valor das quotas far-se-á um balanço especial para apuração dos haveres, arcando o sócio retirante com as despesas de avaliação do ativo e passivo da sociedade.
Parágrafo Segundo – Os sócios não poderão ceder suas quotas ou parte delas a terceiros sem a expressa anuência do sócio remanescente.
Cláusula Décima - A sociedade não se dissolverá pelo falecimento de um dos sócios e continuará com o remanescente.
Parágrafo Primeiro – Até trinta dias contados do falecimento, será elaborado balanço especial e avaliados os bens por valor de mercado.
Parágrafo Segundo – O valor da quota será obtido pela divisão do montante do patrimônio líquido, apurado nos termos do parágrafo anterior, pelo número de quotas do sócio falecido.
Parágrafo 3º – O pagamento do valor das quotas será efetuado, a quem de direito:
a) a importância equivalente a 10% até sessenta dias da data do falecimento; b) o saldo entre 06 e 12 parcelas mensais consecutivas e iguais, corrigíveis monetariamente conforme a variação do IGP-M, ou, no caso da extinção, pelo índice oficial que vier a substituí-lo. A quantidade de parcelas dependerá das condições financeiras da época do evento, podendo ser superior a 12 parcelas.
Parágrafo Terceiro – Enquanto não se iniciar o pagamento dos haveres, os sucessores receberão a título de adiantamento mensal dos haveres, o valor correspondente ao pró-labore até então recebido.
Parágrafo Quarto – Os sucessores do sócio falecido poderão, por sua conta, acompanhar os trabalhos de elaboração do balanço especial por intermédio de um representante.
Parágrafo Quinto – Havendo acordo poderá os sucessores do falecido, passarem a participar da sociedade, na condição de cotista capitalista, sem poder de gestão, até que por deliberação do cotista gestor adquiram esta condição. Basta um dos atuais cotistas não aceitarem os sucessores que estes deverão ser indenizados.
Parágrafo Sexto – O mesmo procedimento será adotado em outros casos em que a sociedade se resolva em relação a seu sócio. (Art. 1.028 e art. 1.031, CC/2002).
Cláusula Décima Primeira - Todos os assuntos que por ventura não tenha previsão expressa neste contrato, serão resolvidos na forma das leis pertinentes em vigor, ficando eleito o foro desta Cidade e Comarca de Mauá, Estado de São Paulo, por dirimir pendências oriundas deste contrato, com renúncia de outro, por mais privilegiado que seja.
Cláusula Décima Segunda - A assinatura de documentos da sociedade, inclusive para os fins de movimentação bancária, deverá ser representada por dois sócios conjuntamente.

E, por estarem justos e contratados, firmam este contrato, em 03 (três) vias de igual teor e forma, para que produza os seus legais efeitos.

Mauá, 20 de maio de 2025.

SÓCIOS:

Tabelião de Notas de Mauá - SP

RODRIGO PORPHIRIO SANT'ANA

Tabelião de Notas de Mauá - SP

THAIS LUCIANE DE LANA SANT'ANA

Visto Conferido

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.



Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

MARCIO LAMAS LOPES

LILIAN DE OLINDA GIANNOCCARO

DE PLENO ACORDO:

MARINA DE FREITAS ABRÃO

TESTEMUNHAS:

ANTÔNIO CARLOS FERNANDES
CPF: 235.529.138-15:

NELSON ROBERTO GONZALEZ GAZA
CPF: 276.458.588-85

ADVOGADO:

NELSON GAZA
O.A.B. SP n.º 53.306

Douglas Queiroz Novai
Escrevente Autorizado

Oficial de Registro Civil das Pessoas Naturais
Flávio Aparecido Rodrigues Gumieri - Oficial
R. Cel. Luis Americano, 228/242 - Tatuapé - São Paulo/SP - CEP 03308-020 - Fone/Fax: (11) 2942-1010 - e-mail: firmas@cartoriotatuape.com.br

Reconheço por semelhança as firmas de: (1) MARCIO LAMAS LOPES e (1) LILIAN DE OLINDA GIANNOCCARO, em documentos com valor econômico.
São Paulo, 24 de junho de 2025.
Dou fé.-Cód.: 1199172025355B004279504-0024a17
Válido somente com selo de autenticidade / Qtd. Z: Total: R$ 26.34
Selos: Selo(s): 2 Atos: C24-[illegible]

1º TABELIÃO DE NOTAS E PROTESTO DE MAUÁ LUCILA CIA MATOSINHO
R. Luis Mariani, nº. 46 - Mauá - SP - CEP: 09390-050 - Fone: (11) 4541-8766 TABELIÃ
RECONHECO por SEMELHANÇA o(s) VALOR DECLARADO 1 firma(s) de:
MARINA DE FREITAS ABRAO
Mauá, 21 de outubro de 2025.
Em test. da verdade. T: 1 VL.:R$ 13.40. C:520058
EDNA APARECIDA TRINDADE - ESCREVENTE
Selo(s): 057OAA-647562
* VÁLIDO SOMENTE COM O SELO DE AUTENTICIDADE SEM RASURAS OU EMENDAS

Visto
Conferido
R$ 27.359.892-2

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.



Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

DECLARAÇÃO DE AUTENTICIDADE

Eu **NELSON ROBERTO GONZALEZ GAZA**, com inscrição ativa no Conselho Regional de Contabilidade de São Paulo sob o nº **SP310557/O-6**, expedida em 14/08/2025, inscrito no CPF nº **276.458.588-85**, DECLARO, sob as penas da Lei penal e, sem prejuízo das sanções administrativas e cíveis, que este documento é autêntico e condiz com o original.

0Documentos apresentados:

1 Via do RG da socia LILIAN DE OLINDA GIANNOCCARO

Mauá, 20/10/2025.

NELSON ROBERTO GONZALEZ GAZA

JUCESP Junta Comercial do Estado de São Paulo

Certifico o registro sob o nº 392.562/25-0 em 12/11/2025 da empresa ABC ENDOSCOPIA LTDA, NIRE nº 35229846938, protocolado sob o nº 5005663253. Esta cópia foi autenticada digitalmente e assinada em 14/11/2025 por MARINA CENTURION DARDANI – Secretário Geral. Autenticação: 280693241. A JUCESP garante a autenticidade do registro e da Certidão de Inteiro Teor quando visualizado diretamente no portal www.jucesponline.sp.gov.br.

FEDERATIVE REPUBLIC OF BRAZIL

NATIONAL REGISTER OF LEGAL ENTITIES

REGISTRATION NUMBER	CERTIFICATE OF ENROLLMENT AND REGISTRATION STATUS	DATE OF INCORPORATION
21.850.272/0001-50 **HEAD OFFICE**		**02/10/2015**

COMPANY NAME
ABC ENDOSCOPIA LTDA

TRADE NAME (DBA)	SIZE
ABC ENDOSCOPIA	**SMALL BUSINESS (EPP)**

CODE AND DESCRIPTION OF MAIN ECONOMIC ACTIVITY
86.40-2-09 - Diagnostic services using optical methods - endoscopy and other similar exams

CODE AND DESCRIPTION OF SECONDARY ECONOMIC ACTIVITIES
85.99-6-04 - Professional and managerial development training
86.30-5-03 - Outpatient medical activity restricted to consultations
86.50-0-02 - Nutritionist activities
86.50-0-03 - Psychology and psychoanalysis activities
86.50-0-04 - Physiotherapy activities

CODE AND DESCRIPTION OF LEGAL NATURE
206-2 - Limited Liability Company

ADDRESS	NUMBER	UNIT
R GENERAL OSORIO	**63**	**APT 04**

ZIP CODE	NEIGHBORHOOD/DISTRICT	CITY	STATE
09.310-050	**VILA BOCAINA**	**MAUA**	**SP**

EMAIL ADDRESS	PHONE NUMBER
CONTABILGAZA@TERRA.COM.BR	**(11) 4514-1490**

RESPONSIBLE FEDERAL ENTITY (RFE)
******

REGISTRATION STATUS	REGISTRATION STATUS DATE
ACTIVE	**02/10/2015**

REASON FOR REGISTRATION STATUS

SPECIAL STATUS	SPECIAL STATUS DATE
*******	*******

It was approved by Normative Instruction RFB No. 2.119, dated December 6, 2022.

It was issued on **11/24/2025** at **2:41:37 PM** (Brasília date and time).

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English, as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

_____ **Date: July 16, 2026**

REPÚBLICA FEDERATIVA DO BRASIL

CADASTRO NACIONAL DA PESSOA JURÍDICA

NÚMERO DE INSCRIÇÃO	COMPROVANTE DE INSCRIÇÃO E DE SITUAÇÃO CADASTRAL	DATA DE ABERTURA
21.850.272/0001-50 **MATRIZ**		**10/02/2015**

NOME EMPRESARIAL
ABC ENDOSCOPIA LTDA

TÍTULO DO ESTABELECIMENTO (NOME DE FANTASIA)	PORTE
ABC ENDOSCOPIA	**EPP**

CÓDIGO E DESCRIÇÃO DA ATIVIDADE ECONÔMICA PRINCIPAL
86.40-2-09 - Serviços de diagnóstico por métodos ópticos - endoscopia e outros exames análogos

CÓDIGO E DESCRIÇÃO DAS ATIVIDADES ECONÔMICAS SECUNDÁRIAS
85.99-6-04 - Treinamento em desenvolvimento profissional e gerencial
86.30-5-03 - Atividade médica ambulatorial restrita a consultas
86.50-0-02 - Atividades de profissionais da nutrição
86.50-0-03 - Atividades de psicologia e psicanálise
86.50-0-04 - Atividades de fisioterapia

CÓDIGO E DESCRIÇÃO DA NATUREZA JURÍDICA
206-2 - Sociedade Empresária Limitada

LOGRADOURO	NÚMERO	COMPLEMENTO
R GENERAL OSORIO	**63**	**APT 04**

CEP	BAIRRO/DISTRITO	MUNICÍPIO	UF
09.310-050	**VILA BOCAINA**	**MAUA**	**SP**

ENDEREÇO ELETRÔNICO	TELEFONE
CONTABILGAZA@TERRA.COM.BR	**(11) 4514-1490**

ENTE FEDERATIVO RESPONSÁVEL (EFR)
*****

SITUAÇÃO CADASTRAL	DATA DA SITUAÇÃO CADASTRAL
ATIVA	**10/02/2015**

MOTIVO DE SITUAÇÃO CADASTRAL

SITUAÇÃO ESPECIAL	DATA DA SITUAÇÃO ESPECIAL
********	********

Aprovado pela Instrução Normativa RFB nº 2.119, de 06 de dezembro de 2022.

Emitido no dia **24/11/2025** às **14:41:37** (data e hora de Brasília).

MINISTRY OF FINANCE
SECRETARIAT OF THE FEDERAL REVENUE
INCOME TAX - INDIVIDUAL
TAX YEAR 2026

INCOME STATEMENT AND INCOME TAX WITHHELD AT SOURCE

Calendar Year 2025

1. PAYING SOURCE LEGAL ENTITY OR INDIVIDUAL

CORPORATE NAME / NAME	CNPJ/CPF
ABC ENDOSCOPIA LTDA ME	21.850.272/0001-50

2. TAXPAYER BENEFICIARY OF THE INCOME

CPF	FULL NAME
287.868.388-90	MARCIO LAMAS LOPES

Nature of Income
INCOME FROM SALARIED EMPLOYMENT

3. TAXABLE INCOME, DEDUCTIONS, AND INCOME TAX WITHHELD AT SOURCE

	VALUES IN REAIS
01. Total income (including vacation pay)	18,216.00
02. Official social security contributions	2,003.76
03. Contributions to complementary pension entities, public or private, and to individual retirement funds (FAPI)	0.00
04. Alimony payments (also fill out Section 7)	0.00
05. Income tax withheld at source	0.00

4. EXEMPT AND NON-TAXABLE INCOME

	VALUES IN REAIS
1. Exempt portion of retirement, reserve pay, military reform, and pension payments (age 65 or older)	0.00
2. Exempt portion of the 13th salary from retirement, reserve pay, military reform, and pension (age 65 or older)	0.00
3. Daily allowances and living expenses	0.00
4. Pension and retirement pay or military reform due to serious illness; retirement or reform due to work-related accident	0.00
5. Profits and dividends, calculated as of 1996, paid by legal entities (under actual, presumed, or arbitrated profit systems)	731,420.56
6. Amounts paid to the owner or partner of a microenterprise or small business, except for profit distribution, rent, or services rendered	0.00
7. Severance payments due to termination of employment contract, including Voluntary Dismissal Programs (PDV) and work-related accidents	0.00
8. Default interest received, due for late payment of remuneration for employment, position, or function	0.00
9. Others (specify)	0.00

5. INCOME SUBJECT TO EXCLUSIVE TAXATION (NET INCOME)

	VALUES IN REAIS
1. 13th salary	0.00
2. Income tax withheld at source on the 13th salary	0.00
3. Others	0.00

6. INCOME RECEIVED ACCUMULATIVELY - Art. 12-A of Law No. 7,713 of 1988 (subject to exclusive taxation)

6.1 Case Number:	Number of months	0.00

Nature of income	VALUES IN REAIS
1. Total taxable income (including vacation pay and 13th salary)	0.00
2. Exclusion: Legal Expenses	0.00
3. Deduction: Official Social Security Contributions	0.00
4. Deduction: Alimony	0.00
5. Income Tax Withheld at Source	0.00
6. Exempt Income from pensions, retirement, or reform due to serious illness or due to a work-related accident	0.00

7. ADDITIONAL INFORMATION

8. PERSON RESPONSIBLE FOR THE INFORMATION

NAME	DATE	SIGNATURE
NELSON GAZA	05/07/2026	NELSON GAZA

Approved by RFB Normative Instruction No. 2,060 of December 13, 2021.

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 17, 2026.

MINISTÉRIO DA FAZENDA SECRETARIA DA RECEITA FEDERAL IMPOSTO SOBRE A RENDA DA PESSOA FÍSICA EXERCÍCIO DE 2026	COMPROVANTE DE RENDIMENTOS PAGOS E DE RETENÇÃO DE IMPOSTO DE RENDA NA FONTE Ano-calendário : 2025

1.FONTE PAGADORA PESSOA JURÍDICA OU PESSOA FÍSICA

NOME EMPRESARIAL/NOME	CNPJ/CPF
ABC ENDOSCOPIA LTDA ME	21.850.272/0001-50

2.PESSOA FÍSICA BENEFICIÁRIA DOS RENDIMENTOS

CPF	NOME COMPLETO
287.868.388-90	MARCIO LAMAS LOPES
NATUREZA DO RENDIMENTO RENDIMENTOS DO TRABALHO ASSALARIADO	

3.RENDIMENTOS TRIBUTÁVEIS, DEDUÇÕES E IMPOSTO RETIDO NA FONTE

	VALORES EM REAIS
01.Total dos Rendimentos (inclusive férias)	18.216,00
02.Contribuição Previdenciária Oficial	2.003,76
03.Contribuições a Entidades de Previdência Complementar, Pública ou Privada, e a Fundos de Aposentadoria Programada Individual (FAPI)	0,00
04.Pensão Alimentícia (informar o beneficiário no Quadro 7)	0,00
05.Imposto de Renda Retido	0,00

4.RENDIMENTOS ISENTOS E NÃO TRIBUTÁVEIS

	VALORES EM REAIS
01.Parcela Isenta dos Proventos de Aposentadoria, Reforma e Pensão (65 anos ou mais)	0,00
02.Parcela isenta do 13º salário de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais)	0,00
03.Diárias e Ajudas de Custo	0,00
04.Pensão, Proventos de Aposentadoria ou Reforma por Moléstia Grave e Aposentadoria ou Reforma por Acidente em Serviço	0,00
05.Lucro e Dividendo Apurado a partir de 1996 pago por PJ (Lucro Real, Presumido ou Arbitrado)	731.420,56
06.Valores Pagos ao Titular ou Sócio da Microempresa ou Empresa de Pequeno Porte, exceto Pro labore, Aluguéis ou Serviços Prestados	0,00
07.Indenizações por rescisão de contrato de trabalho, inclusive a título de PDV, e acidente de trabalho	0,00
08.Juros de mora recebidos, devidos pelos atraso no pagamento de remuneração por exercício de emprego, cargo ou função	0,00
09.Outros (especificar)	0,00

5.RENDIMENTOS SUJEITOS À TRIBUTAÇÃO EXCLUSIVA (RENDIMENTO LÍQUIDO)

	VALORES EM REAIS
01.Décimo Terceiro Salário	0,00
02.Imposto sobre a renda retido na fonte sobre 13º salário	0,00
03.Outros	0,00

6.RENDIMENTOS RECEBIDOS ACUMULADAMENTE - Art. 12-A da Lei nº 7.713, de 1988 (sujeitos à tributação exclusiva)

6.1 Número do Processo:	Quantidade de Meses	0,00
Natureza do Rendimento:		VALORES EM REAIS
01. Total dos Rendimentos Tributáveis (Inclusive Férias e Décimo Terceiro Salário)		0,00
02. Exclusão: Despesas com a Ação Judicial		0,00
03. Dedução: Contribuição Previdenciária Oficial		0,00
04. Dedução: Pensão Alimentícia		0,00
05. Imposto sobre a Renda Retido na Fonte		0,00
06. Rendimentos Isentos de Pensão, Proventos de Aposentadoria ou Reforma por Moléstia Grave ou Aposentadoria ou Reforma por Acidente em Serviço		0,00

7.INFORMAÇÕES COMPLEMENTARES

8.RESPONSÁVEL PELAS INFORMAÇÕES

NOME	DATA	ASSINATURA
NELSON GAZA	07/05/2026	

Aprovado pela Instrução Normativa RFB Nº 2.060, de 13 de dezembro de 2021.

SERVICE AGREEMENT

Identification of the Contracting Parties

CONTRACTING PARTY:

INSTITUIÇÃO PAULISTA ADVENTISTA DE EDUCAÇÃO E ASSISTÊNCIA SOCIAL, a private legal entity, a nonprofit charitable organization engaged in educational and social assistance activities, enrolled with the National Registry of Legal Entities (CNPJ/MF) under No. 43.586.122/0001-14, with its registered office located at Avenida Professora Magdalena Sanseverino Grosso No. 850, Artur Nogueira, SP, the maintaining entity of **HOSPITAL ADVENTISTA DE SÃO PAULO**, enrolled with the CNPJ under No. 43.586.122/0009-71, with its registered office located at Rua Rocha Pombo, No. 49, Liberdade District, ZIP Code 01525-010, São Paulo, SP, herein represented by its directors, Dr. Dorival Duarte Lima, holder of Identity Card No. 265.012-SSP/ES and CPF No. 464.562.797-04, and Rafael Francisco de Almeida, holder of Identity Card No. 42.003.379-1-SSP/SP and CPF No. 299.114.206-17, registered with the National Registry of Healthcare Establishments (CNES), established by Ministry of Health Ordinance MS/MAS No. 376, dated 10/03/2000, and regulated by SAS Ordinance No. 511/2000, under CNES No. 3166597.

CONTRACTED PARTY:

Corporate Name:	ABC ENDOSCOPIA ME				
CNPJ:	21.850.272/001-50	**CCM:**			**CNES:**
Address (Registered Office):		RUA VICENTE ALETTO, 31			
Neighborhood:		JARDIM ANCHIETA		**ZIP Code:**	09360-540
City:	MAUÁ			**State:**	SÃO PAULO
Legal Representative:		RODRIGO PORPHIRIO SANT'ANA			
Position:		PHYSICIAN RESPONSIBLE FOR TECHNICAL SUPERVISION			
ID:	1.344.716	**State:**	ES	**CPF:**	072.042.457-76
Professional Council:	CRM	**State:**	SP	**Registration No.:**	114.910

*CCM - Municipal Taxpayer Registration

The Parties identified above have mutually agreed to enter into this **Service Agreement**, which shall be governed by the following terms and conditions.

CLAUSE ONE - OBJECT

1.1. The object of this Agreement is the provision of medical services in the specialty of Endoscopic Methods by the **CONTRACTED PARTY** to patients of the **CONTRACTING PARTY**, including patients covered by health insurance plans and private-pay patients, under the terms and conditions set forth herein.

1.2. The services referred to in this Clause include:
a) Scheduled consultations; upper gastrointestinal endoscopy with biopsy (urease test); flexible sigmoidoscopy; colonoscopy; anoscopy; endoscopic retrograde cholangiopancreatography (ERCP); enteroscopy; argon plasma coagulation; cyanoacrylate injection (for varices); GTT and endoscopic mucosal resection (EMR); bronchoscopy with bronchoalveolar lavage (BAL) and/or biopsy; polypectomy using biopsy forceps; snare polypectomy; insertion of a nasoenteric tube (NET) or nasogastric tube (NGT); variceal sclerotherapy; sclerotherapy for ulcers or angioectasias; endoscopic band ligation;

placement of hemoclips; placement of endoloops; endoscopic tattooing; application of Hemospray; endoscopic dilation procedures; endoscopic colonic hemostasis; chromoendoscopy; and removal of foreign bodies, all to be performed at the facilities of the **CONTRACTING PARTY,** at the address specified in the preamble to this Agreement, for all health insurance plans accepted by the **CONTRACTING PARTY** and for private-pay patients.

1.3. The services shall be provided by professionals engaged and designated by the **CONTRACTED PARTY**.

1.4. The **CONTRACTED PARTY** may provide services other than those described in this Section, provided that such services are previously agreed upon in writing by the Parties.

CLAUSE TWO – PERFORMANCE OF THE SERVICES

2.1. The **CONTRACTED PARTY** shall provide the services at the facilities of Hospital Adventista de São Paulo on the days and at the times agreed upon by the Parties, always in accordance with the availability communicated by the **CONTRACTED PARTY**.

CLAUSE THREE – COMPENSATION AND PAYMENT TERMS

3.1. For the services contracted herein and effectively rendered, the **CONTRACTING PARTY** shall pay the **CONTRACTED PARTY** the amounts set forth in the table below, upon issuance of the corresponding invoice by the **CONTRACTED PARTY**. Applicable taxes shall be withheld from the amounts payable, in accordance with the legislation in force.

EXAMINATION / PROCEDURE / ACCESSORY	Price
Scheduled Consultation (70% of the amount received from health insurance plans)	70%
UPPER GASTROINTESTINAL ENDOSCOPY + BIOPSY (UREASE TEST)	R$ 80.00
FLEXIBLE SIGMOIDOSCOPY	R$ 80.00
COLONOSCOPY	R$ 160.00
ANOSCOPY	R$ 50.00
ERCP – materials supplied by ABC Endoscopia (without stent)	R$ 1,800.00
ERCP – materials supplied by ABC Endoscopia (with stent)	R$ 2,400.00
ERCP – materials supplied by HASP (without stent)	R$ 1,300.00
ERCP – materials supplied by HASP (with stent)	R$ 1,500.00
ENTEROSCOPY (upper or lower) – PUSH, SINGLE-BALLOON, OR DOUBLE-BALLOON (per route)	R$ 800.00
ARGON PLASMA COAGULATION	R$ 300.00
CYANOACRYLATE INJECTION (VARICES)	R$ 200.00
GTT AND ENDOSCOPIC MUCOSAL RESECTION	R$ 270.00
BRONCHOSCOPY WITH BAL AND/OR BIOPSY	R$ 750.00
BRONCHOSCOPY	R$ 600.00
ON-CALL AVAILABILITY	R$ 3,500.00
TECHNICAL RESPONSIBILITY	R$ 1,000.00
SELF-EXPANDING STENTS	R$ 800.00

** MISCELLANEOUS PROCEDURES:	R$ 80.00 (each)
Forceps polypectomy and snare polypectomy,	
Insertion of a nasoenteric tube (NET) or nasogastric tube (NGT)	
Sclerotherapy for varices, ulcers, or angioectasias,	
Band ligation	
Placement of hemoclips	
Placement of endoloops	
Tattooing	
Application of Hemospray	
Dilation procedures	
Colonic hemostasis	
Chromoendoscopy	
Removal of foreign bodies	
All procedures shall be performed using the equipment and supplies provided by Hospital Adventista de São Paulo (HASP), except where this Agreement expressly states that such materials shall be supplied by ABC Endoscopia.	
The fees for intragastric balloon (IGB) placement and removal procedures shall be paid by the patient directly to Hospital Adventista de São Paulo, in the amount of BRL 300.00 for each procedure, whenever the patient has been referred through the active patient outreach conducted by ABC Endoscopia.	
The package price for placement and removal of an intragastric balloon (IGB) shall be R$ 8,500.00 (or such other amount as may be established by HASP), payable directly by the patient to HASP. The package includes the placement and removal procedures, the balloon itself, and the materials required for its removal. Of this amount, ABC Endoscopia shall receive R$ 800.00 for each procedure (R$ 800.00 for placement and R$ 800.00 for removal).	

* **If more than one procedure is performed on the same patient, each procedure shall be billed separately (for example, ulcer sclerotherapy together with hemoclip placement shall be billed at R$ 80.00 for each procedure, for a total of R$ 160.00).

3.2. Payment shall be made in accordance with the terms set forth below:

Payment Date:	The 45th business day of the month following the provision of services.		
Method of Payment:	Bank transfer		
Bank:	Santander	**Branch:**	3061
Checking Account:	13004249-7		

3.3. The **CONTRACTED PARTY** shall deliver the invoice for services rendered to the **CONTRACTING PARTY** at least five (5) business days prior to the agreed payment date. Failure to comply with this requirement shall result in the rescheduling of the payment. The bank deposit receipt shall constitute proof of payment for all legal purposes.

3.4. The **CONTRACTING PARTY** shall disallow and, consequently, deduct from the amounts payable to the **CONTRACTED PARTY**, any services not provided for in this Agreement, as well as any services that have not received the prior written authorization of the **CONTRACTING PARTY** or of the health plan operators and/or insurance companies under whose coverage the treated patients are beneficiaries.

CLAUSE FOUR – OBLIGATIONS OF THE CONTRACTING PARTY

4.1.In addition to the other obligations set forth in this Agreement and under applicable law, the **CONTRACTING PARTY** shall:

I. Provide the **CONTRACTED PARTY** with the information necessary for the performance of the contracted services.

II. Permit the **CONTRACTED PARTY** access to its facilities, limited to the locations and hours designated for the performance of the services covered by this Agreement.

III. Make payment to the **CONTRACTED PARTY** in accordance with the terms and conditions established herein.

IV. Provide the equipment, materials, and accessories required to perform the procedures in the Endoscopy Department and the Intensive Care Units (ICUs), and be responsible for their maintenance.

CLAUSE FIVE – OBLIGATIONS OF THE CONTRACTED PARTY:

5.1. In addition to the other obligations set forth in this Agreement and under applicable law, the **CONTRACTED PARTY** shall:

I. Perform the services in accordance with the highest standards of professional practice, always seeking the proper and satisfactory performance of the services contracted herein.

II. Respond to requests for medical consultations requested by another attending physician (interconsultations) within a maximum of twenty-four (24) hours and, in cases of urgency or emergency, within a maximum of twelve (12) hours.

III. Comply with the dates and times established for scheduled consultations in accordance with the schedule previously agreed upon by the Parties.

IV. Strictly comply with all applicable technical standards and legislation governing this Agreement, and, at its own expense, satisfy any fines or legal requirements arising from noncompliance with such standards or legal provisions before the competent municipal, state, and/or federal regulatory and supervisory authorities.

V. Issue and deliver to the **CONTRACTING PARTY** the invoices for the services provided under this Agreement.

VI. Be solely responsible for all taxes (including taxes, fees, and contributions) and charges of any nature arising from the services contracted herein, including all labor and social security obligations relating to its employees and representatives. This responsibility shall also extend to any taxes or charges that may subsequently become due pursuant to applicable law.

VII. Be liable for any damages caused to the **CONTRACTING PARTY**, its employees or representatives, or to third parties, resulting from negligence, willful misconduct, or fault in connection with the performance of the services contracted herein, whether on or off the premises of the **CONTRACTING PARTY**.

VIII. Maintain the strictest confidentiality regarding all information, data, documents, and other materials of which it becomes aware or to which it gains access as a result of performing the services under this Agreement, whether obtained from the **CONTRACTING PARTY** or from third parties, and shall not disclose such information, whether orally or in writing, at any time, including after the termination of this Agreement, without the prior written consent of the **CONTRACTING PARTY**.

IX. Provide the adult and pediatric upper gastrointestinal endoscopy equipment, colonoscope, rectoscope, and ERCP equipment to be used for procedures performed in the Surgical Center.

CLAUSE SIX – TERM AND TERMINATION

6.1. This Agreement shall remain in effect for an indefinite term commencing on the date of its execution and may be terminated without cause at any time, without penalty, by either Party upon providing the other Party with at least thirty (30) days' prior written notice.

6.2. Notwithstanding the foregoing, this Agreement may be terminated for cause, as a matter of right and without prior notice, upon written notice to the other Party, in the event of any of the following:

a) Breach or violation of any provision of this Agreement;

b) Failure to comply with the applicable technical standards and/or legislation governing this Agreement;

c) Civil insolvency, judicial or out-of-court reorganization, bankruptcy, or judicial or extrajudicial liquidation of either Party;

d) Assignment, in whole or in part, of the rights or obligations arising under this Agreement without the other Party's prior express written consent;

e) Negligence, recklessness, or lack of professional skill in the performance of the contracted services.

6.3. The Party giving rise to the termination of this Agreement shall pay the other Party liquidated damages in an amount equal to twenty percent (20%) of the average value of the last three invoices issued.

6.4. Termination for cause of this Agreement shall not prejudice or limit the civil, tax, administrative, criminal, or any other liability of the breaching Party; the non-breaching Party shall retain the right to seek additional damages, without prejudice to the recovery of court costs and attorneys' fees incurred in protecting its rights and interests.

CLAUSE SEVEN - GENERAL PROVISIONS

7.1. The following provisions shall apply to this Agreement and shall be binding upon the Parties in all respects:

a) In addition to the contractual relationship established herein, this Agreement shall not establish any form of partnership, association, or joint and several liability between the Parties.

b) Any amendments, additions, deletions, or resolutions of matters omitted from this Agreement shall be subject to the Parties' prior mutual agreement and, in order to be effective, shall be executed in writing and incorporated into this Agreement by means of a written Amendment.

c) All notices and communications required under this Agreement shall be made in writing and acknowledged by means of a dated receipt signed or initialed by the recipient.

d) The declaration of nullity, ineffectiveness, invalidity, or unenforceability of any clause, provision, or condition of this Agreement shall not affect the validity, effectiveness, or enforceability of the remaining provisions, which shall remain in full force and effect for the duration of this Agreement.

e) This Agreement constitutes the entire understanding between the Parties with respect to the subject matter hereof and supersedes all prior agreements, understandings, negotiations, or communications, whether written or oral, prevailing over any other document relating to such subject matter.

f) Any delay or failure by either Party to exercise any right granted under this Agreement, or any failure to require performance of any obligation assumed herein, shall not constitute a waiver or novation of such right or obligation, but shall be deemed merely an act of forbearance, such rights and obligations shall remain valid and enforceable throughout the term of this Agreement.

g) For all legal and contractual purposes, no employment relationship shall exist between the **CONTRACTING PARTY** and the employees and/or representatives of the **CONTRACTED PARTY** assigned to perform the services under this Agreement, the professionals engaged by the **CONTRACTED PARTY** shall not be subject to fixed working hours or hierarchical subordination to the **CONTRACTING PARTY**, and shall perform the contracted services independently, without interference or supervision of any nature by the **CONTRACTING PARTY**.

h) The Parties may enter into agreements with other individuals or legal entities having the same subject matter as this Agreement; accordingly, this Agreement is non-exclusive, and each Party shall have the sole discretion to determine whether to enter into additional agreements.

CLAUSE NINE – JURISDICTION

8.1. To resolve any disputes arising from this Agreement, the Parties select the Central Court of the Judicial District of São Paulo (Capital), waiving any other venue, however privileged it may be or become.

In witness whereof, the Parties, being in full agreement, execute this Agreement in two (2) counterparts of equal form and content, for one and the same legal effect, in the presence of two witnesses.

São Paulo, February 1, 2018

Hospital Adventista de São Paulo
Clinical Director – CRM No. 105977
Dr. Dorival Duarte de Lima

INSTITUIÇÃO PAULISTA ADVENTISTA DE EDUCAÇÃO E ASSISTÊNCIA SOCIAL, maintaining entity of Hospital Adventista de São Paulo
CONTRACTING PARTY

Marcio Lamas Lopes
Physician
CRM No. 133420

ABC Endoscopia ME - CONTRACTED PARTY

Witnesses

1) _____
Name: Sueli Teixeira Rodrigues
ID: 57.384.705-8
CPF: 649.184.249.91

2) _____
Name:
ID:
CPF:

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 16, 2026

CONTRATO DE PRESTAÇÃO DE SERVIÇOS

Identificação das Partes contratantes:

CONTRATANTE:

INSTITUIÇÃO PAULISTA ADVENTISTA DE EDUCAÇÃO E ASSISTÊNCIA SOCIAL, pessoa jurídica de direito privado, entidade de fins filantrópicos, assistências e educacionais, não lucrativos, inscrita no CNPJ/MF sob o no. 43.586.122/0001-14, com sede localizada na Av. Professora Magdalena Sanseverino Grosso n.º 850, Artur Nogueira, SP, mantenedora do **HOSPITAL ADVENTISTA DE SÃO PAULO,** inscrito no CNPJ sob o nº 43.586.122/0009-71, com sede na rua Rocha Pombo, nº 49, Bairro Liberdade, CEP.: 01525-010 São Paulo, representada neste ato por seus diretores, Sr. Dr. Dorival Duarte Lima CI/RG nº 265.012-SSP/ES e CPF/MF nº 464.562797-04, e Sr. Rafael Francisco de Almeida, CI/RG nº 42003379-1-SSP/SP e CPF/MF nº 299.114.206-17, registrado no Cadastro Nacional de Estabelecimentos de Saúde, instituído pela portaria MS/MAS 376, de 03/10/2000 e normatizada pela portaria SAS 511/2000 sob o nº CNES 3166597.

CONTRATADA:

Razão Social:	ABC ENDOSCOPIA ME						
CNPJ:	21.850.272/001-50	**CCM:**		**CNES:**			
Endereço (sede):	RUA VICENTE ALETTO, 31						
Bairro:	JD. ANCHIETA			**CEP:**	09360-540		
Cidade:	MAUÁ			**Estado:**	SÃO PAULO		
Representante Legal:	RODRIGO PORPHIRIO SANT`ANA						
Cargo:	MÉDICO RESPONSÁVEL TÉCNICO						
RG:	1.344.716	**UF:**	ES	**CPF:**	072.042.457-76		
Conselho Profissional:	CRM	**UF:**	SP	**N.º Inscrição:**	114.910		

As Partes acima qualificadas têm, entre si, justo e acordado, o presente **Contrato de Prestação de Serviços**, que se regerá pelas seguintes cláusulas e condições.

CLÁUSULA PRIMEIRA – DO OBJETO

1.1. Constitui objeto do presente Contrato a prestação de serviços médicos na especialidade de Métodos Endoscópicos, pela **CONTRATADA** aos pacientes da **CONTRATANTE,** conveniados e/ou particulares, nos termos e condições previstos neste Instrumento.

1.2. Os serviços mencionados nesta Cláusula compreendem:

a) Consultas eletivas, Endoscopia com Biópsia (Urease), Retossigmoidoscopia, Colonoscopia, Anuscopia, CPRE, Enteroscopia, Aplicação Plasma de Argônio, Aplicação de Cianocrilato, (Varizes), GTT e Mucosectomia, Broncoscopia com LBA e ou Biópsia, polipectomia com pinça, polipectomia com alça, passagem de SNE ou SNG, esclerose de varizes, esclerose de úlceras ou angioectasias, ligadura elástica, colocação de hemoclipe,

colocação de endoloop, tatuagem, aplicação de hemospray, dilatações, hemostasia de cólon, cromoscopia, remoção de CE, nas dependência da **CONTRATANTE**, no endereço definido no preâmbulo desse contrato para todos convênios atendidos pela **CONTRATANTE** e particulares.

1.3. Os serviços serão prestados por profissionais contratados e designados pela **CONTRATADA**.

1.4. A **CONTRATADA** poderá prestar outros serviços, além dos previstos nesta Cláusula, mediante ajuste prévio e por escrito entre as Partes.

CLÁUSULA SEGUNDA – DA PRESTAÇÃO DOS SERVIÇOS

2.1. A **CONTRATADA** prestará os serviços nas dependências do Hospital Adventista de São Paulo nos dias e horários ajustados entre as Partes, sempre de acordo com a disponibilidade informada pela **CONTRATADA.**

CLÁUSULA TERCEIRA – DO VALOR E DAS CONDIÇÕES DE PAGAMENTO

3.1. Pelos serviços ora contratados e efetivamente prestados, a **CONTRATANTE** pagará à **CONTRATADA** o valor indicado na Tabela abaixo, mediante a emissão da respectiva Nota Fiscal pela **CONTRATADA**, sendo certo que do valor a ser pago, conforme quadro abaixo serão descontados os tributos incidentes, nos termos da legislação em vigor:

EXAME/PROCEDIMENTO/ACESSÓRIO	Valor
Consulta Eletiva (repasse de 70% do valor recebido dos convênios)	70%
EDA + BIÓPSIA (UREASE)	R$ 80,00
RETOSSIGMOIDOSCOPIA	R$ 80,00
COLONOSCOPIA	R$ 160,00
ANUSCOPIA	R$ 50,00
CPRE – material fornecido pela ABC Endoscopia - sem prótese	R$ 1.800,00
CPRE – material fornecido pela ABC Endoscopia – com prótese	R$ 2.400,00
CPRE – material fornecido pelo HASP - sem prótese	R$ 1.300,00
CPRE – material fornecido pelo HASP – com prótese	R$ 1.500,00
ENTEROSCOPIA (alta ou baixa) - PUSH, MONO OU DUPLO-BALÃO (cada via)	R$ 800,00
APLICAÇÃO DE PLASMA DE ARGÔNIO	R$ 300,00
APLICACAÇÃO DE CIANOACRILATO (varizes)	R$ 200,00
GTT E MUCOSECTOMIA	R$ 270,00
BONCOSCOPIA + LBA e ou BIÓPSIA	R$ 750,00
BRONCOSCOPIA	R$ 600,00
SOBREAVISO	R$ 3.500,00
RESPONSABILIDADE TÉCNICA	R$ 1.000,00
PRÓTESES AUTOEXPANSIVAS	R$ 800,00

**PROCEDIMENTOS DIVERSOS:	R$ 80,00 (Cada)
Polipectomia com pinça e polipectomia com alça,	
Passagem de SNE ou SNG,	
Esclerose de varizes, esclerose de úlceras ou angioectasias,	
Ligadura elástica,	
Colocação de hemoclipe,	
Colocação de endoloop,	
Tatuagem,	
Aplicação de hemospray,	
Dilatações,	
Hemostasia de cólon,	
Cromoscopia,	
Remoção de CE	
Todos procedimentos com o material de execução fornecido pelo HASP. Exceto quando é descrito que é fornecido pela Empresa ABC Endoscopia.	
Os valores dos exames para colocação e retirada de BIG serão pagos pelo paciente diretamente ao Hospital Adventista de São Paulo uma taxa de R$ 300,00 por cada ato quando o paciente for originado da busca ativa da ABC Endoscopia.	
Valor do pacote para implante e explante de BIG (balão intragástrico) será de R$ 8.500,00 (ou outro definido pelo HASP), pagos pelo paciente diretamente ao HASP, inclusa a colocação e retirada, o balão e seu material de retirada e repassados à ABC Endoscopia os valores de R$ 800,00 por cada ato (colocação R$ 800,00 e retirada R$ 800,00).	

* **havendo mais de um procedimento no mesmo paciente, serão cobrados individualmente cada procedimento (ex.: esclerose de úlcera com colocação de hemoclipe R$80,00 cada, total de R$ 160,00).

3.2. O pagamento será efetuado no prazo e forma abaixo indicados:

Data do pagamento:	45° dia útil do mês subseqüente ao da prestação dos serviços.		
Forma de pagamento:	Depósito bancário		
Banco:	Santander	**Agência:**	3061
Conta-Corrente:	13004249-7		

3.3. A **CONTRATADA** se obriga a entregar à **CONTRATANTE** a nota fiscal de prestação de serviços com antecedência mínima de 5 (cinco) dias úteis da data acordada para o pagamento, sob pena de reprogramação do pagamento em caso de atraso na entrega da nota fiscal. O comprovante de depósito bancário servirá como Recibo de pagamento, para todos os fins de direito.

3.4. Serão glosados pela **CONTRATANTE** e, conseqüentemente, descontados dos valores a serem pagos à **CONTRATADA**, os serviços não previstos neste Contrato, bem como os que não tenham autorização prévia e escrita da **CONTRATANTE** ou das operadoras e/ou seguradoras de planos de saúde de que sejam beneficiários os pacientes atendidos.

CLÁUSULA QUARTA – DAS OBRIGAÇÕES DA CONTRATANTE

4.1. São obrigações da **CONTRATANTE**, além das demais obrigações previstas neste Contrato e na legislação a ele aplicável:

I. Disponibilizar à **CONTRATADA** as informações necessárias para a execução dos serviços contratados.

II. Permitir a entrada da **CONTRATADA** em suas dependências, limitada aos locais e horários de prestação dos serviços ora contratados.

III. Efetuar o pagamento à **CONTRATADA** na forma e condições estabelecidas neste Contrato.

IV. Ceder os equipamentos, materiais e acessórios para a realização do exame no setor de Endoscopia e nas UTIs, assim como a responsabilidade por sua manutenção.

CLÁUSULA QUINTA – DAS OBRIGAÇÕES DA CONTRATADA:

5.1. São obrigações da **CONTRATADA**, além das demais obrigações previstas neste Contrato e na legislação a ele aplicável:

I. Prestar os serviços com a melhor técnica profissional, objetivando sempre a perfeita e adequada execução dos serviços contratos.

II. Atender aos chamados de Inter consulta no prazo máximo de 24 horas e, no caso de urgência e emergência, no máximo em 12 horas.

III. Cumprir com as datas e os horários definidos para as consultas eletivas de acordo com o agendamento pré-definido entre as partes.

IV. Observar rigorosamente todas as normas técnicas e legislação vigente, aplicáveis ao presente Contrato, satisfazendo às suas expensas quaisquer multas ou exigências legais decorrentes da inobservância dos citados dispositivos legais, perante os órgãos de regulação e controle competentes, nas esferas municipal, estadual e/ou federal.

V. Emitir e entregar à **CONTRATANTE** as Notas Fiscais de prestação dos serviços objeto deste Contrato.

VI. Responsabilizar-se por todos os tributos (impostos, taxas e contribuições) e encargos relativos aos serviços ora contratados, de qualquer natureza, oriundos da prestação dos serviços aqui pactuados, inclusive encargos trabalhistas e previdenciárias de seus empregados e prepostos. A responsabilidade prevista neste item abrange ainda todos os tributos e encargos que venham a ser exigidos, nos termos da lei.

VII. Responsabilizar-se por danos causados à **CONTRATANTE** e/ou aos seus empregados e prepostos, bem como a terceiros, decorrentes de culpa ou dolo, nas dependências ou não da **CONTRATANTE**, em razão da execução dos serviços ora contratados.

VIII. Manter, no mais absoluto sigilo e confidencialidade, todas as informações, dados, documentos e demais elementos que venha a ter conhecimento ou acesso em razão da execução dos serviços, objeto deste contrato, seja através da **CONTRATANTE** ou de terceiros, não podendo divulgá-los verbalmente ou por escrito, em qualquer tempo, mesmo após o término do presente Contrato, sem o consentimento prévio e por escrito da **CONTRATANTE.**

IX. Ceder o equipamento de EDA adulto e pediátrico, colono, reto e o de CPRE a serem realizados no Centro Cirurgico.

CLÁUSULA SEXTA – DA VIGÊNCIA E DA RESCISÃO

6.1. O presente contrato vigorará por prazo indeterminado, a partir da data de sua assinatura, podendo ser denunciado imotivadamente, a qualquer tempo, sem qualquer ônus e por qualquer das Partes, mediante notificação por escrito da Parte interessada à outra, com antecedência mínima de 30 (trinta) dias.

6.2. O presente Contrato, todavia, poderá ser denunciado motivadamente, de pleno direito, independente de aviso prévio, mediante notificação por escrito à Parte contrária, na ocorrência das seguintes circunstâncias:

a) Descumprimento ou infração de qualquer das cláusulas do presente Contrato;
b) Inobservância das normas técnicas e/ou da legislação aplicável ao presente Contrato;
c) Insolvência civil, recuperação judicial ou extrajudicial, decretação de falência, bem como liquidação judicial ou extrajudicial, de qualquer das Partes contratantes.
d) Cessão, no todo ou em parte, dos direitos e obrigações ora contratados, sem a prévia, expressa e escrita anuência da outra Parte;
e) Negligência, imprudência ou imperícia na execução dos serviços contratados.

6.3. A Parte que motivar a rescisão do presente Contrato pagará à outra Parte multa compensatória equivalente a 20% (vinte por cento) do valor correspondente à média das três últimas faturas emitidas.

6.4. A rescisão motivada do presente contrato dar-se-á sem prejuízo e independentemente da responsabilidade civil, tributária, administrativa, criminal ou qualquer outra, da Parte infratora, resguardado e assegurado o direito da Parte inocente de pleitear perdas e danos suplementares, sem prejuízo das custas processuais e honorários advocatícios em que esta incorrer na defesa de seus interesses.

CLÁUSULA SÉTIMA – DAS DISPOSIÇÕES GERAIS

7.1. São disposições gerais a este Contrato, obrigando as Partes em todos os seus termos:

a) Além da relação contratual ora regulada, não se estabelece entre as Partes, por força deste Contrato, qualquer forma de sociedade, associação ou responsabilidade solidária;

b) Todas e quaisquer alterações, inclusões, exclusões, solução de casos omissos, ficam sujeitas a prévio acordo entre as Partes que, necessariamente formalizadas por escrito, passarão a fazer parte integrante deste ajuste, na forma de um Termo Aditivo Contratual;

c) As notificações e comunicações de que trata o presente Contrato, deverão ser feitas sempre por escrito e mediante protocolo datado e rubricado pelo destinatário;

d) A eventual decretação de nulidade, ineficácia, invalidade ou de inexequibilidade de cláusula, disposição ou condição do presente Contrato, não afetará as demais, que permanecerão válidas, eficazes e exigíveis enquanto viger esse Contrato;

e) Este Contrato representa a totalidade de entendimentos mantidos pelas Partes com relação à matéria nele contida, sucedendo todos e quaisquer outros anteriores, escritos ou verbais, prevalecendo sobre qualquer outro documento.

f) O retardo ou o não exercício, pelas Partes, de quaisquer direitos outorgados no presente instrumento, bem como a não exigência de cumprimento de quaisquer das obrigações ora assumidas, não implicará renúncia ou novação, configurando-se como mera liberalidade da Parte que assim agir, permanecendo essas obrigações e direitos válidos e exigíveis durante toda a vigência deste Contrato;

g) Para todos os efeitos legais e contratuais, não há qualquer vínculo empregatício entre a **CONTRATANTE** e os empregados e/ou prepostos da **CONTRATADA** designados para a execução dos serviços objeto do presente Contrato, sendo certo que os profissionais da **CONTRATADA** não têm vinculação de horário e/ou subordinação hierárquica com a **CONTRATANTE,** e prestarão os serviços contratados sem interferência e/ou controle de qualquer natureza pela **CONTRATANTE**.

h) As Partes ora contratantes poderão firmar contratos que tenham o mesmo objeto deste com outras pessoas físicas ou jurídicas, não tendo o presente Contrato caráter de exclusividade, cabendo única e exclusivamente a cada Parte avaliar a conveniência e interesse na formalização de novos contratos.

CLÁUSULA NONA – DO FORO

8.1. Para dirimir quaisquer controvérsias oriundas do presente Contrato, as Partes elegem o foro Central da Comarca de São Paulo, Capital, renunciando a qualquer outro, por mais privilegiado que seja ou venha a se tornar.

E por estarem assim, justas e contratadas, as partes assinam o presente instrumento em 2 (duas) vias de igual teor e forma, para um só efeito, na presença de duas testemunhas.

São Paulo, 01 de fevereiro de 2018.

Hospital Adventista de São Paulo
Dr. Dorival Duarte de Lima
Diretor Clínico - CRM 10597

INSTITUIÇÃO PAULISTA ADVENTISTA DE EDUCAÇÃO E ASSISTÊNCIA SOCIAL, mantenedora do HOSPITAL ADVENTISTA DE SÃO PAULO
CONTRATANTE

Marcio Lamas Lopes
Médico
CRM - 133420

Rodrigo P. Sant'Anna

RODRIGO P. SANTANA
CRM 114.910

ABC Endoscopia ME - CONTRATADA

TESTEMUNHAS:

1) _____
Nome: Jacob Tiffeodoro Rodrigues
RG: 57.384.705-8
CPF: 649.184.249.91

2) _____
Nome:
RG:
CPF:

ACCOUNTING STATEMENT

Accountant **NELSON GAZA** - Owner of **ESCRITORIO CONTABIL GAZA LTDA**
CNPJ No. **50.132.323/0001-07**
Regional Accounting Council (CRC) No. 1SP33435/0-6
Address: Rua General Osorio No. 63 room 2 - Vila Bocaina - MAUA

To Whom It May Concern,
I, **NELSON GAZA**, Accountant, owner of **ESCRITORIO CONTABIL GAZA LTDA**, with the National Registry of Legal Entities **CNPJ under No. 50.132.323/0001-07**, hereby declare, for all due purposes, that Mr. **Marcio Lamas Lopes**, Brazilian, married, holder of CPF No. 287.868.388-90, is engaged in full-time professional activities as the **Owner and Manager** of **ABC Endoscopia ME** (*Microenterprise*), registered with the National Registry of Legal Entities (CNPJ) under **No. 21.850.272/0001-50**, and has been our client since **02/10/2015**.

In view of the foregoing, I hereby certify Mr. **Marcio Lamas Lopes**'s expertise as **Owner and Manager** of **ESCRITORIO CONTABIL GAZA LTDA**, which is a well-established company operating in the **technology and consulting** market, with a workforce of **1 employee** and indirect collaborators. The company has demonstrated substantial growth over the past several years, with an emphasis on innovation and international expansion.

The following is a breakdown of the personal income earned by Mr. **Marcio Lamas Lopes** over the past five (5) years, detailing the income sources arising from the **provision of services**, in accordance with the company's financial records and tax returns:

- **In 2021:** R$ **503,152.99**, derived from the provision of services, consisting of **R$ 489,952.99 in profit distributions and R$ 13,200.00 in owner's compensation**.
- **In 2022:** R$ **404,744.00**, derived from the provision of services and social security benefits, consisting of **R$ 390,200.00 in profit distributions and R$ 14,544.00 in owner's compensation**.
- **In 2023:** R$ **623,768.00**, derived from the provision of services and real estate investments, consisting of **R$ 608,000.00 in profit distributions and R$ 15,768.00 in owner's compensation**.
- **In 2024:** R$ **776,944.00**, consisting primarily of **R$ 760,000.00 in profit distributions and R$ 16,944.00 in owner's compensation**.
- **In 2025:** R$ **767,852.56**, consisting primarily of **R$ 731,420.56 in profit distributions and R$ 18,216.00 in owner's compensation**.

These amounts are duly recorded in the financial statements and income tax returns submitted by Mr. **Marcio Lamas Lopes** and his company.

I further emphasize that the company has demonstrated robust growth, as evidenced by the continuous increase in its annual revenue, which over the past four years amounted to: **2022**: R$ 1,946,859.32; **2023**: R$ 2,009,673.65; **2024**: R$ 2,110,167.00; and **2025**: R$ 2,551,063.48. The company also holds a significant

position in the market, operating in a high-demand field, particularly in the sector of **Bariatric Endoscopy**.
We remain at your disposal should any additional information or clarification be required.
Sincerely,

NELSON GAZA
1SP33435/O-6

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 13, 2026.

DECLARAÇÃO CONTÁBIL

Contador **NELSON GAZA** – Titular da **ESCRITORIO CONTABIL GAZA LTDA**
CNPJ nº **50.132.323/0001-07**
CRC nº 1SP33435/O-6
Endereço: Rua General Osorio nº 63sala 2 – Vila Bocaina - MAUA

A quem possa interessar,
Eu, **NELSON GAZA**, contador, titular da **ESCRITORIO CONTABIL GAZA LTDA**, inscrito no Cadastro Nacional da Pessoa Jurídica **CNPJ sob nº 50.132.323/0001-07** declaro, para os devidos fins, que o Sr. **Marcio Lamas Lopes**, brasileiro, casado, portador do CPF nº287.868.388-90, exerce atividades profissionais em tempo integral como **Proprietário e Gestor** da empresa **ABC Endoscopia ME**, inscrita no Cadastro Nacional da Pessoa Jurídica (CNPJ) sob o **nº 21.850.272/0001-50**, sendo nosso cliente desde **10/02/2015.**

Diante do exposto, certifico a expertise do Sr. **Marcio Lamas Lopes** como **Proprietário e Gestor** da **ABC Endoscopia ME**, a qual é uma empresa sólida, com atuação no mercado de **tecnologia e consultoria**, com um quadro de **1 funcionária** colaboradores diretos e indiretos. A empresa tem demonstrado um crescimento substanciàl ao longo dos últimos anos, com ênfase na inovação e na expansão internacional.

A seguir, apresento a discriminação do faturamento pessoal obtido pelo Sr. **Marcio Lamas Lopes** nos últimos 5 (cinco) anos, detalhando as fontes de renda advindas de **prestação de serviços**, conforme os registros financeiros da empresa e declarações de renda:

- **Em 2021**: R$ **503.152,99**, provenientes de prestação de serviços, com **R$ 489.952,99 distribuição de lucro e R$ 13.200,00 referente a pró-labore**.
- **Em 2022**: R$ **404.744,00**, provenientes de prestação de serviços e benefícios previdenciários, com **R$ 390.200,00 distribuição de lucro e R$ 14.544,00 referente a pró-labore.**
- **Em 2023**: R$ **623.768,00**, provenientes de serviços prestados e investimentos imobiliários, com **R$ 608.000,00 distribuição de lucro e R$ 15.768,00 referente a pró-labore.**
- **Em 2024**: R$ **776.944,00**, com ganhos advindos principalmente de **valor R$ 760.000,00 referente a distribuição de lucro e R$ 16.944,00 referente a Pró-labore.**
- **Em 2025: 749.636,56** com ganhos advindos principalmente de **valor R$ 731.420,56 referente a distribuição de lucro e R$ 18.216,00 referente a Pró-labore.**

Esses valores estão devidamente registrados nos informes financeiros e nas declarações de rendimentos apresentados pelo Sr. **Marcio Lamas Lopes** e sua empresa.

Ressalto que a empresa tem apresentado um crescimento robusto, evidenciado pelo aumento contínuo de sua receita anual, que nos últimos quatro anos foi de: **2022:** R$ 1.946.859,32; **2023**: R$ 2.009.673,65; **2024**: R$ 2.110.167,00; **2025:** R$ 2.551.063,48 e possui uma posição relevante no

mercado, atuando em uma área de alta demanda, especialmente no setor de **Endoscopia Bariátrica**.

Permanecemos à disposição para quaisquer esclarecimentos adicionais, caso necessário.

Atenciosamente,

NELSON GAZA
1SP33435/O-6

Exhibit C.I - First Prong - Substantial Merit and National Importance

Advanced Endoscopic Weight Loss Institute

BUSINESS PLAN

2026

Name: Marcio Lamas Lopes
Phone: +55 (11) 98409-6670
E-mail: malamaslopes@gmail.com
Position: General Manager & Managing Director





Prepared by:
Nextus Plan

Contents

1.0 EXECUTIVE SUMMARY 3
1.1 Nature and Scope of the Business 5
1.2 Mr. Marcio Lamas Lopes's Expertise 6
2.0 THE COMPANY 7
2.1 Company's Target 9
2.2 Needs for the Company's Services 10
2.3 Company's Expansion 11
2.4 Company's Economic Benefits 12
2.4.1 Financial Highlights Chart 13
2.4.2 Federal, State and Payroll Taxes Chart 14
2.5 Summary of Investment 14
2.5.1 Startup Requirements Table 15
3.0 COMPANY'S SERVICES 15
4.0 INDUSTRY OVERVIEW 18
4.1 Industry Analysis 19
4.2 Major Market Segmentation 20
4.3 Business Location 21
5.0 STRATEGY AND IMPLEMENTATION 22
5.1 SWOT Analysis 22
5.2 Website and Digital Marketing 24
5.3 Sales Strategy 24
5.4 Sales Forecast 25
5.4.1 Annual Sales Forecast Table and Chart 26
5.5 Research, Education, and Training 27
6.0 MANAGEMENT STRUCTURE 27
6.1 Staffing Requirements 27
6.2 Annual Personnel Plan Table 29
6.3 Five-Year Personnel Plan Table 29
6.4 Organizational Chart - Year 5 30
6.5 Duties and Responsibilities 31
7.0 FINANCIAL SUMMARY 33
7.1 Break-even Analysis 33
7.1.1 Break-even Analysis Table 34
7.2 Profit and Loss Assumptions 34
7.2.1 Annual Profit and Loss Table 35
7.2.2 Annual Expenses x Sales Chart 36
7.2.3 Annual Profit Chart 37
7.3 Cash Flow Assumptions 37
7.3.1 Annual Cash Flow Table 38
7.3.2 Annual Net Cash Flow and Cash Balance Chart 38
7.4 Balance Sheet Assumptions 39
7.4.1 Annual Balance Sheet Table 39
8.0 MR. MARCIO LAMAS LOPES'S NATIONAL-LEVEL IMPACT 40
9.0 INDIRECT JOBS CREATION - ECONOMIC POLICY INSTITUTE 41
9.1 Distressed Communities 42
APPENDIX 1

1.0 Executive Summary

Advanced Endoscopic Weight Loss Institute LLC will be a specialized clinic headquartered in Orlando, Florida, dedicated to the minimally invasive treatment of obesity and related metabolic conditions through bariatric endoscopy and metabolic medicine. The company will establish a structured clinical operation that combines primary endoscopic interventions, revisional endoscopic procedures, and longitudinal metabolic care within a single coordinated setting. All clinical care will be delivered on an outpatient basis using minimally invasive techniques, reducing the recovery burden associated with traditional surgical approaches.

The clinical foundation of the company is the Integrated Weight Management Pathway (IWMP), a structured care model organized in three coordinated tiers. The first tier provides primary endoscopic interventions, including intragastric balloon placement and Endoscopic Sleeve Gastroplasty (ESG). The second tier addresses weight regain after prior bariatric surgery through revisional endoscopy, including Transoral Outlet Reduction (TORe) and Argon Plasma Coagulation (APC). The third tier delivers longitudinal metabolic follow-up and a structured weight-management program supported by nursing, nutrition, and patient-coordination staff.

The IWMP is operationalized through five services that the company will offer: the Intragastric Balloon Program; Endoscopic Sleeve Gastroplasty (ESG); Endoscopic Revision for Weight Regain (TORe/APC); the Structured Weight Management Program; and Clinical and Metabolic Follow-up. Together, these services will allow the company to serve patients across the full continuum of nonsurgical and revisional weight-management care.

The company will be founded and managed by Mr. Marcio Lamas Lopes, MD, who will serve as General Manager & Managing Director. In this capacity, Mr. Lopes will establish, organize, and manage the Institute and design its clinical programs and care protocols. He will not personally perform endoscopic procedures. All endoscopic procedures will be delivered by United States licensed physicians engaged by the company under professional-services agreements and compensated on a per-procedure basis, and a contracted United States licensed Medical Director will provide clinical governance and oversight of patient care.

Founder Background

Mr. Lopes is a physician specialized in General Surgery and Digestive Endoscopy, with more than fifteen years of clinical experience in Brazil and over ten years of focused practice in advanced bariatric endoscopy. He completed residencies in General Surgery and Digestive Endoscopy and earned his MD from Universidade do Vale do Itajai. He has served as endoscopy-service coordinator at Hospital Adventista de Sao Paulo, where he developed experience organizing and directing endoscopy operations. His clinical background includes intragastric balloon placement, Endoscopic Sleeve Gastroplasty, and the management of weight regain after bariatric surgery

using endoscopic techniques, including Argon Plasma Coagulation. The experience he developed coordinating endoscopy services and managing complex bariatric endoscopic care directly informs the design and management of the Institute's clinical programs. Over the course of his career in Brazil, Mr. Lopes has accumulated an extensive clinical background, having performed innumerable advanced bariatric endoscopy procedures.

Market Need

Obesity represents one of the most significant public health challenges in the United States, and demand for effective, minimally invasive treatment options continues to grow.

Approximately forty percent of United States adults, representing more than one hundred million adults, live with obesity, and severe obesity affects approximately nine percent of adults. Obesity-related medical costs are estimated at approximately $173 billion per year, reflecting the substantial economic burden of the condition on the national health system.[1]

Despite the scale of this need, surgical treatment reaches only a small fraction of eligible patients. Bariatric surgery accounts for approximately 280,000 procedures per year in the United States, and fewer than two percent of clinically eligible patients receive surgical treatment, leaving a substantial population underserved by existing surgical capacity.[2]

Obesity is closely associated with serious metabolic comorbidities. Approximately thirty-eight million Americans live with diabetes, and approximately forty-eight percent of adults have hypertension, conditions that frequently accompany obesity and that benefit from sustained, coordinated metabolic care.[3]

The company's minimally invasive and revisional approach addresses this gap by serving patients who are not candidates for, or who prefer alternatives to, conventional bariatric surgery, as well as patients who have experienced weight regain after prior surgical treatment.

Economic Relevance

The company is structured as a financially sustainable clinical operation that will generate measurable economic activity in Orlando, Florida. The company's revenue is projected to grow

[1] U.S. Centers for Disease Control and Prevention (CDC), Adult Obesity Facts and Consequences of Obesity, 2024 (obesity-related medical care costs estimated at $173 billion in 2019 dollars). https://www.cdc.gov/obesity/adult-obesity-facts/index.html

[2] American Society for Metabolic and Bariatric Surgery (ASMBS), Estimate of Bariatric Surgery Numbers, 2011-2022. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers/

[3] U.S. Centers for Disease Control and Prevention (CDC), National Diabetes Statistics Report, 2024, and Facts About Hypertension, 2024. https://www.cdc.gov/diabetes/php/data-research/ ; https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/

from approximately $804,000 in Year 1 to approximately $3,629,000 by Year 5, supported by the staged expansion of its clinical and operational capacity.

To support this growth, the company's team will expand from four employees in Year 1 to fifteen employees by Year 5, creating qualified clinical, administrative, and patient-coordination positions. Over the five-year period, the company is projected to contribute approximately $563,000 in federal, state, and payroll taxes. The operation will be launched with an initial investment of $200,000.

Through this activity, the company will generate the following economic and health-related contributions:

- Creation of qualified clinical and administrative employment, expanding from four to fifteen positions over five years in the Orlando, Florida area.
- Generation of approximately $563,000 in federal, state, and payroll tax contributions over the five-year period.
- Expansion of access to minimally invasive and revisional weight-management care for patients underserved by conventional surgical options.
- Support for coordinated management of obesity-related metabolic conditions through structured, longitudinal follow-up.
- Engagement of United States licensed physicians and clinical staff under structured professional arrangements, strengthening local clinical capacity.

1.1 Nature and Scope of the Business

Advanced Endoscopic Weight Loss Institute LLC will operate as a specialized outpatient clinic focused on the minimally invasive treatment of obesity and related metabolic conditions. The company will deliver care through a structured clinical model that integrates primary endoscopic interventions, revisional endoscopic procedures, and longitudinal metabolic follow-up, allowing patients to be managed across the full continuum of nonsurgical weight-management care within a single coordinated setting.

All clinical care will be provided on an outpatient basis using minimally invasive endoscopic techniques, which reduce procedural risk and recovery time relative to conventional bariatric surgery. The company's operations will be organized around the Integrated Weight Management Pathway (IWMP), ensuring that each patient receives appropriate intervention, follow-up, and metabolic support according to their clinical profile. In addition to its endoscopic procedures, the Institute will integrate pharmacological treatment of obesity, including GLP-1 receptor agonists, both in combination with endoscopic interventions to enhance and sustain weight loss and as a standalone medical weight-management option, within a multidisciplinary

minimally invasive metabolic-medicine model that brings together physicians, nutritionists, psychologists, nursing professionals, and physical-training support.

The clinic will deliver all endoscopic and physician-directed care through United States licensed physicians engaged by the company, operating under the management and program design of Mr. Lopes as General Manager & Managing Director. A contracted United States licensed Medical Director will provide clinical governance, while nursing, nutrition, and patient-coordination staff will support the continuity of care across the pathway.

Core Business Activities

The company will offer five core services that operationalize the Integrated Weight Management Pathway:

- **Intragastric Balloon Program:** The company will provide intragastric balloon placement as a primary, temporary endoscopic intervention for eligible patients, supporting initial weight reduction and behavioral adjustment without permanent anatomical alteration.
- **Endoscopic Sleeve Gastroplasty (ESG):** The company will offer ESG as a primary endoscopic procedure that reduces gastric volume through suturing techniques, providing a minimally invasive alternative to surgical sleeve procedures for appropriate candidates.
- **Endoscopic Revision for Weight Regain (TORe/APC):** The company will provide revisional endoscopic procedures, including Transoral Outlet Reduction and Argon Plasma Coagulation, to address weight regain in patients who have undergone prior bariatric surgery.
- **Structured Weight Management Program**: The company will deliver a structured weight-management program that combines clinical supervision, nutritional guidance, and behavioral support to reinforce and sustain the results of endoscopic intervention.
- **Clinical and Metabolic Follow-up**: The company will provide longitudinal clinical and metabolic follow-up, monitoring patient progress and managing obesity-related metabolic conditions through coordinated, ongoing care.

1.2 Mr. Marcio Lamas Lopes's Expertise

Mr. Marcio Lamas Lopes is a physician specialized in General Surgery and Digestive Endoscopy, with more than fifteen years of clinical experience accumulated in Brazil. He completed residencies in both General Surgery and Digestive Endoscopy and earned his MD from Universidade do Vale do Itajai, establishing a clinical foundation that spans both surgical and endoscopic disciplines.

Over more than ten years, Mr. Lopes has concentrated his practice in advanced bariatric endoscopy. His clinical experience includes intragastric balloon placement and Endoscopic Sleeve Gastroplasty as primary endoscopic interventions, as well as the management of weight regain after bariatric surgery using endoscopic techniques, including Transoral Outlet Reduction and Argon Plasma Coagulation. This breadth of experience covers the full range of procedures that the Institute's clinical programs are designed to deliver. Over the course of his career in Brazil, Mr. Lopes has built an extensive and high-performance front-line clinical experience, performing countless advanced bariatric endoscopy procedures, including intragastric balloon placements, Endoscopic Sleeve Gastroplasty, and Argon Plasma Coagulation, and establishing a consolidated senior clinical leadership spanning over a decade.

As endoscopy-service coordinator at Hospital Adventista de Sao Paulo, Mr. Lopes developed direct experience organizing, coordinating, and directing endoscopy operations within a hospital setting. In this role, he became familiar with the operational, staffing, and quality-management requirements of running an endoscopy service, experience that is directly applicable to the design and management of a specialized clinical operation.

Throughout his career, Mr. Lopes has remained engaged with the scientific and technical development of bariatric endoscopy, maintaining current knowledge of evolving techniques and clinical protocols in the field. This sustained engagement informs the clinical standards and care protocols that he will embed in the Institute's programs.

The combination of Mr. Lopes' clinical training, his focused expertise in bariatric endoscopy, and his experience coordinating endoscopy services equips him to design and manage the Institute's clinical programs and to establish its operational and quality framework. In the United States, his role will be to lead the organization, program design, and management of the company, while licensed United States physicians deliver the procedures under the clinical governance of a contracted Medical Director.

2.0 The Company

Advanced Endoscopic Weight Loss Institute LLC will operate as a specialized clinic in Orlando, Florida, dedicated to the minimally invasive treatment of obesity and metabolic conditions through bariatric endoscopy and metabolic medicine. The Institute will be founded by Mr. Marcio Lamas Lopes, MD, who will serve as General Manager & Managing Director. In this capacity he will establish, organize, and manage the Institute, design its clinical programs, and direct its operational execution. He will not personally perform procedures; clinical procedures will be delivered by United States licensed physicians engaged under professional-services agreements, with clinical governance provided by a contracted United States licensed Medical Director.

The Institute will deliver care through its centerpiece model, the Integrated Weight Management Pathway (IWMP), which will organize services across three tiers: primary endoscopic interventions (intragastric balloon and endoscopic sleeve gastroplasty); revisional endoscopy for weight regain (TORe with APC); and longitudinal metabolic follow-up combined with a structured weight-management program.

The Institute will begin operations in Year 1 with a team of four:

- **General Manager & Managing Director (Mr. Marcio Lamas Lopes)** who will establish, organize, and manage the Institute and design its clinical programs.
- **Medical Assistant** who will support clinical preparation, patient intake, and procedure-day workflows.
- **Patient Care Coordinator** who will guide patients through scheduling, education, and continuity of care.
- **Administrative Assistant** who will manage front-office operations, records, and general administration.

By the fifth year, the Institute will expand its workforce to fifteen salaried team members:

- **General Manager & Managing Director** who will continue to lead strategic, clinical-program, and operational direction.
- **3 Medical Assistants** who will support clinical and procedural workflows across an expanded patient volume.
- **2 Patient Care Coordinators** who will manage patient navigation and continuity of care.
- **1 Administrative Assistant** who will oversee front-office and records administration.
- **1 Bariatric Program Coordinator** who will coordinate the structured weight-management and procedural program.
- **2 Registered Nurses** who will provide clinical care, monitoring, and patient support.
- **2 Nutritionists and Dietitians** who will deliver nutritional assessment and structured dietary management.
- **1 Billing and Insurance Specialist** who will manage claims, reimbursement, and insurance coordination.
- **1 Marketing and Outreach Coordinator** who will manage patient outreach and referral-network development.
- **1 Front Desk and Scheduling Clerk** who will manage reception, scheduling, and patient flow.

Throughout this growth, all clinical procedures will be delivered by contracted United States licensed physicians, and clinical governance will be provided by a contracted United States licensed Medical Director, under the management and operational direction of Mr. Lopes. The professional fees of these contracted physicians will be accounted for as direct costs, and these contractors will appear in the organizational structure but not in the salaried headcount. The Institute's multidisciplinary care model will also incorporate psychology and physical-training professionals, engaged as part of the clinical team to support behavioral change and physical reconditioning across the weight-management pathway.

2.1 Company's Target

The Institute will serve adults with obesity who are not candidates for, do not wish to undergo, or have not responded adequately to traditional bariatric surgery, as well as patients experiencing weight regain after prior bariatric procedures. Its model will address a large and growing patient population in Florida and the broader United States through minimally invasive, evidence-based interventions.

Obesity affects approximately 40 percent of United States adults and is associated with an estimated annual cost of about $173 billion, which establishes a substantial and persistent base of patients who may benefit from minimally invasive treatment options.[4]

Primary Market Focus

1. Adults with obesity seeking minimally invasive alternatives to surgery

The Institute will focus on adults with obesity who are not surgical candidates, who prefer to avoid traditional bariatric surgery, or who have not achieved adequate results through lifestyle and pharmacological approaches. These patients will represent the core population for the intragastric balloon and endoscopic sleeve gastroplasty programs.

In Florida specifically, adult obesity prevalence is approximately 31 percent, which reflects a large in-state population of potential patients for the Institute's services.[5]

2. Patients with weight regain after bariatric surgery

A significant share of patients who undergo traditional bariatric surgery will experience weight regain over time. The Institute will serve this population through endoscopic revision procedures

[4] U.S. Centers for Disease Control and Prevention (CDC), Adult Obesity Facts and Consequences of Obesity, 2024 (obesity-related medical care costs estimated at $173 billion in 2019 dollars). https://www.cdc.gov/obesity/adult-obesity-facts/index.html

[5] U.S. Centers for Disease Control and Prevention (CDC), Behavioral Risk Factor Surveillance System (BRFSS), Adult Obesity Prevalence Maps by State (Florida), 2023. https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html

(TORe with APC), offering a minimally invasive option for patients seeking to address recurrence without repeat surgery.

3. Patients with metabolic comorbidities

The Institute will serve patients presenting with metabolic comorbidities such as type 2 diabetes, hypertension, and dyslipidemia. For these patients, the structured weight-management program and longitudinal metabolic follow-up will provide integrated, continuous care alongside procedural intervention.

4. Referring medical centers and providers

The Institute will develop relationships with referring medical centers, primary care providers, and specialty practices that identify candidates for minimally invasive obesity treatment. These referral sources will form an important channel for sustained patient volume and coordinated care.

2.2 Needs for the Company's Services

The Institute will respond to a series of well-defined and persistent needs in the treatment of obesity and metabolic disease. Each of the following needs reflects a structural gap in current care delivery that the Institute's model is designed to address.

1. Limited access to minimally invasive obesity treatment

Many patients with obesity face limited access to minimally invasive endoscopic treatment options, with care frequently concentrated in surgical pathways or pharmacological management. The Institute will expand access to endoscopic interventions such as the intragastric balloon and endoscopic sleeve gastroplasty, providing alternatives for patients who are not candidates for or do not wish to undergo surgery.

2. Weight regain after bariatric surgery

Patients who have undergone traditional bariatric surgery frequently experience weight regain over the years following their procedure, and revisional surgical options carry elevated risk and complexity. The Institute will address this need through endoscopic revision procedures (TORe with APC), offering a lower-risk pathway to manage recurrence.

3. Rising metabolic disease burden

The prevalence of obesity-related metabolic conditions, including type 2 diabetes, hypertension, and dyslipidemia, continues to increase across the adult population. The Institute will address this growing burden by integrating metabolic medicine and longitudinal follow-up directly into its treatment model, rather than treating weight and metabolic conditions in isolation.

4. Access and cost barriers to comprehensive care

Patients often encounter fragmented care and cost barriers when seeking integrated obesity and metabolic treatment, with procedural, nutritional, and follow-up services delivered across separate providers. The Institute will consolidate these services within a single coordinated pathway, improving continuity and reducing the burden of navigating multiple care settings.

5. Need for structured longitudinal management

Durable results in obesity treatment depend on sustained, structured follow-up rather than isolated interventions. The Institute will meet this need through its structured weight-management program and clinical and metabolic follow-up services, which will provide continuous monitoring, behavioral support, and metabolic management over the long term.

2.3 Company's Expansion

The Institute will establish its initial operations in Orlando, Florida, and will pursue a structured, phased expansion as patient volume, referral networks, and operational capacity mature. The following dimensions will guide this growth.

Service Expansion

The Institute will broaden its service portfolio over time, deepening its primary endoscopic and revisional programs and expanding the scope of its structured weight-management and metabolic follow-up offerings. As clinical demand grows, the Institute will add capacity across all three tiers of the Integrated Weight Management Pathway.

Geographic Expansion

The Institute will pursue geographic expansion to additional locations within Florida and, over the longer term, to other states with high obesity prevalence. The Institute's model, which combines standardized clinical pathways with contracted licensed clinical staff, will be replicable across multiple locations and markets.

Workforce Development

The Institute will grow its workforce from four team members in Year 1 to fifteen salaried team members by Year 5, adding clinical, nutritional, administrative, and outreach roles. This expansion will be supported by structured training and the standardization of clinical and operational protocols across the organization.

Strategic Partnerships

The Institute will develop strategic partnerships with outpatient surgical centers, hospitals, and referring providers. These partnerships will support coordinated patient care, expand referral

channels, and enable the Institute to extend its reach without proportionate increases in fixed infrastructure.

Continuous Clinical Quality and Technology

The Institute will invest continuously in clinical quality and technology, adopting advances in endoscopic technique, metabolic management, and electronic medical records. This focus will support consistent clinical outcomes and operational efficiency as the organization scales.

Long-Term Growth Outlook

Over the long term, the Institute's standardized clinical pathways, contracted-physician model, and replicable operational structure will support measured growth across multiple Florida locations and, subsequently, additional high-prevalence states. This scalable foundation will position the Institute to serve an expanding patient population while maintaining clinical quality and operational discipline.

2.4 Company's Economic Benefits

The Institute will generate measurable economic activity as it grows from a four-person operation in Year 1 to a fifteen-person salaried workforce by Year 5, supported by an expanding base of contracted clinical professionals and a growing patient population.

Revenue will grow from $804,000 in Year 1 to $3,629,000 in Year 5. Over the same period, gross margin will increase from $388,470 (48.3 percent of revenue) in Year 1 to $1,911,120 (52.7 percent of revenue) in Year 5, reflecting improving operating scale and capacity utilization.

The Institute's growth will produce a range of economic contributions, including the following:

- Direct employment, growing from four salaried positions in Year 1 to fifteen salaried positions by Year 5, across clinical, nutritional, administrative, and outreach functions.
- Engagement of contracted United States licensed physicians and a contracted Medical Director, whose professional fees will represent recurring income for independent clinical professionals.
- Procurement of medical supplies, endoscopy-support equipment, and professional services from United States vendors and suppliers.
- Generation of federal, state, and payroll tax revenue across the five-year period.
- Delivery of minimally invasive obesity and metabolic care that will expand local access to treatment options within the Orlando market and the broader Florida population.

The Institute will also contribute meaningful tax revenue. Payroll taxes will grow from approximately $18,587 in Year 1 to approximately $72,250 in Year 5, and federal and state


income tax will increase from $10,138 in Year 1 to $172,547 in Year 5. Across the five-year period, total taxes (federal, state, and payroll) will total approximately $563,000.

These projections use conservative assumptions based on the company's own service model, pricing structure, and staffing plan, rather than aggressive growth scenarios.

The figures presented here are estimates developed from the Institute's internal financial model and are not derived from any single external source. Actual results may vary based on market conditions, patient volume, and operational factors.


Taken together, these contributions reflect the Institute's role as an employer, a purchaser of goods and services, a taxpayer, and a provider of minimally invasive obesity and metabolic care within its market.

2.4.1 Financial Highlights Chart



	Year 1	Year 2	Year 3	Year 4	Year 5
Sales	$804,000	$1,258,000	$1,910,000	$2,698,000	$3,629,000
Gross Margin	$388,470	$623,460	$965,340	$1,391,340	$1,911,120
Net Profit	$28,120	$43,203	$128,228	$256,588	$478,573

2.4.2 Federal, State and Payroll Taxes Chart



	Year 1	Year 2	Year 3	Year 4	Year 5	5 Year Total
Federal and State Taxes	$10,138	$15,577	$46,232	$92,512	$172,547	$337,006
Payroll Taxes	$18,587	$30,940	$44,540	$59,670	$72,250	$225,987
Total	$28,725	$46,517	$90,772	$152,182	$244,797	$562,993

2.5 Summary of Investment

The Institute will require total startup funding of $200,000, which will be self-funded by the founder, Mr. Marcio Lamas Lopes. This capital will be allocated between startup expenses and startup assets, providing the resources necessary to establish operations and sustain the Institute through its initial period.

Startup Expenses

Startup expenses will total $35,000 and will cover legal, incorporation, and permitting costs; website, branding, and launch marketing; initial medical supplies and disposables; credentialing and insurance setup; and IT and EMR software setup. These expenditures will establish the operational and regulatory foundation required to open the Institute.

Startup Assets

Startup assets will total $165,000, comprising a cash reserve of $93,000 and long-term assets of $72,000. The long-term assets will include medical and endoscopy-support equipment, leasehold build-out, and furniture and fixtures, while the cash reserve will provide working capital to support early operations.

This investment structure will reflect a lean, self-funded approach, in which a disciplined initial outlay will establish the Institute's clinical and operational capacity, and subsequent growth will be funded primarily through operating revenue.

2.5.1 Startup Requirements Table

Startup	
Requirements	
Startup Expenses	
Legal, Incorporation and Permits	$7,000
Website, Branding and Launch Marketing	$7,000
Initial Medical Supplies and Disposables	$8,000
Credentialing and Insurance Setup	$5,000
IT / EMR Software Setup	$8,000
Total Startup Expenses	$35,000
Startup Assets	
Cash Required	$93,000
Long-term Assets (Equipment, Build-out, Furniture)	$72,000
Total Assets	$165,000
Total Requirements	**$200,000**

3.0 Company's Services

Advanced Endoscopic Weight Loss Institute LLC will operate as a specialized clinic dedicated to the minimally invasive treatment of obesity and metabolic conditions through bariatric endoscopy and metabolic medicine. The Institute will deliver a structured continuum of care organized around its centerpiece, the Integrated Weight Management Pathway (IWMP), which connects primary endoscopic interventions, revisional procedures for weight regain, and longitudinal metabolic follow-up into a single coordinated program.

All clinical services will be designed and supervised under the coordination of the General Manager & Managing Director, Mr. Marcio Lamas Lopes, MD, who will define the clinical programs and operational standards of the Institute. Endoscopic procedures will be performed by contracted United States licensed physicians, while a contracted Medical Director will provide clinical governance and oversight. The Managing Director will not personally perform procedures; his role will center on program design, quality standards, multidisciplinary coordination, and the overall direction of the Institute.

The following five services will constitute the core clinical offering of the Institute, each mapped to a defined tier of the IWMP and delivered by qualified, licensed clinical professionals under the Managing Director's coordination.

1. Intragastric Balloon Program

The Intragastric Balloon Program will form part of Tier 1 of the IWMP, providing primary endoscopic intervention for patients seeking a non-surgical option for weight reduction. A temporary, space-occupying device will be placed endoscopically by a contracted United States licensed physician to promote early satiety and support behavioral and dietary change. The program will be designed and overseen by the Managing Director and delivered alongside structured nutritional and clinical support.

Key activities include:

- Conducting pre-procedure clinical evaluation and patient eligibility screening.
- Performing endoscopic placement of the intragastric balloon by contracted licensed physicians.
- Providing structured nutritional counseling and behavioral support throughout the device period.
- Monitoring patient tolerance, safety, and weight progress at scheduled intervals.
- Coordinating timely endoscopic removal and transition to longitudinal follow-up.

2. Endoscopic Sleeve Gastroplasty (ESG)

Endoscopic Sleeve Gastroplasty will serve as a Tier 1 primary endoscopic intervention for eligible patients, reducing gastric volume through endoscopic suturing without external incisions. The procedure will be performed by contracted United States licensed physicians in partnered outpatient surgical centers or hospital settings, following clinical protocols designed under the Managing Director's coordination and supported by the multidisciplinary team.

Key activities include:

- Performing comprehensive pre-procedure assessment and candidacy determination.
- Delivering endoscopic suturing to reduce gastric capacity by contracted licensed physicians.
- Coordinating outpatient surgical center or hospital resources for safe procedure delivery.
- Managing post-procedure recovery, nutrition, and early follow-up care.
- Integrating patients into the longitudinal metabolic follow-up component of the IWMP.

3. Endoscopic Revision for Weight Regain (TORe/APC)

Endoscopic Revision for Weight Regain will constitute Tier 2 of the IWMP, addressing patients who experience weight regain after prior bariatric surgery through revisional endoscopy, including Transoral Outlet Reduction (TORe) and Argon Plasma Coagulation (APC). These procedures will be performed by contracted United States licensed physicians under clinical governance provided by the contracted Medical Director and within protocols defined by the Managing Director.

Key activities include:

- Evaluating post-bariatric patients presenting with weight regain and anatomical changes.
- Performing Transoral Outlet Reduction or Argon Plasma Coagulation by contracted licensed physicians.
- Coordinating diagnostic endoscopy to characterize the cause of weight regain.
- Providing post-procedure clinical and nutritional management.
- Enrolling patients into structured weight-management and metabolic follow-up.

4. Structured Weight Management Program

The Structured Weight Management Program will form part of Tier 3 of the IWMP, providing a coordinated, non-procedural program that supports durable results following endoscopic intervention. The program will integrate nutrition, behavioral support, and clinical oversight, delivered by the multidisciplinary team of nutrition and nursing professionals under the coordination of the Managing Director. As part of this program, the Institute will offer pharmacological treatment of obesity, including GLP-1 receptor agonists, prescribed and managed by licensed physicians, either in combination with endoscopic procedures to potentiate weight loss or as a standalone medical weight-management approach.

Key activities include:

- Designing individualized nutrition and lifestyle plans for each patient.
- Providing ongoing behavioral and dietary counseling through the multidisciplinary team.
- Tracking weight, body composition, and adherence over time.
- Coordinating care with referring providers and metabolic specialists.
- Adjusting the program based on individual progress and clinical indicators.

5. Clinical and Metabolic Follow-up

Clinical and Metabolic Follow-up will complete Tier 3 of the IWMP, providing longitudinal management of obesity-related metabolic conditions and sustained monitoring after intervention. This service will be delivered by licensed clinical staff and supported through telemedicine for longitudinal follow-up where permitted, under clinical protocols defined by the Managing Director and governed by the contracted Medical Director.

Key activities include:

- Monitoring metabolic markers and obesity-related comorbidities over time.
- Conducting scheduled in-person and telemedicine follow-up visits where permitted.
- Coordinating medication management and referrals with metabolic specialists.
- Reinforcing nutritional and behavioral strategies for long-term maintenance.
- Documenting outcomes to support continuous quality improvement.

Most care across these five services will be delivered on an outpatient basis, by United States licensed physicians and qualified clinical staff, in the Institute's facilities and through partnerships with outpatient surgical centers and hospitals. All services will operate under the coordination of the Managing Director, who will ensure consistent clinical standards, multidisciplinary integration, and continuity of care across every tier of the IWMP.

4.0 Industry Overview

Obesity represents one of the most significant public health challenges in the United States. Approximately 40 percent of US adults, more than 100 million people, are affected by obesity, while severe obesity affects about 9 percent of adults; obesity-related medical costs are estimated at about $173 billion per year in 2019 dollars. This burden will continue to drive demand for effective and less invasive treatment options.[6]


Despite this scale, surgical and procedural treatment remains markedly underutilized. Roughly 280,000 metabolic and bariatric surgical procedures are performed each year in the United States, yet fewer than 2 percent of clinically eligible patients receive surgical treatment, leaving a large unmet need that minimally invasive endoscopic options are positioned to address.[7]

[6] U.S. Centers for Disease Control and Prevention (CDC), Adult Obesity Facts and Consequences of Obesity, 2024 (obesity-related medical care costs estimated at $173 billion in 2019 dollars). https://www.cdc.gov/obesity/php/data-research/adult-obesity-facts.html

[7] American Society for Metabolic and Bariatric Surgery (ASMBS), Estimate of Bariatric Surgery Numbers, 2011-2022. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers/

Obesity is also closely linked to costly metabolic comorbidities. About 38 million Americans have diabetes and about 48 percent of adults have hypertension, conditions strongly associated with obesity, reinforcing the need for integrated treatment that combines procedural intervention with longitudinal metabolic management.[8]

The market response to this burden is substantial. The US weight management market is valued in the tens of billions of dollars and is projected to grow at a mid-single-digit compound annual rate through the end of the decade, with minimally invasive and endoscopic obesity procedures representing a growing segment of that market.[9]



4.1 Industry Analysis

The US weight management market is valued in the tens of billions of dollars and is projected to grow at a mid-single-digit compound annual rate through the end of the decade. Within this market, minimally invasive and endoscopic obesity procedures will represent a growing segment as patients and providers increasingly seek alternatives to traditional surgery.[10]

[8] U.S. Centers for Disease Control and Prevention (CDC), National Diabetes Statistics Report, 2024, and Facts About Hypertension, 2024. https://www.cdc.gov/diabetes/php/data-research/ ; https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/

[9] Grand View Research, U.S. Weight Management Market Size, Share & Trends Analysis Report, 2024-2030. https://www.grandviewresearch.com/industry-analysis/us-weight-management-market

[10] Grand View Research, U.S. Weight Management Market Size, Share & Trends Analysis Report, 2024-2030. https://www.grandviewresearch.com/industry-analysis/us-weight-management-market

US weight-loss services constitute a multibillion-dollar industry characterized by steady, sustained demand, indicating a stable commercial foundation for specialized providers entering the market.[11]

Obesity prevalence and demand for weight-management solutions continue to rise in the United States, supporting a long-term outlook of expanding patient volumes and treatment needs.[12]

At the same time, fewer than 2 percent of clinically eligible patients currently receive surgical treatment, despite roughly 280,000 metabolic and bariatric procedures performed annually. This gap between eligibility and treatment will create significant opportunity for minimally invasive endoscopic options that can reach patients who decline or do not qualify for conventional surgery.[13]

The opportunity is further reinforced by the prevalence of metabolic comorbidities, with about 38 million Americans living with diabetes and about 48 percent of adults affected by hypertension, conditions strongly associated with obesity that require the kind of integrated procedural and metabolic care the Institute will provide.[14]

4.2 Major Market Segmentation

Primary Obesity, Non-Surgical Candidates

This segment will include adults affected by obesity who seek effective weight reduction but decline conventional bariatric surgery or do not qualify for it. These patients will be primary candidates for Tier 1 endoscopic interventions such as the intragastric balloon and endoscopic sleeve gastroplasty.

Post-Bariatric Weight Regain Patients

This segment will comprise patients who have undergone prior bariatric surgery and subsequently experienced weight regain. These patients will be served by Tier 2 revisional endoscopy, including Transoral Outlet Reduction and Argon Plasma Coagulation, addressing a clinical need that is frequently underserved.

---

[11] IBISWorld, Weight Loss Services in the US, Industry Report, 2024. https://www.ibisworld.com/united-states/market-research-reports/weight-loss-services-industry/

[12] Statista, Obesity and Weight Management in the United States, 2024. https://www.statista.com/

[13] American Society for Metabolic and Bariatric Surgery (ASMBS), Estimate of Bariatric Surgery Numbers, 2011-2022. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers/

[14] U.S. Centers for Disease Control and Prevention (CDC), National Diabetes Statistics Report, 2024, and Facts About Hypertension, 2024. https://www.cdc.gov/diabetes/php/data-research/ ; https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/

Metabolic-Comorbidity Patients

This segment will include patients whose obesity is accompanied by metabolic conditions such as diabetes and hypertension. These patients will benefit from the Institute's integrated model, combining procedural intervention with longitudinal metabolic follow-up under Tier 3 of the IWMP.

Self-Pay and Referred Patients

The Institute will serve both self-pay patients seeking elective minimally invasive treatment and patients referred by primary care providers, metabolic specialists, and surgical centers. This dual channel will broaden access and support consistent patient volume across the service lines.

Outpatient Clinic and Partnered Surgical Centers

By setting, services will be segmented between the Institute's own outpatient clinic, where evaluation, follow-up, and selected procedures will occur, and partnered outpatient surgical centers and hospitals, where more complex endoscopic procedures will be performed. This structure will allow the Institute to scale capacity while maintaining clinical standards across settings.

4.3 Business Location

The Institute will be located in Orlando, within Orange County, Florida. The Orlando metropolitan area is among the fastest-growing US metros in population and employment, with a large and expanding adult population that will sustain growing demand for obesity and metabolic treatment services.[15]

Florida presents a substantial regional need for these services. Florida adult obesity prevalence is about 31 percent, and Florida is among the most populous US states with a large and growing adult population affected by obesity, creating a sizable local patient base for minimally invasive treatment.[16]

Despite this large and growing population affected by obesity, the region offers limited specialized capacity for minimally invasive endoscopic obesity treatment. This gap between local need and available capacity will position the Institute to serve a substantial and underserved patient base within its metropolitan market and the broader state.

[15] Orlando Economic Partnership, Regional Economic and Population Growth, 2024. https://orlando.org/

[16] U.S. Centers for Disease Control and Prevention (CDC), Behavioral Risk Factor Surveillance System (BRFSS), Adult Obesity Prevalence Maps by State (Florida), 2023. https://www.cdc.gov/obesity/data-and-statistics/adult-obesity-prevalence-maps.html

By establishing operations in Orlando, the Institute will expand local access to less invasive obesity and metabolic care, create skilled clinical and administrative jobs, and provide referral support to primary care providers, surgical centers, and metabolic specialists across the region. These contributions will strengthen the local capacity to address a significant and growing health need.

5.0 Strategy and Implementation

The strategy of Advanced Endoscopic Weight Loss Institute LLC will center on establishing a structured, minimally invasive obesity and metabolic treatment practice in Orlando, Florida, built around the Integrated Weight Management Pathway (IWMP). The company will combine the founder's applied clinical expertise in bariatric endoscopy with a disciplined operational model, advancing through phased growth that aligns clinical capacity, staffing, and revenue at each stage.

Implementation will proceed in a sequenced manner. During the initial phase, the practice will establish core clinical and administrative operations, build referral relationships, and launch its primary endoscopic programs. In subsequent years, the company will expand its multidisciplinary team, broaden its service mix, and scale procedure volume in line with operational capacity and demonstrated demand.

5.1 SWOT Analysis

The following SWOT analysis summarizes the internal strengths and weaknesses of Advanced Endoscopic Weight Loss Institute LLC, together with the external opportunities and threats relevant to its market environment. This assessment will inform the company's operational priorities and risk management throughout the planning period.

Strengths

- The founder's applied clinical expertise in bariatric endoscopy and his direct involvement in designing the practice's clinical programs.
- The Integrated Weight Management Pathway (IWMP), which organizes treatment into a structured, tiered model spanning primary procedures, revisional endoscopy, and metabolic follow-up.
- A minimally invasive treatment approach that carries a lower procedural risk profile than conventional bariatric surgery.
- A focus on the underserved post-bariatric weight-regain population, addressing a niche that is frequently overlooked by existing providers.

- A multidisciplinary metabolic-medicine team integrating physicians (endoscopic and pharmacological treatment, including GLP-1), nutrition, psychology, nursing, and physical-training professionals around a coordinated patient pathway.
- An Orlando, Florida location within a large and growing metropolitan market with substantial patient demand.
- A scalable operating model that supports incremental expansion of services, staffing, and procedure volume over time.
- A self-funded capital structure that provides financial independence and operational flexibility during the startup phase.

Weaknesses

- The founder is not yet licensed to practice medicine in the United States and therefore relies on contracted United States licensed physicians to deliver clinical procedures.
- As a newly established practice, the company will start with limited brand recognition in its market.

Opportunities

- High and rising obesity prevalence across the United States, which continues to expand the population in need of treatment.
- Underutilization of bariatric surgery relative to the eligible population, leaving substantial unmet demand for alternative treatment options.
- Growing demand for solutions addressing weight regain following prior bariatric procedures.
- A sizable self-pay market for elective minimally invasive obesity treatments.
- The potential to extend metabolic and clinical follow-up through telemedicine, improving access and patient retention.
- Opportunities to form partnerships with outpatient surgical centers to support procedure delivery and referral flow.
- The potential for multi-state expansion as the operating model matures.
- A growing burden of metabolic disease, which broadens the relevance of the practice's integrated services.

Threats

- Competition from established bariatric surgery centers and other weight-management providers.

- Regulatory and credentialing requirements governing clinical practice, facility operations, and contracted physicians.
- Variability in reimbursement and payer coverage for obesity and metabolic treatments.

5.2 Website and Digital Marketing

Advanced Endoscopic Weight Loss Institute LLC will develop a professional website that serves as the central point of information for prospective patients and referring physicians. The website will present the practice's services, the Integrated Weight Management Pathway, and the qualifications of its clinical team in a clear and accessible format, with patient inquiry and scheduling functions integrated throughout.

Digital marketing will emphasize educational content on minimally invasive obesity and metabolic treatment. The company will publish accessible materials explaining the available procedures, candidacy considerations, and expected outcomes, positioning the practice as a reliable source of accurate information for patients evaluating their treatment options.

The company will apply search engine optimization and structured referral outreach to expand its reach among both patients and the broader medical community. These efforts will operate within applicable advertising and patient privacy regulations, and all patient testimonials will be used only within regulatory limits and with appropriate consent.

The primary components of the digital marketing approach will include the following:

- A professional, mobile-responsive website with integrated patient inquiry and scheduling functions.
- Educational content explaining minimally invasive obesity and metabolic treatment options.
- Search engine optimization to improve visibility for relevant patient searches.
- Referral outreach directed at primary care physicians, endocrinologists, and related specialists.
- A managed social media presence sharing educational and informational content.
- Patient testimonials presented within applicable regulatory limits and with proper consent.

5.3 Sales Strategy

The patient acquisition strategy of Advanced Endoscopic Weight Loss Institute LLC will rest on building durable physician referral relationships. The company will engage primary care physicians, endocrinologists, gastroenterologists, and related specialists to establish reliable

referral channels for patients who are candidates for minimally invasive obesity and metabolic treatment.

The company will also develop partnerships with outpatient surgical centers to support the delivery of endoscopic procedures and to create mutual referral pathways. These relationships will allow the practice to scale procedure volume in line with operational capacity while maintaining clinical quality and continuity of care.

Community education will form a further pillar of patient acquisition. Through informational sessions, educational events, and accessible online content, the practice will raise awareness of minimally invasive treatment options and of the weight-regain solutions that distinguish its service mix. The company will offer clearly defined self-pay packages that provide transparent pricing for prospective patients.

Finally, the practice will convert and retain patients through the Integrated Weight Management Pathway. By guiding patients from initial procedures into structured weight-management programming and ongoing metabolic follow-up, the company will support sustained clinical outcomes while creating recurring engagement across its service lines.

5.4 Sales Forecast

The Sales Forecast for Advanced Endoscopic Weight Loss Institute LLC was constructed by projecting the volume of procedures and programs delivered across each of the five service lines over a five-year period. Projected volumes ramp progressively from Year 1 through Year 5, reflecting the practice's growing referral base, expanding multidisciplinary team, and increasing operational capacity at each stage.

Procedure and program volumes were tied directly to staffing levels and operational capacity, ensuring that projected demand remains consistent with the practice's ability to deliver care. As the team expands and additional clinical and support functions are added, the forecast reflects a corresponding increase in the number of patients served across the Integrated Weight Management Pathway.

Pricing Methodology

Each of the five service lines carries an average price and a corresponding price range that reflects variation in patient needs, clinical complexity, and program scope. The average price and range for each service are as follows:


- **Intragastric Balloon Program** average $8,000, range $7,000 to $9,500.
- **Endoscopic Sleeve Gastroplasty (ESG)** average $14,000, range $12,000 to $16,500.
- **Endoscopic Revision for Weight Regain (TORe/APC)** average $9,000, range $7,500 to $10,500.

- **Structured Weight Management Program** average $2,000, range $1,500 to $2,800.
- **Clinical and Metabolic Follow-up** average $300, range $200 to $400.

For the purposes of this business plan, the average price of each service was used to calculate the Sales Forecast.

5.4.1 Annual Sales Forecast Table and Chart

Sales Forecast					
	Year 1	Year 2	Year 3	Year 4	Year 5
Sales					
Intragastric Balloon Program	$272,000	$400,000	$592,000	$800,000	$1,024,000
Endoscopic Sleeve Gastroplasty (ESG)	$210,000	$336,000	$532,000	$784,000	$1,092,000
Endoscopic Revision for Weight Regain (TORe/APC)	$153,000	$252,000	$378,000	$540,000	$738,000
Structured Weight Management Program	$94,000	$156,000	$240,000	$340,000	$460,000
Clinical and Metabolic Follow-up	$75,000	$114,000	$168,000	$234,000	$315,000
Total Sales	$804,000	$1,258,000	$1,910,000	$2,698,000	$3,629,000
Direct Cost of Services					
Intragastric Balloon Program	$168,640	$244,000	$355,200	$472,000	$593,920
Endoscopic Sleeve Gastroplasty (ESG)	$121,800	$191,520	$297,920	$431,200	$589,680
Endoscopic Revision for Weight Regain (TORe/APC)	$84,150	$136,080	$200,340	$280,800	$376,380
Structured Weight Management Program	$24,440	$39,000	$57,600	$78,200	$101,200
Clinical and Metabolic Follow-up	$16,500	$23,940	$33,600	$44,460	$56,700
Subtotal Direct Cost of Services	$415,530	$634,540	$944,660	$1,306,660	$1,717,880



5.5 Research, Education, and Training

The Institute will advance research, education, and training initiatives that strengthen the practice of bariatric endoscopy and minimally invasive metabolic medicine and that extend the impact of its clinical operation beyond direct patient care. These initiatives will support the dissemination of best practices, the development of specialized clinical expertise, and the generation of outcomes data that benefit patients and the broader medical community.

The Institute will pursue the following research, education, and training initiatives:

- **Physician Education:** structured education and proctoring for physicians and clinical fellows in bariatric endoscopy techniques, including intragastric balloon placement, Endoscopic Sleeve Gastroplasty, Transoral Outlet Reduction, and Argon Plasma Coagulation, together with the principles of minimally invasive metabolic medicine.
- **Bariatric Endoscopy Workshops:** hands-on workshops and continuing-education events that train clinicians in minimally invasive weight-management procedures and protocols.
- **Telemedicine Protocols:** the development of standardized telemedicine protocols for longitudinal metabolic follow-up and remote patient management, expanding access to coordinated care across locations.
- **Training Pipeline:** a structured training pipeline to develop clinical and operational talent and to support the onboarding and credentialing of contracted physicians and clinical staff.
- **Multicenter Outcomes Registry:** the establishment of a multicenter outcomes registry to track procedure outcomes, safety, and long-term weight and metabolic results, contributing to clinical evidence and continuous quality improvement.

6.0 Management Structure

The management structure of Advanced Endoscopic Weight Loss Institute LLC will be organized to support disciplined clinical operations, efficient patient flow, and progressive growth. The structure will combine the founder's program leadership with a multidisciplinary team and contracted clinical professionals, ensuring clear lines of responsibility across clinical, administrative, and operational functions.

6.1 Staffing Requirements

The company will follow a lean, phased hiring plan in which each position is added in line with operational capacity and revenue growth. The practice will begin with a small core team and expand its multidisciplinary staff progressively from Year 1 through Year 5, ensuring that each

addition is supported by demonstrated patient demand and clinical workload. The staffing trajectory for each position is summarized below.

- **General Manager & Managing Director** headcount 1 in every year from Year 1 to Year 5, hired in month 1 of Year 1, at an annual compensation of $96,000; leads the practice, designs its clinical programs, and directs overall operations and strategy.
- **Administrative Assistant** headcount 1 in every year from Year 1 to Year 5, hired in month 1 of Year 1, at an annual compensation of $44,000; supports daily administrative operations, documentation, and office coordination.
- **Medical Assistant** headcount progressing from 1 in Year 1 to 1, 2, 2, and 3 across Years 2 to 5, first hired in month 2 of Year 1, at an annual compensation of $44,000; assists with clinical procedures, patient preparation, and direct patient support.
- **Patient Care Coordinator** headcount progressing from 1 in Year 1 to 1, 1, 2, and 2 across Years 2 to 5, first hired in month 3 of Year 1, at an annual compensation of $46,000; manages patient scheduling, care coordination, and patient communication throughout the treatment pathway.
- **Bariatric Program Coordinator** headcount progressing from 0 in Year 1 to 1, 1, 1, and 1 across Years 2 to 5, at an annual compensation of $58,000; coordinates the clinical programs of the Integrated Weight Management Pathway and oversees program delivery and quality.
- **Registered Nurse** headcount progressing from 0 in Year 1 to 1, 1, 2, and 2 across Years 2 to 5, at an annual compensation of $76,000; provides clinical nursing care, procedural support, and patient monitoring.
- **Nutritionist and Dietitian** headcount progressing from 0 in Years 1 and 2 to 1, 1, and 2 across Years 3 to 5, at an annual compensation of $64,000; delivers nutritional assessment and counseling within the structured weight-management program.
- **Billing and Insurance Specialist** headcount progressing from 0 in Years 1 and 2 to 1, 1, and 1 across Years 3 to 5, at an annual compensation of $52,000; manages billing, patient payments, and insurance and reimbursement processes.
- **Marketing and Outreach Coordinator** headcount progressing from 0 in Years 1 to 3 to 1 in Years 4 and 5, at an annual compensation of $56,000; manages marketing initiatives, referral outreach, and community education efforts.
- **Front Desk and Scheduling Clerk** headcount progressing from 0 in Years 1 to 4 to 1 in Year 5, at an annual compensation of $40,000; handles reception, patient check-in, and appointment scheduling at the front desk.

In Year 1, the General Manager & Managing Director and the Administrative Assistant will be hired in month 1, the Medical Assistant in month 2, and the Patient Care Coordinator in month 3. From Year 2 onward, all hires are counted from month 1 of the respective year. In addition to the salaried team above, clinical procedures will be delivered by contracted United States licensed physicians, and clinical governance will be provided by a contracted Medical Director; the professional fees for these contracted clinicians are accounted for within direct costs and appear in the organizational structure rather than in the salaried headcount.

6.2 Annual Personnel Plan Table


Personnel Plan					
	Year 1	Year 2	Year 3	Year 4	Year 5
General Manager & Managing Director - Mr. Marcio Lamas Lopes	$96,000	$96,000	$96,000	$96,000	$96,000
Medical Assistant	$40,337	$44,000	$88,000	$88,000	$132,000
Patient Care Coordinator	$38,330	$46,000	$46,000	$92,000	$92,000
Administrative Assistant	$44,004	$44,000	$44,000	$44,000	$44,000
Bariatric Program Coordinator	$0	$58,000	$58,000	$58,000	$58,000
Registered Nurse	$0	$76,000	$76,000	$152,000	$152,000
Nutritionist / Dietitian	$0	$0	$64,000	$64,000	$128,000
Billing and Insurance Specialist	$0	$0	$52,000	$52,000	$52,000
Marketing and Outreach Coordinator	$0	$0	$0	$56,000	$56,000
Front Desk / Scheduling Clerk	$0	$0	$0	$0	$40,000
Total People	4	6	9	12	15
Total Payroll	$218,671	$364,000	$524,000	$702,000	$850,000

6.3 Five-Year Personnel Plan Table

Five-Year Personnel Plan					
	Year 1	Year 2	Year 3	Year 4	Year 5
General Manager & Managing Director - Mr. Marcio Lamas Lopes	1	1	1	1	1
Medical Assistant	1	1	2	2	3
Patient Care Coordinator	1	1	1	2	2
Administrative Assistant	1	1	1	1	1
Bariatric Program Coordinator	0	1	1	1	1
Registered Nurse	0	1	1	2	2
Nutritionist / Dietitian	0	0	1	1	2
Billing and Insurance Specialist	0	0	1	1	1
Marketing and Outreach Coordinator	0	0	0	1	1
Front Desk / Scheduling Clerk	0	0	0	0	1
Total People	4	6	9	12	15

6.4 Organizational Chart - Year 5

The following organizational chart presents the projected structure of Advanced Endoscopic Weight Loss Institute LLC by the fifth year of operations. The General Manager & Managing Director leads the organization and is supported by the salaried clinical, nutritional, administrative, and outreach team, while contracted United States licensed physicians and a contracted Medical Director deliver and govern the clinical procedures.



6.5 Duties and Responsibilities

General Manager & Managing Director

- Leads the overall direction, strategy, and operational management of the practice.
- Designs and oversees the clinical programs that compose the Integrated Weight Management Pathway.
- Coordinates contracted clinical professionals and ensures alignment between clinical and operational objectives.
- Oversees financial planning, growth initiatives, and key business relationships.

Medical Assistant

- Assists licensed physicians during endoscopic procedures and clinical examinations.
- Prepares patients for procedures and supports pre- and post-procedure care.
- Maintains clinical supplies, equipment readiness, and examination rooms.
- Records patient information and supports accurate clinical documentation.

Patient Care Coordinator

- Manages patient scheduling and coordinates appointments across the treatment pathway.
- Serves as a primary point of contact for patient questions and communication.
- Guides patients through the stages of the Integrated Weight Management Pathway.
- Coordinates follow-up appointments and supports continuity of care.

Administrative Assistant

- Supports daily administrative operations and office coordination.
- Maintains records, documentation, and general correspondence.
- Assists with scheduling, supply ordering, and routine office tasks.
- Provides general support to clinical and operational staff.

Bariatric Program Coordinator

- Coordinates the clinical programs that compose the Integrated Weight Management Pathway.
- Oversees program delivery, scheduling, and quality across service lines.
- Supports coordination among clinical, nutritional, and operational staff.

- Monitors program outcomes and supports continuous operational improvement.

Registered Nurse

- Provides clinical nursing care before, during, and after endoscopic procedures.
- Monitors patient status and supports procedural and recovery care.
- Administers care in accordance with clinical protocols and physician direction.
- Supports patient education on procedures and post-treatment care.

Nutritionist and Dietitian

- Conducts nutritional assessments and develops individualized dietary plans.
- Provides nutritional counseling within the structured weight-management program.
- Monitors patient progress and adjusts nutritional guidance as needed.
- Collaborates with clinical staff to support integrated patient outcomes.

Billing and Insurance Specialist

- Manages billing, invoicing, and patient payment processing.
- Handles insurance verification, claims, and reimbursement processes.
- Maintains accurate financial and billing records.
- Supports patients with questions regarding payments and coverage.

Marketing and Outreach Coordinator

- Manages marketing initiatives and the practice's digital presence.
- Coordinates referral outreach to physicians and medical partners.
- Organizes community education and patient awareness efforts.
- Supports content development within applicable regulatory limits.

Front Desk and Scheduling Clerk

- Handles reception and patient check-in at the front desk.
- Manages appointment scheduling and front-office patient flow.
- Responds to incoming calls and routine patient inquiries.
- Supports administrative staff with general front-office tasks.

7.0 Financial Summary

This financial summary presents the projected performance of Advanced Endoscopic Weight Loss Institute LLC over its first five years of operation, including break-even analysis, profit and loss, cash flow, and balance sheet assumptions. The projections reflect a disciplined operating model in which an initial investment of $200,000 establishes the Institute's clinical and operational capacity, and revenue from a growing patient base progressively funds the company's expansion.

Revenue is projected to grow from approximately $804,000 in Year 1 to approximately $3,629,000 by Year 5, driven by increasing procedure and program volumes across the five service lines. Direct costs of services, which include medical devices, anesthesia and sedation, disposables, facility and surgical-center fees, and the professional fees of contracted United States licensed physicians, are projected to scale with service-delivery activity while gross margin improves from approximately 48.3 percent in Year 1 to approximately 52.7 percent in Year 5 as the Institute achieves greater operating scale.

Operating expenses, consisting primarily of salaried personnel together with rent, utilities, insurance, equipment, medical software, marketing, professional fees, and depreciation, will increase gradually as the Institute expands its team from four to fifteen employees through a phased hiring plan aligned with operational capacity. Net profit is projected to be positive in every year, growing from approximately $28,120 in Year 1 to approximately $478,573 by Year 5, with net profit margins increasing from approximately 3.5 percent to approximately 13.2 percent over the projection period.

The projections assume no external borrowing; growth is funded entirely by the founder's initial investment and by cash generated from operations. The figures presented in this summary are estimates developed from the Institute's internal financial model, based on its service mix, pricing structure, staffing plan, and operating assumptions, and are not derived from any single external source. These results reflect a feasible, scalable model supported by sound financial discipline and a stable liquidity position throughout the projection period.

7.1 Break-even Analysis

The Break-even Analysis is an essential financial metric for Advanced Endoscopic Weight Loss Institute LLC, identifying the point at which total revenues match total costs. For the Institute, this financial equilibrium is reached at monthly revenue of approximately $60,402. This calculation rests on the following assumptions:

1. Average Monthly Sales: average monthly revenue in Year 1 is projected at approximately $67,000, which exceeds the monthly break-even level and supports a positive result in the first year of operation.

2. Average Gross Margin: the blended gross margin across the five service lines is projected at approximately 48.3 percent in Year 1, reflecting the direct cost of devices, anesthesia, disposables, facility fees, and contracted physician professional fees.

3. Monthly Fixed Costs: the Institute anticipates monthly fixed costs of approximately $29,184, consisting primarily of personnel and overhead that remain relatively constant regardless of procedure volume.

Understanding the break-even point is critical for guiding the Institute's strategic direction. It provides a benchmark for setting achievable patient-volume goals, managing expenditures, and steering the company toward sustained profitability. Given the Institute's structure and the value of its service mix, the break-even point is reached at a manageable level of activity, consistent with the projected ramp-up of procedures and programs during the first year.

7.1.1 Break-even Analysis Table

Break-even Analysis	
Monthly Revenue Break-even	$60,402
Assumptions:	
Average Monthly Sales (Year 1)	$67,000
Average Gross Margin	48.32%
Estimated Monthly Fixed Cost	$29,184

7.2 Profit and Loss Assumptions

Advanced Endoscopic Weight Loss Institute LLC has developed a financial structure designed to support the growth of a specialized clinic in minimally invasive obesity and metabolic treatment. The company's financial strategy prioritizes the engagement of contracted United States licensed physicians for procedure delivery, together with the salaried clinical, nutritional, administrative, and outreach personnel required to operate the Institute and deliver coordinated care across the Integrated Weight Management Pathway.

As the Institute expands its patient base and procedure volume, direct costs of services are expected to scale with service-delivery activity. These costs consist primarily of medical devices, anesthesia and sedation, disposables, facility and surgical-center fees, and the professional fees of contracted licensed physicians, and are projected to decrease gradually as a share of revenue, from approximately 51.7 percent in Year 1 to approximately 47.3 percent in Year 5, as the Institute achieves greater scale and procurement efficiency.

Based on the projected service model, company revenue is expected to grow from approximately $804,000 in Year 1 to approximately $3,629,000 by Year 5. Direct costs of services are projected to increase from approximately $415,530 in Year 1 to approximately $1,717,880 in Year 5, reflecting the scaling of procedure and program activity. The company's gross margin

is projected to increase from approximately $388,470 (48.3 percent) in Year 1 to approximately $1,911,120 (52.7 percent) by Year 5.

Operating expenses will grow gradually as the Institute expands its workforce and operational infrastructure, increasing from approximately $350,212 in Year 1 to approximately $1,260,000 by Year 5, driven primarily by payroll expansion. Operating expenses also include rent and facility costs, utilities, malpractice and liability insurance, equipment lease and maintenance, medical software and EMR, marketing, professional fees, merchant and bank fees, general administration, and depreciation. Payroll taxes and benefits are estimated at approximately twelve percent of salaries, and taxes on income are estimated at a combined federal rate of twenty-one percent and a Florida state rate of five and one-half percent of pre-tax profit.


Profitability is expected to improve as revenue increases. Profit before taxes is projected to rise from approximately $38,258 in Year 1 to approximately $651,120 in Year 5. Net profit is projected to grow from approximately $28,120 in Year 1 to approximately $478,573 by Year 5, with net profit margins increasing from approximately 3.5 percent to approximately 13.2 percent over the projection period. These results reflect the Institute's ability to expand its services while maintaining operational efficiency and financial discipline. The following table and charts present the projected annual profit and loss.

7.2.1 Annual Profit and Loss Table


Pro Forma Profit and Loss					
	Year 1	Year 2	Year 3	Year 4	Year 5
Sales	$804,000	$1,258,000	$1,910,000	$2,698,000	$3,629,000
Direct Cost of Services	$415,530	$634,540	$944,660	$1,306,660	$1,717,880
Total Cost of Services	$415,530	$634,540	$944,660	$1,306,660	$1,717,880
Gross Margin	$388,470	$623,460	$965,340	$1,391,340	$1,911,120
Gross Margin %	48.32%	49.56%	50.54%	51.57%	52.66%
Operating Expenses					
Salaries and Wages	$218,671	$364,000	$524,000	$702,000	$850,000
Payroll Taxes and Benefits	$26,241	$43,680	$62,880	$84,240	$102,000
Rent and Facility	$30,000	$40,000	$52,000	$64,000	$76,000
Utilities	$6,000	$8,000	$10,500	$13,000	$15,500
Insurance (Malpractice and Liability)	$11,000	$16,000	$21,000	$27,000	$33,000
Equipment Lease and Maintenance	$7,000	$10,000	$13,500	$17,500	$21,500
Medical Software / EMR	$6,000	$8,000	$11,000	$14,000	$17,000
Marketing and Advertising	$9,000	$16,000	$24,000	$33,000	$93,000
Professional Fees (Legal and Accounting)	$6,000	$8,500	$11,000	$14,000	$17,000
Merchant and Bank Fees	$5,600	$8,800	$13,400	$18,900	$25,400
Office and General Administration	$14,400	$29,700	$33,600	$38,600	$41,600
Depreciation	$10,300	$12,000	$14,000	$16,000	$18,000
Total Operating Expenses	$350,212	$564,680	$790,880	$1,042,240	$1,260,000

Pro Forma Profit and Loss					
Profit Before Taxes	$38,258	$58,780	$174,460	$349,100	$651,120
Federal Income Tax (21%)	$8,034	$12,344	$36,637	$73,311	$136,735
Florida State Tax (5.5%)	$2,104	$3,233	$9,595	$19,201	$35,812
Net Profit	$28,120	$43,203	$128,228	$256,588	$478,573
Net Profit / Sales	3.50%	3.43%	6.71%	9.51%	13.19%

7.2.2 Annual Expenses x Sales Chart



7.2.3 Annual Profit Chart



7.3 Cash Flow Assumptions

The pro forma cash flow statement for Advanced Endoscopic Weight Loss Institute LLC demonstrates a positive and steadily improving cash position as the Institute expands its operations and increases service-delivery capacity. Because the Institute's services are predominantly paid at or near the time of care, the company collects the majority of its revenue without significant receivable delays, while operating expenses, including payroll and overhead, are paid as incurred.

In Year 1, total cash inflows from operations are projected at approximately $804,000, generated through the Institute's procedures and programs. As the Institute grows and serves additional patients, operational cash inflows are projected to increase to approximately $3,629,000 by Year 5. Operational expenditures consist primarily of direct service costs, payroll, and payments related to business operations such as rent, marketing, software, insurance, and administration. The Institute does not assume any borrowing, and growth is funded entirely by the initial investment of $200,000 and by cash generated from operations.


As a result of its profitability and limited working-capital requirements, the Institute is projected to maintain a positive cash position throughout the projection period, including during the ramp-up months of Year 1, when the minimum monthly cash balance remains positive at approximately $30,691. The company's cash balance is projected to grow from approximately

$143,420 at the end of Year 1 to approximately $1,027,012 by Year 5, providing a strong liquidity position to support continued growth and the reinvestment of capital into additional clinical capacity. The following table and chart present the projected annual cash flow.

7.3.1 Annual Cash Flow Table

Pro Forma Cash Flow					
	Year 1	Year 2	Year 3	Year 4	Year 5
Cash Received					
Cash from Operations (Sales)	$804,000	$1,258,000	$1,910,000	$2,698,000	$3,629,000
New Investment Received	$200,000	$0	$0	$0	$0
Increase in Accounts Payable	$12,000	$4,000	$6,000	$6,000	$6,000
Expenditures					
Direct Cost of Services	$415,530	$634,540	$944,660	$1,306,660	$1,717,880
Operating Cash Expenses (excl. Depreciation)	$339,912	$552,680	$776,880	$1,026,240	$1,242,000
Income Taxes Paid	$10,138	$15,577	$46,232	$92,512	$172,547
Pre-opening Startup Expenses	$35,000	$0	$0	$0	$0
Purchase of Long-term Assets	$72,000	$20,000	$25,000	$30,000	$30,000
Net Cash Flow	$143,420	$39,203	$123,228	$248,588	$472,573
Cash Balance	**$143,420**	**$182,623**	**$305,851**	**$554,439**	**$1,027,012**

7.3.2 Annual Net Cash Flow and Cash Balance Chart



7.4 Balance Sheet Assumptions

The pro forma balance sheet for Advanced Endoscopic Weight Loss Institute LLC reflects a sound financial structure characterized by consistent asset growth, minimal liabilities, and increasing equity over the five-year projection period. The company's assets consist primarily of cash together with the net value of its long-term clinical and office assets, reflecting the outpatient, service-based nature of its operations.

Total assets are projected to grow from approximately $205,120 in Year 1 to approximately $1,133,712 by Year 5, reflecting the company's profitability, the accumulation of operational cash reserves, and continued investment in clinical equipment. The Institute maintains a conservative financial structure with no external borrowing or long-term debt, with current liabilities limited to modest accounts payable arising in the ordinary course of operations.

Paid-in capital will remain stable at $200,000, representing the founder's initial investment. Retained earnings are projected to grow as profits accumulate, increasing from an initial negative balance of approximately ($35,000), corresponding to the company's pre-opening startup expenses, to a substantial positive balance by Year 5. As a result, the company's total equity and net worth are projected to grow steadily over the projection period. The following table presents the projected annual balance sheet.

7.4.1 Annual Balance Sheet Table

Pro Forma Balance Sheet					
	Year 1	Year 2	Year 3	Year 4	Year 5
Assets					
Current Assets					
Cash	$143,420	$182,623	$305,851	$554,439	$1,027,012
Accounts Receivable	$0	$0	$0	$0	$0
Total Current Assets	$143,420	$182,623	$305,851	$554,439	$1,027,012
Long-term Assets					
Long-term Assets (at cost)	$72,000	$92,000	$117,000	$147,000	$177,000
Accumulated Depreciation	($10,300)	($22,300)	($36,300)	($52,300)	($70,300)
Total Long-term Assets	$61,700	$69,700	$80,700	$94,700	$106,700
Total Assets	$205,120	$252,323	$386,551	$649,139	$1,133,712
Liabilities and Capital	Year 1	Year 2	Year 3	Year 4	Year 5
Current Liabilities					
Accounts Payable	$12,000	$16,000	$22,000	$28,000	$34,000
Total Liabilities	$12,000	$16,000	$22,000	$28,000	$34,000
Paid-in Capital	$200,000	$200,000	$200,000	$200,000	$200,000
Retained Earnings	($35,000)	($6,880)	$36,323	$164,551	$421,139
Earnings	$28,120	$43,203	$128,228	$256,588	$478,573

Total Capital	$193,120	$236,323	$364,551	$621,139	$1,099,712
Total Liabilities and Capital	$205,120	$252,323	$386,551	$649,139	$1,133,712
Net Worth	**$193,120**	**$236,323**	**$364,551**	**$621,139**	**$1,099,712**

8.0 Mr. Marcio Lamas Lopes's National-level Impact

Mr. Marcio Lamas Lopes's proposed endeavor through Advanced Endoscopic Weight Loss Institute LLC is designed to generate measurable contributions to public health, access to care, and economic activity in the United States. Through minimally invasive obesity treatment, revisional endoscopy for weight regain, and longitudinal metabolic management, the Institute will address a large and growing health burden while creating skilled employment and contributing tax revenue. The benefits of this endeavor extend beyond the interests of the company itself and are national in scope.

Addressing a Large and Costly Public-Health Burden

Obesity is one of the most prevalent and costly health conditions in the United States. Approximately 40 percent of US adults, more than 100 million people, are affected by obesity, and obesity-related medical costs are estimated at approximately $173 billion per year in 2019 dollars. By expanding access to minimally invasive treatment options, the Institute will contribute to addressing a condition that imposes a substantial burden on patients and on the national health system.[17]

Expanding Access to Underutilized Treatment

Although roughly 280,000 metabolic and bariatric surgical procedures are performed each year in the United States, fewer than 2 percent of clinically eligible patients receive surgical treatment, leaving a large population without access to effective intervention. The Institute will expand access to minimally invasive endoscopic alternatives for patients who are not candidates for, do not wish to undergo, or have not responded adequately to traditional bariatric surgery, including those experiencing weight regain after prior surgery.[18]

Supporting Management of Metabolic Disease

Obesity is closely associated with serious metabolic conditions, including the approximately 38 million Americans living with diabetes and the approximately 48 percent of adults affected by hypertension. By integrating procedural intervention with structured weight management and

[17] U.S. Centers for Disease Control and Prevention (CDC), Adult Obesity Facts and Consequences of Obesity, 2024 (obesity-related medical care costs estimated at $173 billion in 2019 dollars). https://www.cdc.gov/obesity/adult-obesity-facts/index.html

[18] American Society for Metabolic and Bariatric Surgery (ASMBS), Estimate of Bariatric Surgery Numbers, 2011-2022. https://asmbs.org/resources/estimate-of-bariatric-surgery-numbers/

longitudinal metabolic follow-up, the Institute will support the coordinated management of these conditions, contributing to improved clinical outcomes and to the containment of downstream health-care costs.[19]

Strengthening Local Clinical Capacity

By establishing a specialized clinic in Orlando and engaging United States licensed physicians, nursing professionals, nutrition professionals, and trained support staff, the Institute will strengthen local clinical capacity for minimally invasive obesity and metabolic treatment. The Institute's structured clinical protocols and multidisciplinary model will support consistent quality of care and the development of specialized clinical and operational expertise within the region.

Job Creation and Economic Contribution

Advanced Endoscopic Weight Loss Institute LLC will create skilled employment, expanding from four to fifteen salaried employees over five years and contributing approximately $563,000 in federal, state, and payroll taxes during that period. In addition to direct employment, the Institute will engage contracted United States licensed physicians and a contracted Medical Director, and it will procure medical supplies, equipment, and professional services from United States vendors, generating further economic activity. Through job creation, tax contributions, expanded access to care, and support for the management of obesity and metabolic disease, Mr. Lopes's endeavor demonstrates substantial merit and broad importance.

9.0 Indirect Jobs Creation - Economic Policy Institute

Each industry has backward linkages to the economic sectors that provide the materials and services needed for its output, as well as forward linkages to the sectors where its workers spend their income. As a result, in addition to the jobs directly created by a company, a number of indirect jobs are supported throughout the economy. The addition of jobs and output in an industry with meaningful linkages can therefore produce broader ripple effects.

According to the national employment multipliers published by the Economic Policy Institute, employment in the health care services industry supports additional indirect and induced jobs throughout the United States economy. ***Applying the multiplier published for this sector, the 15 direct jobs that Advanced Endoscopic Weight Loss Institute LLC is projected to create by the end of Year 5 are estimated to support approximately 27 jobs in total, including indirect***

[19] U.S. Centers for Disease Control and Prevention (CDC), National Diabetes Statistics Report, 2024, and Facts About Hypertension, 2024. https://www.cdc.gov/diabetes/php/data-research/ ; https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/

employment generated through the company's operations, procurement, and the spending of its workforce.[20]

TABLE 1

Employment multipliers per 100 direct jobs, by major private-sector industry group

Major industry group	Direct jobs	Supplier jobs*	Induced jobs**	Total indirect jobs
Educational services	100	63.8	129.9	193.7
Health care and social assistance	100	69.4	136.2	205.6
Arts, entertainment, and recreation	100	123.3	255.2	378.5
Accommodation and food services	100	53.8	107.4	161.2
Other services (except public administration)	100	70.7	139.6	210.3


In addition to its in-house team, the Institute will engage contracted United States licensed physicians and a contracted Medical Director on a professional-services basis, and it will retain outsourced marketing, accounting, and other professional providers. Through this combination of direct employment, indirect job creation, and the use of contracted and outsourced services, the Institute will contribute positively to the local and national economy, fostering job growth, generating income, and supporting overall economic activity.

9.1 Distressed Communities

Within the Orlando metropolitan area, ZIP code 32805, which includes the historically underserved Parramore neighborhood, is an example of a community facing significant economic challenges. According to demographic and economic data, the area is home to approximately 23,331 residents, with a median household income of about $38,885, substantially below the national figure, and a poverty rate of approximately 16.3 percent, well above the national average. The area's population is predominantly African American, representing about 71 percent of residents.[21]

[20] Economic Policy Institute (Josh Bivens), Updated Employment Multipliers for the U.S. Economy, January 2019. https://www.epi.org/publication/updated-employment-multipliers-for-the-u-s-economy/

[21] U.S. Census Bureau / city-data.com, ZIP Code 32805 (Orlando, FL) demographic and economic profile. https://www.city-data.com/zips/32805.html



Educational attainment in the area also lags national averages, with approximately 16.1 percent of adults holding a bachelor's degree or higher, compared with a national figure of about 35.7 percent. These indicators reflect the structural economic challenges that affect employment, income, and opportunity in distressed communities, consistent with the framework of the Distressed Communities Index, which classifies neighborhoods by economic well-being across measures such as poverty, education, employment, and housing.

By establishing operations in the Orlando area and creating skilled employment, Advanced Endoscopic Weight Loss Institute LLC will contribute to local economic activity and opportunity. The company's growth, hiring, use of local services, and tax contributions support broader efforts to strengthen economic well-being in the region, including communities that face economic distress. By contributing to job creation, income generation, and expanded access to care, the company aims to make a lasting and positive impact on both the local community and the broader United States economy.[22]

[22] Economic Innovation Group, Distressed Communities Index. https://eig.org/distressed-communities/

APPENDIX

Monthly Sales Forecast Table

Sales Forecast													
		Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Sales													
Intragastric Balloon Program		$11,502	$14,209	$16,915	$18,945	$20,975	$23,005	$24,358	$25,711	$27,065	$28,418	$29,771	$31,126
Endoscopic Sleeve Gastroplasty (ESG)		$8,881	$10,970	$13,060	$14,627	$16,194	$17,761	$18,806	$19,851	$20,896	$21,940	$22,985	$24,029
Endoscopic Revision for Weight Regain (TORe/APC)		$6,470	$7,993	$9,515	$10,657	$11,799	$12,940	$13,701	$14,463	$15,224	$15,985	$16,746	$17,507
Structured Weight Management Program		$3,975	$4,910	$5,846	$6,547	$7,249	$7,950	$8,418	$8,886	$9,353	$9,821	$10,289	$10,756
Clinical and Metabolic Follow-up		$3,172	$3,918	$4,664	$5,224	$5,784	$6,343	$6,716	$7,090	$7,463	$7,836	$8,209	$8,581
Total Sales		$34,000	$42,000	$50,000	$56,000	$62,001	$67,999	$71,999	$76,001	$80,001	$84,000	$88,000	$91,999
Direct Cost of Services													
Intragastric Balloon Program		$7,131	$8,810	$10,487	$11,746	$13,005	$14,263	$15,102	$15,941	$16,780	$17,619	$18,458	$19,298
Endoscopic Sleeve Gastroplasty (ESG)		$5,151	$6,363	$7,575	$8,484	$9,393	$10,301	$10,907	$11,514	$12,120	$12,725	$13,331	$13,936
Endoscopic Revision for Weight Regain (TORe/APC)		$3,559	$4,396	$5,233	$5,861	$6,489	$7,117	$7,536	$7,955	$8,373	$8,792	$9,210	$9,629
Structured Weight Management Program		$1,034	$1,277	$1,520	$1,702	$1,885	$2,067	$2,189	$2,310	$2,432	$2,553	$2,675	$2,796
Clinical and Metabolic Follow-up		$698	$862	$1,026	$1,149	$1,272	$1,395	$1,478	$1,560	$1,642	$1,724	$1,806	$1,888
Subtotal Direct Cost of Services		$17,573	$21,708	$25,841	$28,942	$32,044	$35,143	$37,212	$39,280	$41,347	$43,413	$45,480	$47,547

Monthly Personnel Plan Table

Personnel Plan													
		Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
General Manager & Managing Director - Mr. Marcio Lamas Lopes		$8,000	$8,000	$8,000	$8,000	$8,000	$8,000	$8,000	$8,000	$8,000	$8,000	$8,000	$8,000
Medical Assistant		$0	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667
Patient Care Coordinator		$0	$0	$3,833	$3,833	$3,833	$3,833	$3,833	$3,833	$3,833	$3,833	$3,833	$3,833
Administrative Assistant		$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667	$3,667
Bariatric Program Coordinator		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Registered Nurse		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Nutritionist / Dietitian		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Billing and Insurance Specialist		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Marketing and Outreach Coordinator		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Front Desk / Scheduling Clerk		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total People		2	3	4	4	4	4	4	4	4	4	4	4
Total Payroll		$11,667	$15,334	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167

Monthly Profit and Loss Table

Pro Forma Profit and Loss													
		Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Sales		$34,000	$42,000	$50,000	$56,000	$62,001	$67,999	$71,999	$76,001	$80,001	$84,000	$88,000	$91,999
Direct Cost of Services		$17,573	$21,708	$25,841	$28,942	$32,044	$35,143	$37,212	$39,280	$41,347	$43,413	$45,480	$47,547
Gross Margin		$16,427	$20,292	$24,159	$27,058	$29,957	$32,856	$34,787	$36,721	$38,654	$40,587	$42,520	$44,452
Gross Margin %		48.31%	48.31%	48.32%	48.32%	48.32%	48.32%	48.32%	48.32%	48.32%	48.32%	48.32%	48.32%
Operating Expenses													
Salaries and Wages		$11,667	$15,334	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167	$19,167
Payroll Taxes and Benefits		$1,400	$1,840	$2,300	$2,300	$2,300	$2,300	$2,300	$2,300	$2,300	$2,300	$2,300	$2,301
Rent and Facility		$2,500	$2,500	$2,500	$2,500	$2,500	$2,500	$2,500	$2,500	$2,500	$2,500	$2,500	$2,500
Utilities		$500	$500	$500	$500	$500	$500	$500	$500	$500	$500	$500	$500
Insurance		$916	$916	$916	$916	$917	$917	$917	$917	$917	$917	$917	$917
Equipment Lease and Maintenance		$583	$583	$583	$583	$583	$583	$583	$583	$584	$584	$584	$584
Medical Software / EMR		$500	$500	$500	$500	$500	$500	$500	$500	$500	$500	$500	$500
Marketing and Advertising		$750	$750	$750	$750	$750	$750	$750	$750	$750	$750	$750	$750
Professional Fees		$500	$500	$500	$500	$500	$500	$500	$500	$500	$500	$500	$500
Merchant and Bank Fees		$238	$294	$350	$392	$434	$476	$504	$532	$560	$588	$616	$616
Office and General Administration		$1,200	$1,200	$1,200	$1,200	$1,200	$1,200	$1,200	$1,200	$1,200	$1,200	$1,200	$1,200
Depreciation		$858	$858	$858	$858	$858	$858	$858	$858	$859	$859	$859	$859
Total Operating Expenses		$21,612	$25,775	$30,124	$30,166	$30,209	$30,251	$30,279	$30,307	$30,337	$30,365	$30,393	$30,394
Profit Before Taxes		($5,185)	($5,483)	($5,965)	($3,108)	($252)	$2,605	$4,508	$6,414	$8,317	$10,222	$12,127	$14,058
Income Taxes Incurred		$0	$0	$0	$0	$0	$453	$785	$1,116	$1,447	$1,779	$2,111	$2,447
Net Profit		($5,185)	($5,483)	($5,965)	($3,108)	($252)	$2,152	$3,723	$5,298	$6,870	$8,443	$10,016	$11,611
Net Profit / Sales		-15.25%	-13.05%	-11.93%	-5.55%	-0.41%	3.16%	5.17%	6.97%	8.59%	10.05%	11.38%	12.62%

Monthly Cash Flow Table

Pro Forma Cash Flow													
		Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Cash Received													
Cash from Operations (Sales)		$34,000	$42,000	$50,000	$56,000	$62,001	$67,999	$71,999	$76,001	$80,001	$84,000	$88,000	$91,999
Increase in Accounts Payable		$1,000	$1,000	$1,000	$1,000	$1,000	$1,000	$1,000	$1,000	$1,000	$1,000	$1,000	$1,000
Expenditures													
Direct Cost of Services		$17,573	$21,708	$25,841	$28,942	$32,044	$35,143	$37,212	$39,280	$41,347	$43,413	$45,480	$47,547
Operating Cash Expenses		$20,754	$24,917	$29,266	$29,308	$29,351	$29,393	$29,421	$29,449	$29,478	$29,506	$29,534	$29,535
Income Taxes Paid		$0	$0	$0	$0	$0	$453	$785	$1,116	$1,447	$1,779	$2,111	$2,447
Net Cash Flow		($3,327)	($3,625)	($4,107)	($1,250)	$1,606	$4,010	$5,581	$7,156	$8,729	$10,302	$11,875	$13,470
Cash Balance		**$89,673**	**$86,048**	**$81,941**	**$80,691**	**$82,297**	**$86,307**	**$91,888**	**$99,044**	**$107,773**	**$118,075**	**$129,950**	**$143,420**

Monthly Balance Sheet Table

Pro Forma Balance Sheet													
	Starting	Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Assets													
Current Assets													
Cash	$93,000	$89,673	$86,048	$81,941	$80,691	$82,297	$86,307	$91,888	$99,044	$107,773	$118,075	$129,950	$143,420
Total Current Assets	$93,000	$89,673	$86,048	$81,941	$80,691	$82,297	$86,307	$91,888	$99,044	$107,773	$118,075	$129,950	$143,420
Long-term Assets													
Long-term Assets (at cost)	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000	$72,000
Accumulated Depreciation	$0	($858)	($1,716)	($2,574)	($3,432)	($4,290)	($5,148)	($6,006)	($6,864)	($7,723)	($8,582)	($9,441)	($10,300)
Total Long-term Assets	$72,000	$71,142	$70,284	$69,426	$68,568	$67,710	$66,852	$65,994	$65,136	$64,277	$63,418	$62,559	$61,700
Total Assets	$165,000	$160,815	$156,332	$151,367	$149,259	$150,007	$153,159	$157,882	$164,180	$172,050	$181,493	$192,509	$205,120
Liabilities and Capital		Month 1	Month 2	Month 3	Month 4	Month 5	Month 6	Month 7	Month 8	Month 9	Month 10	Month 11	Month 12
Current Liabilities													
Accounts Payable	$0	$1,000	$2,000	$3,000	$4,000	$5,000	$6,000	$7,000	$8,000	$9,000	$10,000	$11,000	$12,000
Total Liabilities	$0	$1,000	$2,000	$3,000	$4,000	$5,000	$6,000	$7,000	$8,000	$9,000	$10,000	$11,000	$12,000
Paid-in Capital	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000	$200,000
Retained Earnings	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)	($35,000)
Earnings	$0	($5,185)	($10,668)	($16,633)	($19,741)	($19,993)	($17,841)	($14,118)	($8,820)	($1,950)	$6,493	$16,509	$28,120
Total Capital	$165,000	$159,815	$154,332	$148,367	$145,259	$145,007	$147,159	$150,882	$156,180	$163,050	$171,493	$181,509	$193,120
Total Liabilities and Capital	$165,000	$160,815	$156,332	$151,367	$149,259	$150,007	$153,159	$157,882	$164,180	$172,050	$181,493	$192,509	$205,120
Net Worth	**$165,000**	**$159,815**	**$154,332**	**$148,367**	**$145,259**	**$145,007**	**$147,159**	**$150,882**	**$156,180**	**$163,050**	**$171,493**	**$181,509**	**$193,120**

: HOUSE APP • REAL-TIME NEWS • LIVE UPDATES • A DIRECT LINE TO THE ADMINISTRATION → DOWNLOAD THE OFFICIAL WHITE HOUSE APP • REAL-TI

FACT SHEETS

Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients

The White House

November 6, 2025

ADVANCING MOST-FAVORED-NATION (MFN) PRICING: Today, President Donald J. Trump announced the latest in a series of the most significant actions ever taken by our Federal government to lower prescription drug prices, unveiling agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk to dramatically reduce the prices Americans pay for some of the world's most popular drugs.

- The agreement represents a historic reduction in prices for Americans on the two drugs with the highest annual expenditures in the United States, both of which help adults struggling with diabetes, heart disease (Ozempic and Wegovy only), obesity, and other conditions.
    - The prices of Ozempic and Wegovy will fall from $1,000 and $1,350 per month, respectively, to $350 when purchased through *TrumpRx*.
    - The price of Zepbound and Orforglipron, if approved, will fall from $1,086 per month to an average of $346 when purchased through *TrumpRx*.
    - In the event that the FDA later approves the Wegovy pill, or certain similar "GLP-1" drugs in each company's pipeline intended to be taken orally rather than as a shot, the initial dose of those drugs will be priced at $150 per month through *TrumpRx*.
- The historic reduction in prices negotiated by President Trump will enable Medicare and Medicaid to cover obesity drugs for adults at a dramatically lower cost to taxpayers than that proposed by the Biden Administration.
    - The Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245, less than half the prices proposed by the Biden Administration on such drugs. State Medicaid programs will also have access to these medications at these prices.
    - The low prices will enable Medicare to cover Wegovy and Ze… obesity and related comorbidities for the first time.

JOIN NOW Click to listen

    - Medicare beneficiaries will pay a co-pay of just $50 per month.

- Additionally, the agreement provides for reduced costs on other Eli Lilly and Novo Nordisk medicines when purchased through *TrumpRx*. For example:
    - Eli Lilly will provide Emgality, a treatment for migraines, at $299 per pen, a discount of $443 off of the list price.
    - Eli Lilly will provide Trulicity, a commonly used diabetes medicine, at $389 per month, a discount of $598 off of the list price.
    - Novo Nordisk will provide widely-used insulin products, including NovoLog and Tresiba, at $35 per month of supply.
- The agreement also provides that Eli Lilly and Novo Nordisk will guarantee MFN prices on all new medicines that they bring to market, repatriate increased foreign revenue on existing products, and provide every State Medicaid program in the country access to MFN drug prices on their products.

INVESTING IN AMERICA TO SECURE PHARMACEUTICAL SUPPLY CHAINS: Eli Lilly and Novo Nordisk are also announcing large investments to expand U.S. manufacturing capacity.

- Novo Nordisk has committed an additional $10 billion investment to strengthen its domestic footprint, including producing the Wegovy tablet, if approved, end-to-end in the U.S.
- Under President Trump's leadership, Eli Lilly has announced at least $27 billion in new U.S. manufacturing investments.

MAKING AMERICA HEALTHY AGAIN: President Trump promised to ensure the American healthcare system is promoting health and addressing the root causes of chronic disease. Today's announcements represent historic progress on meeting this promise.

- The Centers for Disease Control and Prevention (CDC) estimate the prevalence of obesity among American adults to be 40%.
- Obesity is one of the key drivers of chronic disease, increasing the risk of type 2 diabetes, hypertension, heart disease, strokes, and certain cancers, among other conditions.
- Today's announcement makes available potentially life-changing medications to adults struggling with obesity, representing a historic opportunity to reverse the obesity epidemic and associated chronic disease crisis when coupled with lifestyle changes to preserve and improve health gains long-term.
- The Administration remains committed to a comprehensive Make America Healthy Again approach that realigns incentives, fosters private-sector collaboration, increases public awareness of the importance of diet and exercise, and advances critical research.

ENDING GLOBAL FREELOADING ON AMERICAN PHARMACEUTICAL INNOVATION: President Trump is taking decisive action to rebalance a system that has allowed phar

JOIN NOW
Click to listen

manufacturers to offer low prices to other wealthy nations while charging Americans significantly higher prices.

- According to recent data, the prices Americans pay for brand-name drugs are more than three times the price other Organization for Economic Cooperation and Development nations pay, even after accounting for discounts manufacturers provide in the U.S.
- The United States has less than five percent of the world's population, yet roughly 75% of global pharmaceutical profits come from American taxpayers.
- Drug manufacturers benefit from generous research subsidies and enormous healthcare spending by the U.S. Government. Instead of passing that benefit through to American consumers, drug manufacturers then discount their products abroad to gain access to foreign markets and subsidize those discounts through high prices charged in America. Americans are subsidizing drug-manufacturer profits and foreign health systems, both in development and once the drugs are sold.

DELIVERING ON PROMISES TO PUT AMERICAN PATIENTS FIRST: President Trump is delivering on promises for American patients that the political establishment did not believe were possible.

- On May 12, 2025, President Trump signed an Executive Order titled: "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" directing the Administration to take numerous actions to bring American drug prices in line with those paid by similar nations.
- On July 31, 2025, President Trump sent letters to leading pharmaceutical manufacturers outlining the steps they must take to bring down the prices of prescription drugs in the United States to match the lowest price offered in other developed nations.
- Since September 30, 2025, President Trump has announced five deals with major pharmaceutical manufacturers to bring prices in line with those paid in other developed nations, which will provide substantial price relief on numerous products taken by millions of Americans.
- President Trump has been relentless in his effort to address the unfair and outrageous prices Americans pay for prescription drugs:
    - President Trump: "In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home. So we would spend tremendous amounts of money in order to provide inexpensive drugs to another country. And when I say the price is different, you can see some examples where the price is beyond anything — four times, five times different."

JOIN NOW

Click to listen

Related

Fact Sheet: President Donald J. Trump Declares a Crime Emergency to Restore Safety in the District of Columbia

Fact Sheets | August 11, 2025

Fact Sheet: President Donald J. Trump Takes Additional Measures to Address the Crime Emergency in the District of Columbia

Fact Sheets | August 25, 2025

Fact Sheet: President Donald J. Trump Keeps Promises to Our Veterans and Establishes New Center for Homeless Veterans

Fact Sheets | May 9, 2025

Fact Sheet: President Donald J. Trump Addresses Risks from Paul Weiss

Fact Sheets | March 14, 2025

TRUMP EFFECT: A Running List of New U.S. Investment in President Trump's Second Term

Releases | March 10, 2026

PREVIOUS PAGE 1 … 29 30 31 32 33 … 38 NEXT PAGE



MEDIA

News

Gallery

Video Library

Media Offenders

White House Wire

INITIATIVES

Freedom 250

Investments

Working Families Tax Cuts

AI.Gov

DOGE

SUBSCRIBE TO THE WH NEWSLETTER

Your email

SIGN UP

Click here or text 45470 to receive updates



JOIN NOW

Click to listen

HE OFFICIAL WHITE HOUSE APP • REAL-TIME NEWS • LIVE UPDATES • A DIRECT LINE TO THE ADMINISTRATION → DOWNLOAD THE OFFICIAL WHITE HOU

FACT SHEETS

Fact Sheet: President Donald J. Trump Establishes the Make America Healthy Again Commission

The White House

February 13, 2025

MAKING AMERICA HEALTHY AGAIN: Today, President Donald J. Trump signed an Executive Order establishing the President's Make America Healthy Again Commission.

- Chaired by U.S. Health and Human Services Secretary Robert F. Kennedy Jr., the Commission is tasked with investigating and addressing the root causes of America's escalating health crisis, with an initial focus on childhood chronic diseases.
- Within 100 days, the Commission will produce an assessment that summarizes what is known and what questions remain regarding the childhood chronic disease crisis, and include international comparisons.
- Within 180 days, the Commission will produce a strategy, based on the findings of the assessment, to improve the health of America's children.
- The Commission has four main policy directives to reverse chronic disease:
    - Empower Americans through transparency and open-source data and avoid conflicts of interest in all federally funded health research.
    - Prioritize gold-standard research on why Americans are getting sick in all health-related research funded by the federal government.
    - Work with farmers to ensure that U.S. food is the healthy, abundant and affordable.
    - Ensure expanded treatment options and health coverage flexibility for beneficial lifestyle changes and disease prevention.
- The Commission aims to restore trust in medical and scientific institutions and hold public hearings, meetings, roundtables, and similar events to receive expert input from leaders in public health.

AD JOIN NOW **E RISE OF CHRONIC ILLNESSES:** President Trump understands that America's healthcare system is largely focused on treating chronic illnesses rather than preventing them,

leading to a growing health crisis with serious economic and national security consequences.

- Based on all health indicators and global comparisons, Americans are becoming sicker, beset by illnesses that our medical system isn't addressing effectively.
    - In the United States, six in 10 adults have at least one chronic condition, and four in 10 have two or more.
    - Prior to COVID, American life expectancy averaged 78.8 years, while comparable countries averaged 82.6 years, creating a gap that equates to 1.25 billion fewer life years for Americans.
    - The United States has the highest age-standardized cancer incidence rate across 204 countries, nearly double the next-highest rate.
        - From 1990 to 2021, the United States saw an 88% increase in cancer.
    - Asthma is far more common in the United States than in other parts of the world, including most of Europe, Asia, and Africa.
- The rise in chronic conditions is not limited to adults.
    - Childhood is usually the healthiest period of life, yet as of 2022, 30 million (40.7%) United States children had at least one health condition like allergies, asthma, or autoimmune diseases.
    - Autism now affects one in 36 children, a staggering increase from rates of one to four out of 10,000 children identified with the condition during the 1980s.
    - 18% of teens suffer from fatty liver disease, nearly 30% are prediabetic, and more than 40% are overweight or obese – these conditions were virtually unheard of in prior generations.
    - The incidence of childhood cancer, while still rare, increased 0.8% per year since 1975—an over 40% increase over 45 years.
    - Overmedication, particularly among children, is a growing concern. More than 3.4 million children are currently taking medication for ADD/ADHD and diagnoses continue to rise.
- Chronic disease has widespread effects, including on our military and our economy.
    - 77% of young adults do not qualify for military service without a waiver, primary due to being overweight, drug use, or mental and physical health issues.
    - 90% of America's $4.5 trillion healthcare expenditure is directed at managing chronic and mental health conditions.
    - The United States spends almost twice per capita what other wealthy countries spend on healthcare.
- Americans have lost trust in our health system, skeptical as to whether they are receiving honest answers about the causes of the country's health crisis and how to improve it.
    - Only a third of Americans trust the U.S. health system, a near-record low.

JOIN NOW

TAKING ON THE HEALTH CRISIS: President Trump is fulfilling his promise to tackle the health crisis facing America.

- President Trump pledged that upon returning to the White House he would establish a special Presidential Commission that's "not bought and paid for by Big Pharma, and I will charge them with investigating what is causing the decades-long increase in chronic illnesses [...] And then, I will ask them to publish recommendations for how every American child can have a safe and healthy childhood."
- In his first term, President Trump lowered healthcare costs, provided more healthcare options, and ensured better care for the American people.
- President Trump has consistently championed initiatives aimed at improving the health and well-being of Americans. Select actions from the prior Trump Administration include:
    - Passed Right To Try to give terminally ill patients access to lifesaving cures.
    - Signed an executive order to fight kidney disease with more transplants and better treatment.
    - Accelerated medical breakthroughs in genetic treatments for Sickle Cell disease.
    - Declared the opioid crisis a nationwide public health emergency and signed the SUPPORT for Patients and Communities Act, the largest-ever legislative effort to address a drug crisis in our Nation's history.
    - Expanded access to telehealth, especially in rural and underserved communities.

Related

President Trump Delivers Biggest Regulatory Relief in History

Releases | February 13, 2026
Wide Acclaim for President Trump's Visionary AI Action Plan

Releases | July 24, 2025
ICYMI: Celebrating President Trump's Incredible First 100 Days

Releases | April 29, 2025
Major Organizations Commit to Supporting AI Education

Releases | September 9, 2025
WHAT THEY ARE SAYING: Senate Approves Landmark One Big Beautiful Bill

JOIN NOW

Releases | July 1, 2025

PREVIOUS PAGE 1 ... 75 76 77 78 NEXT PAGE



WHWIRE
GET THE FACTS →

ABOUT

Administration

Contact

Internships

Stay Informed

Privacy Policy

MEDIA

News

Gallery

Video Library

Media Offenders

White House Wire

INITIATIVES

Freedom 250

Investments

Working Families Tax Cuts

AI.Gov

JOIN NOW

DOGE

SUBSCRIBE TO THE WH NEWSLETTER

Your email SIGN UP

Click here or text 45470 to receive updates



JOIN NOW

An official website of the United States government

Join HHS in Celebrating Freedom 250 →

U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES

NUTRITION

Under the leadership of Secretary Kennedy, HHS is advancing the Make America Healthy Again agenda by putting nutrition back at the center of health. Food is one of the most powerful tools we have to prevent disease, support healthy development, and improve well-being.

From encouraging Americans to Eat Real Food and teaching practical ways to cook healthy meals at affordable prices to improving the food served in hospitals, HHS is working to restore nutrition as a cornerstone of health. At the same time, we are strengthening nutrition education and preparing the next generation of health professionals to recognize the role of food in prevention and care.

Together, we are empowering individuals and families with the knowledge and resources to make healthier choices and helping build a healthier future for generations to come.

ADVANCING NUTRITION EDUCATION

Learn how America's leading medical education institutions are integrating comprehensive nutrition education and training to improve patient health.

Learn More

MAKE HOSPITAL FOOD HEALTHY AGAIN

Learn how hospitals are improving food service and incorporating the Dietary Guidelines for Americans to support better health outcomes for patients and communities.

Learn More

EAT REAL FOOD

Learn how the new Dietary Guidelines for Americans put real food at the center of health and provide practical guidance for healthier eating.

Learn More

THE REAL FOOD SHOW

Learn how to cook real food at affordable prices.

Learn More

MORE RESOURCES



The Secretary Kennedy Podcast



Resources of a Healthy Lifestyle



Make America Healthy Again

Gain an understanding of our mission by listening to industry professionals discuss nutrition, wellness, and more impacts on America's path to better health.

Find helpful information regarding various health-related issues, from nutrition to exercise, that can help you live a happy and healthy lifestyle.

Follow along with Secretary Kennedy and see how we are reshaping our country in an effort to Make America Healthy Again.



Active

President Trump and Secretary Kennedy are driving a nationwide effort to Make America Healthy Again by confronting the root causes of chronic disease. Through the Take Back Your Health initiative, they are empowering every American to Get Active, Eat Real Food, and Live Real Life—building a stronger future for themselves, their families, and their communities.

Follow the journey

EAL-TIME NEWS • LIVE UPDATES • A DIRECT LINE TO THE ADMINISTRATION →

DOWNLOAD THE OFFICIAL WHITE HOUSE APP • REAL-TIME NEWS • LIVE U

NEWS GALLERY LIVESTREAM ELECTION INTEGRITY SAVE AMERICA TRUMP ACCOUNTS

PRESIDENTIAL ACTIONS

ESTABLISHING THE PRESIDENT'S MAKE AMERICA HEALTHY AGAIN COMMISSION

The White House

February 13, 2025

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered:

Section 1. Purpose. American life expectancy significantly lags behind other developed countries, with pre-COVID-19 United States life expectancy averaging 78.8 years and comparable countries averaging 82.6 years. This equates to 1.25 billion fewer life years for the United States population. Six in 10 Americans have at least one chronic disease, and four in 10 have two or more chronic diseases. An estimated one in five United States adults lives with a mental illness.

These realities become even more painful when contrasted with nations around the globe. Across 204 countries and territories, the United States had the highest age-standardized incidence rate of cancer in 2021, nearly double the next-highest rate. Further, from 1990-2021, the United States experienced an 88 percent increase in cancer, the largest percentage increase of any country evaluated. In 2021, asthma was more than twice as common in the United States than most of Europe, Asia, or Africa. Autism spectrum disorders had the highest prevalence in high-income countries, including the United States, in 2021. Similarly, autoimmune diseases such as inflammatory bowel disease, psoriasis, and multiple sclerosis are more commonly diagnosed in high-income areas such as Europe and North America. Overall, the global comparison data [illegible]tes that the health of Americans is on an alarming trajectory that requires im[illegible]

JOIN NOW

This concern applies urgently to America's children. In 2022, an estimated 30 million children (40.7 percent) had at least one health condition, such as allergies, asthma, or an autoimmune disease. Autism spectrum disorder now affects 1 in 36 children in the United States — a staggering increase from rates of 1 to 4 out of 10,000 children identified with the condition during the 1980s. Eighteen percent of late adolescents and young adults have fatty liver disease, close to 30 percent of adolescents are prediabetic, and more than 40 percent of adolescents are overweight or obese. These health burdens have continued to increase alongside the increased prescription of medication. For example, in the case of Attention Deficit Disorder/Attention Deficit Hyperactivity Disorder, over 3.4 million children are now on medication for the disorder — up from 3.2 million children in 2019-2020 — and the number of children being diagnosed with the condition continues to rise.

This poses a dire threat to the American people and our way of life. Seventy-seven percent of young adults do not qualify for the military based in large part on their health scores. Ninety percent of the Nation's $4.5 trillion in annual healthcare expenditures is for people with chronic and mental health conditions. In short, Americans of all ages are becoming sicker, beset by illnesses that our medical system is not addressing effectively. These trends harm us, our economy, and our security.

To fully address the growing health crisis in America, we must re-direct our national focus, in the public and private sectors, toward understanding and drastically lowering chronic disease rates and ending childhood chronic disease. This includes fresh thinking on nutrition, physical activity, healthy lifestyles, over-reliance on medication and treatments, the effects of new technological habits, environmental impacts, and food and drug quality and safety. We must restore the integrity of the scientific process by protecting expert recommendations from inappropriate influence and increasing transparency regarding existing data. We must ensure our healthcare system promotes health rather than just managing disease.

Sec. 2. Policy. It shall be the policy of the Federal Government to aggressively combat the critical health challenges facing our citizens, including the rising rates of mental health disorders, obesity, diabetes, and other chronic diseases. To do so, executive departments and agencies (agencies) that address health or healthcare must focus on reversing chronic disease. Under this policy:

(a) all federally funded health research should empower Americans through transparency and open-source data, and should avoid or eliminate conflicts of interest that skew outcomes and perpetuate distrust;

(b) the National Institutes of Health and other health-related research funded by the Federal Government should prioritize gold-standard research on the root causes of why Americans are getting sick;

(c) agencies shall work with farmers to ensure that United States food is the healthiest, most abundant, and most affordable in the world; and

JOIN NOW

(d) agencies shall ensure the availability of expanded treatment options and the flexibility for health insurance coverage to provide benefits that support beneficial lifestyle changes and disease prevention.

Sec. 3. Establishment and Composition of the President's Make America Healthy Again Commission. (a) There is hereby established the President's Make America Healthy Again Commission (Commission), chaired by the Secretary of Health and Human Services (Chair), with the Assistant to the President for Domestic Policy serving as Executive Director (Executive Director).

(b) In addition to the Chair and the Executive Director, the Commission shall include the following officials, or their designees:

(i) the Secretary of Agriculture;

(ii) the Secretary of Housing and Urban Development;

(iii) the Secretary of Education;

(iv) the Secretary of Veterans Affairs;

(v) the Administrator of the Environmental Protection Agency;

(vi) the Director of the Office of Management and Budget;

(vii) the Assistant to the President and Deputy Chief of Staff for Policy;

(viii) the Director of the National Economic Council;

(ix) the Chairman of the Council of Economic Advisers;

(x) the Director of the Office of Science and Technology Policy;

(xi) the Commissioner of Food and Drugs;

(xii) the Director for the Centers for Disease Control and Prevention;

(xiii) the Director of the National Institutes of Health; and

(xiv) other members of my Administration invited to participate, at the discretion of the Chair and the Executive Director.

Sec. 4. Fighting Childhood Chronic Disease. The initial mission of the Commission shall be to advise and assist the President on how best to exercise his authority to address the childhood chronic disease crisis. Therefore, the Commission shall:

(a) study the scope of the childhood chronic disease crisis and any potential contributing causes, including the American diet, absorption of toxic material, medical treatments, lifestyle, environmental factors, Government policies, food production techniques, electromagnetic radiation, and corporate influence or cronyism;

(b) advise and assist the President on informing the American people regarding the childhood chronic disease crisis, using transparent and clear facts; and

(c) provide to the President Government-wide recommendations on policy and strategy related to addressing the identified contributing causes of and ending the childhood chronic disease crisis.

Sec. 5. Initial Assessment and Strategy from the Make America Healthy Again Commission. (a) *Make our Children Healthy Again Assessment.* Within 100 days of the date of this order, the

Commission shall submit to the President, through the Chair and the Executive Director, the Make Our Children Healthy Again Assessment, which shall:

(i) identify and describe childhood chronic disease in America compared to other countries;

(ii) assess the threat that potential over-utilization of medication, certain food ingredients, certain chemicals, and certain other exposures pose to children with respect to chronic inflammation or other established mechanisms of disease, using rigorous and transparent data, including international comparisons;

(iii) assess the prevalence of and threat posed by the prescription of selective serotonin reuptake inhibitors, antipsychotics, mood stabilizers, stimulants, and weight-loss drugs;

(iv) identify and report on best practices for preventing childhood health issues, including through proper nutrition and the promotion of healthy lifestyles;

(v) evaluate the effectiveness of existing educational programs with regard to nutrition, physical activity, and mental health for children;

(vi) identify and evaluate existing Federal programs and funding intended to prevent and treat childhood health issues for their scope and effectiveness;

(vii) ensure transparency of all current data and unpublished analyses related to the childhood chronic disease crisis, consistent with applicable law;

(viii) evaluate the effectiveness of current Federal Government childhood health data and metrics, including those from the Federal Interagency Forum on Child and Family Statistics and the National Survey of Children's Health;

(ix) restore the integrity of science, including by eliminating undue industry influence, releasing findings and underlying data to the maximum extent permitted under applicable law, and increasing methodological rigor; and

(x) establish a framework for transparency and ethics review in industry-funded projects.

(b) *Make our Children Healthy Again Strategy.* Within 180 days of the date of this order, the Commission shall submit to the President, through the Chair and the Executive Director, a Make Our Children Healthy Again Strategy (Strategy), based on the findings from the Make Our Children Healthy Again Assessment described in subsection (a) of this section. The Strategy shall address appropriately restructuring the Federal Government's response to the childhood chronic disease crisis, including by ending Federal practices that exacerbate the health crisis or unsuccessfully attempt to address it, and by adding powerful new solutions that will end childhood chronic disease.

(c) The Chair may hold public hearings, meetings, roundtables, and similar events, as appropriate, and may receive expert input from leaders in public health and Government accountability.

Sec. 6. Additional Reports. (a) Following the submission to the President of the Strategy, and any final strategy reports thereafter, the Chair and the Executive Director shall recommend to the President updates to the Commission's mission, including desired reports.

JOIN NOW

(b) The Commission shall not reconvene, following submission of the Strategy, until an updated mission is submitted to the President through the Executive Director.

Sec. 7. General Provisions. (a) Nothing in this order shall be construed to impair or otherwise affect:

(i) the authority granted by law to an executive department or agency, or the head thereof; or

(ii) the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.

(b) This order shall be implemented consistent with applicable law and subject to the availability of appropriations.

(c) This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

THE WHITE HOUSE,

February 13, 2025.

Related

Unlocking Cures for Pediatric Cancer with Artificial Intelligence

Presidential Actions, Executive Orders | September 30, 2025
Establishing the President's Make America Beautiful Again Commission

Presidential Actions, Executive Orders | July 3, 2025
President's Council on Sports, Fitness, and Nutrition, and the Reestablishment of the Presidential Fitness Test

Presidential Actions, Executive Orders | July 31, 2025
Addressing Addiction through the Great American Recovery Initiative

Presidential Actions, Executive Orders | January 29, 2026
National Physical Fitness and Sports Month, 2025

Presidential Actions, Proclamations | May 24, 2025

JOIN NOW

PREVIOUS PAGE 1 2 3 4 ... 70 NEXT PAGE



WHWIRE

GET THE FACTS →

ABOUT

Administration

Contact

Internships

Stay Informed

Privacy Policy

MEDIA

News

Gallery

Video Library

Media Offenders

White House Wire

INITIATIVES

Freedom 250

Investments

Working Families Tax Cuts

AI.Gov

DOGE

JOIN NOW

SUBSCRIBE TO THE WH NEWSLETTER

Your email SIGN UP

Click here or text 45470 to receive updates



JOIN NOW

Exhibit C.II - Second Prong - Well Positioned to Advance the Proposed Endeavor

Please refer to All the documents of Exhibit B

Boston Scientific | EDUCARE

Certification of Participation

Boston Scientific – Professional Education Endoscopy Division Certify that:

Dr. Marcio Lamas

Participated in the event 'Boston Scientific's Endobariatric Course LATAM - IRCAD'
on October 8 and 9, 2024, in Rio de Janeiro, Brazil.

Dr. Luiz Gustavo Quadros
Chief of Endoscopy Kaiser Clinic and Hospital Beneficência Portuguesa

Dr. Camilo Boza
President IFSO World Congress 2025

Dr. Jimi Scarparo
Director Clinica Scarparo Scopia

Dr. Eduardo Grecco
Professor in Centro Universitario Faculdade de Medicina do ABC

Diego Lombera
ProfEd Regional Lead BSCI Endoscopy LATAM

DAD
Digestive System Diseases

CERTIFICATE

We hereby certify that

Marcio Lamas Lopes

Participated in the "Multidisciplinary Continuing Education Course – COLORECTAL CANCER MEDICAL SCREENING PROJECT", delivering a lecture on the topic "Clinical Case Presentation," held on August 19, 2017, at the Auditorium of 9 de Julho Hospital , in São Paulo/São Paulo.

Workload: 8 hours.

São Paulo, August 19, 2017.


NOVE DE JULHO HOSPITAL

SOBED

Artur A. Parada

Thiago F. Secchi

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 29, 2026.

DAD
Doenças do Aparelho Digestivo

CERTIFICADO

Certificamos que

Marcio Lamas Lopes

Participou do "Curso Continuado Multidisciplinar – PROJETO DE RASTREAMENTO MÉDICO DO CÂNCER COLO-RETAL", proferindo palestra sobre o tema "Apresentação de caso clínico", realizado em 19 de Agosto de 2017, no Auditório do Hospital 9 de Julho, em São Paulo/SP.

Carga Horária: 08 horas.

São Paulo, 19 de Agosto, de 2017.

HOSPITAL NOVE DE JULHO

SOBED

Artur A. Parada

Thiago F. Secchi

Certificate

I hereby certify that

MARCIO LAMAS LOPES

participated in the

Cardiopulmonary Resuscitation Response training

provided by **9 de Julho Hospital S/A**

and completed on 03/09/2015 at 1:26 p.m.

Dr. Regina Tranchesi

Technical Director

Organization Accredited by
Joint Commission International

NOVE DE JULHO
HOSPITAL

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 29, 2026.

Certificado

Certifico que

MARCIO LAMAS LOPES

Participou do treinamento

Atendimento à Parada Cardiorrespiratória

Realizado pelo **Hospital 9 de Julho S/A**
e finalizado em 09/03/15 13:26

Drª Regina Tranchesi
Diretora Técnica

Organization Accredited by
Joint Commission International

HOSPITAL NOVE DE JULHO

CERTIFICATE

24th Brazilian Digestive System Week
XXIV SBAD
November 13 to 15 | 2025 | São Paulo | SP

We hereby certify that the work entitled

CRE balloon dilation and triamcinolone injection in rectal stenosis. And argon plasma in rectovaginal fistula: a case report in an 8-month-old infant.

by authors **Charlon Costa de Oliveira, Amanda Ribas Mendes, Marcio Lamas Lopes**, was presented by **Charlon Costa de Oliveira** at the 24th **BRAZILIAN DIGESTIVE SYSTEM WEEK**, held at the **Convention Center - Distrito Anhembi, November 13 to 15, 2025**, in the presentation format: **Approved for Electronic Poster - exhibition**.

São Paulo, November 13 to 15, 2025

To verify the authenticity of this certificate, access https://validacertificados.iweventos.com.br and use the code: 4d1af0f874


Dr. Eduardo Guimarães Hourneaux de Moura
President of SOBED and of the 24th SBAD

Dr. Áureo de Almeida Delqado
President of FBG

Dr. Paulo Kassab
President of CBCD

Organized by: SOBED Brazilian Society of Endoscopy and Digestive Endoscopy · FBG Brazilian Federation of Gastroenterology · Brazilian College of Digestive Surgery

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

CERTIFICADO

XXIV Semana Brasileira do Aparelho Digestivo
XXIV SBAD
13 a 15 de Novembro | 2025 | São Paulo | SP

Certificamos que o trabalho intitulado

Dilatacão com balão CRE e injeção de triancinolona em estenose de reto. E plasma de argônio em fistula reto-vaginal: um relato de caso em lactente de 8 meses.

dos autores **Charlon Costa de Oliveira, Amanda Ribas Mendes, Marcio Lamas Lopes**, foi apresentado por **Charlon Costa de Oliveira** na **XXIV SEMANA BRASILEIRA DO APARELHO DIGESTIVO**, realizado no **Centro de Convenções - Distrito Anhembi**, **13 a 15 de novembro de 2025**, na forma de apresentação: **Aprovado para Pôster Eletrônico - exibição**.

São Paulo, 13 a 15 de novembro de 2025

Para verificar a autenticidade deste certificado acesse https://validacertificados.iweventos.com.br e use o código: 4d1af0f874

Dr. Eduardo Guimarães Hourneaux de Moura
Presidente da SOBED e da XXIV SBAD

Dr. Áureo de Almeida Delgado
Presidente da FBG

Dr. Paulo Kassab
Presidente do CBCD

Realização:

SOBED Sociedade Brasileira de Endoscopia e Endoscopia Digestiva

FBG Federação Brasileira de Gastroenterologia

Colégio Brasileiro de Cirurgia Digestiva

ENDO 2020
Connecting the world of endoscopy

2nd World Congress of GI Endoscopy
24th Pan American Congress of Digestive Endoscopy

March 7-10, 2020
Rio de Janeiro, Brazil

Host WEO World Endoscopy Organization
Co-host SOBED
In collaboration with SIED

CERTIFICATE

This is to certify that the following abstract was accepted for ePoster presentation at

ENDO 2020 - 2nd World Congress of GI Endoscopy and
24th Pan American Congress of Digestive Endoscopy

Presenter: Tarik Walid Omairi

Title: AORTOENTERIC FISTULA TO DUODENUM: CASE REPORT

Authors: Tarik Walid Omairi, Diogo Troiano Neto, Felipe Martins Devai, Muhamed Ali Hijazi, Artur Adolfo Parada, Marcio Lamas Lopes

Jean-François Rey
ENDO 2020 President
WEO President

Jairo Silva Alves
ENDO 2020 Vice-President
SOBED President

Asadur Jorge Tchekmedyian
24th Pan American Congress of Digestive Endoscopy President
SIED President

Johnson & Johnson
MEDICAL BRASIL

Ethicon
Endo-Surgery


CERTIFICATE

We hereby certify that Dr. Marcio Lamas Lopes participated in the theoretical-practical Video Surgery training with emphasis on Endosutures and Laparoscopy, held on August 30, 2012, at the Johnson & Johnson Medical Innovation Institute in São Paulo.

Camila Lucena
Ethicon Endo-Surgery

Dr. Marco Antonio Bassi
Course Preceptor

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

Johnson & Johnson
MEDICAL BRASIL

Ethicon
Endo-Surgery

CERTIFICADO

Certificamos que o Dr. Marcio Lamas Lopes participou do treinamento teórico-prático de Vídeo Cirurgia com ênfase em Endosuturas e Laparoscopia realizado no dia 30 de Agosto de 2012, no Johnson & Johnson Medical Innovation Institute em São Paulo.

Camila Lucena
Ethicon Endo-Surgery

Dr. Marco Antonio Bassi
Preceptor do Curso

CERTIFICATE

We hereby certify that

MARCIO LAMAS LOPES

participated in the Theoretical-Practical Training of the **INTRAGASTRIC BALLOON WORKSHOP** held at Hospital das Clínicas and Hospital Ipiranga on April 25 and 26, 2014, respectively, with a workload of 12 hours, as a **PARTICIPANT**.

São Paulo, April 25, 2014.

João Carlos Andreoli
President of SOBED
(Brazilian Society of Digestive Endoscopy)

Igelmar Barreto Paes
President of the Scientific Committee

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

CERTIFICADO

Certificamos que

MARCIO LAMAS LOPES

participou do Treinamento Teórico-Prático da **OFICINA DE BALÃO INTRAGÁSTRICO** realizada no Hospital das Clínicas e no Hospital Ipiranga respectivamente nos dias 25 e 26 de Abril de 2014, com carga horária de 12 horas, como **PARTICIPANTE.**

São Paulo, 25 de Abril de 2014.

João Carlos Andreoli
Presidente SOBED

Igelmar Barreto Paes
Presidente Comissão Científica

Brazilian Society of Digestive Endoscopy

Endoscopy Department of the Brazilian Medical Association

Affiliated with the World Organisation for Digestive Endoscopy

Affiliated with the Interamerican Society of Digestive Endoscopy

State SOBED - SP

We hereby certify that

Márcio Lamas Lopes

Participated in the "**Monthly Meetings of the Residents' Study Group**" of **Sobed-SP**, in a total of 08 modules in the year 2013.

São Paulo, November 18, 2013.

Dr. Thiago Festa Secchi
President of SOBED - SP

Dr. Dalton Marques Chaves
Vice-President of SOBED - SP

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

Sociedade Brasileira de Endoscopia Digestiva
Departamento de Endoscopia da Associação Médica Brasileira
Filiada à Organização Mundial de Endoscopia Digestiva

Filiada à Sociedade Interamericana de Endoscopia Digestiva

SOBED Estadual - SP

Certificamos que

Márcio Lamas Lopes

Participou das **"Reuniões Mensais do Grupo de Estudo de Residentes"**
Da **Sobed-SP**, no total de 08 módulos no ano de 2013.

São Paulo, 18 de Novembro de 2013.

Dr. Thiago Festa Secchi
Presidente da SOBED - SP

Dr. Dalton Marques Chaves
Vice-Presidente da SOBED - SP

Certificate

XIII SBAD
Brazilian Digestive System Week

November
22 to 26/2014
Rio de Janeiro

We hereby certify that the work

CRITICAL ANALYSIS OF THE USE OF MIDAZOLAM, FENTANYL, AND PROPOFOL IN CONSCIOUS SEDATION FOR UPPER GASTROINTESTINAL ENDOSCOPY IN A NON-HOSPITAL SETTING

was presented in the Training Center category, by Marcio Lamas Lopes, at the XIII Brazilian Digestive System Week, held from November 22 to 26, 2014, at Rio Centro in Rio de Janeiro/RJ.

Rio de Janeiro, November 26, 2014

José Roberto de Almeida
President of the XIII SBAD and the FBG

João Carlos Andreoli
President of SOBED

Ivan Cecconello
President of CBCD


Organized by

SOBED
Brazilian Society of
Digestive Endoscopy

Management

CCM
Worldwide
Medical Congresses

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.



Certificamos que o trabalho

ANÁLISE CRÍTICA DO USO DE MIDAZOLAM, FENTANIL E PROPOFOL NA SEDAÇÃO CONSCIENTE NA ENDOSCOPIA DIGESTIVA ALTA EM AMBIENTE NÃO HOSPITALAR

foi apresentado na modalidade Centro de Treinamento, por Marcio Lamas Lopes, no evento XIII Semana Brasileira do Aparelho Digestivo ocorrido de 22 a 26 de novembro de 2014 no Rio Centro em Rio de Janeiro/RJ.

Rio de Janeiro, 26 de novembro de 2014

José Roberto de Almeida
Presidente da XIII SBAD e da FBG

João Carlos Andreoli
Presidente da SOBED

Ivan Cecconello
Presidente do CBCD

Realização

Gerenciamento



We hereby certify that the work

CRITICAL ANALYSIS OF THE USE OF MIDAZOLAM, FENTANYL, AND PROPOFOL IN CONSCIOUS SEDATION FOR UPPER GASTROINTESTINAL ENDOSCOPY IN A NON-HOSPITAL SETTING

by the authors: MARCIO LAMAS LOPES; PAULA BECHARA POLETTI; RICARDO ANUAR DIB; TOMÁS NAVARRO RODRIGUEZ; ARTUR ADOLFO PARADA, was presented in the Training Center category at the event XIII Brazilian Digestive System Week, held from November 22 to 26, 2014, at Rio Centro in Rio de Janeiro/RJ.

Rio de Janeiro, November 26, 2014

José Roberto de Almeida
President of the XIII SBAD and the FBG

João Carlos Andreoli
President of SOBED

Ivan Cecconello
President of CBCD


Organized by

Brazilian Society of Digestive Endoscopy

Management

CCM Worldwide Medical Congresses

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.



Certificamos que o trabalho

ANÁLISE CRÍTICA DO USO DE MIDAZOLAM, FENTANIL E PROPOFOL NA SEDAÇÃO CONSCIENTE NA ENDOSCOPIA DIGESTIVA ALTA EM AMBIENTE NÃO HOSPITALAR

dos autores: MARCIO LAMAS LOPES; PAULA BECHARA POLETTI; RICARDO ANUAR DIB; TOMÁS NAVARRO RODRIGUEZ; ARTUR ADOLFO PARADA, foi apresentado, na modalidade Centro de Treinamento, no evento XIII Semana Brasileira do Aparelho Digestivo ocorrido de 22 a 26 de novembro de 2014 no Rio Centro em Rio de Janeiro/RJ.

Rio de Janeiro, 26 de novembro de 2014

José Roberto de Almeida
Presidente da XIII SBAD e da FBG

João Carlos Andreoli
Presidente da SOBED

Ivan Cecconello
Presidente do CBCD

Realização

Gerenciamento



We hereby certify that

MARCIO LAMAS LOPES

participated in the event "XIII Brazilian Digestive System Week", held from November 22 to 26, 2014, at Rio Centro in Rio de Janeiro/RJ.

Workload: 33 hours

Rio de Janeiro, November 26, 2014

José Roberto de Almeida
President of the XIII SBAD and the FBG

João Carlos Andreoli
President of SOBED

Ivan Cecconello
President of CBCD

Organized by

SOBED
Brazilian Society of
Digestive Endoscopy

Management

CCM
Worldwide
Medical Congresses

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.



Certificamos que

MARCIO LAMAS LOPES

participou do evento "XIII Semana Brasileira do Aparelho Digestivo", realizado de 22 a 26 de novembro de 2014, no Rio Centro em Rio de Janeiro/RJ.

Carga Horária: 33 horas

Rio de Janeiro, 26 de novembro de 2014

José Roberto de Almeida
Presidente da XIII SBAD e da FBG

João Carlos Andreoli
Presidente da SOBED

Ivan Cecconello
Presidente do CBCD

Realização

Gerenciamento

Certificate

I Course on Diagnostic and Therapeutic Digestive Echoendoscopy (CEDIT)

We hereby certify ***that Marcio Lamas Lopes***

Participated in the I Course on Diagnostic and Therapeutic Digestive Echoendoscopy, held at 9 de Julho Hospital on March 8, 2014, from 8:00 a.m to 3:15 p.m"

São Paulo, March 8, 2014.

Prof. Dr. José Celso Ardengh
Professor at the University of São Paulo
Coordinator & Organizer

Dr. Artur Adolfo Parada
Head of the Endoscopy Department at H9J
Coordinator & Organizer

Prof. Dr. Everson Artifon
Professor at the University of São Paulo,
Coordinator & Organizer

NOVE DE JULHO
Study Center

Boston Scientific
Advancing science for life™

NOVE DE JULHO HOSPITAL

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and thatthefollowingisanaccurateandcomplete translationofthedocument.



Date: August 17,2026.

Certificado

I Curso de Ecoendoscopia Digestiva Diagnóstica e Terapêutica (CEDIT)

Certificamos que ***Marcio Lamas Lopes***

Participou do I Curso de Ecoendoscopia Digestiva Diagnóstica e Terapêutica, realizado no Hospital 9 de Julho, dia 8 de março de 2014, das 8h às 15h15".

São Paulo, 8 de março de 2014.

Prof. Dr. José Celso Ardengh
Livre Docente pela Universidade de São Paulo
Coordenador & Organizador

Dr. Artur Adolfo Parada
Responsável pelo Setor de Endoscopia do H9J
Coordenador & Organizador

Prof. Dr. Everson Artifon
Livre Docente pela Universidade de São Paulo
Coordenador & Organizador

Centro de Estudos NOVE DE JULHO

Boston Scientific
Advancing science for life™

HOSPITAL NOVE DE JULHO

DAD
Digestive System Diseases

CERTIFICATE

We hereby certify that

Marcio Lamas Lopes

Participated as a Debater in the "Monthly Multidisciplinary Continuing Education – Session: Upper Gastrointestinal Bleeding", held on February 27, 2016, at the Auditorium of 9 de Julho Hospital, in São Paulo/SP.

Workload: 8 hours.

São Paulo, February 27, 2016.

Artur A. Parada

Thiago F. Secchi

NOVE DE JULHO HOSPITAL

SOBED

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

DAD
Doenças do Aparelho Digestivo

CERTIFICADO

Certificamos que

Marcio Lamas Lopes

Participou como Debatedor do "Curso Continuado Multidisciplinar Mensal – Sessão: Hemorragia Digestiva Alta", realizado em 27 de Fevereiro de 2016, no Auditório do Hospital 9 de Julho, em São Paulo/SP.

Carga Horária: 08 horas.

São Paulo, 27 de Fevereiro, de 2016.

Artur A. Parada

Thiago F. Secchi

HOSPITAL NOVE DE JULHO

SOBED

DAD
Digestive System Diseases

CERTIFICATE

We hereby certify that

Marcio Lamas Lopes

Participated in the "Monthly Multidisciplinary Continuing Education Course - Session: LGIB, ANEMIA, AND OGIB", delivering a lecture on the topic "Clinical Case Presentation," held on April 30, 2016, at the Auditorium of 9 de Julho Hospital , in São Paulo/SP.

Workload: 8 hours.

São Paulo, April 30, 2016.

Artur A. Parada

Thiago F. Secchi

NOVE DE JULHO HOSPITAL

SOBED

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

DAD
Doenças do Aparelho Digestivo

CERTIFICADO

Certificamos que

Marcio Lama Lopes

Participou do "Curso Continuado Multidisciplinar Mensal – Sessão: HDB, ANEMIA E SGIO", proferindo palestra sobre o tema "Apresentação de Caso Clínico", realizado em 30 de Abril de 2016, no Auditório do Hospital 9 de Julho, em São Paulo/SP.

Carga Horária: 08 horas.

São Paulo, 30 de Abril, de 2016.

Artur A. Parada

Thiago F. Secchi

HOSPITAL NOVE DE JULHO

SOBED

DAD

Digestive System Diseases

CERTIFICATE

We hereby certify that

Marcio Lamas Lopes

Participated in the "Monthly Multidisciplinary Continuing Education Course - Session: LGIB, ANEMIA, AND OGIB", delivering a lecture on the topic "Vascular Malformations and Dieulafoy," held on April 30, 2016, at the Auditorium of 9 de Julho Hospital , in São Paulo/SP.

Workload: 8 hours.

São Paulo, April 30, 2016.

Artur A. Parada

Thiago F. Secchi

NOVE DE JULHO HOSPITAL

SOBED

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

DAD
Doenças do Aparelho Digestivo

CERTIFICADO

Certificamos que

Marcio Lamas Lopes

Participou do "Curso Continuado Multidisciplinar Mensal – Sessão: HDB, ANEMIA E SGIO", proferindo palestra sobre o tema "Alterações Vasculares e Dieulafoy", realizado em 30 de Abril de 2016, no Auditório do Hospital 9 de Julho, em São Paulo/SP.

Carga Horária: 08 horas.

São Paulo, 30 de Abril, de 2016.

Artur A. Parada

Thiago F. Secchi

HOSPITAL NOVE DE JULHO

SOBED

DAD
Digestive System Diseases

CERTIFICATE

We hereby certify that

Marcio Lamas Lopes

Participated as a Debater in the "Monthly Multidisciplinary Continuing Education Course – Session: LGIB, ANEMIA, AND OGIB", held on April 30, 2016, at the Auditorium of 9 de Julho Hospital, in São Paulo/SP.

Workload: 8 hours.

São Paulo, April 30, 2016.

Artur A. Parada

Thiago F. Secchi

NOVE DE JULHO HOSPITAL

SOBED

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

DAD

Doenças do Aparelho Digestivo

CERTIFICADO

Certificamos que

Marcio Lamas Lopes

Participou como Debatedor do "Curso Continuado Multidisciplinar Mensal – Sessão: HDB, ANEMIA E SGIO", realizado em 30 de Abril de 2016, no Auditório do Hospital 9 de Julho, em São Paulo/SP.

Carga Horária: 08 horas.

São Paulo, 30 de Abril, de 2016.

Artur A. Parada

Thiago F. Secchi

HOSPITAL NOVE DE JULHO

SOBED

DAD

Digestive System Diseases

CERTIFICATE

We hereby certify that

Marcio Lamas Lopes

Participated in the "Monthly Multidisciplinary Continuing Education Course – Session: OBESITY", delivering a lecture on the topic "Interface of bariatric endoscopy with complications. Sleeve Gastrectomy", held on June 18, 2016, at the Auditorium of 9 de Julho Hospital, in São Paulo/SP.

Workload: 8 hours.

São Paulo, June 18, 2016.

Artur A. Parada

Thiago F. Secchi

NOVE DE JULHO HOSPITAL

SOBED

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

CERTIFICADO

DAD
Doenças do Aparelho Digestivo

Certificamos que

Marcio Lamas Lopes

Participou do "Curso Continuado Multidisciplinar Mensal – Sessão: OBESIDADE", proferindo palestra sobre o tema "Interface da endoscopia bariátrica com complicações. Gastrectomia Vertical", realizado em 18 de Junho de 2016, no Auditório do Hospital 9 de Julho, em São Paulo/SP.

Carga Horária: 08 horas.

São Paulo, 18 de Junho, de 2016.

Artur A. Parada

Thiago F. Secchi

HOSPITAL NOVE DE JULHO

SOBED

DAD

Digestive System Diseases

CERTIFICATE

We hereby certify that

Marcio Lamas Lopes

Participated in the "Monthly Multidisciplinary Continuing Education Course – Session: OBESITY", delivering a lecture on the topic "Clinical Case Presentation", held on June 18, 2016, at the Auditorium of 9 de Julho Hospital, in São Paulo/SP.

Workload: 8 hours.

São Paulo, June 18, 2016.

Artur A. Parada

Thiago F. Secchi

NOVE DE JULHO HOSPITAL

SOBED

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

DAD

Doenças do Aparelho Digestivo

CERTIFICADO

Certificamos que

Marcio Lamas Lopes

Participou do "Curso Continuado Multidisciplinar Mensal – Sessão: OBESIDADE", proferindo palestra sobre o tema "Apresentação de Caso Clínico", realizado em 18 de Junho de 2016, no Auditório do Hospital 9 de Julho, em São Paulo/SP.

Carga Horária: 08 horas.

São Paulo, 18 de Junho, de 2016.

Artur A. Parada

Thiago F. Secchi

HOSPITAL NOVE DE JULHO

SOBED

XIV Brazilian Digestive System Week

XIV SBAD

November 21 to 25 | 2015 | ExpoCuritiba | Curitiba

Certificate

We hereby certify that

MARCIO LAMAS LOPES

participated in the event "XIV Brazilian Digestive System Week", held from November 21 to 25, 2015, at Expo Unimed Curitiba in Curitiba/PR.

Workload: 40 hours.

Curitiba, November 25, 2015

Ramiro Robson Fernandes Mascarenhas
President of the XIV SBAD and the SOBED

Maria do Carmo Friche Passos
President of FBG

Bruno Zilberstein
President of CBCD

ORGANIZED BY

MANAGEMENT

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and thatthefollowingisanaccurateandcomplete translationofthedocument.



Date: August 17,2026.

XIV Semana Brasileira do Aparelho Digestivo

XIV SBAD

21 a 25 novembro | 2015 | ExpoCuritiba | Curitiba

Certificado

Certificamos que

MARCIO LAMAS LOPES

participou do evento "XIV Semana Brasileira do Aparelho Digestivo", realizado de 21 a 25 de novembro de 2015, no Expo Unimed Curitiba em Curitiba/PR.

Carga Horária: 40h

Curitiba, 25 de novembro de 2015

Ramiro Robson Fernandes Mascarenhas
Presidente da XIV SBAD e da SOBED

Maria do Carmo Friche Passos
Presidente da FBG

Bruno Zilberstein
Presidente do CBCD

REALIZAÇÃO SOBED

GERENCIAMENTO CCM Worldwide

CERTIFICATE

XVI Brazilian Digestive System Week

SBAD

November 11 to 15, 2017
CICB | Brasília | DF
www.sbad2017.com.br

We hereby certify that

MARCIO LAMAS LOPES

participated in the event "XVI Brazilian Digestive System Week", held from November 11 to 15, 2017, at the International Convention Center of Brazil - CICB in Brasília/DF.

Workload: 36 h

Brasília, November 15, 2017.

DR. FLAVIO EJIMA
President of the XVI SBAD and President of the SOBED

DR. FLAVIO GUILICI
President of FBG

DR. NICOLAU GREGORI CZEZKO
President of CBCD

Organized by

Sobed Brazilian Society of Digestive Endoscopy

fbg Brazilian Federation of Gastroenterology

Brazilian College of Digestive Surgery 1988

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.

XVI Semana Brasileira do Aparelho Digestivo

CERTIFICADO

XVI SBAD

11 a 15 de novembro de 2017
CICB | Brasília | DF
www.sbad2017.com.br

Certificamos que

MARCIO LAMAS LOPES

participou do evento "XVI Semana Brasileira do Aparelho Digestivo ", realizado de 11 a 15 de novembro de 2017, no Centro Internacional de Convenções do Brasil - CICB em Brasília/DF.

Carga Horária: 36h

Brasília, 15 de novembro de 2017.

DR. FLAVIO EJIMA
Presidente XVI SBAD e Presidente SOBED

DR. FLAVIO GUILICI
Presidente FBG

DR. NICOLAU GREGORI CZEZKO
Presidente CBCD

Realização

STATE DEPARTMENT OF HEALTH

IPIRANGA HOSPITAL

IPIRANGA HOSPITAL

CERTIFICATE

We hereby certify that

Dr. Marcio Lamas Lopes

Regional Medical Council (CRM) 133420 State - SP.

completed the Specialization Program in

Endoscopy,

at this institution, from March 1, 2013 to February 28, 2015,

on a full-time basis.

São Paulo, February 28, 2015

Dr. Ricardo Anuar Dib
Coordinator of the Specialization Program

Physician

Dr. Roberto Rivetti Suelotto
President of the Teaching and Internship Committee

This certificate was registered on 03 / 27 / 2015

under No. 30, Book No. 01, Page 04, in this

Committee. WORKLOAD 6240h

Medical Education Committee
Ipiranga Hospital - São Paulo

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: May 12, 2026.

SECRETARIA DE ESTADO DA SAÚDE

HOSPITAL IPIRANGA

HOSPITAL IPIRANGA

CERTIFICADO

Certificamos que o

Dr. Marcio Lamas Lopes

CRM 133420 U.F. – SP.

concluiu o Curso de Especialização em

Endoscopia,

nesta Instituição, no período de 1 de março de 2013 a 28 de fevereiro de 2015,

em regime de tempo integral.

São Paulo, 28 de fevereiro de 2015

Dr. Ricardo Anuar Dib
Coordenador do Curso de Especialização

Médico

Dr. Roberto Rivetti Suelotto
Presidente da Comissão de Ensino e Estágios

Este certificado foi registrado em 27/03/2015, sob. N.º 30, Livro n.º 01, Fls. 04, nesta Comissão. CARGA HORÁRIA 6240

Comissão de Ensino Médico
Hospital Ipiranga - SP

São Paulo State Department of Health

Ipiranga Hospital

Certificate

We hereby certify, for all due purposes, that

Dr. Marcio Lamas Lopes

Regional Medical Council (CRM) 133.420 - State - SP

completed the Internship Program in the specialty of

General Surgery

at this institution from February 1, 2011 to January 31, 2013,
on a full-time basis.

São Paulo, January 31, 2013

Dr. Hisashi Aoyagi
Program Coordinator

Physician

Dr. Fernando Lara Roquette
President of the Medical Education Committee

This certificate was registered on 02/01/2013
under No. 0246, Book No. 01, Page 15, in this
Committee.

Medical Education Committee
Ipiranga Hospital - São Paulo

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: May 12, 2026.

Secretaria de Estado da Saúde do Estado de São Paulo

Hospital Ipiranga

Certificado

Certificamos para os devidos fins que o

Dr. Marcio Lamas Lopes

CRM 133.420 - U.F. - SP

concluiu o Programa de Estágio na Especialidade de

Cirurgia Geral

nesta Instituição no período de 01 de fevereiro de 2011 à 31 de janeiro de 2013,
em regime de tempo integral.

São Paulo, 31 de janeiro de 2013

Dr. Hisashi Aoyagi
Coordenador do Programa

Médico

Dr. Fernando Lara Roquette
Presidente da Comissão de Ensino Médico

Este certificado foi registrado em 1º/02/2013, sob. N.º 0246, Livro n.º 01, Fls. 15, nesta Comissão.

Comissão de Ensino Médico
Hospital Ipiranga - SP

AMB
Brazilian Medical Association

Brazilian Medical Association
Brazilian Society of
Digestive Endoscopy

SOBED

grant the

Endoscopy Specialist Certification

to

Dr. Marcio Lamas Lopes

for having obtained approval in an examination conducted in accordance with the rules established by the Brazilian Medical Association and the Brazilian Society of Digestive Endoscopy (SOBED).

São Paulo, November 15, 2017

Dr. Lincoln Lopes Ferreira
President of AMB

Dr. Antônio Jorge Salomão
Secretary General of AMB

Dr. Flávio Hayato Ejima
President of SOBED

Dr. Afonso Celso da Silva Paredes
1st Secretary of SOBED

Registration 172136

Signed by the President and the Acting Secretary General on the date of registration.

NOTARY OFFICE

12th NOTARY OFFICE

Alameda Santos, 1470 - São Paulo - SP - ZIP Code 01418-100

BACHELOR HOMERO SANTI - NOTARY PUBLIC - Phone (11) 3549-4277 - Fax (11) 254-6362

I notarize the signatures: LINCOLN LOPES FERREIRA, ANTÔNIO JORGE SALOMÃO, which corresponds to the specimen signatures on file at the Notary Office.

São Paulo, June 21, 2018

In witness _____ whereof.

Jefferson de Souza: Authorized Clerk

180621142305: Signature authentication fee: R$ 6.00; Total: R$ 12.00

VALID ONLY WITH THE SEAL OF AUTHENTICITY

12th NOTARY OFFICE
ALAMEDA SANTOS 1470
Jefferson de Souza
Authorized Clerk

Notarial College of Brazil

SIGNATURE 2

104ZAA057630

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: May 12, 2026.

AMB
Associação Médica Brasileira

SOBED

Associação Médica Brasileira
Sociedade Brasileira de
Endoscopia Digestiva

conferem o

Título de Especialista em Endoscopia

ao

Dr. Marcio Lamas Lopes

por ter obtido aprovação em concurso realizado segundo as normas estabelecidas pela Associação Médica Brasileira e a Sociedade Brasileira de Endoscopia Digestiva.

São Paulo, 15 de novembro de 2017

Dr. Lincoln Lopes Ferreira
Presidente da AMB

Dr. Antônio Jorge Salomão
Secretário Geral da AMB

Dr. Flávio Hayato Ejima
Presidente da SOBED

Dr. Afonso Celso da Silva Paredes
1º Secretário da SOBED

Registro 172136

Assinaram o Presidente e o Secretário Geral em exercício na data do registro.



CREMESP
REGIONAL COUNCIL OF MEDICINE OF THE STATE OF SÃO PAULO

FEDERAL TAXES CLEARANCE CERTIFICATE

The **REGIONAL COUNCIL OF MEDICINE OF THE STATE OF SÃO PAULO** hereby certifies that the professional identified in this document is in good financial standing with respect to his obligations before this Regional Council.

REGISTRATION INFORMATION:

NAME: MARCIO LAMAS LOPES
REGISTRATION NO.: 133420

This Certificate neither settles nor invalidates any debts or violations that may subsequently be identified by CRM-SP in relation to the above registration.

This Certificate pertains to the taxpayer's status before the Regional Council of Medicine of the State of São Paulo, covering professional category contributions ("annual fees") and taxes established under Law No. 3,268, of September 30, 1957, Law No. 11,000, of December 15, 2004, and Law No. 12,514, of October 28, 2011. It does not cover debts owed to other agencies or entities of the federal, state, or municipal public administration, whether direct or indirect.

Certificate issued electronically, free of charge, on 04/25/2026, at 6:09:41 p.m.
Valid through: 06/24/2026
Protocol Code: 1808554

To verify the authenticity of this certificate, visit the CREMESP website or use a QR Code reader: https://www.cremesp.org.br/?siteAcao=ConsultaCertidoes

Rua Frei Caneca, No. 1,282, Consolação ZIP Code: 01307-002 – São Paulo/SP
Telephone: (11) 4349-9900 / www.cremesp.org.br

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana _____ **Date: June 29, 2026**

CREMESP
CONSELHO REGIONAL DE MEDICINA DO ESTADO DE SÃO PAULO

CERTIDÃO NEGATIVA DE DÉBITOS RELATIVOS AOS TRIBUTOS FEDERAIS

O CONSELHO REGIONAL DE MEDICINA DO ESTADO DE SÃO PAULO certifica que o(a) profissional identificado(a) no presente documento encontra-se em regularidade fiscal com seus débitos perante este Regional.

IDENTIFICAÇÃO DO REGISTRO:

NOME: MARCIO LAMAS LOPES REGISTRO: 133420

A presente CERTIDÃO não quita nem invalida quaisquer débitos ou infrações que, posteriormente, venham a ser apurados pelo CRM-SP contra o referido registro.

Esta certidão se refere à situação do sujeito passivo no âmbito do Conselho Regional de Medicina do Estado de São Paulo, abrangendo as contribuições de interesse da categoria profissional ("anuidades") e taxas, previstas na Lei nº 3.268, de 30 de setembro de 1957, na Lei nº 11.000, de 15 de dezembro de 2004, e na Lei nº 12.514, de 28 de outubro de 2011. Não estão abrangidos débitos de responsabilidade de outros órgãos e entidades da administração pública federal, estadual ou municipal, direta ou indireta.

Certidão emitida gratuitamente em meio eletrônico em 25/04/2026 às 18:09:41
Válida até 24/06/2026
Código de protocolo: 1808554

Para verificar a autenticidade, consulte o site do Cremesp ou utilize um leitor de qrCode
https://www.cremesp.org.br/?siteAcao=ConsultaCertidoes

FEDERAL COUNCIL OF MEDICINE

REGIONAL COUNCIL OF MEDICINE – STATE OF SÃO PAULO

PHYSICIAN IDENTITY CARD

NAME
MARCIO LAMAS LOPES

CRM/UF
133420/SP



PARENTS
JANETE DIAS LAMAS LOPES

ERALDO LOPES

DATE OF REGISTRATION
08/19/2008

ISSUE
01

CARDHOLDER'S SIGNATURE

CPF
287.868.388-90

IDENTITY CARD / ISSUING AUTHORITY
249949829 / SSP-SP

VOTER REGISTRATION
252550780116

POLLING STATION
0027

ELECTORAL DISTRICT
0253

DATE OF BIRTH
10/08/1981

PLACE OF BIRTH
SAO PAULO-SP

PLACE AND DATE OF ISSUE
SÃO PAULO – SP 03/04/2022

549789

SIGNATURE OF THE PRESIDENT OF THE CRM

VALID AS PROOF OF IDENTITY FOR ALL LEGAL PURPOSES IN ACCORDANCE WITH LAW NO. 6,206/75.

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana _____ **Date: June 29, 2026**

CONSELHO FEDERAL DE MEDICINA

CONSELHO REGIONAL DE MEDICINA - SÃO PAULO
CÉDULA DE IDENTIDADE DE MÉDICO

NOME
MARCIO LAMAS LOPES

CRM/UF
133420/SP



FILIAÇÃO
JANETE DIAS LAMAS LOPES

ERALDO LOPES

DATA DE INSCRIÇÃO
19/08/2008

VIA
01

ASSINATURA DO PORTADOR

CPF
287.868.388-90

IDENTIDADE/ÓRGÃO EMISSOR
249949829 / SSP-SP

TÍTULO DE ELEITOR
252550780116

SEÇÃO
0027

ZONA
0253

DATA DE NASCIMENTO
08/10/1981


NATURALIDADE
SAO PAULO-SP

LOCAL E DATA DE EXPEDIÇÃO
SÃO PAULO-SP 04/03/2022

549789

ASSINATURA DO PRESIDENTE DO CRM

VÁLIDA COMO PROVA DE IDENTIDADE PARA QUALQUER EFEITO DE ACORDO COM A LEI 6.206/75.



CHINARTE
CULTURA MEDIA STUDIO
巴西华夏文化传媒

Handbook of COVID-19 Prevention and Treatment

First Affiliated Hospital, Zhejiang University School of Medicine
Handbook based on clinical and hospital experience

马云公益基金会 Jack Ma Foundation | 浙江大学 ZHEJIANG UNIVERSITY | 浙江大学附属第一医院 | Alibaba Cloud | AliHealth 阿里健康 | 圣保罗亚洲文化中心

Handbook of COVID-19 Prevention and Treatment

First Affiliated Hospital, Zhejiang University
School of Medicine

Translation/Version

General Coordinator :

Bob Wei

Translators:

Gilson J. Akutagawa

Matheus G. Arantes

Paulo Cesar C. Valverde

Rogério F. Macedo

Technical Review:

Dr. André Giannini Rodrigues - Gynecologist and Obstetrician

Dr. Gardenia da Silva - Cardiologist

Dr. Marcio Lamas Lopes - Surgeon and Endoscopist

Dr. Raphael M. Oishi - General Practitioner

Dr. Reginaldo Filho - Dr. PhD in Chinese Acupuncture

Brazilian Portuguese Version by **Chinarte Cultura Media**

Version 1.2





Editor's Note

In the face of an unknown virus, sharing and collaboration are the best remedies.

The publication of this handbook is one of the best ways to record the courage and wisdom that our healthcare professionals have demonstrated over the past two months.

Thanks to everyone who contributed to this handbook, sharing invaluable experience with healthcare colleagues around the world and saving patients' lives.

We appreciate the support of healthcare colleagues in China, who provided an experience capable of inspiring and motivating us.

We thank the Jack Ma Foundation for initiating this program and AliHealth for the technical support, making it possible to create this handbook as supporting material in the fight against the epidemic.

The handbook is available to everyone free of charge. However, due to limited time, there may be some errors. Your comments and advice are very welcome!

LIANG Tingbo

Editor-in-Chief of the "Handbook of COVID-19 Prevention and Treatment"

President of the First Affiliated Hospital, Zhejiang University School of Medicine



Preface

We are facing an unprecedented global war, and humanity is fighting a common enemy: the novel coronavirus. In this war, the first battlefield is the hospital, where our doctors are the soldiers.

To ensure that this war can be won, we must first ensure that our medical staff has sufficient resources, including experience and technologies. In addition, we must ensure that the hospital is the environment where we eliminate the virus, and not where the virus defeats us.

Therefore, the Jack Ma Foundation and the Alibaba Foundation gathered a group of medical experts who returned from the front lines of the fight against the pandemic. With the support of the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), they quickly published a guide on the clinical experience of how to treat this novel coronavirus. The guide offers advice and references that can be used by medical staff around the world who are about to enter the war against COVID-19.

My special thanks to the FAHZU medical staff. While taking great risks in treating COVID-19 patients, they recorded their daily experience, reflected in this handbook. Over the past 50 days, 104 confirmed patients were admitted to FAHZU, including 78 severely ill patients. Thanks to the pioneering efforts of the medical staff and the application of new technologies, to date, we have witnessed a miracle. No staff member was infected, and there were no missed diagnoses or patient deaths.

Today, with the spread of the pandemic, these experiences are the most valuable sources of information and the most important weapon for doctors and hospital staff on the front lines. This is a brand-new disease, and China was the first to suffer from the pandemic. Isolation, diagnosis, treatment, protective measures, and rehabilitation all started from scratch. We hope this handbook provides doctors and nurses in other affected areas with valuable information so that they do not have to enter the battlefield alone.

This pandemic is a collective challenge faced by humanity in the era of globalization. At this moment, sharing resources, experiences, and lessons, regardless of who you are, is our only chance to win. The real remedy for this pandemic is not isolation, but cooperation.

This war is just beginning.

Editorial Group

Editor-in-Chief:

Liang Tingbo

Committee:

Cai Hongliu, Chen Yu, Chen Zuobing, Fang Qiang, Han Weili, Hu Shaohua, Li Jianping,

Li Tong, Lu Xiaoyang, Qiu Yunqing, Qu Tingting, Shen Yihong, Sheng Jifang, Wang Huafen, Wei Guoqing, Xu Kaijin, Zhao Xuehong, Zhong Zifeng and Zhou Jianying

Translation/Version

Coordinator:

Bob Wei

Version:

Rogério F. Macedo, Matheus G. Arantes, Gilson J. Akutagawa, Paulo Cesar Castilho Valverde

Technical Review

Dr. André Giannini Rodrigues - Gynecologist and Obstetrician / Dr. Gardenia da Silva - Cardiologist / Dr. Marcio Lamas Lopes - Surgeon and Endoscopist / Dr.Reginaldo Filho - Dr. PhD in Chinese Acupuncture / Dr. Raphael M. Oishi - General Practitioner

Referências

1. National Health Commission and National Administration of Traditional Chinese Medicine of the People's Republic of China. Protocols for Diagnosis and Treatment of COVID-19 (7th trial version) [EB / OL]. (2020-03-04) [2020-03-15].

http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml (in Chinese)

2. National Health Commission of the People's Republic of China. Protocols for prevention and control of COVID-19 (6th Version) [EB / OL]. (2020-03-09) [2020-03-15] http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtm (in Chinese)

3. Chinese Center for Disease Control and Prevention. Guidelines for epidemiological investigation of COVID-19 [EB / OL]. (in Chinese) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

4. Chinese Center for Disease Control and Prevention. Guidelines for investigation and management of close contacts of COVID-19 patients [EB / OL]. (in Chinese) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

5. Chinese Center for Disease Control and Prevention. Technical guidelines for COVID-19 laboratory testing [EB / OL]. (in Chinese) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

6. Chinese Center for Disease Control and Prevention. Technical guidelines for disinfection of special places [EB / OL]. (in Chinese) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

7. Chinese Center for Disease Control and Prevention. Guidelines for personal protection of specific groups

[EB / OL]. (in Chinese) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

8. Technical Guidelines for Prevention and Control of COVID-19, Part 3: Medical Institutions, Local Standards of Zhejiang Province DB33 / T 2241.3-2020. Hangzhou, 2020 (in Chinese)

9. Chinese Center for Disease Control and Prevention. Distribution of novel coronavirus pneumonia [EB / OL]. (in Chinese) [2020-03-15].

http://2019ncov.chinacdc.cn/2019-nCoV/

10. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern [J]. Lancet 2020; 395 (10223): 470-473. doi: 10.1016 / S0140-6736 (20) 30185-9.

11. China CDC detected novel coronaviruses in Wuhan's Huanan Seafood Market [EB / OL]. (in Chinese) (2020-01-27) [2020-03-15]. http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html

12. National Health Commission of the People's Republic of China. Notification of novel coronavirus pneumonia temporarily named by the National Health Commission of the People's Republic of China [EB / OL]. (in Chinese) (2020-02-07) [2020-03-15]. http://www.nhc.gov.cn/mohwsbwstjxxzx/s2908/202002/f15dda000f6a46b2a1ea1377cd80434 d.shtml.

13. Gorbalenya AE, Baker SC, Baric RS, et al. Severe acute respiratory syndrome-related coronavirus - The species and its viruses – a statement of the Coronavirus Study Group [J / OL]. bioRxiv 2020. doi:10.1101/2020.02.07.937862.

14. WHO. Novel Coronavirus (2019-nCoV) Situation Report – 22 [EB / OL]. (2020-02-11) [2020-03-15]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/

15. Bureau of Disease Prevention and Control, National Health Commission of the People's Republic of China. Novel coronavirus-infected pneumonia is included in the management of notifiable infectious diseases [EB / OL]. (in Chinese) (2020-01-20) [2020-02-15]. http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8d f3f6701d49f33.shtml


16. Chen Y, Liang W, Yang S, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and viral genome characterization [J]. Lancet 2013; 381 (9881): 1916-1925. doi:10.1016/S0140-6736(13)60903-4.

17. Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection [J]. N Engl J Med 2013; 368 (24): 2277-2285. doi:10.1056/NEJMoa1305584.

18. Liu X, Zhang Y, Xu X, et al. Evaluation of plasma exchange and continuous venovenous hemofiltration in the treatment of severe avian influenza A (H7N9): a cohort study [J]. Ther Apher Dial 2015; 19 (2): 178-184. doi:10.1111/1744-9987.12240.

19. National Clinical Research Center for Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases. Expert consensus on novel coronavirus pneumonia treated with artificial liver blood purification system [J]. Chinese Journal of Clinical Infectious Diseases 2020, 13. (in Chinese) doi:10.3760/cma.j.issn.1674-2397.2020.0003.

20. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014 - An update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation [J]. J Heart Lung Transplant 2015; 34 (1): 1-15. doi:10.1016 / j.healun.2014.06.014.


浙大一院

Hospital Overview

The first affiliated hospital, Zhejiang University School of Medicine is a "national team" hospital that integrates medical treatment, teaching, scientific research, prevention, and healthcare. The first batch of commissions jointly established the National Medical Center and the National Regional Medical Center. The hospital is well-known both at home and abroad for its comprehensive strength, excellent medical quality, and distinctive patient care features. The hospital ranks 14th in the country overall and has maintained the first place in Zhejiang for 10 consecutive years.

The first affiliated hospital, Zhejiang University School of Medicine was founded in 1947 and was the first affiliated hospital established by Zhejiang University. The hospital has 6 campuses, including Qingchun, Yuhang, and Zhijiang, with more than 4.000 beds. In 2019, the number of emergency outpatient visits reached 5 million, and 214.300 patients were discharged. Currently, the hospital has more than 6,500 employees, including 364 with senior professional certifications and 545 with associate senior certifications. It has great talents, in the Chinese Academy of Engineering, National Jieqing and special professors 'Changjiang Scholars.

The hospital carried out projects at the national level, such as the National Science and Technology Project, the National R&D Plan and the National Natural Science Foundation of China. The funding for research in force in the last ten years remained above 100 million RMB, of which more than 200 million RMB over six years. For many years, the hospital has a good reputation in the areas of organ transplantation, pancreatic diseases, infectious diseases, blood diseases, kidney diseases, urinary diseases, clinical pharmacy and other disciplines. It established a modern and innovative technical system for the diagnosis and treatment of pancreas cancer and successfully developed liver, pancreas and lung, kidney, small intestine and heart transplantation. Since 2003, the hospital gained a rich experience in the fight against SARS, the H7N9 avian influenza and COVID-19. It was published in major journals such as NEJM, Lancet, Nature, Science, etc, and authorized more than 300 patents and published 200 theses.

The hospital has long promoted global exchanges and cooperation, establishing deep collaborative relationships with more than 30 world-leading universities and medical institutions, such as Stanford University and The Johns Hopkins Hospital in the United States. In addition, the hospital has extended its advanced technology and talents to Central and Eastern European and Southeast Asian countries, such as Hungary, Indonesia, and Malaysia, achieving fruitful results in medical exchanges.

The hospital bears in mind the mission of 'promoting human health with excellent medical quality,' adheres to the development thinking of 'science and technology leadership, innovative development, scientific management, and quality service,' while adhering to the core values of 'rigor and pragmatism' and committing itself to offering patients high-quality medical services, to soon become a large, first-class international medical center.

CHINARTE
CULTURA MEDIA STUDIO
巴西华夏文化传媒

圣保罗亚洲文化中心
ASIAN CULTURAL CENTER IN SÃO PAULO


马云公益基金会 Jack Ma Foundation | 浙江大学 ZHEJIANG UNIVERSITY | 浙江大学医学院附属第一医院 浙江省第一医院

Alibaba Cloud | AliHealth 阿里健康

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.



CHINARTE
CULTURA MEDIA STUDIO
巴西华夏文化传媒

Manual de Prevenção e Tratamento contra o COVID-19

Primeiro Hospital Afiliado da Faculdade de Medicina da Universidade de Zhejiang
Manual baseado em experiências médicas e hospitalares

马云公益基金会 Jack Ma Foundation | 浙江大学 ZHEJIANG UNIVERSITY | Alibaba Cloud | AliHealth 阿里健康 | 圣保罗亚洲文化中心

Manual de Prevenção e Tratamento contra o COVID-19

Primeiro Hospital Afiliado da Faculdade de Medicina da Universidade de Zhejiang

Tradução/Versão

Coodernador Geral :

Bob Wei

Tradutores:

Gilson J. Akutagawa

Matheus G. Arantes

Paulo Cesar C. Valverde

Rogério F. Macedo

Revisão Técnica:

Dr. André Giannini Rodrigues - Ginecologista e Obstetra

Dr. Gardenia da Silva - Cardiologista

Dr. Marcio Lamas Lopes - Cirurgião e Endoscopista

Dr. Raphael M. Oishi - Clínico Geral

Dr. Reginaldo Filho - Dr. PhD em Acupuntura Chinesa

Versão Português Brasileiro por **Chinarte Cultura Media**

Versão 1.2





Nota do Editor

Diante de um vírus desconhecido, o compartilhamento e a colaboração são os melhores remédios.

A publicação deste manual é uma das melhores maneiras de registrar a coragem e a sabedoria que nossos profissionais de saúde demonstraram nos últimos dois meses.

Obrigado a todos que contribuíram para este manual, compartilhando uma experiência inestimável com colegas da área de saúde em todo o mundo e salvando a vida de pacientes.

Agradecemos ao apoio dos colegas da área de saúde na China, que forneceram uma experiência capaz de nos inspirar e motivar.

Agradecemos à Fundação Jack Ma por iniciar este programa e ao AliHealth pelo suporte técnico, tornando possível a criação deste Manual como material de suporte à luta contra a epidemia.

O Manual está disponível para todos gratuitamente. No entanto, devido ao tempo limitado, é possível que hajam alguns erros. Seus comentários e conselhos são muito bem-vindos!

LIANG Tingbo

Editor Chefe do "Manual de Prevenção e Tratamento contra o COVID-19"

Presidente do Primeiro Hospital Afiliado da Faculdade de Medicina da Universidade de Zhejiang



Prefácio

Estamos enfrentando uma guerra global sem precedentes, e a humanidade está combatendo um inimigo em comum: o novo coronavírus. Nesta guerra o primeiro campo de batalha é o hospital, onde nossos médicos são os soldados.

Para garantir que essa guerra possa ser vencida, precisamos primeiro garantir que nossa equipe médica tenha recursos suficientes, incluindo experiência e tecnologias. Além disso, precisamos garantir que o hospital seja o ambiente onde extinguiremos o vírus, e não onde o vírus nos derrotará.

Portanto, a Fundação Jack Ma e a Fundação Alibaba reuniram um grupo de médicos especialistas que retornaram das linhas de frente do combate à pandemia e, com o apoio do Primeiro Hospital Afiliado da Faculdade de Medicina da Universidade de Zhejiang (*FAHZU - Zhejiang University School of Medicine*), eles rapidamente publicaram um guia sobre a experiência clínica de como tratar esse novo coronavírus. O guia oferece aconselhamento e referências que podem ser usadas por equipes médicas de todo o mundo que estão prestes a ingressar na guerra contra o COVID-19.

Meus agradecimentos especiais à equipe médica da *FAHZU*. Embora assumindo grandes riscos no tratamento de pacientes com COVID-19, eles registraram sua experiência diária, refletida neste Manual. Nos últimos 50 dias, 104 pacientes confirmados foram recebidos na *FAHZU*, incluindo 78 pacientes gravemente enfermos. Graças aos esforços pioneiros da equipe médica e à aplicação de novas tecnologias, até o momento, testemunhamos um milagre. Nenhuma equipe foi infectada e não houve diagnóstico perdido ou mortes de pacientes.

Hoje, com a disseminação da pandemia, essas experiências são as fontes de informação mais valiosas e a arma mais importante para os médicos e funcionários hospitalares que se encontram na linha de frente. Esta é uma doença totalmente nova e a China foi a primeira a sofrer com a pandemia. Isolamento, diagnóstico, tratamento, medidas de proteção e reabilitação começaram do zero. Esperamos que este manual forneça a médicos e enfermeiros de outras áreas afetadas informações valiosas, para que não precisem entrar no campo de batalha sozinhos.

Essa pandemia é um desafio coletivo enfrentado pela humanidade na era da globalização. Neste momento, compartilhar recursos, experiências e lições, independentemente de quem você seja, é a nossa única chance de vencer. O verdadeiro remédio para essa pandemia não é o isolamento, mas a cooperação.

Esta guerra está apenas começando.

Grupo Editorial

Editor Chefe:

Liang Tingbo

Comissão:

Cai Hongliu, Chen Yu, Chen Zuobing, Fang Qiang, Han Weili, Hu Shaohua, Li Jianping, Li Tong, Lu Xiaoyang, Qiu Yunqing, Qu Tingting, Shen Yihong, Sheng Jifang, Wang Huafen, Wei Guoqing, Xu Kaijin, Zhao Xuehong, Zhong Zifeng e Zhou Jianying

Tradução/Versão

Coodernador:

Bob Wei

Versão:

Rogério F. Macedo, Matheus G. Arantes, Gilson J. Akutagawa, Paulo Cesar Castilho Valverde

Revisão Técnica

Dr. André Giannini Rodrigues - Ginecologista e Obstetra / Dr. Gardenia da Silva - Cardiologista / Dr. Marcio Lamas Lopes - Cirurgião e Endoscopista / Dr.Reginaldo Filho - Dr. PhD em Acupuntura Chinesa / Dr. Raphael M. Oishi - Clínico Geral

Referências

1. Comissão Nacional de Saúde e Administração Nacional de Medicina Tradicional Chinesa da República Popular da China. Protocolos para diagnóstico e tratamento de COVID-19 (7ª versão de teste) [EB / OL]. (2020-03-04) [2020-03-15].

http://www.nhc.gov.cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml (em chinês)

2. Comissão Nacional de Saúde da República Popular da China. Protocolos para prevenção e controle do COVID-19 (6ª versão) [EB / OL]. (2020-03-09) [2020-03-15]. http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml (em chinês)

3. Centro Chinês de Controle e Prevenção de Doenças. Diretrizes para investigação epidemiológica do COVID-19 [EB / OL]. (em chinês) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

4. Centro Chinês de Controle e Prevenção de Doenças. Diretrizes para investigação e gerenciamento de contatos próximos de pacientes com COVID-19 [EB / OL]. (em chinês) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

5. Centro Chinês de Controle e Prevenção de Doenças. Diretrizes técnicas para testes de laboratório COVID-19 [EB / OL]. (em chinês) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

6. Centro Chinês de Controle e Prevenção de Doenças. Diretrizes técnicas para desinfecção de locais especiais [EB / OL]. (em chinês) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

7. Centro Chinês de Controle e Prevenção de Doenças. Diretrizes para proteção pessoal de grupos específicos

[EB / OL]. (em chinês) (2020-03-09) [2020-03-15]. http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html

8. Diretrizes Técnicas para Prevenção e Controle da COVID-19, Parte 3: Instituições Médicas, Padrões Locais da Província de Zhejiang DB33 / T 2241.3-2020. Hangzhou, 2020 (em chinês)

9. Centro Chinês de Controle e Prevenção de Doenças. Distribuição de nova pneumonia por coronavírus [EB / OL]. (em chinês) [2020-03-15].

http ://2019ncov.chinacdc.cn/2019-nCoV/

10. Wang C, Horby PW, Hayden FG, et ai. Um novo surto de coronavírus de interesse global à saúde [J]. Lancet 2020; 395 (10223): 470-473. doi: 10.1016 / S0140-6736 (20) 30185-9.

11. O China CDC detectou novos coronavírus no mercado de frutos do mar da China Meridional de Wuhan [EB / OL]. (em chinês) (2020-01-27) [2020-03-15]. http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html

12. Comissão Nacional de Saúde da República Popular da China. Notificação de nova pneumonia por coronavírus temporariamente nomeada pela Comissão Nacional de Saúde da República Popular da China [EB / OL]. (em chinês) (2020-02-07) [2020-03-15]. http://www.nhc.gov.cn/mohwsbwstjxxzx/s2908/202002/f15dda000f6a46b2a1ea1377cd80434 d.shtml.

13. Gorbalenya AE, Baker SC, Baric RS, et al. Coronavírus relacionado à síndrome respiratória aguda grave - As espécies e seus vírus, uma declaração do Grupo de Estudo sobre Coronavírus [J / OL]. BioRxiv 2020. doi: 10.1101 / 2020.02.07.937862.

14. OMS. Relatório da situação do novo coronavírus (2019-nCoV) - 22 [EB / OL]. (2020-02-11) [2020-03-15]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/

15. Departamento de Controle e Prevenção de Doenças, Comissão Nacional de Saúde da República Popular da China. A nova pneumonia por infecção por coronavírus está incluída no tratamento de doenças infecciosas notificáveis [EB / OL]. (em chinês) (2020-01-20) [2020-02-15]. http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8d f3f6701d49f33.shtml

16. Chen Y, Liang W, Yang S, et al. Infecções humanas com o vírus da gripe aviária emergente A H7N9 de aves domésticas do mercado úmido: análise clínica e caracterização do genoma viral [J]. Lancet 2013; 381 (9881): 1916-1925. doi: 10.1016 / S0140-6736 (13) 60903-4.

17. Gao HN, Lu HZ, Cao B, et al. Achados clínicos em 111 casos de infecção pelo vírus influenza A (H7N9) [J]. N Engl J Med 2013; 368 (24): 2277-2285. doi: 10.1056 / NEJMoa1305584.

18. Liu X, Zhang Y, Xu X, et al. Avaliação da troca plasmática e hemofiltração venosa contínua no tratamento da gripe aviária grave A (H7N9): um estudo de coorte [J]. Ther Apher Dial 2015; 19 (2): 178-184. doi: 10.1111 / 1744-9987.12240.

19. Centro Nacional de Pesquisa Clínica para Doenças Infecciosas, Laboratório Estatal Chave para Diagnóstico e Tratamento de Doenças Infecciosas. Consenso de especialistas sobre a nova pneumonia por coronavírus tratada com sistema artificial de purificação do sangue hepático [J]. Revista Chinesa de Doenças Infecciosas Clínicas 2020,13. (em chinês) doi: 10.3760 / cma.j.issn.1674-2397.2020.0003.

20. Weill D, Benden C, Corris PA, et al. Um documento de consenso para a seleção de candidatos a transplante de pulmão: 2014 - Atualização do Conselho de Transplante Pulmonar da Sociedade Internacional de Transplante de Coração e Pulmão [J]. J Heart Lung Transplant 2015; 34 (1): 1-15. doi: 10.1016 / j.healun.2014.06.014.


浙大一院

Apresentação do Hospital

O primeiro hospital afiliado da Faculdade de Medicina da Universidade de Zhejiang é um hospital de "equipe nacional" que integra tratamento médico, ensino, pesquisa científica, prevenção e assistência à saúde. O primeiro lote de comissões estabeleceu conjuntamente o Centro Médico Nacional e o Centro Médico Regional Nacional. O hospital é conhecido tanto em casa quanto no exterior por sua força abrangente, excelente qualidade médica e características distintivas dos pacientes. O hospital ocupa a 14ª posição no país de forma abrangente e mantém o primeiro lugar em Zhejiang por 10 anos consecutivos.

O primeiro hospital afiliado da Faculdade de Medicina da Universidade de Zhejiang foi fundado em 1947 e foi o primeiro hospital afiliado criado pela Universidade de Zhejiang. O hospital possui 6 campus, incluindo Qingchun, Yuhang e Zhejiang, com mais de 4.000 leitos. Em 2019, o número de pacientes ambulatoriais de emergência atingiu 5 milhões e 214.300 receberam alta. Atualmente, o hospital possui mais de 6.500 funcionários, 364 com altos cargos profissionais e 545 com altos cargos de vice. Possui grandes talentos, na Academia Chinesa de Engenharia, National Jieqing e professores especiais "*Changjiang Scholars*".

O hospital realizou projetos em nível nacional, como o Projeto Nacional de Ciência e Tecnologia, o Plano Nacional de P&D e a Fundação Nacional de Ciências Naturais da China. O financiamento para pesquisas em vigor nos últimos dez anos permaneceu acima de 100 milhões de RMB, dos quais mais de 200 milhões de *RMB* ao longo de seis anos. Por muitos anos, o hospital tem uma boa reputação nas áreas de transplante de órgãos, doenças pancreáticas, doenças infecciosas, doenças do sangue, doenças renais, doenças urinárias, farmácia clínica e outras disciplinas. Ele estabeleceu um sistema técnico moderno e inovador para o diagnóstico e tratamento do câncer de pâncreas e desenvolveu com sucesso fígado, pâncreas e pulmão, rim, intestino delgado e transplante de coração. Desde 2003, o hospital ganhou uma rica experiência na luta contra a SARS, a gripe aviária H7N9 e a COVID-19. Ele foi publicado em grandes periódicos como *NEJM, Lancet, Nature, Science*, etc, e autorizou mais de 300 patentes e publicou 200 monografias.

O hospital continuou promovendo intercâmbios e cooperações globais por um longo tempo e estabeleceu profundas relações de cooperação com mais de 30 universidades e instituições médicas líderes mundiais, como a *Stanford University* e o *Johns Hopkins Hospital*, nos Estados Unidos. Além disso, o hospital irradiou tecnologia e talentos avançados para países da Europa Central e Oriental e do Sudeste Asiático, como Hungria, Indonésia e Malásia, e obteve resultados de intercâmbios médicos frutíferos.

O hospital tem em mente a missão de "promover a saúde humana com excelente qualidade médica", adere ao pensamento de desenvolvimento de "liderança em ciência e tecnologia, desenvolvimento inovador, gestão científica e serviço de qualidade", aderindo aos valores fundamentais de "rigoroso e pragmático" e comprometido em oferecer aos pacientes alta qualidade. Com seus serviços médicos, em breve, se tornarão um grande centro médico internacional de primeira classe.

CHINARTE
CULTURA MEDIA STUDIO
巴西华夏文化传媒

圣保罗亚洲文化中心
CENTRO CULTURAL DA ÁSIA EM SÃO PAULO

马云公益基金会
Jack Ma Foundation

浙江大学
ZHEJIANG UNIVERSITY

浙江大学医学院附属第一医院
THE FIRST AFFILIATED HOSPITAL, COLLEGE OF MEDICINE, ZHEJIANG UNIVERSITY
浙江省第一医院
THE FIRST HOSPITAL OF ZHEJIANG PROVINCE

Alibaba Cloud

AliHealth
阿里健康

GROSS OPERATING REVENUE	**1,952,632.26**
OPERATING REVENUES	1,952,632.26
CASH SERVICES RENDERED	1,952,632.26
DEDUCTIONS FROM GROSS REVENUE	**0.00**
NET REVENUE	**1,952,632.26**
COSTS	**0.00**
GROSS PROFIT	**1,952,632.26**
OPERATING EXPENSES	**610,588.42**
OPERATING EXPENSES	**632,245.92**
SELLING AND SERVICE EXPENSES	441,834.10
SALARIES AND WAGES	14,814.80
SOCIAL SECURITY	9,701.63
SEVERANCE INDEMNITY FUND (FGTS)	1,331.44
LABOR INDEMNITIES	0.00
VACATION PAY	622.25
THIRTEENTH-MONTH SALARY	1,305.63
BASIC FOOD BASKET ALLOWANCE	2,348.10
CONSUMABLE AND SUPPLIES	410,507.01
TRANSPORTATION ALLOWANCE	1,203.24
EMPLOYEE EXPENSES	0.00
ADMINISTRATIVE EXPENSES	33,225.00
MANAGEMENT COMPENSATION	26,400.00
ACCOUNTING FEES	6,825.00
TAX EXPENSES	157,186.82
TAXES AND FEES	2,343.08
SOCIAL INTEGRATION PROGRAM (PIS)	12,692.13
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS)	58,578.96
TAX ON SERVICES OF ANY NATURE (ISSQN)	39,052.64
CORPORATE INCOME TAX (IRPJ)	23,431.58
SOCIAL CONTRIBUTION ON NET INCOME (CSLL)	21,088.43
NON-OPERATING REVENUE	**21,657.50**
OTHER REVENUE	21,657.50
PROMOTIONAL GIFTS	21,657.50
INCOME BEFORE FINANCIAL RESULTS	**1,342,043.84**
FINANCIAL REVENUE	**46.83**
FINANCIAL REVENUE	46.83
DISCOUNTS EARNED	46.83
FINANCIAL EXPENSES	**41.11**
FINANCIAL EXPENSES	41.11
INTEREST EXPENSE	0.00
FINES	41.11
INCOME BEFORE TAX PROVISIONS	**1,342,049.56**
NET INCOME FOR THE PERIOD	**1,342,049.56**

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA:01646133820 Date: 2026.06.02 09:11:29 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

RECEITA OPERACIONAL BRUTA	**1.952.632,26**
RECEITAS OPERACIONAIS	1.952.632,26
SERVICOS PRESTADOS A VISTA	1.952.632,26
DEDUÇÕES DA RECEITA BRUTA	**0,00**
RECEITA LÍQUIDA	**1.952.632,26**
CUSTOS	**0,00**
LUCRO BRUTO	**1.952.632,26**
DESPESAS OPERACIONAIS	**610.588,42**
DESPESAS OPERACIONAIS	**632.245,92**
DESPESAS COM VENDAS/SERVICOS	441.834,10
SALARIOS E ORDENADOS	14.814,80
PREVIDENCIA SOCIAL	9.701,63
FGTS	1.331,44
INDENIZACOES TRABALHISTAS	0,00
FERIAS	622,25
13? SALARIO	1.305,63
CESTA BASICA	2.348,10
MATERIAL DE CONSUMO E USO	410.507,01
VALE TRANSPORTE	1.203,24
DESPESAS COM FUNCIONARIOS	0,00
DESPESAS ADMINISTRATIVAS	33.225,00
PRO-LABORE	26.400,00
HONORARIOS CONTABEIS	6.825,00
DESPESAS TRIBUTARIAS	157.186,82
IMPOSTOS E TAXAS	2.343,08
PIS	12.692,13
COFINS	58.578,96
ISSQN	39.052,64
IRPJ	23.431,58
CSLL	21.088,43
RECEITAS NÃO OPERACIONAIS	**21.657,50**
OUTRAS RECEITAS	21.657,50
BRINDES	21.657,50
RESULTADO ANTES DAS OPERAÇÕES FINANCEIRAS	**1.342.043,84**
RECEITAS FINANCEIRAS	**46,83**
RECEITA FINANCEIRA	46,83
DESCONTOS OBTIDOS	46,83
DESPESAS FINANCEIRAS	**41,11**
DESPESAS FINANCEIRAS	41,11
JUROS PASSIVOS	0,00
MULTAS	41,11
RESULTADO ANTES DAS PROVISÕES TRIBUTÁRIAS	**1.342.049,56**
LUCRO LÍQUIDO DO EXERCÍCIO	**1.342.049,56**

NELSON GAZA:01646133820 Assinado de forma digital por NELSON GAZA:01646133820 Dados: 2026.06.02 09:11:29 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

GROSS OPERATING REVENUE	**1,946,859.32**
OPERATING REVENUES	1,946,859.32
CASH SERVICES RENDERED	1,946,859.32
DEDUCTIONS FROM GROSS REVENUE	**0.00**
NET REVENUE	**1,946,859.32**
COSTS	**0.00**
COST OF GOODS SOLD	21,770.00
PURCHASE OF GOODS	21,770.00
GROSS PROFIT	**1,946,859.32**
OPERATING EXPENSES	**467,230.90**
OPERATING EXPENSES	**489,000.90**
SELLING AND SERVICE EXPENSES	271,187.53
SALARIES AND WAGES	15,816.20
SOCIAL SECURITY	10,226.90
SEVERANCE INDEMNITY FUND (FGTS)	1,316.28
TELECOMMUNICATIONS	80.00
VACATION PAY	1,348.59
THIRTEENTH-MONTH SALARY	0.00
MEAL EXPENSES	50.28
BASIC FOOD BASKET ALLOWANCE	2,570.04
CONSUMABLE AND SUPPLIES	238,400.00
TRANSPORTATION ALLOWANCE	1,379.24
ADMINISTRATIVE EXPENSES	35,838.00
MANAGEMENT COMPENSATION	29,088.00
ACCOUNTING FEES	6,750.00
TAX EXPENSES	181,975.37
TAXES AND FEES	0.00
SOCIAL INTEGRATION PROGRAM (PIS)	15,183.34
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS)	66,390.63
TAX ON SERVICES OF ANY NATURE (ISSQN)	44,260.42
CORPORATE INCOME TAX (IRPJ)	29,547.89
SOCIAL CONTRIBUTION ON NET INCOME (CSLL)	26,593.09
NON-OPERATING REVENUE	21,770.00
OTHER REVENUE	21,770.00
PROMOTIONAL GIFTS	21,770.00
INCOME BEFORE FINANCIAL RESULTS	**1,457,858.42**
FINANCIAL REVENUE	**0.00**
FINANCIAL REVENUE	0.00
DISCOUNTS EARNED	0.00
FINANCIAL EXPENSES	**1,491.47**
FINANCIAL EXPENSES	1,491.47
BANK CHARGES	1,349.65
INTEREST EXPENSE	28.59
FINES	113.23
INCOME BEFORE TAX PROVISIONS	**1,456,366.95**
NET INCOME FOR THE PERIOD	**1,456,366.95**

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA: 01646133820 Date: 2026.06.02 09:12:24 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

RECEITA OPERACIONAL BRUTA	**1.946.859,32**
RECEITAS OPERACIONAIS	1.946.859,32
SERVICOS PRESTADOS A VISTA	1.946.859,32
DEDUÇÕES DA RECEITA BRUTA	**0,00**
RECEITA LÍQUIDA	**1.946.859,32**
CUSTOS	**21.770,00**
CUSTO DAS MERCADORIAS VENDIDAS	21.770,00
COMPRAS DE MERCADORIAS	21.770,00
LUCRO BRUTO	**1.925.089,32**
DESPESAS OPERACIONAIS	**467.230,90**
DESPESAS OPERACIONAIS	**489.000,90**
DESPESAS COM VENDAS/SERVICOS	271.187,53
SALARIOS E ORDENADOS	15.816,20
PREVIDENCIA SOCIAL	10.226,90
FGTS	1.316,28
TELECOMUNICACAO	80,00
FERIAS	1.348,59
13? SALARIO	0,00
DESPESAS COM REFEICOES	50,28
CESTA BASICA	2.570,04
MATERIAL DE CONSUMO E USO	238.400,00
VALE TRANSPORTE	1.379,24
DESPESAS ADMINISTRATIVAS	35.838,00
PRO-LABORE	29.088,00
HONORARIOS CONTABEIS	6.750,00
DESPESAS TRIBUTARIAS	181.975,37
IMPOSTOS E TAXAS	0,00
PIS	15.183,34
COFINS	66.390,63
ISSQN	44.260,42
IRPJ	29.547,89
CSLL	26.593,09
RECEITAS NÃO OPERACIONAIS	**21.770,00**
OUTRAS RECEITAS	21.770,00
BRINDES	21.770,00
RESULTADO ANTES DAS OPERAÇÕES FINANCEIRAS	**1.457.858,42**
RECEITAS FINANCEIRAS	**0,00**
RECEITA FINANCEIRA	0,00
DESCONTOS OBTIDOS	0,00
DESPESAS FINANCEIRAS	**1.491,47**
DESPESAS FINANCEIRAS	1.491,47
DESPESAS BANCARIAS	1.349,65
JUROS PASSIVOS	28,59
MULTAS	113,23
RESULTADO ANTES DAS PROVISÕES TRIBUTÁRIAS	**1.456.366,95**
LUCRO LÍQUIDO DO EXERCÍCIO	**1.456.366,95**

NELSON GAZA:01646133820

Assinado de forma digital por NELSON GAZA:01646133820
Dados: 2026.06.02 09:12:24 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

GROSS OPERATING REVENUE	**2,008,398.65**
OPERATING REVENUES	2,008,398.65
CASH SERVICES RENDERED	2,008,398.65
DEDUCTIONS FROM GROSS REVENUE	**0.00**
NET REVENUE	**2,008,398.65**
COSTS	**0.00**
COST OF GOODS SOLD	3,500.00
PURCHASE OF GOODS	3,500.00
GROSS PROFIT	**2,008,398.65**
OPERATING EXPENSES	**505,338.48**
OPERATING EXPENSES	**505,338.48**
SELLING AND SERVICE EXPENSES	273,353.20
SALARIES AND WAGES	17,252.69
SOCIAL SECURITY	11,706.65
SEVERANCE INDEMNITY FUND (FGTS)	1,611.84
MEDICAL ASSISTANCE	74,505.56
TELECOMMUNICATIONS	95.00
VACATION PAY	2,324.32
THIRTEENTH-MONTH SALARY	1,590.57
MEAL EXPENSES	26.04
BASIC FOOD BASKET ALLOWANCE	2,764.28
CONSUMABLE AND SUPPLIES	142,500.00
TRANSPORTATION ALLOWANCE	1,331.95
MANAGEMENT FEE	16,544.38
MISCELLANEOUS EXPENSES	1,099.92
ADMINISTRATIVE EXPENSES	45,936.00
MANAGEMENT COMPENSATION	31,536.00
ACCOUNTING FEES	14,400.00
TAX EXPENSES	189,549.28
TAXES AND FEES	14,657.31
SOCIAL INTEGRATION PROGRAM (PIS)	14,271.03
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS)	65,866.28
TAX ON SERVICES OF ANY NATURE (ISSQN)	43,910.85
CORPORATE INCOME TAX (IRPJ)	26,759.90
SOCIAL CONTRIBUTION ON NET INCOME (CSLL)	24,083.91
NON-OPERATING REVENUE	**3,500.00**
OTHER REVENUE	3,500.00
PROMOTIONAL GIFTS	3,500.00
INCOME BEFORE FINANCIAL RESULTS	**1,499,560.17**
FINANCIAL EXPENSES	**317,510.36**
FINANCIAL EXPENSES	317,510.36
BANK CHARGES	1,611.20
FINANCIAL EXPENSES	315,899.16
INTEREST EXPENSE	0.00
FINES	0.00
INCOME BEFORE TAX PROVISIONS	**1,182,049.81**
NET INCOME FOR THE PERIOD	**1,182,049.81**

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA:01646133820
Date: 2026.06.02 09:14:13 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

Consolidação: Empresa **Grau: 5** **Período: 01/2023 a 12/2023**

RECEITA OPERACIONAL BRUTA	**2.008.398,65**
RECEITAS OPERACIONAIS	2.008.398,65
SERVICOS PRESTADOS A VISTA	2.008.398,65
DEDUÇÕES DA RECEITA BRUTA	**0,00**
RECEITA LÍQUIDA	**2.008.398,65**
CUSTOS	**3.500,00**
CUSTO DAS MERCADORIAS VENDIDAS	3.500,00
COMPRAS DE MERCADORIAS	3.500,00
LUCRO BRUTO	**2.004.898,65**
DESPESAS OPERACIONAIS	**505.338,48**
DESPESAS OPERACIONAIS	**508.838,48**
DESPESAS COM VENDAS/SERVICOS	273.353,20
SALARIOS E ORDENADOS	17.252,69
PREVIDENCIA SOCIAL	11.706,65
FGTS	1.611,84
ASSISTENCIA MEDICA	74.505,56
TELECOMUNICACAO	95,00
FERIAS	2.324,32
13? SALARIO	1.590,57
DESPESAS COM REFEICOES	26,04
CESTA BASICA	2.764,28
MATERIAL DE CONSUMO E USO	142.500,00
VALE TRANSPORTE	1.331,95
TAXA DE ADMINISTRACAO	16.544,38
DESPESAS DIVERSAS	1.099,92
DESPESAS ADMINISTRATIVAS	45.936,00
PRO-LABORE	31.536,00
HONORARIOS CONTABEIS	14.400,00
DESPESAS TRIBUTARIAS	189.549,28
IMPOSTOS E TAXAS	14.657,31
PIS	14.271,03
COFINS	65.866,28
ISSQN	43.910,85
IRPJ	26.759,90
CSLL	24.083,91
RECEITAS NÃO OPERACIONAIS	**3.500,00**
OUTRAS RECEITAS	3.500,00
BRINDES	3.500,00
RESULTADO ANTES DAS OPERAÇÕES FINANCEIRAS	**1.499.560,17**
DESPESAS FINANCEIRAS	**317.510,36**
DESPESAS FINANCEIRAS	317.510,36
DESPESAS BANCARIAS	1.611,20
DESPESAS FINANCEIRAS	315.899,16
JUROS PASSIVOS	0,00
MULTAS	0,00
RESULTADO ANTES DAS PROVISÕES TRIBUTÁRIAS	**1.182.049,81**
LUCRO LÍQUIDO DO EXERCÍCIO	**1.182.049,81**

NELSON GAZA:01646133820
Assinado de forma digital por NELSON GAZA:01646133820
Dados: 2026.06.02 09:14:13 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

GROSS OPERATING REVENUE	**2,110,167.00**
OPERATING REVENUES	2,110,167.00
CASH SERVICES RENDERED	2,110,167.00
DEDUCTIONS FROM GROSS REVENUE	**0.00**
NET REVENUE	**2,110,167.00**
COSTS	**0.00**
COST OF GOODS SOLD	0.00
PURCHASE OF GOODS	0.00
GROSS PROFIT	**2,110,167.00**
OPERATING EXPENSES	**248,540.97**
OPERATING EXPENSES	**248,540.97**
SELLING AND SERVICE EXPENSES	40,316.74
SALARIES AND WAGES	18,422.52
SOCIAL SECURITY	12,506.42
SEVERANCE INDEMNITY FUND (FGTS)	1,710.12
MEDICAL ASSISTANCE	0.00
TELECOMMUNICATIONS	0.00
VACATION PAY	2,120.76
THIRTEENTH-MONTH SALARY	1,640.00
MEAL EXPENSES	15.20
BASIC FOOD BASKET ALLOWANCE	2,870.64
CONSUMABLE AND SUPPLIES	0.00
TRANSPORTATION ALLOWANCE	1,031.08
MANAGEMENT FEE	0.00
MISCELLANEOUS EXPENSES	0.00
ADMINISTRATIVE EXPENSES	40,888.00
MANAGEMENT COMPENSATION	33,888.00
ACCOUNTING FEES	7,000.00
TAX EXPENSES	167,336.23
TAXES AND FEES	0.00
SOCIAL INTEGRATION PROGRAM (PIS)	13,716.08
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS)	63,305.01
TAX ON SERVICES OF ANY NATURE (ISSQN)	42,203.34
CORPORATE INCOME TAX (IRPJ)	25,322.00
SOCIAL CONTRIBUTION ON NET INCOME (CSLL)	22,789.80
NON-OPERATING REVENUE	**0.00**
OTHER REVENUE	0.00
PROMOTIONAL GIFTS	0.00
INCOME BEFORE FINANCIAL RESULTS	**1,861,626.03**
FINANCIAL EXPENSES	**128.06**
FINANCIAL EXPENSES	128.06
BANK CHARGES	0.00
FINANCIAL EXPENSES	0.00
INTEREST EXPENSE	109.34
FINES	18.72
INCOME BEFORE TAX PROVISIONS	**1,861,497.97**
NET INCOME FOR THE PERIOD	**1,861,497.97**

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA: 01646133820
Date: 2026.06.02 09:15:02 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 28, 2026

Consolidação: Empresa **Grau: 5** **Período: 01/2024 a 12/2024**

RECEITA OPERACIONAL BRUTA	**2.110.167,00**
RECEITAS OPERACIONAIS	2.110.167,00
SERVICOS PRESTADOS A VISTA	2.110.167,00
DEDUÇÕES DA RECEITA BRUTA	**0,00**
RECEITA LÍQUIDA	**2.110.167,00**
CUSTOS	**0,00**
CUSTO DAS MERCADORIAS VENDIDAS	0,00
COMPRAS DE MERCADORIAS	0,00
LUCRO BRUTO	**2.110.167,00**
DESPESAS OPERACIONAIS	**248.540,97**
DESPESAS OPERACIONAIS	**248.540,97**
DESPESAS COM VENDAS/SERVICOS	40.316,74
SALARIOS E ORDENADOS	18.422,52
PREVIDENCIA SOCIAL	12.506,42
FGTS	1.710,12
ASSISTENCIA MEDICA	0,00
TELECOMUNICACAO	0,00
FERIAS	2.120,76
13? SALARIO	1.640,00
DESPESAS COM REFEICOES	15,20
CESTA BASICA	2.870,64
MATERIAL DE CONSUMO E USO	0,00
VALE TRANSPORTE	1.031,08
TAXA DE ADMINISTRACAO	0,00
DESPESAS DIVERSAS	0,00
DESPESAS ADMINISTRATIVAS	40.888,00
PRO-LABORE	33.888,00
HONORARIOS CONTABEIS	7.000,00
DESPESAS TRIBUTARIAS	167.336,23
IMPOSTOS E TAXAS	0,00
PIS	13.716,08
COFINS	63.305,01
ISSQN	42.203,34
IRPJ	25.322,00
CSLL	22.789,80
RECEITAS NÃO OPERACIONAIS	**0,00**
OUTRAS RECEITAS	0,00
BRINDES	0,00
RESULTADO ANTES DAS OPERAÇÕES FINANCEIRAS	**1.861.626,03**
DESPESAS FINANCEIRAS	**128,06**
DESPESAS FINANCEIRAS	128,06
DESPESAS BANCARIAS	0,00
DESPESAS FINANCEIRAS	0,00
JUROS PASSIVOS	109,34
MULTAS	18,72
RESULTADO ANTES DAS PROVISÕES TRIBUTÁRIAS	**1.861.497,97**
LUCRO LÍQUIDO DO EXERCÍCIO	**1.861.497,97**

NELSON GAZA:01646133820

Assinado de forma digital por NELSON GAZA:01646133820
Dados: 2026.06.02 09:15:02 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

Consolidation: Company | **Level: 5** | **Period: 01/2025 to 12/2025**

GROSS OPERATING REVENUE	**2,551,063.48**
OPERATING REVENUES	2,551,063.48
CASH SERVICES RENDERED	2,551,063.48
DEDUCTIONS FROM GROSS REVENUE	**0.00**
NET REVENUE	**2,551,063.48**
COSTS	**575,622.80**
COST OF GOODS SOLD	287,811.40
COST OF SERVICES RENDERED	287,811.40
COST OF SERVICES RENDERED	287,811.40
GROSS PROFIT	**1,975,440.68**
OPERATING EXPENSES	**330,676.23**
OPERATING EXPENSES	**330,676.23**
SELLING AND SERVICE EXPENSES	51,234.14
SALARIES AND WAGES	17,816.00
SOCIAL SECURITY	12,382.90
SEVERANCE INDEMNITY FUND (FGTS)	1,686.20
VACATION PAY	2,186.66
THIRTEENTH-MONTH SALARY	1,804.00
MEAL EXPENSES	38.94
BASIC FOOD BASKET ALLOWANCE	2,725.14
CONSUMABLE AND SUPPLIES	9,300.00
TRANSPORTATION ALLOWANCE	1,282.05
MISCELLANEOUS EXPENSES	2,012.25
ADMINISTRATIVE EXPENSES	43,406.00
MANAGEMENT COMPENSATION	33,396.00
ACCOUNTING FEES	10,010.00
TAX EXPENSES	236,036.09
SOCIAL INTEGRATION PROGRAM (PIS)	16,581.92
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS)	76,531.91
TAX ON SERVICES OF ANY NATURE (ISSQN)	33,463.26
CORPORATE INCOME TAX (IRPJ)	51,294.77
SOCIAL CONTRIBUTION ON NET INCOME (CSLL)	27,551.48
NON-OPERATING REVENUE	**0.00**
OTHER REVENUE	0.00
PROMOTIONAL GIFTS	0.00
INCOME BEFORE FINANCIAL RESULTS	**1,644,764.45**
FINANCIAL EXPENSES	**0.00**
FINANCIAL EXPENSES	0.00
INTEREST EXPENSE	0.00
FINES	0.00
INCOME BEFORE TAX PROVISIONS	**1,644,764.45**
NET INCOME FOR THE PERIOD	**1,644,764.45**

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA: 01646133820 Date: 2026.06.02 09:15:39 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

_____ **Date: July 28, 2026**

RECEITA OPERACIONAL BRUTA	**2.551.063,48**
RECEITAS OPERACIONAIS	2.551.063,48
SERVICOS PRESTADOS A VISTA	2.551.063,48
DEDUÇÕES DA RECEITA BRUTA	**0,00**
RECEITA LÍQUIDA	**2.551.063,48**
CUSTOS	**575.622,80**
CUSTO DAS MERCADORIAS VENDIDAS	287.811,40
CUSTO DOS SERVICOS PRESTADOS	287.811,40
CUSTO DOS SERVICOS PRESTADOS	287.811,40
LUCRO BRUTO	**1.975.440,68**
DESPESAS OPERACIONAIS	**330.676,23**
DESPESAS OPERACIONAIS	**330.676,23**
DESPESAS COM VENDAS/SERVICOS	51.234,14
SALARIOS E ORDENADOS	17.816,00
PREVIDENCIA SOCIAL	12.382,90
FGTS	1.686,20
FERIAS	2.186,66
13? SALARIO	1.804,00
DESPESAS COM REFEICOES	38,94
CESTA BASICA	2.725,14
MATERIAL DE CONSUMO E USO	9.300,00
VALE TRANSPORTE	1.282,05
DESPESAS DIVERSAS	2.012,25
DESPESAS ADMINISTRATIVAS	43.406,00
PRO-LABORE	33.396,00
HONORARIOS CONTABEIS	10.010,00
DESPESAS TRIBUTARIAS	236.036,09
PIS	16.581,92
COFINS	76.531,91
ICMS	33.463,26
ISSQN	51.294,77
IRPJ	30.612,75
CSLL	27.551,48
RECEITAS NÃO OPERACIONAIS	**0,00**
OUTRAS RECEITAS	0,00
BRINDES	0,00
RESULTADO ANTES DAS OPERAÇÕES FINANCEIRAS	**1.644.764,45**
DESPESAS FINANCEIRAS	**0,00**
DESPESAS FINANCEIRAS	0,00
JUROS PASSIVOS	0,00
MULTAS	0,00
RESULTADO ANTES DAS PROVISÕES TRIBUTÁRIAS	**1.644.764,45**
LUCRO LÍQUIDO DO EXERCÍCIO	**1.644.764,45**

NELSON GAZA:01646133820

Assinado de forma digital por NELSON GAZA:01646133820
Dados: 2026.06.02 09:15:39 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

CNPJ: 21.850.272/0001-50
NIRE No. 35129941301, dated 02/10/2015
Consolidation: Company **Level: 5** **Closed on: 12/31/2021**

ASSETS		**150,806.07**
CURRENT ASSETS		**148,793.82**
CASH AND CASH EQUIVALENTS		64,493.82
CASH		64,493.82
CASH AND CASH EQUIVALENTS		64,493.82
INVENTORIES		**84,300.00**
INVENTORIES		84,300.00
GOODS ON CONSIGNMENT		84,300.00
NON-CURRENT ASSETS		**2,012.25**
FIXED ASSETS		2,012.25
PROPERTY AND EQUIPMENT		2,012.25
INSTALLATIONS		2,012.25
TOTAL ASSETS	150,806.07	
LIABILITIES		**150,806.07**
CURRENT LIABILITIES		**104,316.94**
OBLIGATIONS		104,316.94
TAX LIABILITIES		14,457.54
TAX ON SERVICES (ISS) PAYABLE		2,627.54
CORPORATE INCOME TAX (IRPJ) PAYABLE		4,384.39
SOCIAL CONTRIBUTION ON NET INCOME(CSLL) PAYABLE		4,500.80
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS) PAYABLE		2,420.40
SOCIAL INTEGRATION PROGRAM (PIS) PAYABLE		524.41
SOCIAL AND LABOR OBLIGATIONS		5,034.40
SALARIES AND WAGES PAYABLE		3,041.40
NATIONAL SOCIAL SECURITY INSTITUTE (INSS) PAYABLE		1,132.88
SEVERANCE INDEMNITY FUND (FGTS) PAYABLE		167.12
EMPLOYEES' UNION CONTRIBUTION PAYABLE		35.00
CONFEDERATION CONTRIBUTION PAYABLE		338.00
EMPLOYER UNION CONTRIBUTION PAYABLE		320.00
OTHER ACCOUNTS PAYABLE		525.00
ACCOUNTING FEES PAYABLE		525.00
GOODS ON CONSIGNMENT		84,300.00
GOODS ON CONSIGNMENT		84,300.00
QUOTAHOLDERS' EQUITY		**46,489.13**
QUOTAHOLDERS' EQUITY		46,489.13
SHARE CAPITAL		40,000.00
SUBSCRIBED CAPITAL		40,000.00
RETAINED EARNINGS		6,489.13
RETAINED EARNINGS		6,489.13
TOTAL LIABILITIES	150,806.07	

We acknowledge the accuracy of this Balance Sheet based on the information and documentation provided, as of 12/31/2021, with total Assets and total Liabilities amounting to R$ 150,806.07 (one hundred fifty thousand, eight hundred six reais and seven centavos).

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA: 01646133820 Date: 2026.06.02 09:06:44 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

CNPJ: 21.850.272/0001-50
NIRE nº 35129941301 de 10/02/2015
Consolidação: Empresa **Grau: 5** **Encerrado em: 31/12/2021**

ATIVO		**150.806,07**
CIRCULANTE		**148.793,82**
DISPONIVEL		64.493,82
CAIXA		64.493,82
CAIXA E EQUIVALENTES DE CAIXA		64.493,82
ESTOQUES		84.300,00
ESTOQUES		84.300,00
MERCADORIA EM CONSIGNACAO		84.300,00
NAO CIRCULANTE		**2.012,25**
PERMANENTE		2.012,25
IMOBILIZADO		2.012,25
INSTALACOES		2.012,25
TOTAL DO ATIVO	150.806,07	
PASSIVO		**150.806,07**
CIRCULANTE		**104.316,94**
OBRIGACOES		104.316,94
OBRIGACOES FISCAIS		14.457,54
ISS A RECOLHER		2.627,54
IRPJ A RECOLHER		4.384,39
CSLL A RECOLHER		4.500,80
COFINS A RECOLHER		2.420,40
PIS A RECOLHER		524,41
OBRIGACOES SOCIAIS E TRABALHISTAS		5.034,40
SALARIOS E ORDENADOS A PAGAR		3.041,40
INSS A RECOLHER		1.132,88
FGTS A RECOLHER		167,12
CONTR. SIND. EMPREGADOS A RECOLHER		35,00
CONTR. CONFED. A RECOLHER		338,00
CONTRIBUICAO SIND. PATRONAL A RECOLHER		320,00
OUTRAS CONTAS A PAGAR		525,00
HONORARIOS CONTABEIS A PAGAR		525,00
MERCADORIA EM CONSIGNACAO		84.300,00
MERCADORIA EM CONSIGNACAO		84.300,00
PATRIMONIO LIQUIDO		**46.489,13**
PATRIMONIO LIQUIDO		46.489,13
CAPITAL SOCIAL		40.000,00
CAPITAL SUBSCRITO		40.000,00
LUCROS ACUMULADOS		6.489,13
LUCROS ACUMULADOS		6.489,13
TOTAL DO PASSIVO	150.806,07	

Reconhecemos a exatidão do presente Balanço Patrimonial com base nas informações e na documentação apresentada, encerrado em 31/12/2021, somando tanto no Ativo como no Passivo, a importância de R$ 150.806,07 (cento e cinquenta mil, oitocentos e seis reais e sete centavos).

NELSON GAZA:01646133820 Assinado de forma digital por NELSON GAZA:01646133820 Dados: 2026.06.02 09:06:44 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

CNPJ: 21.850.272/0001-50
NIRE No. 35129941301, dated 02/10/2015
Consolidation: Company **Level: 5** **Closed on: 12/31/2022**

ASSETS		**674,952.00**
CURRENT ASSETS		**672,939.75**
CASH AND CASH EQUIVALENTS		259,202.11
CASH		160,490.26
CASH AND CASH EQUIVALENTS		160,490.26
FINANCIAL INVESTMENTS		98,711.85
FIXED-INCOME INVESTMENTS		98,711.85
RECEIVABLES		316,567.64
ACCOUNTS RECEIVABLE		316,567.64
CUSTOMERS		316,567.64
DEFERRED TAX ASSETS		55.00
DEFERRED INSS TAX		55.00
INVENTORIES		**97,170.00**
INVENTORIES		97,170.00
GOODS ON CONSIGNMENT		97,170.00
NON-CURRENT ASSETS		**2,012.25**
FIXED ASSETS		2,012.25
PROPERTY AND EQUIPMENT		2,012.25
INSTALLATIONS		2,012.25
TOTAL ASSETS	674,952.00	
LIABILITIES		**674,952.00**
CURRENT LIABILITIES		**144,694.00**
OBLIGATIONS		144,694.00
TAX LIABILITIES		42,551.04
TAX ON SERVICES (ISS) PAYABLE		8,364.11
CORPORATE INCOME TAX (IRPJ) PAYABLE		7,933.03
SOCIAL CONTRIBUTION ON NET INCOME (CSLL) PAYABLE		7,876.65
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS) PAYABLE		16,874.42
SOCIAL INTEGRATION PROGRAM (PIS) PAYABLE		1,502.83
SOCIAL AND LABOR OBLIGATIONS		4,432.96
SALARIES AND WAGES PAYABLE		1,457.00
OWNERS' COMPENSATION PAYABLE		2,157.36
NATIONAL SOCIAL SECURITY INSTITUTE (INSS) PAYABLE		704.75
SEVERANCE INDEMNITY FUND (FGTS) PAYABLE		113.85
OTHER ACCOUNTS PAYABLE		540.00
ACCOUNTING FEES PAYABLE		540.00
GOODS ON CONSIGNMENT		97,170.00
GOODS ON CONSIGNMENT		97,170.00
QUOTAHOLDERS' EQUITY		**530,258.00**
QUOTAHOLDERS' EQUITY		530,258.00
SHARE CAPITAL		40,000.00
SUBSCRIBED CAPITAL		40,000.00
RETAINED EARNINGS		490,258.00
RETAINED EARNINGS		490,258.00
TOTAL LIABILITIES	674,952.00	

We acknowledge the accuracy of this Balance Sheet based on the information and documentation provided, as of 12/31/2022, with total Assets and total Liabilities amounting to R$ 674,952.00 (six hundred and seventy-four thousand, nine hundred and fifty-two reais)

CNPJ: 21.850.272/0001-50
NIRE No. 35129941301, dated 02/10/2015
Consolidation: Company **Level: 5** **Closed on: 12/31/2022**

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA: 01646133820 Date: 2026.06.02 09:07:27 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

CNPJ: 21.850.272/0001-50
NIRE nº 35129941301 de 10/02/2015
Consolidação: Empresa **Grau: 5** **Encerrado em: 31/12/2022**

ATIVO		**674.952,00**
CIRCULANTE		**672.939,75**
DISPONIVEL		259.202,11
CAIXA		160.490,26
CAIXA E EQUIVALENTES DE CAIXA		160.490,26
APLICACOES FINANCEIRAS		98.711,85
APLICACOES FINANCEIRAS DE RENDA FIXA		98.711,85
CREDITOS		316.567,64
CONTAS A RECEBER		316.512,64
CLIENTES		316.512,64
IMPOSTOS A RECUPERAR		55,00
INSS A RECUPERAR		55,00
ESTOQUES		97.170,00
ESTOQUES		97.170,00
MERCADORIA EM CONSIGNACAO		97.170,00
NAO CIRCULANTE		**2.012,25**
PERMANENTE		2.012,25
IMOBILIZADO		2.012,25
INSTALACOES		2.012,25
TOTAL DO ATIVO	674.952,00	
PASSIVO		**674.952,00**
CIRCULANTE		**144.694,00**
OBRIGACOES		144.694,00
OBRIGACOES FISCAIS		42.551,04
ISS A RECOLHER		8.364,11
IRPJ A RECOLHER		7.933,03
CSLL A RECOLHER		7.876,65
COFINS A RECOLHER		16.874,42
PIS A RECOLHER		1.502,83
OBRIGACOES SOCIAIS E TRABALHISTAS		4.432,96
SALARIOS E ORDENADOS A PAGAR		1.457,00
PRO-LABORE A PAGAR		2.157,36
INSS A RECOLHER		704,75
FGTS A RECOLHER		113,85
OUTRAS CONTAS A PAGAR		540,00
HONORARIOS CONTABEIS A PAGAR		540,00
MERCADORIA EM CONSIGNACAO		97.170,00
MERCADORIA EM CONSIGNACAO		97.170,00
PATRIMONIO LIQUIDO		**530.258,00**
PATRIMONIO LIQUIDO		530.258,00
CAPITAL SOCIAL		40.000,00
CAPITAL SUBSCRITO		40.000,00
LUCROS ACUMULADOS		490.258,00
LUCROS ACUMULADOS		490.258,00
TOTAL DO PASSIVO	674.952,00	

Reconhecemos a exatidão do presente Balanço Patrimonial com base nas informações e na documentação apresentada, encerrado em 31/12/2022, somando tanto no Ativo como no Passivo, a importância de R$ 674.952,00 (seiscentos e setenta e quatro mil, novecentos e cinquenta e dois reais).

CNPJ: 21.850.272/0001-50
NIRE nº 35129941301 de 10/02/2015
Consolidação: Empresa **Grau: 5** **Encerrado em: 31/12/2022**

NELSON GAZA:01646133820 Assinado de forma digital por NELSON GAZA:01646133820 Dados: 2026.06.02 09:07:27 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

CNPJ: 21.850.272/0001-50
NIRE No. 35129941301, dated 02/10/2015
Consolidation: Company **Level: 5** **Closed on: 12/31/2023**

ASSETS		**277,266.25**
CURRENT ASSETS		**275,254.00**
CASH AND CASH EQUIVALENTS		163,217.44
CASH		49,253.47
CASH AND CASH EQUIVALENTS		49,253.47
FINANCIAL INVESTMENTS		113,963.97
FIXED-INCOME INVESTMENTS		113,963.97
RECEIVABLES		14,866.56
ACCOUNTS RECEIVABLE		14,866.56
CUSTOMERS		14,866.56
INVENTORIES		**97,170.00**
INVENTORIES		97,170.00
GOODS ON CONSIGNMENT		97,170.00
NON-CURRENT ASSETS		**2,012.25**
FIXED ASSETS		2,012.25
PROPERTY AND EQUIPMENT		2,012.25
INSTALLATIONS		2,012.25
TOTAL ASSETS	277,266.25	
LIABILITIES		**277,266.25**
CURRENT LIABILITIES		**229,658.88**
OBLIGATIONS		229,658.88
SUPPLIERS		102,176.25
SUPPLIERS PAYABLE		102,176.25
TAX LIABILITIES		23,977.18
TAX ON SERVICES (ISS) PAYABLE		3,710.70
CORPORATE INCOME TAX (IRPJ) PAYABLE		5,062.49
SOCIAL CONTRIBUTION ON NET INCOME (CSLL) PAYABLE		4,299.17
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS) PAYABLE		8,962.86
SOCIAL INTEGRATION PROGRAM (PIS) PAYABLE		1,941.96
SOCIAL AND LABOR OBLIGATIONS		5,735.45
SALARIES AND WAGES PAYABLE		1,827.00
OWNERS' COMPENSATION PAYABLE		2,349.60
NATIONAL SOCIAL SECURITY INSTITUTE (INSS) PAYABLE		1,367.99
SEVERANCE INDEMNITY FUND (FGTS) PAYABLE		190.86
OTHER ACCOUNTS PAYABLE		600.00
ACCOUNTING FEES PAYABLE		600.00
GOODS ON CONSIGNMENT		97,170.00
GOODS ON CONSIGNMENT		97,170.00
NON-CURRENT LIABILITIES		**148,731.47**
LONG-TERM LIABILITIES		148,731.47
LOANS		148,731.47
PARTNER LOANS		148,731.47
QUOTAHOLDERS' EQUITY		**-101,124.10**
QUOTAHOLDERS' EQUITY		-101,124.10
SHARE CAPITAL		40,000.00
SUBSCRIBED CAPITAL		40,000.00
RETAINED EARNINGS		-141,124.10
RETAINED EARNINGS		-141,124.10
TOTAL LIABILITIES	277,266.25	

CNPJ: 21.850.272/0001-50
NIRE No. 35129941301, dated 02/10/2015
Consolidation: Company **Level: 5** **Closed on: 12/31/2023**

We acknowledge the accuracy of this Balance Sheet based on the information and documentation provided, as of 12/31/2023, with total Assets and total Liabilities amounting to R$ 277,266.25 (two hundred and seventy-seven thousand, two hundred and sixty-six reais and twenty-five centavos).

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA: 01646133820
Date: 2026.06.02 09:08:19 AM -03'00'

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

CNPJ: 21.850.272/0001-50
NIRE nº 35129941301 de 10/02/2015
Consolidação: Empresa **Grau: 5** **Encerrado em: 31/12/2023**

ATIVO		**277.266,25**
CIRCULANTE		**275.254,00**
DISPONIVEL		163.217,44
CAIXA		49.253,47
CAIXA E EQUIVALENTES DE CAIXA		49.253,47
APLICACOES FINANCEIRAS		113.963,97
APLICACOES FINANCEIRAS DE RENDA FIXA		113.963,97
CREDITOS		14.866,56
CONTAS A RECEBER		14.866,56
CLIENTES		14.866,56
ESTOQUES		97.170,00
ESTOQUES		97.170,00
MERCADORIA EM CONSIGNACAO		97.170,00
NAO CIRCULANTE		**2.012,25**
PERMANENTE		2.012,25
IMOBILIZADO		2.012,25
INSTALACOES		2.012,25
TOTAL DO ATIVO	277.266,25	
PASSIVO		**277.266,25**
CIRCULANTE		**229.658,88**
OBRIGACOES		229.658,88
FORNECEDORES		102.176,25
FORNECEDOR A PAGAR		102.176,25
OBRIGACOES FISCAIS		23.977,18
ISS A RECOLHER		3.710,70
IRPJ A RECOLHER		5.062,49
CSLL A RECOLHER		4.299,17
COFINS A RECOLHER		8.962,86
PIS A RECOLHER		1.941,96
OBRIGACOES SOCIAIS E TRABALHISTAS		5.735,45
SALARIOS E ORDENADOS A PAGAR		1.827,00
PRO-LABORE A PAGAR		2.349,60
INSS A RECOLHER		1.367,99
FGTS A RECOLHER		190,86
OUTRAS CONTAS A PAGAR		600,00
HONORARIOS CONTABEIS A PAGAR		600,00
MERCADORIA EM CONSIGNACAO		97.170,00
MERCADORIA EM CONSIGNACAO		97.170,00
NAO CIRCULANTE		**148.731,47**
EXIGIVEL A LONGO PRAZO		148.731,47
EMPRESTIMOS		148.731,47
EMPRESTIMOS DE SOCIOS		148.731,47
PATRIMONIO LIQUIDO		**-101.124,10**
PATRIMONIO LIQUIDO		-101.124,10
CAPITAL SOCIAL		40.000,00
CAPITAL SUBSCRITO		40.000,00
LUCROS ACUMULADOS		-141.124,10
LUCROS ACUMULADOS		-141.124,10
TOTAL DO PASSIVO	277.266,25	

Reconhecemos a exatidão do presente Balanço Patrimonial com base nas informações e na documentação

CNPJ: 21.850.272/0001-50
NIRE nº 35129941301 de 10/02/2015
Consolidação: Empresa **Grau: 5** **Encerrado em: 31/12/2023**

apresentada, encerrado em 31/12/2023, somando tanto no Ativo como no Passivo, a importância de R$ 277.266,25 (duzentos e setenta e sete mil, duzentos e sessenta e seis reais e vinte e cinco centavos).

NELSON GAZA:01646133820
Assinado de forma digital por NELSON GAZA:01646133820
Dados: 2026.06.02 09:08:19 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

CNPJ: 21.850.272/0001-50
NIRE No. 35129941301, dated 02/10/2015
Consolidation: Company **Level: 5** **Closed on: 12/31/2024**

ASSETS	**2,305,750.20**
CURRENT ASSETS	**2,305,750.20**
CASH AND CASH EQUIVALENTS	2,198,535.70
CASH	2,084,571.73
CASH AND CASH EQUIVALENTS	2,084,571.73
FINANCIAL INVESTMENTS	113,963.97
FIXED-INCOME INVESTMENTS	113,963.97
RECEIVABLES	8,032.25
ACCOUNTS RECEIVABLE	7,977.25
CUSTOMERS	7,977.25
DEFERRED TAX ASSETS	55.00
DEFERRED INSS TAX	55.00
INVENTORIES	**97,170.00**
INVENTORIES	97,170.00
GOODS ON CONSIGNMENT	97,170.00
NON-CURRENT ASSETS	**2,012.25**
FIXED ASSETS	2,012.25
PROPERTY AND EQUIPMENT	2,012.25
INSTALLATIONS	2,012.25
TOTAL ASSETS	2,305,750.20
LIABILITIES	**2,305,750.20**
CURRENT LIABILITIES	**103,212.95**
OBLIGATIONS	103,212.95
TAX LIABILITIES	170.00
TAX ON SERVICES (ISS) PAYABLE	170.00
SOCIAL AND LABOR OBLIGATIONS	5,872.95
SALARIES AND WAGES PAYABLE	1,738.00
OWNERS' COMPENSATION PAYABLE	2,513.36
NATIONAL SOCIAL SECURITY INSTITUTE (INSS) PAYABLE	1,424.79
SEVERANCE INDEMNITY FUND (FGTS) PAYABLE	196.80
GOODS ON CONSIGNMENT	97,170.00
GOODS ON CONSIGNMENT	97,170.00
NON-CURRENT LIABILITIES	**148,731.47**
LONG-TERM LIABILITIES	148,731.47
LOANS	148,731.47
PARTNER LOANS	148,731.47
QUOTAHOLDERS' EQUITY	**2,202,537.25**
QUOTAHOLDERS' EQUITY	2,202,537.25
SHARE CAPITAL	40,000.00
SUBSCRIBED CAPITAL	40,000.00
RETAINED EARNINGS	2,202,537.25
RETAINED EARNINGS	262,537.25
PROFIT DISTRIBUTION	1,900,000.00
TOTAL LIABILITIES	2,305,750.20

We acknowledge the accuracy of this Balance Sheet based on the information and documentation provided, as of 12/31/2024, with total Assets and total Liabilities amounting to R$ 2,305,750.20 (two million, three hundred and five thousand, seven hundred and fifty reais and twenty centavos).

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA: 01646133820 Date: 2026.06.02 09:09:03 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

CNPJ: 21.850.272/0001-50
NIRE nº 35129941301 de 10/02/2015
Consolidação: Empresa **Grau: 5** **Encerrado em: 31/12/2024**

ATIVO		**2.305.750,20**
CIRCULANTE		**2.303.737,95**
DISPONIVEL		2.198.535,70
CAIXA		2.084.571,73
CAIXA E EQUIVALENTES DE CAIXA		2.084.571,73
APLICACOES FINANCEIRAS		113.963,97
APLICACOES FINANCEIRAS DE RENDA FIXA		113.963,97
CREDITOS		8.032,25
CONTAS A RECEBER		7.977,25
CLIENTES		7.977,25
IMPOSTOS A RECUPERAR		55,00
INSS A RECUPERAR		55,00
ESTOQUES		97.170,00
ESTOQUES		97.170,00
MERCADORIA EM CONSIGNACAO		97.170,00
NAO CIRCULANTE		**2.012,25**
PERMANENTE		2.012,25
IMOBILIZADO		2.012,25
INSTALACOES		2.012,25
TOTAL DO ATIVO	2.305.750,20	
PASSIVO		**2.305.750,20**
CIRCULANTE		**103.212,95**
OBRIGACOES		103.212,95
OBRIGACOES FISCAIS		170,00
ISS A RECOLHER		170,00
OBRIGACOES SOCIAIS E TRABALHISTAS		5.872,95
SALARIOS E ORDENADOS A PAGAR		1.738,00
PRO-LABORE A PAGAR		2.513,36
INSS A RECOLHER		1.424,79
FGTS A RECOLHER		196,80
MERCADORIA EM CONSIGNACAO		97.170,00
MERCADORIA EM CONSIGNACAO		97.170,00
PATRIMONIO LIQUIDO		**2.202.537,25**
PATRIMONIO LIQUIDO		2.202.537,25
CAPITAL SOCIAL		40.000,00
CAPITAL SUBSCRITO		40.000,00
LUCROS ACUMULADOS		2.162.537,25
LUCROS ACUMULADOS		262.537,25
DISTRIBUIÇÃO DE LUCROS		1.900.000,00
TOTAL DO PASSIVO	2.305.750,20	

Reconhecemos a exatidão do presente Balanço Patrimonial com base nas informações e na documentação apresentada, encerrado em 31/12/2024, somando tanto no Ativo como no Passivo, a importância de R$ 2.305.750,20 (dois milhões, trezentos e cinco mil, setecentos e cinquenta reais e vinte centavos).

NELSON GAZA:01646133820
Assinado de forma digital por NELSON GAZA:01646133820
Dados: 2026.06.02 09:09:03 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

CNPJ: 21.850.272/0001-50
NIRE No. 35129941301, dated 02/10/2015
Consolidation: Company **Level: 5** **Closed on: 12/31/2025**

ASSETS		**322,876.21**
CURRENT ASSETS		**322,876.21**
CASH AND CASH EQUIVALENTS		187,934.09
CASH		187,934.09
CASH AND CASH EQUIVALENTS		187,934.09
RECEIVABLES		134,942.12
ACCOUNTS RECEIVABLE		133,557.99
CUSTOMERS		133,557.99
WITHHELD TAXES		360.00
WITHHOLDING INCOME TAX (IRRF)		360.00
DEFERRED TAX ASSETS		1,024.13
DEFERRED INSS TAX		1,024.13
TOTAL ASSETS	322,876.21	
LIABILITIES		**322,876.21**
CURRENT LIABILITIES		**12,554.06**
OBLIGATIONS		12,554.06
SUPPLIERS		1,155.00
SUPPLIERS PAYABLE		1,155.00
TAX LIABILITIES		10,629.06
TAX ON SERVICES (ISS) PAYABLE		3,019.96
CORPORATE INCOME TAX (IRPJ) PAYABLE		1,850.49
SOCIAL CONTRIBUTION ON NET INCOME (CSLL) PAYABLE		2,980.96
SOCIAL SECURITY FINANCING CONTRIBUTION (COFINS) PAYABLE		2,283.00
SOCIAL INTEGRATION PROGRAM (PIS) PAYABLE		494.65
OTHER ACCOUNTS PAYABLE		770.00
ACCOUNTING FEES PAYABLE		770.00
QUOTAHOLDERS' EQUITY		**310,322.15**
QUOTAHOLDERS' EQUITY		310,322.15
SHARE CAPITAL		40,000.00
SUBSCRIBED CAPITAL		40,000.00
RETAINED EARNINGS		270,322.15
RETAINED EARNINGS		270,322.15
TOTAL LIABILITIES	322,876.21	

We acknowledge the accuracy of this Balance Sheet based on the information and documentation provided, as of 12/31/2025, with total Assets and total Liabilities amounting to R$ 322,876.21 (three hundred and twenty-two thousand, eight hundred and seventy-six reais and twenty-one centavos).

NELSON GAZA:01646133820 Digitally signed by NELSON GAZA:01646133820
Date: 2026.06.02 09:10:14 AM -03'00'

RODRIGO PORPHIRIO SANT'ANA
MANAGER
CPF No. 072.042.457-76

NELSON GAZA
ACCOUNTANT
CRC No. 33.435/O-6

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: July 27, 2026

CNPJ: 21.850.272/0001-50
NIRE nº 35129941301 de 10/02/2015
Consolidação: Empresa **Grau: 5** **Encerrado em: 31/12/2025**

ATIVO		**322.876,21**
CIRCULANTE		**322.876,21**
DISPONIVEL		187.934,09
CAIXA		187.934,09
CAIXA E EQUIVALENTES DE CAIXA		187.934,09
CREDITOS		134.942,12
CONTAS A RECEBER		133.557,99
CLIENTES		133.557,99
IMPOSTOS RETIDOS		360,00
IRRF		360,00
IMPOSTOS A RECUPERAR		1.024,13
INSS A RECUPERAR		1.024,13
TOTAL DO ATIVO	322.876,21	
PASSIVO		**322.876,21**
CIRCULANTE		**12.554,06**
OBRIGACOES		12.554,06
FORNECEDORES		1.155,00
FORNECEDOR A PAGAR		1.155,00
OBRIGACOES FISCAIS		10.629,06
ISS A RECOLHER		3.019,96
IRPJ A RECOLHER		1.850,49
CSLL A RECOLHER		2.980,96
COFINS A RECOLHER		2.283,00
PIS A RECOLHER		494,65
OUTRAS CONTAS A PAGAR		770,00
HONORARIOS CONTABEIS A PAGAR		770,00
PATRIMONIO LIQUIDO		**310.322,15**
PATRIMONIO LIQUIDO		310.322,15
CAPITAL SOCIAL		40.000,00
CAPITAL SUBSCRITO		40.000,00
LUCROS ACUMULADOS		270.322,15
LUCROS ACUMULADOS		270.322,15
TOTAL DO PASSIVO	322.876,21	

Reconhecemos a exatidão do presente Balanço Patrimonial com base nas informações e na documentação apresentada, encerrado em 31/12/2025, somando tanto no Ativo como no Passivo, a importância de R$ 322.876,21 (trezentos e vinte e dois mil, oitocentos e setenta e seis reais e vinte e um centavos).

NELSON GAZA:01646133820
Assinado de forma digital por NELSON GAZA:01646133820
Dados: 2026.06.02 09:10:14 -03'00'

RODRIGO PORPHIRIO SANT ANA
ADMINISTRADOR
CPF 072.042.457-76

NELSON GAZA
CONTADOR
CRC 33.435/O-6

NAME: MARCIO LAMAS LOPES CPF: 287.868.388-90

INCOME TAX - INDIVIDUAL

ANNUAL ADJUSTMENT DECLARATION **TAX YEAR 2024** **CALENDAR YEAR 2023**

TAXPAYER IDENTIFICATION

Name:	MARCIO LAMAS LOPES	CPF:	287.868.388-90
Date of Birth:	10/08/1981	Voter ID:	252550780116
Do you have a spouse or partner?	Yes	CPF of the Spouse or partner:	322.255.848-50

Were you a resident abroad and became a resident in Brazil in 2023? No

Were there any changes to the registration details? No

Is one of the declarants a person with a serious illness or a physical or mental disability? No

Address:	RUA TUIUTI	Number:	732
Unit:	APT 172	Neighborhood/District:	TATUAPE
City:	SAO PAULO	State:	SP
ZIP Code:	03081-015	Area Code/Telephone:	
E-mail:		Area Code/Mobile:	(11) 98409-6670

Occupation Type:	01 - Employee of a private sector company, except financial institutions
Main Occupation:	225 - Physician
Professional registration:	133420
Type of Declaration:	Original Annual Adjustment Declaration

Receipt Number of the last declaration filed in the 2023 tax year: 34.29.75.74.05-54

DEPENDENTS

No Information

ALIMONY RECIPIENTS

No Information

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY THE TAXPAYER

(Values in Reais)

NAME OF THE PAYING SOURCE	INCOME RECEIVED FROM LEGAL ENTITY	OFFICIAL SOCIAL SECURITY CONTRIBUTION	WITHHELD TAX	13th SALARY	INCOME TAX WITHHELD ON 13th SALARY
ABC ENDOSCOPIA LTDA ME	15.768,00	1.734,48	0,00	0,00	0,00
CNPJ/CPF: 21.850.272/0001-50					
TOTAL	15.768,00	1.734,48	0,00	0,00	0,00

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY DEPENDENTS

No Information

NAME: MARCIO LAMAS LOPES CPF: 287.868.388-90 **INCOME TAX - INDIVIDUAL**

ANNUAL ADJUSTMENT DECLARATION **TAX YEAR 2024** **CALENDAR YEAR 2023**

TAXABLE INCOME RECEIVED FROM INDIVIDUALS AND ABROAD BY THE TAXPAYER (Values in Reais)

NIT/PIS/PASEP*: 127.85666.89-7

INCOMES

	NON-SALARIED WORK	RENTALS	OTHERS	ABROAD
JAN	825,00	0,00	0,00	0,00
FEB	350,00	0,00	0,00	0,00
MAR	870,00	0,00	0,00	0,00
APR	0,00	0,00	0,00	0,00
MAY	0,00	0,00	0,00	0,00
JUN	0,00	0,00	0,00	0,00
JUL	0,00	0,00	0,00	0,00
AUG	0,00	0,00	0,00	0,00
SEP	0,00	0,00	0,00	0,00
OCT	0,00	0,00	0,00	0,00
NOV	0,00	0,00	0,00	0,00
DEC	0,00	0,00	0,00	0,00
TOTAL	2.045,00	0,00	0,00	0,00

DEDUCTIONS — CARNÊ-LEÃO*

	OFFICIAL PENSION	NUMBER OF DEPENDENTS	ALIMONY	CASH BOOK	PAID DARF* CODE 0190
JAN	0,00	0	0,00	0,00	0,00
FEB	0,00	0	0,00	0,00	0,00
MAR	0,00	0	0,00	0,00	0,00
APR	0,00	0	0,00	0,00	0,00
MAY	0,00	0	0,00	0,00	0,00
JUN	0,00	0	0,00	0,00	0,00
JUL	0,00	0	0,00	0,00	0,00
AUG	0,00	0	0,00	0,00	0,00
SEP	0,00	0	0,00	0,00	0,00
OCT	0,00	0	0,00	0,00	0,00
NOV	0,00	0	0,00	0,00	0,00
DEC	0,00	0	0,00	0,00	0,00
TOTAL	0,00		0,00	0,00	0,00

* NIT - Worker's Identification Number

* PIS - Program for Social Integration

* PASEP - Public Servant's Property Formation Program

* CARNÊ-LEÃO - Income tax that must be paid monthly, mandatorily, by individuals residing in Brazil who receive income from another individual or from abroad

* DARF - Tax Payment Document

TAXABLE INCOME RECEIVED FROM INDIVIDUALS AND ABROAD BY DEPENDENTS

No Information

EXEMPT AND NON-TAXABLE INCOME

(Values in Reais)

12. Income from savings accounts, mortgage bonds, agribusiness, and real estate letters of credit (LCA and LCI), and certificates of agribusiness and real estate receivables (CRA and CRI) 62.355,22

Beneficiary	CPF	CNPJ of the Paying Source	Name of the Paying Source	Amount
Taxpayer	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	26.128,51
Taxpayer	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	20.468,81
Taxpayer	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	15.757,90

99. Others 624.424,24

Beneficiary	CPF	CPF/CNPJ of the Paying Source	Name of the Paying Source	Description	Amount
Taxpayer	287.868.388-90	21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME	PROFIT DISTRIBUTION	608.000,00
Taxpayer	287.868.388-90	11.664.201/0001-00	FATOR VERITA FII	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	2.449,04
Taxpayer	287.868.388-90	26.091.656/0001-50	OURINVEST JPP FUNDO DE INVESTIMENTO IMOBILIARIO	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	1.545,50
Taxpayer	287.868.388-90	28.830.325/0001-10	FUNDO DE INVESTIMENTO IMOBILIARIO IRIDIUM RECEBIVEIS IMOBILI	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	681,32
Taxpayer	287.868.388-90	40.011.251/0001-96	FUNDO DE INVESTIMENTO IMOBILIARIO DE CRI INTEGRAL BREI	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	111,00
Taxpayer	287.868.388-90	35.754.164/0001-99	PATRIA LOGISTICA FUNDO DE INVESTIMENTO IMOBILIARIO	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	1.775,00
Taxpayer	287.868.388-90	03.017.677/0001-20	FII JS REAL	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	619,38
Taxpayer	287.868.388-90	62.285.390/0001-40	FIAGRO GLPG	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	9.243,00

TOTAL 686.779,46

INCOME SUBJECT TO EXCLUSIVE/DEFINITIVE TAXATION

(Values in Reais)

06. Income from financial investments 74.744,03

Beneficiary	CPF	CNPJ of the Paying Source	Name of the Paying Source	Amount
Taxpayer	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S.A CORRETORA DE TITULOS, CAMBIO E VALOR	66.709,18
Taxpayer	287.868.388-90	90.400.888/0001-42	BANCO SANTANDER (BRASIL) SA	25,91
Taxpayer	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	3.713,98
Taxpayer	287.868.388-90	00.840.011/0001-80	BTG PACTUAL YIELD DI FI REF CP	11,78
Taxpayer	287.868.388-90	17.162.002/0001-80	OCCAM RETORNO ABSOLUTO FIC FIM	208,95
Taxpayer	287.868.388-90	29.826.089/0001-21	GIANT SIGMA FIC FIM	354,24
Taxpayer	287.868.388-90	30.586.677/0001-14	LEGACY CAPITAL FIC FIM	2.373,59
Taxpayer	287.868.388-90	42.887.856/0001-70	GALAPAGOS IGUANA FIRF LIQUIDEZ TOP CP	25,80
Taxpayer	287.868.388-90	47.610.970/0001-72	GALAPAGOS ALBATROZ FIRF LP	23,12
Taxpayer	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	252,42
Taxpayer	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON REFERENCIADO DI	20,95
Taxpayer	287.868.388-90	38.065.012/0001-77	CAPITANIA INFRA FUNDO DE INVESTIMENTO EM COTAS DE FUNDOS INC	502,00
Taxpayer	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	427,43
Taxpayer	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON FIRF REF DI	94,68

TOTAL 74.744,03

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY THE TAXPAYER (TAX WITH SUSPENDED EXIGIBILITY)

No Information

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY THE DEPENDENTS (TAX WITH SUSPENDED EXIGIBILITY)

No Information

TAXABLE INCOME FROM LEGAL ENTITY RECEIVED CUMULATIVELY BY THE TAXPAYER

No Information

TAXABLE INCOME FROM LEGAL ENTITY RECEIVED CUMULATIVELY BY THE DEPENDENTS

No Information

TAX PAID / WITHHELD

No Information

PAYMENTS MADE

(Values in Reais)

CODE	BENEFICIARY NAME	BENEFICIARY CPF/CNPJ	AMOUNT PAID	NON-DEDUCTIBLE PORTION
Taxpayer				
26	QUALICORP ADMINISTRADORA DE BENEFICIOS S.A.	07.658.098/0001-18	9.564,29	0,00

Description:

DONATIONS MADE

(Values in Reais)

CODE	BENEFICIARY NAME	BENEFICIARY CPF/CNPJ	AMOUNT PAID	NON-DEDUCTIBLE PORTION
80	LILIAN DE OLINDA GIANNOCCARO	322.255.848-50	65.000,00	0,00

STATEMENTS OF ASSETS AND RIGHTS

(Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
01	11	50% OF - APT 172 - RUA TUIUTI, 732, JOINTLY WITH LILIAN DE OLINDA GIANNOCCARO - CPF 322.255.848-50 - ACQUIRED IN AUGUST 2017 – FROM ITANGUA EMPREENDIMENTOS IMOB. LTDA - CNPJ 44.078.491-69 -FINANCED.BY BANCO SANTANDER IN 12/2017. – AMOUNTS PAID IN 2017 R$ 185.000,00 , OF WHICH R$ 164.772,50 -ITANGUA, R$ 7.177,50 REAL ESTATE BROKER FEE. , R$ 5.220,00 REAL ESTATE AGENCY AND R$ 7.830,00 BROKER FEE- AMOUNTS PAID IN 2018 R$ 263.268,56- OUTSTANDING BALANCE ON 12.31.2018 - R$ 53.986,28- PAID OFF IN 2019 - PAID R$ 27.709,08	475.977,64	495.977,64

105 - Brazil

Municipal Registration (IPTU): 06211014619

Address: RUA TUIUTI
No.: 732
Unit: APT. 172
Neighborhood: TATUAPE
City: SAO PAULO
State: SP ZIP Code: 03081-015
Total Area: 127,0 m²
Acquisition Date: 07/23/2017
Registered at the Notary Office: Yes
Name of the Registry office: 9th REAL ESTATE REGISTRY OFFICE
Registration: 302629

02	01	HONDA CITY 2016 VEHICLE, ACQUIRED ON 07/14/16 FROM HONDA AUT.DO BRASIL LTDA , CNPJ 01.192.333/0001-22. SOLD TO MR. GUSTAVO JOAO, IN SEP/23, BY THE AMOUNT OF R$ 52.000,00.	69.174,79	0,00

105 - Brazil

RENAVAM (National Registry of Motor Vehicles): 01092987603

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
02	01	SPIN LTZ 2019 VEHICLE. ACQUIRED ON 01/22/2019 FROM FELICIO VIGORITO E FILHO LTDA	81.510,00	81.510,00

105 - Brazil

RENAVAM: 00000104647

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
03	01	AMZN SHARES - 64,3719	0,00	34.006,99

249 - United States

Trust or foreign-controlled entity whose assets and rights will be individually reported and detailed in this declaration, in accordance with Articles 8 and 11 of Law No. 14,754, of 2023: No

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
03	01	GOOGL SHARES - 7,6064	0,00	4.939,70

249 - United States

Trust or foreign-controlled entity whose assets and rights will be individually reported and detailed in this declaration, in accordance with Articles 8 and 11 of Law No. 14,754, of 2023: No

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
03	01	MSFT SHARES - 16,69628	0,00	20.807,47

249 - United States

Trust or foreign-controlled entity whose assets and rights will be individually reported and detailed in this declaration, in accordance with Articles 8 and 11 of Law No. 14,754, of 2023: No

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Exchange-Traded: No

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023	
03	02	CAPITAL SHARES OF ABC ENDOSCOPIA LTDA - CNPJ 21.850.272/0001-50 STARTED IN MARCH 2016	16.000,00	16.000,00	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 21.850.272/0001-50					
04	02	SANTANDER - FIXED INCOME INVESTMENT	21.725,55	26.821,03	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 90.400.888/0001-42					
04	02	LC (Letter of Credits) FACTA FINANCEIRA S/A CFI7 - FIXED INCOME (ACTIVE)	28.283,17	21.535,44	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 15.581.638/0001-30					
04	02	CRI (certificates of real estate receivables) ISEC SECURITIZADORA - FIXED INCOME (ACTIVE)		41.802,21	0,00
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 08.769.451/0001-08					
04	02	LC SIGHT CREDIT CARD ADMINISTRATOR - FIXED INCOME (ACTIVE)	25.896,84	0,00	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 04.533.779/0001-61					

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	CDB (Certificate of Deposit) BANCO MASTER - FIXED INCOME (ACTIVE)	50.000,00	50.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 33.886.862/0001-12

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DRI OURINVEST SECURITIZADORA S/A - FIXED INCOME (ACTIVE)	69.058,20	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 12.320.349/0001-90

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	CRI RB CAPITAL SECUTIZADORA SA - FIXED INCOME (ACTIVE)	53.930,28	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 03.559.006/0001-91

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	COMPANHIA SECURITIZADORA DE CREDITOS FINANCEIROS VOLCANO II	15.000,00	19.950,34

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 39.615.622/0001-60

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DEBENTURE SKYNSTORE	15.000,00	11.505,21

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 12.979.552/0001-72

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DEBENTURE EDITORA SANAR	16.625,63	13.612,04

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 18.990.682/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	GOVERNMENT BONDS - LFT (Treasury Financial Bills)	50.024,38	50.024,38

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 33.775.974/0001-04

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DEBENTURE - LOG ENERGIA COMERCIALIZADORA S/A	0,00	5.552,68

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 15.042.149/0001-00

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	ISEC SECURITIZADORA S.A (ACTIVE)	21.584,90	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 08.769.451/0001-08

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	RB SEC SECURITIZATION COMPANY (ACTIVE)	19.891,11	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 03.559.006/0001-91

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	VERT SECURITIZATION COMPANY (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 25.005.683/0001-09	19.454,77	0,00
04	03	CRI - SECURITIZATION COMPANY (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	33.467,70	0,00
04	03	CRA (certificates of agribusiness receivables) - VORTX DTVM 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	61.357,00	0,00
04	03	RF - CRA PLANNER CV (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 00.806.535/0001-54	25.000,00	0,00
04	03	CRA VIRGO SEC (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	50.022,19	0,00

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRI HABITASEC (ACTIVE)	26.494,38	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 09.304.427/0001-58

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRA VORTIX (ACTIVE)	15.000,00	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 22.610.500/0001-88

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRI VORTIX (ACTIVE)	12.000,00	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 22.610.500/0001-88

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRA - GALAPAGOS	0,00	260.550,08

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRI - GALAPAGOS	0,00	371.835,46

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	GOVERNMENT BONDS - NTN (National Treasury Notes)	24.125,59	18.375,85

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 00.394.460/0409-50

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	NC PLASCAR (ACTIVE)	15.922,73	10.268,45

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	FIDC (Receivables Investment Fund) ANGA MULTIESTRATEGIA	2.413,99	1.279,77

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.796.939/0001-23

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	FIDC SANTA CRUZ	0,00	5.005,02

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
05	01	LOAN TO LILIAN GIANNOCCARO.	0,00	50.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 32225584850

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	01	OVERSEAS ACCOUNT - NOMAD	4.667,43	4.330,68

249 - United States

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Branch: Account:

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	10	CASH	112.000,00	150.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	99	ACTIVE CHECKING ACCOUNT BALANCE - INVESTMENTS	24.756,02	3.943,35

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

CNPJ: 33.775.974/0001-04

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	99	GALAPAGOS INVESTMENTS CHECKING ACCOUNT BALANCE	0,00	2.633,67

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	01	ARX ELBRUS DEB INC FIM CP - FUND (ACTIVE)	32.900,00	32.900,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

CNPJ Fund: 30.910.199/0001-56

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	01	GIANT VISIA SIGMA FIC FIM - FUND (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 29.826.089/0001-21	19.590,37	19.944,61
07	01	LEGACY CAPITAL FC FI MULT - FUND (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 30.586.677/0001-14	34.049,13	36.422,72
07	01	OCCAM ABSOLUTE RETURN FIC FIM - FUND (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 17.162.002/0001-80	22.833,47	23.042,42
07	01	GALAPAGOS IGUANA - FUND (ACTIVE) - 0,00 IN 2023 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 42.887.856/0001-70	2.541,17	0,00
07	03	REAL ESTATE INVESTMENT FUND SHARE - IBCR11 (10 TO 96,25) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 59.281.253/0001-23 Exchange-Traded: No	962,50	962,50

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - OUJP11 (110 TO R$ 92,00)	10.120,00	10.120,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 26.091.656/0001-50
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - JSRE11 (111 TO R$ 109,30)	12.132,30	12.132,30

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 13.371.132/0001-71
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - VRTA11 (242 TO R$ 105,2956)	25.481,54	25.481,54

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 11.664.201/0001-00
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - PATL11 (250 TO R$ 100,00)	25.000,00	25.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 35.754.164/0001-99
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - IRDM11 (67 A R$ 108,97)	7.300,99	7.300,99

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 59.281.253/0001-23
Exchange-Traded: No

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - GCRA11 - GALAPAGOS AGRIBUSINESS RECEIVABLES AGRONEGOCIO FIAGRO (780 TO R$ 97,11)	75.745,80	75.745,80
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 62.285.390/0001-40
Exchange-Traded: Yes Trading Code: GCRA11

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - CPTI11 (251 TO 99,75)	0,00	25.037,25
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 38.065.012/0001-77
Exchange-Traded: Yes Trading Code: CPTI11

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	06	GALAPAGOS BLUE OCEAN INVESTMENT FUND IN MULTISTRATEGY INVESTMENT FUND SHARES - REPORTED UNDER CNPJ 28.650.236/0001-92	0,00	10.679,93
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 49.450.009/0001-93
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	06	GALAPAGOS PINZON DI-REFERENCED FIXED INCOME INVESTMENT FUND - REPORTED UNDER CNPJ 28.650.236/0001-92	0,00	16.235,02
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 50.821.045/0001-03
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	09	ETF QQQ - 28,70859	0,00	42.919,53
249 - United States				

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
Exchange-Traded: No

STATEMENTS OF ASSETS AND RIGHTS

(Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
TOTAL			1.760.076,04	2.101.137,59

ENCUMBRANCES AND REAL LIABILITIES

No Information

DONATIONS TO POLITICAL PARTIES AND CANDIDATES FOR ELECTIVE OFFICES

No Information

STATEMENT OF RURAL ACTIVITY - BRAZIL

IDENTIFICATION DATA OF THE EXPLORED PROPERTY - BRAZIL

No Information

INCOME AND EXPENSES - BRAZIL

No Information

CALCULATION OF THE RESULT - BRAZIL

No Information

LIVESTOCK ACTIVITY - BRAZIL

No Information

ASSETS OF RURAL ACTIVITY - BRAZIL

No Information

DEBTS RELATED TO RURAL ACTIVITY - BRAZIL

No Information

STATEMENT OF RURAL ACTIVITY - ABROAD

IDENTIFICATION DATA OF THE EXPLORED PROPERTY - ABROAD

No Information

INCOME AND EXPENSES - ABROAD

No Information

CALCULATION OF THE RESULT - ABROAD

No Information

LIVESTOCK ACTIVITY - ABROAD

No Information

ASSETS OF RURAL ACTIVITY - ABROAD

No Information

DEBTS RELATED TO RURAL ACTIVITY - ABROAD

No Information

STATEMENT OF CAPITAL GAINS CALCULATION

No Information

VARIABLE INCOME - COMMON OPERATIONS/DAY TRADE - TAXPAYER

NET GAINS OR LOSSES - JAN

No Information

NET GAINS OR LOSSES - FEB

No Information

NET GAINS OR LOSSES - MAR

No Information

NET GAINS OR LOSSES - APR

No Information

NET GAINS OR LOSSES - MAY

No Information

NET GAINS OR LOSSES - JUN

No Information

NET GAINS OR LOSSES - JUL

No Information

NET GAINS OR LOSSES - AUG

No Information

NET GAINS OR LOSSES - SEP

No Information

NET GAINS OR LOSSES - OCT

No Information

NET GAINS OR LOSSES - NOV

No Information

NET GAINS OR LOSSES - DEC

No Information

VARIABLE INCOME - COMMON OPERATIONS/DAY TRADE - DEPENDENTS

No Information

REAL ESTATE INVESTMENT FUNDS OR IN AGRO-INDUSTRIAL PRODUCTION CHAINS - TAXPAYER

No Information

REAL ESTATE INVESTMENT FUNDS OR IN AGRO-INDUSTRIAL PRODUCTION CHAINS - DEPENDENTS

No Information

DONATIONS DIRECTLY IN THE DECLARATION – ECA (STATUTE OF THE CHILD AND ADOLESCENT)

No Information

DONATIONS DIRECTLY IN THE DECLARATION - ELDERLY

No Information

SUMMARY — TAXATION USING THE LEGAL DEDUCTION

TAXABLE INCOME

Received from Legal Entity by the taxpayer	15.768,00
Received from Legal Entity by dependents	0,00
Received from Individual/Abroad by the taxpayer	2.045,00
Received from Individual/Abroad by Dependents	0,00
Received Cumulatively by the taxpayer	0,00
Received Cumulatively by dependents	0,00
Taxable Income from Rural Activity	0,00
TOTAL	17.813,00

DEDUCTIONS

Contributions to the official and closed complementary pension systems referred to in § 15 of Article 40 of the CF (Federal Constitution)/1988 (up to the sponsor limit)	1.734,48
Contribution to the official pension system (Income received cumulatively)	0,00
Contribution to the complementary pension system, including the amount for the closed systems referred to in Article 40, § 15, of the CF (Federal Constitution)/1988, which exceeds the sponsor's limit	0,00
Dependents	0,00
Education Expenses	0,00
Medical Expenses	9.564,29
Judicial Alimony	0,00
Alimony by Public Deed	0,00
Judicial Alimony (Income received cumulatively)	0,00
Cash book	0,00
TOTAL	11.298,77

TAX DUE

Tax Base	6.514,23
Tax Due	0,00
Incentive Deduction	0,00
Tax Due I	0,00
Tax Due RRA (on received accumulated income)	0,00
Effective Tax Rate (%)	0,00
Total Tax Due	0,00

TAX DUE

Tax Withheld at Source by the Taxpayer	0,00
Tax Withheld at Source by Dependents	0,00
Taxpayer's Carnê-Leão	0,00
Dependents' Carnê-Leão	0,00
Complementary Tax	0,00
Tax Paid Abroad	0,00
Tax Withheld at Source (Law No. 11.033/2004)	0,00
Tax Withheld RRA	0,00
Total Tax Paid	0,00

TAX TO BE REFUNDED	0,00
BALANCE OF TAX PAYABLE	0,00

INSTALLMENT PLAN

Installment Amount	0,00
Number of Installments	0

BANKING INFORMATION

Automatic debit: NO

Bank	
Branch (without verification digit)	
Account for credit	


ASSET EVOLUTION

Assets and Rights on 12/31/2022	1.760.076,04
Assets and Rights on 12/31/2023	2.101.137,59
Encumbrances and Real Liabilities on 12/31/2022	0,00
Encumbrances and Real Liabilities on 12/31/2023	0,00

OTHER INFORMATION

Exempt and non-taxable income	686.779,46
Income subject to exclusive/definitive taxation	74.744,03
Taxable income - tax with suspended liability	0,00
Judicial Deposits of Tax	0,00
Tax Paid on Capital Gains	0,00
Tax Paid on Capital Gains Foreign Currency - Assets, Rights, and Financial Investments	0,00
Total tax withheld at source (Law No. 11.033/2004), as per the data provided by the taxpayer	0,00
Tax Paid on Variable Income	0,00
Donations to Political Parties and Candidates for Elective Office	0,00
Tax Payable on Capital Gain - Foreign Currency in Cash	0,00
Deferred Tax on Capital Gains	0,00
Tax Due on Capital Gains	0,00
Tax Due on Net Income from Variable Income	0,00
Tax Due on Capital Gains in Foreign Currency - Assets, Rights, and Financial Investments	0,00

I, André Vinícius Inacio Penna Mello, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

NOME: MARCIO LAMAS LOPES
CPF: 287.868.388-90 **IMPOSTO SOBRE A RENDA - PESSOA FÍSICA**
DECLARAÇÃO DE AJUSTE ANUAL **EXERCÍCIO 2024** **ANO-CALENDÁRIO 2023**

IDENTIFICAÇÃO DO CONTRIBUINTE

Nome:	MARCIO LAMAS LOPES	CPF:	287.868.388-90
Data de Nascimento:	08/10/1981	Título Eleitoral:	252550780116
Possui cônjuge ou companheiro(a)?	Sim	CPF do cônjuge ou companheiro(a):	322.255.848-50

Era residente no exterior e passou a ser residente no Brasil em 2023? Não

Houve alteração de dados cadastrais? Não

Um dos declarantes é pessoa com doença grave ou portadora de deficiência física ou mental? Não

Endereço:	RUA TUIUTI	Número:	732
Complemento:	APT 172	Bairro/Distrito:	TATUAPE
Município:	SAO PAULO	UF:	SP
CEP:	03081-015	DDD/Telefone:	
E-mail:		DDD/Celular:	(11) 98409-6670

Natureza da Ocupação:	01 - Empregado de empresa do setor privado, exceto de instituições financeiras
Ocupação Principal:	225 - Médico
Registro profissional:	133420
Tipo de declaração:	Declaração de Ajuste Anual Original

Nº do recibo da última declaração entregue do exercício de 2023: 34.29.75.74.05-54

DEPENDENTES

Sem Informações

ALIMENTANDOS

Sem Informações

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELO TITULAR

(Valores em Reais)

NOME DA FONTE PAGADORA	REND. RECEBIDOS DE PES. JURÍDICA	CONTR. PREVID. OFICIAL	IMPOSTO RETIDO NA FONTE	13º SALÁRIO	IRRF SOBRE 13º SALÁRIO
ABC ENDOSCOPIA LTDA ME	15.768,00	1.734,48	0,00	0,00	0,00
CNPJ/CPF: 21.850.272/0001-50					
TOTAL	15.768,00	1.734,48	0,00	0,00	0,00

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELOS DEPENDENTES

Sem Informações

PROTEGIDA POR SIGILO FISCAL

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA FÍSICA E DO EXTERIOR PELO TITULAR

(Valores em Reais)

NIT/PIS/PASEP: 127.85666.89-7

	RENDIMENTOS			
	TRABALHO NÃO ASSALARIADO	ALUGUÉIS	OUTROS	EXTERIOR
JAN	825,00	0,00	0,00	0,00
FEV	350,00	0,00	0,00	0,00
MAR	870,00	0,00	0,00	0,00
ABR	0,00	0,00	0,00	0,00
MAI	0,00	0,00	0,00	0,00
JUN	0,00	0,00	0,00	0,00
JUL	0,00	0,00	0,00	0,00
AGO	0,00	0,00	0,00	0,00
SET	0,00	0,00	0,00	0,00
OUT	0,00	0,00	0,00	0,00
NOV	0,00	0,00	0,00	0,00
DEZ	0,00	0,00	0,00	0,00
TOTAL	2.045,00	0,00	0,00	0,00

	DEDUÇÕES				CARNÊ-LEÃO
	PREVIDÊNCIA OFICIAL	QUANTIDADE DE DEPENDENTES	PENSÃO ALIMENTÍCIA	LIVRO CAIXA	DARF PAGO CÓD. 0190
JAN	0,00	0	0,00	0,00	0,00
FEV	0,00	0	0,00	0,00	0,00
MAR	0,00	0	0,00	0,00	0,00
ABR	0,00	0	0,00	0,00	0,00
MAI	0,00	0	0,00	0,00	0,00
JUN	0,00	0	0,00	0,00	0,00
JUL	0,00	0	0,00	0,00	0,00
AGO	0,00	0	0,00	0,00	0,00
SET	0,00	0	0,00	0,00	0,00
OUT	0,00	0	0,00	0,00	0,00
NOV	0,00	0	0,00	0,00	0,00
DEZ	0,00	0	0,00	0,00	0,00
TOTAL	0,00		0,00	0,00	0,00

PROTEGIDA POR SIGILO FISCAL

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA FÍSICA E DO EXTERIOR PELOS DEPENDENTES

Sem Informações

RENDIMENTOS ISENTOS E NÃO TRIBUTÁVEIS

(Valores em Reais)

12. Rendimentos de cadernetas de poupança, letras hipotecárias, letras de crédito do agronegócio e imobiliário (LCA e LCI) e certificados de recebíveis do agronegócio e imobiliários (CRA e CRI) 62.355,22

Beneficiário	CPF	CNPJ da Fonte Pagadora	Nome da Fonte Pagadora	Valor
Titular	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	26.128,51
Titular	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	20.468,81
Titular	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	15.757,90

99. Outros 624.424,24

Beneficiário	CPF	CPF/CNPJ da Fonte Pagadora	Nome da Fonte Pagadora	Descrição	Valor
Titular	287.868.388-90	21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME	DISTRIBUICAO DE LUCROS	608.000,00
Titular	287.868.388-90	11.664.201/0001-00	FATOR VERITA FII	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	2.449,04
Titular	287.868.388-90	26.091.656/0001-50	OURINVEST JPP FUNDO DE INVESTIMENTO IMOBILIARIO	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	1.545,50
Titular	287.868.388-90	28.830.325/0001-10	FUNDO DE INVESTIMENTO IMOBILIARIO IRIDIUM RECEBIVEIS IMOBILI	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	681,32
Titular	287.868.388-90	40.011.251/0001-96	FUNDO DE INVESTIMENTO IMOBILIARIO DE CRI INTEGRAL BREI	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	111,00
Titular	287.868.388-90	35.754.164/0001-99	PATRIA LOGISTICA FUNDO DE INVESTIMENTO IMOBILIARIO	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	1.775,00
Titular	287.868.388-90	03.017.677/0001-20	FII JS REAL	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	619,38
Titular	287.868.388-90	62.285.390/0001-40	FIAGRO GLPG	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	9.243,00

PROTEGIDA POR SIGILO FISCAL

TOTAL 686.779,46

RENDIMENTOS SUJEITOS À TRIBUTAÇÃO EXCLUSIVA / DEFINITIVA

(Valores em Reais)

06. Rendimentos de aplicações financeiras 74.744,03

Beneficiário	CPF	CNPJ da Fonte Pagadora	Nome da Fonte Pagadora	Valor
Titular	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S.A CORRETORA DE TITULOS, CAMBIO E VALOR	66.709,18
Titular	287.868.388-90	90.400.888/0001-42	BANCO SANTANDER (BRASIL) SA	25,91
Titular	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	3.713,98
Titular	287.868.388-90	00.840.011/0001-80	BTG PACTUAL YIELD DI FI REF CP	11,78
Titular	287.868.388-90	17.162.002/0001-80	OCCAM RETORNO ABSOLUTO FIC FIM	208,95
Titular	287.868.388-90	29.826.089/0001-21	GIANT SIGMA FIC FIM	354,24
Titular	287.868.388-90	30.586.677/0001-14	LEGACY CAPITAL FIC FIM	2.373,59
Titular	287.868.388-90	42.887.856/0001-70	GALAPAGOS IGUANA FIRF LIQUIDEZ TOP CP	25,80
Titular	287.868.388-90	47.610.970/0001-72	GALAPAGOS ALBATROZ FIRF LP	23,12
Titular	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	252,42
Titular	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON REFERENCIADO DI	20,95
Titular	287.868.388-90	38.065.012/0001-77	CAPITANIA INFRA FUNDO DE INVESTIMENTO EM COTAS DE FUNDOS INC	502,00
Titular	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	427,43
Titular	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON FIRF REF DI	94,68

TOTAL 74.744,03

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELO TITULAR (IMPOSTO COM EXIGIBILIDADE SUSPENSA)

Sem Informações

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELOS DEPENDENTES (IMPOSTO COM EXIGIBILIDADE SUSPENSA)

Sem Informações

RENDIMENTOS TRIBUTÁVEIS DE PESSOA JURÍDICA RECEBIDOS ACUMULADAMENTE PELO TITULAR

Sem Informações

RENDIMENTOS TRIBUTÁVEIS DE PESSOA JURÍDICA RECEBIDOS ACUMULADAMENTE PELOS DEPENDENTES

Sem Informações

IMPOSTO PAGO / RETIDO

Sem Informações

PROTEGIDA POR SIGILO FISCAL

PAGAMENTOS EFETUADOS

(Valores em Reais)

CÓD.	NOME DO BENEFICIÁRIO	CPF/CNPJ DO BENEFICIÁRIO	VALOR PAGO	PARC. NÃO DEDUTÍVEL
Titular				
26	QUALICORP ADMINISTRADORA DE BENEFICIOS S.A.	07.658.098/0001-18	9.564,29	0,00

Descrição:

DOAÇÕES EFETUADAS

(Valores em Reais)

CÓD.	NOME DO BENEFICIÁRIO	CPF/CNPJ DO BENEFICIÁRIO	VALOR PAGO	PARC. NÃO DEDUTÍVEL
80	LILIAN DE OLINDA GIANNOCCARO	322.255.848-50	65.000,00	0,00

DECLARAÇÃO DE BENS E DIREITOS

(Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
01	11	50% DO - APT 172 - RUA TUIUTI, 732 , EM CONJUNTO COM LILIAN DE OLINDA GIANNOCCARO - CPF 322.255.848-50 - ADQ. EM AGOSTO DE 2017 - DE ITANGUA EMPREENDIMENTOS IMOB. LTDA - CNPJ 44.078.491-69 -FIN.PELO BANCO SANTANDER EM 12/2017. - VALORES PAGOS EM 2017 R$ 185.000,00 , SENDO R$ 164.772,50 -ITANGUA, R$ 7.177,50 JD IMOB. , R$ 5.220,00 IMOB. E R$ 7.830,00 CORRETOR- VALORES PAGOS EM 2018 R$ 263.268,56- SALDO DEVEDOR EM 31.12.2018 - R$ 53.986,28- QUITADO EM 2019 - PAGO R$ 27.709,08	475.977,64	495.977,64

105 - Brasil

Inscrição Municipal (IPTU): 06211014619

Logradouro: RUA TUIUTI
Nº: 732
Comp.: APT. 172
Bairro: TATUAPE
Município: SAO PAULO
UF: SP CEP: 03081-015
Área Total: 127,0 m²
Data de Aquisição: 23/07/2017
Registrado no Cartório: Sim
Nome Cartório: 9o CARTORIO DE REGISTRO DE IMOVEIS
Matrícula: 302629

02	01	UM VEICULO HONDA CITY 2016, ADQ EM 14/07/16 DE HONDA AUT.DO BRASIL LTDA , CNPJ 01.192.333/0001-22. VENDIDO AO SR. GUSTAVO JOAO, EM SET/23, PELO VALOR DE R$ 52.000,00.	69.174,79	0,00

105 - Brasil

RENAVAM: 01092987603

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
02	01	VEICULO SPIN LTZ 2019. ADQUIRIDO EM 22/01/2019 DE FELICIO VIGORITO E FILHO LTDA	81.510,00	81.510,00

105 - Brasil

RENAVAM: 00000104647

03	01	ACOES AMZN - 64,3719	0,00	34.006,99

249 - Estados Unidos

Trust ou entidade controlada no exterior cujos bens e direitos serão individualmente informados e detalhados nesta declaração, nos termos dos arts. 8º e 11 da Lei nº 14.754, de 2023: Não

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Negociados em Bolsa: Não

03	01	ACOES GOOGL - 7,6064	0,00	4.939,70

249 - Estados Unidos

Trust ou entidade controlada no exterior cujos bens e direitos serão individualmente informados e detalhados nesta declaração, nos termos dos arts. 8º e 11 da Lei nº 14.754, de 2023: Não

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Negociados em Bolsa: Não

03	01	ACOES MSFT - 16,69628	0,00	20.807,47

249 - Estados Unidos

Trust ou entidade controlada no exterior cujos bens e direitos serão individualmente informados e detalhados nesta declaração, nos termos dos arts. 8º e 11 da Lei nº 14.754, de 2023: Não

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Negociados em Bolsa: Não

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
03	02	QUOTAS DE CAPITAL DA EMPRESA ABC ENDOSCOPIA LTDA - CNPJ 21.850.272/0001-50 INICIO EM MARCO DE 2016	16.000,00	16.000,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 21.850.272/0001-50				
04	02	SANTANDER - APLICACAO RENDA FIXA	21.725,55	26.821,03
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 90.400.888/0001-42				
04	02	LC FACTA FINANCEIRA S/A CFI7 - RF (ATIVA)	21.535,44	28.283,17
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 15.581.638/0001-30				
04	02	CRI ISEC SECURITIZADORA - RF (ATIVA)	41.802,21	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 08.769.451/0001-08				
04	02	LC A VISTA ADMINISTRADORA DE CARTOES DE CREDITO - RF (ATIVA)	25.896,84	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 04.533.779/0001-61				

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	02	CDB BANCO MASTER - RF (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 33.886.862/0001-12	50.000,00	50.000,00
04	02	DRI OURINVEST SECURITIZADORA S/A - RF (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 12.320.349/0001-90	69.058,20	0,00
04	02	CRI RB CAPITAL SECUTIZADORA SA - RF (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 03.559.006/0001-91	53.930,28	0,00
04	02	COMPANHIA SECURITIZADORA DE CREDITOS FINANCEIROS VOLCANO II 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 39.615.622/0001-60	15.000,00	19.950,34
04	02	DEBENTURE SKYNSTORE 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 12.979.552/0001-72	15.000,00	11.505,21

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	02	DEBENTURE EDITORA SANAR	16.625,63	13.612,04
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 18.990.682/0001-92				
04	02	TITULOS PUBLICOS - LFT	50.024,38	50.024,38
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 33.775.974/0001-04				
04	02	DEBENTURE - LOG ENERGIA COMERCIALIZADORA S/A	0,00	5.552,68
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 15.042.149/0001-00				
04	03	ISEC SECURITIZADORA S.A (ATIVA)	21.584,90	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 08.769.451/0001-08				
04	03	RB SEC COMPANHIA DE SECURITIZACAO (ATIVA)	19.891,11	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 03.559.006/0001-91				

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	03	VERT COMPANHIA SECURITIZADORA (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 25.005.683/0001-09	19.454,77	0,00
04	03	CRI - VIRGO COMPANHIA DE SECURITIZACAO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	33.467,70	0,00
04	03	CRA - VORTX DTVM 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	61.357,00	0,00
04	03	RF - CRA PLANNER CV (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 00.806.535/0001-54	25.000,00	0,00
04	03	CRA VIRGO SEC (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	50.022,19	0,00

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	03	CRI HABITASEC (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 09.304.427/0001-58	26.494,38	0,00
04	03	CRA VORTIX (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	15.000,00	0,00
04	03	CRI VORTIX (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	12.000,00	0,00
04	03	CRA - GALAPAGOS 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 28.650.236/0001-92	0,00	260.550,08
04	03	CRI - GALAPAGOS 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 28.650.236/0001-92	0,00	371.835,46

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	99	TITULOS PUBLICOS - NTN	24.125,59	18.375,85

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 00.394.460/0409-50

04	99	NC PLASCAR (ATIVA)	15.922,73	10.268,45

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

04	99	FIDC ANGA MULTIESTRATEGIA	2.413,99	1.279,77

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.796.939/0001-23

04	99	FIDC SANTA CRUZ	0,00	5.005,02

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

05	01	EMPRESTIMO A LILIAN GIANNOCCARO.	0,00	50.000,00

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 32225584850

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
06	01	CONTA NO EXTERIOR - NOMAD	4.667,43	4.330,68

249 - Estados Unidos

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não
Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Agência: Conta:

06	10	DINHEIRO EM ESPECIE	112.000,00	150.000,00

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

06	99	SALDO CONTA CORRENTE ATIVA INVESTIMENTOS	24.756,02	3.943,35

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 33.775.974/0001-04

06	99	SALDO CONTA CORRENTE GALAPAGOS INVESTIMENTOS	0,00	2.633,67

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

07	01	ARX ELBRUS DEB INC FIM CP - FUNDO (ATIVA)	32.900,00	32.900,00

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ do Fundo: 30.910.199/0001-56

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
07	01	GIANT VISIA SIGMA FIC FIM - FUNDO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 29.826.089/0001-21	19.590,37	19.944,61
07	01	LEGACY CAPITAL FC FI MULT - FUNDO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 30.586.677/0001-14	34.049,13	36.422,72
07	01	OCCAM RETORNO ABSOLUTO FIC FIM - FUNDO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 17.162.002/0001-80	22.833,47	23.042,42
07	01	GALAPAGOS IGUANA - FUNDO (ATIVA) - 0,00 EM 2023 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 42.887.856/0001-70	2.541,17	0,00
07	03	COTAS FII - IBCR11 (10 A 96,25) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 59.281.253/0001-23 Negociados em Bolsa: Não	962,50	962,50

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
07	03	COTAS FII - OUJP11 (110 A R$ 92,00) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 26.091.656/0001-50 Negociados em Bolsa: Não	10.120,00	10.120,00
07	03	COTAS FII - JSRE11 (111 A R$ 109,30) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 13.371.132/0001-71 Negociados em Bolsa: Não	12.132,30	12.132,30
07	03	COTAS FII - VRTA11 (242 A R$ 105,2956) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 11.664.201/0001-00 Negociados em Bolsa: Não	25.481,54	25.481,54
07	03	COTAS FII - PATL11 (250 A R$ 100,00) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 35.754.164/0001-99 Negociados em Bolsa: Não	25.000,00	25.000,00
07	03	COTAS FII - IRDM11 (67 A R$ 108,97) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 59.281.253/0001-23 Negociados em Bolsa: Não	7.300,99	7.300,99

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
07	03	COTAS FII - GCRA11 - GALAPAGOS RECEBIVEIS DO AGRONEGOCIO FIAGRO (780 A R$ 97,11) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 62.285.390/0001-40 Negociados em Bolsa: Sim Código de Negociação: GCRA11	75.745,80	75.745,80
07	03	COTAS FII - CPTI11 (251 A 99,75) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 38.065.012/0001-77 Negociados em Bolsa: Sim Código de Negociação: CPTI11	0,00	25.037,25
07	06	GALAPAGOS BLUE OCEAN FI EM COTAS DE FUNDOS DE INVESTIMENTO MULTIMERCADO - INFORMADO POR CNPJ 28.650.236/0001-92 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 49.450.009/0001-93 Negociados em Bolsa: Não	0,00	10.679,93
07	06	GALAPAGOS PINZON FUNDO DE INVESTIMENTO RENDA FIXA REFERENCIADO DI - INFORMADO POR CNPJ 28.650.236/0001-92 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 50.821.045/0001-03 Negociados em Bolsa: Não	0,00	16.235,02
07	09	ETF QQQ - 28,70859 249 - Estados Unidos Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 Negociados em Bolsa: Não	0,00	42.919,53

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS

(Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
TOTAL			1.760.076,04	2.101.137,59

DÍVIDAS E ÔNUS REAIS

Sem Informações

DOAÇÕES A PARTIDOS POLÍTICOS E CANDIDATOS A CARGOS ELETIVOS

Sem Informações

PROTEGIDA POR SIGILO FISCAL

DEMONSTRATIVO DE ATIVIDADE RURAL - BRASIL

DADOS E IDENTIFICAÇÃO DO IMÓVEL EXPLORADO - BRASIL

Sem Informações

RECEITAS E DESPESAS - BRASIL

Sem Informações

APURAÇÃO DO RESULTADO - BRASIL

Sem Informações

MOVIMENTAÇÃO DO REBANHO - BRASIL

Sem Informações

BENS DA ATIVIDADE RURAL - BRASIL

Sem Informações

DÍVIDAS VINCULADAS À ATIVIDADE RURAL - BRASIL

Sem Informações

PROTEGIDA POR SIGILO FISCAL

DEMONSTRATIVO DE ATIVIDADE RURAL - EXTERIOR

DADOS E IDENTIFICAÇÃO DO IMÓVEL EXPLORADO - EXTERIOR

Sem Informações

RECEITAS E DESPESAS - EXTERIOR

Sem Informações

APURAÇÃO DO RESULTADO - EXTERIOR

Sem Informações

MOVIMENTAÇÃO DO REBANHO - EXTERIOR

Sem Informações

BENS DA ATIVIDADE RURAL - EXTERIOR

Sem Informações

DÍVIDAS VINCULADAS À ATIVIDADE RURAL - EXTERIOR

Sem Informações

DEMONSTRATIVO DA APURAÇÃO DOS GANHOS DE CAPITAL

Sem Informações

PROTEGIDA POR SIGILO FISCAL

RENDA VARIÁVEL - OPERAÇÕES COMUNS/DAYTRADE - TITULAR

GANHOS LÍQUIDOS OU PERDAS - JAN

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - FEV

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - MAR

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - ABR

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - MAI

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - JUN

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - JUL

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - AGO

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - SET

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - OUT

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - NOV

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - DEZ

Sem Informações

RENDA VARIÁVEL - OPERAÇÕES COMUNS/DAYTRADE - DEPENDENTES

Sem Informações

FUNDOS DE INVESTIMENTO IMOBILIÁRIO OU NAS CADEIAS PRODUTIVAS AGROINDUSTRIAIS - TITULAR

Sem Informações

FUNDOS DE INVESTIMENTO IMOBILIÁRIO OU NAS CADEIAS PRODUTIVAS AGROINDUSTRIAIS - DEPENDENTES

Sem Informações

DOAÇÕES DIRETAMENTE NA DECLARAÇÃO - ECA

Sem Informações

DOAÇÕES DIRETAMENTE NA DECLARAÇÃO - IDOSO

Sem Informações

PROTEGIDA POR SIGILO FISCAL

RESUMO — TRIBUTAÇÃO UTILIZANDO AS DEDUÇÕES LEGAIS

RENDIMENTOS TRIBUTÁVEIS

Recebidos de Pessoa Jurídica pelo titular	15.768,00
Recebidos de Pessoa Jurídica pelos dependentes	0,00
Recebidos de Pessoa Física/Exterior pelo titular	2.045,00
Recebidos de Pessoa Física/Exterior pelos dependentes	0,00
Recebidos acumuladamente pelo titular	0,00
Recebidos acumuladamente pelos dependentes	0,00
Resultado tributável da Atividade Rural	0,00
TOTAL	17.813,00

DEDUÇÕES

Contribuições às previdências oficial e complementar fechada de que trata o § 15 do art. 40 da CF/1988 (até o limite do patrocinador)	1.734,48
Contribuição à previdência oficial (Rendimentos recebidos acumuladamente)	0,00
Contribuição à prev. complementar, inclusive o valor para as fechadas de que trata o § 15 do art. 40 da CF/1988 que exceder o limite do patrocinador	0,00
Dependentes	0,00
Despesas com instrução	0,00
Despesas médicas	9.564,29
Pensão alimentícia judicial	0,00
Pensão alimentícia por escritura pública	0,00
Pensão alimentícia judicial (Rendimentos recebidos acumuladamente)	0,00
Livro caixa	0,00
TOTAL	11.298,77

IMPOSTO DEVIDO

Base de cálculo do imposto	6.514,23
Imposto devido	0,00
Dedução de incentivo	0,00
Imposto devido I	0,00
Imposto devido RRA	0,00
Aliquota efetiva (%)	0,00
Total do imposto devido	0,00

IMPOSTO PAGO

Imposto retido na fonte do titular	0,00
Imp. retido na fonte dos dependentes	0,00
Carnê-Leão do titular	0,00
Carnê-Leão dos dependentes	0,00
Imposto complementar	0,00
Imposto pago no exterior	0,00
Imposto retido na fonte (Lei nº 11.033/2004)	0,00
Imposto retido RRA	0,00
Total do imposto pago	0,00

IMPOSTO A RESTITUIR	0,00
SALDO DE IMPOSTO A PAGAR	0,00

PARCELAMENTO

Valor da quota	0,00
Número de Quotas	0

INFORMAÇÕES BANCÁRIAS

Débito automático: NÃO

Banco	
Agência (sem DV)	
Conta para crédito	

PROTEGIDA POR SIGILO FISCAL

EVOLUÇÃO PATRIMONIAL

Bens e direitos em 31/12/2022	1.760.076,04
Bens e direitos em 31/12/2023	2.101.137,59
Dívidas e ônus reais em 31/12/2022	0,00
Dívidas e ônus reais em 31/12/2023	0,00

OUTRAS INFORMAÇÕES

Rendimentos isentos e não tributáveis	686.779,46
Rendimentos sujeitos à tributação exclusiva/definitiva	74.744,03
Rendimentos tributáveis - imposto com exigibilidade suspensa	0,00
Depósitos judiciais do imposto	0,00
Imposto pago sobre Ganhos de Capital	0,00
Imposto pago Ganhos de Capital Moeda Estrangeira - Bens, direitos e Aplicações Financeiras	0,00
Total do imposto retido na fonte (Lei nº11.033/2004), conforme dados informados pelo contribuinte	0,00
Imposto pago sobre Renda Variável	0,00
Doações a Partidos Políticos e Candidatos a Cargos Eletivos	0,00
Imposto a pagar sobre o Ganho de Capital - Moeda Estrangeira em Espécie	0,00
Imposto diferido dos Ganhos de Capital	0,00
Imposto devido sobre Ganhos de Capital	0,00
Imposto devido sobre ganhos líquidos em Renda Variável	0,00
Imposto devido sobre Ganhos de Capital Moeda Estrangeira - Bens, direitos e aplic. financeiras	0,00

PROTEGIDA POR SIGILO FISCAL

NAME: MARCIO LAMAS LOPES CPF: 287.868.388-90

INCOME TAX - INDIVIDUAL

ANNUAL ADJUSTMENT DECLARATION **TAX YEAR 2024** **CALENDAR YEAR 2023**

TAXPAYER IDENTIFICATION

Name:	MARCIO LAMAS LOPES	CPF:	287.868.388-90
Date of Birth:	10/08/1981	Voter ID:	252550780116
Do you have a spouse or partner?	Yes	CPF of the Spouse or partner:	322.255.848-50

Were you a resident abroad and became a resident in Brazil in 2023? No

Were there any changes to the registration details? No

Is one of the declarants a person with a serious illness or a physical or mental disability? No

Address:	RUA TUIUTI	Number:	732
Unit:	APT 172	Neighborhood/District:	TATUAPE
City:	SAO PAULO	State:	SP
ZIP Code:	03081-015	Area Code/Telephone:	
E-mail:		Area Code/Mobile:	(11) 98409-6670

Occupation Type:	01 - Employee of a private sector company, except financial institutions
Main Occupation:	225 - Physician
Professional registration:	133420
Type of Declaration:	Original Annual Adjustment Declaration

Receipt Number of the last declaration filed in the 2023 tax year: 34.29.75.74.05-54

DEPENDENTS

No Information

ALIMONY RECIPIENTS

No Information

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY THE TAXPAYER

(Values in Reais)

NAME OF THE PAYING SOURCE	INCOME RECEIVED FROM LEGAL ENTITY	OFFICIAL SOCIAL SECURITY CONTRIBUTION	WITHHELD TAX	13th SALARY	INCOME TAX WITHHELD ON 13th SALARY
ABC ENDOSCOPIA LTDA ME	15.768,00	1.734,48	0,00	0,00	0,00
CNPJ/CPF: 21.850.272/0001-50					
TOTAL	15.768,00	1.734,48	0,00	0,00	0,00

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY DEPENDENTS

No Information

NAME: MARCIO LAMAS LOPES CPF: 287.868.388-90 **INCOME TAX - INDIVIDUAL**

ANNUAL ADJUSTMENT DECLARATION **TAX YEAR 2024** **CALENDAR YEAR 2023**

TAXABLE INCOME RECEIVED FROM INDIVIDUALS AND ABROAD BY THE TAXPAYER (Values in Reais)

NIT/PIS/PASEP*: 127.85666.89-7

INCOMES

	NON-SALARIED WORK	RENTALS	OTHERS	ABROAD
JAN	825,00	0,00	0,00	0,00
FEB	350,00	0,00	0,00	0,00
MAR	870,00	0,00	0,00	0,00
APR	0,00	0,00	0,00	0,00
MAY	0,00	0,00	0,00	0,00
JUN	0,00	0,00	0,00	0,00
JUL	0,00	0,00	0,00	0,00
AUG	0,00	0,00	0,00	0,00
SEP	0,00	0,00	0,00	0,00
OCT	0,00	0,00	0,00	0,00
NOV	0,00	0,00	0,00	0,00
DEC	0,00	0,00	0,00	0,00
TOTAL	2.045,00	0,00	0,00	0,00

DEDUCTIONS — CARNÊ-LEÃO*

	OFFICIAL PENSION	NUMBER OF DEPENDENTS	ALIMONY	CASH BOOK	PAID DARF* CODE 0190
JAN	0,00	0	0,00	0,00	0,00
FEB	0,00	0	0,00	0,00	0,00
MAR	0,00	0	0,00	0,00	0,00
APR	0,00	0	0,00	0,00	0,00
MAY	0,00	0	0,00	0,00	0,00
JUN	0,00	0	0,00	0,00	0,00
JUL	0,00	0	0,00	0,00	0,00
AUG	0,00	0	0,00	0,00	0,00
SEP	0,00	0	0,00	0,00	0,00
OCT	0,00	0	0,00	0,00	0,00
NOV	0,00	0	0,00	0,00	0,00
DEC	0,00	0	0,00	0,00	0,00
TOTAL	0,00		0,00	0,00	0,00

* NIT - Worker's Identification Number

* PIS - Program for Social Integration

* PASEP - Public Servant's Property Formation Program

* CARNÊ-LEÃO - Income tax that must be paid monthly, mandatorily, by individuals residing in Brazil who receive income from another individual or from abroad

* DARF - Tax Payment Document

TAXABLE INCOME RECEIVED FROM INDIVIDUALS AND ABROAD BY DEPENDENTS

No Information

EXEMPT AND NON-TAXABLE INCOME

(Values in Reais)

12. Income from savings accounts, mortgage bonds, agribusiness, and real estate letters of credit (LCA and LCI), and certificates of agribusiness and real estate receivables (CRA and CRI) 62.355,22

Beneficiary	CPF	CNPJ of the Paying Source	Name of the Paying Source	Amount
Taxpayer	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	26.128,51
Taxpayer	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	20.468,81
Taxpayer	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	15.757,90

99. Others 624.424,24

Beneficiary	CPF	CPF/CNPJ of the Paying Source	Name of the Paying Source	Description	Amount
Taxpayer	287.868.388-90	21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME	PROFIT DISTRIBUTION	608.000,00
Taxpayer	287.868.388-90	11.664.201/0001-00	FATOR VERITA FII	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	2.449,04
Taxpayer	287.868.388-90	26.091.656/0001-50	OURINVEST JPP FUNDO DE INVESTIMENTO IMOBILIARIO	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	1.545,50
Taxpayer	287.868.388-90	28.830.325/0001-10	FUNDO DE INVESTIMENTO IMOBILIARIO IRIDIUM RECEBIVEIS IMOBILI	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	681,32
Taxpayer	287.868.388-90	40.011.251/0001-96	FUNDO DE INVESTIMENTO IMOBILIARIO DE CRI INTEGRAL BREI	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	111,00
Taxpayer	287.868.388-90	35.754.164/0001-99	PATRIA LOGISTICA FUNDO DE INVESTIMENTO IMOBILIARIO	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	1.775,00
Taxpayer	287.868.388-90	03.017.677/0001-20	FII JS REAL	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	619,38
Taxpayer	287.868.388-90	62.285.390/0001-40	FIAGRO GLPG	FINANCIAL INVESTMENTS IN REAL ESTATE INVESTMENT FUNDS	9.243,00

TOTAL 686.779,46

INCOME SUBJECT TO EXCLUSIVE/DEFINITIVE TAXATION

(Values in Reais)

06. Income from financial investments 74.744,03

Beneficiary	CPF	CNPJ of the Paying Source	Name of the Paying Source	Amount
Taxpayer	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S.A CORRETORA DE TITULOS, CAMBIO E VALOR	66.709,18
Taxpayer	287.868.388-90	90.400.888/0001-42	BANCO SANTANDER (BRASIL) SA	25,91
Taxpayer	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	3.713,98
Taxpayer	287.868.388-90	00.840.011/0001-80	BTG PACTUAL YIELD DI FI REF CP	11,78
Taxpayer	287.868.388-90	17.162.002/0001-80	OCCAM RETORNO ABSOLUTO FIC FIM	208,95
Taxpayer	287.868.388-90	29.826.089/0001-21	GIANT SIGMA FIC FIM	354,24
Taxpayer	287.868.388-90	30.586.677/0001-14	LEGACY CAPITAL FIC FIM	2.373,59
Taxpayer	287.868.388-90	42.887.856/0001-70	GALAPAGOS IGUANA FIRF LIQUIDEZ TOP CP	25,80
Taxpayer	287.868.388-90	47.610.970/0001-72	GALAPAGOS ALBATROZ FIRF LP	23,12
Taxpayer	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	252,42
Taxpayer	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON REFERENCIADO DI	20,95
Taxpayer	287.868.388-90	38.065.012/0001-77	CAPITANIA INFRA FUNDO DE INVESTIMENTO EM COTAS DE FUNDOS INC	502,00
Taxpayer	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	427,43
Taxpayer	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON FIRF REF DI	94,68

TOTAL 74.744,03

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY THE TAXPAYER (TAX WITH SUSPENDED EXIGIBILITY)

No Information

TAXABLE INCOME RECEIVED FROM LEGAL ENTITY BY THE DEPENDENTS (TAX WITH SUSPENDED EXIGIBILITY)

No Information

TAXABLE INCOME FROM LEGAL ENTITY RECEIVED CUMULATIVELY BY THE TAXPAYER

No Information

TAXABLE INCOME FROM LEGAL ENTITY RECEIVED CUMULATIVELY BY THE DEPENDENTS

No Information

TAX PAID / WITHHELD

No Information

PAYMENTS MADE

(Values in Reais)

CODE	BENEFICIARY NAME	BENEFICIARY CPF/CNPJ	AMOUNT PAID	NON-DEDUCTIBLE PORTION
Taxpayer				
26	QUALICORP ADMINISTRADORA DE BENEFICIOS S.A.	07.658.098/0001-18	9.564,29	0,00

Description:

DONATIONS MADE

(Values in Reais)

CODE	BENEFICIARY NAME	BENEFICIARY CPF/CNPJ	AMOUNT PAID	NON-DEDUCTIBLE PORTION
80	LILIAN DE OLINDA GIANNOCCARO	322.255.848-50	65.000,00	0,00

STATEMENTS OF ASSETS AND RIGHTS

(Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
01	11	50% OF - APT 172 - RUA TUIUTI, 732, JOINTLY WITH LILIAN DE OLINDA GIANNOCCARO - CPF 322.255.848-50 - ACQUIRED IN AUGUST 2017 – FROM ITANGUA EMPREENDIMENTOS IMOB. LTDA - CNPJ 44.078.491-69 -FINANCED.BY BANCO SANTANDER IN 12/2017. – AMOUNTS PAID IN 2017 R$ 185.000,00 , OF WHICH R$ 164.772,50 -ITANGUA, R$ 7.177,50 REAL ESTATE BROKER FEE. , R$ 5.220,00 REAL ESTATE AGENCY AND R$ 7.830,00 BROKER FEE- AMOUNTS PAID IN 2018 R$ 263.268,56- OUTSTANDING BALANCE ON 12.31.2018 - R$ 53.986,28- PAID OFF IN 2019 - PAID R$ 27.709,08	475.977,64	495.977,64

105 - Brazil

Municipal Registration (IPTU): 06211014619

Address: RUA TUIUTI
No.: 732
Unit: APT. 172
Neighborhood: TATUAPE
City: SAO PAULO
State: SP ZIP Code: 03081-015
Total Area: 127,0 m²
Acquisition Date: 07/23/2017
Registered at the Notary Office: Yes
Name of the Registry office: 9th REAL ESTATE REGISTRY OFFICE
Registration: 302629

02	01	HONDA CITY 2016 VEHICLE, ACQUIRED ON 07/14/16 FROM HONDA AUT.DO BRASIL LTDA , CNPJ 01.192.333/0001-22. SOLD TO MR. GUSTAVO JOAO, IN SEP/23, BY THE AMOUNT OF R$ 52.000,00.	69.174,79	0,00

105 - Brazil

RENAVAM (National Registry of Motor Vehicles): 01092987603

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
02	01	SPIN LTZ 2019 VEHICLE. ACQUIRED ON 01/22/2019 FROM FELICIO VIGORITO E FILHO LTDA	81.510,00	81.510,00

105 - Brazil

RENAVAM: 00000104647

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
03	01	AMZN SHARES - 64,3719	0,00	34.006,99

249 - United States

Trust or foreign-controlled entity whose assets and rights will be individually reported and detailed in this declaration, in accordance with Articles 8 and 11 of Law No. 14,754, of 2023: No

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
03	01	GOOGL SHARES - 7,6064	0,00	4.939,70

249 - United States

Trust or foreign-controlled entity whose assets and rights will be individually reported and detailed in this declaration, in accordance with Articles 8 and 11 of Law No. 14,754, of 2023: No

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
03	01	MSFT SHARES - 16,69628	0,00	20.807,47

249 - United States

Trust or foreign-controlled entity whose assets and rights will be individually reported and detailed in this declaration, in accordance with Articles 8 and 11 of Law No. 14,754, of 2023: No

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Exchange-Traded: No

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023	
03	02	CAPITAL SHARES OF ABC ENDOSCOPIA LTDA - CNPJ 21.850.272/0001-50 STARTED IN MARCH 2016	16.000,00	16.000,00	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 21.850.272/0001-50					
04	02	SANTANDER - FIXED INCOME INVESTMENT	21.725,55	26.821,03	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 90.400.888/0001-42					
04	02	LC (Letter of Credits) FACTA FINANCEIRA S/A CFI7 - FIXED INCOME (ACTIVE)	28.283,17	21.535,44	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 15.581.638/0001-30					
04	02	CRI (certificates of real estate receivables) ISEC SECURITIZADORA - FIXED INCOME (ACTIVE)		41.802,21	0,00
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 08.769.451/0001-08					
04	02	LC SIGHT CREDIT CARD ADMINISTRATOR - FIXED INCOME (ACTIVE)	25.896,84	0,00	
105 - Brazil					
Asset or right belonging to:		Taxpayer	CPF: 287.868.388-90		
CNPJ: 04.533.779/0001-61					

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	CDB (Certificate of Deposit) BANCO MASTER - FIXED INCOME (ACTIVE)	50.000,00	50.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 33.886.862/0001-12

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DRI OURINVEST SECURITIZADORA S/A - FIXED INCOME (ACTIVE)	69.058,20	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 12.320.349/0001-90

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	CRI RB CAPITAL SECUTIZADORA SA - FIXED INCOME (ACTIVE)	53.930,28	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 03.559.006/0001-91

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	COMPANHIA SECURITIZADORA DE CREDITOS FINANCEIROS VOLCANO II	15.000,00	19.950,34

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 39.615.622/0001-60

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DEBENTURE SKYNSTORE	15.000,00	11.505,21

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 12.979.552/0001-72

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DEBENTURE EDITORA SANAR	16.625,63	13.612,04

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 18.990.682/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	GOVERNMENT BONDS - LFT (Treasury Financial Bills)	50.024,38	50.024,38

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 33.775.974/0001-04

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	02	DEBENTURE - LOG ENERGIA COMERCIALIZADORA S/A	0,00	5.552,68

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 15.042.149/0001-00

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	ISEC SECURITIZADORA S.A (ACTIVE)	21.584,90	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 08.769.451/0001-08

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	RB SEC SECURITIZATION COMPANY (ACTIVE)	19.891,11	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 03.559.006/0001-91

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	VERT SECURITIZATION COMPANY (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 25.005.683/0001-09	19.454,77	0,00
04	03	CRI - SECURITIZATION COMPANY (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	33.467,70	0,00
04	03	CRA (certificates of agribusiness receivables) - VORTX DTVM 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	61.357,00	0,00
04	03	RF - CRA PLANNER CV (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 00.806.535/0001-54	25.000,00	0,00
04	03	CRA VIRGO SEC (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	50.022,19	0,00

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRI HABITASEC (ACTIVE)	26.494,38	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 09.304.427/0001-58

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRA VORTIX (ACTIVE)	15.000,00	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 22.610.500/0001-88

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRI VORTIX (ACTIVE)	12.000,00	0,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 22.610.500/0001-88

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRA - GALAPAGOS	0,00	260.550,08

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	03	CRI - GALAPAGOS	0,00	371.835,46

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	GOVERNMENT BONDS - NTN (National Treasury Notes)	24.125,59	18.375,85

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 00.394.460/0409-50

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	NC PLASCAR (ACTIVE)	15.922,73	10.268,45

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	FIDC (Receivables Investment Fund) ANGA MULTIESTRATEGIA	2.413,99	1.279,77

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.796.939/0001-23

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
04	99	FIDC SANTA CRUZ	0,00	5.005,02

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
05	01	LOAN TO LILIAN GIANNOCCARO.	0,00	50.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ: 32225584850

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	01	OVERSEAS ACCOUNT - NOMAD	4.667,43	4.330,68

249 - United States

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

Branch: Account:

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	10	CASH	112.000,00	150.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	99	ACTIVE CHECKING ACCOUNT BALANCE - INVESTMENTS	24.756,02	3.943,35

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

CNPJ: 33.775.974/0001-04

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
06	99	GALAPAGOS INVESTMENTS CHECKING ACCOUNT BALANCE	0,00	2.633,67

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

CNPJ: 28.650.236/0001-92

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	01	ARX ELBRUS DEB INC FIM CP - FUND (ACTIVE)	32.900,00	32.900,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90

CNPJ Fund: 30.910.199/0001-56

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	01	GIANT VISIA SIGMA FIC FIM - FUND (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 29.826.089/0001-21	19.590,37	19.944,61
07	01	LEGACY CAPITAL FC FI MULT - FUND (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 30.586.677/0001-14	34.049,13	36.422,72
07	01	OCCAM ABSOLUTE RETURN FIC FIM - FUND (ACTIVE) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 17.162.002/0001-80	22.833,47	23.042,42
07	01	GALAPAGOS IGUANA - FUND (ACTIVE) - 0,00 IN 2023 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 42.887.856/0001-70	2.541,17	0,00
07	03	REAL ESTATE INVESTMENT FUND SHARE - IBCR11 (10 TO 96,25) 105 - Brazil Asset or right belonging to: Taxpayer CPF: 287.868.388-90 CNPJ Fund: 59.281.253/0001-23 Exchange-Traded: No	962,50	962,50

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - OUJP11 (110 TO R$ 92,00)	10.120,00	10.120,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 26.091.656/0001-50
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - JSRE11 (111 TO R$ 109,30)	12.132,30	12.132,30

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 13.371.132/0001-71
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - VRTA11 (242 TO R$ 105,2956)	25.481,54	25.481,54

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 11.664.201/0001-00
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - PATL11 (250 TO R$ 100,00)	25.000,00	25.000,00

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 35.754.164/0001-99
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - IRDM11 (67 A R$ 108,97)	7.300,99	7.300,99

105 - Brazil

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 59.281.253/0001-23
Exchange-Traded: No

STATEMENTS OF ASSETS AND RIGHTS (Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - GCRA11 - GALAPAGOS AGRIBUSINESS RECEIVABLES AGRONEGOCIO FIAGRO (780 TO R$ 97,11)	75.745,80	75.745,80
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 62.285.390/0001-40
Exchange-Traded: Yes Trading Code: GCRA11

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	03	REAL ESTATE INVESTMENT FUND SHARE - CPTI11 (251 TO 99,75)	0,00	25.037,25
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 38.065.012/0001-77
Exchange-Traded: Yes Trading Code: CPTI11

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	06	GALAPAGOS BLUE OCEAN INVESTMENT FUND IN MULTISTRATEGY INVESTMENT FUND SHARES - REPORTED UNDER CNPJ 28.650.236/0001-92	0,00	10.679,93
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 49.450.009/0001-93
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	06	GALAPAGOS PINZON DI-REFERENCED FIXED INCOME INVESTMENT FUND - REPORTED UNDER CNPJ 28.650.236/0001-92	0,00	16.235,02
105 - Brazil				

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
CNPJ Fund: 50.821.045/0001-03
Exchange-Traded: No

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
07	09	ETF QQQ - 28,70859	0,00	42.919,53
249 - United States				

Option to update the value of the asset or right abroad to its market value as of 12/31/2023, in accordance with Article 14 of Law No. 14,754, of 2023: No

Asset or right belonging to: Taxpayer CPF: 287.868.388-90
Exchange-Traded: No

STATEMENTS OF ASSETS AND RIGHTS

(Values in Reais)

GROUP	CODE	DISCLOSURE	STATUS ON 12/31/2022	STATUS ON 12/31/2023
TOTAL			1.760.076,04	2.101.137,59

ENCUMBRANCES AND REAL LIABILITIES

No Information

DONATIONS TO POLITICAL PARTIES AND CANDIDATES FOR ELECTIVE OFFICES

No Information

STATEMENT OF RURAL ACTIVITY - BRAZIL

IDENTIFICATION DATA OF THE EXPLORED PROPERTY - BRAZIL

No Information

INCOME AND EXPENSES - BRAZIL

No Information

CALCULATION OF THE RESULT - BRAZIL

No Information

LIVESTOCK ACTIVITY - BRAZIL

No Information

ASSETS OF RURAL ACTIVITY - BRAZIL

No Information

DEBTS RELATED TO RURAL ACTIVITY - BRAZIL

No Information

STATEMENT OF RURAL ACTIVITY - ABROAD

IDENTIFICATION DATA OF THE EXPLORED PROPERTY - ABROAD

No Information

INCOME AND EXPENSES - ABROAD

No Information

CALCULATION OF THE RESULT - ABROAD

No Information

LIVESTOCK ACTIVITY - ABROAD

No Information

ASSETS OF RURAL ACTIVITY - ABROAD

No Information

DEBTS RELATED TO RURAL ACTIVITY - ABROAD

No Information

STATEMENT OF CAPITAL GAINS CALCULATION

No Information

VARIABLE INCOME - COMMON OPERATIONS/DAY TRADE - TAXPAYER

NET GAINS OR LOSSES - JAN

No Information

NET GAINS OR LOSSES - FEB

No Information

NET GAINS OR LOSSES - MAR

No Information

NET GAINS OR LOSSES - APR

No Information

NET GAINS OR LOSSES - MAY

No Information

NET GAINS OR LOSSES - JUN

No Information

NET GAINS OR LOSSES - JUL

No Information

NET GAINS OR LOSSES - AUG

No Information

NET GAINS OR LOSSES - SEP

No Information

NET GAINS OR LOSSES - OCT

No Information

NET GAINS OR LOSSES - NOV

No Information

NET GAINS OR LOSSES - DEC

No Information

VARIABLE INCOME - COMMON OPERATIONS/DAY TRADE - DEPENDENTS

No Information

REAL ESTATE INVESTMENT FUNDS OR IN AGRO-INDUSTRIAL PRODUCTION CHAINS - TAXPAYER

No Information

REAL ESTATE INVESTMENT FUNDS OR IN AGRO-INDUSTRIAL PRODUCTION CHAINS - DEPENDENTS

No Information

DONATIONS DIRECTLY IN THE DECLARATION – ECA (STATUTE OF THE CHILD AND ADOLESCENT)

No Information

DONATIONS DIRECTLY IN THE DECLARATION - ELDERLY

No Information

SUMMARY — TAXATION USING THE LEGAL DEDUCTION

TAXABLE INCOME

Received from Legal Entity by the taxpayer	15.768,00
Received from Legal Entity by dependents	0,00
Received from Individual/Abroad by the taxpayer	2.045,00
Received from Individual/Abroad by Dependents	0,00
Received Cumulatively by the taxpayer	0,00
Received Cumulatively by dependents	0,00
Taxable Income from Rural Activity	0,00
TOTAL	17.813,00

DEDUCTIONS

Contributions to the official and closed complementary pension systems referred to in § 15 of Article 40 of the CF (Federal Constitution)/1988 (up to the sponsor limit)	1.734,48
Contribution to the official pension system (Income received cumulatively)	0,00
Contribution to the complementary pension system, including the amount for the closed systems referred to in Article 40, § 15, of the CF (Federal Constitution)/1988, which exceeds the sponsor's limit	0,00
Dependents	0,00
Education Expenses	0,00
Medical Expenses	9.564,29
Judicial Alimony	0,00
Alimony by Public Deed	0,00
Judicial Alimony (Income received cumulatively)	0,00
Cash book	0,00
TOTAL	11.298,77

TAX DUE

Tax Base	6.514,23
Tax Due	0,00
Incentive Deduction	0,00
Tax Due I	0,00
Tax Due RRA (on received accumulated income)	0,00
Effective Tax Rate (%)	0,00
Total Tax Due	0,00

TAX DUE

Tax Withheld at Source by the Taxpayer	0,00
Tax Withheld at Source by Dependents	0,00
Taxpayer's Carnê-Leão	0,00
Dependents' Carnê-Leão	0,00
Complementary Tax	0,00
Tax Paid Abroad	0,00
Tax Withheld at Source (Law No. 11.033/2004)	0,00
Tax Withheld RRA	0,00
Total Tax Paid	0,00

TAX TO BE REFUNDED	0,00
BALANCE OF TAX PAYABLE	0,00

INSTALLMENT PLAN

Installment Amount	0,00
Number of Installments	0

BANKING INFORMATION

Automatic debit: NO

Bank	
Branch (without verification digit)	
Account for credit	


ASSET EVOLUTION

Assets and Rights on 12/31/2022	1.760.076,04
Assets and Rights on 12/31/2023	2.101.137,59
Encumbrances and Real Liabilities on 12/31/2022	0,00
Encumbrances and Real Liabilities on 12/31/2023	0,00

OTHER INFORMATION

Exempt and non-taxable income	686.779,46
Income subject to exclusive/definitive taxation	74.744,03
Taxable income - tax with suspended liability	0,00
Judicial Deposits of Tax	0,00
Tax Paid on Capital Gains	0,00
Tax Paid on Capital Gains Foreign Currency - Assets, Rights, and Financial Investments	0,00
Total tax withheld at source (Law No. 11.033/2004), as per the data provided by the taxpayer	0,00
Tax Paid on Variable Income	0,00
Donations to Political Parties and Candidates for Elective Office	0,00
Tax Payable on Capital Gain - Foreign Currency in Cash	0,00
Deferred Tax on Capital Gains	0,00
Tax Due on Capital Gains	0,00
Tax Due on Net Income from Variable Income	0,00
Tax Due on Capital Gains in Foreign Currency - Assets, Rights, and Financial Investments	0,00

I, André Vinícius Inacio Penna Mello, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

NOME: MARCIO LAMAS LOPES
CPF: 287.868.388-90 **IMPOSTO SOBRE A RENDA - PESSOA FÍSICA**
DECLARAÇÃO DE AJUSTE ANUAL **EXERCÍCIO 2024** **ANO-CALENDÁRIO 2023**

IDENTIFICAÇÃO DO CONTRIBUINTE

Nome:	MARCIO LAMAS LOPES	CPF:	287.868.388-90
Data de Nascimento:	08/10/1981	Título Eleitoral:	252550780116
Possui cônjuge ou companheiro(a)?	Sim	CPF do cônjuge ou companheiro(a):	322.255.848-50

Era residente no exterior e passou a ser residente no Brasil em 2023? Não

Houve alteração de dados cadastrais? Não

Um dos declarantes é pessoa com doença grave ou portadora de deficiência física ou mental? Não

Endereço:	RUA TUIUTI	Número:	732
Complemento:	APT 172	Bairro/Distrito:	TATUAPE
Município:	SAO PAULO	UF:	SP
CEP:	03081-015	DDD/Telefone:	
E-mail:		DDD/Celular:	(11) 98409-6670

Natureza da Ocupação:	01 - Empregado de empresa do setor privado, exceto de instituições financeiras
Ocupação Principal:	225 - Médico
Registro profissional:	133420
Tipo de declaração:	Declaração de Ajuste Anual Original

Nº do recibo da última declaração entregue do exercício de 2023: 34.29.75.74.05-54

DEPENDENTES

Sem Informações

ALIMENTANDOS

Sem Informações

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELO TITULAR

(Valores em Reais)

NOME DA FONTE PAGADORA	REND. RECEBIDOS DE PES. JURÍDICA	CONTR. PREVID. OFICIAL	IMPOSTO RETIDO NA FONTE	13º SALÁRIO	IRRF SOBRE 13º SALÁRIO
ABC ENDOSCOPIA LTDA ME	15.768,00	1.734,48	0,00	0,00	0,00
CNPJ/CPF: 21.850.272/0001-50					
TOTAL	15.768,00	1.734,48	0,00	0,00	0,00

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELOS DEPENDENTES

Sem Informações

PROTEGIDA POR SIGILO FISCAL

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA FÍSICA E DO EXTERIOR PELO TITULAR

(Valores em Reais)

NIT/PIS/PASEP: 127.85666.89-7

	RENDIMENTOS			
	TRABALHO NÃO ASSALARIADO	ALUGUÉIS	OUTROS	EXTERIOR
JAN	825,00	0,00	0,00	0,00
FEV	350,00	0,00	0,00	0,00
MAR	870,00	0,00	0,00	0,00
ABR	0,00	0,00	0,00	0,00
MAI	0,00	0,00	0,00	0,00
JUN	0,00	0,00	0,00	0,00
JUL	0,00	0,00	0,00	0,00
AGO	0,00	0,00	0,00	0,00
SET	0,00	0,00	0,00	0,00
OUT	0,00	0,00	0,00	0,00
NOV	0,00	0,00	0,00	0,00
DEZ	0,00	0,00	0,00	0,00
TOTAL	2.045,00	0,00	0,00	0,00

	DEDUÇÕES				CARNÊ-LEÃO
	PREVIDÊNCIA OFICIAL	QUANTIDADE DE DEPENDENTES	PENSÃO ALIMENTÍCIA	LIVRO CAIXA	DARF PAGO CÓD. 0190
JAN	0,00	0	0,00	0,00	0,00
FEV	0,00	0	0,00	0,00	0,00
MAR	0,00	0	0,00	0,00	0,00
ABR	0,00	0	0,00	0,00	0,00
MAI	0,00	0	0,00	0,00	0,00
JUN	0,00	0	0,00	0,00	0,00
JUL	0,00	0	0,00	0,00	0,00
AGO	0,00	0	0,00	0,00	0,00
SET	0,00	0	0,00	0,00	0,00
OUT	0,00	0	0,00	0,00	0,00
NOV	0,00	0	0,00	0,00	0,00
DEZ	0,00	0	0,00	0,00	0,00
TOTAL	0,00		0,00	0,00	0,00

PROTEGIDA POR SIGILO FISCAL

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA FÍSICA E DO EXTERIOR PELOS DEPENDENTES

Sem Informações

RENDIMENTOS ISENTOS E NÃO TRIBUTÁVEIS

(Valores em Reais)

12. Rendimentos de cadernetas de poupança, letras hipotecárias, letras de crédito do agronegócio e imobiliário (LCA e LCI) e certificados de recebíveis do agronegócio e imobiliários (CRA e CRI) 62.355,22

Beneficiário	CPF	CNPJ da Fonte Pagadora	Nome da Fonte Pagadora	Valor
Titular	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	26.128,51
Titular	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S/A CORRETORA DE TITULOS, CAMBIO E VALOR	20.468,81
Titular	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	15.757,90

99. Outros 624.424,24

Beneficiário	CPF	CPF/CNPJ da Fonte Pagadora	Nome da Fonte Pagadora	Descrição	Valor
Titular	287.868.388-90	21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME	DISTRIBUICAO DE LUCROS	608.000,00
Titular	287.868.388-90	11.664.201/0001-00	FATOR VERITA FII	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	2.449,04
Titular	287.868.388-90	26.091.656/0001-50	OURINVEST JPP FUNDO DE INVESTIMENTO IMOBILIARIO	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	1.545,50
Titular	287.868.388-90	28.830.325/0001-10	FUNDO DE INVESTIMENTO IMOBILIARIO IRIDIUM RECEBIVEIS IMOBILI	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	681,32
Titular	287.868.388-90	40.011.251/0001-96	FUNDO DE INVESTIMENTO IMOBILIARIO DE CRI INTEGRAL BREI	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	111,00
Titular	287.868.388-90	35.754.164/0001-99	PATRIA LOGISTICA FUNDO DE INVESTIMENTO IMOBILIARIO	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	1.775,00
Titular	287.868.388-90	03.017.677/0001-20	FII JS REAL	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	619,38
Titular	287.868.388-90	62.285.390/0001-40	FIAGRO GLPG	APLICACOES FINANCEIRAS EM FUNDOS DE INVESTIMENTO IMOBILIARIO	9.243,00

PROTEGIDA POR SIGILO FISCAL

TOTAL 686.779,46

RENDIMENTOS SUJEITOS À TRIBUTAÇÃO EXCLUSIVA / DEFINITIVA

(Valores em Reais)

06. Rendimentos de aplicações financeiras 74.744,03

Beneficiário	CPF	CNPJ da Fonte Pagadora	Nome da Fonte Pagadora	Valor
Titular	287.868.388-90	33.775.974/0001-04	ATIVA INVESTIMENTOS S.A CORRETORA DE TITULOS, CAMBIO E VALOR	66.709,18
Titular	287.868.388-90	90.400.888/0001-42	BANCO SANTANDER (BRASIL) SA	25,91
Titular	287.868.388-90	28.650.236/0001-92	GALAPAGOS CAPITAL DISTRIBUIDORA DE TITULOS E VALORES MOBILIA	3.713,98
Titular	287.868.388-90	00.840.011/0001-80	BTG PACTUAL YIELD DI FI REF CP	11,78
Titular	287.868.388-90	17.162.002/0001-80	OCCAM RETORNO ABSOLUTO FIC FIM	208,95
Titular	287.868.388-90	29.826.089/0001-21	GIANT SIGMA FIC FIM	354,24
Titular	287.868.388-90	30.586.677/0001-14	LEGACY CAPITAL FIC FIM	2.373,59
Titular	287.868.388-90	42.887.856/0001-70	GALAPAGOS IGUANA FIRF LIQUIDEZ TOP CP	25,80
Titular	287.868.388-90	47.610.970/0001-72	GALAPAGOS ALBATROZ FIRF LP	23,12
Titular	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	252,42
Titular	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON REFERENCIADO DI	20,95
Titular	287.868.388-90	38.065.012/0001-77	CAPITANIA INFRA FUNDO DE INVESTIMENTO EM COTAS DE FUNDOS INC	502,00
Titular	287.868.388-90	49.450.009/0001-93	GALAPAGOS BLUE OCEAN FIC FIM	427,43
Titular	287.868.388-90	50.821.045/0001-03	GALAPAGOS PINZON FIRF REF DI	94,68

TOTAL 74.744,03

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELO TITULAR (IMPOSTO COM EXIGIBILIDADE SUSPENSA)

Sem Informações

RENDIMENTOS TRIBUTÁVEIS RECEBIDOS DE PESSOA JURÍDICA PELOS DEPENDENTES (IMPOSTO COM EXIGIBILIDADE SUSPENSA)

Sem Informações

RENDIMENTOS TRIBUTÁVEIS DE PESSOA JURÍDICA RECEBIDOS ACUMULADAMENTE PELO TITULAR

Sem Informações

RENDIMENTOS TRIBUTÁVEIS DE PESSOA JURÍDICA RECEBIDOS ACUMULADAMENTE PELOS DEPENDENTES

Sem Informações

IMPOSTO PAGO / RETIDO

Sem Informações

PROTEGIDA POR SIGILO FISCAL

PAGAMENTOS EFETUADOS

(Valores em Reais)

CÓD.	NOME DO BENEFICIÁRIO	CPF/CNPJ DO BENEFICIÁRIO	VALOR PAGO	PARC. NÃO DEDUTÍVEL
Titular				
26	QUALICORP ADMINISTRADORA DE BENEFICIOS S.A.	07.658.098/0001-18	9.564,29	0,00

Descrição:

DOAÇÕES EFETUADAS

(Valores em Reais)

CÓD.	NOME DO BENEFICIÁRIO	CPF/CNPJ DO BENEFICIÁRIO	VALOR PAGO	PARC. NÃO DEDUTÍVEL
80	LILIAN DE OLINDA GIANNOCCARO	322.255.848-50	65.000,00	0,00

DECLARAÇÃO DE BENS E DIREITOS

(Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
01	11	50% DO - APT 172 - RUA TUIUTI, 732 , EM CONJUNTO COM LILIAN DE OLINDA GIANNOCCARO - CPF 322.255.848-50 - ADQ. EM AGOSTO DE 2017 - DE ITANGUA EMPREENDIMENTOS IMOB. LTDA - CNPJ 44.078.491-69 -FIN.PELO BANCO SANTANDER EM 12/2017. - VALORES PAGOS EM 2017 R$ 185.000,00 , SENDO R$ 164.772,50 -ITANGUA, R$ 7.177,50 JD IMOB. , R$ 5.220,00 IMOB. E R$ 7.830,00 CORRETOR- VALORES PAGOS EM 2018 R$ 263.268,56- SALDO DEVEDOR EM 31.12.2018 - R$ 53.986,28- QUITADO EM 2019 - PAGO R$ 27.709,08	475.977,64	495.977,64

105 - Brasil

Inscrição Municipal (IPTU): 06211014619

Logradouro: RUA TUIUTI
Nº: 732
Comp.: APT. 172
Bairro: TATUAPE
Município: SAO PAULO
UF: SP CEP: 03081-015
Área Total: 127,0 m²
Data de Aquisição: 23/07/2017
Registrado no Cartório: Sim
Nome Cartório: 9o CARTORIO DE REGISTRO DE IMOVEIS
Matrícula: 302629

02	01	UM VEICULO HONDA CITY 2016, ADQ EM 14/07/16 DE HONDA AUT.DO BRASIL LTDA , CNPJ 01.192.333/0001-22. VENDIDO AO SR. GUSTAVO JOAO, EM SET/23, PELO VALOR DE R$ 52.000,00.	69.174,79	0,00

105 - Brasil

RENAVAM: 01092987603

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
02	01	VEICULO SPIN LTZ 2019. ADQUIRIDO EM 22/01/2019 DE FELICIO VIGORITO E FILHO LTDA	81.510,00	81.510,00

105 - Brasil

RENAVAM: 00000104647

03	01	ACOES AMZN - 64,3719	0,00	34.006,99

249 - Estados Unidos

Trust ou entidade controlada no exterior cujos bens e direitos serão individualmente informados e detalhados nesta declaração, nos termos dos arts. 8º e 11 da Lei nº 14.754, de 2023: Não

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Negociados em Bolsa: Não

03	01	ACOES GOOGL - 7,6064	0,00	4.939,70

249 - Estados Unidos

Trust ou entidade controlada no exterior cujos bens e direitos serão individualmente informados e detalhados nesta declaração, nos termos dos arts. 8º e 11 da Lei nº 14.754, de 2023: Não

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Negociados em Bolsa: Não

03	01	ACOES MSFT - 16,69628	0,00	20.807,47

249 - Estados Unidos

Trust ou entidade controlada no exterior cujos bens e direitos serão individualmente informados e detalhados nesta declaração, nos termos dos arts. 8º e 11 da Lei nº 14.754, de 2023: Não

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Negociados em Bolsa: Não

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
03	02	QUOTAS DE CAPITAL DA EMPRESA ABC ENDOSCOPIA LTDA - CNPJ 21.850.272/0001-50 INICIO EM MARCO DE 2016	16.000,00	16.000,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 21.850.272/0001-50				
04	02	SANTANDER - APLICACAO RENDA FIXA	21.725,55	26.821,03
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 90.400.888/0001-42				
04	02	LC FACTA FINANCEIRA S/A CFI7 - RF (ATIVA)	21.535,44	28.283,17
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 15.581.638/0001-30				
04	02	CRI ISEC SECURITIZADORA - RF (ATIVA)	41.802,21	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 08.769.451/0001-08				
04	02	LC A VISTA ADMINISTRADORA DE CARTOES DE CREDITO - RF (ATIVA)	25.896,84	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 04.533.779/0001-61				

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	02	CDB BANCO MASTER - RF (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 33.886.862/0001-12	50.000,00	50.000,00
04	02	DRI OURINVEST SECURITIZADORA S/A - RF (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 12.320.349/0001-90	69.058,20	0,00
04	02	CRI RB CAPITAL SECUTIZADORA SA - RF (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 03.559.006/0001-91	53.930,28	0,00
04	02	COMPANHIA SECURITIZADORA DE CREDITOS FINANCEIROS VOLCANO II 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 39.615.622/0001-60	15.000,00	19.950,34
04	02	DEBENTURE SKYNSTORE 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 12.979.552/0001-72	15.000,00	11.505,21

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	02	DEBENTURE EDITORA SANAR	16.625,63	13.612,04
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 18.990.682/0001-92				
04	02	TITULOS PUBLICOS - LFT	50.024,38	50.024,38
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 33.775.974/0001-04				
04	02	DEBENTURE - LOG ENERGIA COMERCIALIZADORA S/A	0,00	5.552,68
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 15.042.149/0001-00				
04	03	ISEC SECURITIZADORA S.A (ATIVA)	21.584,90	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 08.769.451/0001-08				
04	03	RB SEC COMPANHIA DE SECURITIZACAO (ATIVA)	19.891,11	0,00
105 - Brasil				
Bem ou direito pertencente ao: Titular		CPF: 287.868.388-90		
CNPJ: 03.559.006/0001-91				

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	03	VERT COMPANHIA SECURITIZADORA (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 25.005.683/0001-09	19.454,77	0,00
04	03	CRI - VIRGO COMPANHIA DE SECURITIZACAO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	33.467,70	0,00
04	03	CRA - VORTX DTVM 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	61.357,00	0,00
04	03	RF - CRA PLANNER CV (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 00.806.535/0001-54	25.000,00	0,00
04	03	CRA VIRGO SEC (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 08.769.451/0001-08	50.022,19	0,00

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	03	CRI HABITASEC (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 09.304.427/0001-58	26.494,38	0,00
04	03	CRA VORTIX (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	15.000,00	0,00
04	03	CRI VORTIX (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 22.610.500/0001-88	12.000,00	0,00
04	03	CRA - GALAPAGOS 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 28.650.236/0001-92	0,00	260.550,08
04	03	CRI - GALAPAGOS 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ: 28.650.236/0001-92	0,00	371.835,46

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
04	99	TITULOS PUBLICOS - NTN	24.125,59	18.375,85

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 00.394.460/0409-50

04	99	NC PLASCAR (ATIVA)	15.922,73	10.268,45

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

04	99	FIDC ANGA MULTIESTRATEGIA	2.413,99	1.279,77

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.796.939/0001-23

04	99	FIDC SANTA CRUZ	0,00	5.005,02

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

05	01	EMPRESTIMO A LILIAN GIANNOCCARO.	0,00	50.000,00

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 32225584850

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
06	01	CONTA NO EXTERIOR - NOMAD	4.667,43	4.330,68

249 - Estados Unidos

Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não
Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

Agência: Conta:

06	10	DINHEIRO EM ESPECIE	112.000,00	150.000,00

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90

06	99	SALDO CONTA CORRENTE ATIVA INVESTIMENTOS	24.756,02	3.943,35

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 33.775.974/0001-04

06	99	SALDO CONTA CORRENTE GALAPAGOS INVESTIMENTOS	0,00	2.633,67

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ: 28.650.236/0001-92

07	01	ARX ELBRUS DEB INC FIM CP - FUNDO (ATIVA)	32.900,00	32.900,00

105 - Brasil

Bem ou direito pertencente ao: Titular CPF: 287.868.388-90
CNPJ do Fundo: 30.910.199/0001-56

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
07	01	GIANT VISIA SIGMA FIC FIM - FUNDO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 29.826.089/0001-21	19.590,37	19.944,61
07	01	LEGACY CAPITAL FC FI MULT - FUNDO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 30.586.677/0001-14	34.049,13	36.422,72
07	01	OCCAM RETORNO ABSOLUTO FIC FIM - FUNDO (ATIVA) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 17.162.002/0001-80	22.833,47	23.042,42
07	01	GALAPAGOS IGUANA - FUNDO (ATIVA) - 0,00 EM 2023 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 42.887.856/0001-70	2.541,17	0,00
07	03	COTAS FII - IBCR11 (10 A 96,25) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 59.281.253/0001-23 Negociados em Bolsa: Não	962,50	962,50

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
07	03	COTAS FII - OUJP11 (110 A R$ 92,00) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 26.091.656/0001-50 Negociados em Bolsa: Não	10.120,00	10.120,00
07	03	COTAS FII - JSRE11 (111 A R$ 109,30) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 13.371.132/0001-71 Negociados em Bolsa: Não	12.132,30	12.132,30
07	03	COTAS FII - VRTA11 (242 A R$ 105,2956) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 11.664.201/0001-00 Negociados em Bolsa: Não	25.481,54	25.481,54
07	03	COTAS FII - PATL11 (250 A R$ 100,00) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 35.754.164/0001-99 Negociados em Bolsa: Não	25.000,00	25.000,00
07	03	COTAS FII - IRDM11 (67 A R$ 108,97) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 59.281.253/0001-23 Negociados em Bolsa: Não	7.300,99	7.300,99

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS (Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
07	03	COTAS FII - GCRA11 - GALAPAGOS RECEBIVEIS DO AGRONEGOCIO FIAGRO (780 A R$ 97,11) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 62.285.390/0001-40 Negociados em Bolsa: Sim Código de Negociação: GCRA11	75.745,80	75.745,80
07	03	COTAS FII - CPTI11 (251 A 99,75) 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 38.065.012/0001-77 Negociados em Bolsa: Sim Código de Negociação: CPTI11	0,00	25.037,25
07	06	GALAPAGOS BLUE OCEAN FI EM COTAS DE FUNDOS DE INVESTIMENTO MULTIMERCADO - INFORMADO POR CNPJ 28.650.236/0001-92 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 49.450.009/0001-93 Negociados em Bolsa: Não	0,00	10.679,93
07	06	GALAPAGOS PINZON FUNDO DE INVESTIMENTO RENDA FIXA REFERENCIADO DI - INFORMADO POR CNPJ 28.650.236/0001-92 105 - Brasil Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 CNPJ do Fundo: 50.821.045/0001-03 Negociados em Bolsa: Não	0,00	16.235,02
07	09	ETF QQQ - 28,70859 249 - Estados Unidos Opção pela atualização do valor do bem ou direito no exterior para o valor de mercado em 31/12/2023, nos termos do art. 14 da Lei nº 14.754, de 2023: Não Bem ou direito pertencente ao: Titular CPF: 287.868.388-90 Negociados em Bolsa: Não	0,00	42.919,53

PROTEGIDA POR SIGILO FISCAL

DECLARAÇÃO DE BENS E DIREITOS

(Valores em Reais)

GRUPO	CÓDIGO	DISCRIMINAÇÃO	SITUAÇÃO EM 31/12/2022	SITUAÇÃO EM 31/12/2023
TOTAL			1.760.076,04	2.101.137,59

DÍVIDAS E ÔNUS REAIS

Sem Informações

DOAÇÕES A PARTIDOS POLÍTICOS E CANDIDATOS A CARGOS ELETIVOS

Sem Informações

PROTEGIDA POR SIGILO FISCAL

DEMONSTRATIVO DE ATIVIDADE RURAL - BRASIL

DADOS E IDENTIFICAÇÃO DO IMÓVEL EXPLORADO - BRASIL

Sem Informações

RECEITAS E DESPESAS - BRASIL

Sem Informações

APURAÇÃO DO RESULTADO - BRASIL

Sem Informações

MOVIMENTAÇÃO DO REBANHO - BRASIL

Sem Informações

BENS DA ATIVIDADE RURAL - BRASIL

Sem Informações

DÍVIDAS VINCULADAS À ATIVIDADE RURAL - BRASIL

Sem Informações

PROTEGIDA POR SIGILO FISCAL

DEMONSTRATIVO DE ATIVIDADE RURAL - EXTERIOR

DADOS E IDENTIFICAÇÃO DO IMÓVEL EXPLORADO - EXTERIOR

Sem Informações

RECEITAS E DESPESAS - EXTERIOR

Sem Informações

APURAÇÃO DO RESULTADO - EXTERIOR

Sem Informações

MOVIMENTAÇÃO DO REBANHO - EXTERIOR

Sem Informações

BENS DA ATIVIDADE RURAL - EXTERIOR

Sem Informações

DÍVIDAS VINCULADAS À ATIVIDADE RURAL - EXTERIOR

Sem Informações

DEMONSTRATIVO DA APURAÇÃO DOS GANHOS DE CAPITAL

Sem Informações

PROTEGIDA POR SIGILO FISCAL

RENDA VARIÁVEL - OPERAÇÕES COMUNS/DAYTRADE - TITULAR

GANHOS LÍQUIDOS OU PERDAS - JAN

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - FEV

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - MAR

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - ABR

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - MAI

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - JUN

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - JUL

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - AGO

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - SET

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - OUT

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - NOV

Sem Informações

GANHOS LÍQUIDOS OU PERDAS - DEZ

Sem Informações

RENDA VARIÁVEL - OPERAÇÕES COMUNS/DAYTRADE - DEPENDENTES

Sem Informações

FUNDOS DE INVESTIMENTO IMOBILIÁRIO OU NAS CADEIAS PRODUTIVAS AGROINDUSTRIAIS - TITULAR

Sem Informações

FUNDOS DE INVESTIMENTO IMOBILIÁRIO OU NAS CADEIAS PRODUTIVAS AGROINDUSTRIAIS - DEPENDENTES

Sem Informações

DOAÇÕES DIRETAMENTE NA DECLARAÇÃO - ECA

Sem Informações

DOAÇÕES DIRETAMENTE NA DECLARAÇÃO - IDOSO

Sem Informações

PROTEGIDA POR SIGILO FISCAL

RESUMO — TRIBUTAÇÃO UTILIZANDO AS DEDUÇÕES LEGAIS

RENDIMENTOS TRIBUTÁVEIS

Recebidos de Pessoa Jurídica pelo titular	15.768,00
Recebidos de Pessoa Jurídica pelos dependentes	0,00
Recebidos de Pessoa Física/Exterior pelo titular	2.045,00
Recebidos de Pessoa Física/Exterior pelos dependentes	0,00
Recebidos acumuladamente pelo titular	0,00
Recebidos acumuladamente pelos dependentes	0,00
Resultado tributável da Atividade Rural	0,00
TOTAL	17.813,00

DEDUÇÕES

Contribuições às previdências oficial e complementar fechada de que trata o § 15 do art. 40 da CF/1988 (até o limite do patrocinador)	1.734,48
Contribuição à previdência oficial (Rendimentos recebidos acumuladamente)	0,00
Contribuição à prev. complementar, inclusive o valor para as fechadas de que trata o § 15 do art. 40 da CF/1988 que exceder o limite do patrocinador	0,00
Dependentes	0,00
Despesas com instrução	0,00
Despesas médicas	9.564,29
Pensão alimentícia judicial	0,00
Pensão alimentícia por escritura pública	0,00
Pensão alimentícia judicial (Rendimentos recebidos acumuladamente)	0,00
Livro caixa	0,00
TOTAL	11.298,77

IMPOSTO DEVIDO

Base de cálculo do imposto	6.514,23
Imposto devido	0,00
Dedução de incentivo	0,00
Imposto devido I	0,00
Imposto devido RRA	0,00
Aliquota efetiva (%)	0,00
Total do imposto devido	0,00

IMPOSTO PAGO

Imposto retido na fonte do titular	0,00
Imp. retido na fonte dos dependentes	0,00
Carnê-Leão do titular	0,00
Carnê-Leão dos dependentes	0,00
Imposto complementar	0,00
Imposto pago no exterior	0,00
Imposto retido na fonte (Lei nº 11.033/2004)	0,00
Imposto retido RRA	0,00
Total do imposto pago	0,00

IMPOSTO A RESTITUIR	0,00
SALDO DE IMPOSTO A PAGAR	0,00

PARCELAMENTO

Valor da quota	0,00
Número de Quotas	0

INFORMAÇÕES BANCÁRIAS

Débito automático: NÃO

Banco	
Agência (sem DV)	
Conta para crédito	

PROTEGIDA POR SIGILO FISCAL

EVOLUÇÃO PATRIMONIAL

Bens e direitos em 31/12/2022	1.760.076,04
Bens e direitos em 31/12/2023	2.101.137,59
Dívidas e ônus reais em 31/12/2022	0,00
Dívidas e ônus reais em 31/12/2023	0,00

OUTRAS INFORMAÇÕES

Rendimentos isentos e não tributáveis	686.779,46
Rendimentos sujeitos à tributação exclusiva/definitiva	74.744,03
Rendimentos tributáveis - imposto com exigibilidade suspensa	0,00
Depósitos judiciais do imposto	0,00
Imposto pago sobre Ganhos de Capital	0,00
Imposto pago Ganhos de Capital Moeda Estrangeira - Bens, direitos e Aplicações Financeiras	0,00
Total do imposto retido na fonte (Lei nº11.033/2004), conforme dados informados pelo contribuinte	0,00
Imposto pago sobre Renda Variável	0,00
Doações a Partidos Políticos e Candidatos a Cargos Eletivos	0,00
Imposto a pagar sobre o Ganho de Capital - Moeda Estrangeira em Espécie	0,00
Imposto diferido dos Ganhos de Capital	0,00
Imposto devido sobre Ganhos de Capital	0,00
Imposto devido sobre ganhos líquidos em Renda Variável	0,00
Imposto devido sobre Ganhos de Capital Moeda Estrangeira - Bens, direitos e aplic. financeiras	0,00

PROTEGIDA POR SIGILO FISCAL

MINISTRY OF ECONOMY
Special Secretariat of the Federal Revenue of Brazil
Income Tax - Individual
Tax Year 2023

Certificate of Income Paid and Income Tax Withheld at Source

Calendar Year 2022

Check the conditions and deadlines for filing the Individual Income Tax Return for this calendar year on the website of the Special Secretariat of the Federal Revenue of Brazil on the Internet, at <https://www.gov.br/receitafederal/pt-br>.

1. Legal Entity Paying Source

CNPJ	Corporate Name
21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME

2. Individual Beneficiary of Income

CPF	Full Name
287.868.388-90	MARCIO LAMAS LOPES

Nature of Income
Salaried employment income

3. Taxable Income, Deductions and Income Tax Withheld at Source

	Values in Reais
1. Total income (including vacation pay)	14.544,00
2. Official social security contribution	1.599,84
3. Contributions to supplementary pension entities, public or private, and to individual programmed retirement funds (Fapi) (also complete section 7)	0,00
4. Alimony (also complete section 7)	0,00
5. Income tax withheld at source	0,00

4. Exempt and Non-Taxable Income

	Values in Reais
1. Exempt portion of retirement, paid reserve, reform and pension benefits (age 65 or older), except the exempt portion of the 13th (thirteenth) salary	0,00
2. Exempt portion of the 13th salary of retirement, paid reserve, reform and pension (age 65 or older)	0,00
3. Daily allowances and cost-of-living assistance	0,00
4. Pension and retirement or reform benefits due to serious illness; retirement or reform benefits due to on-the-job accident	0,00
5. Profits and dividends, calculated from 1996 onwards, paid by a legal entity (actual, presumed or arbitrated profit)	390.200,00
6. Amounts paid to the owner or partner of a micro-enterprise or small business, except pro labore, rent or services rendered	0,00
7. Severance pay upon termination of employment contract, including voluntary separation programs (PDV) and workplace accident compensation	0,00
8. Late payment interest received, due to delayed payment of compensation for employment, office or function	0,00
9. Others:	0,00

5. Income Subject to Exclusive Taxation (net income)

	Values in Reais
1. Thirteenth salary	0,00
2. Income tax withheld at source on 13th salary	0,00
3. Other	0,00

6. Accumulated Income Received - Art. 12-A of Law No. 7,713, of 1988 (subject to exclusive taxation)

6.1 Case number:	Number of months	0,0
Nature of income:		

	Values in Reais
1. Total taxable income (including vacation pay and thirteenth salary)	0,00
2. Exclusion: Legal action expenses	0,00
3. Deduction: Official social security contribution	0,00
4. Deduction: Alimony (also complete section 7)	0,00
5. Income tax withheld at source (IRRF)	0,00
6. Exempt income from pension, retirement or reform benefits due to serious illness or retirement or reform due to on-the-job accident	0,00

7. Supplementary Information

MINISTRY OF ECONOMY Special Secretariat of the Federal Revenue of Brazil Income Tax - Individual Tax Year 2023	Certificate of Income Paid and Income Tax Withheld at Source Calendar Year 2022

8. Person Responsible for the Information

Name	Date	Signature
NELSON GAZA	04/06/2023	

Approved by RFB Normative Instruction No. 2,060, of December 13, 2021.

I, André Vinícius Inacio Penna Mello, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

MINISTÉRIO DA ECONOMIA
Secretaria Especial da Receita Federal do Brasil
Imposto sobre a Renda da Pessoa Física
Exercício de 2023

Comprovante de Rendimentos Pagos e de Imposto sobre a Renda Retido na Fonte

Ano-calendário de 2022

Verifique as condições e o prazo para a apresentação da Declaração do Imposto sobre a Renda da Pessoa Física para este ano-calendário no sítio da Secretaria Especial da Receita Federal do Brasil na Internet, no endereço <https://www.gov.br/receitafederal/pt-br>.

1. Fonte Pagadora Pessoa Jurídica

CNPJ	Nome Empresarial
21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME

2. Pessoa Física Beneficiária dos Rendimentos

CPF	Nome Completo
287.868.388-90	MARCIO LAMAS LOPES

Natureza do Rendimento
Rendimentos do trabalho assalariado

3. Rendimentos Tributáveis, Deduções e Imposto sobre a Renda Retido da Fonte

	Valores em reais
1. Total dos rendimentos (inclusive férias)	14.544,00
2. Contribuição previdenciária oficial	1.599,84
3. Contribuição a entidades de previdência complementar, pública ou privada, e a fundos de aposentadoria programada individual (Fapi)(preencher também o quadro 7)	0,00
4. Pensão alimentícia (preencher também o quadro 7)	0,00
5. Imposto sobre a renda retido na fonte	0,00

4. Rendimentos Isentos e Não Tributáveis

	Valores em reais
1. Parcela isenta dos proventos de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais), exceto a parcela isenta do 13º (décimo terceiro) salário	0,00
2. Parcela isenta do 13º salário de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais)	0,00
3. Diárias e ajuda de custo	0,00
4. Pensão e proventos de aposentadoria ou reforma por moléstia grave; proventos de aposentadoria ou reforma por acidente em serviço	0,00
5. Lucros e dividendos, apurados a partir de 1996, pagos por pessoa jurídica (lucro real, presumido ou arbitrado)	390.200,00
6. Valores pagos ao titular ou sócio da microempresa ou empresa de pequeno porte, exceto pro labore, aluguéis ou serviços prestados	0,00
7. Indenizações por rescisão de contrato de trabalho, inclusive a título de PDV e por acidente de trabalho	0,00
8. Juros de mora recebidos, devidos pelo atraso no pagamento de remuneração por exercício de emprego, cargo ou função	0,00
9. Outros:	0,00

5. Rendimentos Sujeitos à Tributação Exclusiva (rendimento líquido)

	Valores em reais
1. Décimo terceiro salário	0,00
2. Imposto sobre a renda retido na fonte sobre 13º salário	0,00
3. Outros	0,00

6. Rendimentos Recebidos Acumuladamente - Art. 12-A da Lei nº 7.713, de 1988 (sujeitos à tributação exclusiva)

6.1 Número do processo:	Quantidade de meses	0,0
Natureza do rendimento:		

Valores em reais

1. Total dos rendimentos tributáveis (inclusive férias e décimo terceiro salário)	0,00
2. Exclusão: Despesas com a ação judicial	0,00
3. Dedução: Contribuição previdenciária oficial	0,00
4. Dedução: Pensão alimentícia (preencher também o quadro 7)	0,00
5. Imposto sobre a renda retido na fonte (IRRF)	0,00
6. Rendimentos isentos de pensão, proventos de aposentadoria ou reforma por moléstia grave ou aposentadoria ou reforma por acidente em serviço	0,00

7. Informações Complementares

	MINISTÉRIO DA ECONOMIA Secretaria Especial da Receita Federal do Brasil Imposto sobre a Renda da Pessoa Física Exercício de 2023	Comprovante de Rendimentos Pagos e de Imposto sobre a Renda Retido na Fonte Ano-calendário de 2022

8. Responsável pelas Informações

Nome	Data	Assinatura
NELSON GAZA	06/04/2023	

Aprovado pela Instrução Normativa RFB nº 2.060, de 13 de dezembro de 2021.

MINISTRY OF ECONOMY
Special Secretariat of the Federal Revenue of Brazil
Income Tax - Individual
Tax Year 2024

Certificate of Income Paid and Income Tax Withheld at Source

Calendar Year 2023

Check the conditions and deadlines for filing the Individual Income Tax Return for this calendar year on the website of the Special Secretariat of the Federal Revenue of Brazil on the Internet, at <https://www.gov.br/receitafederal/pt-br>.

1. Legal Entity Paying Source

CNPJ	Corporate Name
21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME

2. Individual Beneficiary of Income

CPF	Full Name
287.868.388-90	MARCIO LAMAS LOPES

Nature of Income
Salaried employment income

3. Taxable Income, Deductions and Income Tax Withheld at Source

	Values in Reais
1. Total income (including vacation pay)	15.768,00
2. Official social security contribution	1.734,48
3. Contributions to supplementary pension entities, public or private, and to individual programmed retirement funds (Fapi) (also complete section 7)	0,00
4. Alimony (also complete section 7)	0,00
5. Income tax withheld at source	0,00

4. Exempt and Non-Taxable Income

	Values in Reais
1. Exempt portion of retirement, paid reserve, reform and pension benefits (age 65 or older), except the exempt portion of the 13th (thirteenth) salary	0,00
2. Exempt portion of the 13th salary of retirement, paid reserve, reform and pension (age 65 or older)	0,00
3. Daily allowances and cost-of-living assistance	0,00
4. Pension and retirement or reform benefits due to serious illness; retirement or reform benefits due to on-the-job accident	0,00
5. Profits and dividends, calculated from 1996 onwards, paid by a legal entity (actual, presumed or arbitrated profit)	0,00
6. Amounts paid to the owner or partner of a micro-enterprise or small business, except pro labore, rent or services rendered	0,00
7. Severance pay upon termination of employment contract, including voluntary separation programs (PDV) and workplace accident compensation	0,00
8. Late payment interest received, due to delayed payment of compensation for employment, office or function	0,00
9. Others:	608.000,00

5. Income Subject to Exclusive Taxation (net income)

	Values in Reais
1. Thirteenth salary	0,00
2. Income tax withheld at source on 13th salary	0,00
3. Other	0,00

6. Accumulated Income Received - Art. 12-A of Law No. 7,713, of 1988 (subject to exclusive taxation)

6.1 Case number::	Number of months	0,0
Nature of income:		

	Values in Reais
1. Total taxable income (including vacation pay and thirteenth salary)	0,00
2. Exclusion: Legal action expenses	0,00
3. Deduction: Official social security contribution	0,00
4. Deduction: Alimony (also complete section 7)	0,00
5. Income tax withheld at source (IRRF)	0,00
6. Exempt income from pension, retirement or reform benefits due to serious illness or retirement or reform due to on-the-job accident	0,00

7. Supplementary Information

Other exempt income:

- Other: PROFIT DISTRIBUTION: R$ 608.000,00

8. Person Responsible for the Information

Name	Date	Signature
NELSON GAZA	04/03/2024	

Approved by RFB Normative Instruction No. 2,060, of December 13, 2021.

I, André Vinícius Inacio Penna Mello, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

MINISTÉRIO DA FAZENDA
Secretaria Especial da Receita Federal do Brasil
Imposto sobre a Renda da Pessoa Física
Exercício de 2024

Comprovante de Rendimentos Pagos e de Imposto sobre a Renda Retido na Fonte

Ano-calendário de 2023

Verifique as condições e o prazo para a apresentação da Declaração do Imposto sobre a Renda da Pessoa Física para este ano-calendário no sítio da Secretaria Especial da Receita Federal do Brasil na Internet, no endereço <https://www.gov.br/receitafederal/pt-br>.

1. Fonte Pagadora Pessoa Jurídica

CNPJ	Nome Empresarial
21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME

2. Pessoa Física Beneficiária dos Rendimentos

CPF	Nome Completo
287.868.388-90	MARCIO LAMAS LOPES

Natureza do Rendimento
Rendimentos do trabalho assalariado

3. Rendimentos Tributáveis, Deduções e Imposto sobre a Renda Retido da Fonte

	Valores em reais
1. Total dos rendimentos (inclusive férias)	15.768,00
2. Contribuição previdenciária oficial	1.734,48
3. Contribuição a entidades de previdência complementar, pública ou privada, e a fundos de aposentadoria programada individual (Fapi)(preencher também o quadro 7)	0,00
4. Pensão alimentícia (preencher também o quadro 7)	0,00
5. Imposto sobre a renda retido na fonte	0,00

4. Rendimentos Isentos e Não Tributáveis

	Valores em reais
1. Parcela isenta dos proventos de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais), exceto a parcela isenta do 13º (décimo terceiro) salário	0,00
2. Parcela isenta do 13º salário de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais)	0,00
3. Diárias e ajuda de custo	0,00
4. Pensão e proventos de aposentadoria ou reforma por moléstia grave; proventos de aposentadoria ou reforma por acidente em serviço	0,00
5. Lucros e dividendos, apurados a partir de 1996, pagos por pessoa jurídica (lucro real, presumido ou arbitrado)	0,00
6. Valores pagos ao titular ou sócio da microempresa ou empresa de pequeno porte, exceto pro labore, aluguéis ou serviços prestados	0,00
7. Indenizações por rescisão de contrato de trabalho, inclusive a título de PDV e por acidente de trabalho	0,00
8. Juros de mora recebidos, devidos pelo atraso no pagamento de remuneração por exercício de emprego, cargo ou função	0,00
9. Outros: DISTRIBUIÇÃO DE LUCROS	608.000,00

5. Rendimentos Sujeitos à Tributação Exclusiva (rendimento líquido)

	Valores em reais
1. Décimo terceiro salário	0,00
2. Imposto sobre a renda retido na fonte sobre 13º salário	0,00
3. Outros	0,00

6. Rendimentos Recebidos Acumuladamente - Art. 12-A da Lei nº 7.713, de 1988 (sujeitos à tributação exclusiva)

6.1 Número do processo:	Quantidade de meses	0,0
Natureza do rendimento:		

	Valores em reais
1. Total dos rendimentos tributáveis (inclusive férias e décimo terceiro salário)	0,00
2. Exclusão: Despesas com a ação judicial	0,00
3. Dedução: Contribuição previdenciária oficial	0,00
4. Dedução: Pensão alimentícia (preencher também o quadro 7)	0,00
5. Imposto sobre a renda retido na fonte (IRRF)	0,00
6. Rendimentos isentos de pensão, proventos de aposentadoria ou reforma por moléstia grave ou aposentadoria ou reforma por acidente em serviço	0,00

7. Informações Complementares

Rendimentos isentos outros:

- Outros: DISTRIBUIÇÃO DE LUCROS: R$ 608.000,00

8. Responsável pelas Informações

Nome	Data	Assinatura
NELSON GAZA	03/04/2024	

Aprovado pela Instrução Normativa RFB nº 2.060, de 13 de dezembro de 2021.

MINISTRY OF ECONOMY
Special Secretariat of the Federal Revenue of Brazil
Income Tax - Individual
Tax Year 2025

Certificate of Income Paid and Income Tax Withheld at Source

Calendar Year 2024

Check the conditions and deadlines for filing the Individual Income Tax Return for this calendar year on the website of the Special Secretariat of the Federal Revenue of Brazil on the Internet, at <https://www.gov.br/receitafederal/pt-br>.

1. Legal Entity Paying Source

CNPJ	Corporate Name
21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME

2. Individual Beneficiary of Income

CPF	Full Name
287.868.388-90	MARCIO LAMAS LOPES
Nature of Income	
Salaried employment income	

3. Taxable Income, Deductions and Income Tax Withheld at Source

	Values in Reais
1. Total income (including vacation pay)	16.944,00
2. Official social security contribution	1.863,84
3. Contributions to supplementary pension entities, public or private, and to individual programmed retirement funds (Fapi) **(also complete section 7)**	0,00
4. Alimony **(also complete section 7)**	0,00
5. Income tax withheld at source	0,00

4. Exempt and Non-Taxable Income

	Values in Reais
1. Exempt portion of retirement, paid reserve, reform and pension benefits (age 65 or older), except the exempt portion of the 13th (thirteenth) salary	0,00
2. Exempt portion of the 13th salary of retirement, paid reserve, reform and pension (age 65 or older)	0,00
3. Daily allowances and cost-of-living assistance	0,00
4. Pension and retirement or reform benefits due to serious illness; retirement or reform benefits due to on-the-job accident	0,00
5. Profits and dividends, calculated from 1996 onwards, paid by a legal entity (actual, presumed or arbitrated profit)	760.000,00
6. Amounts paid to the owner or partner of a micro-enterprise or small business, except pro labore, rent or services rendered	0,00
7. Severance pay upon termination of employment contract, including voluntary separation programs (PDV) and workplace accident compensation	0,00
8. Late payment interest received, due to delayed payment of compensation for employment, office or function	0,00
9. Others:	0,00

5. Income Subject to Exclusive Taxation (net income)

	Values in Reais
1. Thirteenth salary	0,00
2. Income tax withheld at source on 13th salary	0,00
3. Others	0,00

6. Accumulated Income Received - Art. 12-A of Law No. 7,713, of 1988 (subject to exclusive taxation)

6.1 Case number:	Number of months	0.0
Nature of income:		

	Values in Reais
1. Total taxable income (including vacation pay and thirteenth salary)	0,00
2. Exclusion: Legal action expenses	0,00
3. Deduction: Official social security contribution	0,00
4. Deduction: Alimony **(also complete section 7)**	0,00
5. Income tax withheld at source (IRRF)	0,00
6. Exempt income from pension, retirement or reform benefits due to serious illness or retirement or reform due to on-the-job accident	0,00

7. Supplementary Information

8. Person Responsible for the Information

Name	Date	Signature
NELSON GAZA	05/08/2025	

Approved by RFB Normative Instruction No. 2,060, of December 13, 2021.

I, André Vinícius Inacio Penna Mello, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

MINISTÉRIO DA FAZENDA
Secretaria Especial da Receita Federal do Brasil
Imposto sobre a Renda da Pessoa Física
Exercício de 2025

Comprovante de Rendimentos Pagos e de
Imposto sobre a Renda Retido na Fonte

Ano-calendário de 2024

Verifique as condições e o prazo para a apresentação da Declaração do Imposto sobre a Renda da Pessoa Física para este ano-calendário no sítio da Secretaria Especial da Receita Federal do Brasil na Internet, no endereço <https://www.gov.br/receitafederal/pt-br>.

1. Fonte Pagadora Pessoa Jurídica

CNPJ	Nome Empresarial
21.850.272/0001-50	ABC ENDOSCOPIA LTDA ME

2. Pessoa Física Beneficiária dos Rendimentos

CPF	Nome Completo
287.868.388-90	MARCIO LAMAS LOPES

Natureza do Rendimento
Rendimentos do trabalho assalariado

3. Rendimentos Tributáveis, Deduções e Imposto sobre a Renda Retido da Fonte

	Valores em reais
1. Total dos rendimentos (inclusive férias)	16.944,00
2. Contribuição previdenciária oficial	1.863,84
3. Contribuição a entidades de previdência complementar, pública ou privada, e a fundos de aposentadoria programada individual (Fapi) **(preencher também o quadro 7)**	0,00
4. Pensão alimentícia **(preencher também o quadro 7)**	0,00
5. Imposto sobre a renda retido na fonte	0,00

4. Rendimentos Isentos e Não Tributáveis

	Valores em reais
1. Parcela isenta dos proventos de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais), exceto a parcela isenta do 13º (décimo terceiro) salário	0,00
2. Parcela isenta do 13º salário de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais)	0,00
3. Diárias e ajuda de custo	0,00
4. Pensão e proventos de aposentadoria ou reforma por moléstia grave; proventos de aposentadoria ou reforma por acidente em serviço	0,00
5. Lucros e dividendos, apurados a partir de 1996, pagos por pessoa jurídica (lucro real, presumido ou arbitrado)	760.000,00
6. Valores pagos ao titular ou sócio da microempresa ou empresa de pequeno porte, exceto pro labore, aluguéis ou serviços prestados	0,00
7. Indenizações por rescisão de contrato de trabalho, inclusive a título de PDV e por acidente de trabalho	0,00
8. Juros de mora recebidos, devidos pelo atraso no pagamento de remuneração por exercício de emprego, cargo ou função	0,00
9. Outros:	0,00

5. Rendimentos Sujeitos à Tributação Exclusiva (rendimento líquido)

	Valores em reais
1. Décimo terceiro salário	0,00
2. Imposto sobre a renda retido na fonte sobre 13º salário	0,00
3. Outros	0,00

6. Rendimentos Recebidos Acumuladamente - Art. 12-A da Lei nº 7.713, de 1988 (sujeitos à tributação exclusiva)

6.1 Número do processo:	Quantidade de meses	0,0

Natureza do rendimento:

	Valores em reais
1. Total dos rendimentos tributáveis (inclusive férias e décimo terceiro salário)	0,00
2. Exclusão: Despesas com a ação judicial	0,00
3. Dedução: Contribuição previdenciária oficial	0,00
4. Dedução: Pensão alimentícia **(preencher também o quadro 7)**	0,00
5. Imposto sobre a renda retido na fonte (IRRF)	0,00
6. Rendimentos isentos de pensão, proventos de aposentadoria ou reforma por moléstia grave ou aposentadoria ou reforma por acidente em serviço	0,00

7. Informações Complementares

8. Responsável pelas Informações

Nome	Data	Assinatura
NELSON GAZA	08/05/2025	

Aprovado pela Instrução Normativa RFB nº 2.060, de 13 de dezembro de 2021.

MINISTRY OF ECONOMY

SPECIAL SECRETARIAT OF THE FEDERAL REVENUE

INCOME TAX - INDIVIDUAL

TAX YEAR 2026

CERTIFICATE OF INCOME PAID AND INCOME TAX WITHHELD AT SOURCE

Calenar Year: 2025

1.LEGAL ENTITY OR INDIVIDUAL PAYING SOURCE

CORPORATE NAME/NAME	CNPJ/CPF
ABC ENDOSCOPIA LTDA ME	21.850.272/0001-50

2.INDIVIDUAL BENEFICIARY OF INCOME

CPF	FULL NAME
287.868.388-90	MARCIO LAMAS LOPES
NATURE OF INCOME SALARIED EMPLOYMENT INCOME	

3.TAXABLE INCOME, DEDUCTIONS AND INCOME TAX WITHHELD AT SOURCE

	VALUES IN REAIS
01. Total income (including vacation pay)	18.216,00
02. Official social security contribution	2.003,76
03. Contributions to supplementary pension entities, public or private, and to individual programmed retirement funds (FAPI)	0,00
04. Alimony (also complete section 7)	0,00
05. Income tax withheld at source	0,00

4.EXEMPT AND NON-TAXABLE INCOME

	VALUES IN REAIS
01. Exempt Portion of Retirement, Reform and Pension Benefits (age 65 or older)	0,00
02. Exempt portion of the 13th salary of retirement, paid reserve, reform and pension (age 65 or older)	0,00
03. Daily allowances and cost-of-living assistance	0,00
04. Pension and retirement or reform benefits due to serious illness; retirement or reform benefits due to on-the-job accident	0,00
05. Profits and dividends, calculated from 1996 onwards, paid by a legal entity (actual, presumed or arbitrated profit)	731.420,56
06. Amounts paid to the owner or partner of a micro-enterprise or small business, except pro labore, rent or services rendered	0,00
07. Severance pay upon termination of employment contract, including voluntary separation programs (PDV) and workplace accident compensation	0,00
08. Late payment interest received, due to delayed payment of compensation for employment, office or function	0,00
09. Other (specify)	0,00

5.INCOME SUBJECT TO EXCLUSIVE TAXATION (NET INCOME)

	VALUES IN REAIS
01. Thirteenth salary	0,00
02. Income tax withheld at source on 13th salary	0,00
03. Other	0,00

6.ACCUMULATED INCOME RECEIVED - ART. 12-A OF LAW NO. 7,713, OF 1988 (SUBJECT TO EXCLUSIVE TAXATION)

6.1 Case Number:	Number of months	0,00
Nature of income:		

	VALUES IN REAIS
01. Total taxable income (including vacation pay and thirteenth salary)	0,00
02. Exclusion: Legal action expenses	0,00
03. Deduction: Official social security contribution	0,00
04. Deduction: Alimony	0,00
05. Income tax withheld at source	0,00
06. Exempt income from pension, retirement or reform benefits due to serious illness or retirement or reform due to on-the-job accident	0,00

7.SUPPLEMENTARY INFORMATION

8.PERSON RESPONSIBLE FOR THE INFORMATION

NAME	DATE	SIGNATURE
NELSON GAZA	05/07/2026	

Approved by RFB Normative Instruction No. 2,060, of December 13, 2021.

I, André Vinícius Inacio Penna Mello, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 14, 2026.

MINISTÉRIO DA FAZENDA
SECRETARIA DA RECEITA FEDERAL
IMPOSTO SOBRE A RENDA DA PESSOA FÍSICA
EXERCÍCIO DE 2026

COMPROVANTE DE RENDIMENTOS PAGOS E DE RETENÇÃO DE IMPOSTO DE RENDA NA FONTE

Ano-calendário : 2025

1.FONTE PAGADORA PESSOA JURÍDICA OU PESSOA FÍSICA

NOME EMPRESARIAL/NOME	CNPJ/CPF
ABC ENDOSCOPIA LTDA ME	21.850.272/0001-50

2.PESSOA FÍSICA BENEFICIÁRIA DOS RENDIMENTOS

CPF	NOME COMPLETO
287.868.388-90	MARCIO LAMAS LOPES

NATUREZA DO RENDIMENTO
RENDIMENTOS DO TRABALHO ASSALARIADO

3.RENDIMENTOS TRIBUTÁVEIS, DEDUÇÕES E IMPOSTO RETIDO NA FONTE

	VALORES EM REAIS
01.Total dos Rendimentos (inclusive férias)	18.216,00
02.Contribuição Previdenciária Oficial	2.003,76
03.Contribuições a Entidades de Previdência Complementar, Pública ou Privada, e a Fundos de Aposentadoria Programada Individual (FAPI)	0,00
04.Pensão Alimentícia (informar o beneficiário no Quadro 7)	0,00
05.Imposto de Renda Retido	0,00

4.RENDIMENTOS ISENTOS E NÃO TRIBUTÁVEIS

	VALORES EM REAIS
01.Parcela Isenta dos Proventos de Aposentadoria, Reforma e Pensão (65 anos ou mais)	0,00
02.Parcela isenta do 13º salário de aposentadoria, reserva remunerada, reforma e pensão (65 anos ou mais)	0,00
03.Diárias e Ajudas de Custo	0,00
04.Pensão, Proventos de Aposentadoria ou Reforma por Moléstia Grave e Aposentadoria ou Reforma por Acidente em Serviço	0,00
05.Lucro e Dividendo Apurado a partir de 1996 pago por PJ (Lucro Real, Presumido ou Arbitrado)	731.420,56
06.Valores Pagos ao Titular ou Sócio da Microempresa ou Empresa de Pequeno Porte, exceto Pro labore, Aluguéis ou Serviços Prestados	0,00
07.Indenizações por rescisão de contrato de trabalho, inclusive a título de PDV, e acidente de trabalho	0,00
08.Juros de mora recebidos, devidos pelos atraso no pagamento de remuneração por exercício de emprego, cargo ou função	0,00
09.Outros (especificar)	0,00

5.RENDIMENTOS SUJEITOS À TRIBUTAÇÃO EXCLUSIVA (RENDIMENTO LÍQUIDO)

	VALORES EM REAIS
01.Décimo Terceiro Salário	0,00
02.Imposto sobre a renda retido na fonte sobre 13º salário	0,00
03.Outros	0,00

6.RENDIMENTOS RECEBIDOS ACUMULADAMENTE - Art. 12-A da Lei nº 7.713, de 1988 (sujeitos à tributação exclusiva)

6.1 Número do Processo:	Quantidade de Meses	0,00
Natureza do Rendimento:		VALORES EM REAIS

01. Total dos Rendimentos Tributáveis (Inclusive Férias e Décimo Terceiro Salário)	0,00
02. Exclusão: Despesas com a Ação Judicial	0,00
03. Dedução: Contribuição Previdenciária Oficial	0,00
04. Dedução: Pensão Alimentícia	0,00
05. Imposto sobre a Renda Retido na Fonte	0,00
06. Rendimentos Isentos de Pensão, Proventos de Aposentadoria ou Reforma por Moléstia Grave ou Aposentadoria ou Reforma por Acidente em Serviço	0,00

7.INFORMAÇÕES COMPLEMENTARES

8.RESPONSÁVEL PELAS INFORMAÇÕES

NOME	DATA	ASSINATURA
NELSON GAZA	07/05/2026	

Aprovado pela Instrução Normativa RFB Nº 2.060, de 13 de dezembro de 2021.

SOBED

MEMBERSHIP CERTIFICATE

The Brazilian Society of Digestive Endoscopy (SOBED) is pleased to announce the admission of

MARCIO LAMAS LOPES

as a Member, in accordance with Article 20 of the current Bylaws.

Welcome!

São Paulo, March 28, 2017

President

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English, as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 14, 2026

SOBED

CERTIFICADO DE ASSOCIADO

É com satisfação que a Sociedade Brasileira de Endoscopia Digestiva (SOBED) comunica a inclusão de

MARCIO LAMAS LOPES

como Associado(a), conforme Artigo 20 do Estatuto Social vigente.

Seja bem-vindo(a)!

São Paulo, *28* **de** *março* **de** *2017*

Presidente

Eduardo Guimarães Hourneaux de Moura
President

Paulo Fernando Souto Bittencourt
Vice President

Ricardo Rangel de Paula Pessoa
1st Secretary

Raquel Canzi Almada de Souza
2nd Secretary

Sylon Ribeiro de Britto Junior
1st Treasurer

Matheus Cavalcante Franco
2nd Treasurer

Bruno da Costa Martins
Headquarters Director

Declaration

DECLARATION

We hereby certify, for all due purposes, that Dr. MARCIO LAMAS LOPES, holder of ID No. 28786838890, is a member of SOBED, State of São Paulo (Brazil), in the capacity of FULL MEMBER.

This declaration is valid through 12/31/2026.

São Paulo, April 27, 2026.

In witness whereof, we have dated and signed this declaration.

ADMINISTRATIVE MANAGER

BRAZILIAN SOCIETY OF ENDOSCOPY AND DIGESTIVE ENDOSCOPY

www.sobed.org.br
Rua Peixoto Gomide, 515
4th Floor – Suite 44
01409-001 - São Paulo, SP

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 14, 2026

Eduardo Guimarães Hourneaux de Moura
Presidente

Paulo Fernando Souto Bittencourt
Vice-presidente

Ricardo Rangel de Paula Pessoa
1° Secretário

Raquel Canzi Almada de Souza
2° Secretário

Sylon Ribeiro de Britto Junior
1° Tesoureiro

Matheus Cavalcante Franco
2° Tesoureiro

Bruno da Costa Martins
Diretor de Sede

DECLARAÇÃO

DECLARAÇÃO

Declaramos para os devidos fins, que o (a) Dr.(a) MARCIO LAMAS LOPES , portador (a) do 28786838890 , integra o quadro de Associados da SOBED, UF: São Paulo (BR) na qualidade de membro TITULAR

Declaração válida até 31/12/2026 .

São Paulo, 27 de abril de 2026 .

Por ser verdade, datamos e assinamos o presente.

GESTORA ADMINISTRATIVA

SOCIEDADE BRASILEIRA DE ENDOSCOPIA E ENDOSCOPIA DIGESTIVA

www.sobed.org.br
Rua Peixoto Gomide, 515
4° andar - Conjunto 44
01409-001 - São Paulo, SP

BYLAWS OF THE BRAZILIAN SOCIETY OF ENDOSCOPY AND DIGESTIVE ENDOSCOPY

CHAPTER I

NAME, DESIGNATION, THE SOCIETY, AND ITS PURPOSES

Article 1 – The Brazilian Society of Endoscopy and Digestive Endoscopy, also referred to simply by the acronym SOBED, founded on July 25, 1975, in the city of Curitiba, State of Paraná, with its own legal personality, registered with the CNPJ under No. 89.863.765/0001-69, is an association composed of physicians who practice Endoscopy and Digestive Endoscopy, with a technical, scientific, cultural, and associative nature, without profit-making purposes, established for an indefinite term, and governed by these Bylaws, its internal regulations, and the laws applicable thereto. Its purpose is to bring together medical professionals in Endoscopy and Digestive Endoscopy and to act as the highest representative body of the professional class engaged in Endoscopy and Digestive Endoscopy.

Paragraph 1 – SOBED is an autonomous entity, with its registered office and legal jurisdiction in the city of São Paulo, State of São Paulo, at Rua Peixoto Gomide, No. 515, Suites 44, 45, and 46, Cerqueira César neighborhood, ZIP Code 01409-001, and is not dependent on any other national or international association, while maintaining scientific ties and cultural exchanges with other similar and related societies.

Paragraph 2 - SOBED is organized nationally and consists of State-level units (Chapters) and Sub-State units (Subchapters), established in accordance with the provisions of these Bylaws and applicable legislation.

Article 2 – SOBED brings together medical professionals in Endoscopy and Digestive Endoscopy who are registered with the Regional Council of Medicine in accordance with the applicable laws.

Article 3 – The purposes of SOBED are:

a) To organize and represent the professional class of Digestive System Endoscopists before the constituted authorities and the general public, as well as before similar national and international entities, professional representative bodies, and official regulatory agencies;

b) To represent, judicially and extrajudicially, the interests of its members, regardless of individual authorization or prior authorization from the higher deliberative bodies, provided that such interests may be characterized as collective or diffuse and may result in direct or indirect benefits to the class of medical professionals in Endoscopy and Digestive Endoscopy as a whole, as well as for the protection of public health, public and social property, the environment, consumers, the economic order, free

competition, the rights of racial, ethnic, or religious groups, and artistic, aesthetic, historical, tourist, and scenic heritage;

c) To promote the development of education, research, and the practice of Endoscopy and Digestive System Endoscopy;

d) To accredit services for training and specialization in Digestive Endoscopy that comply with the program and provisions established in the Internal Regulations;

e) To collaborate with public authorities and entities connected with the healthcare sector in carrying out scientific activities related to the specialty, safeguarding high technical and moral standards;

f) To promote initiatives aimed at expanding, disseminating, and encouraging, among the population at all levels, knowledge, prevention, and treatment of digestive diseases;

g) To safeguard the ethical standards and technical and professional efficiency of the endoscopist physician as both a citizen and medical professional, based on high social and moral standards;

h) To safeguard the practice of Digestive Endoscopy and represent Brazilian endoscopists in defending their professional, social, and economic rights;

i) To keep its members informed about the entity's activities, as well as about scientific advances in the specialty, through periodic publications;

j) To collect annual membership dues from its members and remit to each State Regional Chapter 50% (fifty percent) of the amount collected from professionals belonging to each such Chapter;

k) To provide and assess courses, accredit and withdraw accreditation from institutions offering Specialization Courses in Digestive Endoscopy, and periodically monitor the quality of the education provided;

l) To organize and promote courses, symposia, congresses, trade fairs, events, digestive health improvement projects, scientific and cultural activities, and other events;

m) To support and encourage its affiliated societies and events recognized by it;

n) To hold the Brazilian Digestive System Week annually.

Paragraph 1 – SOBED shall not engage in political party, religious, or any other activities or statements that may give rise to ideological divisions among its members.

e) To nominate new members for the Organization;

f) To encourage the establishment of Training Centers in Digestive Endoscopy;

g) To collaborate in holding national events sponsored by the Organization;

h) To defend the interests of Digestive System Endoscopists, whether individually or collectively, provided that they are members of the Organization;

i) To indicate in all of its printed materials and documents its status as a body of the Organization;

j) To submit to the Organization, by March 31 of each year, a detailed report on the administrative, scientific, and financial activities of the preceding year, as well as its strategic plan for the current year;

k) To inform the corresponding Organization of situations that appear to warrant the application of disciplinary measures to Digestive System Endoscopists;

CHAPTER III – MEMBERS

SECTION I

MEMBERSHIP CATEGORIES

Article 15 - The membership of SOBED consists of the following categories:

a) Founding Member;

b) Full Member;

c) Certified Member;

d) Aspiring Member;

e) Collaborating Member;

f) International Corresponding Member;

g) Honorary Member;

h) Meritorious Member;

i) Exempt Member;

j) Foreign Member.

Article 16 - SOBED Founding Members are the signatories of the Founding Minutes of Curitiba and Salvador and those who effectively participated in the establishment of the State Units.

Sole Paragraph – The status of Founding Member may be held independently or jointly with the status of Full Member or Aspiring Member.

Article 17 – Full Members are those who are admitted to SOBED's membership upon satisfying every one of the following requirements:

a) Hold a Specialist Certification in Digestive Endoscopy or Endoscopy issued by the Brazilian Medical Association (AMB) in partnership with SOBED;

b) Be a physician and be duly registered with the Regional Council of Medicine**.**

Sole Paragraph – Upon fully exercising their statutory rights, Full Members automatically acquire the status of Delegates of the Unit in which they are registered and regularly practice their profession.

Article 18 – Certified Members are those who are admitted to SOBED's membership upon satisfying all of the following requirements:

a) Hold a Certificate in the Area of Practice of Digestive Endoscopy issued by the Brazilian Medical Association (AMB) in partnership with SOBED;

b) Be a physician and be duly registered with the Regional Council of Medicine.

Article 19 – Aspiring Members are holders of a medical degree who are admitted to SOBED's membership upon satisfying the requirements set forth in the Admission Committee Regulations.

Paragraph 1 – A SOBED Aspiring Member shall be elevated to the category of Full Member upon obtaining the Specialist Certification in Endoscopy, or to the category of Certified Member upon obtaining the Certificate in the Area of Practice of Digestive Endoscopy.

Paragraph 2 – Also considered Aspiring Members shall be Trainee Aspiring Members, who are admitted to SOBED's membership and enrolled in centers accredited under SOBED's Education and Training Program – CET, or in Medical Residency Programs in Endoscopy duly recognized by the National Commission for Medical Residency (CNRM)/Ministry of Education (MEC) and hosted by centers accredited by SOBED – CET.

Paragraph 3 – Trainee Aspiring Members shall be exempt from annual membership dues during the program period, which may be one or two years of membership.

Article 20 – Collaborating Members shall be citizens of recognized moral and professional integrity who, having undertaken activities of interest to Digestive Endoscopy, are granted such status by the SOBED Deliberative Council for that reason.

Article 21 – International Corresponding Members shall be physicians, whether foreign nationals or Brazilian citizens residing outside the country, of recognized moral and professional integrity who, having provided significant assistance to SOBED, are nominated for such status by the Board of Directors and approved by the SOBED Deliberative Council.

Article 22 – Honorary Members shall be Brazilian or foreign physicians of recognized expertise who have made outstanding contributions to Digestive Endoscopy and who, for such purpose, have been nominated by the Board of Directors and approved by the SOBED Deliberative Council.

Article 23 – Meritorious Members shall be citizens of recognized moral integrity who have made a significant contribution to the development of SOBED and who have been granted such status by the SOBED Deliberative Council.

Article 24 – Exempt Members shall be those Full Members and Aspiring Members who are members of SOBED and are 75 (seventy-five) years of age or older.

Sole Paragraph – Only those who are up to date with financial obligations regarding the fiscal year immediately preceding the request may apply to change their category to Lifetime Member.

Article 25 – Foreign Members shall be physicians who reside in another country, where they practice their profession, are duly registered with the body that regulates the practice of medicine, and are admitted to SOBED's membership upon satisfying the admission requirements for this membership category**.**

Paragraph 1 – For foreign physicians who practice their profession in another country to become members of SOBED under the category of Foreign Members, they must satisfy the following requirements:

a) Be a physician and be duly registered with the body or institution officially designated for this purpose in the country where they reside;

b) Submit an application requesting membership and provide their name, date of birth, registration with the body in their country that regulates the practice of medicine, and personal identification number (equivalent to the CPF in Brazil);

c) Submit copies of the following documents: identification document (equivalent to the ID or CPF in Brazil, or passport); proof of residence/address; and proof of professional practice in Endoscopy or Digestive Endoscopy issued by the institution where they are affiliated.

Paragraph 2 – Meet one of the following requirements and submit the corresponding supporting documentation:

a) Hold a Specialist Certification in Digestive Endoscopy issued by a body or institution officially designated for this purpose in the country where they reside.

b) Have completed or be undergoing regular training in an official specialization program in Digestive Endoscopy for at least 2 (two) years (equivalent to the Brazilian medical residency program or training at SOBED-accredited training centers/CETs).

c) Provide proof of having practiced Digestive Endoscopy for at least 2 (two) years, certified by the physician responsible for the institution's technical operations (or equivalent) where the physician works.

Paragraph 3 – All applications, statements, certificates, and documents must be submitted with a Sworn Translation and a Hague Apostille.

Paragraph 4 – Foreign Members shall not have voting rights or the right to hold positions on the Board of Directors or in administrative offices, while retaining the other rights and privileges corresponding to their respective membership category.

Paragraph 5 – Foreign Members shall not be exempt from annual membership dues.

SECTION II

RIGHTS AND DUTIES OF MEMBERS

Article 26 – The rights and duties of SOBED Full Members are:

a) To vote and be eligible for election;

b) To convene General Assemblies pursuant to Article 31, Sole Paragraph, of these Bylaws;

c) To resign from membership in the Organization by written notice;

d) To use the designation SOBED Full Member;

e) To participate in regular activities promoted by the Organization;

f) To receive communications issued by the Organization;

g) To appeal, to the appropriate authority, decisions of the Organization that they deem inconsistent with these Bylaws or applicable law;

h) To receive a certificate issued by the Executive Board certifying their membership status;

i) To give lectures at Congresses and other events promoted by SOBED, when invited by the Scientific Committee, the National SOBED Board, or the Regional SOBED Board, or the

f) Specialist Certification and Continuing Education Commission.

Paragraph 2 – Provisional Committees are those established due to emerging facts or circumstances, and their duration shall be limited to the resolution of the matter or exhaustion of the subject for which they were established.

Paragraph 3 – Committees shall be governed by their own Internal Rules and/or Internal Regulations, approved by the Board of Directors and/or the Deliberative Council.

Paragraph 4 – Committees shall consist of a minimum of 6 (six) SOBED Full Members, with one-third (1/3) of their members being replaced upon each new term of office of the SOBED Board of Directors. Exceptions are the Committee for the Assessment and Accreditation of Training Centers and the Committee for the Specialist Certification and Its Renewal, which shall consist of at least 9 (nine) members, and the Headquarters Committee, which shall consist of at least 1 (one) SOBED Member, all of whom must be Full Members and current with their financial obligations to the Treasurer's Office.

Paragraph 5 – The appointment of Committee members and their respective coordinators shall be the exclusive responsibility of the SOBED Board of Directors, and they shall mandatorily take office at the same time as the elected Board of Directors.

Article 69 – The Electoral, Bylaws, Internal Rules and Regulations Committee shall be responsible for:

a) Reviewing and issuing opinions on all matters about the SOBED Bylaws, particularly proposals for amendments thereto, as well as its Internal Rules and Regulations;

b) Regulating the electoral process and supervising elections, ensuring strict compliance with the provisions of the Bylaws and applicable laws;

c) Approving or denying the registration of candidate slates for elections, ensuring the possibility of filing an appeal, which shall be considered and decided by the Electoral Committee itself, with a reasoned decision, as a single and final instance.

Article 70 – The Admissions Committee shall be responsible for reviewing and issuing opinions on applications for admission to membership in SOBED.

Article 71 – The Scientific and Editorial Committee shall be responsible for:

a) Reviewing and issuing opinions on Digestive System Endoscopy procedures, both those currently in use and potential innovations;

b) Organizing courses, research projects, and scientific surveys in the specialty;

c) Proposing the agenda of national scientific events.

Article 81 – The date and location of national scientific events shall be determined by SOBED Full Members who are current with their obligations, through a joint vote with the members of the other entities that comprise the Brazilian Digestive System Association (SBAD), during the Brazilian Digestive System Week.

Sole Paragraph – A technical, economic, and financial feasibility study, including a detailed cost spreadsheet, shall be submitted when the candidate city applies to be selected as the host city. The study shall then be reviewed by the SOBED Deliberative Council and the SBAD Organizing Committee, in accordance with the provisions of the SBAD Internal Rules.

Article 82 – The Organizing Committees of national scientific events shall prepare Internal Rules governing such events.

Article 83 – The National Lecturer shall be nominated, from a list of three candidates, by the Organizing Committee and the SOBED Board of Directors, and selected by the Deliberative Council.

Article 84 – The establishment of awards within the specialty shall be the responsibility of the SOBED Board of Directors, which shall issue the respective rules, subject to review and approval by the Deliberative Council.

Sole Paragraph – Institutional actions for recognition and appreciation, such as tributes, medals, commemorative plaques, and honorary distinctions granted to the profession, scientific initiation, members, institutions, and the specialty, shall not require specific regulations and shall be the exclusive responsibility of the SOBED Board of Directors.

Article 85 – Scientific Conferences, Continuing Education Courses, and other types of scientific meetings may be organized at any time, subject to agreement between the Boards of Directors of the interested State Units and the SOBED Board of Directors.

CHAPTER VII

SPECIALIST CERTIFICATION

Article 86 – SOBED reserves the right to regulate, through its own rules and those established by specific legislation, the granting of the Specialist Certification in Digestive Endoscopy, as well as its renewal, jointly with the Brazilian Medical Association.

Article 87 – Such rules, after being drafted by the Committee for the Specialist Certification and Its Renewal and approved by the Deliberative Council and the General Assembly, shall be disseminated through any means of communication.

Article 88 – Pursuant to a determination by the Federal Council of Medicine, the Specialist Certification must be registered with the Regional Council of Medicine with which the physician is registered.

CHAPTER VIII

VIOLATIONS AND PENALTIES

Article 89 – Any SOBED Member shall be subject to disciplinary action for conduct that violates the provisions of these Bylaws and the regulations governing unethical practices, the laws governing the medical profession in Brazil, and the Code of Medical Ethics.

Article 90 – Penalties shall be imposed according to the nature and severity of the violation, as well as whether the member is a repeat offender.

Paragraph 1 – The penalties are as follows:

a) Warning, in the case of minor offenses, whereby the offender shall be notified of the penalty through a confidential communication, and disclosure thereof shall be prohibited;

b) Public Reprimand, applicable to repeat offenders who have previously received a warning or to those responsible for offenses considered to be of moderate severity. The member subject to the penalty and the membership body shall be notified thereof;

c) Suspension, applicable to repeat offenders who have previously received a public reprimand or to those responsible for offenses considered serious, whose rights shall be suspended for a period of 6 (six) months to 1 (one) year;

d) Expulsion, the most severe penalty, which shall be imposed on repeat offenders who commit serious offenses or on those responsible for extremely serious offenses against ethical standards or personal or professional dignity, as well as on those who act against the existence of the Society, those who fail to comply with decisions of the Bylaws or governing bodies, and those who refuse to pay membership dues for two consecutive years.

Paragraph 2 – Proceedings for the expulsion and readmission of members subject to the cases involving physicians who act against the existence of the Society or fail to comply with decisions of the Bylaws or governing bodies shall be ratified by the General Assembly.

Article 91 – Disciplinary proceedings shall be initiated by the Ethics and Professional Defense Committee or by the SOBED Board of Directors, in accordance with the applicable specific regulations.

Article 92 – During proceedings to investigate a statutory or ethical violation, the Member shall always be guaranteed full access to the proceedings and the right to present a defense.

Article 93 – Appeals against decisions rendered in such proceedings may be filed within 30 (thirty) days following the date on which the interested party becomes aware of the decision. Appeals shall be reviewed by the Ethics and Professional Defense Committee and decided by the General Assembly.

Article 94 – The following shall be expelled from SOBED:

a) Those who act against the existence of the Society;

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 14, 2026

ESTATUTO SOCIAL DA SOCIEDADE BRASILEIRA DE ENDOSCOPIA E ENDOSCOPIA DIGESTIVA

CAPÍTULO I

DO NOME, DA DENOMINAÇÃO, DA SOCIEDADE E SUAS FINALIDADES

Artigo 1º – A Sociedade Brasileira de Endoscopia e Endoscopia Digestiva, também designada simplesmente pela sigla SOBED, fundada em 25 de julho de 1975, na cidade de Curitiba, Estado do Paraná, com personalidade jurídica própria, inscrita no CNPJ sob o nº 89.863.765/0001-69, é uma associação constituída por médicos que exercem a medicina em Endoscopia e Endoscopia Digestiva, com caráter técnico, científico, cultural e associativo, sem fins lucrativos, com prazo de duração indeterminado, que se rege por este Estatuto, seus regimentos e pelas leis aplicáveis à espécie que tem por finalidade congregar os profissionais médicos em Endoscopia e Endoscopia Digestiva e atuar como órgão máximo da classe dos que exercem a Endoscopia e a Endoscopia Digestiva.

Parágrafo 1º – A SOBED é uma entidade autônoma, com sede e foro na cidade de São Paulo, Estado de São Paulo, na Rua Peixoto Gomide, nº 515, conjuntos 44, 45 e 46, bairro Cerqueira César, CEP 01409-001, e não dependente de nenhuma outra associação nacional ou internacional mantendo, todavia, vínculos científicos e intercâmbio cultural com outras sociedades congêneres e afins.

Parágrafo 2º - A SOBED é organizada nacionalmente, composta por unidades Estaduais (Capítulos) e Sub-Estaduais (subcapítulos), criadas em conformidade com o disposto neste Estatuto, e na legislação em vigor.

Artigo 2º – A SOBED congrega profissionais médicos em Endoscopia e Endoscopia Digestiva, inscritos no Conselho Regional de Medicina na conformidade das leis pertinentes.

Artigo 3º – São finalidades da SOBED:

a) Organizar e representar a classe dos Médicos Endoscopistas do Sistema Digestivo perante os poderes constituídos e o público em geral, assim como perante as entidades congêneres nacionais, internacionais, representação de classe e órgãos oficiais de regulação;

b) Representar judicial e extrajudicialmente os interesses de seus associados, independentemente da outorga individual ou de autorização prévia dos órgãos de deliberação superiores, desde que tais interesses possam ser caracterizados como coletivos ou difusos e possam acarretar benefícios diretos ou indiretos para a classe dos profissionais médicos em endoscopia e endoscopia digestiva como um todo, bem como para proteção à saúde pública, ao patrimônio público e social, ao meio ambiente, ao

consumidor, à ordem econômica, à livre concorrência, aos direitos de grupos raciais, étnicos ou religiosos ou ao patrimônio artístico, estético, histórico, turístico e paisagístico;

c) Promover o desenvolvimento do ensino, da pesquisa e da prática da Endoscopia e Endoscopia do Sistema Digestivo;

d) Credenciar serviços para treinamento e especialização em Endoscopia Digestiva que cumpram programa e disposições definidas em Regimento;

e) Colaborar com o Poder Público e entidades vinculadas à área de saúde na realização de atividades científicas relacionadas com a especialidade, zelando pelo seu alto padrão técnico e moral;

f) Promover iniciativas com vistas a expandir, divulgar e incentivar na população, em todos os níveis, o conhecimento, a prevenção e o tratamento de doenças digestivas;

g) Zelar pela ética e pela eficiência técnico-profissional do médico endoscopista cidadão e médico, tendo por base elevados preceitos sociais e morais;

h) Resguardar o exercício da Endoscopia Digestiva e representar os médicos endoscopistas brasileiros na defesa de seus direitos profissionais, sociais e econômicos;

i) Manter seus associados informados sobre as atividades da entidade, bem como sobre os progressos científicos da especialidade, por meio de publicações periódicas.

j) Proceder arrecadação das contribuições anuais junto aos Associados e repassar a cada Regional estadual, o percentual de 50% (cinquenta por cento) na proporção arrecadada por profissionais pertencentes a cada uma delas;

k) Ministrar, avaliar, credenciar e descredenciar instituições para ministrarem Curso de Especialização em Endoscopia Digestiva, monitorando periodicamente a qualidade do ensino oferecido;

l) Organizar e promover cursos, simpósios, congressos, feiras, eventos, projetos de melhoria da saúde digestiva, atividades científicas e culturais e outros eventos;

m) Prestigiar e incentivar as sociedades filiadas e os eventos por ele reconhecidos;

n) Realizar anualmente a Semana Brasileira do Aparelho Digestivo.

Parágrafo 1º – À SOBED são vedadas manifestações de caráter político partidário, religioso ou quaisquer outras que importem dissensões ideológicas entre seus associados;

e) Indicar novos associados para a Entidade;

f) Estimular a criação de Centros de Treinamento em Endoscopia Digestiva.

g) Colaborar na realização de eventos nacionais patrocinados pela Entidade;

h) Defender os interesses dos Médicos Endoscopistas do Sistema Digestivo quer tenham eles configuração individual ou coletiva, desde que sejam Associados da Entidade;

i) Indicar em todos os seus impressos e documentos a sua condição de órgão da Entidade;

j) Encaminhar à Entidade, até o dia 31 de março de cada ano, relatório detalhado das atividades administrativa, científica e financeira do ano anterior e seu planejamento estratégico para o ano em curso.

k) Informar, à Entidade correspondente, sobre situações que pareçam exigir a aplicação de medidas punitivas a Médicos Endoscopistas do Sistema Digestivo;

CAPÍTULO III - DOS ASSOCIADOS

SEÇÃO I

DAS CATEGORIAS DOS ASSOCIADOS

Artigo 15º - O quadro de associados da SOBED é constituído das seguintes categorias:

a) Associado Fundador;

b) Associado Titular;

c) Associado Certificado;

d) Associado Aspirante;

e) Associado Colaborador;

f) Associado Correspondente Internacional;

g) Associado Honorário;

h) Associado Benemérito;

i) Associado Remido;

j) Associado Estrangeiro.

Artigo 16º - São Associados Fundadores da SOBED os signatários das Atas de Fundação de Curitiba e de Salvador, e os que efetivamente participaram da Fundação das Unidades Estaduais.

Parágrafo único - A condição de Associado Fundador poderá ser exercida isolada ou conjuntamente com a de Associado Titular ou a de Associado Aspirante.

Artigo 17º - São Associados Titulares aqueles que forem aceitos no quadro social da SOBED, por satisfazerem todas e cada uma das seguintes condições:

a) Possuir Título de Especialista em Endoscopia Digestiva ou Endoscopia, emitido pela AMB em convenio com a SOBED;

b) Ser médico e estar regularmente inscrito no Conselho Regional de Medicina;

Parágrafo único - Os Associados Titulares adquirem, automaticamente, no gozo pleno de seus direitos estatutários, a condição de Delegados da Unidade onde estiverem inscritos e regularmente exercerem suas atividades profissionais.

Artigo 18º - São Associados Certificados aqueles que forem aceitos no quadro social da SOBED, por satisfazerem todas as condições abaixo:

a) Possuir o Certificado em Área de Atuação em Endoscopia Digestiva, emitido pela AMB em convênio com a SOBED;

b) Ser médico e estar regularmente inscrito no Conselho Regional de Medicina;

Artigo 19º - São Associados Aspirantes àqueles portadores de diploma médico, que forem aceitos no quadro da SOBED, por satisfazerem os requisitos do Regulamento da Comissão de Admissão.

Parágrafo 1º. O Associado Aspirante da SOBED terá sua elevação à categoria de Associado Titular, a partir da obtenção do Título de Especialista em Endoscopia ou Associado Certificado, quando da obtenção do Certificado de Área de Atuação em Endoscopia Digestiva.

Parágrafo 2º. Serão também considerados Associados Aspirantes Trainee, àqueles que forem aceitos nos quadros da SOBED e estarem inscritos nos centros credenciados do programa de Ensino e Treinamento da SOBED – CET ou em Programas de Residência Médica em Endoscopia, devidamente reconhecido pelo CNRM/MEC acolhidos pelos centros credenciados pela SOBED – CET.

Parágrafo 3º. os Aspirantes Trainee terão isenção de sua anuidade durante o período do programa, podendo ser um ou dois anos no quadro associativo.

Artigo 20º - Serão Associados Colaboradores os cidadãos de reconhecida idoneidade moral e profissional que, tendo empreendido atividades de interesse da Endoscopia Digestiva, forem, por esta razão, agraciados com aquela condição pelo Conselho Deliberativo da SOBED.

Artigo 21º - Serão Associados Correspondentes Internacionais os médicos, estrangeiros ou brasileiros residentes fora do país, de reconhecida idoneidade moral e profissional que, tendo prestado relevante colaboração à SOBED, sejam para tal condição indicados pela Diretoria e aprovados pelo Conselho Deliberativo da SOBED.

Artigo 22º - Serão Associados Honorários os médicos, brasileiros ou estrangeiros, de notória competência que tenham prestado notáveis contribuições à Endoscopia Digestiva e que, para tal condição, tenham sido propostos pela Diretoria e aprovados pelo Conselho Deliberativo da SOBED.

Artigo 23º - Serão Associados Beneméritos os cidadãos de reconhecida idoneidade moral que hajam contribuído de maneira relevante para o desenvolvimento da SOBED e que tenham sido agraciados com aquela condição pelo Conselho Deliberativo da SOBED.

Artigo 24º - Serão considerados Associados Remidos os membros Titulares e Aspirantes que integrem os quadros da SOBED e que possuam idade igual ou superior a 75 (setenta e cinco) anos.

Parágrafo único. Somente poderá requerer a alteração de sua categoria para Associado Remido aquele que estiver quite com as obrigações financeiras relativas ao exercício imediatamente anterior ao do pedido.

Artigo 25º - Serão Associados Estrangeiros, os médicos que residam em outro país, onde exerçam suas atividades, devidamente registrados no órgão que regulamenta o exercício da profissão e que forem aceitos no quadro da SOBED, por satisfazerem os requisitos de admissão para esta categoria de associado.

Parágrafo 1º – Para os médicos estrangeiros, que exerçam suas atividades em outro país, pertencerem ao quadro de associado da SOBED, na modalidade Associados Estrangeiros, deverão satisfazer as seguintes condições abaixo:

a) Ser médico e estar regularmente inscrito no órgão ou instituição oficialmente designada para este fim no país onde reside;

b) Enviar requerimento solicitando filiação e informar nome, data de nascimento, registro no órgão de seu País que regulamenta o exercício da medicina e identificação pessoal (equivalente ao CPF no Brasil);

c) Enviar cópia dos seguintes documentos: Identidade (equivalente ao RG ou CPF no Brasil ou passaporte); Comprovante de residência/endereço; Comprovante de atuação em Endoscopia ou Endoscopia Digestiva emitido pelo Serviço onde está vinculado;

Parágrafo 2º - Preencher um dos seguintes requisitos, apresentando a documentação comprobatória:

a) Possuir o Título de especialista em Endoscopia Digestiva emitido por órgão ou instituição oficialmente designada para este fim no país onde reside.

b) Ter ou estar realizado formação regular em programa oficial de especialização em Endoscopia Digestiva por no mínimo 2 (dois) anos (equivalente ao programa brasileiro de residência médica, ou treinamento nos CETs da SOBED).

c) Comprovar exercer Endoscopia Digestiva por no mínimo 2 (dois) anos assinada pelo médico responsável técnico (ou correlato) da instituição onde trabalha.

Parágrafo 3º – Todos os requerimentos, declarações, certificados e documentos devem ser apresentados com Tradução Juramentada e Apostilamento de Haia.

Parágrafo 4º – Aos Associados Estrangeiros são vetados o direito a voto e a participação em cargo de diretoria e administrativos, mantendo-se as demais prerrogativas equivalentes a respectiva categoria de associados.

Parágrafo 5º – Os Associados Estrangeiros não terão isenção de sua anuidade.

SEÇÃO II

DOS DIREITOS E DEVERES DOS ASSOCIADOS

Artigo 26º - São direitos e deveres dos Associados Titulares da SOBED:

a) Votar e ser votado;

b) Convocar, nos termos do Artigo 31º, Parágrafo Único deste Estatuto, Assembleias Gerais;

c) Demitir-se da condição de Associado da Entidade, mediante comunicação escrita;

d) Usar a nominação de Associado Titular da SOBED;

e) Participar das atividades regulares promovidas pela Entidade;

f) Receber comunicações emitidas pela Entidade;

g) Recorrer, a quem de direito, das decisões da Entidade que lhes parecerem desconformes com este Estatuto e com a legislação vigente.

h) Receber um certificado comprovador de sua condição emitido pela Diretoria Executiva.

i) Ministrar palestras nos Congressos e outros eventos promovidos pela SOBED, quando convidados pela Comissão Científica ou pela diretoria da SOBED Nacional ou pela SOBED Regional ou das

f) Comissão de Título de Especialista e sua Atualização.

Parágrafo 2º - Comissões Provisórias são aquelas cuja criação se der em razão de fatos ou circunstâncias emergentes e sua duração limitar-se-á ao esgotamento do tema ou solução do caso em virtude dos quais se originaram.

Parágrafo 3º - As Comissões são regulamentadas por Regimento Interno e/ou Regulamentos Internos próprios, aprovados pela Diretoria e/ou Conselho Deliberativo.

Parágrafo 4º - As Comissões serão compostas por um mínimo de 06 (seis) Associados Titulares da SOBED, com renovação de 1/3 (um terço) dos seus membros a cada novo mandato da Diretoria da SOBED. Exceções para a Comissão de Centros de Avaliação e Credenciamento de Centros de Treinamento e Comissão de Título de Especialista e Atualização, as quais serão compostas por, no mínimo 09 (nove) associados e a Comissão de Sede que será composta de no mínimo 01 (um) Associado da SOBED, sempre Titulares e quites com a tesouraria.

Parágrafo 5º - A nomeação dos integrantes e dos respectivos coordenadores das Comissões é competência exclusiva da Diretoria da SOBED sendo obrigatoriamente empossados no mesmo momento da posse da Diretoria eleita.

Artigo 69º - Compete à Comissão Eleitoral, de Estatuto, Regimentos e Regulamentos:

a) estudar e dar parecer sobre toda a matéria pertinente ao estatuto da SOBED, especialmente sobre as propostas de reforma estatutária, e seus Regimentos e Regulamentos;

b) regulamentar o processo eleitoral e supervisionar a realização dos pleitos, zelando pela rigorosa observância aos dispositivos estatutários e legais.

c) deferir ou indeferir o registro das chapas concorrentes às eleições, assegurando a possibilidade de interposição de recurso, o qual será apreciado e julgado pela própria Comissão Eleitoral, de forma fundamentada, em instância única e definitiva.

Artigo 70º - Compete à Comissão de Admissão apreciar e emitir parecer sobre pedidos de admissão ao quadro social da SOBED.

Artigo 71º - Compete à Comissão Científica e Editorial:

a) estudar e emitir parecer sobre procedimentos da endoscopia do sistema digestivo, tanto quanto aos procedimentos em uso como em relação a possíveis inovações;

b) organizar cursos, pesquisas e inquéritos científicos da especialidade;

c) sugerir o temário dos eventos científicos nacionais;

Artigo 81º - A data e o local dos eventos científicos nacionais deverão ser definidos pelos associados titulares da SOBED, quites com suas obrigações, em votação conjunta com os associados das demais entidades que integram a SBAD, durante a Semana Brasileira do Aparelho Digestivo.

Parágrafo Único - O estudo de viabilidade técnica, econômica e financeira, contendo planilha detalhada de custos, deverá ser apresentado no momento da inscrição da Candidata para a escolha da cidade-sede, sendo após analisada pelo Conselho Deliberativo da SOBED Comissão Organizadora da SBAD, seguindo-se os termos previstos no Regimento da SBAD.

Artigo 82º - As Comissões Organizadoras dos eventos científicos nacionais elaborarão regimentos a que estarão subordinados os referidos conclaves.

Artigo 83º - O Conferencista Nacional será indicado, em lista tríplice, pela Comissão Organizadora e pela Diretoria da SOBED, e escolhido pelo Conselho Deliberativo.

Artigo 84º - A instituição de prêmios no âmbito da especialidade caberá à Diretoria da SOBED, a quem compete editar as respectivas normas, as quais deverão ser submetidas à apreciação e aprovação do Conselho Deliberativo.

Parágrafo Único – As ações institucionais de reconhecimento e valorização, tais como homenagens, medalhas, placas comemorativas e distinções honoríficas concedidas à profissão, à iniciação científica, aos associados, à instituição e à especialidade, não dependem de regulamentação específica, sendo de competência exclusiva da Diretoria da SOBED.

Artigo 85º - As Jornadas Científicas e Cursos de Atualização, ou outros tipos de reunião científica, poderão ser organizados em qualquer época, em conformidade com o entendimento entre a Diretoria das Unidades Estaduais interessadas e a Diretoria da SOBED.

CAPÍTULO VII

DO TÍTULO DE ESPECIALISTA

Artigo 86º - A SOBED reserva-se o direito de disciplinar, através de normas próprias e daquelas constantes de legislação específica, a concessão de Título de Especialista em Endoscopia Digestiva, bem como sua atualização, em conjunto com a Associação Médica Brasileira.

Artigo 87º - Tais normas próprias, após serem elaboradas pela Comissão de Título de Especialista e sua Atualização e aprovadas pelo Conselho Deliberativo e Assembleia Geral, deverão ser divulgadas por qualquer meio de comunicação.

Artigo 88º - Por determinação do Conselho Federal de Medicina o Título de Especialista deve ser registrado junto ao Conselho Regional de Medicina em que o médico estiver inscrito

CAPÍTULO VIII

DAS INFRAÇÕES E PENALIDADES

Artigo 89º - Qualquer Associado da SOBED é passível de punição por conduta em desacordo com o preceituado neste estatuto e no regimento de práticas antiéticas, nos diplomas legais que regulam a medicina brasileira da entidade e no Código de Ética Médica.

Artigo 90º - As penalidades graduar-se-ão de acordo com a natureza e gravidade da infração, bem como com a existência de reincidência.

Parágrafo 1º - As penalidades são as seguintes:

a) advertência, no caso de faltas leves, quando o culpado tomará ciência da punição por meio de expediente reservado, vedada a divulgação;

b) censura pública, aplicável aos reincidentes em penalidade de advertência ou autores de faltas consideradas de média gravidade, da qual será dada ciência ao punido e ao quadro associativo;

c) Suspensão, a que ficarão sujeitos os reincidentes em cominações de censura pública ou autores de faltas consideradas graves, os quais terão seus direitos suspensos de 6 (seis) meses a 1 (um) ano;

d) Exclusão, penalidade máxima, que será imposta aos reincidentes em faltas graves ou autores de faltas gravíssimas contra a ética e o decoro pessoal ou profissional, bem como os que atentarem contra a existência da Sociedade, os que desrespeitarem as decisões estatutárias e dos órgãos diretivos e os que recusarem pagar anuidades estipuladas por dois anos consecutivos.

Parágrafo 2º - Os processos de exclusão e de readmissão dos inclusos nos casos de médicos que atentarem contra a existência as Sociedade e os que desrespeitarem as decisões estatutárias e dos órgãos diretivos deverão ser referendados pela Assembleia Geral.

Artigo 91º - O processo de punição será instaurado pela Comissão de Ética e Defesa Profissional ou pela Diretoria da SOBED, de acordo com o regimento específico.

Artigo 92º - Durante o processo de apuração de infração estatutária ou ética será sempre assegurado ao Associado amplo direito de acesso ao processo e de defesa.

Artigo 93º - Os recursos contra decisões dadas ao processo poderão ser interpostos dentro dos 30 (trinta) dias subsequentes àquela data em que o interessado tiver ciência das mesmas, devendo ser apreciados pela Comissão de Ética e de Defesa Profissional e decididos pela Assembleia Geral.

Artigo 94º - Serão excluídos da SOBED:

a) Os que atentarem contra a existência da Sociedade;



REPORTER 1:
The celebration for the reopening of the city of Wuhan, the birthplace of the coronavirus epidemic in China. A handbook that will help Brazilian doctors. And an exclusive interview with Bill Gates. These are the topics of this week's Mundo China. A joint production by CCTV and Bandnews.

0:21s
REPORTER 2:
Hello everyone. We are broadcasting live from São Paulo, home to CCTV's Latin America studios. After 11 weeks of strict lockdown, the quarantine in the city of Wuhan, the capital of Hubei where the Covid-19 outbreak began, officially comes to an end, and the city can resume activities after the coronavirus risk. The end of the lockdown was marked by a special light show that illuminated the Wuhan sky at midnight on Wednesday. In the following news report, we will see how the return to normalcy went during the city's reopening. Check it out!

1:03s
REPORTER 3:
The impressive light show also paid tribute to healthcare professionals from other regions of China who came to help the city overcome the outbreak, as a token of Wuhan's gratitude. Several skyscrapers and bridges project colorful images of healthcare workers, police troops, and key workers from other professions who made invaluable contributions to keeping the city going during its toughest times. Toll booths opened their barriers to allow vehicles through for the first time since January 23rd. A total of 276 passenger trains were scheduled to leave Wuhan on Wednesday, carrying an estimated 55,000 travelers. To go through the boarding process, passengers must first present a valid health code via a mobile app upon entering the train station, in addition to having their body temperature checked. Passengers are also

advised to keep their masks on at all times during train travel. Wuhan Tianhe International Airport began resuming domestic passenger flights this Wednesday. Strict measures remain in place at the airport, with passengers required to undergo mandatory temperature checks and display a health verification pass obtained by scanning QR codes on mobile phones before entering the terminal building or the airport's arrival hall.

2:35s
INTERVIEWEE 1:
Now everything has come to life and people are going out and moving around. I feel like I am gradually stepping out of the darkness and into the light that brightens our hearts.

2:46s
INTERVIEWEE 2:
I truly feel like we have been through all four seasons. I can really feel the willpower of the people of Wuhan. I am certain that Wuhan will regain its past vitality and vigor.

3:04s
REPORTER 2:
Microsoft founder Bill Gates shared his thoughts on the global prevention and control of the virus in an exclusive interview with CCTV, expressing his respect and admiration for the medical professionals fighting Covid-19 around the world.

3:29
BILL GATES
Once the government became fully involved in the second half of January, the idea of reducing this contact emerged, reviving the quarantine concept that had been discussed for a long time, and it was executed in a very serious manner. So, I am very glad it worked, because it creates a blueprint, at least for wealthy countries like China. They will handle it in their own way, they won't do the exact same thing, as it depends on the society. China was the first to have to deal with this... It is always difficult to be the country where something first emerges because so little is known about it. But now, what China did has helped the rest of the world. Now that China is, for the most part, back to work, the fact that China is participating in supplying some of the critical supplies can make a huge difference. It is incredible, particularly in the early days when very little was known about the risks, that even doctors who were not specifically working with coronavirus patients had significant exposure. Just the fact that they continued to work while realizing that something was spreading is very impressive. The hours they worked, the difficult conditions they were in, sometimes having to isolate from family because of this infection risk, wherever the disease is, we see how healthcare professionals step up their efforts, first in China, now in Europe and the United States. It is amazing what they are doing. Unfortunately, underdeveloped countries will likely be the next big wave, and their capacities will be even lower. Therefore, healthcare professionals will face an even tougher situation.

5:28s
REPORTER 2:

Based on the experiences lived in China against the coronavirus, a special team of translators and healthcare professionals launched a free Portuguese version of the Handbook of Covid-19 Prevention and Treatment. The handbook was developed from the Mandarin original with the aim of helping Brazilian healthcare professionals combat the pandemic.

5:54s
REPORTER 4:
The Covid-19 Prevention and Treatment Handbook was recently released in its digital version. Next week, they will launch the printed version, which will be distributed to hospitals free of charge.

6:15s
BOB WEI:
Our work was based on the original Chinese version produced by Jinan University in China, by its affiliated hospital. And this handbook covers how doctors and nurses should perform care and treatment procedures for both confirmed and suspected Covid-19 patients. Our intention is for Brazilian doctors to benefit from the experience of the Chinese people, Chinese doctors, and Chinese hospitals, you know? Trying to reach zero medical staff contamination, helping them, right? The idea was to help the medical staff, nurses, and hospital staff avoid getting infected by the novel coronavirus. And in this version of the handbook, we tried to be as faithful as possible, staying as close to the original version as we could, and we sought help from several Brazilian doctors and specialists so that the terminology used aligns with their daily routine, to make it easier for everyone to read and understand.



07:42s:
MARCIO LAMAS LOPES:
Iam one of the doctors who was invited to assist with the technical review of the COVID-19 handbook, which is of utmost importance for the country. It helps us right from the moment of

admission, during patient triage in the emergency room, and with the proper workflow for hospitalization or discharge. The essential part of putting on and removing personal protective equipment so that the professional does not become contaminated with aerosol secretions from patients, guidance on the medication part, medications that are having good efficacy in treating patients, the issue of mechanical ventilation also helps us a lot in this part of the conducts to be taken, for the benefit of the patient. So, it is a handbook that came to add value, it helps all our healthcare professionals a lot, and I am sure that with it many patients will benefit and will be able to fight this Covid-19, this pandemic that Brazil and the world are facing.

Interview link: https://www.facebook.com/502267346597124/videos/223552235590269

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 17, 2026.



REPÓRTER 1:
A festa pela reabertura da cidade de Wuhan, lugar onde surgiu a epidemia de coronavírus na China. Um manual que vai ajudar os médicos brasileiros. E uma entrevista exclusiva com Bill Gates. São assuntos do Mundo China desta semana. Uma produção da parceria CCTV e Bandnews.

0:21s
REPÓRTER 2:
Olá a todos. Falamos direto de São Paulo, onde ficam os estúdios da CCTV na América Latina. Depois de 11 semanas de rígido confinamento, a quarentena na cidade de Wuhan, capital de Hubei, onde começou o surto do Covid-19, chega oficialmente ao fim, e a cidade pode retomar as atividades após o risco do coronavírus. O fim do bloqueio foi marcado por um show especial de luzes que iluminou o céu de Wuhan, à meia-noite da quarta-feira. Na seguinte reportagem, vamos ver como foi o retorno à normalidade na reabertura da cidade. Acompanhe!

1:03s
REPÓRTER 3:
O impressionante show de luzes também prestou homenagem aos profissionais de saúde de outras regiões da China, que vieram ajudar a cidade a superar o surto, como sinal de gratidão de Wuhan. Vários arranha-céus e pontes irradiam imagens coloridas de profissionais de saúde, tropas policiais e trabalhadores-chaves de outras profissões que fizeram contribuições inestimáveis para manter a cidade em seus momentos mais difíceis. Os pedágios abriram suas barreiras para permitir a passagem de veículos pela primeira vez desde 23 de janeiro. Um total de 276 trens e passageiros estavam planejados para deixar o Wuhan na quarta-feira, com um total estimado de 55 mil viajantes. Ao passar pelo processo de embarque, os passageiros precisam primeiro apresentar um código de saúde válido por meio de um aplicativo de celular ao entrar na estação de trem, além de verificar a temperatura corporal. Os passageiros também são aconselhados a manter suas máscaras

o tempo todo durante as viagens de trem. O aeroporto internacional Wuhan Tianhe começou a retomar os voos domésticos de passageiros nesta quarta-feira. Medidas rígidas permanecem em vigor no aeroporto, com os passageiros sendo obrigados a passar por verificações obrigatórias de temperatura e mostrar um passe de verificação de saúde obtido pela digitação de códigos QR em telefones celulares antes de entrar no edifício do terminal ou no saguão de chegada do aeroporto.

2:35s
ENTREVISTADA 1:
Agora tudo veio à vida e as pessoas estão saindo e se movimentando. Sinto que estou gradualmente saindo da escuridão para a luz que ilumina nossos corações.

2:46s
ENTREVISTADA 2:
Realmente sinto que passamos pelas quatro estações. Realmente sinto a força de vontade do povo Wuhan. Estou certa de que Wuhan recuperará sua vitalidade e vigor do passado.

3:04s
REPÓRTER 2:
O fundador da Microsoft, Bill Gates, compartilhou em uma entrevista exclusiva com a CCTV seus pensamentos sobre a prevenção e controle globais do vírus e expressou seu respeito e admiração pelos profissionais médicos que lutam contra o Covid-19 em todo o mundo.

3:29
BILL GATES
Uma vez que o governo estava totalmente envolvido na segunda metade de janeiro, surgiu a ideia de reduzir esse contato, retomando a ideia de quarentena, que vinha sendo discutida há muito tempo, foi feita de forma muito séria. Então, estou muito feliz que isso funcionou, porque isso cria, pelo menos para países que são ricos como a China, ou cria um modelo. Eles farão tudo da sua própria forma, não farão o mesmo, isso depende da sociedade. A China foi a primeira que teve que lidar com isso... É sempre difícil ser o país onde algo surge primeiro porque pouco é conhecido sobre isso. Mas agora o que a China fez foi ajudar o resto do mundo. Agora que a China está, em grande parte, de volta ao trabalho, o fato de a China participar do fornecimento de alguns dos suprimentos críticos pode fazer uma enorme diferença. É incrível, particularmente nos primeiro dias, quando muito pouco era sabido sobre os riscos, mesmo os médicos que não estavam trabalhando especificamente com pacientes que tinham coronavírus tinham significativas exposições, apenas a ideia de que eles continuaram a trabalhar enquanto começaram a perceber que algo estava se espalhando, é muito impressionante. As horas que eles trabalharam, as condições difíceis que estão em, às vezes terem que isolar-se da família por causa desse risco de infecção, onde quer que a doença esteja, nós vemos como os profissionais de saúde intensificam seus esforços, primeiro na China, agora na Europa e nos Estados Unidos. É incrível o que eles estão fazendo. Infelizmente, países subdesenvolvidos provavelmente serão a próxima grande onda e suas capacidades vão ser ainda mais baixas. Então, os profissionais de saúde vão enfrentar uma situação ainda mais difícil.

5:28s
REPÓRTER 2:

A partir das experiências vividas na China contra o coronavírus, uma equipe especial de tradutores e profissionais da área da saúde lançaram, em português, em versão gratuita, o manual de prevenção e tratamento contra o Covid-19. O manual foi realizado a partir do original em Mandarim, com objetivos de ajudar os profissionais brasileiros da saúde no combate à pandemia.

5:54s
REPÓRTER 4:
O Manual de Prevenção e Tratamento contra o Covid-19 foi lançado recentemente na sua versão digital. Na próxima semana, lançarão a versão impressa, que será distribuída para os hospitais de forma gratuita.

6:15s
BOB WEI:
Nosso trabalho foi baseado no seu original feito em chinês pela faculdade de Jinan na China, pelo seu hospital afiliado à faculdade Jinan. E esse manual trata assuntos de como os médicos e os enfermeiros devem fazer os procedimentos de cuidados e tratamentos de pacientes e suspeitos do Covid-19. A nossa intenção é para que os médicos brasileiros tenham um pouco de experiência do povo chinês, do médico chinês, dos hospitais chineses, né? Tentar chegar a zero (a) contaminação da equipe médica ajudando, né? A ideia era ajudar a equipe médica, enfermeiros e as pessoas que trabalham no hospital a não se infectar pelo novo coronavírus. E nessa versão deste manual a gente procurou ser o mais fiel possível, o mais real da sua versão original e buscamos ajuda de vários médicos e doutores brasileiros para que as palavras usadas no manual sejam de acordo com o dia a dia deles, para facilitar a leitura e compreensão de todos.



07:42s:
MARCIO LAMAS LOPES:
Eu sou um dos médicos que foi convidado para auxiliar na correção técnica do manual COVID-19, em que ele tem extrema importância para o país, por nos auxiliar desde o

momento da admissão, da triagem de um paciente no pronto atendimento, o fluxo correto para internação ou não, ou sua alta. A parte essencial de colocação dos equipamentos de proteção individual e retirada destes para que o profissional não se contamine com secreções aerossóis dos pacientes, conduta auxílio na parte medicamentosa, medicamentos que estão tendo uma boa eficácia no tratamento dos pacientes, a questão da ventilação mecânica também nos auxilia bastante nessa parte de condutas a serem tomadas, para o benefício do paciente. Então é um manual que veio agregar, ajuda bastante todos os nossos profissionais da saúde e tenho certeza que com ele muitos pacientes vão ser beneficiados e vão conseguir combater essa Covid-19, essa pandemia que o Brasil e o mundo estão enfrentando.

Link da entrevista: https://www.facebook.com/502267346597124/videos/223552235590269

Exhibit C.II - Second Prong - Letters of Support and Resume

06/02/2026

To the USCIS Immigration Officer,

My name is José Celso Ardengh, and in my dual capacity as Chief of the Gastrointestinal Endoscopy Service and President of the Research Ethics Committee at Hospital Moriah, I have spent decades evaluating the technical progression and clinical integrity of gastrointestinal specialists. My perspective is shaped by senior academic roles at the University of São Paulo and a career dedicated to the complexities of biliopancreatic endoscopy and surgical gastroenterology. It is from this objective, institutional standpoint that I provide my assessment of Marcio Lamas Lopes, a professional whose clinical trajectory I have monitored since 2013.

The field of digestive endoscopy, particularly when involving high complexity interventions like Endoscopic Retrograde Cholangiopancreatography, commonly known as ERCP, and the management of postoperative complications, demands more than just rote technical skill. It requires a specific caliber of clinical decision making that I have seen Mr. Lopes master over the years. During our long term professional relationship, which began during his specialized residency, I have observed him navigating the nuances of complex biliary obstructions. In these scenarios, the ability to determine the most effective therapeutic route is what separates a standard practitioner from an expert. Mr. Lopes's performance in these high stakes environments is characterized by a level of composure and precision that is uncommon among his contemporaries.


Furthermore, the scientific engagement of Mr. Lopes has provided tangible benefits to our department and the broader medical community. He has been instrumental in the implementation of clinical protocols and the optimization of workflow standards under my supervision. His role in research is evidenced by his documented work on advanced topics, such as the use of endoscopic dilation combined with triamcinolone for rectal stenosis and the diagnostic challenges of colorectal Non Hodgkin lymphoma. These are not merely academic exercises but represent significant contributions to the clinical literature that directly inform how we treat difficult cases today. His active participation in major gastrosurgical forums further validates his commitment to the ongoing evolution of our specialty.

Beyond his technical and scientific output, I must emphasize the leadership role Mr. Lopes occupies within the hospital environment. In coordinating medical teams and training residents and fellows, he does more than fulfill what is expected of a competent physician. He brings a level of calm, practical judgment, and interpersonal balance that makes difficult work proceed more smoothly for the entire team. I have observed that his ability to aggregate people around a common purpose is one of his most valuable qualities, especially in moments that require steadiness and clear decision making. This is not a common trait, and in my experience it distinguishes him from many of his peers. He contributes not only by performing well himself, but by helping others work better around him, which is a meaningful strength in any medical service.

Based on my extensive experience as a senior academic and head of service, I position the technical and institutional impact of Mr. Lopes well above the average of his peers. His work

reflects a rare combination of procedural mastery and scientific rigor that is essential for the advancement of modern gastroenterology. In my view, his expertise is perfectly aligned with the high standards of the United States healthcare system, where his ability to manage complex clinical cases and lead medical teams will contribute directly to American clinical innovation and patient safety. I offer my full professional endorsement for his future contributions to the medical field in the United States and remain available to clarify any aspect of this evaluation.

Sincerely,



José Celso Ardengh
Chief of the Gastrointestinal Endoscopy Service
President of the Research Ethics Committee, Hospital Moriah
E-mail: jardengh@gmail.com
Phone: +55 11 996886312

Assinado digitalmente por:
JOSE CELSO ARDENGH
Data: 15/06/2026 - 17:03:56h

Contact
www.linkedin.com/in/josé-celso-ardengh-3302746 (LinkedIn)

Top Skills
Clinical Research
Surgery
Medicine

Languages
Portuguese
English
Spanish

José Celso Ardengh

Head of Gastrointestinal Service at Hospital Moriah
Greater São Paulo Area

Summary

Graduated from the School of Medical Sciences of São Francisco University - Bragança Paulista (1987). Medical Residency in Surgery/Gastroenterology at Servidor Público Municipal Hospital (1988/1989). Specialization in Digestive Endoscopy at the Hospital das Clínicas of the School of Medicine of the University of São Paulo (1990). Specialization in Biliopancreatic Endoscopy and Endoscopic Ultrasound at Clinique D'Alma in Paris (1991). Master's degree (1999) and Ph.D. (2002) in Medicine (Surgery) from the School of Medical Sciences of Santa Casa of São Paulo. Professor (2009) in Surgical Gastroenterology (RCG 324) from the Department of Surgery and Anatomy of the Ribeirão Preto School of Medicine (University of São Paulo). Full Professor in the Graduate Studies Program of the Department of Diagnostic Imaging (DDI) at Paulista School of Medicine - UNIFESP. Head of the Gastrointestinal Endoscopy Service and President of the Research Ethics Committee at Moriah Hospital since 2015. Full Member of the Brazilian Society of Digestive Endoscopy and the Brazilian Federation of Gastroenterology. Gastroenterologist licensed to perform upper and lower gastrointestinal endoscopy. Expertise and skills in highly complex diagnostic and therapeutic gastrointestinal endoscopic procedures. Specialized in biliopancreatic diseases and neoplasms of the digestive system. Experience in the field of Medicine, particularly in clinical and surgical.

Experience

REDE MORIAH SAUDE LTDA
Head of the Gastrointestinal Endoscopy Service at Moriah Hospital
January 2015 - Present (11 years 8 months)
São Paulo, São Paulo, Brasil

IPIRANGA HOSPITAL
Assistant doctor, Digestive Endoscopy Unit
September 2009 - December 2021 (12 years 4 months)

São Paulo

Endoscopist specializing in biliary tract and pancreatic procedures.

HOSPITAL DAS CLÍNICAS, RIBEIRÃO PRETO MEDICAL SCHOOL – UNIVERSITY OF SÃO PAULO

Assistant doctor in the Digestive Endoscopy Section of the Department of Surgery and Anatomy

August 2004 - December 2021 (17 years 5 months)
Ribeirão Preto e Região

Develop the physicians skills in diagnostic and therapeutic endoscopic ultrasound.

Advanced research in EUS-guided pancreatic and biliary therapy.

HOSPITAL 9 DE JULHO

Assistant doctor in the Digestive Endoscopy Service and Head of the Biliary Tract and Pancreas Unit

August 2000 - December 2021 (21 years 5 months)
São Paulo, Brasil

Diagnostic and Therapeutic Upper gastrointestinal Endoscopic procedures

Diagnostic and Therapeutic Lower gastrointestinal Endoscopic procedures

Diagnostic Endoscopic Ultrasound

Therapeutic Endoscopic Ultrasound

Therapeutic Endoscopic Retrograde Cholangiopancreatography

PAULISTA SCHOOL OF MEDICINE

Assistant doctor of the Endoscopic Service

January 1997 - September 2004 (7 years 9 months)

Developed the sectorial EUS techniques for the diagnosis and therapeutic procedures.

ISRAELITA ALBERT EINSTEIN HOSPITAL

Assistant doctor of the Endoscopic Service

January 1990 - August 2002 (12 years 8 months)

Developed diagnostic and therapeutic endoscopy area, introduced the radial endoscopic ultrasound technique for the diagnosis in 1991 and the sectorial endoscopic ultrasound for the diagnosis and therapeutic procedures in 1997.

Education

USP - University of São Paulo

Professor, Department of Surgery and Anatomy, HCFMRP-USP · (2009 - 2009)

Santa Casa de São Paulo School of Medicine

PhD, in Medicine · (1999 - 2002)

Santa Casa de São Paulo School of Medicine

MD, Master degree in Medicine · (1998 - 1999)

School of Medical Sciences of Santa Casa of São Paulo

Master Degree in School of Medical Sciences of Santa Casa of São Paulo, Clinical, Hospital, and Managed Care Pharmacy · (1997 - 1999)

São Francisco University

Graduated, Medicine · (1982 - 1987)

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 17, 2026

Contact

www.linkedin.com/in/josé-celso-ardengh-3302746 (LinkedIn)

Top Skills

Clinical Research
Surgery
Medicine

Languages

Portuguese
English
Spanish

José Celso Ardengh

Head of Gastrointestinal Service at Hospital Moriah
Greater São Paulo Area

Summary

Graduado pela Faculdade de Ciências Médicas da Universidade São Francisco - Bragança Paulista (1987). Residência Médica em Cirurgia/Gastrenterologia no Hospital do Servidor Público Municipal (1988/1989). Especialização em Endoscopia Digestiva no Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (1990). Especialização em Endoscopia Biliopancreática e Ecoendoscopia na Clinique D´Alma em Paris (1991). Mestrado (1999) e doutorado (2002) em Medicina (Cirurgia) pela Faculdade de Ciências Médicas da Santa Casa de São Paulo. Título de Professor Livre-docente (2009) em Gastrenterologia Cirúrgica (RCG 324) pelo Departamento de Cirurgia e Anatomia da Faculdade de Medicina de Ribeirão Preto (Universidade de São Paulo). Professor Pleno do Curso de Pós-graduação do Departamento de Diagnóstico por Imagem (DDI) da Escola Paulista de Medicina - UNIFESP. Chefe do Serviço de Endoscopia Gastrintestinal e Presidente do Comitê de Ética em Pesquisa do Hospital Moriah, desde 2015. Titular da Sociedade Brasileira de Endoscopia Digestiva e da Federação Brasileira de Gastrenterologia. Gastrenterologista licenciado em endoscopia digestiva alta e baixa. Competências e habilidades em procedimentos endoscópicos digestivos de alta complexidade diagnóstica e terapêutica. Especializado em doença biliopancreática e neoplasias do sistema digestório. Experiência na área da Medicina em especial na gastrenterologia clínica e cirúrgica.

Experience

REDE MORIAH SAUDE LTDA

Head of the Gastrointestinal Endoscopy Service at Hospital Moriah
January 2015 - Present (11 years 8 months)
São Paulo, São Paulo, Brasil

Hospital Ipiranga

Médico assistente do Setor de Endoscopia Digestiva
September 2009 - December 2021 (12 years 4 months)

São Paulo

Médico endoscopista especializado em realizar procedimentos sobre a via biliar e pâncreas.

Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto - Universidade de São Paulo

Médico assistente da Secção de Endoscopia Digestiva do Depto. de Cirurgia e Anatomia

August 2004 - December 2021 (17 years 5 months)

Ribeirão Preto e Região

Develop the physicians skills in diagnostic and therapeutic endoscopic ultrasound.

Advanced research in EUS-guided pancreatic and biliary therapy.

Hospital 9 de Julho

Médico assistente do Serviço de Endoscopia Digestiva e Responsável pela Via Biliar e Pâncreas

August 2000 - December 2021 (21 years 5 months)

São Paulo, Brasil

Diagnostic and Therapeutic Upper gastrointestinal Endoscopic procedures

Diagnostic and Therapeutic Lower gastrointestinal Endoscopic procedures

Diagnostic Endoscopic Ultrasound

Therapeutic Endoscopic Ultrasound

Therapeutic Endoscopic Retrograde Cholangiopancreatography

Escola Paulista de Medicina

Assistant doctor of the Endoscopic Service

January 1997 - September 2004 (7 years 9 months)

Developed the sectorial EUS techniques for the diagnosis and therapeutic procedures.

Hospital Israelita Albert Einstein

Assistant doctor of the Endoscopic Service

January 1990 - August 2002 (12 years 8 months)

Developed diagnostic and therapeutic endoscopy area, introduced the radial endoscopic ultrasound technique for the diagnosis in 1991 and the sectorial endoscopic ultrasound for the diagnosis and therapeutic procedures in 1997.

Education

USP - Universidade de São Paulo

Livre-docência, Departamento de Cirurgia e Anatomia do HCFMRP-USP · (2009 - 2009)

Faculdade de Medicina da Santa Casa de São Paulo

PhD, in Medicine · (1999 - 2002)

Faculdade de Medicina da Santa Casa de São Paulo

MD, Master degree in Medicine · (1998 - 1999)

the School of Medical Sciences of Santa

Master Degree in Faculdade de Medicina da Santa Casa de São Paulo, Clinical, Hospital, and Managed Care Pharmacy · (1997 - 1999)

Universidade São Francisco

Graduated, Medicine · (1982 - 1987)

May 15th, 2026

To Whom It May Concern,

As a Professor of Digestive System Surgery at the University of São Paulo and Supervisor of the Bariatric and Metabolic Surgery Unit at Hospital das Clínicas, my professional focus is centered on the complex management of patients with severe obesity. Throughout my career as a lead surgeon, particularly at Hospital 9 de Julho, I have navigated the critical intersection between surgical interventions and endoscopic support. It is within this demanding environment that I first began working with Marcio Lamas Lopes in 2013, during his first year of medical residency in endoscopy.

Observing a physician's transition from training to senior practice provides a clear perspective on their technical trajectory. Over the last decade, I have worked directly alongside Mr. Lamas Lopes as he performed diagnostic and therapeutic endoscopic exams for both my inpatient and outpatient cases. In the context of bariatric surgery, the endoscopic interface is not merely diagnostic; it is often the first-line treatment for high-stakes complications.

I had direct contact with Marcio Lamas Lopes' work in treating acute post-operative issues such as gastrointestinal bleeding, stenoses, and fistulas following Bypass and Sleeve procedures. In my extensive experience supervising surgical teams, his performance in these high-stakes scenarios has set him apart from his peers. He has demonstrated a level of technical mastery and diagnostic intuition that has made him a primary reference within our department; in fact, his medical approaches and procedural protocols are frequently adopted and modeled by other specialists in our unit. Among the many physicians I have trained and worked with across prestigious institutions, his ability to manage complex endoscopic bariatric complications is the highest I have seen from colleagues consistently seeking guidance in challenging cases.

Furthermore, his presence in the endoscopy service has had a tangible impact on the department's institutional standing. Mr. Lamas Lopes contributed significantly to the processes that led the service to obtain quality seals and its subsequent recognition as a primary training center for endoscopists by the Brazilian Society of Digestive Endoscopy (SOBED). This level of institutional accreditation is only possible when the surgical staff operates at a high standard of procedural consistency and technical safety.

The rising prevalence and complexity of obesity represent a critical healthcare challenge, particularly in the United States, where the demand for safe and minimally invasive treatment pathways is urgent. Based on my experience, integrating advanced endoscopic procedures such as gastric balloon placement, endoscopic gastroplasty, and bariatric revisions is essential for improving long-term outcomes and reducing the economic and surgical burden of obesity-related complications. I believe that Mr. Lamas Lopes' technical maturity and proven ability to deliver consistent results in these high-stakes areas will have a direct, positive impact on the U.S. healthcare system. His presence in the American medical community would contribute significantly to the evolution of treatment standards by providing more patients with access to surgical-level outcomes through the safer, less traumatic lens of advanced endoscopy. In my view, he is a specialist who operates at the highest level of his field and holds the capacity to influence the future of obesity management on a broader scale.

Sincerely,



Dr. Denis Pajecki
Professor and Head Surgeon
Hospital das Clínicas, Faculty of Medicine, University of São Paulo (USP)
denis.pajecki@hc.fm.usp.br | +55 11 98190-2622

Contact

www.linkedin.com/in/denis-pajecki-918b112a (LinkedIn)

Top Skills

Educational Technologies
Career Planning
Instruction

Denis Pajecki

Surgeon, Professor, and Researcher
São Paulo, São Paulo, Brazil

Summary

For more than two decades, I have dedicated my career to surgical excellence and medical education at the Hospital das Clínicas of the School of Medicine of USP. As a Professor, I share my passion for the field of Digestive Tract Surgery, inspiring the next generations of physicians.

My surgical journey includes working as a Digestive and Bariatric Surgeon, where I strive to provide quality care to patients. Since 2002, I have had the privilege of being part of the outstanding team at Nove de Julho Hospital.

In addition to clinical practice, I am also Director of the Obesity Control Center, where I lead initiatives that promote the health and well-being of patients with a focus on obesity. My commitment to transforming lives is grounded in a solid education, with Master's and Doctoral degrees in Digestive Tract Surgery, obtained from the School of Medicine of USP.

My career has been driven by the pursuit of contributing to digestive health and the advancement of medical education. I am dedicated to providing quality care, sharing knowledge, and inspiring the next generation of surgeons.

Experience

Hospital das Clínicas, University of São Paulo Medical School

24 years 1 month

Supervisor of the Bariatric and Metabolic Surgery Unit at HCFMUSP
December 2024 - Present (1 year 9 months)
São Paulo, Brazil

Professor
December 2020 - Present (5 years 9 months)

Digestive Tract-Bariatric Surgeon
August 2002 - Present (24 years 1 month)
São Paulo, São Paulo, Brazil

9 de Julho Hospital
Bariatric Surgeon
May 2009 - Present (17 years 4 months)
São Paulo, São Paulo, Brazil

Obesity Control Center
Director
March 2008 - Present (18 years 6 months)

Education

University of São Paulo (USP) Medical School

Master's (2001) and Doctorate (2005) in Digestive Tract Surgery · (1989 - 1994)

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 17, 2026

Contato

www.linkedin.com/in/denis-pajecki-918b112a (LinkedIn)

Principais competências

Tecnologias educacionais
Planejamento de carreira
Instrução

Denis Pajecki

Cirurgião, Professor e Pesquisador
São Paulo, São Paulo, Brasil

Resumo

Há mais de duas décadas venho dedicando minha carreira à excelência cirúrgica e ao ensino médico no Hospital das Clínicas da Faculdade de Medicina da USP. Como Professor Livre-Docente, compartilho minha paixão pelo campo da Cirurgia do Aparelho Digestivo, inspirando as próximas gerações de médicos.

Minha jornada cirúrgica inclui a atuação como Cirurgião do Aparelho Digestivo e Bariátrico, onde trabalho para proporcionar tratamento de qualidade aos pacientes. Desde 2002, tenho o privilégio de fazer parte da equipe de excelência no Hospital Nove de Julho.

Além da prática clínica, sou também Diretor do Centro de Controle da Obesidade, onde lidero iniciativas que promovem a saúde e o bem-estar dos pacientes com foco na obesidade. Meu compromisso em transformar vidas é fundamentado em uma sólida educação, com Mestrado e Doutorado em Cirurgia do Aparelho Digestivo, obtidos na Faculdade de Medicina da USP.

Minha trajetória tem sido impulsionada pela busca em contribuir para a saúde digestiva e o avanço da educação médica. Estou dedicado a oferecer tratamento de qualidade, compartilhar conhecimento e inspirar a próxima geração de cirurgiões.

Experiência

Hospital das Clínicas da Faculdade de Medicina da USP
24 anos 1 mês

Supervisor da Unidade de Cirurgia Bariátrica e Metabólica do HCFMUSP
dezembro de 2024 - Present (1 ano 9 meses)
São Paulo, Brasil

Professor Livre-Docente
dezembro de 2020 - Present (5 anos 9 meses)

Cirurgiao do Aparelho Digestivo -Bariatrico
agosto de 2002 - Present (24 anos 1 mês)
São Paulo, São Paulo, Brasil

Hospital 9 de Julho
Cirurgião Bariatrico
maio de 2009 - Present (17 anos 4 meses)
São Paulo, São Paulo, Brasil

Centro de Controle da Obesidade
Diretor
março de 2008 - Present (18 anos 6 meses)

Formação acadêmica

Faculdade de Medicina da USP
Mestre (2001) e Doutor (2005) em Cirurgia do Aparelho Digestivo · (1989 - 1994)

May 15th, 2026


To the USCIS Immigration Officer,

In obesity care, the outcomes we hope for in the operating room often depend on what happens well before surgery. When a patient arrives with severe obesity and significant clinical risk, the pathway that prepares them safely is not abstract to me. It is a daily, practical sequence of decisions, procedures, and follow-up that has to be executed with consistency and technical control.

My name is José Afonso Sallet. I am the Medical Director of Instituto de Medicina Sallet in São Paulo, Brazil, where I care for patients in clinical and surgical treatment for obesity. I completed my medical training in Brazil and later earned a Master's degree in Digestive Surgery at the State University of Campinas. I have worked for many years in digestive and bariatric surgery, and I hold a Master Surgeon certification in Bariatric and Metabolic Surgery by the Surgical Review Corporation. In 1999, I was responsible for obtaining approval for the intragastric balloon protocol from the Brazilian Ministry of Health, and since then, I have remained closely involved with endoscopic approaches to obesity management.

I first met Marcio Lamas Lopes in April 2017 through a professional referral, at a time when I was seeking an endoscopist with the experience and precision needed to perform intragastric balloon placement and removal for my patients. From the beginning, our collaboration was straightforward. I followed his work directly in clinical practice, and he became part of the care pathway for patients who needed endoscopic interventions as a bridge to bariatric surgery or as part of endoscopic obesity treatments.

Over the years, I have observed Mr. Lopes performing procedures that require technical discipline and calm execution. In our routine, this has included intragastric balloon implantation and explantation, argon plasma coagulation, and endoscopic gastroplasty. I recall an especially complex endoscopic gastroplasty in which he demonstrated clear command of the technique and the ability to make quick, appropriate intraoperative decisions when the procedure presented challenges. In my field, it is easy for people to describe endoscopy as a set of manual steps. In reality, the difference between acceptable and truly safe practice is judgment under pressure and consistency across hundreds of repetitions.



His contribution to my program has been measurable not only in volume but in the consistency and reliability he brought to a critical stage of obesity treatment. Over approximately five years, Mr. Lamas Lopes performed an average of ten intragastric balloon procedures per month for patients in my weight-loss program, totaling more than 600 successful interventions. This level of sustained performance was only possible because of his precise, standardized approach to these procedures, which ensured predictable outcomes and minimized variability in patient responses. As a result, his method for conducting balloon placement and removal became a reference point in the clinical workflow, influencing how these procedures are performed in my practice. In practical terms, this consistency played a direct role in improving preoperative preparation for patients with morbid obesity, reducing surgical risk, and enabling definitive treatment under safer clinical conditions.

I trust and recommend Mr. Lopes's work without hesitation because I have seen how he operates in real clinical settings, combining technical competence in complex endoscopic procedures with a professional presence that supports a rigorous safety culture. Based on our continued collaboration, I expect that his ability to implement and scale high-yield endoscopic treatments will remain evident throughout his future practice. In my professional estimation, his expertise will have a direct and significant impact on the field of obesity management, specifically by increasing the availability of safe and effective non-surgical weight loss solutions. This contribution is particularly critical in healthcare systems facing high rates of morbid obesity where clinicians with his level of procedural consistency and clinical judgment are needed to improve patient safety and long-term health outcomes on a broader scale.

Sincerely,



José Afonso Sallet, MD
Medical Director, Instituto de Medicina Sallet
São Paulo, Brazil
atendimento@sallet.com.br
+55 11 92108 5532

Contact

www.linkedin.com/in/josé-sallet (LinkedIn)

Top Skills

Teaching

Team Development

Bariatric Surgery

Publications

AGEANDGENDER MAY INFLUENCE THE RESULTS OF ROUX-EN-Y GASTRIC BYPASS? Metabolic syndrome parameters. ARQUIVOS DE GASTROENTEROLOGIA (IMPRESSO), v. 51, p. 171-179, 2014.

The Impact of Temperament and Character Inventory Personality Traits on Long-Term Outcome of Roux-en-Y Gastric Bypass.

Eating Behavior as a Prognostic Factor for Weight Loss after Gastric Bypass.

.Early Post-operative Weight Change After Roux-en-Y Gastric Bypass Predicts Weight Loss at 12-Month Follow-up. OBESITY SURGERY, v. 8, p. 0.1007/s11695-0, 2020.

Application of BAROS' questionnaire in obese patients undergoing bariatric surgery with 2 years of evolution. ARQUIVOS DE GASTROENTEROLOGIA (ONLINE), v. 54, p. 60-64, 2017.

Dr. José Afonso Sallet

CEO and Medical Director at Sallet Institute of Medicine | Digestive Tract Surgeon

São Paulo, Brazil

Summary

Holds a degree in Medicine from Federal University of Santa Maria (1988), a specialization in Digestive Tract Surgery from the Brazilian College of Digestive Surgery (1995), a Master's degree in Digestive Tract Surgery from State University of Campinas (1997), a medical residency at 9 de Julho Hospital-SP and São Paulo State Medical School (1992), and a medical residency at the Study Center of 9 de Julho Hospital (1993). Currently, he is the Owner of Sallet Institute of Medicine. His main areas of practice include digestive surgery, bariatric surgery, and intragastric balloon procedures.

Experience

Sallet Institute of Medicine

Medical Director

April 1999 - Present (27 years 5 months)

São Paulo, Brazil

United States Surgical - USS

Visiting Professor, Functional Position: Consultant

January 2006 - December 2008 (3 years)

United State of America

9 de Julho Hospital-SP and São Paulo State Medical School

Fellowship, Position: Medical Residency Internship

1991 - 1993 (2 years)

Education

State University of Campinas

Master's Degree in Digestive Tract Surgery, Medicine · (1994 - 1997)

Brazilian College of Digestive Surgery (CBCD), Brazil.

Specialization in Digestive System Surgery, Medicine · (January 1993 – December 1995)

9 de Julho Hospital-SP and São Paulo State Medical School

Specialization - Medical Residency, Medicine · (January 1989 - December 1992)

Digestive System Surgical Clinic Study Center (CECCAD), Brazil.

University Extension Program in Continuing Course in Gastroenterology (Course load: 64 hours), Medicine · (1990 - 1990)

Study Center of 9 de Julho Hospital (CEH9J), Brazil.

5th Digestive Endoscopy Update Course (Course load: 28 hours), Medicine · (1990 - 1990)

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 17, 2026

Contato

www.linkedin.com/in/josé-sallet (LinkedIn)

Principais competências

Docência

Desenvolvimento de equipes

Cirurgia bariátrica

Publications

AGE AND GENDER MAY INFLUENCE THE RESULTS OF ROUX-EN-Y GASTRIC BYPASS? Metabolic syndrome parameters. ARQUIVOS DE GASTROENTEROLOGIA (IMPRESSO), v. 51, p. 171-179, 2014.

The Impact of Temperament and Character Inventory Personality Traits on Long-Term Outcome of Roux-en-Y Gastric Bypass.

Eating Behavior as a Prognostic Factor for Weight Loss after Gastric Bypass.

.Early Post-operative Weight Change After Roux-en-Y Gastric Bypass Predicts Weight Loss at 12-Month Follow-up. OBESITY SURGERY, v. 8, p. 0.1007/s11695-0, 2020.

Application of BAROS' questionnaire in obese patients undergoing bariatric surgery with 2 years of evolution. ARQUIVOS DE GASTROENTEROLOGIA (ONLINE), v. 54, p. 60-64, 2017.

Dr. José Afonso Sallet

CEO e Diretor Médico no Instituto de Medicina Sallet | Cirurgião do aparelho digestivo

São Paulo, Brasil

Resumo

Possui graduação em Medicina pela Universidade Federal de Santa Maria(1988), especialização em Cirurgia do Aparelho Digestivo pelo Colégio Brasileiro de Cirurgia Digestiva(1995), mestrado em Cirurgia do Aparelho Digestivo pela Universidade Estadual de Campinas(1997), residência médica pelo Hospital 9 de Julho-SP e Faculdade de Medicina do Estado de São Paulo(1992) e residência médica pelo Centro de Estudos do Hospital 9 de julho(1993). Atualmente é Proprietário do Instituto de Medicina Sallet. Atuando principalmente nos seguintes temas: cirurgia digestiva, cirurgia bariátrica e balão intragástrico.

Experiência

Instituto de Medicina Sallet

Diretor médico

abril de 1999 - Present (27 anos 5 meses)

São Paulo, Brasil

United States Surgical - USS

Professor Visitante, Enquadramento Funcional: Consultor

janeiro de 2006 - dezembro de 2008 (3 anos)

Estados Unidos

Hospital 9 de Julho-SP e Faculdade de Medicina do Estado de São Paulo

Bolsista, Enquadramento Funcional: Estágio de Residência Médica

1991 - 1993 (2 anos)

Formação acadêmica

Universidade Estadual de Campinas

Mestrado em Cirurgia do Aparelho Digestivo., Medicina · (1994 - 1997)

Colégio Brasileiro de Cirurgia Digestiva, CBCD, Brasil.
Especialização em Cirurgia do Aparelho Digestivo., Medicina · (janeiro de 1993 - dezembro de 1995)

Hospital 9 de Julho-SP e Faculdade de Medicina do Estado de São Paulo
Especialização - Residência médica., Medicina · (janeiro de 1989 - dezembro de 1992)

Centro de Estudos da Clinica Cirúrgica do Aparelho Digestivo, CECCAD, Brasil.
Extensão universitária em Curso Continuado em Gastroenterologia. (Carga horária: 64h)., Medicina · (1990 - 1990)

Centro de Estudos do Hospital 9 de julho, CEH9J, Brasil.
V Curso de atualização em endoscopia digestiva. (Carga horária: 28h)., Medicina · (1990 - 1990)

Artur Parada

05/15/2026

São Paulo, Brazil

To USCIS,

When you spend decades building and running an endoscopy service, you learn to separate good clinicians from the few physicians who make the entire team work better. Technical ability matters, of course, but what sustains quality in a real service is repeatability, sound judgment, and the ability to teach others without diluting standards.

My name is Artur Adolfo Parada, MD. I founded and coordinated the Gastrointestinal Endoscopy Sector at Hospital 9 de Julho, where I worked for more than forty years, and I serve as Medical Director of Artur Parada Medicina Diagnóstica in São Paulo, Brazil. I have also served as President of the Brazilian Society of Digestive Endoscopy. I am writing to share my professional assessment of Marcio Lamas Lopes based on years of direct observation of his work and development.

I met Marcio Lamas Lopes in February 2013, when he began his medical training in Digestive Endoscopy at Hospital Ipiranga and at Hospital 9 de Julho, within the program I coordinated at the time. I followed his performance during residency and, after he completed his training in 2015, I kept him on the team as an attending physician. That decision reflected more than competence. It reflected trust, the kind of trust that allows a service to assign complex responsibilities without hesitation.

In daily practice, Mr. Lopes demonstrated consistent execution in advanced endoscopic procedures. He did not approach endoscopy as a sequence of isolated techniques. He worked with a disciplined method, preparing, performing, and concluding procedures in a way that promoted safety and predictability. This is precisely what a high-functioning service requires, as it reduces outcome variability and reinforces a culture in which the team can rely on the same standard every day. Over time, I also relied on him in the educational environment. He assisted in training new residents, teaching in the procedure room, and helping junior physicians adopt a structured rather than improvisational approach. In 2016 and 2017, he participated as a speaker and discussant in educational courses I organized with support from the Brazilian Society of Digestive Endoscopy, including the DAD Course focused on diseases of the digestive system.

One concrete example of his practical contribution was a study he conducted in my medical clinic regarding sedation safety for endoscopic exams performed in a non-hospital setting. Sedation is routine in endoscopy, and it is also a frequent source of avoidable risk when standards are inconsistent. Mr. Lopes approached the topic with clinical seriousness and a focus on real-world safety, and his work demonstrated safety and effectiveness in that setting. This kind of initiative is uncommon among physicians who are focused solely on completing procedures. It reflects a broader professional maturity and attention to system-level quality.

As his career progressed, he remained part of the Gastrointestinal Endoscopy Service at Hospital 9 de Julho and became one of the attendings of the residency program. In my experience, that role is earned by physicians who stand out among their peers for reliability, technical clarity, and the ability to elevate others through consistent teaching and example.

Looking forward, the United States faces an ongoing and complex burden related to obesity, and effective care increasingly depends on safe, minimally invasive interventions and well-trained endoscopy teams. Based on what I have observed, Mr. Lopes has the technical discipline and clinical mindset to contribute meaningfully in this environment, both through advanced endoscopic practice and through the training culture that sustains high-quality care.

Sincerely,

Artur Adolfo Parada, MD
Medical Director, Artur Parada Medicina Diagnóstica
Former Founder and Coordinator, Gastrointestinal Endoscopy Sector, Hospital

arturparada1@gmail.com, artur@arturparada.com.br
+55 11 99613 0857, +55 11 3170 8787

Contact

www.linkedin.com/in/artur-adolfo-parada-31463565 (LinkedIn)
www.arturparada.com.br (Company)

Top Skills

Gastroenterology
Medical Care
Healthcare Services Management

Honors-Awards

President of the Brazilian Society of Digestive Endoscopy - 2006-2008

Artur Adolfo Parada

Digestive Endoscopy Specialist | Pioneer in Advanced Diagnostics and Therapeutics | Former President of SOBED | Leader in Physician Training and Humanization of Care
São Paulo, São Paulo, Brazil

Summary

Over more than four decades dedicated to gastroenterology, I have combined science, technology, and humanity to transform the way we care for digestive health. My mission has always been clear: to provide accurate diagnoses, innovative treatments, and genuine compassionate care to patients.

I pioneered the implementation of diagnostic and therapeutic endoscopy methods that raised the standards of quality and safety in Brazil. Founder of the Endoscopy Service at Hospital 9 de Julho, I served as its coordinator for more than 40 years, in addition to serving as President of the Brazilian Society of Digestive Endoscopy (2006–2008).

My work extends beyond clinical practice: as an author and co-author of books and scientific articles, I have had the opportunity to contribute to the training of hundreds of professionals and share knowledge at national and international congresses.

Today, at the helm of Artur Parada Medicina Diagnóstica, I remain committed to integrating technological innovation, scientific research, and humanized care, strengthening a legacy that inspires physicians, patients, and institutions to always prioritize quality of life.

Experience

Artur Parada Medicina Diagnóstica
Medical Director
August 1978 - Present (48 years 1 month)
São Paulo, São Paulo, Brazil

9 de julho Hospital
Founder and Coordinator of the Gastrointestinal Endoscopy Department

June 1978 - December 2021 (43 years 7 months)
São Paulo, São Paulo, Brazil

Founder and Coordinator of the Endoscopy Department at 9 de Julho Hospital.

Education

Mackenzie Evangelical College of Paraná / Institute for Medical Research IPEM

Doctorate, Graduate Studies Program in Principles of
Surgery · (December 2016)

Ribeirão Preto Medical School (USP)

Medicine

Mackenzie Evangelical College of Paraná / Institute for Medical Research IPEM

Master's Degree · (December 2016)

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 17, 2026

Contato

www.linkedin.com/in/artur-adolfo-parada-31463565 (LinkedIn)
www.arturparada.com.br (Company)

Principais competências

Gastroenterologia
Assistência médica
Gestão de serviços de saúde

Honors-Awards

Presidente Sociedade Brasileira de Endoscopia Digestiva - 2006-2008

Artur Adolfo Parada

Médico especialista em Endoscopia Digestiva | Pioneiro em diagnósticos e terapêuticas avançadas | Ex-Presidente SOBED | Líder na formação de médicos e humanização do cuidado
São Paulo, São Paulo, Brasil

Resumo

Ao longo de mais de quatro décadas dedicadas à gastroenterologia, tenho unido ciência, tecnologia e humanidade para transformar a forma como cuidamos da saúde digestiva. Minha missão sempre foi clara: oferecer diagnósticos precisos, tratamentos inovadores e acolhimento verdadeiro aos pacientes.

Fui pioneiro na implementação de métodos de endoscopia diagnóstica e terapêutica que elevaram o padrão de qualidade e segurança no Brasil. Fundador do Serviço de Endoscopia do Hospital 9 de Julho, atuei como coordenador por mais de 40 anos, além de presidir a Sociedade Brasileira de Endoscopia Digestiva (2006–2008).

Minha atuação vai além da prática clínica: como autor e coautor de livros e artigos científicos, tive a oportunidade de contribuir para a formação de centenas de profissionais e de compartilhar conhecimento em congressos nacionais e internacionais.

Hoje, à frente da Artur Parada Medicina Diagnóstica, sigo comprometido em integrar inovação tecnológica, produção científica e cuidado humanizado, fortalecendo um legado que inspira médicos, pacientes e instituições a priorizarem sempre a qualidade de vida.

Experiência

Artur Parada Medicina Diagnóstica
Diretor médico
agosto de 1978 - Present (48 anos 1 mês)
São Paulo, São Paulo, Brasil

Hospital 9 de julho
Fundador e Coordenador do Setor de Endoscopia Gastrointestinal

junho de 1978 - dezembro de 2021 (43 anos 7 meses)
São Paulo, São Paulo, Brasil

Fundador e Coordenador do Setor de Endoscopia do Hospital 9 de Julho.

Formação acadêmica

Faculdade Evangelica Mackenzie do Paraná / Instituto de Pesquisas Médicas IPEM

Doutorado, Programa de Pos-Graduacao em Princípios da Cirurgia · (dezembro de 2016)

Faculdade de Medicina de Ribeirao Preto. USP

Medicina

Faculdade Evangelica Mackenzie do Paraná / Instituto de Pesquisas Médicas IPEM

Mestrado · (dezembro de 2016)

06/02/2026

To USCIS,

My name is Manoel dos Passos Galvão Neto, and I currently serve as the Director of Bariatric Research at Orlando Health and as the Scientific Director at IRCAD India. Over the course of my career in digestive surgery, gastroenterology, and bariatric innovation, I have remained deeply involved in clinical teaching and advancing high-level endoscopic practice. In the field of endoscopy, one quickly learns to distinguish between those who have mastered the mechanics of a procedure and those who have developed the clinical judgment to apply advanced techniques consistently and safely. It is from this professional perspective, and from many years of working closely with physician training and the evolution of bariatric surgery, that I have been able to closely follow the trajectory of Marcio Lamas Lopes and assess the caliber of professionals who truly elevate the quality of care in our specialty.

My firsthand observation of Mr. Lopes began in 2013, when he started his medical residency and specialization at Hospital 9 de Julho, a traditional and renowned hospital in São Paulo, Brazil, widely recognized as a leading center for high complexity medicine in Latin America. From those early stages, I saw him navigate a demanding training environment where technical precision and discipline are absolute requirements. During that period, I watched him perform endoscopic examinations and therapeutic procedures with notable skill, including the application of argon plasma. What stood out was not only his manual dexterity but also the palpable confidence and control he maintained during complex therapeutic interventions.

As his specialization progressed, Mr. Lopes established himself as an expert in minimally invasive endoscopic procedures, with a particular focus on the bariatric field. This expertise was evident in his contributions to the medical community, specifically during the 2016 and 2017 DAD courses, for which I served as his mentor and advisor on bariatric endoscopy topics due to my role in this specialized field at the time. In these events, which drew an average of 100 physicians from Hospital 9 de Julho, he delivered critical lectures on the complications of bariatric surgery and the endoscopic therapies used to manage them. The management of altered gastrointestinal anatomy after weight loss surgery requires a technical maturity that Mr. Lopes demonstrated by showing how to connect precise diagnosis with immediate therapeutic action. His role in these courses proved that he had moved beyond being a practitioner to becoming a communicator of complex medical reasoning.

Today, Mr. Lopes remains integral to the endoscopy residency at Hospital 9 de Julho, where he participates in training new generations of endoscopists. His pedagogical work involves teaching a wide range of techniques, specifically those related to bariatric endoscopy. Every year, he conducts a specialized class on identifying surgical techniques through endoscopy

and managing gastric alterations, covering procedures like intragastric balloon implantation, argon plasma, and endoscopic gastroplasty. This consistency in an educational role within a major hospital infrastructure reflects a high level of institutional trust that is only granted to professionals of proven capability.

What most distinguishes Mr. Lopes is that he does not simply perform complex bariatric endoscopy, he does so with a level of precision, control, and clinical judgment that goes well beyond routine practice. In my experience, that combination is uncommon and reflects a degree of technical maturity that is not easily found. In complex patients, this kind of performance has a direct effect on patient safety, procedural success, and the confidence of the team involved. It is exactly the sort of capability that signals an exceptional endoscopist, not merely a competent one.

For these reasons, I express my full professional support for Marcio Lamas Lopes. His expertise in complex therapeutic and bariatric endoscopy, together with his ongoing role in teaching other physicians, reflects a level of professional maturity that would be valuable in high complexity medical settings in the United States. I am confident that his experience and technical judgment would contribute meaningfully to patient care and to the training of other physicians, and I remain available to provide any further information that may be required.

Over the years, I have interacted with and trained hundreds of endoscopists throughout Brazil, Latin America, Europe, India, and the United States. Based on this experience, I consider Dr. Lopes to be among the most capable bariatric endoscopists I have encountered at a similar stage of career development. His combination of technical expertise, teaching ability, and commitment to advancing the field distinguishes him from the vast majority of his peers

Sincerely,

Manoel dos Passos Galvão Neto
Global Leader in Bariatric Endoscopy Innovation
Research Director, Orlando Health Weight Loss & Bariatric Surgery Institute
Scientific Director, IRCAD India
Email: galvaon@gmail.com GALVAON@GMAIL.COM

Contact

www.linkedin.com/in/galvaon (LinkedIn)
eliasortiz.co (Company)
mohakbariatrics.in (Company)
www.orlandohealth.com/services-and-specialties/bariatric-surgery-institute/our-team (Company)

Top Skills

First in Human trialist
Healthcare Consulting
Medical-Surgical

Languages

English
Spanish
Portuguese (Native or Bilingual)

Certifications

CITI Good Clinical Practice Course
CITI Health Information Privacy and Security (HIPS) for Clinicians

Honors-Awards

Endoscopic Robotic ESD (video) - Best of the best Award on ESD and Submucosal category

Patents

DEVICE FOR TIME DELAYED DISPENSING OF BILE
Use of a gastrointestinal sleeve to treat bariatric surgery fistulas and leaks description/claims
A DEVICE AND METHOD FOR DIRECTING BILE FROM THE GALLBLADDER IN THE INTESTINE
A SYSTEM REGULATING THE DISPENSING OF A BODY FLUID
A DEVICE FOR AN ENDOLUMINAL CHOLECYSTO - ENTEROSTOMY

Manoel Galvao Neto MD MSc FASGE IFASMBS

Global Leader in Bariatric Endoscopy Innovation | Research Director, Orlando Health | Scientific Director, IRCAD India | Bariatric Endoscopy and ESG Pioneer | FDA IDE Trials | 9,000+ Citations H-Index 50+
Orlando, Florida, United States

Summary

I am the Bariatric Research Director at Orlando Health, leading a portfolio of eight FDA IDE bariatric and metabolic trials in just two years, including a landmark magnetic bowel anastomosis study that resulted in FDA approval of a magnetic compression anastomosis technology.
I also serve as Associate Editor for the journals Obesity Surgery and Clinical Obesity, helping to shape and disseminate high-impact research in bariatric and metabolic medicine. My work has been cited over 9,000 times, with an h-index above 50, reflecting sustained impact in bariatric and metabolic innovation.
I am a bariatric and metabolic endoscopy pioneer, dedicated to advancing minimally invasive solutions for obesity and related metabolic diseases. My career has focused on developing, refining, and teaching endoscopic techniques such as ESG and revisional endoscopy to surgeons and endoscopists around the world.
As Scientific Director at IRCAD India and an active contributor to international societies, I combine academic rigor, clinical experience, and hands-on teaching, delivering high-impact training programs, proctorships, and live demonstrations across multiple continents. I work closely with industry partners on device development, clinical trials, and guideline-shaping initiatives, translating innovation into safe, reproducible practice and scalable training ecosystems.

Experience

Orlando Health
Director of Bariatric Research
January 2024 - Present (2 years 8 months)
Orlando, FL

Obesity Surgery Journal
16 years 8 months

Associate Editor
August 2024 - Present (2 years 1 month)

Reviewer
January 2010 - Present (16 years 8 months)

Review articles on Bariatric Endoscopy

IRCAD India
Scientific Director
December 2023 - Present (2 years 9 months)
Indore, Madhya Pradesh, India

Sri Aurobindo Institute of Medical Science, Indore
Clinical Professor of Gastroenterology and Surgery
August 2021 - Present (5 years 1 month)
Indore, Madhya Pradesh, India

Mohak Bariatrics and Robotics
Head of Bariatric Endoscopy
August 2021 - Present (5 years 1 month)
Indore, Madhya Pradesh, India

American Foregut Society
Committee Member
June 2020 - Present (6 years 3 months)
California, United States

SAGES
Flexible Endoscopy Committee Member
July 2020 - Present (6 years 2 months)
United States

International Bariatric Club
Director of Innovation
2012 - Present (14 years)

IBC is group is dedicated for experts in bariatric and metabolic medicine and surgery. It contains highly professional content only. www.ibcclub.org
Shares and archives bariatric surgery videos, articles, and presentations relevant to management of intraoperative and post-operative complications.

Serves as a forum for daily requests for opinions and live discussions by members on clinical questions and problems.
Hosts a monthly, live video-streaming Webinars.
Participates in national and international meetings relevant to Bariatric and Metabolic Surgery.

Sociedade Brasileira de Endoscopia Digestiva
Board Certified (expert)
2011 - Present (15 years)
Sao Paulo

Boar certified Endoscopist by Brazilian Society of Digestive Endoscopy

Federação brasileira de Gastroenterologia
Board Certified (expert)
January 1995 - Present (31 years 8 months)
Sao Paulo

Board Certified Gastroenterologist by Brazilian Federation of Gastroenterology since 1995

Colegio brasileiro de Cirurgia Digestiva
Board Certified (expert)
January 1992 - Present (34 years 8 months)
Sao Paulo

Board certified by Brazilian College of Digestive Surgery since 1992

Instituto EndoVitta
Scientific Director
May 2017 - December 2023 (6 years 8 months)
São Paulo Area, Brazil

Faculdade de Medicina do ABC - FMABC
Affiliate professor of Surgery
January 2014 - December 2023 (10 years)
Santo André, São Paulo, Brazil

International Federation fo Surgery of Obesity - IFSO
Bariatric Endoscopy Committee member
December 2017 - January 2023 (5 years 2 months)
Napoli, Campania, Italy

Sri Aurobindo Institute of Medical Science, Indore

Honorary Professor of Surgery
November 2020 - November 2020 (1 month)
Indore, Madhya Pradesh, India

Made Honorary professor of Surgery after teaching and mentoring on the field of Bariatric Endoscopy, helping establish the Endoscopic Sleeve Gastroplasty program

Association of Bariatric Endoscopy - ABE / ASGE
Advisory Board Member
March 2016 - June 2020 (4 years 4 months)
3300 Woodcreek Dr. Downers Grove, IL 60515 | 630-573-0600

The Association for Bariatric Endoscopy (ABE) was established in October 2015 as a Division of ASGE to provide state-of-the-art information, education and practice support to gastrointestinal endoscopists with an interest in endoscopic bariatric therapies that improve the health and wellness of patients with obesity.

ABE members are GI endoscopists who are currently offering– or preparing to offer–the latest bariatric endoscopic procedures. The Association gives members access to the best information available from experts in this rapidly changing and growing field, and provides an active community for information sharing and practice support.

Florida International University
Clinical Associate Professor of Surgery
January 2015 - August 2018 (3 years 8 months)
miami

Carry the name of University on meetings, presentations and trainings regarding Bariatric Endoscopy

Hospital 9 de Julho
Coordinator - Bariatric Endoscopy Service
February 2012 - November 2017 (5 years 10 months)
São Paulo Area, Brazil

Responsible for all endoscopic bariatric procedures on the hospital with the main focus on complex complications and revisional cases.
Also in charge of endoscopic treatment of obesity with intragastric balloons
Will be in charge of EndoSleeve (gastric plication) and Apollo overstitch for obesity treatment and EndoBarrier for treatment of Type 2 Diabetes

Hospital Estadual Mário Covas

Coordinator - Esophageal Motility Lab
January 2012 - March 2017 (5 years 3 months)
Santo Andre, Sao Paulo, Brazil

Reference lab for a big metropolitan area on Sao paulo, the ABC also connected with ABC university providing Esophageal manometry and pHmetry on clinical bases and on research projects.
Currently developing hardware and software on Hi-resolution manometry and pH-Impedance in a a joint project with ALACER Biomedical company

Gastro Obeso Center
17 years

Bariatric Endoscopy service chair
January 2001 - 2017 (16 years)
Sao Paulo, Brazil

In charge for the scientific production and training program the helps Gastro Obeso Center to be the leading bariatric center in Latin America with more than 20 articles published in peer reviewed journal and had trained over 700 bariatric surgeons worldwide
Also developed a new endoscopic sub-speciality, the "bariatric endoscopy" that now goes side-to-side with bariatric surgery treating its complications and treating obesity itself. Editor of two books published on this matter in Portuguese and Spanish. More than 30 articles publish on this specifics.

Scientic Coordinator
2000 - 2011 (11 years)

Design and follow the scientific articles, training models and presentations for the group

The Chinese University of Hong Kong
Dr Anthony PC Yim Visiting Professorship in Minimally rnvasive Surgery and Innovative Technology 16
November 2016 - November 2016 (1 month)

The purpose of this Visiting Professorship is to advance minimally invasive surgical knowledge and techniques and to foster collaborations between Hong Kong and major medical centers around the World

IFSO - International Federation for the Surgery of Obesity and Metabolic Disorders
Committee Chair - INVESTIGATIONAL SURGICAL AND ENDOSCOPIC PROCEDURES COMMITTEE
January 2012 - March 2016 (4 years 3 months)

This committee was created to evaluate the new bariatric procedures (surgical and endoscopic) under the scrutiny of evidence based medicine but also screen it as soon as the first researches are published. Committee activities include the Bariatric Endoscopy courses for the last and the next IFSO congress were all those innovations are presented by its authors and discussed in deep. White papers are also being prepared

Education

Escola Bahiana de Medicina e Saúde Pública

MD, Medicine · (1984 - 1989)

Universidade de São Paulo

Master's degree, Digestive Surgery · (2001 - 2003)

USP - Universidade de São Paulo

Master of Science - MS, Digestive Surgery

02.06.2026

To Whom It May Concern,

In the field of digestive endoscopy, the evaluation of a physician should take into account not only technical ability, but also the capacity to practice safely across different levels of procedural complexity and to contribute to the training of other physicians. It is within this context that I submit this statement regarding Mr. Marcio Lamas Lopes.

My name is Eduardo Grecco, and I serve at the ABC Medical School University Center (FMABC), located at Avenida Lauro Gomes, 2000, Santo André, São Paulo, Brazil. I graduated in Medicine from FMABC in 1999 and completed my residency in Digestive Surgery at the Real and Benemérita Sociedade Portuguesa de Beneficência de São Paulo, followed by specialization in Upper Gastrointestinal Endoscopy at the Hospital das Clínicas of the University of São Paulo School of Medicine (FMUSP). I currently hold academic and clinical positions as Professor in the Department of General and Digestive Surgery, Coordinator of the Endoscopy Service and Medical Residency Program in Endoscopy at FMABC, Director of Education, Research, and Services at FMABC and FUABC (Fundação do ABC), and practicing endoscopist in my private clinic. My professional activities also include participation in specialty medical societies and service as a reviewer for national and international scientific journals.

I became professionally familiar with Mr. Lopes's work indirectly through scientific meetings organized by SOBED (Brazilian Society of Digestive Endoscopy) and through the professional relationship between our team at FMABC and the teams at Hospital 9 de Julho, where he serves as an endoscopist. In addition, I have had the opportunity to be present during endoscopic procedures alongside him in a clinical setting. Although our relationship was not one of direct supervision, this contact allowed me to observe important aspects of his professional practice.

Within his field of expertise, I recognize Mr. Lopes as a specialist in digestive endoscopy, including advanced procedures. What stands out most in his career is not only the high technical quality of the examinations he performs, but also the breadth and consistency of his professional work over the years. For this reason, Mr. Lopes is well known within the hospital community, extending beyond his immediate workplace, and is regarded as a reference in his specialty. This recognition is also supported by his clinical responsibilities in prominent hospitals in São Paulo, where he performs diagnostic and therapeutic procedures, including elective, emergency, and highly complex cases, while also holding a leadership position within an endoscopy service. Furthermore, his experience includes the management of gastrointestinal bleeding, colorectal diseases, and endoscopic bariatric interventions, demonstrating comprehensive technical expertise within the specialty. In my assessment, this combination of responsibilities and competencies does not represent an ordinary professional profile, as it reflects practical mastery, sound clinical judgment, and responsibility across diverse areas of endoscopic medicine.

Another aspect that I consider particularly significant is the fact that his work is carried out within a medical residency training environment. This alone gives his professional activities a dimension that extends beyond routine patient care. In my view, not every specialist combines

active patient care responsibilities, involvement in elective, emergency, and highly complex procedures, and participation in a setting directly connected to physician training. In Mr. Lopes's case, this combination makes his professional trajectory distinctive because it integrates substantial practical experience with an academic environment that contributes to the education of future physicians. For this reason, I believe that his work has an impact not only on patient treatment, but also on the advancement of medical education and professional qualification.

Given these considerations, I believe that Mr. Lopes can make a highly positive contribution in both clinical and educational settings, including in the United States, where he would be able to add value to local institutions through both patient care and teaching activities. Considering his training, his experience with procedures of varying levels of complexity, and his involvement in a medical residency environment, his presence would strengthen clinical practice as well as the development of physicians in training. He possesses a profile that combines technical expertise with academic experience, facilitating the integration of patient care and structured medical education. I remain available to provide any additional information or clarification if needed.

Sincerely,

Eduardo Grecco
Professor of the Discipline of General and Digestive System Surgery
Coordinator of the Endoscopy Service and Medical Residency
Director of Teaching, Research, and Services, ABC Medical School, FUABC
Centro Universitário Faculdade de Medicina do ABC
Av. Lauro Gomes, 2000, Santo André, SP, Brazil
Email: dreduardogrecco@gmail.com
Phone: +55 11 98162 0911

Contact
www.linkedin.com/in/eduardo-grecco-948717158 (LinkedIn)

Top Skills
Medical Care
Customer Service

Eduardo Grecco

Endoscopist at Clinica Eduardo Grecco /FMABC
Brazil

Experience

Fundação do ABC
General Director of Mario Covas State Hospital (Santo André)
March 2025 - Present (1 year 6 months)
Sao Paulo

Clinica Eduardo Grecco
Medical Director
February 2024 - Present (2 years 7 months)
São Paulo, Brazil

Brazilian Society of Endoscopy
Full Member, SOBED
January 2005 - Present (21 years 8 months)

Instituto EndoVitta
Bariatric Endoscopist
July 2016 - February 2024 (7 years 8 months)

Brazilian Society of Bariatric and Metabolic Surgery (SBCBM)
Member, SBCBM
June 2015 - June 2018 (3 years 1 month)

Education

ABC Medical School (FMABC)
Coordinator of the Digestive Endoscopy Service and Medical Residency Program

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 17, 2026

Contato
www.linkedin.com/in/eduardo-grecco-948717158 (LinkedIn)

Principais competências

Assistência médica
Atendimento ao cliente

Eduardo Grecco

Endoscopista da Clinica Eduardo Grecco /FMABC
Brasil

Experiência

Fundação do ABC
Diretor Geraldo Hospital Estadual Mario Covas de Santo André
março de 2025 - Present (1 ano 6 meses)
Sao Saulo

Clinica Eduardo Grecco
Diretor médico
fevereiro de 2024 - Present (2 anos 7 meses)
São Paulo, Brasil

Sociedade Brasileira de Endoscopia
Membro Titular SOBED
janeiro de 2005 - Present (21 anos 8 meses)

Instituto EndoVitta
Endoscopista Bariátrico
julho de 2016 - fevereiro de 2024 (7 anos 8 meses)

Sociedade Brasileira de Cirurgia Bariátrica e Metabólica
Membro SBCBM
junho de 2015 - junho de 2018 (3 anos 1 mês)

Formação acadêmica

Faculdade de Medicina do ABC
Coordenador do Serviço e da Residência Médica em Endoscopia Digestiva

June, 4, 2026

To Whom It May Concern,

I am writing this letter in strong support of **Dr. Marcio Lamas Lopes** and his petition for permanent residence in the United States under **the EB-2 National Interest Waiver category**.

I serve as the **Medical Director of the Hospital Adventista de São Paulo**, a premier healthcare institution in Brazil and a key member of the Adventist Health Brazil (A.H.B.) group. As an integral part of the global network of the Seventh-day Adventist Church, A.H.B. is connected to a long-standing tradition of medical excellence, particularly in the United States, where the Church operates some of the most advanced healthcare systems in the world, such as AdventHealth and Loma Linda University Health. Having supervised Dr. Marcio Lamas Lopes's professional activities for several years, I can personally attest to his exceptional clinical skills, leadership, and significant contributions to the field of Gastroenterology and Digestive Endoscopy.

Dr. Lopes has served as an Endoscopist Physician and Coordinator of the Endoscopy Service at our institution since 2018. Throughout this period, he has distinguished himself as an exceptionally skilled physician, an effective clinical leader, and a highly valuable contributor to the advancement of gastrointestinal endoscopy and patient care.

As Coordinator of the Endoscopy Service, **Dr. Lopes** has been directly responsible for supervising and optimizing the operational, clinical, and quality aspects of a high-volume endoscopy unit. His leadership has contributed to improvements in procedural efficiency, patient safety standards, multidisciplinary integration, and the overall quality of gastrointestinal care delivered at our institution.

Beyond his administrative role, **Dr. Lopes** is recognized for his advanced technical expertise in diagnostic and therapeutic endoscopy, his excellent clinical judgment, and his ability to manage complex gastrointestinal cases with precision and professionalism. His work has had a meaningful impact on patient outcomes and on the delivery of specialized medical care.

Importantly, **Dr. Lopes's** contributions extend beyond routine clinical practice. His expertise in gastrointestinal endoscopy addresses an area of substantial importance to public health, as digestive diseases represent a major source of

morbidity and healthcare burden worldwide. Physicians with his level of training, technical ability, and leadership are essential for improving access to high-quality minimally invasive procedures, reducing complications, and enhancing healthcare efficiency.

In my opinion, **Dr. Lopes** possesses a combination of clinical excellence, leadership capacity, and professional integrity that clearly places him among the most distinguished physicians with whom I have worked during my career.

I firmly believe that his continued professional activities in the United States would provide substantial benefit to the American healthcare system, particularly in the fields of gastrointestinal endoscopy, patient safety, and specialized procedural medicine. His work has clear merit and national importance, and I strongly support his request for permanent residence under the National Interest Waiver category.

I recommend **Dr. Lopes** without reservation and with the highest degree of professional confidence.

Please feel free to contact me should additional information be required.

Sincerely,

Dr. Douglas Charpinel
CRM-SP 157752
Diretor Médico

Dr. Douglas Charpinel
Diretor Médico
CRM-SP:157.752

Contact
www.linkedin.com/in/douglas-charpinel-5a912677 (LinkedIn)

Top Skills
Medical Care
Healthcare Services Management
Data Analysis

Douglas Charpinel

Medical Executive in Supplementary Healthcare | Medical Management | Medical Regulation | Medical Director of Adventista Hospital of São Paulo
São Paulo, São Paulo, Brazil

Summary

Medical Director with a solid background in Intensive Care Medicine (Sírio Libanês Hospital) and Healthcare Services Management (FGV-CEAHS). My expertise combines extensive clinical and strategic experience, focused on exponential results in the healthcare sector. I have proven experience in Emergency Medicine, Intensive Care Medicine, Medical Billing Auditing, and leadership of hospital Quality Processes. With a strong career progression—from working as an on-call physician at major hospitals in the capital, to Emergency Department Coordinator for more than a decade, Medical Manager for 7 years, and Technical Director for 2 years—I have developed a 360-degree view of hospital operations and supplementary healthcare. Currently serving as Technical Director of Adventista Hospital of São Paulo, I have been an active member of the medical staff leadership for 9 years, working with healthcare operators (external and in-house) and managing multidisciplinary teams and medical staff, always focused on the Triple Aim (prevention, experience, and cost). My leadership extends to certification and quality processes, both from a healthcare perspective for hospitals and in processes for healthcare operators, with experience in vertically integrated systems. As CEO of the MedHealth Soluções em Saúde group and Operations Advisor at GFP Soluções em Saúde, I specialize in implementing and evaluating concurrent and qualitative medical record audits, with a deep understanding of the revenue cycle. I possess a strong leadership mindset, with proven ability in the strategic management of teams, processes, and medical regulations, always driven by results and continuous innovation. I am also an AI enthusiast, seeking knowledge and professional development to apply it to the optimization of healthcare management.

Experience

Adventista Hospital São Paulo

13 years 4 months

Medical Director
April 2024 - May 2026 (2 years 2 months)
São Paulo, Brazil

Medical Manager
October 2017 - April 2024 (6 years 7 months)
Rua rocha pombo, 44

Responsible for the strategic and operational planning of the managed departments.
Commercial relations with clients and healthcare operators, focused on sector negotiations based on sustainability.
Quantitative and qualitative analysis of healthcare services through indicators on the managed platforms (SCOPI).
Development of institutional protocols for certification.
Mediator of conflicts between healthcare teams and management.
Responsible for the institution's medical billing audit.

Medical Coordinator of the Emergency Department
November 2013 - April 2024 (10 years 6 months)
São Paulo, Brazil

Coordinator of the medical team and schedules, responsible for preparing schedules, analyzing indicators, developing protocols, and serving as an interface between administrative and healthcare management.

Emergency Medicine Physician
February 2013 - April 2014 (1 year 3 months)
Estrada de Itapecerica, 5859

Provided urgent and emergency care in the emergency department.

Forthia - Soluções em Saúde
Operations Director
June 2020 - March 2026 (5 years 10 months)
São Paulo, Brazil

Operations Director for qualitative auditing of operations at UNIMED FESP member units.

Med Health
CEO
January 2013 - April 2020 (7 years 4 months)
São Paulo

Urgent and emergency care through advanced life support transport is basic.

Medical Director and CEO of the MEDHEALTHSS group.

Hospital Vital
Medical Coordinator
February 2014 - May 2015 (1 year 4 months)
Mauá, São Paulo, Brazil

Coordinator of medical schedules, preparing schedules for regular on-call physicians and coverage physicians, providing guidance on clinical practices and addressing questions from medical teams.
Member of the Mortality Committee.
Liaison between the medical staff leadership and the emergency department healthcare team.

Education

Getulio Vargas Foundation
Healthcare Services Management, Hospital Management · (2018)

Sírio-Libanês Institute for Education and Research
Graduate Studies Degree, Intensive Care Medicine · (2016)

Santo Amaro University - Unisa
Medicine, Emergency Medicine · (2007 – 2012)

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana

Date: August 17, 2026

Contato

www.linkedin.com/in/douglas-charpinel-5a912677 (LinkedIn)

Principais competências

Assistência médica
Gestão de serviços de saúde
Análise de dados

Douglas Charpinel

Executivo Médico em Saúde Suplementar | Gestão Médica | Regulação Médica | Diretor Médico do Hospital Adventista São Paulo

São Paulo, São Paulo, Brasil

Resumo

Diretor Médico com sólida formação em Medicina Intensiva (Hospital Sírio Libanês) e Gestão em Serviços de Saúde (FGV-CEAHS). Minha expertise alia profunda vivência clínica e estratégica, focada em resultados exponenciais no setor de saúde. Possuo atuação comprovada em Medicina de Emergência, Medicina Intensiva, Auditoria de Contas e liderança de Processos de Qualidade hospitalar.Com uma progressão de carreira robusta – de plantonista em grandes hospitais da capital, a Coordenador de Pronto-Socorro por mais de uma década, Gerente Médico por 7 anos e Diretor Técnico por 2 anos – desenvolvi uma visão 360º da operação hospitalar e da saúde suplementar. Atualmente como Diretor Técnico do Hospital Adventista de São Paulo, sou membro ativo da diretoria clínica há 9 anos, atuando no relacionamento com operadoras (externas e próprias), e na gestão de equipes multidisciplinares e corpo clínico, sempre com foco no Triple Aim (prevenção, experiência e custo).Minha liderança estende-se à frente de processos de certificação e qualidade, tanto com olhar assistencial para hospitais quanto em processos para operadoras, com experiência em sistemas verticalizados. Como CEO do grupo MedHealth Soluções em Saúde e conselheiro de Operações no grupo GFP Soluções em Saúde, sou especialista em implantação e avaliação de auditoria concorrente e qualitativa de prontuário, com profundo entendimento do ciclo de receita.Possuo um espírito de liderança elevado, com habilidade comprovada na gestão estratégica de equipes, processos e regulação, sempre pautado por resultados e inovação contínua. Sou também um entusiasta na IA, buscando conhecimento e aprimoramento para aplicá-los na otimização da gestão em saúde.

Experiência

Hospital Adventista de São Paulo

13 anos 4 meses

Diretor médico
abril de 2024 - maio de 2026 (2 anos 2 meses)
São Paulo, Brasil

Gerente médico
outubro de 2017 - abril de 2024 (6 anos 7 meses)
Rua rocha pombo, 44

Atuante no planejamento estratégico e operacional dos setores gerenciados.
Relacionamento comercial com clientes e operadoras, focado em negociações do setor, com base na sustentabilidade.
Análise quantitativa e qualitativa dos serviços assistenciais através de indicadores nas plataformas gerenciadas (SCOPI).
Elaboração de protocolos institucionais para certificação.
Mediador de conflitos entre equipe assistencial e diretoria.
Atuação na Auditoria de contas médicas da instituição.

Coordenador médico do pronto atendimento
novembro de 2013 - abril de 2024 (10 anos 6 meses)
São Paulo, Brasil

Coordenador de equipe e escalas médicas, atuando na elaboração de escalas, análise de indicadores, estruturação de protocolos, interface entre gestão administrativa e assistencial.

Médico de medicina de emergência
fevereiro de 2013 - abril de 2014 (1 ano 3 meses)
Estrada de itapecerica, 5859

Atendimento a urgência e emergência no pronto atendimento

Forthia - Soluções em Saúde
Diretor de operações
junho de 2020 - março de 2026 (5 anos 10 meses)
São Paulo, Brasil

Diretor de operações de auditoria qualitativa para operações nas singulares da UNIMED FESP

Med Health
CEO
janeiro de 2013 - abril de 2020 (7 anos 4 meses)
São Paulo

Atendimento de urgência e emergência através de remoção de suporte avançado é básico.

Diretor médico e CEO do grupo MEDHEALTHSS.

Hospital Vital
Médico coordenador
fevereiro de 2014 - maio de 2015 (1 ano 4 meses)
Mauá, São Paulo, Brazil

Coordenador de escalas médicas, elaborando as escalas de plantonistas fixos e de coberturas, orientando condutas clínicas e dirimindo dúvidas das equipes médicas.
Membro da comissão de óbito.
Interlocutor entre diretoria clínica e equipe assistencial do pronto socorro.

Formação acadêmica

Fundação Getulio Vargas
Gestão em serviços de Saúde, Gestão Hospitalar · (2018)

Instituto de Ensino e Pesquisa do Hospital Sírio Libanês
Postgraduate Degree, Medicina intensiva · (2016)

Universidade Santo Amaro - Unisa
Medicina, Emergência · (2007 - 2012)

Exhibit C.II - Second Prong - Financial Feasibility

2601 Bayshore DR.
Suite 1100 - Miami. FL 33133
+1 (786) 220-7233
customer@avenue.us

March 01, 2026 - March 31, 2026

MARCIO LAMAS LOPES
LÍLIAN DE OLINDA GIANNOCCARO
RUA TUIUTI 732 APTO 172
TATUAPÉ
03081015 SÃO PAULO
BRAZIL


Your Account Instructions

- Hold Securities in Account
- Hold Proceeds

CASH & CASH EQUIVALENTS

	OPENING BALANCE	CLOSING BALANCE
Total Cash & Cash Equivalents	$ 54.14	$ 80.71
Net Account Balance	54.14	80.71
Securities	43,182.60	41,590.14
Total Priced Portfolio	43,182.60	41,590.14
Total Equity Holdings	**$ 43,236.74**	**$ 41,670.85**

PORTFOLIO EQUITY ALLOCATION



ACCOUNT SUMMARY

	THIS PERIOD	YEAR TO DATE
Taxable dividends	$ 37.96	$ 60.90
Non-resident tax paid	$ 11.39	$ 18.27

Brokerage services provided by Avenue Securities LLC, member FINRA/SIPC (800) 544-6666. Brokerage accounts carried by Apex Clearing Corporation, Member FINRA/SIPC and Velocity Clearing LLC, member FINRA/SIPC.

2601 Bayshore DR.
Suite 1100 - Miami. FL 33133
+1 (786) 220-7233
customer@avenue.us

March 01, 2026 - March 31, 2026

MARCIO LAMAS LOPES
LÍLIAN DE OLINDA GIANNOCCARO

PORTFOLIO SUMMARY - AVENUE ACCOUNT NUMBER: 287868388

DESCRIPTION	SYMBOL/ CUSIP	ACCOUNT TYPE	QUANTITY	PRICE	MARKET VALUE	LAST PERIOD'S MARKET VALUE	% CHANGE	EST. ANNUAL INCOME	% OF TOTAL PORTFOLIO
EQUITIES / OPTIONS									
Amazon.com Inc.	AMZN	C	64.3719	208.27	$ 13,406.74	$ 13,518.10	-0.82%		32.173%
Microsoft Corporation	MSFT	C	16.69628	370.17	6,180.46	6,557.30	-5.75	6,267	14.832
Alphabet Inc - Class A	GOOGL	C	7.6064	287.56	2,187.30	2,371.37	-7.76	671	5.249
NVIDIA Corp	NVDA	C	18	174.40	3,139.20	3,189.42	-1.57	76	7.533
Invesco QQQ Trust Series1	QQQ	C	28.89296	577.18	16,676.44	17,546.41	-4.96	8,399	40.019
Total Equities					**$ 41,590.14**				**99.806%**
Total Cash (Net Portfolio Balance)					**$ 80.71**				**0.194%**
TOTAL PRICED PORTFOLIO					**$ 41,670.85**				

All investment positions held in an Apex Clearing Corporation or Velocity Clearing LLC cash account unless indicated otherwise.
Excess cash in your brokerage account will be swept into a money market mutual fund that will be held at JP Morgan as part of the Sweep Program, unless indicated otherwise.
Total cost does not include the cost basis on money market mutual funds or other positions where the cost basis is unknown or not applicable.

2601 Bayshore DR.
Suite 1100 - Miami. FL 33133
+1 (786) 220-7233
customer@avenue.us

March 01, 2026 - March 31, 2026

MARCIO LAMAS LOPES
LÍLIAN DE OLINDA GIANNOCCARO

ACCOUNT ACTIVITY - AVENUE ACCOUNT NUMBER: 287868388

TRANSACTION	DATE	ACCOUNT TYPE	DESCRIPTION	QUANTITY	PRICE	DEBIT	CREDIT
DIVIDENDS AND INTEREST							
DIVIDEND	03/13/2026	C	Dividend Credit MSFT				$ 15.19
DIVIDEND	03/13/2026	C	Dividend Withholding Tax MSFT			$ 4.56	
DIVIDEND	03/17/2026	C	Dividend Withholding Tax GOOGL			$ 0.48	
DIVIDEND	03/17/2026	C	Dividend Credit GOOGL				$ 1.60
DIVIDEND	03/30/2026	C	Dividend Credit QQQ				$ 21.17
DIVIDEND	03/30/2026	C	Dividend Withholding Tax QQQ			$ 6.35	
Total Dividends And Interest						**$ 11.39**	**$ 37.96**

All investment positions held in an Apex Clearing Corporation or Velocity Clearing LLC cash account unless indicated otherwise.
Excess cash in your brokerage account will be swept into a money market mutual fund that will be held at JP Morgan as part of the Sweep Program, unless indicated otherwise.
Total cost does not include the cost basis on money market mutual funds or other positions where the cost basis is unknown or not applicable.

2601 Bayshore DR.
Suite 1100 - Miami. FL 33133
+1 (786) 220-7233
customer@avenue.us

March 01, 2026 - March 31, 2026

MARCIO LAMAS LOPES
LÍLIAN DE OLINDA GIANNOCCARO

CASH & CASH EQUIVALENTS - AVENUE ACCOUNT NUMBER: 287868388

DESCRIPTION	AMOUNT
TotalCash & Cash Equivalents	$ 80.71
JP Morgan Bank DDA	$ 0.00
JP Morgan U.S Government Money Market	$ 80.71
Apex Cash	$ 0.00
Velocity Cash	$ 0.00

All investment positions held in an Apex Clearing Corporation or Velocity Clearing LLC cash account unless indicated otherwise.
Excess cash in your brokerage account will be swept into a money market mutual fund that will be held at JP Morgan as part of the Sweep Program, unless indicated otherwise.
Total cost does not include the cost basis on money market mutual funds or other positions where the cost basis is unknown or not applicable.

2601 Bayshore DR.
Suite 1100 - Miami. FL 33133
+1 (786) 220-7233
customer@avenue.us

March 01, 2026 - March 31, 2026

MARCIO LAMAS LOPES
LÍLIAN DE OLINDA GIANNOCCARO

DISCLOSURES

Statement Mailing: We deliver statements at least four times during the calendar year for each quarter's activities for any account with a balance. Statement Discrepancies: Please review your statement and report any inaccuracies or discrepancies. Inquiries, concerns or questions regarding your brokerage account or the activity therein should be directed to Avenue Securities by calling +1 786-220-7233 or emailing customer@avenue.us, Apex, who custodies your investments, by calling +1 214-765-1009 or Velocity by calling + 201-706-7157. Any oral communications regarding inaccuracies or discrepancies should be reconfirmed in writing to protect your rights, including those under the Securities Investor Protection Act (SIPA). This statement shall be deemed conclusive unless objected to in writing within 10 business days of the statement closing date. Material Changes: Please advise us of material changes in your investment objectives or financial situation related to your brokerage account(s). Mutual Funds and Performance: Before investing, consider the funds' investment objectives, risks, charges and expenses. Contact Avenue for a prospectus containing this information. Read it carefully. Performance data shown represents past performance and is no guarantee of future results. Investment return and principal value will fluctuate, so you may have a gain or loss when shares are sold. Current performance may be higher or lower than that quoted. Visit avenue.us for most recent month- end performance.

Sales Loads & Fees: Each fund reserves the right to terminate or modify its exchange privilege in the future. In connection with (i) access to, purchase, sale, exchange or redemption of, and/or maintenance of positions in mutual funds, ETFs and other investment products ("funds") or (ii) infrastructure needed to support such funds, some funds, or their investment affiliates, pay FBS and/or NFS sales loads and 12b-1 fees described in the prospectus as well as additional compensation for shareholder services, start-up fees, platform support and maintenance, and marketing, engagement and analytics programs. Additional information about the source(s) and amount(s) of compensation as well as other remuneration received by Avenue will be furnished to you upon written request. At the time you purchase shares of funds those shares will be assigned either a load, transaction fee (TF) or no transaction fee (NTF) status. When you subsequently sell those shares, any fees applicable to your transaction will be assessed based on the status assigned to the shares at the time of purchase.

Free Credit Balances (Excess Cash): Your free credit balances are payable on demand to you. You have authorized us in writing to sweep your free credit balances into a money market mutual fund that is in the Sweep Program. Money may be withdrawn from the Sweep Program within 1 business day of the request. You have been notified of the terms and conditions of the Sweep Program. Avenue will be able to change products available under the Sweep Program. Avenue will provide written notice at least 30 calendar days before such a change.

Order Routing: The SEC requires all broker-dealers that route orders in equity securities and options to make available quarterly reports that present a general overview of their routing practices. The reports must identify the significant venues to which customer orders were routed for execution during the applicable quarter and disclose the material aspects of the broker-dealer's relationship with such venues. In addition, the Rule (SEC 606) requires broker dealers to disclose upon customer request, the venues to which the individual customers orders were routed for the six months prior to the request, and the execution time for the order that were executed. For further information please contact customer@avenue.us.

2601 Bayshore DR.
Suite 1100 - Miami. FL 33133
+1 (786) 220-7233
customer@avenue.us

March 01, 2026 - March 31, 2026

MARCIO LAMAS LOPES
LÍLIAN DE OLINDA GIANNOCCARO

DISCLOSURES

The Market Value of a security, including those priced at par value, may differ from its purchase price and may not closely reflect the value at which the security may be sold or purchased based on various market factors. The sale or redemption of any fixed income security prior to maturity may result in a loss.

Prices for Certificates of Deposits (CDs) on your statement are generally estimates and are not based on actual market prices. The secondary market for CDs is generally illiquid. You should always request a current valuation for your securities prior to making a financial decision or placing an order. The Value provided for your brokered CDs is indicative and their actual value may differ if sold on the secondary market. Avenue determines the value of your brokered CDs based on their par value, given the CD's illiquidity, plus the accrued interest based on the contract yield. The actual value of the CDs may be different from their purchase price; and a significant loss of principal could result if brokered CDs were to be sold prior to maturity.

SIPC Securities in accounts carried by Avenue Securities, Velocity Clearing and Apex Clearing are protected in accordance with the SIPC up to $500,000 (including cash claims limited to $250,000). For details, including the SIPC brochure, please see www.sipc.org or call 1-202-371-8300. Apex has arranged for additional protection for cash and covered securities to supplement its SIPC coverage. Neither coverage protects against a decline in the market value of securities.

Brokerage services are provided by Avenue, which clears all transactions through Apex and Velocity. Apex Clearing and Velocity Clearing hold all investments, and all excess cash is held in a money market mutual fund in Avenue Securities omnibus account. Both Apex and Avenue are members of FINRA and SIPC. Upon written request, Avenue will provide Avenue's and Apex's financial statement, which is also available for inspection at its office.

Avenue (with logo) is a trademark of Avenue Holding LLC.

Non-deposit investment products offered by Avenue Securities are not insured or guaranteed by the Federal Deposit Insurance Corporation (FDIC) or any other government agency, are not obligations of any bank, and are subject to risk, including possible loss of principal.

The summary statement is provided for the customer's convenience and includes assets that may not be held by the broker-dealer.

Summary statement does not replace any other statement(s) the customer may receive from other financial institutions that hold the customer's assets.

To the extent this summary statement aggregates the values of the various accounts summarized or portions thereof, such aggregation is recognizable as having been arithmetically derived from the separately stated totals or their components.

Investment Account Statement

Detailed Investment Information

MARCIO LAMAS LOPES

Investment Account: 005877090
CPF 287.868.388-90

TUIUTI 732 172 - TATUAPE - SAO PAULO - SP - 03081015

Period 04/29/26 to 04/29/26
Issued on 04/29/26 4:51 PM

table of contents


- Summary
- Investment Funds
- Fixed Income
- Variable Income
- Checking Account

Mandatory reading in conjunction with the other notices: The contents of this document should not be relied upon as an official source of information for investment decision-making, tax guidance, or any purpose other than general informational reference. The information contained herein is subject to change without prior notice.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Portfolio Allocation



INVESTMENT FUNDS*	54.76%
FIXED INCOME*	35.50%
VARIABLE INCOME	9.65%
CHECKING ACCOUNT	0.07%

Summary – Portfolio Allocation as of 04/29/2026


Investment Category	Gross Balance R$ 04/28/26	Net Balance R$ [2] 04/28/26	Gross Balance R$ 04/29 / 26	Net Balance R$ [1] 04/29 / 26
Investment Funds*	564,678.13	561,810.95	564,757.10	561,864.04
Fixed Income*	366,075.37	362,492.81	366,146.01	362,550.85
Variable Income	99,438.72	99,438.72	99,554.66	99,554.66
Checking Account	763.98	763.98	763.98	763.98
Total	**1,030.956.20**	**1,024.506.46**	**1,031.221.75**	**1,024.733.53**

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Portfolio Allocation – Investment Funds



BTG CDB PLUS FIRF CRPR	19.54%
ARX ELBRUS FIC INCENT INFRA RF	11.00%
MAG CASH FIRF LP	10.72%
OTHERS	10.47%
ECHOS DEBENTURES INCENTIVADAS INFRA IPCA	9.92%
BTGP CRED AGRICOLA BTAG II CDI AGRO DC RIZA	9.00%
ONYX FI IMOBILIARIO RL	8.58%
POLIGONO DELTA FIDC	7.80%
PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP	7.09%
GUARDIAN FIC FIDC RL	5.82%

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Investment Funds – Position – Funds Portfolio

Reference Date	Net Balance R$ 04/28/26	Number of Units	Current Unit Value R$ [2]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$	Net Balance R$	Nominal Change R$ [1]
ARX ELBRUS FIC INCENT INFRA RF – Class CNPJ: 30.910.199/0001-56*								
04/28/26	62,158.34	28,675.89949000	2.16761591	62,158.34	-	-	62,158.34	-
BTG CDB Plus FIRF CrPr - Class CNPJ: 27.717.359/0001-30								
04/29/26	109,673.89	30,728.11900278	3.59289956	110,403.04	556.04	137.00	109.710,00	36.11
BTG PACTUAL PRIME LOGÍSTICA FII RL - Class CNPJ: 60.922.008/0001-37* - Subclass Code: J4UGU1749234022								
04/28/26	30,834.53	3,000.00000000	10.34772028	31,043.16	208.63	-	30,834.53	-
BTG Total Incentivado Infr FIRF - Class CNPJ: 54.517.219/0001-91*								
04/28/26	28,135.75	22,114.16553700	1.27229540	28,135.75	-	-	28,135.75	-
BTGP CRED AGRICOLA BTAG II CDI AGRO DC - Class CNPJ: 58.600.779/0001-66*								
04/28/26	50,676.48	500.00000000	101.69120874	50,845.60	169.12	-	50,676.48	-
Echos Debentures Incentivadas Infr IPCA - Class CNPJ: 55.713.743/0001-09*								
04/28/26	56,054.13	48,973.47195200	1.14458160	56,054.13	-	-	56,054.13	-
GUARDIAN FIC FIDC RL - Class CNPJ: 62.254.086/0001-36 - Subclass Code: Y77NE1755690828								
04/29/26	32,428.21	2,988.64300000	11.007.4868	32,896.74	451.55	-	32,445.19	16.98
MAG CASH FIRF LP - Class CNPJ: 17.899.612/0001-60*								
04/28/26	59,788.39	19,406.34091900	3.11985889	60,545.05	756.66	-	59,788.39	-
PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP - Class CNPJ: 63.141.710/0001-51*								
04/28/26	40,088.70	400.00000000	100.22175772	40,088.70	-	-	40,088.70	-
POLIGONO DELTA FIDC - Class CNPJ: 61.536.498/0001-04* - Subclass Code: ZEO1P1751392010								
04/28/26	43,479.70	400.00000000	110.23440239	44,093.76	614.06	-	43,479.70	-
RIZA ONYX FI IMOBILIARIO RL - Class CNPJ: 59.337.307/0001-25*								
04/28/26	48,492.83	500.00000000	96.98566418	48,492.83	-	-	48,492.83	-
Total Investment Funds				**564,757.10**	**2,756.06**	**137.00**	**561,864.04**	**53.09**

Investment Fund – Details – ARX ELBRUS FIC INCENT INFRA RF – Class CNPJ: 30.910.199/0001-56*

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
08/02/19	28,675.89949000	1.14730490	32,900.00	62.158,34	-	-	62,158.34
To t al	**28,675.89949**			**62,158.34**	**–**	**–**	**62,158.34**

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Investment Fund - Details - BTG CDB Plus FIRF CrPr - Class CNPJ: 27.717.359/0001-30

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
07/25/25	7,446.44233300	3.23344434	24,077.66	26,754.32	356.66	-	26,397.66
10/13/25	1,528.00334000	3.33461604	5,095.30	5,489.96	65.38	-	5,424.58
12/26/25	1.532,33319682	3.43145995	5,258.14	5,505.52	55.66	-	5,449.86
02/26/26	2,152.33305115	3.51081353	7,556.44	7,733.12	39.75	-	7,693.37
03/18/26	1,446.66539555	3.53837177	5,118.84	5,197.72	17.75	-	5,179.97
04/16/26	1,255.91362939	3.57728421	4,492.76	4,512.37	1.94	10,98	4,499.45
04/17/26	15,366.42805684	3.57923128	55,000.00	55,210.03	18.90	126,02	55,065.11
To t al	**30,728.11900278970**			**110,403.04**	**556.04**	**137.00**	**109,710.00**

Investment Fund - Details - BTG PACTUAL PRIME LOGÍSTICA FII RL - Class CNPJ: 60.922.008/0001-37* - Subclass Code: J4UGU1749234022

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
06/27/25	3,000.00000000	10.00000000	30,000.00	31,043.16	208.63	-	30,834.53
Total	**3,000.0**			**31,043.16**	**208.63**	-	**30,834.53**

Investment Fund - Details - BTG Total Incentivado Infra FIRF - Class CNPJ: 54.517.219/0001-91*

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
10/07/24	22,114.16553700	1.06385520	23,526.27	28,135.75	-	-	28,135.75
Total	**22,114.165537**			**28,135.75**	-	-	**28,135.75**

Investment Fund - Details - BTGP CRED AGRICOLA BTAG II CDI AGRO DC - Class CNPJ: 58.600.779/0001-66*

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
01/30/25	500.00000000	100.00000000	50,000.00	50,845.60	169.12	-	50,676.48
Total	**500.0**			**50,845.60**	**169.12**	-	**50,676.48**

Investment Fund - Details - Echos Debentures Incentivadas Infra IPCA - Class CNPJ: 55.713.743/0001-09*

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
11/26/24	48.973,47195200	1,02096090	50.000,00	56.054,13	-	-	56.054,13
Total	**48,973.471952**			**56,054.13**	-	-	**56,054.13**

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Investment Fund - Details - GUARDIAN FIC FIDC RL - Class CNPJ: 62.254.086/0001-36 - Subclass Code: Y77NE1755690828

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
09/10/25	2,988.64300000	10.00000000	29,886.43	32,896.74	451.55	-	32,445.19
Total	**2,988.643**			**32,896.74**	**451.55**	-	**32,445.19**

Investment Fund - Details - MAG CASH FIRF LP - Class CNPJ: 17.899.612/0001-60*

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
11/26/24	19,406.34091900	2.58677988	50,199.93	60,545.05	756.66	-	59,788.39
Total	**19,406.340919**			**60,545.05**	**756.66**	-	**59,788.39**

Investment Fund - Details - PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP - Class CNPJ: 63.141.710/0001-51*

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
10/30/25	400.00000000	100.00000000	40,000.00	40,088.70		-	40,088.70
Total	**400.0**			**40,088.70**	-	-	**40,088.70**

Investment Fund - Details - POLIGONO DELTA FIDC - Class CNPJ: 61.536.498/0001-04* - Subclass Code: ZEO1P1751392010

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
07/31/25	400.00000000	100.00000000	40,000.00	44,093.76	614.06	-	43,479.70
Total	**400.0**			**44,093.76**	**614.06**	-	**43,479.70**

Investment Fund - Details - RIZA ONYX FI IMOBILIARIO RL - Class CNPJ: 59.337.307/0001-25*

Purchase Date	Number of Units	Purchase Unit Value R$	Adjusted Purchase Value R$ [1]	Gross Balance R$	Income Tax Provision R$	IOF Tax Provision R$ [2]	Net Balance R$ [3]
03/10/25	500.00000000	100.00000000	50,000.00	48,492.83	-	-	48,492.83
Total	**500.0**			**48,492.83**	-	-	**48,492.83**

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Investment Fund - Performance

Fund	Benchmark [1]	Month Fund % [2]	Month Benchmark %	Year Fund % [3]	Year Benchmark %	12 months Fund % [4]	12 months Benchmark %
ARX ELBRUS FIC INCENT INFRA RF	IMA-B5	-0.75	1.21	2.47	5.12	11.16	11.96
BTG CDB Plus FIRF CrPr	CDI	1.04	1.04	4.52	4.48	14.88	14.83
BTG PACTUAL PRIME LOGÍSTICA FII RL	-	1.23	-	3.65	-	9.38	-
BTG Total Incentivado Infr FIRF	CDI	-0.33	1.04	2.20	4.48	12.14	14.83
BTGP CRED AGRICOLA BTAG II CDI AGRO DC	-	0.00	-	3.94	-	15.10	-
Echos Debentures Incentivadas Infr IPCA	-	-0.35	-	1.40	-	8.91	-
GUARDIAN FIC FIDC RL	-	1.16	-	4.98	-	10.07	-
MAG CASH FIRF LP	CDI	0.94	1.04	4.43	4.48	14.66	14.83
PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP	-	-	-	3.28	-	5.33	-
POLIGONO DELTA FIDC	CDI	1.19	1.04	5.40	4.48	-	14.83
RIZA ONYX FI IMOBILIARIO RL	-	-	-	1.38	-	1.34	-

Fixed Income - Position - CDB

Issuer:
BANCO BTG PACTUAL S A

Asset:	Issue Date:	Maturity Date:	Liquidity: [4]	Liquidity lock-up days:	Initial liquidity date:
CDB-CDBC24BFRGK	12/24/24	12/28/26	Yes	1	12/25/24

Weighted average rate:	Quantity:	Price R$: [1]	Gross Balance R$:	Income Tax R$:	IOF R$: [2]
CDI	10,130,000.0	0.011965	121,211.52	3,484.51	-

Net Balance R$: [3]
117,727.01

Issuer:
BANCOBTG PACTUAL S A

Asset:	Issue Date:	Maturity Date:	Liquidity: [4]	Liquidity lock-up days:	Initial liquidity date:
CDB-CDBB25CE6L4	11/28/25	11/29/27	Yes	1	11/29/25

Weighted average rate:	Quantity:	Price R$: [1]	Gross Balance R$:	Income Tax R$:	IOF R$: [2]
CDI	854,123.0	0.010575	9,033.13	110.65	-

Net Balance R$: [3]
8,922.48

Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$: [2]	Total Net Balance R$: [3]
130,244.65	**3,595.16**	**-**	**126,649.49**

Fixed Income – Position - CRA

Issuer:
BOA SAFRA

Asset:	Issue Date:	Maturity Date:	Liquidity: [4]	Liquidity lock-up days:	Initial liquidity date:
CRA-CRA02500001*	01/15/25	01/15/30	No	-	-

Weighted average rate:	Quantity:	Price R$: [1]	Gross Balance R$: [5]	Income Tax R$:	IOF R$: [2]
15.41% a.a.	25.0	1,004.560289	25.114,00	-	-

Net Balance R$: [3]
25,114.00

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Issuer:
CERRADAO

Asset:	Issue Date:	Maturity Date:	Liquidity: 4	Liquidity lock-up days:	Initial liquidity date:
CRA-CRA022004XY*	05/15/22	05/15/28	No	-	-

Weighted average rate:	Quantity:	Price R$: 1	Gross Balance R$: 5	Income Tax R$:	IOF R$: 2
IPCA + 7.15%	27.0	1,214.557117	32,793.04	-	-

Net Balance R$: 3
32,793.04

Issuer:
ECTP II

Asset:	Issue Date:	Maturity Date:	Liquidity: 4	Liquidity lock-up days:	Initial liquidity date:
CRA-CRA02300HWH*	08/31/23	09/15/33	No	-	-

Weighted average rate:	Quantity:	Price R$: 1	Gross Balance R$: 5	Income Tax R$:	IOF R$: 2
102.00% do CDI	29.0	1,055.516487	30,609.97	-	-

Net Balance R$: 3
30,609.97

Issuer:
MARFRIG

Asset:	Issue Date:	Maturity Date:	Liquidity: 4	Liquidity lock-up days:	Initial liquidity date:
CRA-CRA0250018K*	03/15/25	04/16/40	No	-	-

Weighted average rate:	Quantity:	Price R$: 1	Gross Balance R$: 5	Income Tax R$:	IOF R$: 2
IPCA + 8.25%	20.0	1,049.114272	20.982.28	-	-

Net Balance R$: 3
20,982.28

Issuer:
MINERVA

Asset:	Issue Date:	Maturity Date:	Liquidity: 4	Liquidity lock-up days:	Initial liquidity date:
CRA-CRA02400AYL*	11/29/24	11/16/29	No	-	-

Weighted average rate:	Quantity:	Price R$: 1	Gross Balance R$: 5	Income Tax R$:	IOF R$: 2
105.00% do CDI	30.0	1,064.879150	31,946.37	-	-

Net Balance R$: 3
31,946.37

Total Gross Balance R$: 5	Total Income Tax R$:	Total IOF R$: 2	Total Net Balance R$: 3
141,445.66	-	-	**141,445.66**

Fixed Income – Position - CRI

Issuer:
MRV

Asset:	Issue Date:	Maturity Date:	Liquidity: 4	Liquidity lock-up days:	Initial liquidity date:
CRI-25G5121905*	07/15/25	07/15/32	No	-	-

Weighted average rate:	Quantity:	Price R$: 1	Gross Balance R$: 5	Income Tax R$:	IOF R$: 2
IPCA + 8.26%	30.0	1,055.532564	31,665.97	-	-

Net Balance R$: 3
31,665.97

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Issuer:
PATRIMAR

Asset:	Issue Date:	Maturity Date:	Liquidity: [4]	Liquidity lock-up days:	Initial liquidity date:
CRI-24K0003001*	11/01/24	11/23/29	No	-	-

Weighted average rate:	Quantity:	Price R$: [1]	Gross Balance R$: [5]	Income Tax R$:	IOF R$: [2]
14.20% a.a.	29.0	1,081.584264	31,365.94	-	-

Net Balance R$: [3]
31,365.94

Issuer:
PRATI DONADUZZI

Asset:	Issue Date:	Maturity Date:	Liquidity: [4]	Liquidity lock-up days:	Initial liquidity date:
CRI-25F0010603*	06/17/25	06/17/32	No	-	-

Weighted average rate:	Quantity:	Price R$: [1]	Gross Balance R$: [5]	Income Tax R$:	IOF R$: [2]
14.20% a.a.	30.0	1,047.459813	31,423.79	-	-

Net Balance R$: [3]
31,423.79

Total Gross Balance R$: [5]	Total Income Tax R$:	Total IOF R$: [2]	Total Net Balance R$: [3]
94,455.70	-	-	94,455.70

Fixed Income - Details - CDB | BTG Pactual Bank S.A.

Asset:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: [1]	Liquidity lock-up days:
CDB-CDBC24BFRGK	12/24/24	12/28/26	12/24/24	Yes	1

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
12/25/24	CDI	10,130,000.0	0.0100	101,300.00	0.011965

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
121,211.52	3,484.51	-	117,727.01

Asset:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: [1]	Liquidity lock-up days:
CDB-CDBB25CE6L4	11/28/25	11/29/27	11/28/25	Yes	1

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
11/29/25	CDI	854,132.0	0.0100	8,541.32	0.010575

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
9,033.13	110.65	-	8,922.48

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
109,841.32	130,244.65	3.595,16	-	126,649.49

Fixed Income - Details - CRA | BOA SAFRA

Asset:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: [1]	Liquidity lock-up days:
CRA-CRA02500001	01/15/25	01/15/30	01/31/25	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	15.41% a.a.	25.0	1,000.0000	25,000.00	1,004.560289

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
25,114.00	-	-	25,114.00

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
25,000.00	25,114.00	-	-	25,114.00

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Fixed Income - Details - CRA | CERRADAO

Issuer:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: 1	Liquidity lock-up days:
CRA-CRA022004XY	05/15/22	05/15/28	09/18/24	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	IPCA + 7.15%	27.0	1,111.2366	30,003.38	1,214.557117

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
32,793.04	-	-	32,793.04

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
30,003.38	32,793.04	-	-	32,793.04

Fixed Income - Details - CRA | ECTP II

Issuer:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: 1	Liquidity lock-up days:
CRA-CRA02300HWH	08/31/23	09/15/33	09/18/24	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	102.00% of CDI	29.0	1,04.,4052	30,345.75	1,055.516487

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
30,609.97	-	-	30,609.97

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
30,345.75	30,609.97	-	-	30,609.97

Fixed Income - Details - CRA | MARFRIG

Issuer:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: 1	Liquidity lock-up days:
CRA-CRA0250018K	03/15/25	04/16/40	04/03/25	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	IPCA + 8,25%	20.0	1,000.0000	20,000.00	1,049.114272

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
20,982.28	-	-	20,982.28

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
20,000.00	20,982.28	-	-	20,982.28

Fixed Income - Details - CRA | MINERVA

Issuer:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: 1	Liquidity lock-up days:
CRA-CRA02400AYL	11/29/24	11/16/29	12/04/24	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	105.00% of CDI	30.0	1,000.0000	30,000.00	1,064.879150

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
31,946.37	-	-	31,946.37

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
30,000.00	31,946.37	-	-	31,946.37

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Fixed Income - Details - CRI | MRV

Issuer:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: [1]	Liquidity lock-up days:
CRI-25G5121905	07/15/25	07/15/32	08/05/25	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	IPCA + 8.26%	30.0	1,000.0000	30,000.00	1,055.532564

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
31,665.97	-	-	31,665.97

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
30,000.00	31,665.97	-	-	31,665.97

Fixed Income - Details - CRI | PATRIMAR

Issuer:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: [1]	Liquidity lock-up days:
CRI-24K0003001	11/01/24	11/23/29	11/26/24	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	14.20% a.a.	29.0	1,035.9535	30,042.65	1,081.584264

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
31,365.94	-	-	31,365.94

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
30,042.65	31,365.94	-	-	31,365.94

Fixed Income - Details - CRI | PRATI DONADUZZI

Issuer:	Issue Date:	Maturity Date:	Acquisition:	Liquidity: [1]	Liquidity lock-up days:
CRI-25F0010603	06/17/25	06/17/32	06/17/25	No	-

Weighted average rate:	Purchase Fee:	Quantity:	Purchase Price R$:	Purchase Value R$:	Price R$:
-	14.20% a.a.	30.0	1,000.0000	30,000.00	1,047.459813

Gross Balance R$:	Income Tax R$:	IOF R$:	Net Balance R$:
31,423.79	-	-	31,423.79

Total Purchase Value R$:	Total Gross Balance R$:	Total Income Tax R$:	Total IOF R$:	Total Net Balance R$:
30,000.00	31,423.79	-	-	31,423.79

Fixed Income – Consolidated Position by Issuer

Issuer	Gross Balance R$
BANCO BTG PACTUAL S A	130,244.65
BOA SAFRA	25,114.00
CE RRAD AO	32,793.04
ECTP II	30,609.97
M ARFRI G	20,982.28
MINERVA	31,946.37
MRV	31,665.97
PATRIMAR	31,365.94
PRATI DONADUZZI	31,423.79

Investment Account Statement

Statement Period 04/29/2026 to 04/29/2026

Variable Income – Position – Listed Funds

Code	Asset	Type	Qty.	Closing Price R$	Average Price R$	Gross Balance R$
G CRA1 1 *	FIAGRO GLPG CI	FI AG RO	780	54.41	-	42,354.00
I BCR1 1 *	FII BREI CI	FII	10	52.50	-	529.80
IRIM11*	FII IRIM CI	FII	59	65.55	83.39	3,886.92
JSRE11*	FII JS REAL CI	FII	111	65.61	-	7,281.60
OUJP1 1 *	FII OURI JPPCI	FII	110	88.37	-	9,687.70
PAT L1 1 *	FII PATL VBICI	FII	250	66.25	-	16,595.00
VR TA1 1 *	FII FATOR VECI	FII	242	78.68	-	19,219.64
Total in Listed Funds R$						**99,554.66**

Current account - Position

Date	Financial value R$
04/29/26	**763.98**

Disclaimer: This section includes assets valued as of a date prior to the date on which this statement was generated.

Risk Profile

Moderate Risk Profile



Conservative

An investor with a low tolerance for risk who seeks, above all, to preserve capital and achieve greater security in investments.

Moderate

An investor who is willing to allocate a portion of their assets to higher-risk investments and may incur some loss of invested capital in pursuit of above-average long-term returns.

Sophisticated

An investor with a high tolerance for risk who seeks substantial investment returns, including through the use of leverage.

Disclaimers

Investment Funds – Chart

1. The percentages shown are based solely on the allocation to investment funds and do not take into account other investments, such as stocks, debentures, government securities, and similar assets.

Investment Funds – Details

1. AMOUNT INVESTED – TAXES (COME-COTAS).
The amount may have been affected by mandatory tax withholding (*come-cotas*) and therefore may not reflect the actual adjusted acquisition cost.
2. Amount estimated for taxes as of the specified date.
3. Net Balance as of the reference date, after deduction of the Income Tax and Financial Transactions Tax (IOF) provisions.

Investment Funds – Performance

1. The benchmarks used are provided solely as economic references and do not constitute objective performance parameters for the investment funds.
2. Performance is calculated based on the variation between the last business day of the month preceding the calculation period and the last business day of the reference month ("30-to-30"). Performance for closed-end funds is not presented because such funds are subject to unit amortizations, which distort cumulative performance.
3. The fund's unit value is negatively affected when a unit amortization event occurs. Accordingly, the performance presented in this report is based on the fund's unit value and does not include gains received by unit holders through amortization payments already made.
   Pursuant to CVM Instruction No. 465, effective 05/02/2008, investment funds composed of equity assets no longer calculate their performance based on the average stock price and instead use the closing market price. Performance figures for periods before 08/01/2005 were recalculated in accordance with ANBID Circular No. 010/05 to establish a standardized basis for comparison throughout the investment fund industry. Accordingly, unit holders are advised that any differences between previously published cumulative performance and the current figures are solely attributable to the change in the calculation methodology. This change does not result in any actual gain or loss for unit holders, as it does not affect the value of the fund units. Fund units continue to be valued in accordance with the applicable Fund Regulations and governing regulations.
4. Accordingly, performance comparisons should use the average stock index prices for periods before 05/02/2008, and closing stock index prices for periods after that date. This change does not apply to Exclusive Investment Funds of Closed Private Pension Entities governed by National Monetary Council (CMN) Resolution No. 3,456/2007.

Investment Funds - Position

1. Nominal Change = (Net Value at the End of the Period) – (Net Value at the Beginning of the Period) + (Net Value of Outgoing Transactions) - (Net Value of Incoming Transactions).
2. Pursuant to CVM Instruction No. 472, Article 39, Item I, the net asset value per unit of Real Estate Investment Funds (FIIs) must be disclosed monthly through the Monthly Report on the fundos.net platform within fifteen (15) days after the end of each month. The unit value shown on this statement refers to: (i) the net asset value calculated using daily valuation adjustments and therefore reflects the managerial net asset value for transparency purposes only, without guaranteeing that such value may be used by investors for investment decisions, transfers, usufruct rights, or similar purposes; or (ii) the stock exchange closing price, in the case of Real Estate Investment Funds traded on B3 and acquired through the stock exchange.

Fixed Income - Positions

1. Asset prices are provided for reference purposes only and do not necessarily represent actual trading prices.
2. Net Balance as of the reference date, after deduction of the Income Tax and IOF provisions.
3. Income generated by LCA, LCI, CRI, and LH investments is exempt from Income Tax for individuals, provided the investment is held to maturity, except for capital gains realized upon disposition.
4. For information regarding the liquidity of repurchase agreements and DI investments, please contact your service channel.
5. The stated amount reflects market conditions applicable to the [public/private security], taking into account characteristics such as credit risk and duration. It does not consider factors relating to immediate liquidity on a specific date and therefore does not necessarily represent the price at which the [public/private security] may actually be traded.

Fixed Income - Detailed Positions

1. For information regarding the liquidity of repurchase agreements and DI investments, please contact your service channel.

Disclaimers

Summary

1. For purposes of calculating the Net Balance, any Income Tax and IOF that may be deducted upon redemption of assets held in the managed portfolio have not been taken into account.
2. For purposes of calculating the Net Balance, any Income Tax and IOF that may be deducted upon redemption of assets held in the managed portfolio have not been taken into account.

Suitability

1. The Suitability process reflects the criteria established by BTG Pactual to determine whether your investments are appropriate for your account's risk profile. If you have any questions, please contact your relationship manager.

General

1. Past performance is not indicative of future results.
2. When evaluating the performance of Investment Funds, an analysis covering a minimum period of twelve (12) months is recommended. Investment Funds are not guaranteed by the fund administrator, the portfolio manager, or the Credit Guarantee Fund (FGC).
3. Before making an initial investment in a Fund, investors are advised to carefully read the applicable prospectus (when available) and fund regulations. Particular attention should be given to the provisions concerning the Fund's investment objective, investment policy, and the risk factors to which it is exposed.
4. Additional copies of the regulations governing the Investment Funds administered by BTG PACTUAL SERVIÇOS FINANCEIROS S.A. DTVM are available upon request from our investment advisors.
5. The Investment Funds administered by BTG PACTUAL SERVIÇOS FINANCEIROS S.A. DTVM are audited by one of the four largest independent auditing firms, in accordance with the auditor rotation requirements established by law.
6. Although the information contained in this statement accurately reflects the records maintained by this financial institution for the respective unit holder, it should not be used for tax reporting purposes or for filing tax returns with the Brazilian Federal Revenue Service. The information required for such filings is provided in the income statements issued by this institution.
7. Pursuant to National Monetary Council (CMN) Resolution No. 4,688/2018, balances maintained in checking accounts, savings accounts, and time deposits (CDB/RDB), as well as investments in Bills of Exchange, Mortgage Notes, Real Estate Credit Bills (LCI), Agribusiness Credit Bills (LCA), among other eligible financial instruments held with this financial institution, are protected by the Credit Guarantee Fund (FGC).

Contact Us



Ombudsman Office

0800-722-0048

Monday through Friday, from 9:00 a.m. to 6:00 p.m., excluding public holidays.

ouvidoria@btgpactual.com

I, Marina Viana Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that I have performed the professional translation of this document from Portuguese to English as a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.

Marina Viana
_____

Date: July 7, 2026

Extrato da Conta Investimento

Informações detalhadas sobre investimentos

MARCIO LAMAS LOPES

Conta investimento 005877090

CPF 287.868.388-90

TUIUTI 732 172 - TATUAPE - SAO PAULO - SP - 03081015

Período de 29/04/26 a 29/04/26

Emitido em 29/04/26 16:51

índice


- Sumário
- Fundo de Investimento
- Renda fixa
- Renda variável
- Conta corrente

Leitura obrigatória em conjunto com os demais avisos:O conteúdo desse documento não deve servir como fonte oficial de informações no processo decisório do investidor ou como base para a orientação sobre tributos ou para qualquer outro fim que não o de mero indicativo. As informações estão sujeitas a alteração sem aviso prévio.

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Distribuição da Carteira



FUNDOS DE INVESTIMENTO*	54.76%
RENDA FIXA*	35.50%
RENDA VARIÁVEL	9.65%
CONTA CORRENTE	0.07%

Sumário - Distribuição em 29/04/26


Mercados	Saldo Bruto R$ 28/04/26	Saldo Líquido R$ [2] 28/04/26	Saldo Bruto R$ 29/04/26	Saldo Líquido R$ [1] 29/04/26
Fundos de Investimento*	564.678,13	561.810,95	564.757,10	561.864,04
Renda Fixa*	366.075,37	362.492,81	366.146,01	362.550,85
Renda Variável	99.438,72	99.438,72	99.554,66	99.554,66
Conta Corrente	763,98	763,98	763,98	763,98
Total	**1.030.956,20**	**1.024.506,46**	**1.031.221,75**	**1.024.733,53**

Disclaimers: Seção com ativos calculados em data anterior à data da geração do extrato

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Distribuição - Fundos de Investimento



BTG CDB PLUS FIRF CRPR	19.54%
ARX ELBRUS FIC INCENT INFRA RF	11.00%
MAG CASH FIRF LP	10.72%
OUTROS	10.47%
ECHOS DEBENTURES INCENTIVADAS INFRA IPCA	9.92%
BTGP CRED AGRICOLA BTAG II CDI AGRO DC	9.00%
RIZA ONYX FI IMOBILIARIO RL	8.58%
POLIGONO DELTA FIDC	7.80%
PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP	7.09%
GUARDIAN FIC FIDC RL	5.82%

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Fundo de Investimento - Posição - Portfólio de fundos

Data Referência	Saldo Líquido R$ 28/04/26	Quantidade de Cotas	Cotação Atual R$ [2]	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$	Saldo Líquido R$	Variação Nominal R$ [1]
ARX ELBRUS FIC INCENT INFRA RF - Classe CNPJ: 30.910.199/0001-56*								
28/04/26	62.158,34	28.675,89949000	2,16761591	62.158,34	-	-	62.158,34	-
BTG CDB Plus FIRF CrPr - Classe CNPJ: 27.717.359/0001-30								
29/04/26	109.673,89	30.728,11900278	3,59289956	110.403,04	556,04	137,00	109.710,00	36,11
BTG PACTUAL PRIME LOGÍSTICA FII RL - Classe CNPJ: 60.922.008/0001-37* - Cód. Subclasse: J4UGU1749234022								
28/04/26	30.834,53	3.000,00000000	10,34772028	31.043,16	208,63	-	30.834,53	-
BTG Total Incentivado Infra FIRF - Classe CNPJ: 54.517.219/0001-91*								
28/04/26	28.135,75	22.114,16553700	1,27229540	28.135,75	-	-	28.135,75	-
BTGP CRED AGRICOLA BTAG II CDI AGRO DC - Classe CNPJ: 58.600.779/0001-66*								
28/04/26	50.676,48	500,00000000	101,69120874	50.845,60	169,12	-	50.676,48	-
Echos Debentures Incentivadas Infra IPCA - Classe CNPJ: 55.713.743/0001-09*								
28/04/26	56.054,13	48.973,47195200	1,14458160	56.054,13	-	-	56.054,13	-
GUARDIAN FIC FIDC RL - Classe CNPJ: 62.254.086/0001-36 - Cód. Subclasse: Y77NE1755690828								
29/04/26	32.428,21	2.988,64300000	11,00724868	32.896,74	451,55	-	32.445,19	16,98
MAG CASH FIRF LP - Classe CNPJ: 17.899.612/0001-60*								
28/04/26	59.788,39	19.406,34091900	3,11985889	60.545,05	756,66	-	59.788,39	-
PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP - Classe CNPJ: 63.141.710/0001-51*								
28/04/26	40.088,70	400,00000000	100,22175772	40.088,70	-	-	40.088,70	-
POLIGONO DELTA FIDC - Classe CNPJ: 61.536.498/0001-04* - Cód. Subclasse: ZEO1P1751392010								
28/04/26	43.479,70	400,00000000	110,23440239	44.093,76	614,06	-	43.479,70	-
RIZA ONYX FI IMOBILIARIO RL - Classe CNPJ: 59.337.307/0001-25*								
28/04/26	48.492,83	500,00000000	96,98566418	48.492,83	-	-	48.492,83	-
Total em fundos				**564.757,10**	**2.756,06**	**137,00**	**561.864,04**	**53,09**

Fundo de Investimento - Detalhamento - ARX ELBRUS FIC INCENT INFRA RF - Classe CNPJ: 30.910.199/0001-56*

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra Ajustado R$ [1]	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
02/08/19	28.675,89949000	1,14730490	32.900,00	62.158,34	-	-	62.158,34
Total	**28.675,89949**			**62.158,34**	**-**	**-**	**62.158,34**

Disclaimers: Seção com ativos calculados em data anterior à data da geração do extrato

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Fundo de Investimento - Detalhamento - BTG CDB Plus FIRF CrPr - Classe CNPJ: 27.717.359/0001-30

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
25/07/25	7.446,44233300	3,23344434	24.077,66	26.754,32	356,66	-	26.397,66
13/10/25	1.528,00334000	3,33461604	5.095,30	5.489,96	65,38	-	5.424,58
26/12/25	1.532,33319682	3,43145995	5.258,14	5.505,52	55,66	-	5.449,86
26/02/26	2.152,33305115	3,51081353	7.556,44	7.733,12	39,75	-	7.693,37
18/03/26	1.446,66539555	3,53837177	5.118,84	5.197,72	17,75	-	5.179,97
16/04/26	1.255,91362939	3,57728421	4.492,76	4.512,37	1,94	10,98	4.499,45
17/04/26	15.366,42805684	3,57923128	55.000,00	55.210,03	18,90	126,02	55.065,11
Total	**30.728,11900278970**			**110.403,04**	**556,04**	**137,00**	**109.710,00**

Fundo de Investimento - Detalhamento - BTG PACTUAL PRIME LOGÍSTICA FII RL - Classe CNPJ: 60.922.008/0001-37* - Cód. Subclasse: J4UGU1749234022

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
27/06/25	3.000,00000000	10,00000000	30.000,00	31.043,16	208,63	-	30.834,53
Total	**3.000,0**			**31.043,16**	**208,63**	**-**	**30.834,53**

Fundo de Investimento - Detalhamento - BTG Total Incentivado Infra FIRF - Classe CNPJ: 54.517.219/0001-91*

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
07/10/24	22.114,16553700	1,06385520	23.526,27	28.135,75	-	-	28.135,75
Total	**22.114,165537**			**28.135,75**	**-**	**-**	**28.135,75**

Fundo de Investimento - Detalhamento - BTGP CRED AGRICOLA BTAG II CDI AGRO DC - Classe CNPJ: 58.600.779/0001-66*

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
30/01/25	500,00000000	100,00000000	50.000,00	50.845,60	169,12	-	50.676,48
Total	**500,0**			**50.845,60**	**169,12**	**-**	**50.676,48**

Fundo de Investimento - Detalhamento - Echos Debentures Incentivadas Infra IPCA - Classe CNPJ: 55.713.743/0001-09*

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
26/11/24	48.973,47195200	1,02096090	50.000,00	56.054,13	-	-	56.054,13
Total	**48.973,471952**			**56.054,13**	**-**	**-**	**56.054,13**

Disclaimers: Seção com ativos calculados em data anterior à data da geração do extrato

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Fundo de Investimento - Detalhamento - GUARDIAN FIC FIDC RL - Classe CNPJ: 62.254.086/0001-36 - Cód. Subclasse: Y77NE1755690828

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
10/09/25	2.988,64300000	10,00000000	29.886,43	32.896,74	451,55	-	32.445,19
Total	**2.988,643**			**32.896,74**	**451,55**	**-**	**32.445,19**

Fundo de Investimento - Detalhamento - MAG CASH FIRF LP - Classe CNPJ: 17.899.612/0001-60*

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
26/11/24	19.406,34091900	2,58677988	50.199,93	60.545,05	756,66	-	59.788,39
Total	**19.406,340919**			**60.545,05**	**756,66**	**-**	**59.788,39**

Fundo de Investimento - Detalhamento - PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP - Classe CNPJ: 63.141.710/0001-51*

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
30/10/25	400,00000000	100,00000000	40.000,00	40.088,70	-	-	40.088,70
Total	**400,0**			**40.088,70**	**-**	**-**	**40.088,70**

Fundo de Investimento - Detalhamento - POLIGONO DELTA FIDC - Classe CNPJ: 61.536.498/0001-04* - Cód. Subclasse: ZEO1P1751392010

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
31/07/25	400,00000000	100,00000000	40.000,00	44.093,76	614,06	-	43.479,70
Total	**400,0**			**44.093,76**	**614,06**	**-**	**43.479,70**

Fundo de Investimento - Detalhamento - RIZA ONYX FI IMOBILIARIO RL - Classe CNPJ: 59.337.307/0001-25*

Data Compra	Quantidade de Cotas	Cotação Compra R$	Valor de Compra [1] Ajustado R$	Saldo Bruto R$	Provisão de IR R$	Provisão de IOF R$ [2]	Saldo Líquido R$ [3]
10/03/25	500,00000000	100,00000000	50.000,00	48.492,83	-	-	48.492,83
Total	**500,0**			**48.492,83**	**-**	**-**	**48.492,83**

Disclaimers: Seção com ativos calculados em data anterior à data da geração do extrato

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Fundo de Investimento - Rentabilidade

Fundo	Benchmark [1]	Fundo Mês % [2]	Benchmark Mês %	Fundo Ano % [3]	Benchmark Ano %	Fundo 12 meses % [4]	Benchmark 12 meses %
ARX ELBRUS FIC INCENT INFRA RF	IMA-B5	-0,75	1,21	2,47	5,12	11,16	11,96
BTG CDB Plus FIRF CrPr	CDI	1,04	1,04	4,52	4,48	14,88	14,83
BTG PACTUAL PRIME LOGÍSTICA FII RL	-	1,23	-	3,65	-	9,38	-
BTG Total Incentivado Infra FIRF	CDI	-0,33	1,04	2,20	4,48	12,14	14,83
BTGP CRED AGRICOLA BTAG II CDI AGRO DC	-	0,00	-	3,94	-	15,10	-
Echos Debentures Incentivadas Infra IPCA	-	-0,35	-	1,40	-	8,91	-
GUARDIAN FIC FIDC RL	-	1,16	-	4,98	-	10,07	-
MAG CASH FIRF LP	CDI	0,94	1,04	4,43	4,48	14,66	14,83
PÁTRIA INFRAESTRUTURA CRÉDITO DI II FIP	-	-	-	3,28	-	5,33	-
POLIGONO DELTA FIDC	CDI	1,19	1,04	5,40	4,48	-	14,83
RIZA ONYX FI IMOBILIARIO RL	-	-	-	1,38	-	1,34	-

Renda fixa - Posição - CDB

Emissor :
BANCO BTG PACTUAL S A

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CDB-CDBC24BFRGK	24/12/24	28/12/26	Sim	1	25/12/24
Taxa Média Ponderada : CDI	**Quantidade :** 10.130.000,0	**Preço R$: [1]** 0,011965	**Saldo Bruto R$:** 121.211,52	**IR R$:** 3.484,51	**IOF R$: [2]** -
Saldo Líquido R$: [3] 117.727,01					

Emissor :
BANCO BTG PACTUAL S A

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CDB-CDBB25CE6L4	28/11/25	29/11/27	Sim	1	29/11/25
Taxa Média Ponderada : CDI	**Quantidade :** 854.132,0	**Preço R$: [1]** 0,010575	**Saldo Bruto R$:** 9.033,13	**IR R$:** 110,65	**IOF R$: [2]** -
Saldo Líquido R$: [3] 8.922,48					

Total Saldo Bruto R$:	Total IR R$:	Total IOF R$: [2]	Total Saldo Líquido R$: [3]
130.244,65	**3.595,16**	**-**	**126.649,49**

Renda fixa - Posição - CRA

Emissor :
BOA SAFRA

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CRA-CRA02500001*	15/01/25	15/01/30	Não	-	-
Taxa Média Ponderada : 15,41% a.a.	**Quantidade :** 25,0	**Preço R$: [1]** 1.004,560289	**Saldo Bruto R$: [5]** 25.114,00	**IR R$:** -	**IOF R$: [2]** -
Saldo Líquido R$: [3] 25.114,00					

Disclaimers: Seção com ativos calculados em data anterior à data da geração do extrato

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Emissor :
CERRADAO

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CRA-CRA022004XY*	15/05/22	15/05/28	Não	-	-
Taxa Média Ponderada : IPCA + 7,15%	**Quantidade :** 27,0	**Preço R$:** [1] 1.214,557117	**Saldo Bruto R$:** [5] 32.793,04	**IR R$:** -	**IOF R$:** [2] -
Saldo Líquido R$: [3] 32.793,04					

Emissor :
ECTP II

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CRA-CRA02300HWH*	31/08/23	15/09/33	Não	-	-
Taxa Média Ponderada : 102,00% do CDI	**Quantidade :** 29,0	**Preço R$:** [1] 1.055,516487	**Saldo Bruto R$:** [5] 30.609,97	**IR R$:** -	**IOF R$:** [2] -
Saldo Líquido R$: [3] 30.609,97					

Emissor :
MARFRIG

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CRA-CRA0250018K*	15/03/25	16/04/40	Não	-	-
Taxa Média Ponderada : IPCA + 8,25%	**Quantidade :** 20,0	**Preço R$:** [1] 1.049,114272	**Saldo Bruto R$:** [5] 20.982,28	**IR R$:** -	**IOF R$:** [2] -
Saldo Líquido R$: [3] 20.982,28					

Emissor :
MINERVA

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CRA-CRA02400AYL*	29/11/24	16/11/29	Não	-	-
Taxa Média Ponderada : 105,00% do CDI	**Quantidade :** 30,0	**Preço R$:** [1] 1.064,879150	**Saldo Bruto R$:** [5] 31.946,37	**IR R$:** -	**IOF R$:** [2] -
Saldo Líquido R$: [3] 31.946,37					

Total Saldo Bruto R$: [5]	Total IR R$:	Total IOF R$: [2]	Total Saldo Líquido R$: [3]
141.445,66	**-**	**-**	**141.445,66**

Renda fixa - Posição - CRI

Emissor :
MRV

Ativo :	Emissão :	Vencimento :	Liquidez : [4]	Dias de carência para liquidez :	Data inicial de liquidez :
CRI-25G5121905*	15/07/25	15/07/32	Não	-	-
Taxa Média Ponderada : IPCA + 8,26%	**Quantidade :** 30,0	**Preço R$:** [1] 1.055,532564	**Saldo Bruto R$:** [5] 31.665,97	**IR R$:** -	**IOF R$:** [2] -
Saldo Líquido R$: [3] 31.665,97					

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Emissor : PATRIMAR					
Ativo : CRI-24K0003001*	**Emissão :** 01/11/24	**Vencimento :** 23/11/29	**Liquidez :** [4] Não	**Dias de carência para liquidez :** -	**Data inicial de liquidez :** -
Taxa Média Ponderada : 14,20% a.a.	**Quantidade :** 29,0	**Preço R$:** [1] 1.081,584264	**Saldo Bruto R$:** [5] 31.365,94	**IR R$:** -	**IOF R$:** [2] -
Saldo Líquido R$: [3] 31.365,94					
Emissor : PRATI DONADUZZI					
Ativo : CRI-25F0010603*	**Emissão :** 17/06/25	**Vencimento :** 17/06/32	**Liquidez :** [4] Não	**Dias de carência para liquidez :** -	**Data inicial de liquidez :** -
Taxa Média Ponderada : 14,20% a.a.	**Quantidade :** 30,0	**Preço R$:** [1] 1.047,459813	**Saldo Bruto R$:** [5] 31.423,79	**IR R$:** -	**IOF R$:** [2] -
Saldo Líquido R$: [3] 31.423,79					
Total Saldo Bruto R$: [5] **94.455,70**	**Total IR R$:** **-**	**Total IOF R$:** [2] **-**	**Total Saldo Líquido R$:** [3] **94.455,70**		

Renda fixa - Detalhamento - CDB | BANCO BTG PACTUAL S A

Ativo : CDB-CDBC24BFRGK	**Emissão :** 24/12/24	**Vencimento :** 28/12/26	**Aquisição :** 24/12/24	**Liquidez :** [1] Sim	**Dias de carência para liquidez :** 1
Data inicial de liquidez : 25/12/24	**Taxa Compra :** CDI	**Quantidade :** 10.130.000,0	**Preço Compra R$:** 0,0100	**Valor Compra R$:** 101.300,00	**Preço R$:** 0,011965
Saldo Bruto R$: 121.211,52	**IR R$:** 3.484,51	**IOF R$:** -	**Saldo Líquido R$:** 117.727,01		
Ativo : CDB-CDBB25CE6L4	**Emissão :** 28/11/25	**Vencimento :** 29/11/27	**Aquisição :** 28/11/25	**Liquidez :** [1] Sim	**Dias de carência para liquidez :** 1
Data inicial de liquidez : 29/11/25	**Taxa Compra :** CDI	**Quantidade :** 854.132,0	**Preço Compra R$:** 0,0100	**Valor Compra R$:** 8.541,32	**Preço R$:** 0,010575
Saldo Bruto R$: 9.033,13	**IR R$:** 110,65	**IOF R$:** -	**Saldo Líquido R$:** 8.922,48		
Total Valor Compra R$: **109.841,32**	**Total Saldo Bruto R$:** **130.244,65**	**Total IR R$:** **3.595,16**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **126.649,49**	

Renda fixa - Detalhamento - CRA | BOA SAFRA

Ativo : CRA-CRA02500001	**Emissão :** 15/01/25	**Vencimento :** 15/01/30	**Aquisição :** 31/01/25	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** 15,41% a.a.	**Quantidade :** 25,0	**Preço Compra R$:** 1.000,0000	**Valor Compra R$:** 25.000,00	**Preço R$:** 1.004,560289
Saldo Bruto R$: 25.114,00	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 25.114,00		
Total Valor Compra R$: **25.000,00**	**Total Saldo Bruto R$:** **25.114,00**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **25.114,00**	

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Renda fixa - Detalhamento - CRA | CERRADAO

Ativo : CRA-CRA022004XY	**Emissão :** 15/05/22	**Vencimento :** 15/05/28	**Aquisição :** 18/09/24	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** IPCA + 7,15%	**Quantidade :** 27,0	**Preço Compra R$:** 1.111,2366	**Valor Compra R$:** 30.003,38	**Preço R$:** 1.214,557117
Saldo Bruto R$: 32.793,04	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 32.793,04		
Total Valor Compra R$: **30.003,38**	**Total Saldo Bruto R$:** **32.793,04**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **32.793,04**	

Renda fixa - Detalhamento - CRA | ECTP II

Ativo : CRA-CRA02300HWH	**Emissão :** 31/08/23	**Vencimento :** 15/09/33	**Aquisição :** 18/09/24	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** 102,00% do CDI	**Quantidade :** 29,0	**Preço Compra R$:** 1.046,4052	**Valor Compra R$:** 30.345,75	**Preço R$:** 1.055,516487
Saldo Bruto R$: 30.609,97	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 30.609,97		
Total Valor Compra R$: **30.345,75**	**Total Saldo Bruto R$:** **30.609,97**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **30.609,97**	

Renda fixa - Detalhamento - CRA | MARFRIG

Ativo : CRA-CRA0250018K	**Emissão :** 15/03/25	**Vencimento :** 16/04/40	**Aquisição :** 03/04/25	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** IPCA + 8,25%	**Quantidade :** 20,0	**Preço Compra R$:** 1.000,0000	**Valor Compra R$:** 20.000,00	**Preço R$:** 1.049,114272
Saldo Bruto R$: 20.982,28	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 20.982,28		
Total Valor Compra R$: **20.000,00**	**Total Saldo Bruto R$:** **20.982,28**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **20.982,28**	

Renda fixa - Detalhamento - CRA | MINERVA

Ativo : CRA-CRA02400AYL	**Emissão :** 29/11/24	**Vencimento :** 16/11/29	**Aquisição :** 04/12/24	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** 105,00% do CDI	**Quantidade :** 30,0	**Preço Compra R$:** 1.000,0000	**Valor Compra R$:** 30.000,00	**Preço R$:** 1.064,879150
Saldo Bruto R$: 31.946,37	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 31.946,37		
Total Valor Compra R$: **30.000,00**	**Total Saldo Bruto R$:** **31.946,37**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **31.946,37**	

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Renda fixa - Detalhamento - CRI | MRV

Ativo : CRI-25G5121905	**Emissão :** 15/07/25	**Vencimento :** 15/07/32	**Aquisição :** 05/08/25	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** IPCA + 8,26%	**Quantidade :** 30,0	**Preço Compra R$:** 1.000,0000	**Valor Compra R$:** 30.000,00	**Preço R$:** 1.055,532564
Saldo Bruto R$: 31.665,97	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 31.665,97		
Total Valor Compra R$: **30.000,00**	**Total Saldo Bruto R$:** **31.665,97**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **31.665,97**	

Renda fixa - Detalhamento - CRI | PATRIMAR

Ativo : CRI-24K0003001	**Emissão :** 01/11/24	**Vencimento :** 23/11/29	**Aquisição :** 26/11/24	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** 14,20% a.a.	**Quantidade :** 29,0	**Preço Compra R$:** 1.035,9535	**Valor Compra R$:** 30.042,65	**Preço R$:** 1.081,584264
Saldo Bruto R$: 31.365,94	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 31.365,94		
Total Valor Compra R$: **30.042,65**	**Total Saldo Bruto R$:** **31.365,94**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **31.365,94**	

Renda fixa - Detalhamento - CRI | PRATI DONADUZZI

Ativo : CRI-25F0010603	**Emissão :** 17/06/25	**Vencimento :** 17/06/32	**Aquisição :** 17/06/25	**Liquidez :** [1] Não	**Dias de carência para liquidez :** -
Data inicial de liquidez : -	**Taxa Compra :** 14,20% a.a.	**Quantidade :** 30,0	**Preço Compra R$:** 1.000,0000	**Valor Compra R$:** 30.000,00	**Preço R$:** 1.047,459813
Saldo Bruto R$: 31.423,79	**IR R$:** -	**IOF R$:** -	**Saldo Líquido R$:** 31.423,79		
Total Valor Compra R$: **30.000,00**	**Total Saldo Bruto R$:** **31.423,79**	**Total IR R$:** **-**	**Total IOF R$:** **-**	**Total Saldo Líquido R$:** **31.423,79**	

Renda fixa - Posição Consolidada Por Emissor

Emissor	Saldo Bruto R$
BANCO BTG PACTUAL S A	130.244,65
BOA SAFRA	25.114,00
CERRADAO	32.793,04
ECTP II	30.609,97
MARFRIG	20.982,28
MINERVA	31.946,37
MRV	31.665,97
PATRIMAR	31.365,94
PRATI DONADUZZI	31.423,79

Disclaimers: Seção com ativos calculados em data anterior à data da geração do extrato

Extrato da Conta Investimento

Período de 29/04/26 a 29/04/26

Renda variável - Posição - Fundos Listados

Código	Ativo	Tipo	Qtde.	Preço Fechamento R$	Preço Médio R$ [1]	Saldo Bruto R$
GCRA11*	FIAGRO GLPG CI	FIAGRO	780	54,41	-	42.354,00
IBCR11*	FII BREI CI	FII	10	52,50	-	529,80
IRIM11*	FII IRIM CI	FII	59	65,55	83,39	3.886,92
JSRE11*	FII JS REAL CI	FII	111	65,61	-	7.281,60
OUJP11*	FII OURI JPPCI	FII	110	88,37	-	9.687,70
PATL11*	FII PATL VBICI	FII	250	66,25	-	16.595,00
VRTA11*	FII FATOR VECI	FII	242	78,68	-	19.219,64
Total em Fundos Listados R$						**99.554,66**

Conta corrente - Posição

Data	Valor financeiro R$
29/04/26	**763,98**

Disclaimers: Seção com ativos calculados em data anterior à data da geração do extrato

Perfil de Risco

Perfil de Risco **Moderado**





Conservador

Investidor que possui baixa tolerância a risco e que busca, principalmente, preservação do seu capital e maior segurança seus investimentos.



Moderado

Investidor que está disposto a destinar parte dos seus rescursos a investimentos de maior risco, sendo possivel sofrer alguma perda de capital investido com objetivo de obter retornos acima da média a longo prazo.



Sofisticado

Investidor que possui alta tolerância a risco e busca retornos expressivos em seus investimentos, inclusive através de alavancagem.

Disclaimers

Fundos de Investimento - Gráfico

1. Os percentuais exibidos têm como base a alocação apenas em fundos de investimento, não sendo considerados os outros investimentos, tais como ações, debêntures, títulos públicos, etc.

Fundos de Investimento - Detalhamento

1. VALOR APLICADO – IMPOSTOS (COME-COTAS).
   O valor pode ter sofrido impacto de amortização e que pode não refletir o real custo de aquisição ajustado.
2. Valor previsto para os impostos na data informada.
3. Saldo Líquido na data de referência, deduzido das provisões de IR e IOF.

Fundos de Investimento - Rentabilidade

1. Os Benchmarks utilizados são mera referência econômica e não parâmetro objetivo dos fundos.
2. A apuração da rentabilidade é baseada na variação do último dia útil do mês anterior ao período de cálculo e ao último dia útil do mês de referência ('30 a 30'). Não está indicada a rentabilidade de fundos fechados, já que estão sujeitos a amortização de cotas que distorcem a rentabilidade acumulada.
3. A cota do fundo é impactada negativamente quando há evento de amortização de cotas. Dessa forma, a rentabilidade demonstrada neste relatório é baseada na cota do fundo, não sendo considerados os ganhos auferidos pelos cotistas com as amortizações já pagas.
   Em atendimento à Instrução CVM nº 465, desde 02/05/2008, os fundos compostos por ativos de renda variável deixaram de apurar suas rentabilidades com base na cotação média das ações e passaram a fazê-lo com base na cotação de fechamento.
   As rentabilidades relativas ao período anterior a 01/08/2005 foram recalculadas, conforme Circular 010/05 da Anbid, com o objetivo de estabelecer um padrão de comparação para toda a indústria de fundos. Assim, ficam os Srs. cotistas cientes de que eventual diferença entre a rentabilidade acumulada divulgada no passado e a presente deve-se apenas à mudança efetuada na sistemática de apuração da rentabilidade. Esta alteração não implica em perda ou ganho real para o cotista, uma vez que não há qualquer impacto no valor da cota do fundo. A cota permanece sendo calculada segundo o que dispõe o Regulamento e a regulamentação vigentes.
4. Assim, comparações de rentabilidade devem utilizar, para períodos anteriores a 02/05/2008, a cotação média dos índices de ações e, para períodos posteriores a esta data, a cotação de fechamento. A alteração não se aplica aos Fundos Exclusivos de Entidades Fechadas de Previdência Complementar, regulamentados pela Resolução 3.456/2007 do Conselho Monetário Nacional - CMN.

Fundos de Investimento - Posição

1. Variação Nominal = (Valor Líquido no Final do Período) - (Valor Líquido no Inicio do Período) + (Valor Líquido Movimentações de Saída) - (Valor Líquido Movimentações de Entrada)
2. Conforme ICVM 472 em seu art. 39, inciso I, a cota patrimonial dos Fundos Imobiliários deve ser disponibilizada mensalmente via "Informe Mensal" no fundos.net até 15 dias após o encerramento do mês. O valor de cota constante no extrato refere-se: (i) ao preço patrimonial considerando variações diárias e, portanto, reflete seu valor patrimonial gerencial para fins de maior transparência, não sendo garantido que este valor poderá ser utilizado pelo investidor no caso de eventual tomada de decisão, e/ou valor base para cessão, usufruto, etc; ou; (ii) ao preço da cotação de fechamento em bolsa de valores em caso de Fundos Imobiliários negociados na B3 e adquiridos em mercado de bolsa de valores.

Renda Fixa - Posição

1. Os preços dos ativos são meramente indicativos e não representam necessariamente os valores de negociação.
2. Saldo Líquido na data de referência, deduzido das provisões de IR e IOF.
3. A remuneração produzida por LCA, LCI, CRI e LH para pessoas físicas é isenta de imposto de renda se o ativo for levado até o vencimento, exceto o ganho de capital auferido na alienação.
4. Para informações sobre liquidez da compromissada e DI, entre em contato com seu canal de atendimento.
5. O referido valor indica as condições de mercado para o [título público/privado] considerando características do papel como o risco de crédito e duration, não sendo contemplados aspectos referentes a garantia de liquidez imediata em data específica, não refletindo, necessariamente, o preço em que o [título público/privado] será negociado.

Renda Fixa - Posições Detalhadas

1. Para informações sobre liquidez da compromissada e DI, entre em contato com seu canal de atendimento.

Disclaimers

Sumário

1. Para o cálculo do saldo líquido, não estão sendo contabilizados os possíveis valores de IR e IOF a serem deduzidos em resgastes da carteira administrada.
2. Para o cálculo do saldo líquido, não estão sendo contabilizados os possíveis valores de IR e IOF a serem deduzidos em resgastes da carteira administrada.

Suitability

1. O processo de Suitability reflete os critérios estabelecidos pelo BTG Pactual que possibilitam verificar a adequação de seus investimentos ao perfil de risco de sua conta. Em caso de dúvida, favor entrar em contato com seu gerente de relacionamento.

Geral

1. A rentabilidade passada não é garantia de rentabilidade futura.
2. Para avaliação da performance de Fundos de Investimento, é recomendável uma análise de período mínimo de 12 (doze) meses. Fundos de Investimento não contam com a garantia do administrador do fundo de investimento, do administrador da carteira ou do Fundo Garantidor de Créditos (FGC).
3. Antes do investimento inicial no Fundo, recomenda-se a leitura atenta do respectivo prospecto (quando existente) e regulamento disponibilizados. Especial atenção deve ser dada às cláusulas relativas ao objetivo e à política de investimento do fundo, bem como às disposições que tratam dos fatores de risco a que está exposto.
4. Cópias adicionais dos regulamentos dos Fundos de Investimento administrados pelo BTG PACTUAL SERVIÇOS FINANCEIROS S.A. DTVM encontram-se à sua disposição com os nossos consultores de investimento.
5. Os Fundos de Investimento administrados pela BTG PACTUAL SERVIÇOS FINANCEIROS S.A. DTVM são auditados por uma das quatro maiores empresas de auditoria independente, conforme rodizio exigido por lei.
6. As informações constantes no presente extrato, apesar de fiéis aos registros existentes nesta instituição financeira em nome do respectivo cotista, não devem ser utilizadas para avaliação de efeitos fiscais das operações realizadas e declarações à Receita Federal. Os dados necessários às declarações à Receita Federal devem ser obtidos nos informes de rendimentos disponibilizados por esta instituição.
7. Em cumprimento a Resolução do Conselho Monetário Nacional nº 4.688/2018, informamos que saldos em depósito em dinheiro em conta corrente, aplicação em caderneta de poupança ou investimentos em depósitos a prazo (CDB/RDB), Letras de Câmbio, Letras Hipotecárias, LCI e LCA, entre outros, mantidos nesta instituição financeira, são garantidos pelo Fundo Garantidor de Créditos (FGC). Isso quer dizer que o FGC assegura que você receberá seu dinheiro de volta em casos de intervenção ou de liquidação de instituição financeira pelo Banco Central do Brasil, limitado a R$ 250 mil (duzentos e cinquenta mil reais) por CPF ou por CNPJ e por instituição financeira. Lembre-se que se você receber a garantia do FGC em decorrência de mais de uma intervenção ou liquidação de instituição financeira, o limite total da garantia é de R$ 1 milhão, a cada período de 4 anos, a partir do primeiro pagamento de garantia. Encerrado esse período, o limite de cobertura é restabelecido. Atenção: O FGC garante somente os instrumentos financeiros indicados em seu Regulamento, nos limites e nas condições ali descritos. O FGC não garante aplicações em fundos de investimento, letras financeiras, letras imobiliárias garantidas (LIG), ações e títulos de capitalização, entre outras. Para mais informações acesse o site www.fgc.org.br

Fale Conosco



Nossa ouvidoria

0800-722-0048

Das 9h às 18h de segunda à sexta-feira, exceto feriados.

ouvidoria@btgpactual.com

BANCO CENTRAL DO BRASIL

Currency Converter

Quotation date 08/07/2026

Value

1.024.733,53

Convert from

Real (BRL)

To

United States Dollar (USD)

Conversion result

Conversion from: Real/BRL (790)
Amount to convert: 1,024,733.53

To: United States Dollar/USD (220)
Conversion result: 201.291,2568

Exchange rate used: 07/08/2026
Rate:
1 Real/BRL (790) = 0.1964328 US Dollar/USD (220)
1 US Dollar/USD (220) = 5.0908 Real/BRL (790)

- The calculation performed is for informational purposes only and does not replace the provisions of Brazilian exchange regulations for specific conversion cases.
- Conversions are available for dates entered from 01/02/1999 onwards.
- For non-working days, the exchange rate of the immediately preceding working day is assumed.
- The Central Bank assumes no responsibility for the non-simultaneous or lack of information provided, as well as for any errors in currency parities, or any other error, except for the parity relative to the United States dollar in relation to the Real. Likewise, it is not responsible for delays or unavailability of telecommunications services, interruptions, failures, or inaccuracies in the provision of services or information. It also assumes no responsibility for any loss or damage arising from such interruptions, delays, failures, or imperfections, as well as for the improper use of the information contained in the transaction.

Follow the BC

<http://br.linkedin.com/company/banco-central-do-brasil>
<http://www.instagram.com/bancocentralbrasil/>
<http://pt-br.facebook.com/bancocentraldobrasil/>
<http://www.bcb.gov.br/pt-br/b34175749@N03/>

Access to information

Monetary policy

Financial stability

Statistics

Banknotes and coins

Publications and research

To guarantee price stability, to safeguard a sound and efficient financial system, and to promote the economic well-being of society.

Customer service: 145 (local call cost)

Contact us | Privacy Policy | Accessibility policy
© Central Bank of Brazil - All rights reserved

Exhibit D - Personal Documents

No. 989

REGISTRY OFFICE
Avenida Celso Garcia, 1211
Phone: 93-2702

FEDERATIVE REPUBLIC OF BRAZIL

Civil Registry Office of NATURAL PERSONS of the 10th Subdistrict

BELENZINHO

District of São Paulo - Judicial District of the Capital - Brazil

1st COPY EXEMPT FROM STAMPS

Dr. Jarbas Tupinambá de Oliveira Filho

CLERK

BIRTH CERTIFICATE

No. 50 153 **BOOK A No.** 42 **Page** 260

I CERTIFY that in Birth Record Book A No. 42, MÁRCIO LAMAS LOPES. - _____ is registered male, born on October eight, nineteen eighty-one (10-08-1981). - at 11:00 a.m., at São Jose do Brás Maternity Hospital. - _____ son of ERALDO LOPES and Ms. JANETE DIAS LAMAS LOPES. - _____ paternal grandparents are JACYNTHO LOPES and Ms. AMELIA TRIQUES LOPES. - _____ and maternal are ALVARO DIAS LAMAS and Ms. ISABEL OLHER LAMAS. - _____

Notes Record made today. The father was the informant. - _____

The above is true and I certify.

São Paulo, October 22 19 81

THE CLERK

-----//Signature//----

NOTARIZE THE SIGNATURE AT
17th Notary Public Office - Bachelor Sergio Salles
RUA FELIPE DE OLIVEIRA, 32
(Near the Palace of Justice)
PHONE: 37.1191 (INTERNAL NETWORK) SÃO PAULO

CIVIL REGISTRY OFFICE
10th Subdistrict - Belenzinho
Avenida Celso Garcia, 1.211 Phone 93-2702
São Paulo ----- Capital
Dr. JARBAS TUPINAMBÁ DE OLIVEIRA FILHO
Clerk
NOÊMIA DE LOURDES ANDRÉ
Deputy Registrar
DALVA NASCIMENTO

Dalva Nascimento

16TH MILITARY SERVICE OFFICE -
4TH MILITARY DISTRICT OFFICE

MILITARY SERVICE
BOARD
TATUAPÉ

No. 101

2F318F

RA 0.4.1.9.11

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



_____ Date: August 17, 2026.

N. 989

CARTÓRIO
Av. Celso Garcia, 1211
Fone: 93-2702

REPÚBLICA FEDERATIVA DO BRASIL

Cartório do Registro Civil das PESSÔAS NATURAIS do 10º Subdistrito
BELENZINHO
Distrito de São Paulo - Comarca da Capital - Brasil

1ª VIA ISENTA DE SÊLOS

Dr. Jarbas Tupinambá de Oliveira Filho
ESCRIVÃO

CERTIDÃO DE NASCIMENTO

N.o 50 153 LIVRO A N.o 42 Fls 260

CERTIFICO, que no livro A N.o 42, de registro de nascimento, está Registrado o MARCIO LAMAS LOPES.-

do sexo masculino, nascido no dia oito de outubro de mil novecentos e oitenta e um (8-10-1981).-

às 11 horas e - minutos, em a Maternidade São Jose do Brás.

filho de ERALDO LOPES e dona JANETE DIAS LAMAS LOPES.-

avós paternos JACYNTHO LOPES e dona AMELIA TRIQUES LOPES.-

e maternos ALVARO DIAS LAMAS e dona ISABEL OLHER LAMAS.-

Observações Registro feito hoje.Foi declarante o pai.-

O referido é verdade e dou fé.

São Paulo, 22 de outubro de 19 81

O ESCRIVÃO

Dalva Nascimento

RECONHECER A FIRMA NO
17.o Cartório de Notas - Bel Sergio Salles
RUA FELIPE DE OLIVEIRA, 32
(Próximo ao Palácio da Justiça)
FONE: 37.1191 (REDE INTERNA) SÃO PAULO

CARTORIO DO REGISTRO CIVIL
10º Subdistrito - Belenzinho
Av. Celso Garcia, 1.211 - Fone 93-2702
São Paulo — Capital
Dr. JARBAS TUPINAMBÁ DE OLIVEIRA FILHO
Escrivão
NOÊMIA DE LOURDES ANDRÉ
Oficial Maior
DALVA NASCIMENTO

16.ª DEL SM - 4.ª CSM
JUNTA DO SERVIÇO
MILITAR
TATUAPÉ
- N.º 101

3/3/96

RA 0 4 1 0 1

Assinatura do titular / *Signature du titulaire /*
Bearer's signature / Firma del titular

REPÚBLICA FEDERATIVA DO BRASIL

GM101655

Este passaporte deve ser assinado pelo titular, salvo em caso de incapacidade.

Ce passeport doit être signé par le titulaire, sauf en cas d'incapacité.

This passport must be signed, except where the bearer is unable to do so.

Este pasaporte debe ser firmado por el titular, salvo en caso de incapacidad.



PASSAPORTE
PASSPORT

REPÚBLICA FEDERATIVA DO BRASIL

TIPO / *TYPE*: **P**

PAÍS EMISSOR / *ISSUING COUNTRY*: **BRA**

PASSAPORTE Nº / *PASSPORT No.*: **GM101655**

SOBRENOME / *SURNAME*: **LAMAS LOPES**





NOME / *GIVEN NAMES*: **MARCIO**

NACIONALIDADE / *NATIONALITY*: **BRASILEIRO(A)**

DATA DO NASCIMENTO / *DATE OF BIRTH*: **08 OUT/OCT 1981**

CPF / *PERSONAL NUMBER*: **287868388-90**

SEXO / *SEX*: **M**

NATURALIDADE / *PLACE OF BIRTH*: **SÃO PAULO/SP**

FILIAÇÃO / *FILIATION*: **ERALDO LOPES**

JANETE DIAS LAMAS LOPES

DATA DE EXPEDIÇÃO / *DATE OF ISSUE*: **30 JUL/JUL 2025**

AUTORIDADE / *AUTHORITY*: **SR/PF/SP**

VÁLIDO ATÉ / *DATE OF EXPIRY*: **29 JUL/JUL 2035**

P<BRALAMAS<LOPES<<MARCIO<<<<<<<<<<<<<<<<<<<<

GM101655<8BRA8110088M3507290287868388 90<<<38

FP134946

Assinatura do titular / Signature du titulaire
Bearer's signature / Firma del titular

Este passaporte deve ser assinado pelo titular, salvo em caso de incapacidade.

Ce passeport doit être signé par le titulaire, sauf en cas d'incapacité.

This passport must be signed, except where the bearer is unable to do so.

Este pasaporte debe ser firmado por el titular, salvo en caso de incapacidad.

REPÚBLICA FEDERATIVA DO BRASIL

PASSAPORTE
PASSPORT



TIPO / TYPE: P
PAÍS EMISSOR / ISSUING COUNTRY: BRA
PASSAPORTE Nº / PASSPORT No: FP134946

SOBRENOME / SURNAME: LAMAS LOPES

NOME / GIVEN NAMES: MARCIO

NACIONALIDADE / NATIONALITY: BRASILEIRO(A)

DATA DO NASCIMENTO / DATE OF BIRTH: 08 OUT/OCT 1981

IDENTIDADE Nº / PERSONAL No:

SEXO / SEX: M

NATURALIDADE / PLACE OF BIRTH: SÃO PAULO/SP

FILIAÇÃO / FILIATION: ERALDO LOPES

JANETE DIAS LAMAS LOPES

DATA DE EXPEDIÇÃO / DATE OF ISSUE: 25 JAN/JAN 2016

AUTORIDADE / AUTHORITY: SR/DPF/SP

VÁLIDO ATÉ / DATE OF EXPIRY: 24 JAN/JAN 2026

BRA

P<BRALAMAS<LOPES<<MARCIO<<<<<<<<<<<<<<<<<<<<
FP134946<9BRA8110088M2601249<<<<<<<<<<<<<<04

VISTOS VISAS

VISA

UNITED STATES OF AMERICA



Issuing Post Name
SAO PAULO

Control Number
20220625730010

Surname
LAMAS LOPES

Given Name
MARCIO

Visa Type /Class
R B1/B2

Passport Number
FP134946

Sex
M

Birth Date
08OCT1981

Nationality
BRZL

Entries
M

Issue Date
08MAR2022

Expiration Date
02MAR2032

0111

Annotation

P8155257

*

VNUSALAMAS<LOPES<<MARCIO<<<<<<<<<<<<<<<<<<<<

FP134946<9BRA8110088M3203020B3SPL39F2W452147

CIVIL REGISTRY STAMP

FEDERATIVE REPUBLIC OF BRAZIL
CIVIL REGISTRY OF NATURAL PERSONS

MARRIAGE CERTIFICATE

NAMES:

*** MARCIO LAMAS LOPES***
*** LILIAN DE OLINDA GIANNOCCARO ***

REGISTRATION:
143032 01 55 20112 00093 117 0041715-53

FULL BIRTH NAMES, DATES AND PLACES OF BIRTH, NATIONALITY, AND FILIATION OF THE SPOUSES

HE: MARCIO LAMAS LOPES, born on October eighth, nineteen eighty-one, (10/08/1981), São Paulo, State of São Paulo (registered at the Belenzinho Service Unit, São Paulo, São Paulo), Brazilian, son of Eraldo Lopes and Janete Dias Lamas Lopes. ***

SHE: LILIAN DE OLINDA GIANNOCCARO, born on April twenty-second, nineteen eighty-three (04/22/1983), in São Paulo, State of São Paulo (registered at the Cerqueira César Service Unit, São Paulo, São Paulo), Brazilian, daughter of Antonio Vito Giannoccaro and Araguacy de Olinda Giannoccaro. ***

DATE OF MARRIAGE REGISTRATION (IN FULL)	DAY	MONTH	YEAR
SEPTEMBER FIRST, TWO THOUSAND ELEVEN	01	09	2011

MARITAL PROPERTY REGIME

PARTIAL COMMUNITY PROPERTY ***

NAME EACH SPOUSE BEGAN TO USE (IF CHANGED)

HE: Continues to use the SAME NAME. ***
SHE: Continues to use the SAME NAME. ***

NOTES

This certificate was extracted from Book B-0093, pages 117, entry no. 41715. **NOTHING FURTHER. *****

The content of this certificate is true. I certify.
São Paulo, September 1, 2011

----//signature//----

ADRIANA VIEIRA RIBEIRO CAMARGO
Authorized Clerk

27TH Tatuapé

Civil Registry Office of Natural Persons of the 27th Subdistrict - Tatuapé

EXEMPT FROM FEES

Flávio Aparecido Rodrigues Gumieri - REGISTRAR

City and Judicial District of São Paulo - State of São Paulo

Rua Coronel Luis Americano, 228/242 - Tatuapé - São Paulo - ZIP Code: 03308-020 - Phone/Fax: (11) 2093-0580 - email: certidao@cartoriotatuape.com.br

VALID THROUGHOUT THE NATIONAL TERRITORY WITHOUT ALTERATIONS AND/OR ERASURES

0115G - AA 201066

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: August 13, 2026.

REPÚBLICA FEDERATIVA DO BRASIL
REGISTRO CIVIL DAS PESSOAS NATURAIS

CERTIDÃO DE CASAMENTO

NOMES:
*** MARCIO LAMAS LOPES ***
*** LILIAN DE OLINDA GIANNOCCARO ***

MATRÍCULA:
143032 01 55 2011 2 00093 117 0041715-53

NOMES COMPLETOS, DATAS E LOCAIS DE NASCIMENTO, NACIONALIDADE E FILIAÇÕES DOS CÔNJUGES

ELE: MARCIO LAMAS LOPES, nascido no dia oito de outubro de mil novecentos e oitenta e um (08/10/1981), em São Paulo, Estado de São Paulo (registrado na Unidade de Serviço do Belenzinho, São Paulo, SP), nacionalidade brasileira, filho de Eraldo Lopes e de Janete Dias Lamas Lopes. ***

ELA: LILIAN DE OLINDA GIANNOCCARO, nascida no dia vinte e dois de abril de mil novecentos e oitenta e três (22/04/1983), em São Paulo, Estado de São Paulo (registrada na Unidade de Serviço de Cerqueira Cesar, São Paulo, SP), nacionalidade brasileira, filha de Antonio Vito Giannoccaro e de Araquacy de Olinda Giannoccaro. ***

DATA DE REGISTRO DO CASAMENTO (POR EXTENSO)
PRIMEIRO DE SETEMBRO DE DOIS MIL E ONZE

DIA	MES	ANO
01	09	2011

REGIME DE BENS DO CASAMENTO
COMUNHÃO PARCIAL DE BENS ***

NOME QUE CADA UM DOS CÔNJUGES PASSOU A UTILIZAR (QUANDO HOUVER ALTERAÇÃO)
ELE: Continua a usar o MESMO NOME. ***
ELA: Continua a usar o MESMO NOME. ***

OBSERVAÇÕES
Esta certidão foi extraída do Livro B-0093, fls. 117, termo nº 41715. NADA MAIS. ***

O conteúdo da certidão é verdadeiro. Dou fé.
São Paulo, 01 de setembro de 2011

ADRIANA VIEIRA RIBEIRO CAMARGO
Escrevente Autorizada

ISENTO DE EMOLUMENTOS

27º Tatuapé
Oficial de Registro Civil das Pessoas Naturais do 27º Subdistrito - Tatuapé
Flávio Aparecido Rodrigues Gumieri - OFICIAL
Município e Comarca de São Paulo - Estado de São Paulo
R. Coronel Luis Americano, 228/242 - Tatuapé - São Paulo - CEP: 03308-020
- Fone/Fax: (11) 2093-0580 - e-mail: certidao@cartoriotatuape.com.br

VÁLIDO EM TODO O TERRITÓRIO NACIONAL SEM EMENDAS E/OU RASURAS

0115G-AA 201066
0115G-200001-206000-0711

FEDERATIVE REPUBLIC OF BRAZIL

STATE OF SÃO PAULO

Civil Registry Office of Natural Persons - CERQUEIRA LOPES - 34th Subdistrict
of the Capital of São Paulo, located at Rua Augusta, 1300 - Mezzanine

PAULO WANDERLEY BROSSI
REGISTRAR

JOSÉ FLORESTANO V. BROSSI
DEPUTY REGISTRAR

BIRTH CERTIFICATE

AT THE 21st NOTARY PUBLIC'S OFFICE
Rua Xavier de Toledo, 44
Mezzanine

Book 194 Page 036 No. 115 978

I HEREBY CERTIFY that, in the appropriate BIRTH register book of this Registry Office, there is the record of LILIAN DE OLINDA GIANNOCCARO -
born on April twenty-second, nineteen eighty-three-
at 8:30 AM, At São Paulo Maternity, in this Subdistrict -
-female-, daughter of -Antonio Vito Giannoccaro
born in this Capital -
and -Araguacy de Olinda Giannoccaro-born in Bahia -
Paternal grandparents are -Lourenço Giannoccaro -
and -Maria Santa Pontes Giannoccaro -
and maternal grandparents are -João Paulo de Olinda -
and -Vasti de Almeida Olinda -
The registration was drawn up today-

Notes: PS: I hereby certify where it reads: Araguacy - -----//Signature//----

Certificate typed by: -----//Signature//----

The above is true and I certify.

TO NOTARIZE THE SIGNATURE

HOURS:
From 9:00 a.m. to 12:00 p.m. –
from 2:00 p.m. to 5:00 p.m.

São Paulo, April 30, 19 83

Mary Lopes de Sousa
Authorized Clerk

CIVIL REGISTRY CLERK

-----//Signature//----

STAMP TAX PAID IN CURRENCY

Form No. 99 / 83

FEES,

PAULO WANDERLEY BROSSI
CIVIL REGISTRY REGISTRAR

JOSÉ FLORESTANO V. BROSSI
DEPUTY REGISTRAR

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 26, 2026.

REPÚBLICA FEDERATIVA DO BRASIL

ESTADO DE SÃO PAULO

Oficio do Registro Civil das Pessôas Naturais da Capital de São Paulo, sito à Rua Augusta, 1300 - Sobreloja — CERQUEIRA CESAR — 34.o Subdistrito

PAULO WANDERLEY BROSSI
OFICIAL DO REGISTRO CIVIL

JOSÉ FLORESTANO V. BROSSI
OFICIAL MAIOR

CERTIDÃO DE NASCIMENTO

Livro 194 Fôlha 036 N.o 115 978

CERTIFICO que, no livro competente de NASCIMENTO, dêste cartório consta o assento de LILIAN DE OLINDA GIANNOCCARO -

nascido a vinte e dois de abril de mil novecentos e oitenta e tres-

às 08:30, horas na Mat. São Paulo, neste subdtº -

do sexo -feminino- ,filh a de -Antonio Vito Giannoccaro nat. desta Capital -

e de -Araguacy de Olinda Giannoccaro-nat. da Bahia -

São avós paternos -Lourenço Giannoccaro -

e -Maria Santa Pontes Giannoccaro -

e maternos -João Paulo de Olinda -

e -Vasti de Almeida Olinda -

Registro lavrado no dia hoje-

Observações: ET: ressalvo onde se lê: Araguacy, dou fé -

Certidão datilografada por:

O referido é verdade e dou fé.

São Paulo, 30 de abril de 1983

ESCRIVÃO DO REGISTRO CIVIL

PAULO WANDERLEY BROSSI
OFICIAL DO REGISTRO CIVIL
JOSÉ FLORESTANO V. BROSSI
OFICIAL MAIOR

HORÁRIO:

Das 9,00 às 12 - das 14,00 às 17hs.

SELOS PAGOS POR VERBA
GUIA N.o 99 / 83
EMOLUMENTOS,

NO 21.o TABELIONATO
R. Xavier de Toledo, 44
Sobreloja

RECONHECER FIRMA

FEDERATIVE REPUBLIC OF BRAZIL
CIVIL REGISTRY OF NATURAL PERSONS

BIRTH CERTIFICATE

NAME

LAVÍNIA GIANNOCCARO LOPES

CPF

55884706804

REGISTRATION

143032 01 55 2018 1 00242 166 0198371 31

DATE OF BIRTH (IN FULL)	DAY	MONTH	YEAR
OCTOBER NINTH, TWO THOUSAND EIGHTEEN	**09**	**10**	**2018**

TIME OF BIRTH	CITY OF BIRTH
1:22 PM	**SÃO PAULO - SÃO PAULO**

CITY OF REGISTRATION AND STATE	PLACE, CITY OF BIRTH AND STATE	SEX
SÃO PAULO - 27TH SUBDISTRICT - TATUAPÉ- SÃO PAULO	**REDE DOR SÃO LUIZ MEDICAL SERVICES ANÁLIA FRANCO - RUA FRANCISCO MARENGO, 1312 - SÃO PAULO - SP**	**FEMALE**

FILIATION

MARCIO LAMAS LOPES - BORN IN SÃO PAULO - SP - RESIDENT AND DOMICILED IN SÃO PAULO - SP
LILIAN DE OLINDA GIANNOCCARO - BORN IN SÃO PAULO - SP - RESIDENT AND DOMICILED IN SÃO PAULO - SP

GRANDPARENTS

ERALDO LOPES AND JANETE DIAS LAMAS LOPES
ANTONIO VITO GIANNOCCARO AND ARAGUACY DE OLINDA GIANNOCCARO

TWIN	NAME AND REGISTRATION OF THE TWIN(S)
NO	**NO RECORD.**

DATE OF REGISTRATION (IN FULL)	NUMBER OF LIVE BIRTH CERTIFICATE
OCTOBER TENTH, TWO THOUSAND EIGHTEEN	**30-77435723-3**

NOTES / ANNOTATIONS TO BE ADDED

NO RECORD.

REGISTRATION NOTES

NO RECORD.

Certificate drawn up by Andréa Silva Ramos - clerk of the Civil Registry of São Paulo - 27th Subdistrict - Tatuapé, who signed it electronically, pursuant to Article 13 of CNJ (*National Council of Justice*) Provision No. 13.

I certify that, on October 10, 2018, this certificate was extracted from the Integrated Birth Registry System, and I verified the authenticity of its ICP-Brasil standard digital signature.

Civil Registry Office of Natural Persons
São Paulo - 27th Subdistrict - Tatuapé - São Paulo
Flávio Aparecido Rodrigues Gumieri - Registrar
Rua Coronel Luiz Americano, 228/242 - ZIP Code: 03308-020
Email: flavio@cartoriotatuape.com.br
Phone: (11) 2942-1010

The content of this certificate is true. I certify.

----//signature//----

Sulivan Soler Fernandes
Clerk
1st Copy of the certificate
EXEMPT FROM FEES

Digital Seal: 1430322PV000000000758018Z
Consult electronic validity at the website: https://selodigital.tjsp.jus.br/

14303-2 - AA 000175802

14303-2-170001-176000-0518

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 26, 2026.

REPÚBLICA FEDERATIVA DO BRASIL
REGISTRO CIVIL DAS PESSOAS NATURAIS

CERTIDÃO DE NASCIMENTO

NOME

LAVÍNIA GIANNOCCARO LOPES

CPF
55884706804

MATRÍCULA
143032 01 55 2018 1 00242 166 0198371 31

DATA DE NASCIMENTO (POR EXTENSO): NOVE DE OUTUBRO DE DOIS MIL E DEZOITO
DIA: 09 | MÊS: 10 | ANO: 2018

HORA DE NASCIMENTO: 13:22 HORAS
NATURALIDADE: SÃO PAULO - SP

MUNICÍPIO DE REGISTRO E UNIDADE DA FEDERAÇÃO: SÃO PAULO - 27º SUBDISTRITO - TATUAPÉ - SP

LOCAL, MUNICÍPIO DE NASCIMENTO E UF: REDE DOR SÃO LUIZ SERVIÇOS MÉDICOS ANÁLIA FRANCO - RUA FRANCISCO MARENGO, 1312 - SÃO PAULO - SP

SEXO: FEMININO

FILIAÇÃO
MARCIO LAMAS LOPES - NATURAL DE SÃO PAULO - SP - RESIDENTE E DOMICILIADO EM SÃO PAULO - SP
LILIAN DE OLINDA GIANNOCCARO - NATURAL DE SÃO PAULO - SP - RESIDENTE E DOMICILIADA EM SÃO PAULO - SP

AVÓS
ERALDO LOPES E JANETE DIAS LAMAS LOPES
ANTONIO VITO GIANNOCCARO E ARAGUACY DE OLINDA GIANNOCCARO

GÊMEOS: NÃO
NOME E MATRÍCULA DOS GÊMEOS: NADA CONSTA.

DATA DO REGISTRO (POR EXTENSO): DEZ DE OUTUBRO DE DOIS MIL E DEZOITO
NÚMERO DA DNV/DECLARAÇÃO DE NASCIDO VIVO: 30-77435723-3

AVERBAÇÕES / ANOTAÇÕES À ACRESCER
NADA CONSTA.

ANOTAÇÕES DE CADASTRO
SEM INFORMAÇÕES.

Certidão lavrada por Andréa Silva Ramos - escrevente do Registro Civil São Paulo - 27º Subdistrito - Tatuapé, o(a) qual assinou eletronicamente, nos termos do artigo 13 do Provimento nº 13 do CNJ.

Certifico que, em data de 10 de Outubro de 2018, foi extraída esta certidão do Sistema Interligado de Registro de Nascimento, sendo a autenticidade de sua assinatura digital padrão ICP-Brasil por mim conferida

Oficial de Registro Civil das Pessoas Naturais
São Paulo - 27º Subdistrito - Tatuapé - SP
Flavio Aparecido Rodrigues Gumieri - Oficial
Rua Coronel Luiz Americano, 228 / 242 - CEP: 03308-020
E-mail: flavio@cartoriotatuape.com.br
Tel: (11) 2942-1010

O conteúdo da certidão é verdadeiro. Dou fé

Sulivan Soler Fernandes
Escrevente
1ª Via certidão
ISENTO DE EMOLUMENTOS

Selo Digital: 1430322PV0000000007580l8Z
Consulte a validade no site:
https://selodigital.tjsp.jus.br/

14303-2 - AA 00017580 2

14303-2-170001-176000-051B

FEDERATIVE REPUBLIC OF BRAZIL
CIVIL REGISTRY OF NATURAL PERSONS

BIRTH CERTIFICATE

Name

BRUNO GIANNOCCARO LOPES

REGISTRATION:

122044 01 55 2016 1 00555 121 0268591 78

DATE OF BIRTH IN FULL	DAY	MONTH	YEAR
August seventeenth, two thousand sixteen	17	08	2016

TIME OF BIRTH	CITY OF BIRTH AND STATE
2:05 PM	São Paulo - São Paulo

CITY OF REGISTRATION AND STATE	PLACE OF BIRTH	SEX
São Paulo - 9th Subdistrict - Vila Mariana - São Paulo	Santa Joana Hospital and Maternity - Rua do Paraíso, 432	Male

FILIATION

MARCIO LAMAS LOPES - Born in São Paulo - São Paulo
LILIAN DE OLINDA GIANNOCCARO - Born in São Paulo - São Paulo

GRANDPARENTS

ERALDO LOPES and JANETE DIAS LAMAS LOPES
ANTONIO VITO GIANNOCCARO and ARAGUACY DE OLINDA GIANNOCCARO

TWIN	NAME AND REGISTRATION OF THE TWIN(S)
No	No Record.

DATE OF REGISTRATION IN FULL	NUMBER OF LIVE BIRTH CERTIFICATE
August eighteenth, two thousand sixteen	30-73436416-6

NOTES / ANNOTATIONS

Registered with the CPF under No. 51647233879, in accordance with RFB (*Federal Revenue of Brazil*) Normative Instruction No. 1548/15.

Certificate drawn up by Natasha Caroline Pleul Alves - Clerk of the Civil Registry of Natural Persons of São Paulo - 9th Subdistrict - Vila Mariana, who signed it electronically, pursuant to Article 13 of CNJ (*National Council of Justice*) Provision No. 13.

I certify that, on August 18, 2016, this certificate was extracted from the Integrated Birth Registry System, and I verified the authenticity of its ICP-Brasil standard digital signature.

The content of this certificate is true. I certify.

----//signature//----

1st Copy of the certificate
EXEMPT FROM FEES

Aline da Costa Santos
Authorized Clerk

Civil Registry Office of Natural Persons
São Paulo - 9th Subdistrict - Vila Mariana

João Baptista Martelletto
Registrar

City of São Paulo - São Paulo
Praça Oswaldo Cruz, No. 39 - ZIP Code: 04004-070
Phone: (11) 3059-2210 / (11) 3059-2211 - E-mail: saopaulo9@arpensp.org.br

12204-4 - AA 000118017

12204-4-116091-122000-0716

I, Carolina Favero da Silva, telephone number 415 425-2508, mailing address P.O. Box 90487, San Diego, CA 92169, certify that the professional translation of this document from Portuguese to English has been performed by myself, a qualified translator fluent in both languages, and that the following is an accurate and complete translation of the document.



Date: June 26, 2026.

REPÚBLICA FEDERATIVA DO BRASIL
REGISTRO CIVIL DAS PESSOAS NATURAIS

CERTIDÃO DE NASCIMENTO

Nome
BRUNO GIANNOCCARO LOPES

MATRÍCULA:
122044 01 55 2016 1 00555 121 0268591 78

DATA DE NASCIMENTO POR EXTENSO	DIA	MÊS	ANO
dezessete de agosto de dois mil e dezesseis	17	08	2016

HORA	MUNICÍPIO DE NASCIMENTO E UNIDADE DA FEDERAÇÃO
14:05 horas	São Paulo - SP

MUNICÍPIO DE REGISTRO E UNIDADE DA FEDERAÇÃO	LOCAL DE NASCIMENTO	SEXO
São Paulo - 9º Subdistrito - Vila Mariana - SP	Hospital e Maternidade Santa Joana - Rua do Paraíso, 432	Masculino

FILIAÇÃO
MARCIO LAMAS LOPES - Natural de São Paulo - SP
LILIAN DE OLINDA GIANNOCCARO - Natural de São Paulo - SP

AVÓS
ERALDO LOPES e JANETE DIAS LAMAS LOPES
ANTONIO VITO GIANNOCCARO e ARAGUACY DE OLINDA GIANNOCCARO

GÊMEOS	NOME E MATRÍCULA DO(S) GÊMEO(S)
Não	Nada Consta.

DATA DO REGISTRO POR EXTENSO	Nº DA DECLARAÇÃO DE NASCIDO VIVO
dezoito de agosto de dois mil e dezesseis	30-73436416-6

OBSERVAÇÕES AVERBAÇÕES
Inscrito(a) no CPF sob o nº 51647233879, conforme Instrução Normativa RFB nº 1548/15.

Certidão lavrada por Natasha Caroline Pleul Alves - Escrevente do Registro Civil São Paulo - 9º Subdistrito - Vila Mariana, o(a) qual assinou eletronicamente, nos termos do artigo 13 do Provimento nº 13 do CNJ.

Certifico que, em data de 18 de agosto de 2016, foi extraída esta certidão do Sistema Interligado de Registro de Nascimento, sendo a autenticidade de sua assinatura digital padrão ICP-Brasil por mim conferida.

O conteúdo da certidão é verdadeiro. Dou fé

Aline da Costa Santos
Escrevente Autorizada

1ª via certidão
ISENTO DE EMOLUMENTOS

Oficial de Registro Civil das Pessoas Naturais
São Paulo - 9º Subdistrito - Vila Mariana

João Baptista Martelletto
Oficial

Município de São Paulo - SP
Praça Oswaldo Cruz, 39 - CEP: 04004-070
Tel: 3059-2210 / 3059-2211 - E-mail: saopaulo9@arpensp.org.br

12204-4 - AA 000118017

12204-4-116001-122000-0716

FV301771

Assinatura do titular / Signature du titulaire
Bearer's signature / Firma del titular

Este passaporte deve ser assinado pelo titular, salvo em caso de incapacidade.

Ce passeport doit être signé par le titulaire, sauf en cas d'incapacité.

This passport must be signed, except where the bearer is unable to do so.

Este pasaporte debe ser firmado por el titular, salvo en caso de incapacidad.

REPÚBLICA FEDERATIVA DO BRASIL

PASSAPORTE
PASSPORT



TIPO / TYPE: P
PAÍS EMISSOR / ISSUING COUNTRY: BRA
PASSAPORTE Nº / PASSPORT No: FV301771

SOBRENOME / SURNAME
DE OLINDA GIANNOCCARO

NOME / GIVEN NAMES
LILIAN

NACIONALIDADE / NATIONALITY
BRASILEIRO(A)

DATA DO NASCIMENTO / DATE OF BIRTH
22 ABR/APR 1983

IDENTIDADE Nº / PERSONAL No

SEXO / SEX
F

NATURALIDADE / PLACE OF BIRTH
SÃO PAULO/SP

FILIAÇÃO / FILIATION
ANTONIO VITO GIANNOCCARO

ARAGUACY DE OLINDA GIANNOCCARO

DATA DE EXPEDIÇÃO / DATE OF ISSUE
27 FEV/FEB 2018

AUTORIDADE / AUTHORITY
SR/DPF/SP

VALIDO ATÉ / DATE OF EXPIRY
26 FEV/FEB 2028

P<BRADE<OLINDA<GIANNOCCARO<<LILIAN<<<<<<<<<<
FV301771<3BRA8304221F2802264<<<<<<<<<<<<<<08

Menor de 12 anos de idade
Child under the age of 12

Assinatura do titular / *Signature du titulaire /*
Bearer's signature / Firma del titular

REPÚBLICA FEDERATIVA DO BRASIL

GM101657

Este passaporte deve ser assinado pelo titular, salvo em caso de incapacidade.

Ce passeport doit être signé par le titulaire, sauf en cas d'incapacité.

This passport must be signed, except where the bearer is unable to do so.

Este pasaporte debe ser firmado por el titular, salvo en caso de incapacidad.



PASSAPORTE
PASSPORT

REPÚBLICA FEDERATIVA DO BRASIL

TIPO / *TYPE*: P
PAÍS EMISSOR / *ISSUING COUNTRY*: BRA
PASSAPORTE Nº / *PASSPORT No.*: GM101657

SOBRENOME / *SURNAME*
GIANNOCCARO LOPES





NOME / *GIVEN NAMES*
LAVÍNIA

NACIONALIDADE / *NATIONALITY*
BRASILEIRO(A)

DATA DO NASCIMENTO / *DATE OF BIRTH*: 09 OUT/OCT 2018
CPF / *PERSONAL NUMBER*: 558847068-04

SEXO / *SEX*: F
NATURALIDADE / *PLACE OF BIRTH*: SÃO PAULO/SP

FILIAÇÃO / *FILIATION*
LILIAN DE OLINDA GIANNOCCARO
MARCIO LAMAS LOPES

O titular, enquanto menor, está autorizado pelos genitores, pelo prazo deste documento, a viajar apenas com um dos pais, indistintamente. Res. CNJ 131/11, Art. 13.

DATA DE EXPEDIÇÃO / *DATE OF ISSUE*: 30 JUL/JUL 2025
AUTORIDADE / *AUTHORITY*: SR/PF/SP

VÁLIDO ATÉ / *DATE OF EXPIRY*: 29 JUL/JUL 2030

P<BRAGIANNOCCARO<LOPES<<LAVINIA<<<<<<<<<<<<<
GM101657<4BRA1810091F3007295558847068O4<<<14

Menor não alfabetizado.

Illiterate minor.

GA803078

Assinatura do titular / Signature du titulaire
Bearer's signature / Firma del titular

Este passaporte deve ser assinado pelo titular, salvo em caso de incapacidade.

Ce passeport doit être signé par le titulaire, sauf en cas d'incapacité.

This passport must be signed, except where the bearer is unable to do so.

Este pasaporte debe ser firmado por el titular, salvo en caso de incapacidad.

REPÚBLICA FEDERATIVA DO BRASIL

PASSAPORTE
PASSPORT



P BRA GA803078

SOBRENOME / SURNAME
GIANNOCCARO LOPES

NOME / GIVEN NAMES
LAVINIA

NACIONALIDADE / NATIONALITY
BRASILEIRO(A)

DATA DO NASCIMENTO / DATE OF BIRTH
09 OUT/OCT 2018

IDENTIDADE Nº / PERSONAL No.

SEXO / SEX
F

NATURALIDADE / PLACE OF BIRTH
SÃO PAULO/SP

FILIAÇÃO / FILIATION
MARCIO LAMAS LOPES

LILIAN DE OLINDA GIANNOCCARO

O titular, enquanto menor, está autorizado pelos genitores, pelo prazo deste documento, a viajar apenas com um dos pais, indistintamente. Res. CNJ 131/11, Art. 13.

DATA DE EXPEDIÇÃO / DATE OF ISSUE
11 NOV/NOV 2019

AUTORIDADE / AUTHORITY
SR/DPF/SP

VALIDO ATÉ / DATE OF EXPIRY
10 NOV/NOV 2021

BRA

P<BRAGIANNOCCARO<LOPES<<LAVINIA<<<<<<<<<<<<<
GA803078<2BRA1810091F2111108<<<<<<<<<<<<<<08

Menor de 12 anos de idade
Child under the age of 12

REPÚBLICA FEDERATIVA DO BRASIL

Assinatura do titular / *Signature du titulaire / Bearer's signature / Firma del titular*

GM101656

Este passaporte deve ser assinado pelo titular, salvo em caso de incapacidade.

Ce passeport doit être signé par le titulaire, sauf en cas d'incapacité.

This passport must be signed, except where the bearer is unable to do so.

Este pasaporte debe ser firmado por el titular, salvo en caso de incapacidad.



REPÚBLICA FEDERATIVA DO BRASIL

PASSAPORTE
PASSPORT

TIPO / *TYPE*: P
PAÍS EMISSOR / *ISSUING COUNTRY*: BRA
PASSAPORTE Nº / *PASSPORT NO.*: GM101656

SOBRENOME / *SURNAME*
GIANNOCCARO LOPES

NOME / *GIVEN NAMES*
BRUNO

NACIONALIDADE / *NATIONALITY*
BRASILEIRO(A)

DATA DO NASCIMENTO / *DATE OF BIRTH*: 17 AGO/AUG 2016
CPF / *PERSONAL NUMBER*: 516472338-79

SEXO / *SEX*: M
NATURALIDADE / *PLACE OF BIRTH*: SÃO PAULO/SP

FILIAÇÃO / *FILIATION*
LILIAN DE OLINDA GIANNOCCARO

MARCIO LAMAS LOPES

O titular, enquanto menor, está autorizado pelos genitores, pelo prazo deste documento, a viajar apenas com um dos pais, indistintamente. Res. CNJ 131/11, Art. 13.

DATA DE EXPEDIÇÃO / *DATE OF ISSUE*: 30 JUL/JUL 2025
AUTORIDADE / *AUTHORITY*: SR/PF/SP
VÁLIDO ATÉ / *DATE OF EXPIRY*: 29 JUL/JUL 2030





P<BRAGIANNOCCARO<LOPES<<BRUNO<<<<<<<<<<<<<<<

GM101656<1BRA1608171M3007295516472338 79<<<98

Menor não alfabetizado.
Illiterate minor.

Assinatura do titular / Signature du titulaire
Bearer's signature / Firma del titular

FV301772

Este passaporte deve ser assinado pelo titular, salvo em caso de incapacidade.

Ce passeport doit être signé par le titulaire, sauf en cas d'incapacité.

This passport must be signed, except where the bearer is unable to do so.

Este pasaporte debe ser firmado por el titular, salvo en caso de incapacidad.

REPÚBLICA FEDERATIVA DO BRASIL

PASSAPORTE
PASSPORT



P BRA FV301772

SOBRENOME / SURNAME
GIANNOCCARO LOPES

NOME / GIVEN NAMES
BRUNO

NACIONALIDADE / NATIONALITY
BRASILEIRO(A)

DATA DO NASCIMENTO / DATE OF BIRTH
17 AGO/AUG 2016

IDENTIDADE Nº / PERSONAL No.

SEXO / SEX
M

NATURALIDADE / PLACE OF BIRTH
SÃO PAULO/SP

FILIAÇÃO / FILIATION
LILIAN DE OLINDA GIANNOCCARO

MARCIO LAMAS LOPES

O titular, enquanto menor, está autorizado pelos genitores, pelo prazo deste documento, a viajar apenas com um dos pais, indistintamente. Res. CNJ 131/11, Art. 13.

DATA DE EXPEDIÇÃO / DATE OF ISSUE
27 FEV/FEB 2018

AUTORIDADE / AUTHORITY
SR/DPF/SP

VÁLIDO ATÉ / DATE OF EXPIRY
26 FEV/FEB 2020

P<BRAGIANNOCCARO<LOPES<<BRUNO<<<<<<<<<<<<<<
FV301772<6BRA1608171M2002260<<<<<<<<<<<<<<00

VISTOS VISAS

VISA

UNITED STATES OF AMERICA



Issuing Post Name
SAO PAULO

Control Number
20193544070016

Surname
DE OLINDA GIANNOCCARO

Given Name
LILIAN

Visa Type /Class
R B1/B2

Passport Number
FV301771

Sex
F

Birth Date
22APR1983

Nationality
BRZL

Entries
M

Issue Date
26DEC2019

Expiration Date
19DEC2029

0100

Annotation

P4633040

**

VNUSADE<OLINDA<GIANNOCCARO<<LILIAN<<<<<<<<<<

FV301771<3BRA8304221F2912198B3SPL35YQ5942297

VISTOS VISAS

VISA

UNITED STATES OF AMERICA



Issuing Post Name
SAO PAULO

Control Number
20193544070017

Surname
GIANNOCCARO LOPES

Given Name
LAVINIA

Visa Type /Class
R B1/B2

Passport Number	Sex	Birth Date	Nationality
GA803078	F	09OCT2018	BRZL

Entries	Issue Date	Expiration Date	
M	26DEC2019	19DEC2029	0110

Annotation

P4632985

*

VNUSAGIANNOCCARO<LOPES<<LAVINIA<<<<<<<<<<<<<

GA803078<2BRA1810091F2912198B3SPL35YNA263594


DEPARTMENT OF HOMELAND SECURITY • U.S. CUSTOMS AND BORDER PROTECTION
ADMITTED
ORL
/B2
Class
Until
OCT 19 2018
VISTOS VISAS


VISA
UNITED STATES OF AMERICA
Issuing Post Name
SAO PAULO
Control Number
20180741600010
Surname
GIANNOCCARO LOPES
Given Name
BRUNO
Visa Type /Class
R B1/B2
Passport Number
FV301772
Sex
M
Birth Date
17AUG2016
Nationality
BRZL
Entries
M
Issue Date
19MAR2018
Expiration Date
14MAR2028
0110
Annotation
M9181488
* *
VNUSAGIANNOCCARO<LOPES<<BRUNO<<<<<<<<<<<<<<<
FV301772<6BRA1608171M2803146B3SPL2U8ET820436